{
    "FullStudiesResponse": {
        "APIVrs": "1.01.05",
        "DataVrs": "2022:04:28 23:02:19.210",
        "Expression": "tacs",
        "NStudiesAvail": 413389,
        "NStudiesFound": 1274,
        "MinRank": 1,
        "MaxRank": 50,
        "NStudiesReturned": 50,
        "FullStudies": [
            {
                "Rank": 1,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT00890968",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "TAC-202"
                            },
                            "Organization": {
                                "OrgFullName": "ZARS Pharma Inc.",
                                "OrgClass": "INDUSTRY"
                            },
                            "BriefTitle": "Safety and Efficacy Study of Triamcinolone Acetonide DuraPeel to Treat Hand Dermatitis",
                            "OfficialTitle": "A Multi-Center Randomized, Double-Blind, Placebo Controlled, Parallel Group Comparison Study of Once Daily Triamcinolone Acetonide 0.5% DuraPeel™ Versus Placebo DuraPeel in the Treatment of Hand Dermatitis",
                            "Acronym": "TAC-202"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "March 2012",
                            "OverallStatus": "Completed",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "April 2009"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "June 2009",
                                "PrimaryCompletionDateType": "Actual"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "August 2009",
                                "CompletionDateType": "Actual"
                            },
                            "StudyFirstSubmitDate": "April 28, 2009",
                            "StudyFirstSubmitQCDate": "April 28, 2009",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "April 30, 2009",
                                "StudyFirstPostDateType": "Estimate"
                            },
                            "DispFirstSubmitDate": "March 14, 2012",
                            "DispFirstSubmitQCDate": "March 14, 2012",
                            "DispFirstPostDateStruct": {
                                "DispFirstPostDate": "March 16, 2012",
                                "DispFirstPostDateType": "Estimate"
                            },
                            "LastUpdateSubmitDate": "March 14, 2012",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "March 16, 2012",
                                "LastUpdatePostDateType": "Estimate"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Sponsor"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "ZARS Pharma Inc.",
                                "LeadSponsorClass": "INDUSTRY"
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "The purpose of this study is to determine whether Triamcinolone Acetonide (TAC) DuraPeel is safe and effective in the treatment of hand dermatitis.",
                            "DetailedDescription": "Triamcinolone acetonide is a commonly used, safe, and effective topical corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. However, the effectiveness of topical agents such as creams or ointments is limited by patients' routine activities using bare hands that may remove the topical agent from the hands. The use of a topical corticosteroid in a vehicle that allows the product to remain in contact with the skin and is not susceptible to inadvertent removal would be beneficial.\n\nThe DuraPeel membrane is expected to optimize exposure to the steroid by remaining on the treatment area for a prolonged period of time.\n\nThis study is designed to evaluate the efficacy and safety of Triamcinolone Acetonide 0.5% DuraPeel. Eligible subjects will receive Triamcinolone Acetonide 0.5% DuraPeel or Placebo DuraPeel. The study duration will be approximately 4 weeks."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Hand Dermatoses"
                                ]
                            },
                            "KeywordList": {
                                "Keyword": [
                                    "hand dermatitis",
                                    "hand eczema",
                                    "triamcinolone acetonide"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Phase 2"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "Randomized",
                                "DesignInterventionModel": "Parallel Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "Double",
                                    "DesignWhoMaskedList": {
                                        "DesignWhoMasked": [
                                            "Participant",
                                            "Investigator"
                                        ]
                                    }
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "56",
                                "EnrollmentType": "Actual"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "Triamcinolone Acetonide (TAC) DuraPeel",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: Triamcinolone Acetonide (TAC) DuraPeel"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "Placebo",
                                        "ArmGroupType": "Placebo Comparator",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: Placebo DuraPeel"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "Triamcinolone Acetonide (TAC) DuraPeel",
                                        "InterventionDescription": "topical gel; once daily (nightly); total duration: 4 weeks",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Triamcinolone Acetonide (TAC) DuraPeel"
                                            ]
                                        },
                                        "InterventionOtherNameList": {
                                            "InterventionOtherName": [
                                                "TAC DuraPeel"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "Placebo DuraPeel",
                                        "InterventionDescription": "topical gel; once daily (nightly); total duration: 4 weeks",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Placebo"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Response as assessed by Investigator Global Assessment (IGA)",
                                        "PrimaryOutcomeTimeFrame": "Baseline, Week 1, Week 2, Week 4"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "Subject's Global Impression of Change (SGIC)",
                                        "SecondaryOutcomeTimeFrame": "Week 4 (end-of-treatment)"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Individual Primary Parameters of Hand Dermatitis",
                                        "SecondaryOutcomeTimeFrame": "Baseline, Week 1, Week 2, Week 4"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Signs or symptoms of hand dermatitis",
                                        "SecondaryOutcomeTimeFrame": "Baseline, Week 1, Week 2, Week 4"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Subject's self-assessment of overall hand disease",
                                        "SecondaryOutcomeTimeFrame": "Baseline, Week 4"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Study medication assessment",
                                        "SecondaryOutcomeTimeFrame": "Week 1, Week 2, Week 4"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nClinical diagnosis of stable chronic hand dermatitis (greater than 6 weeks duration) that is KOH-negative\nDermatitis of mild to moderate severity, as defined by an Investigator's Global Assessment (a score of 2 or 3 on the Target Hand)\nIndividual signs of hand dermatitis disease of at least mild scaling and mild erythema (a score of 2 or more on the Target Hand)\nWritten informed consent\n\nExclusion Criteria:\n\nSubject is female and is pregnant, lactating, or is planning to become pregnant during the study\nSpontaneously improving or rapidly deteriorating hand dermatitis at the time of enrollment; subject may have history of waxing and waning disease in the past\nHistory of hand dermatitis that has been shown to be unresponsive to super potent (Group 1) topical steroids\nConcurrent flaring of inflammatory skin disease (e.g., atopic dermatitis or psoriasis) anywhere on the body outside the study areas\nBullous disorders or hand, foot, and mouth disease (HFMD); however, subjects with dyshidrotic hand dermatitis or pompholyx are allowed to participate provided they meet all other Inclusion/Exclusion criteria\nKnown allergic mediated hand dermatitis (e.g., allergic to latex, etc.)\nConcurrent skin diseases in the study area that require concomitant topical treatment (e.g., tinea manuum, scabies, infected eczema, and paronychia) that could interfere with the evaluation of his/her dermatitis\nPustular diseases of the hands (e.g., acrodermatitis perstans continua).\nUsed photo-therapy, photo-chemotherapy, systemic immunomodulatory therapy (such as systemic corticosteroids, methotrexate, retinoids or cyclosporine), or other therapy within 30 days prior to the first application of study medication that is known or suspected, in the opinion of the investigator, to have an effect on hand dermatitis\nProlonged exposure to natural or artificial sources (e.g., UVB, UVA, etc.) of ultraviolet radiation within 30 days prior to the first application of study medication or is intending to have such exposure during the study\nReceived intralesional therapy to the hands (e.g., corticosteroids) within 30 days prior to first application of study medication\nTreated with Grenz ray or soft x-ray therapy to the hands within 6 months of first application of study medication\nTreated with topical hand therapy (e.g., tar, topical corticosteroids, topical retinoids, topical antimicrobials, topical calcineurin inhibitors, Burrow's solution soaks) within 7 days prior to first application of study medication that is known or suspected to have an effect on hand dermatitis\nReceived systemic antibiotics for infections of the hands within 7 days prior to the first application of study medication",
                            "HealthyVolunteers": "No",
                            "Gender": "All",
                            "MinimumAge": "18 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Daniel Piacquadio, MD",
                                        "OverallOfficialAffiliation": "Therapeutics, Inc.",
                                        "OverallOfficialRole": "Study Director"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "Therapeutics Clinical Research",
                                        "LocationCity": "San Diego",
                                        "LocationState": "California",
                                        "LocationZip": "92123",
                                        "LocationCountry": "United States"
                                    },
                                    {
                                        "LocationFacility": "Michigan Center for Skin Care Research",
                                        "LocationCity": "Clinton Township",
                                        "LocationState": "Michigan",
                                        "LocationZip": "48038",
                                        "LocationCountry": "United States"
                                    },
                                    {
                                        "LocationFacility": "DermResearch Inc.",
                                        "LocationCity": "Austin",
                                        "LocationState": "Texas",
                                        "LocationZip": "78759",
                                        "LocationCountry": "United States"
                                    }
                                ]
                            }
                        }
                    },
                    "ResultsSection": {
                        "MoreInfoModule": {}
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000003872",
                                        "ConditionMeshTerm": "Dermatitis"
                                    },
                                    {
                                        "ConditionMeshId": "D000012871",
                                        "ConditionMeshTerm": "Skin Diseases"
                                    },
                                    {
                                        "ConditionMeshId": "D000006229",
                                        "ConditionMeshTerm": "Hand Dermatoses"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M6219",
                                        "ConditionBrowseLeafName": "Dermatitis",
                                        "ConditionBrowseLeafAsFound": "Dermatitis",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M6807",
                                        "ConditionBrowseLeafName": "Eczema",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M14826",
                                        "ConditionBrowseLeafName": "Skin Diseases",
                                        "ConditionBrowseLeafAsFound": "Dermatoses",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M8473",
                                        "ConditionBrowseLeafName": "Hand Dermatoses",
                                        "ConditionBrowseLeafAsFound": "Hand Dermatoses",
                                        "ConditionBrowseLeafRelevance": "high"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC17",
                                        "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionMeshList": {
                                "InterventionMesh": [
                                    {
                                        "InterventionMeshId": "D000014221",
                                        "InterventionMeshTerm": "Triamcinolone"
                                    },
                                    {
                                        "InterventionMeshId": "D000014222",
                                        "InterventionMeshTerm": "Triamcinolone Acetonide"
                                    },
                                    {
                                        "InterventionMeshId": "C000005900",
                                        "InterventionMeshTerm": "Triamcinolone hexacetonide"
                                    },
                                    {
                                        "InterventionMeshId": "C000030262",
                                        "InterventionMeshTerm": "Triamcinolone diacetate"
                                    }
                                ]
                            },
                            "InterventionAncestorList": {
                                "InterventionAncestor": [
                                    {
                                        "InterventionAncestorId": "D000000893",
                                        "InterventionAncestorTerm": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000005938",
                                        "InterventionAncestorTerm": "Glucocorticoids"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006728",
                                        "InterventionAncestorTerm": "Hormones"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006730",
                                        "InterventionAncestorTerm": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045505",
                                        "InterventionAncestorTerm": "Physiological Effects of Drugs"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007166",
                                        "InterventionAncestorTerm": "Immunosuppressive Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007155",
                                        "InterventionAncestorTerm": "Immunologic Factors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000004791",
                                        "InterventionAncestorTerm": "Enzyme Inhibitors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045504",
                                        "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                                    }
                                ]
                            },
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafAsFound": "Deep",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M3369",
                                        "InterventionBrowseLeafName": "Anti-Inflammatory Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8199",
                                        "InterventionBrowseLeafName": "Glucocorticoids",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8941",
                                        "InterventionBrowseLeafName": "Hormones",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8940",
                                        "InterventionBrowseLeafName": "Hormone Antagonists",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9364",
                                        "InterventionBrowseLeafName": "Immunosuppressive Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9353",
                                        "InterventionBrowseLeafName": "Immunologic Factors",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 2,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT04727151",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "TAC01-HER2-03"
                            },
                            "Organization": {
                                "OrgFullName": "Triumvira Immunologics, Inc.",
                                "OrgClass": "INDUSTRY"
                            },
                            "BriefTitle": "TAC T-cells for the Treatment of HER2-positive Solid Tumors",
                            "OfficialTitle": "A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting HER2 in Relapsed or Refractory Solid Tumors",
                            "Acronym": "TACTIC-2"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "April 2022",
                            "OverallStatus": "Recruiting",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "April 19, 2021",
                                "StartDateType": "Actual"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "November 2024",
                                "PrimaryCompletionDateType": "Anticipated"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "February 2025",
                                "CompletionDateType": "Anticipated"
                            },
                            "StudyFirstSubmitDate": "January 20, 2021",
                            "StudyFirstSubmitQCDate": "January 26, 2021",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "January 27, 2021",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "April 27, 2022",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "April 29, 2022",
                                "LastUpdatePostDateType": "Estimate"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Sponsor"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Triumvira Immunologics, Inc.",
                                "LeadSponsorClass": "INDUSTRY"
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "Yes",
                            "IsFDARegulatedDrug": "Yes",
                            "IsFDARegulatedDevice": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "TAC01-HER2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognizes human epidermal growth factor receptor 2 (HER2). TAC directs T-cells to the targeted antigen (HER2), and once engaged with the target, activates them via the endogenous T cell receptor.\n\nThis is an open-label, multicenter Phase 1/2 study that aims to establish safety, Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (RP2D), pharmacokinetic profile and efficacy of TAC01-HER2 in subjects with relapsed or refractory solid tumors.",
                            "DetailedDescription": "Phase I: Dose escalation in any 3+ HER2-positive solid tumor.\n\nPhase II: Dose expansion cohorts: 3+ HER2-positive breast cancer (a) and other solid tumors (b) 2+HER2-positive solid tumors (c)."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "HER2-Positive Solid Tumors"
                                ]
                            },
                            "KeywordList": {
                                "Keyword": [
                                    "HER2-Positive Breast Cancer",
                                    "HER2-Positive Gastric Cancer",
                                    "HER2 Protein Overexpression",
                                    "Solid Tumor",
                                    "HER2"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Phase 1",
                                    "Phase 2"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "N/A",
                                "DesignInterventionModel": "Single Group Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "None (Open Label)"
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "70",
                                "EnrollmentType": "Anticipated"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "TAC01-HER2",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "Lymphodepletion followed by TAC01-HER2 as a single IV infusion.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Biological: TAC01-HER2"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Biological",
                                        "InterventionName": "TAC01-HER2",
                                        "InterventionDescription": "TAC01-HER2, fludarabine, cyclophosphamide.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "TAC01-HER2"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Incidence of Treatment-Emergent Adverse Events",
                                        "PrimaryOutcomeDescription": "Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 5 and American Society for Transplantation and Cellular Therapy (ASTCT) 2018 criteria.",
                                        "PrimaryOutcomeTimeFrame": "24 Months"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "Determine MTD or RP2D",
                                        "SecondaryOutcomeDescription": "Assessed by incidence of Dose-Limiting Toxicities.",
                                        "SecondaryOutcomeTimeFrame": "28-42 Days Post-Treatment"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Determine expansion of TAC01-HER2",
                                        "SecondaryOutcomeDescription": "Assessed by vector copy number.",
                                        "SecondaryOutcomeTimeFrame": "24 Months"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Determine persistence of TAC01-HER2",
                                        "SecondaryOutcomeDescription": "Assessed by vector copy number.",
                                        "SecondaryOutcomeTimeFrame": "24 Months"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Evaluate Overall Response Rate (ORR)",
                                        "SecondaryOutcomeDescription": "Assessed by imaging using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.",
                                        "SecondaryOutcomeTimeFrame": "1, 3, 6, 9, 12, 18 and 24 months"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Evaluate Overall Survival (OS)",
                                        "SecondaryOutcomeDescription": "Defined as the time between the date of TAC01-HER2 infusion and death due to any cause.",
                                        "SecondaryOutcomeTimeFrame": "24 Months"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nAge ≥ 18 years.\nA recent tumor sample to confirm HER2-protein expression on tumor cell surface.\n\nRelapsed or refractory disease after at least two prior lines of therapy.\n\na. For breast cancer patients, both prior lines of therapy must include HER2 targeted agents.\n\nMeasurable disease per RECIST Version 1.1.\nEastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\nLife expectancy of at least 12 weeks.\nAdequate organ function.\n\nExclusion Criteria:\n\nActive inflammatory or neurological disorder, autoimmune disease or infection\nAcute cardiovascular disease",
                            "HealthyVolunteers": "No",
                            "Gender": "All",
                            "MinimumAge": "18 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "CentralContactList": {
                                "CentralContact": [
                                    {
                                        "CentralContactName": "Nathan Ternus",
                                        "CentralContactRole": "Contact",
                                        "CentralContactPhone": "(512) 646-4516",
                                        "CentralContactEMail": "patient.info@triumvira.com"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "University of Chicago",
                                        "LocationStatus": "Recruiting",
                                        "LocationCity": "Chicago",
                                        "LocationState": "Illinois",
                                        "LocationZip": "60637",
                                        "LocationCountry": "United States",
                                        "LocationContactList": {
                                            "LocationContact": [
                                                {
                                                    "LocationContactName": "Brooke Pieke, MS",
                                                    "LocationContactRole": "Contact",
                                                    "LocationContactPhone": "773-834-9636",
                                                    "LocationContactEMail": "cancerclinicaltrials@bsd.uchicago.edu"
                                                },
                                                {
                                                    "LocationContactName": "Andrea Fadel, BSN, RN",
                                                    "LocationContactRole": "Contact",
                                                    "LocationContactPhone": "773-702-4779",
                                                    "LocationContactEMail": "cancerclinicaltrials@bsd.uchicago.edu"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "LocationFacility": "Dana Farber Cancer Institute",
                                        "LocationStatus": "Recruiting",
                                        "LocationCity": "Boston",
                                        "LocationState": "Massachusetts",
                                        "LocationZip": "02215",
                                        "LocationCountry": "United States",
                                        "LocationContactList": {
                                            "LocationContact": [
                                                {
                                                    "LocationContactName": "Riemke Bouvier",
                                                    "LocationContactRole": "Contact",
                                                    "LocationContactPhone": "617-582-8529",
                                                    "LocationContactEMail": "Riemke_Bouvier@dfci.harvard.edu"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "LocationFacility": "Rutgers Cancer Institute of New Jersey",
                                        "LocationStatus": "Recruiting",
                                        "LocationCity": "Newark",
                                        "LocationState": "New Jersey",
                                        "LocationZip": "08901",
                                        "LocationCountry": "United States",
                                        "LocationContactList": {
                                            "LocationContact": [
                                                {
                                                    "LocationContactName": "Kelly Gruber",
                                                    "LocationContactRole": "Contact",
                                                    "LocationContactPhone": "732-258-8453",
                                                    "LocationContactEMail": "Kjg172@cinj.rutgers.edu"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "LocationFacility": "MD Anderson Cancer Center",
                                        "LocationStatus": "Recruiting",
                                        "LocationCity": "Houston",
                                        "LocationState": "Texas",
                                        "LocationZip": "77030",
                                        "LocationCountry": "United States",
                                        "LocationContactList": {
                                            "LocationContact": [
                                                {
                                                    "LocationContactName": "Ecaterina Dumbrava, MD",
                                                    "LocationContactRole": "Contact",
                                                    "LocationContactPhone": "713-792-3934",
                                                    "LocationContactEMail": "eeileana@mdanderson.org"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "LocationFacility": "Princess Margaret Cancer Centre",
                                        "LocationStatus": "Recruiting",
                                        "LocationCity": "Toronto",
                                        "LocationState": "Ontario",
                                        "LocationZip": "M5G 2C1",
                                        "LocationCountry": "Canada",
                                        "LocationContactList": {
                                            "LocationContact": [
                                                {
                                                    "LocationContactName": "Samuel Saibil, MD",
                                                    "LocationContactRole": "Contact",
                                                    "LocationContactPhone": "416-946-4501",
                                                    "LocationContactPhoneExt": "4831",
                                                    "LocationContactEMail": "Sam.Saibil@uhn.ca"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "IPDSharingStatementModule": {
                            "IPDSharing": "No"
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000009369",
                                        "ConditionMeshTerm": "Neoplasms"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M4372",
                                        "ConditionBrowseLeafName": "Breast Neoplasms",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M15216",
                                        "ConditionBrowseLeafName": "Stomach Neoplasms",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "T5486",
                                        "ConditionBrowseLeafName": "Stomach Cancer",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC04",
                                        "ConditionBrowseBranchName": "Neoplasms"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC17",
                                        "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC06",
                                        "ConditionBrowseBranchName": "Digestive System Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "Rare",
                                        "ConditionBrowseBranchName": "Rare Diseases"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M283219",
                                        "InterventionBrowseLeafName": "Fludarabine",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M5879",
                                        "InterventionBrowseLeafName": "Cyclophosphamide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M225481",
                                        "InterventionBrowseLeafName": "Fludarabine phosphate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "ANeo",
                                        "InterventionBrowseBranchName": "Antineoplastic Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "ARhu",
                                        "InterventionBrowseBranchName": "Antirheumatic Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 3,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT03378076",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "FX006-2017-012"
                            },
                            "Organization": {
                                "OrgFullName": "Flexion Therapeutics, Inc.",
                                "OrgClass": "INDUSTRY"
                            },
                            "BriefTitle": "Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA",
                            "OfficialTitle": "A Randomized, Open-label, Parallel Group Study in Patients With Bilateral Knee Osteoarthritis Comparing the Systemic Exposure of Triamcinolone Acetonide Following Administration Into Both Knees of Either Extended-release FX006 or Immediate-release TAcs (Triamcinolone Acetonide Suspension)"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "November 2019",
                            "OverallStatus": "Completed",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "December 6, 2017",
                                "StartDateType": "Actual"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "March 14, 2018",
                                "PrimaryCompletionDateType": "Actual"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "March 14, 2018",
                                "CompletionDateType": "Actual"
                            },
                            "StudyFirstSubmitDate": "December 8, 2017",
                            "StudyFirstSubmitQCDate": "December 17, 2017",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "December 19, 2017",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "ResultsFirstSubmitDate": "March 4, 2019",
                            "ResultsFirstSubmitQCDate": "April 11, 2019",
                            "ResultsFirstPostDateStruct": {
                                "ResultsFirstPostDate": "May 1, 2019",
                                "ResultsFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "November 20, 2019",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "December 5, 2019",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Sponsor"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Flexion Therapeutics, Inc.",
                                "LeadSponsorClass": "INDUSTRY"
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "No",
                            "IsFDARegulatedDrug": "Yes",
                            "IsFDARegulatedDevice": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "This is a randomized, open-label, parallel group study to compare systemic exposure of triamcinolone acetonide following administration into both knees of either FX006 or TAcs.",
                            "DetailedDescription": "This is a randomized, open label, parallel group study that will be conducted in male and female patients ≥ 40 years of age with bilateral knee OA.\n\nApproximately 24 patients will be randomized to one of two treatment groups (1:1) and treated with IA injections to both knees of either:\n\nextended-release FX006 64 mg total dose (approximately 12 patients) or\nimmediate-release TAcs 80 mg total dose (approximately 12 patients) Each patient will be screened to confirm the diagnosis of OA and eligibility based on the inclusion/exclusion requirements and will be randomized to treatment on Day 1. Following screening, pharmacokinetics (PK) and safety will be evaluated at 6 out-patient visits scheduled on Study Days 1 [calendar day of injection], 2, 8, 15, 29, and 43."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Bilateral Knee Osteoarthritis"
                                ]
                            },
                            "KeywordList": {
                                "Keyword": [
                                    "Osteoarthritis",
                                    "Knee",
                                    "Corticosteroid",
                                    "Bilateral",
                                    "Pain",
                                    "Intra-articular",
                                    "Injection"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Phase 2"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "Randomized",
                                "DesignInterventionModel": "Parallel Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "None (Open Label)"
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "24",
                                "EnrollmentType": "Actual"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "FX006 32 mg",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "Two intra-articular (IA) injections of FX006 32 mg (total dose of 64 mg)",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: FX006 32 mg"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "TAcs 40 mg",
                                        "ArmGroupType": "Active Comparator",
                                        "ArmGroupDescription": "Two intra-articular (IA) injections of TAcs 40 mg (total dose of 80 mg)",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: TAcs 40 mg"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "FX006 32 mg",
                                        "InterventionDescription": "Drug: Extended-release 32 mg FX006 IA injection into each knee (total 64 mg dose)",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "FX006 32 mg"
                                            ]
                                        },
                                        "InterventionOtherNameList": {
                                            "InterventionOtherName": [
                                                "Zilretta"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "TAcs 40 mg",
                                        "InterventionDescription": "Drug: Immediate-release 40mg TAcs IA injection into each knee (total 80 mg dose)",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "TAcs 40 mg"
                                            ]
                                        },
                                        "InterventionOtherNameList": {
                                            "InterventionOtherName": [
                                                "Kenalog®-40 Injection",
                                                "Triamcinolone Acetonide Crystalline Suspension (TAcs)",
                                                "TCA-IR 40"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Measure the Concentration of Triamcinolone Acetonide (TA) in Blood Plasma",
                                        "PrimaryOutcomeDescription": "Plasma drug concentrations (pg/mL) by Time Point across FX006 and TAcs treatment arms in plasma.\n\nFor the PK analysis and individual concentration vs. time plots, a concentration that is BLOQ is assigned a value of zero if it occurs in a profile before the first measurable concentration. If a BLOQ value occurs after a measurable concentration in a profile and is followed by a value above the lower limit of quantification, then the BLOQ is treated as missing data. If a BLOQ value occurs at the end of the collection interval (after the last quantifiable concentration) it is set to zero. If two BLOQ values occur in succession after Cmax, the profile is deemed to have terminated at the first BLOQ value and any subsequent concentrations are set to zero for PK calculations",
                                        "PrimaryOutcomeTimeFrame": "43 days"
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "Incidence of Treatment Emergent Adverse Events",
                                        "PrimaryOutcomeDescription": "Safety analyses were conducted using the safety population.\n\nAnalyses of adverse events will be performed for those events that are considered treatment emergent, where treatment emergent is defined as any adverse event with onset after the administration of study medication in the first knee through the end of the study or any event that was present at baseline but worsened in intensity through the end of the study. Severity of Adverse events were graded by the Principal Investigator using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The grading went from Grade 1 (Mild) to Grade 5 (Death related to AE).",
                                        "PrimaryOutcomeTimeFrame": "43 days"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nWritten consent to participate in the study\nMale or female greater than or equal to 40 years of age\nSymptoms consistent with OA in both knees for greater than or equal to 6 months prior to Screening (patient reported is acceptable)\nCurrently meets ACR Criteria (clinical and radiological) for OA in both knees\nKnee pain in both knees for greater than 15 days over the last month (as reported by the patient)\nBody mass index (BMI) less than or equal to 40 kg/m2\nMorning serum cortisol result within normal range at Screening (5-23 mcg/dL or 138-635 nmol/dL)\nAmbulatory and in good general health\nWilling and able to comply with the study procedures and visit schedules and able to follow verbal and written instructions.\nWilling to abstain from use of protocol-restricted medications during the study\n\nExclusion Criteria:\n\nReactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease\nHistory of infection in either knee joint\nClinical signs and symptoms of active knee infection or crystal disease in either knee within 1 month of Screening\nUnstable joint (such as a torn anterior cruciate ligament) in either knee within 12 months of Screening\nPresence of surgical hardware or other foreign body in either knee\nSurgery or arthroscopy of either knee within 12 months of Screening\nIA treatment of any joint with any of the following agents within six (6) months of Screening: any corticosteroid preparation (investigational or marketed, including FX006), any biologic agent (e.g., platelet rich plasma (PRP) injection, stem cells, prolotherapy, amniotic fluid injection; investigational or marketed).\nIA treatment in either knee with hyaluronic acid (investigational or marketed) within 6 months of Screening\nParenteral or oral corticosteroids (investigational or marketed) within 3 months of Screening\nInhaled, intranasal or topical corticosteroids (investigational or marketed) within 2 weeks of Screening\nFemales who are pregnant or nursing or plan to become pregnant during the study; men who plan to conceive during the study",
                            "HealthyVolunteers": "No",
                            "Gender": "All",
                            "MinimumAge": "40 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Scott Kelley, MD",
                                        "OverallOfficialAffiliation": "Flexion Therapeutics, Inc.",
                                        "OverallOfficialRole": "Study Director"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "LA Biomed at Harbor-UCLA Medical Center",
                                        "LocationCity": "Torrance",
                                        "LocationState": "California",
                                        "LocationZip": "90509",
                                        "LocationCountry": "United States"
                                    },
                                    {
                                        "LocationFacility": "Rochester Clinical Research",
                                        "LocationCity": "Rochester",
                                        "LocationState": "New York",
                                        "LocationZip": "14609",
                                        "LocationCountry": "United States"
                                    },
                                    {
                                        "LocationFacility": "Altoona Center for Clinical Research",
                                        "LocationCity": "Duncansville",
                                        "LocationState": "Pennsylvania",
                                        "LocationZip": "16635",
                                        "LocationCountry": "United States"
                                    }
                                ]
                            }
                        },
                        "ReferencesModule": {
                            "ReferenceList": {
                                "Reference": [
                                    {
                                        "ReferencePMID": "31662801",
                                        "ReferenceType": "derived",
                                        "ReferenceCitation": "Kivitz A, Kwong L, Shlotzhauer T, Lufkin J, Cinar A, Kelley S. A randomized, phase IIa study to assess the systemic exposure of triamcinolone acetonide following injection of extended-release triamcinolone acetonide or traditional triamcinolone acetonide into both knees of patients with bilateral knee osteoarthritis. Ther Adv Musculoskelet Dis. 2019 Oct 16;11:1759720X19881309. doi: 10.1177/1759720X19881309. eCollection 2019."
                                    }
                                ]
                            }
                        }
                    },
                    "ResultsSection": {
                        "ParticipantFlowModule": {
                            "FlowGroupList": {
                                "FlowGroup": [
                                    {
                                        "FlowGroupId": "FG000",
                                        "FlowGroupTitle": "FX006 32 mg",
                                        "FlowGroupDescription": "12 subjects received FX006 32 mg as a single 5 mL IA injection into each knee for a total of total 64 mg dose"
                                    },
                                    {
                                        "FlowGroupId": "FG001",
                                        "FlowGroupTitle": "TAcs IR 40 mg",
                                        "FlowGroupDescription": "12 subjects received TAcs 40 mg as a single 5 mL IA injection into each knee for a total 80 mg dose"
                                    }
                                ]
                            },
                            "FlowPeriodList": {
                                "FlowPeriod": [
                                    {
                                        "FlowPeriodTitle": "Overall Study",
                                        "FlowMilestoneList": {
                                            "FlowMilestone": [
                                                {
                                                    "FlowMilestoneType": "STARTED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "12"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG001",
                                                                "FlowAchievementNumSubjects": "12"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowMilestoneType": "COMPLETED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "12"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG001",
                                                                "FlowAchievementNumSubjects": "12"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowMilestoneType": "NOT COMPLETED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "0"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG001",
                                                                "FlowAchievementNumSubjects": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "BaselineCharacteristicsModule": {
                            "BaselineGroupList": {
                                "BaselineGroup": [
                                    {
                                        "BaselineGroupId": "BG000",
                                        "BaselineGroupTitle": "FX006 64 mg",
                                        "BaselineGroupDescription": "Single 5 mL IA injection into each knee"
                                    },
                                    {
                                        "BaselineGroupId": "BG001",
                                        "BaselineGroupTitle": "TAcs IR 80mg",
                                        "BaselineGroupDescription": "Single 5 mL IA injection into each knee"
                                    },
                                    {
                                        "BaselineGroupId": "BG002",
                                        "BaselineGroupTitle": "Total",
                                        "BaselineGroupDescription": "Total of all reporting groups"
                                    }
                                ]
                            },
                            "BaselineDenomList": {
                                "BaselineDenom": [
                                    {
                                        "BaselineDenomUnits": "Participants",
                                        "BaselineDenomCountList": {
                                            "BaselineDenomCount": [
                                                {
                                                    "BaselineDenomCountGroupId": "BG000",
                                                    "BaselineDenomCountValue": "12"
                                                },
                                                {
                                                    "BaselineDenomCountGroupId": "BG001",
                                                    "BaselineDenomCountValue": "12"
                                                },
                                                {
                                                    "BaselineDenomCountGroupId": "BG002",
                                                    "BaselineDenomCountValue": "24"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "BaselineMeasureList": {
                                "BaselineMeasure": [
                                    {
                                        "BaselineMeasureTitle": "Age, Continuous",
                                        "BaselineMeasureParamType": "Mean",
                                        "BaselineMeasureDispersionType": "Standard Deviation",
                                        "BaselineMeasureUnitOfMeasure": "years",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "61.8",
                                                                            "BaselineMeasurementSpread": "6.45"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "61.6",
                                                                            "BaselineMeasurementSpread": "8.17"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "61.7",
                                                                            "BaselineMeasurementSpread": "7.20"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Sex: Female, Male",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineCategoryTitle": "Female",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "10"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "9"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "19"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Male",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "2"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "3"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "5"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Ethnicity (NIH/OMB)",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineCategoryTitle": "Hispanic or Latino",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "2"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "2"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Not Hispanic or Latino",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "10"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "12"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "22"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Unknown or Not Reported",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Race (NIH/OMB)",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineCategoryTitle": "American Indian or Alaska Native",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Asian",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Native Hawaiian or Other Pacific Islander",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Black or African American",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "2"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "2"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "4"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "White",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "10"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "10"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "20"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "More than one race",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Unknown or Not Reported",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Body Mass Index (BMI)",
                                        "BaselineMeasureParamType": "Mean",
                                        "BaselineMeasureDispersionType": "Standard Deviation",
                                        "BaselineMeasureUnitOfMeasure": "kg/m^2",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "33.31",
                                                                            "BaselineMeasurementSpread": "3.669"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "30.35",
                                                                            "BaselineMeasurementSpread": "4.955"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "31.83",
                                                                            "BaselineMeasurementSpread": "4.524"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomeMeasuresModule": {
                            "OutcomeMeasureList": {
                                "OutcomeMeasure": [
                                    {
                                        "OutcomeMeasureType": "Primary",
                                        "OutcomeMeasureTitle": "Measure the Concentration of Triamcinolone Acetonide (TA) in Blood Plasma",
                                        "OutcomeMeasureDescription": "Plasma drug concentrations (pg/mL) by Time Point across FX006 and TAcs treatment arms in plasma.\n\nFor the PK analysis and individual concentration vs. time plots, a concentration that is BLOQ is assigned a value of zero if it occurs in a profile before the first measurable concentration. If a BLOQ value occurs after a measurable concentration in a profile and is followed by a value above the lower limit of quantification, then the BLOQ is treated as missing data. If a BLOQ value occurs at the end of the collection interval (after the last quantifiable concentration) it is set to zero. If two BLOQ values occur in succession after Cmax, the profile is deemed to have terminated at the first BLOQ value and any subsequent concentrations are set to zero for PK calculations",
                                        "OutcomeMeasurePopulationDescription": "All patients who received 2 IA injections (one in each knee) of study drug, completed scheduled sampling, and had sufficient plasma concentration data",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Geometric Mean",
                                        "OutcomeMeasureDispersionType": "95% Confidence Interval",
                                        "OutcomeMeasureUnitOfMeasure": "pg/mL",
                                        "OutcomeMeasureTimeFrame": "43 days",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "FX006 32 mg",
                                                    "OutcomeGroupDescription": "Two 5 mL IA injections (total dose of 64 mg)"
                                                },
                                                {
                                                    "OutcomeGroupId": "OG001",
                                                    "OutcomeGroupTitle": "TAcs 40 mg",
                                                    "OutcomeGroupDescription": "Two 1mL IA injections (total dose of 80 mg)"
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "12"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG001",
                                                                "OutcomeDenomCountValue": "12"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeClassTitle": "Day 1- Hour 1",
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "1801.5",
                                                                            "OutcomeMeasurementLowerLimit": "1261.50",
                                                                            "OutcomeMeasurementUpperLimit": "2572.77"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "4507.9",
                                                                            "OutcomeMeasurementLowerLimit": "1205.43",
                                                                            "OutcomeMeasurementUpperLimit": "16857.74"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Day 1 - Hour 2",
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "1893.6",
                                                                            "OutcomeMeasurementLowerLimit": "1328.58",
                                                                            "OutcomeMeasurementUpperLimit": "2698.84"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "5140.1",
                                                                            "OutcomeMeasurementLowerLimit": "1327.67",
                                                                            "OutcomeMeasurementUpperLimit": "19899.79"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Day 1 - Hour 3",
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "1958.1",
                                                                            "OutcomeMeasurementLowerLimit": "1336.54",
                                                                            "OutcomeMeasurementUpperLimit": "2868.86"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "5443.8",
                                                                            "OutcomeMeasurementLowerLimit": "1357.81",
                                                                            "OutcomeMeasurementUpperLimit": "21825.90"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Day 1 - Hour 4",
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "2013.8",
                                                                            "OutcomeMeasurementLowerLimit": "1381.39",
                                                                            "OutcomeMeasurementUpperLimit": "2935.59"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "5454.2",
                                                                            "OutcomeMeasurementLowerLimit": "1409.98",
                                                                            "OutcomeMeasurementUpperLimit": "21098.36"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Day 1 - Hour 5",
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "1914.4",
                                                                            "OutcomeMeasurementLowerLimit": "1291.93",
                                                                            "OutcomeMeasurementUpperLimit": "2836.82"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "5338.9",
                                                                            "OutcomeMeasurementLowerLimit": "1366.93",
                                                                            "OutcomeMeasurementUpperLimit": "20852.59"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Day 1 - Hour 6",
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "1900.2",
                                                                            "OutcomeMeasurementLowerLimit": "1293.77",
                                                                            "OutcomeMeasurementUpperLimit": "2790.96"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "5430.6",
                                                                            "OutcomeMeasurementLowerLimit": "1442.24",
                                                                            "OutcomeMeasurementUpperLimit": "20448.57"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Day 1 - Hour 8",
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "1928.1",
                                                                            "OutcomeMeasurementLowerLimit": "1288.45",
                                                                            "OutcomeMeasurementUpperLimit": "2885.17"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "5199.0",
                                                                            "OutcomeMeasurementLowerLimit": "1418.52",
                                                                            "OutcomeMeasurementUpperLimit": "19054.80"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Day 1 - Hour 10",
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "1839.8",
                                                                            "OutcomeMeasurementLowerLimit": "1241.72",
                                                                            "OutcomeMeasurementUpperLimit": "2725.96"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "4948.8",
                                                                            "OutcomeMeasurementLowerLimit": "1392.07",
                                                                            "OutcomeMeasurementUpperLimit": "17593.31"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Day 1 - Hour 12",
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "1793.9",
                                                                            "OutcomeMeasurementLowerLimit": "1247.06",
                                                                            "OutcomeMeasurementUpperLimit": "2580.66"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "4507.8",
                                                                            "OutcomeMeasurementLowerLimit": "1294.51",
                                                                            "OutcomeMeasurementUpperLimit": "15697.14"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Day 2 - Hour 24",
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "1948.8",
                                                                            "OutcomeMeasurementLowerLimit": "1349.93",
                                                                            "OutcomeMeasurementUpperLimit": "2813.36"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "4185.4",
                                                                            "OutcomeMeasurementLowerLimit": "1614.39",
                                                                            "OutcomeMeasurementUpperLimit": "10850.75"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Day 8",
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "1397.0",
                                                                            "OutcomeMeasurementLowerLimit": "1073.13",
                                                                            "OutcomeMeasurementUpperLimit": "1818.65"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "450.8",
                                                                            "OutcomeMeasurementLowerLimit": "230.66",
                                                                            "OutcomeMeasurementUpperLimit": "880.92"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Day 15",
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "956.2",
                                                                            "OutcomeMeasurementLowerLimit": "759.23",
                                                                            "OutcomeMeasurementUpperLimit": "1204.25"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "428.7",
                                                                            "OutcomeMeasurementLowerLimit": "231.92",
                                                                            "OutcomeMeasurementUpperLimit": "792.29"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Day 29",
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "445.8",
                                                                            "OutcomeMeasurementLowerLimit": "313.12",
                                                                            "OutcomeMeasurementUpperLimit": "634.80"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "334.6",
                                                                            "OutcomeMeasurementLowerLimit": "182.45",
                                                                            "OutcomeMeasurementUpperLimit": "613.80"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Day 43",
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "265.8",
                                                                            "OutcomeMeasurementLowerLimit": "199.56",
                                                                            "OutcomeMeasurementUpperLimit": "354.03"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "241.0",
                                                                            "OutcomeMeasurementLowerLimit": "119.11",
                                                                            "OutcomeMeasurementUpperLimit": "487.54"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Primary",
                                        "OutcomeMeasureTitle": "Incidence of Treatment Emergent Adverse Events",
                                        "OutcomeMeasureDescription": "Safety analyses were conducted using the safety population.\n\nAnalyses of adverse events will be performed for those events that are considered treatment emergent, where treatment emergent is defined as any adverse event with onset after the administration of study medication in the first knee through the end of the study or any event that was present at baseline but worsened in intensity through the end of the study. Severity of Adverse events were graded by the Principal Investigator using the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The grading went from Grade 1 (Mild) to Grade 5 (Death related to AE).",
                                        "OutcomeMeasurePopulationDescription": "All patients who received study drug (injection in at least one knee).",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Number",
                                        "OutcomeMeasureUnitOfMeasure": "participants",
                                        "OutcomeMeasureTimeFrame": "43 days",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "FX006 32 mg",
                                                    "OutcomeGroupDescription": "Two 5 mL IA injections (total dose of 64 mg)"
                                                },
                                                {
                                                    "OutcomeGroupId": "OG001",
                                                    "OutcomeGroupTitle": "TAcs 40 mg",
                                                    "OutcomeGroupDescription": "Two 1mL IA injections (total dose of 80 mg)"
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "12"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG001",
                                                                "OutcomeDenomCountValue": "12"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeClassTitle": "Patients with TEAE Grade 1",
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "6"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "3"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Patients with TEAE Grade 2",
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "1"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "2"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Patients with TEAE Grade 3",
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "1"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Patients with TEAE Grade 4",
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Patients with TEAE Grade 5",
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "AdverseEventsModule": {
                            "EventsFrequencyThreshold": "0",
                            "EventsTimeFrame": "Adverse Events were collected following IA administration through the final study visit at 43 days.",
                            "EventGroupList": {
                                "EventGroup": [
                                    {
                                        "EventGroupId": "EG000",
                                        "EventGroupTitle": "FX006 32 mg",
                                        "EventGroupDescription": "Two 5 mL intra-articular injection\n\nFX006: Sustained Release Steroid",
                                        "EventGroupDeathsNumAffected": "0",
                                        "EventGroupDeathsNumAtRisk": "12",
                                        "EventGroupSeriousNumAffected": "0",
                                        "EventGroupSeriousNumAtRisk": "12",
                                        "EventGroupOtherNumAffected": "8",
                                        "EventGroupOtherNumAtRisk": "12"
                                    },
                                    {
                                        "EventGroupId": "EG001",
                                        "EventGroupTitle": "TAcs 40 mg",
                                        "EventGroupDescription": "Commercially available triamcinolone acetonide, two 1 mL intra-articular injection\n\nTAcs: Immediate Release Steroid",
                                        "EventGroupDeathsNumAffected": "0",
                                        "EventGroupDeathsNumAtRisk": "12",
                                        "EventGroupSeriousNumAffected": "0",
                                        "EventGroupSeriousNumAtRisk": "12",
                                        "EventGroupOtherNumAffected": "5",
                                        "EventGroupOtherNumAtRisk": "12"
                                    }
                                ]
                            },
                            "OtherEventList": {
                                "OtherEvent": [
                                    {
                                        "OtherEventTerm": "Haemorrhoids",
                                        "OtherEventOrganSystem": "Gastrointestinal disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Vomiting",
                                        "OtherEventOrganSystem": "Gastrointestinal disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Fatigue",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Injection Site Pain",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Vessel Puncture Site Haematoma",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Food Allergy",
                                        "OtherEventOrganSystem": "Immune system disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Bronchitis",
                                        "OtherEventOrganSystem": "Infections and infestations",
                                        "OtherEventSourceVocabulary": "MedDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Nasopharyngitis",
                                        "OtherEventOrganSystem": "Infections and infestations",
                                        "OtherEventSourceVocabulary": "MedDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Sinusitis",
                                        "OtherEventOrganSystem": "Infections and infestations",
                                        "OtherEventSourceVocabulary": "MedDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Neutrophil Count Decreased",
                                        "OtherEventOrganSystem": "Investigations",
                                        "OtherEventSourceVocabulary": "MedDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "White Blood Cell Count Decreased",
                                        "OtherEventOrganSystem": "Investigations",
                                        "OtherEventSourceVocabulary": "MedDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Arthralgia",
                                        "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Back Pain",
                                        "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Fibromyalgia",
                                        "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Joint Swelling",
                                        "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Headache",
                                        "OtherEventOrganSystem": "Nervous system disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Oropharyngeal Pain",
                                        "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Rhinorrhoea",
                                        "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Hot Flush",
                                        "OtherEventOrganSystem": "Vascular disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "MoreInfoModule": {
                            "CertainAgreement": {
                                "AgreementPISponsorEmployee": "No",
                                "AgreementRestrictiveAgreement": "Yes"
                            },
                            "PointOfContact": {
                                "PointOfContactTitle": "Scott Kelley, Chief Medical Officer",
                                "PointOfContactOrganization": "Flexion Therapeutics",
                                "PointOfContactEMail": "skelley@flexiontherapeutics.com",
                                "PointOfContactPhone": "781-305-7142"
                            }
                        }
                    },
                    "DocumentSection": {
                        "LargeDocumentModule": {
                            "LargeDocList": {
                                "LargeDoc": [
                                    {
                                        "LargeDocTypeAbbrev": "Prot",
                                        "LargeDocHasProtocol": "Yes",
                                        "LargeDocHasSAP": "No",
                                        "LargeDocHasICF": "No",
                                        "LargeDocLabel": "Study Protocol",
                                        "LargeDocDate": "November 10, 2017",
                                        "LargeDocUploadDate": "01/03/2019 14:38",
                                        "LargeDocFilename": "Prot_000.pdf"
                                    },
                                    {
                                        "LargeDocTypeAbbrev": "SAP",
                                        "LargeDocHasProtocol": "No",
                                        "LargeDocHasSAP": "Yes",
                                        "LargeDocHasICF": "No",
                                        "LargeDocLabel": "Statistical Analysis Plan",
                                        "LargeDocDate": "March 8, 2018",
                                        "LargeDocUploadDate": "01/03/2019 14:39",
                                        "LargeDocFilename": "SAP_001.pdf"
                                    }
                                ]
                            }
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000010003",
                                        "ConditionMeshTerm": "Osteoarthritis"
                                    },
                                    {
                                        "ConditionMeshId": "D000020370",
                                        "ConditionMeshTerm": "Osteoarthritis, Knee"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000001168",
                                        "ConditionAncestorTerm": "Arthritis"
                                    },
                                    {
                                        "ConditionAncestorId": "D000007592",
                                        "ConditionAncestorTerm": "Joint Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009140",
                                        "ConditionAncestorTerm": "Musculoskeletal Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000012216",
                                        "ConditionAncestorTerm": "Rheumatic Diseases"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M12078",
                                        "ConditionBrowseLeafName": "Osteoarthritis",
                                        "ConditionBrowseLeafAsFound": "Osteoarthritis",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M21321",
                                        "ConditionBrowseLeafName": "Osteoarthritis, Knee",
                                        "ConditionBrowseLeafAsFound": "Knee Osteoarthritis",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M12218",
                                        "ConditionBrowseLeafName": "Pain",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M3628",
                                        "ConditionBrowseLeafName": "Arthritis",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M9773",
                                        "ConditionBrowseLeafName": "Joint Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M11249",
                                        "ConditionBrowseLeafName": "Musculoskeletal Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M14197",
                                        "ConditionBrowseLeafName": "Rheumatic Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M5475",
                                        "ConditionBrowseLeafName": "Collagen Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC05",
                                        "ConditionBrowseBranchName": "Musculoskeletal Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC23",
                                        "ConditionBrowseBranchName": "Symptoms and General Pathology"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC17",
                                        "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionMeshList": {
                                "InterventionMesh": [
                                    {
                                        "InterventionMeshId": "D000014221",
                                        "InterventionMeshTerm": "Triamcinolone"
                                    },
                                    {
                                        "InterventionMeshId": "D000014222",
                                        "InterventionMeshTerm": "Triamcinolone Acetonide"
                                    },
                                    {
                                        "InterventionMeshId": "C000005900",
                                        "InterventionMeshTerm": "Triamcinolone hexacetonide"
                                    },
                                    {
                                        "InterventionMeshId": "C000631825",
                                        "InterventionMeshTerm": "FX006"
                                    },
                                    {
                                        "InterventionMeshId": "C000030262",
                                        "InterventionMeshTerm": "Triamcinolone diacetate"
                                    }
                                ]
                            },
                            "InterventionAncestorList": {
                                "InterventionAncestor": [
                                    {
                                        "InterventionAncestorId": "D000000893",
                                        "InterventionAncestorTerm": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000005938",
                                        "InterventionAncestorTerm": "Glucocorticoids"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006728",
                                        "InterventionAncestorTerm": "Hormones"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006730",
                                        "InterventionAncestorTerm": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045505",
                                        "InterventionAncestorTerm": "Physiological Effects of Drugs"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007166",
                                        "InterventionAncestorTerm": "Immunosuppressive Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007155",
                                        "InterventionAncestorTerm": "Immunologic Factors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000004791",
                                        "InterventionAncestorTerm": "Enzyme Inhibitors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045504",
                                        "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                                    }
                                ]
                            },
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafAsFound": "Deep",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M270065",
                                        "InterventionBrowseLeafName": "FX006",
                                        "InterventionBrowseLeafAsFound": "Stage III colon cancer",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M3369",
                                        "InterventionBrowseLeafName": "Anti-Inflammatory Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8199",
                                        "InterventionBrowseLeafName": "Glucocorticoids",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8941",
                                        "InterventionBrowseLeafName": "Hormones",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8940",
                                        "InterventionBrowseLeafName": "Hormone Antagonists",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9364",
                                        "InterventionBrowseLeafName": "Immunosuppressive Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9353",
                                        "InterventionBrowseLeafName": "Immunologic Factors",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 4,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT00077142",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "ID01-007"
                            },
                            "SecondaryIdInfoList": {
                                "SecondaryIdInfo": [
                                    {
                                        "SecondaryId": "P30CA016672",
                                        "SecondaryIdType": "U.S. NIH Grant/Contract",
                                        "SecondaryIdLink": "https://reporter.nih.gov/quickSearch/P30CA016672"
                                    },
                                    {
                                        "SecondaryId": "MDA-ID-01007",
                                        "SecondaryIdType": "Other Identifier",
                                        "SecondaryIdDomain": "UT MD Anderson Cancer Center"
                                    },
                                    {
                                        "SecondaryId": "TAIHO-TAC101"
                                    },
                                    {
                                        "SecondaryId": "NCI-1528"
                                    },
                                    {
                                        "SecondaryId": "CDR0000349508",
                                        "SecondaryIdType": "Registry Identifier",
                                        "SecondaryIdDomain": "NCI PDQ"
                                    }
                                ]
                            },
                            "Organization": {
                                "OrgFullName": "M.D. Anderson Cancer Center",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)",
                            "OfficialTitle": "Phase I/II Dose Escalation, Pharmacokinetic, Safety, and Efficacy Study of Oral TAC-101 in Patients With Advanced Hepatocellular Carcinoma"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "October 2018",
                            "OverallStatus": "Completed",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "April 2001"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "July 2005",
                                "PrimaryCompletionDateType": "Actual"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "August 2005",
                                "CompletionDateType": "Actual"
                            },
                            "StudyFirstSubmitDate": "February 10, 2004",
                            "StudyFirstSubmitQCDate": "February 10, 2004",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "February 11, 2004",
                                "StudyFirstPostDateType": "Estimate"
                            },
                            "LastUpdateSubmitDate": "October 30, 2018",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "October 31, 2018",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Sponsor"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "M.D. Anderson Cancer Center",
                                "LeadSponsorClass": "OTHER"
                            },
                            "CollaboratorList": {
                                "Collaborator": [
                                    {
                                        "CollaboratorName": "National Cancer Institute (NCI)",
                                        "CollaboratorClass": "NIH"
                                    },
                                    {
                                        "CollaboratorName": "Taiho Pharmaceutical Co., Ltd.",
                                        "CollaboratorClass": "INDUSTRY"
                                    }
                                ]
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "RATIONALE: TAC-101 may stop the growth of cancer by stopping blood flow to the tumor.\n\nPURPOSE: This phase I/II trial is studying the side effects and best dose of TAC-101 and to see how well it works in treating patients with advanced hepatocellular carcinoma (liver cancer).",
                            "DetailedDescription": "OBJECTIVES:\n\nPhase I\n\nPrimary\n\nDetermine the maximum tolerated dose (MTD) of TAC-101 in patients with advanced hepatocellular carcinoma.\nDetermine the safety of 2 consecutive courses of this drug in these patients.\nDetermine the pharmacokinetics of this drug in these patients.\nDetermine the toxic and adverse effects profile of this drug in these patients.\n\nPhase II\n\nPrimary\n\nDetermine the objective antitumor response rate in patients treated with this drug at the MTD.\n\nSecondary\n\nDetermine the overall survival time of patients treated with this drug.\nDetermine the time to disease progression in patients treated with this drug.\nDetermine the duration of observed objective response, using WHO criteria and measurements of serum alpha-fetoprotein concentrations, in patients treated with this drug.\nDetermine the time to treatment failure in patients treated with this drug.\nDetermine the safety and tolerability of intermittent treatment with this drug in these patients.\n\nOUTLINE: This is an open-label, dose-escalation study.\n\nPhase I: Patients receive oral TAC-101 once daily on days 1-14. Treatment repeats every 21 days for 2 courses in the absence of disease progression or unacceptable toxicity.\n\nCohorts of 6 patients receive escalating doses of TAC-101 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.\n\nPhase II: Patients receive oral TAC-101 at the MTD (determined in phase I) once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nPatients are followed at 35-60 days.\n\nPROJECTED ACCRUAL: A total of 6-18 patients for the phase I portion and 21-41 patients for the phase II portion will be accrued for this study."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Liver Cancer"
                                ]
                            },
                            "KeywordList": {
                                "Keyword": [
                                    "advanced adult primary liver cancer",
                                    "recurrent adult primary liver cancer",
                                    "adult primary hepatocellular carcinoma",
                                    "localized unresectable adult primary liver cancer",
                                    "Oral TAC-101"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Phase 1",
                                    "Phase 2"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "Non-Randomized",
                                "DesignInterventionModel": "Single Group Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "None (Open Label)"
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "37",
                                "EnrollmentType": "Actual"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "TAC-101",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "Oral TAC-101 daily Days 1-14, repeats every 21 days for 2 courses.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: TAC-101"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "TAC-101",
                                        "InterventionDescription": "Once daily by mouth on days 1-14, repeat every 21 days for 2 courses.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "TAC-101"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Maximum Tolerated Dose (MTD) of TAC-101",
                                        "PrimaryOutcomeTimeFrame": "60 Days"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "DISEASE CHARACTERISTICS:\n\nHistologically or cytologically confirmed hepatocellular carcinoma\nAt least 1 previously unirradiated, bidimensionally measurable lesion greater than 20 mm by MRI or conventional CT scan OR at least 10 mm by spiral CT scan\nPatients with CNS involvement must have completed appropriate treatment and have no progressive neurologic deficits within the past 28 days\nNo carcinomatous meningitis\n\nPATIENT CHARACTERISTICS:\n\nAge\n\n18 to 80\n\nPerformance status\n\nECOG 0-2\n\nLife expectancy\n\nMore than 12 weeks\n\nHematopoietic\n\nHemoglobin ≥ 10.0 g/dL\nWBC ≥ 2,000/mm^3\nAbsolute neutrophil count ≥ 1,000/mm^3\nPlatelet count ≥ 40,000/mm^3\nNo abnormal bleeding or clotting\n\nHepatic\n\nNo grade C Child-Pugh cirrhosis\nAST and ALT ≤ 2.5 times upper limit of normal (ULN)\nAlbumin ≥ 2.8 g/dL\nINR ≤ 1.5 times ULN\nBilirubin ≤ 2.0 mg/dL\n\nRenal\n\nCreatinine ≤ 1.5 times ULN\n\nCardiovascular\n\nNo prior deep vein thrombosis\nNo prior superficial venous thrombosis\nNo family history of thromboembolism in a first-degree relative\nNo lower extremity thromboses by Doppler ultrasound (unless a subsequent venous angiography confirms a false positive ultrasound)\n\nPulmonary\n\nNo prior pulmonary embolism\n\nOther\n\nNot pregnant or nursing\nNegative pregnancy test\nFertile patients must use effective contraception, except oral contraceptives containing estrogen\nFasting triglycerides ≤ 400 mg/dL for men or ≤ 325 mg/dL for women\nNo other malignancy within the past 3 years except inactive nonmelanoma skin cancer or carcinoma in situ of the cervix\nNo uncontrolled metabolic disorders, other nonmalignant organ or systemic disease, or secondary effects of cancer that induce a high medical risk\nNo known allergy or hypersensitivity to TAC-101 or its components\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\nNo prior thalidomide\nNo prior putative antiangiogenesis therapy\nPrior interferon allowed\n\nChemotherapy\n\nNo more than 2 prior chemotherapy regimens\n\nEndocrine therapy\n\nNo concurrent estrogen products\n\nRadiotherapy\n\nSee Disease Characteristics\nMore than 21 days since prior radiotherapy, except small portal radiotherapy used for the palliation of isolated, symptomatic, osseous metastases\nNo prior radiotherapy to evaluable lesions\nNo concurrent radiotherapy unless for bone pain that is present before beginning study\n\nSurgery\n\nNot specified\n\nOther\n\nPrior anticancer treatment allowed provided there is clear evidence of progressive disease after the most recent treatment\nMore than 21 days since prior anticancer therapy and recovered\nNo more than 2 prior treatment regimens\n\nNo concurrent therapeutic anticoagulants\n\nConcurrent low-dose warfarin for prophylactic care of indwelling venous access devices allowed\nNo concurrent azoles or tetracyclines\nNo concurrent medications known or suspected to increase risk of venous thromboembolism\nNo other concurrent retinoids",
                            "HealthyVolunteers": "No",
                            "Gender": "All",
                            "MinimumAge": "18 Years",
                            "MaximumAge": "80 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Melanie B. Thomas, MD",
                                        "OverallOfficialAffiliation": "M.D. Anderson Cancer Center",
                                        "OverallOfficialRole": "Study Chair"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "MD Anderson Cancer Center at University of Texas",
                                        "LocationCity": "Houston",
                                        "LocationState": "Texas",
                                        "LocationZip": "77030-4009",
                                        "LocationCountry": "United States"
                                    }
                                ]
                            }
                        },
                        "ReferencesModule": {
                            "ReferenceList": {
                                "Reference": [
                                    {
                                        "ReferencePMID": "18504614",
                                        "ReferenceType": "result",
                                        "ReferenceCitation": "Higginbotham KB, Lozano R, Brown T, Patt YZ, Arima T, Abbruzzese JL, Thomas MB. A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma. J Cancer Res Clin Oncol. 2008 Dec;134(12):1325-35. doi: 10.1007/s00432-008-0406-2. Epub 2008 May 27."
                                    }
                                ]
                            },
                            "SeeAlsoLinkList": {
                                "SeeAlsoLink": [
                                    {
                                        "SeeAlsoLinkLabel": "UT MD Anderson Cancer Center website",
                                        "SeeAlsoLinkURL": "http://www.mdanderson.org"
                                    }
                                ]
                            }
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000002277",
                                        "ConditionMeshTerm": "Carcinoma"
                                    },
                                    {
                                        "ConditionMeshId": "D000006528",
                                        "ConditionMeshTerm": "Carcinoma, Hepatocellular"
                                    },
                                    {
                                        "ConditionMeshId": "D000008113",
                                        "ConditionMeshTerm": "Liver Neoplasms"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000009375",
                                        "ConditionAncestorTerm": "Neoplasms, Glandular and Epithelial"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009370",
                                        "ConditionAncestorTerm": "Neoplasms by Histologic Type"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009369",
                                        "ConditionAncestorTerm": "Neoplasms"
                                    },
                                    {
                                        "ConditionAncestorId": "D000000230",
                                        "ConditionAncestorTerm": "Adenocarcinoma"
                                    },
                                    {
                                        "ConditionAncestorId": "D000004067",
                                        "ConditionAncestorTerm": "Digestive System Neoplasms"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009371",
                                        "ConditionAncestorTerm": "Neoplasms by Site"
                                    },
                                    {
                                        "ConditionAncestorId": "D000004066",
                                        "ConditionAncestorTerm": "Digestive System Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000008107",
                                        "ConditionAncestorTerm": "Liver Diseases"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M10265",
                                        "ConditionBrowseLeafName": "Liver Neoplasms",
                                        "ConditionBrowseLeafAsFound": "Liver Cancer",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M4686",
                                        "ConditionBrowseLeafName": "Carcinoma",
                                        "ConditionBrowseLeafAsFound": "Carcinoma",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M8765",
                                        "ConditionBrowseLeafName": "Carcinoma, Hepatocellular",
                                        "ConditionBrowseLeafAsFound": "Hepatocellular Carcinoma",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M11472",
                                        "ConditionBrowseLeafName": "Neoplasms, Glandular and Epithelial",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M11467",
                                        "ConditionBrowseLeafName": "Neoplasms by Histologic Type",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M2737",
                                        "ConditionBrowseLeafName": "Adenocarcinoma",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M8038",
                                        "ConditionBrowseLeafName": "Gastrointestinal Neoplasms",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M6408",
                                        "ConditionBrowseLeafName": "Digestive System Neoplasms",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M8035",
                                        "ConditionBrowseLeafName": "Gastrointestinal Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M6407",
                                        "ConditionBrowseLeafName": "Digestive System Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M10259",
                                        "ConditionBrowseLeafName": "Liver Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "T4700",
                                        "ConditionBrowseLeafName": "Primary Liver Cancer",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC04",
                                        "ConditionBrowseBranchName": "Neoplasms"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC06",
                                        "ConditionBrowseBranchName": "Digestive System Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "Rare",
                                        "ConditionBrowseBranchName": "Rare Diseases"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M10262",
                                        "InterventionBrowseLeafName": "Liver Extracts",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "Hemat",
                                        "InterventionBrowseBranchName": "Hematinics"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 5,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT04515433",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "NP3847"
                            },
                            "Organization": {
                                "OrgFullName": "Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Gamma tACS in Alzheimer's Disease",
                            "OfficialTitle": "Interventional Cross-over Study to Evaluate the Efficacy on Cognitive Performance of Alternating Current Brain Stimulation (tACS) in Patients Suffering From Neurodegenerative Diseases",
                            "Acronym": "GammAD"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "March 2021",
                            "OverallStatus": "Completed",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "August 20, 2020",
                                "StartDateType": "Actual"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "September 30, 2020",
                                "PrimaryCompletionDateType": "Actual"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "September 30, 2020",
                                "CompletionDateType": "Actual"
                            },
                            "StudyFirstSubmitDate": "August 11, 2020",
                            "StudyFirstSubmitQCDate": "August 14, 2020",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "August 17, 2020",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "March 17, 2021",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "March 19, 2021",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Principal Investigator",
                                "ResponsiblePartyInvestigatorFullName": "Barbara Borroni",
                                "ResponsiblePartyInvestigatorTitle": "Professor",
                                "ResponsiblePartyInvestigatorAffiliation": "Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia",
                                "LeadSponsorClass": "OTHER"
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "No",
                            "IsFDARegulatedDrug": "No",
                            "IsFDARegulatedDevice": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "Brain oscillations are ubiquitous in the human brain and have been implicated in cognitive and behavioral states defined in precisely tuned neural networks. In neurodegenerative disorders, neurodegeneration is accompanied by changes in oscillatory activity leading to the emerging concept of neurological and psychiatric disorders as \"oscillopathies\". Alzheimer's disease, which accounts for the vast majority of age-related dementias, is characterised by a prominent disruption of oscillations in the gamma frequency band. The restoration of gamma oscillations by neural entrainment in animal models of Alzheimer's disease have shown a remarkable decrease in the pathological burden of amyloid and tau via increased microglial activity, resulting in a significant increase of cognitive performances.\n\nTranscranial alternating current brain stimulation (tACS), is a neurophysiological method of non-invasive modulation of the excitability of the central nervous system that is having an increasingly numerous spectrum of potential therapeutic applications. Recent studies have demonstrated the effectiveness of this method in modulating the natural frequencies of cerebral oscillation, underlying multiple cognitive processes such as verbal memory, perception and working memory.\n\nOn the basis of these premises, the treatment with gamma tACS is proposed in patients affected by Alzheimer's disease.\n\nIn this randomized, double-blind, sham-controlled, cross-over study, the investigators will evaluate whether a single stimulation with gamma tACS on the posterior parietal cortex can improve symptoms in patients with Mild Cognitive Impairment due to Alzheimer's disease.",
                            "DetailedDescription": "Brain oscillations are ubiquitous in the human brain and have been implicated in cognitive and behavioral states defined in precisely tuned neural networks. In neurodegenerative disorders, neurodegeneration is accompanied by changes in oscillatory activity leading to the emerging concept of neurological and psychiatric disorders as \"oscillopathies\". Alzheimer's disease, which accounts for the vast majority of age-related dementias, is characterised by a prominent disruption of oscillations in the gamma frequency band. The restoration of gamma oscillations by neural entrainment in animal models of Alzheimer's disease have shown a remarkable decrease in the pathological burden of amyloid and tau via increased microglial activity, resulting in a significant increase of cognitive performances.\n\nTranscranial alternating current brain stimulation (tACS), is a neurophysiological method of non-invasive modulation of the excitability of the central nervous system that is having an increasingly numerous spectrum of potential therapeutic applications. Recent studies have demonstrated the effectiveness of this method in modulating the natural frequencies of cerebral oscillation, underlying multiple cognitive processes such as verbal memory, perception and working memory.\n\nOn the basis of these premises, the treatment with gamma tACS is proposed in patients affected by Alzheimer's disease.\n\nIn this randomized, double-blind, sham-controlled, cross-over study, the investigators will evaluate whether a single stimulation with gamma tACS on the posterior parietal cortex can improve symptoms in patients with Mild Cognitive Impairment due to Alzheimer's disease.\n\nSubjects will be randomized in two groups, one receiving a single treatment with gamma tACS (40 Hz) first and the other receiving sham stimulation. After one week the treatments will be exchanged. Patients will be evaluated with neuropsychological tests and neurophysiological measures of cholinergic transmission."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Alzheimer Disease"
                                ]
                            },
                            "KeywordList": {
                                "Keyword": [
                                    "Alzheimer's disease",
                                    "transcranial Alternating Current Stimulation",
                                    "tACS",
                                    "Gamma stimulation"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Not Applicable"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "Randomized",
                                "DesignInterventionModel": "Crossover Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "Quadruple",
                                    "DesignWhoMaskedList": {
                                        "DesignWhoMasked": [
                                            "Participant",
                                            "Care Provider",
                                            "Investigator",
                                            "Outcomes Assessor"
                                        ]
                                    }
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "20",
                                "EnrollmentType": "Actual"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "real tACS",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "Single session of gamma tACS (40 Hz) at 3 mA over the superior parietal cortex (Precuneus)",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: Gamma tACS (40 Hz) over the superior parietal cortex"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "sham tACS",
                                        "ArmGroupType": "Placebo Comparator",
                                        "ArmGroupDescription": "Single session of sham tACS over the superior parietal cortex (Precuneus)",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: Gamma tACS (40 Hz) over the superior parietal cortex"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "Gamma tACS (40 Hz) over the superior parietal cortex",
                                        "InterventionDescription": "Single session of gamma tACS (40 Hz) over the superior parietal cortex",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "real tACS",
                                                "sham tACS"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Changes in Rey Auditory Verbal Learning Test scores",
                                        "PrimaryOutcomeDescription": "Participants are given a list of 15 unrelated words repeated over five different trials and are asked to repeat. Another list of 15 unrelated words are given and the patient must again repeat the original list of 15 words and then again after 30 minutes.\n\nThe score ranges from 0 (worse performance) to 15 (best performance).",
                                        "PrimaryOutcomeTimeFrame": "Baseline (immediately before the intervention) - Immediately after the intervention"
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "Changes in Face-Name Associative Memory Test scores",
                                        "PrimaryOutcomeDescription": "The Face-Name Associative Memory Test is a cross-modal associative memory test, it includes 20 face-name pairs. The administration procedure starts with the presentation of 20 faces with each name and participants should read the name underneath the faces and try to learn each face-name pair. After 5 minutes, the faces are shown one by one and participants are asked to recall the associated names from 4 different names. The correct number of pairs recalled is recorded.\n\nThe score ranges from 0 (worse performance) to 20 (best performance).",
                                        "PrimaryOutcomeTimeFrame": "During the intervention"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "Change in SAI measurements",
                                        "SecondaryOutcomeDescription": "By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of gamma tACS on short latency afferent inhibition (SAI), which is a marker of cholinergic transmission.",
                                        "SecondaryOutcomeTimeFrame": "Baseline (immediately before the intervention) - Immediately after the intervention"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\n- Mild Cognitive Impairment due to Alzheimer's disease (according to Albert et al., Alzheimers Dement 2011).\n\nExclusion Criteria:\n\nCerebrovascular disorders, previous stroke, hydrocephalus, and intra-cranial mass documented by MRI.\nHistory of traumatic brain injury or other neurological diseases.\nSerious medical illness other than FTD\nHistory of seizures\nPregnancy\nMetal implants in the head (except dental fillings)\nElectronic implants (i.e. pace-maker, implanted medical pump)\nAge <18 years",
                            "HealthyVolunteers": "No",
                            "Gender": "All",
                            "MinimumAge": "18 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Barbara Borroni, MD",
                                        "OverallOfficialAffiliation": "Azienda Ospedaliera Spedali Civili, Brescia",
                                        "OverallOfficialRole": "Principal Investigator"
                                    },
                                    {
                                        "OverallOfficialName": "Alberto Benussi, MD",
                                        "OverallOfficialAffiliation": "Azienda Ospedaliera Spedali Civili, Brescia",
                                        "OverallOfficialRole": "Principal Investigator"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "AO Spedali Civili",
                                        "LocationCity": "Brescia",
                                        "LocationState": "BS",
                                        "LocationZip": "25100",
                                        "LocationCountry": "Italy"
                                    }
                                ]
                            }
                        },
                        "ReferencesModule": {
                            "ReferenceList": {
                                "Reference": [
                                    {
                                        "ReferencePMID": "19400723",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Fries P. Neuronal gamma-band synchronization as a fundamental process in cortical computation. Annu Rev Neurosci. 2009;32:209-24. doi: 10.1146/annurev.neuro.051508.135603. Review."
                                    },
                                    {
                                        "ReferencePMID": "27929004",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Iaccarino HF, Singer AC, Martorell AJ, Rudenko A, Gao F, Gillingham TZ, Mathys H, Seo J, Kritskiy O, Abdurrob F, Adaikkan C, Canter RG, Rueda R, Brown EN, Boyden ES, Tsai LH. Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature. 2016 Dec 7;540(7632):230-235. doi: 10.1038/nature20587. Erratum in: Nature. 2018 Oct;562(7725):E1."
                                    },
                                    {
                                        "ReferencePMID": "31076275",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Adaikkan C, Middleton SJ, Marco A, Pao PC, Mathys H, Kim DN, Gao F, Young JZ, Suk HJ, Boyden ES, McHugh TJ, Tsai LH. Gamma Entrainment Binds Higher-Order Brain Regions and Offers Neuroprotection. Neuron. 2019 Jun 5;102(5):929-943.e8. doi: 10.1016/j.neuron.2019.04.011. Epub 2019 May 7."
                                    },
                                    {
                                        "ReferencePMID": "30879788",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Martorell AJ, Paulson AL, Suk HJ, Abdurrob F, Drummond GT, Guan W, Young JZ, Kim DN, Kritskiy O, Barker SJ, Mangena V, Prince SM, Brown EN, Chung K, Boyden ES, Singer AC, Tsai LH. Multi-sensory Gamma Stimulation Ameliorates Alzheimer's-Associated Pathology and Improves Cognition. Cell. 2019 Apr 4;177(2):256-271.e22. doi: 10.1016/j.cell.2019.02.014. Epub 2019 Mar 14."
                                    },
                                    {
                                        "ReferencePMID": "23785325",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Herrmann CS, Rach S, Neuling T, Strüber D. Transcranial alternating current stimulation: a review of the underlying mechanisms and modulation of cognitive processes. Front Hum Neurosci. 2013 Jun 14;7:279. doi: 10.3389/fnhum.2013.00279. eCollection 2013."
                                    }
                                ]
                            }
                        },
                        "IPDSharingStatementModule": {
                            "IPDSharing": "Yes",
                            "IPDSharingDescription": "All data, including outcome measure results, study protocol and statistical analysis plan, will be shared upon reasonable request.",
                            "IPDSharingInfoTypeList": {
                                "IPDSharingInfoType": [
                                    "Study Protocol",
                                    "Statistical Analysis Plan (SAP)"
                                ]
                            },
                            "IPDSharingTimeFrame": "Data will be shared after the study completion indefinitely.",
                            "IPDSharingAccessCriteria": "Reasonable request"
                        }
                    },
                    "DocumentSection": {
                        "LargeDocumentModule": {
                            "LargeDocList": {
                                "LargeDoc": [
                                    {
                                        "LargeDocTypeAbbrev": "Prot_SAP",
                                        "LargeDocHasProtocol": "Yes",
                                        "LargeDocHasSAP": "Yes",
                                        "LargeDocHasICF": "No",
                                        "LargeDocLabel": "Study Protocol and Statistical Analysis Plan",
                                        "LargeDocDate": "December 17, 2019",
                                        "LargeDocUploadDate": "08/11/2020 12:54",
                                        "LargeDocFilename": "Prot_SAP_000.pdf"
                                    }
                                ]
                            }
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000000544",
                                        "ConditionMeshTerm": "Alzheimer Disease"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000003704",
                                        "ConditionAncestorTerm": "Dementia"
                                    },
                                    {
                                        "ConditionAncestorId": "D000001927",
                                        "ConditionAncestorTerm": "Brain Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000002493",
                                        "ConditionAncestorTerm": "Central Nervous System Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009422",
                                        "ConditionAncestorTerm": "Nervous System Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000024801",
                                        "ConditionAncestorTerm": "Tauopathies"
                                    },
                                    {
                                        "ConditionAncestorId": "D000019636",
                                        "ConditionAncestorTerm": "Neurodegenerative Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000019965",
                                        "ConditionAncestorTerm": "Neurocognitive Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000001523",
                                        "ConditionAncestorTerm": "Mental Disorders"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M20711",
                                        "ConditionBrowseLeafName": "Neurodegenerative Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M3037",
                                        "ConditionBrowseLeafName": "Alzheimer Disease",
                                        "ConditionBrowseLeafAsFound": "Alzheimer's Disease",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M6056",
                                        "ConditionBrowseLeafName": "Dementia",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M4356",
                                        "ConditionBrowseLeafName": "Brain Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M4894",
                                        "ConditionBrowseLeafName": "Central Nervous System Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M22155",
                                        "ConditionBrowseLeafName": "Tauopathies",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M20989",
                                        "ConditionBrowseLeafName": "Neurocognitive Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M3967",
                                        "ConditionBrowseLeafName": "Mental Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M13625",
                                        "ConditionBrowseLeafName": "Psychotic Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "T2192",
                                        "ConditionBrowseLeafName": "Familial Alzheimer Disease",
                                        "ConditionBrowseLeafAsFound": "Alzheimer's Disease",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "T4202",
                                        "ConditionBrowseLeafName": "Oculocerebral Syndrome With Hypopigmentation",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC10",
                                        "ConditionBrowseBranchName": "Nervous System Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BXM",
                                        "ConditionBrowseBranchName": "Behaviors and Mental Disorders"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "Rare",
                                        "ConditionBrowseBranchName": "Rare Diseases"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 6,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT03382262",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "FX006-2017-013"
                            },
                            "Organization": {
                                "OrgFullName": "Flexion Therapeutics, Inc.",
                                "OrgClass": "INDUSTRY"
                            },
                            "BriefTitle": "Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip",
                            "OfficialTitle": "A Randomized, Open-label Study Comparing the Systemic Exposure to Triamcinolone Acetonide Following a Single Intra-articular Dose of Extended-release FX006 or Immediate-release TAcs (Triamcinolone Acetonide Suspension) in Patients With Osteoarthritis of the Shoulder (Glenohumeral Joint) or Hip"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "November 2019",
                            "OverallStatus": "Completed",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "December 18, 2017",
                                "StartDateType": "Actual"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "October 9, 2018",
                                "PrimaryCompletionDateType": "Actual"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "October 9, 2018",
                                "CompletionDateType": "Actual"
                            },
                            "StudyFirstSubmitDate": "December 6, 2017",
                            "StudyFirstSubmitQCDate": "December 18, 2017",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "December 22, 2017",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "ResultsFirstSubmitDate": "October 4, 2019",
                            "ResultsFirstSubmitQCDate": "November 20, 2019",
                            "ResultsFirstPostDateStruct": {
                                "ResultsFirstPostDate": "December 9, 2019",
                                "ResultsFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "November 20, 2019",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "December 9, 2019",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Sponsor"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Flexion Therapeutics, Inc.",
                                "LeadSponsorClass": "INDUSTRY"
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "No",
                            "IsFDARegulatedDrug": "Yes",
                            "IsFDARegulatedDevice": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "This is an open-label study to compare systemic exposure to triamcinolone acetonide following a dose of extended-release FX006 or immediate-release TAcs (triamcinolone acetonide suspension) in patients with osteoarthritis of the shoulder (glenohumeral joint) or hip",
                            "DetailedDescription": "This is a randomized, open-label, single dose study that will be conducted in male and female patients ≥40 years of age with OA of either the shoulder or the hip.\n\nApproximately 24 patients with OA of the shoulder and approximately 24 patients with OA of the hip will be randomized to one of two treatment groups (1:1) and treated with a single IA injection of either:\n\n32 mg FX006 (approximately 12 patients per joint) or\n40 mg TAcs (approximately 12 patients per joint)\n\nEach patient will be screened to confirm the diagnosis of OA of either the shoulder or hip and eligibility based on the other inclusion/exclusion requirements and will be randomized to treatment on Day 1. Each patient will be evaluated for a total of 12 weeks following the IA injection. Following screening, sampling for pharmacokinetics (PK) and safety will be completed at 10 out-patient visits scheduled on Study Days 1 [calendar day of injection], 2, 3, 5, 8, 15, 22, 29, 57, and 85."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Osteoarthritis of the Shoulder",
                                    "Osteoarthritis of the Hip"
                                ]
                            },
                            "KeywordList": {
                                "Keyword": [
                                    "Osteoarthritis",
                                    "Shoulder",
                                    "Hip",
                                    "Pain",
                                    "Intra-articular",
                                    "Injection",
                                    "Corticosteroid"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Phase 2"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "Randomized",
                                "DesignInterventionModel": "Parallel Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "None (Open Label)"
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "55",
                                "EnrollmentType": "Actual"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "FX006 32 mg",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "Single intra-articular (IA) injection of FX006 32 mg",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: FX006 32 mg"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "TAcs 40 mg",
                                        "ArmGroupType": "Active Comparator",
                                        "ArmGroupDescription": "Single intra-articular (IA) injection of TAcs 40 mg",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: TAcs 40 mg"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "FX006 32 mg",
                                        "InterventionDescription": "Extended-release 32 mg FX006 IA injection",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "FX006 32 mg"
                                            ]
                                        },
                                        "InterventionOtherNameList": {
                                            "InterventionOtherName": [
                                                "Zilretta"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "TAcs 40 mg",
                                        "InterventionDescription": "Immediate-release 40mg TAcs IA injection",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "TAcs 40 mg"
                                            ]
                                        },
                                        "InterventionOtherNameList": {
                                            "InterventionOtherName": [
                                                "Kenalog®-40 Injection",
                                                "Triamcinolone Acetonide Crystalline Suspension (TAcs)",
                                                "TCA-IR 40"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Concentration of Triamcinolone Acetonide (TA) in Blood Plasma",
                                        "PrimaryOutcomeDescription": "Characterize the Pharmacokinetic Profile of FX006 and TCA IR [Time Frame: Day 1 (pre-treatment,1, 2, 3, 4, 5, 6, 8,10, and 12 hrs. post-dose) and Days 2, 3, 5, 8, 15, 22, 29, 57,and 85]\n\nFor the PK analysis and individual concentration vs. time plots, a concentration that is BLOQ is assigned a value of zero if it occurs in a profile before the first measurable concentration. If a BLOQ value occurs after a measurable concentration in a profile and is followed by a value above the lower limit of quantification, then the BLOQ is treated as missing data. If a BLOQ value occurs at the end of the collection interval (after the last quantifiable concentration) it is set to zero. If two BLOQ values occur in succession after Cmax, the profile is deemed to have terminated at the first BLOQ value and any subsequent concentrations are set to zero for PK calculations",
                                        "PrimaryOutcomeTimeFrame": "12 Weeks"
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "Total Number of Treatment Emergent Adverse Events",
                                        "PrimaryOutcomeDescription": "Analyses of adverse events (AE) were performed for events considered treatment-emergent (TE). TE was defined as any AE with onset after administration of the 1st dose of study drug or any event present at baseline but worsened in intensity through the study. Severity was graded by the PI using the Common Terminology Criteria for AEs Version 4.0. Grading went from Grade 1 (Mild) to Grade 5 (Death Related to AE).",
                                        "PrimaryOutcomeTimeFrame": "12 Weeks"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nWritten consent to participate in the study\nMale or female greater than or equal to 40 years of age\nBody mass index (BMI) less than or equal to 40 kg/m2\nAmbulatory and in good general health\nWilling and able to comply with the study procedures and visit schedules and able to follow verbal and written instructions\nWilling to abstain from use of protocol-restricted treatments from Screening through End-of-Study visit\nSymptoms consistent with OA of the index joint for ≥ 6 months prior to Screening (patient reported is acceptable)\nPain in the index joint for greater than15 days over the last month (as reported by the patient)\nFor Shoulder OA patients: Radiologic findings of OA of the index shoulder meeting the Samilson-Prieto (S-P) Classification Grades 2 or 3\nFor Hip OA patients: ACR Criteria (clinical and radiological) for OA of the index hip\n\nExclusion Criteria:\n\nReactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated with inflammatory bowel disease\nHistory of infection in the index joint\nClinical findings consistent with active infection or crystal disease in the index joint within 1 month of Screening\nHistory of fracture in the index limb within 12 months of Screening, or fracture with sequelae at any time\nPlanned or anticipated surgery of the index joint during the study period\nIndex joint instability or history of acute dislocation within 12 months of Screening\nIf shoulder is the index joint, history of full or partial rotator cuff tear or significantly compromised rotator cuff function that, in the opinion for the Investigator, increases the difficulty or risk of IA injection\nPresence of surgical hardware or other foreign body in the index joint\nSurgery or arthroscopy of the index joint within 12 months of Screening\nIA treatment of any joint with any of the following agents within 6 months of Screening:\nAny corticosteroid preparation (investigational or marketed, including FX006), any biologic agent (e.g., platelet rich plasma (PRP) injection, stem cells, prolotherapy, amniotic fluid injection; investigational or marketed)\nIA treatment of the index joint with hyaluronic acid (investigational or marketed) within 6 months of Screening\nParenteral or oral corticosteroids (investigational or marketed) within 3 months of Screening\nInhaled, intranasal or topical corticosteroids (investigational or marketed) within 2 weeks of Screening\nFemales who are pregnant or nursing or plan to become pregnant during the study; men who plan to conceive during the study",
                            "HealthyVolunteers": "No",
                            "Gender": "All",
                            "MinimumAge": "40 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Scott Kelley, MD",
                                        "OverallOfficialAffiliation": "Flexion Therapeutics, Inc.",
                                        "OverallOfficialRole": "Study Director"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "TriWest Research Associates, LLC",
                                        "LocationCity": "El Cajon",
                                        "LocationState": "California",
                                        "LocationZip": "92020",
                                        "LocationCountry": "United States"
                                    },
                                    {
                                        "LocationFacility": "Biosolutions Clinical Research Center",
                                        "LocationCity": "La Mesa",
                                        "LocationState": "California",
                                        "LocationZip": "91942",
                                        "LocationCountry": "United States"
                                    },
                                    {
                                        "LocationFacility": "Artemis Institute for Clinical Research",
                                        "LocationCity": "San Diego",
                                        "LocationState": "California",
                                        "LocationZip": "92103",
                                        "LocationCountry": "United States"
                                    },
                                    {
                                        "LocationFacility": "LA Biomed at Harbor-UCLA Medical Center",
                                        "LocationCity": "Torrance",
                                        "LocationState": "California",
                                        "LocationZip": "90509",
                                        "LocationCountry": "United States"
                                    },
                                    {
                                        "LocationFacility": "Rochester Clinical Research",
                                        "LocationCity": "Rochester",
                                        "LocationState": "New York",
                                        "LocationZip": "14609",
                                        "LocationCountry": "United States"
                                    },
                                    {
                                        "LocationFacility": "Altoona Center for Clinical Research",
                                        "LocationCity": "Duncansville",
                                        "LocationState": "Pennsylvania",
                                        "LocationZip": "16635",
                                        "LocationCountry": "United States"
                                    }
                                ]
                            }
                        },
                        "ReferencesModule": {
                            "ReferenceList": {
                                "Reference": [
                                    {
                                        "ReferencePMID": "35258839",
                                        "ReferenceType": "derived",
                                        "ReferenceCitation": "Kivitz A, Mehra P, Hanson P, Kwong L, Cinar A, Lufkin J, Kelley S. A Randomized, Open-Label, Single-Dose Study to Assess Safety and Systemic Exposure of Triamcinolone Acetonide Extended-Release in Patients With Hip Osteoarthritis. Rheumatol Ther. 2022 Apr;9(2):679-691. doi: 10.1007/s40744-022-00430-3. Epub 2022 Mar 8."
                                    },
                                    {
                                        "ReferencePMID": "34350546",
                                        "ReferenceType": "derived",
                                        "ReferenceCitation": "Hanson P, Kivitz A, Mehra P, Kwong L, Cinar A, Lufkin J, Kelley SD. Safety and Systemic Exposure of Triamcinolone Acetonide Following Ultrasound-Guided Intra-Articular Injection of Triamcinolone Extended-Release or Standard Triamcinolone Acetonide in Patients with Shoulder Osteoarthritis: An Open-Label, Randomized Study. Drugs R D. 2021 Sep;21(3):285-293. doi: 10.1007/s40268-021-00348-1. Epub 2021 Aug 4."
                                    }
                                ]
                            }
                        }
                    },
                    "ResultsSection": {
                        "ParticipantFlowModule": {
                            "FlowRecruitmentDetails": "The recruitment period for this study was from December 2017 to July 2018. The patients were enrolled at medical clinics.",
                            "FlowGroupList": {
                                "FlowGroup": [
                                    {
                                        "FlowGroupId": "FG000",
                                        "FlowGroupTitle": "FX006 32 mg Shoulder",
                                        "FlowGroupDescription": "Single intra-articular (IA) injection of FX006 32 mg\n\nFX006 32 mg: Extended-release 32 mg FX006 IA injection in the Shoulder"
                                    },
                                    {
                                        "FlowGroupId": "FG001",
                                        "FlowGroupTitle": "TAcs 40 mg Shoulder",
                                        "FlowGroupDescription": "Single intra-articular (IA) injection of TAcs 40 mg\n\nTAcs 40 mg: Immediate-release 40mg TAcs IA injection in the Shoulder"
                                    },
                                    {
                                        "FlowGroupId": "FG002",
                                        "FlowGroupTitle": "FX006 32 mg Hip",
                                        "FlowGroupDescription": "Single intra-articular (IA) injection of FX006 32 mg\n\nFX006 32 mg: Extended-release 32 mg FX006 IA injection in the Hip"
                                    },
                                    {
                                        "FlowGroupId": "FG003",
                                        "FlowGroupTitle": "TAcs 40 mg Hip",
                                        "FlowGroupDescription": "Single intra-articular (IA) injection of TAcs 40 mg\n\nTAcs 40 mg: Immediate-release 40mg TAcs IA injection in the Hip"
                                    }
                                ]
                            },
                            "FlowPeriodList": {
                                "FlowPeriod": [
                                    {
                                        "FlowPeriodTitle": "Overall Study",
                                        "FlowMilestoneList": {
                                            "FlowMilestone": [
                                                {
                                                    "FlowMilestoneType": "STARTED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "12"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG001",
                                                                "FlowAchievementNumSubjects": "13"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG002",
                                                                "FlowAchievementNumSubjects": "15"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG003",
                                                                "FlowAchievementNumSubjects": "15"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowMilestoneType": "COMPLETED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "12"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG001",
                                                                "FlowAchievementNumSubjects": "13"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG002",
                                                                "FlowAchievementNumSubjects": "14"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG003",
                                                                "FlowAchievementNumSubjects": "14"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowMilestoneType": "NOT COMPLETED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "0"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG001",
                                                                "FlowAchievementNumSubjects": "0"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG002",
                                                                "FlowAchievementNumSubjects": "1"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG003",
                                                                "FlowAchievementNumSubjects": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "FlowDropWithdrawList": {
                                            "FlowDropWithdraw": [
                                                {
                                                    "FlowDropWithdrawType": "Physician Decision",
                                                    "FlowReasonList": {
                                                        "FlowReason": [
                                                            {
                                                                "FlowReasonGroupId": "FG000",
                                                                "FlowReasonNumSubjects": "0"
                                                            },
                                                            {
                                                                "FlowReasonGroupId": "FG001",
                                                                "FlowReasonNumSubjects": "0"
                                                            },
                                                            {
                                                                "FlowReasonGroupId": "FG002",
                                                                "FlowReasonNumSubjects": "1"
                                                            },
                                                            {
                                                                "FlowReasonGroupId": "FG003",
                                                                "FlowReasonNumSubjects": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowDropWithdrawType": "Withdrawal by Subject",
                                                    "FlowReasonList": {
                                                        "FlowReason": [
                                                            {
                                                                "FlowReasonGroupId": "FG000",
                                                                "FlowReasonNumSubjects": "0"
                                                            },
                                                            {
                                                                "FlowReasonGroupId": "FG001",
                                                                "FlowReasonNumSubjects": "0"
                                                            },
                                                            {
                                                                "FlowReasonGroupId": "FG002",
                                                                "FlowReasonNumSubjects": "0"
                                                            },
                                                            {
                                                                "FlowReasonGroupId": "FG003",
                                                                "FlowReasonNumSubjects": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "BaselineCharacteristicsModule": {
                            "BaselineGroupList": {
                                "BaselineGroup": [
                                    {
                                        "BaselineGroupId": "BG000",
                                        "BaselineGroupTitle": "FX006 32 mg Shoulder",
                                        "BaselineGroupDescription": "Single intra-articular (IA) injection of FX006 32 mg in the Shoulder\n\nFX006 32 mg: Extended-release 32 mg FX006 IA injection"
                                    },
                                    {
                                        "BaselineGroupId": "BG001",
                                        "BaselineGroupTitle": "TAcs 40 mg Shoulder",
                                        "BaselineGroupDescription": "Single intra-articular (IA) injection of TAcs 40 mg in the Shoulder\n\nTAcs 40 mg: Immediate-release 40mg TAcs IA injection"
                                    },
                                    {
                                        "BaselineGroupId": "BG002",
                                        "BaselineGroupTitle": "FX006 32 mg Hip",
                                        "BaselineGroupDescription": "Single intra-articular (IA) injection of FX006 32 mg in the Hip\n\nFX006 32 mg: Extended-release 32 mg FX006 IA injection"
                                    },
                                    {
                                        "BaselineGroupId": "BG003",
                                        "BaselineGroupTitle": "TAcs 40 mg Hip",
                                        "BaselineGroupDescription": "Single intra-articular (IA) injection of TAcs 40 mg in the Hip\n\nTAcs 40 mg: Immediate-release 40mg TAcs IA injection"
                                    },
                                    {
                                        "BaselineGroupId": "BG004",
                                        "BaselineGroupTitle": "Total",
                                        "BaselineGroupDescription": "Total of all reporting groups"
                                    }
                                ]
                            },
                            "BaselineDenomList": {
                                "BaselineDenom": [
                                    {
                                        "BaselineDenomUnits": "Participants",
                                        "BaselineDenomCountList": {
                                            "BaselineDenomCount": [
                                                {
                                                    "BaselineDenomCountGroupId": "BG000",
                                                    "BaselineDenomCountValue": "12"
                                                },
                                                {
                                                    "BaselineDenomCountGroupId": "BG001",
                                                    "BaselineDenomCountValue": "13"
                                                },
                                                {
                                                    "BaselineDenomCountGroupId": "BG002",
                                                    "BaselineDenomCountValue": "15"
                                                },
                                                {
                                                    "BaselineDenomCountGroupId": "BG003",
                                                    "BaselineDenomCountValue": "15"
                                                },
                                                {
                                                    "BaselineDenomCountGroupId": "BG004",
                                                    "BaselineDenomCountValue": "55"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "BaselineMeasureList": {
                                "BaselineMeasure": [
                                    {
                                        "BaselineMeasureTitle": "Age, Continuous",
                                        "BaselineMeasureDescription": "Age at Consent",
                                        "BaselineMeasureParamType": "Mean",
                                        "BaselineMeasureDispersionType": "Standard Deviation",
                                        "BaselineMeasureUnitOfMeasure": "years",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "63.2",
                                                                            "BaselineMeasurementSpread": "11.39"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "61.9",
                                                                            "BaselineMeasurementSpread": "8.10"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "58.1",
                                                                            "BaselineMeasurementSpread": "7.60"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG003",
                                                                            "BaselineMeasurementValue": "60.1",
                                                                            "BaselineMeasurementSpread": "7.09"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG004",
                                                                            "BaselineMeasurementValue": "60.7",
                                                                            "BaselineMeasurementSpread": "8.53"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Sex: Female, Male",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineCategoryTitle": "Female",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "9"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "6"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "8"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG003",
                                                                            "BaselineMeasurementValue": "5"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG004",
                                                                            "BaselineMeasurementValue": "28"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Male",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "3"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "7"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "7"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG003",
                                                                            "BaselineMeasurementValue": "10"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG004",
                                                                            "BaselineMeasurementValue": "27"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Ethnicity (NIH/OMB)",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineCategoryTitle": "Hispanic or Latino",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "3"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "1"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG003",
                                                                            "BaselineMeasurementValue": "1"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG004",
                                                                            "BaselineMeasurementValue": "5"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Not Hispanic or Latino",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "9"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "13"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "14"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG003",
                                                                            "BaselineMeasurementValue": "14"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG004",
                                                                            "BaselineMeasurementValue": "50"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Unknown or Not Reported",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG003",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG004",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Race (NIH/OMB)",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineCategoryTitle": "American Indian or Alaska Native",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG003",
                                                                            "BaselineMeasurementValue": "1"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG004",
                                                                            "BaselineMeasurementValue": "1"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Asian",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "1"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG003",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG004",
                                                                            "BaselineMeasurementValue": "1"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Native Hawaiian or Other Pacific Islander",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "1"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG003",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG004",
                                                                            "BaselineMeasurementValue": "1"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Black or African American",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "1"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "2"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "5"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG003",
                                                                            "BaselineMeasurementValue": "5"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG004",
                                                                            "BaselineMeasurementValue": "13"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "White",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "10"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "11"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "8"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG003",
                                                                            "BaselineMeasurementValue": "9"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG004",
                                                                            "BaselineMeasurementValue": "38"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "More than one race",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG003",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG004",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Unknown or Not Reported",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "1"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG003",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG004",
                                                                            "BaselineMeasurementValue": "1"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Region of Enrollment",
                                        "BaselineMeasureParamType": "Number",
                                        "BaselineMeasureUnitOfMeasure": "participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineClassTitle": "United States",
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "12"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "13"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "15"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG003",
                                                                            "BaselineMeasurementValue": "15"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG004",
                                                                            "BaselineMeasurementValue": "55"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Body Mass Index (BMI)",
                                        "BaselineMeasureDescription": "Body Mass Index calculated at Baseline",
                                        "BaselineMeasureParamType": "Mean",
                                        "BaselineMeasureDispersionType": "Standard Deviation",
                                        "BaselineMeasureUnitOfMeasure": "kg/mg^2",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "28.9",
                                                                            "BaselineMeasurementSpread": "5.98"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "30.7",
                                                                            "BaselineMeasurementSpread": "3.59"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "29.3",
                                                                            "BaselineMeasurementSpread": "3.49"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG003",
                                                                            "BaselineMeasurementValue": "31.0",
                                                                            "BaselineMeasurementSpread": "4.40"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG004",
                                                                            "BaselineMeasurementValue": "30.01",
                                                                            "BaselineMeasurementSpread": "4.367"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomeMeasuresModule": {
                            "OutcomeMeasureList": {
                                "OutcomeMeasure": [
                                    {
                                        "OutcomeMeasureType": "Primary",
                                        "OutcomeMeasureTitle": "Concentration of Triamcinolone Acetonide (TA) in Blood Plasma",
                                        "OutcomeMeasureDescription": "Characterize the Pharmacokinetic Profile of FX006 and TCA IR [Time Frame: Day 1 (pre-treatment,1, 2, 3, 4, 5, 6, 8,10, and 12 hrs. post-dose) and Days 2, 3, 5, 8, 15, 22, 29, 57,and 85]\n\nFor the PK analysis and individual concentration vs. time plots, a concentration that is BLOQ is assigned a value of zero if it occurs in a profile before the first measurable concentration. If a BLOQ value occurs after a measurable concentration in a profile and is followed by a value above the lower limit of quantification, then the BLOQ is treated as missing data. If a BLOQ value occurs at the end of the collection interval (after the last quantifiable concentration) it is set to zero. If two BLOQ values occur in succession after Cmax, the profile is deemed to have terminated at the first BLOQ value and any subsequent concentrations are set to zero for PK calculations",
                                        "OutcomeMeasurePopulationDescription": "All patients in the Safety population who received study drug, completed scheduled sampling and had sufficient plasma concentration data. 50 of 55 patients were included. Four unique patients for whom hip was the index joint were excluded due to IP administration deviations. One of the four was also found to be enrolled at 2 separate study centers.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Geometric Mean",
                                        "OutcomeMeasureDispersionType": "95% Confidence Interval",
                                        "OutcomeMeasureUnitOfMeasure": "pg/mL",
                                        "OutcomeMeasureTimeFrame": "12 Weeks",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "FX006 32 mg Shoulder",
                                                    "OutcomeGroupDescription": "Single intra-articular (IA) injection of FX006 32 mg in the Shoulder\n\nFX006 32 mg: Extended-release 32 mg FX006 IA injection"
                                                },
                                                {
                                                    "OutcomeGroupId": "OG001",
                                                    "OutcomeGroupTitle": "TAcs 40 mg Shoulder",
                                                    "OutcomeGroupDescription": "Single intra-articular (IA) injection of TAcs 40 mg in the Shoulder\n\nTAcs 40 mg: Immediate-release 40mg TAcs IA injection"
                                                },
                                                {
                                                    "OutcomeGroupId": "OG002",
                                                    "OutcomeGroupTitle": "FX006 32 mg Hip",
                                                    "OutcomeGroupDescription": "Single intra-articular (IA) injection of FX006 32 mg in the Hip\n\nFX006 32 mg: Extended-release 32 mg FX006 IA injection"
                                                },
                                                {
                                                    "OutcomeGroupId": "OG003",
                                                    "OutcomeGroupTitle": "TAcs 40 mg Hip",
                                                    "OutcomeGroupDescription": "Single intra-articular (IA) injection of TAcs 40 mg in the Hip\n\nTAcs 40 mg: Immediate-release 40mg TAcs IA injection"
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "12"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG001",
                                                                "OutcomeDenomCountValue": "13"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG002",
                                                                "OutcomeDenomCountValue": "11"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG003",
                                                                "OutcomeDenomCountValue": "14"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeClassTitle": "Day 1 - Hour 1",
                                                    "OutcomeClassDenomList": {
                                                        "OutcomeClassDenom": [
                                                            {
                                                                "OutcomeClassDenomUnits": "Participants",
                                                                "OutcomeClassDenomCountList": {
                                                                    "OutcomeClassDenomCount": [
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG000",
                                                                            "OutcomeClassDenomCountValue": "12"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG001",
                                                                            "OutcomeClassDenomCountValue": "13"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG002",
                                                                            "OutcomeClassDenomCountValue": "11"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG003",
                                                                            "OutcomeClassDenomCountValue": "14"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    },
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "1061.8",
                                                                            "OutcomeMeasurementLowerLimit": "819.95",
                                                                            "OutcomeMeasurementUpperLimit": "1375.09"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "1104.1",
                                                                            "OutcomeMeasurementLowerLimit": "578.17",
                                                                            "OutcomeMeasurementUpperLimit": "2108.52"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG002",
                                                                            "OutcomeMeasurementValue": "681.8",
                                                                            "OutcomeMeasurementLowerLimit": "334.47",
                                                                            "OutcomeMeasurementUpperLimit": "1389.69"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG003",
                                                                            "OutcomeMeasurementValue": "3862.3",
                                                                            "OutcomeMeasurementLowerLimit": "2024.11",
                                                                            "OutcomeMeasurementUpperLimit": "7370.02"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Day 1 - Hour 2",
                                                    "OutcomeClassDenomList": {
                                                        "OutcomeClassDenom": [
                                                            {
                                                                "OutcomeClassDenomUnits": "Participants",
                                                                "OutcomeClassDenomCountList": {
                                                                    "OutcomeClassDenomCount": [
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG000",
                                                                            "OutcomeClassDenomCountValue": "12"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG001",
                                                                            "OutcomeClassDenomCountValue": "13"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG002",
                                                                            "OutcomeClassDenomCountValue": "11"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG003",
                                                                            "OutcomeClassDenomCountValue": "14"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    },
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "1117.6",
                                                                            "OutcomeMeasurementLowerLimit": "838.98",
                                                                            "OutcomeMeasurementUpperLimit": "1488.62"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "1344.8",
                                                                            "OutcomeMeasurementLowerLimit": "682.40",
                                                                            "OutcomeMeasurementUpperLimit": "2650.05"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG002",
                                                                            "OutcomeMeasurementValue": "752.2",
                                                                            "OutcomeMeasurementLowerLimit": "364.55",
                                                                            "OutcomeMeasurementUpperLimit": "1551.90"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG003",
                                                                            "OutcomeMeasurementValue": "4052.4",
                                                                            "OutcomeMeasurementLowerLimit": "2134.61",
                                                                            "OutcomeMeasurementUpperLimit": "7693.33"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Day 1 - Hour 3",
                                                    "OutcomeClassDenomList": {
                                                        "OutcomeClassDenom": [
                                                            {
                                                                "OutcomeClassDenomUnits": "Participants",
                                                                "OutcomeClassDenomCountList": {
                                                                    "OutcomeClassDenomCount": [
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG000",
                                                                            "OutcomeClassDenomCountValue": "12"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG001",
                                                                            "OutcomeClassDenomCountValue": "13"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG002",
                                                                            "OutcomeClassDenomCountValue": "11"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG003",
                                                                            "OutcomeClassDenomCountValue": "14"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    },
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "1140.0",
                                                                            "OutcomeMeasurementLowerLimit": "849.77",
                                                                            "OutcomeMeasurementUpperLimit": "1529.44"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "1501.8",
                                                                            "OutcomeMeasurementLowerLimit": "774.05",
                                                                            "OutcomeMeasurementUpperLimit": "2913.69"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG002",
                                                                            "OutcomeMeasurementValue": "748.0",
                                                                            "OutcomeMeasurementLowerLimit": "349.37",
                                                                            "OutcomeMeasurementUpperLimit": "1601.44"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG003",
                                                                            "OutcomeMeasurementValue": "4519.3",
                                                                            "OutcomeMeasurementLowerLimit": "2286.88",
                                                                            "OutcomeMeasurementUpperLimit": "8930.88"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Day 1 - Hour 4",
                                                    "OutcomeClassDenomList": {
                                                        "OutcomeClassDenom": [
                                                            {
                                                                "OutcomeClassDenomUnits": "Participants",
                                                                "OutcomeClassDenomCountList": {
                                                                    "OutcomeClassDenomCount": [
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG000",
                                                                            "OutcomeClassDenomCountValue": "12"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG001",
                                                                            "OutcomeClassDenomCountValue": "13"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG002",
                                                                            "OutcomeClassDenomCountValue": "11"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG003",
                                                                            "OutcomeClassDenomCountValue": "14"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    },
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "1142.4",
                                                                            "OutcomeMeasurementLowerLimit": "822.55",
                                                                            "OutcomeMeasurementUpperLimit": "1586.49"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "1594.1",
                                                                            "OutcomeMeasurementLowerLimit": "856.43",
                                                                            "OutcomeMeasurementUpperLimit": "2967.05"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG002",
                                                                            "OutcomeMeasurementValue": "776.1",
                                                                            "OutcomeMeasurementLowerLimit": "352.73",
                                                                            "OutcomeMeasurementUpperLimit": "1707.82"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG003",
                                                                            "OutcomeMeasurementValue": "4557.8",
                                                                            "OutcomeMeasurementLowerLimit": "2362.49",
                                                                            "OutcomeMeasurementUpperLimit": "8793.00"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Day 1 - Hour 5",
                                                    "OutcomeClassDenomList": {
                                                        "OutcomeClassDenom": [
                                                            {
                                                                "OutcomeClassDenomUnits": "Participants",
                                                                "OutcomeClassDenomCountList": {
                                                                    "OutcomeClassDenomCount": [
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG000",
                                                                            "OutcomeClassDenomCountValue": "12"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG001",
                                                                            "OutcomeClassDenomCountValue": "13"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG002",
                                                                            "OutcomeClassDenomCountValue": "11"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG003",
                                                                            "OutcomeClassDenomCountValue": "14"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    },
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "1093.8",
                                                                            "OutcomeMeasurementLowerLimit": "759.94",
                                                                            "OutcomeMeasurementUpperLimit": "1574.40"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "1662.7",
                                                                            "OutcomeMeasurementLowerLimit": "861.73",
                                                                            "OutcomeMeasurementUpperLimit": "3208.09"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG002",
                                                                            "OutcomeMeasurementValue": "792.9",
                                                                            "OutcomeMeasurementLowerLimit": "360.39",
                                                                            "OutcomeMeasurementUpperLimit": "1744.51"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG003",
                                                                            "OutcomeMeasurementValue": "4672.6",
                                                                            "OutcomeMeasurementLowerLimit": "2429.24",
                                                                            "OutcomeMeasurementUpperLimit": "8987.65"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Day 1 - Hour 6",
                                                    "OutcomeClassDenomList": {
                                                        "OutcomeClassDenom": [
                                                            {
                                                                "OutcomeClassDenomUnits": "Participants",
                                                                "OutcomeClassDenomCountList": {
                                                                    "OutcomeClassDenomCount": [
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG000",
                                                                            "OutcomeClassDenomCountValue": "12"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG001",
                                                                            "OutcomeClassDenomCountValue": "13"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG002",
                                                                            "OutcomeClassDenomCountValue": "11"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG003",
                                                                            "OutcomeClassDenomCountValue": "14"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    },
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "1052.8",
                                                                            "OutcomeMeasurementLowerLimit": "729.94",
                                                                            "OutcomeMeasurementUpperLimit": "1518.37"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "1689.6",
                                                                            "OutcomeMeasurementLowerLimit": "893.53",
                                                                            "OutcomeMeasurementUpperLimit": "3194.85"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG002",
                                                                            "OutcomeMeasurementValue": "743.5",
                                                                            "OutcomeMeasurementLowerLimit": "331.07",
                                                                            "OutcomeMeasurementUpperLimit": "1669.73"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG003",
                                                                            "OutcomeMeasurementValue": "4469.8",
                                                                            "OutcomeMeasurementLowerLimit": "2393.87",
                                                                            "OutcomeMeasurementUpperLimit": "8346.03"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Day 1 - Hour 8",
                                                    "OutcomeClassDenomList": {
                                                        "OutcomeClassDenom": [
                                                            {
                                                                "OutcomeClassDenomUnits": "Participants",
                                                                "OutcomeClassDenomCountList": {
                                                                    "OutcomeClassDenomCount": [
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG000",
                                                                            "OutcomeClassDenomCountValue": "12"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG001",
                                                                            "OutcomeClassDenomCountValue": "13"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG002",
                                                                            "OutcomeClassDenomCountValue": "11"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG003",
                                                                            "OutcomeClassDenomCountValue": "14"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    },
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "1016.2",
                                                                            "OutcomeMeasurementLowerLimit": "702.66",
                                                                            "OutcomeMeasurementUpperLimit": "1469.64"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "1668.3",
                                                                            "OutcomeMeasurementLowerLimit": "887.88",
                                                                            "OutcomeMeasurementUpperLimit": "3134.86"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG002",
                                                                            "OutcomeMeasurementValue": "705.0",
                                                                            "OutcomeMeasurementLowerLimit": "307.07",
                                                                            "OutcomeMeasurementUpperLimit": "1618.77"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG003",
                                                                            "OutcomeMeasurementValue": "4102.3",
                                                                            "OutcomeMeasurementLowerLimit": "2232.93",
                                                                            "OutcomeMeasurementUpperLimit": "7536.76"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Day 1 - Hour 10",
                                                    "OutcomeClassDenomList": {
                                                        "OutcomeClassDenom": [
                                                            {
                                                                "OutcomeClassDenomUnits": "Participants",
                                                                "OutcomeClassDenomCountList": {
                                                                    "OutcomeClassDenomCount": [
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG000",
                                                                            "OutcomeClassDenomCountValue": "12"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG001",
                                                                            "OutcomeClassDenomCountValue": "13"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG002",
                                                                            "OutcomeClassDenomCountValue": "11"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG003",
                                                                            "OutcomeClassDenomCountValue": "14"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    },
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "951.4",
                                                                            "OutcomeMeasurementLowerLimit": "670.78",
                                                                            "OutcomeMeasurementUpperLimit": "1349.34"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "1506.3",
                                                                            "OutcomeMeasurementLowerLimit": "819.27",
                                                                            "OutcomeMeasurementUpperLimit": "2769.61"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG002",
                                                                            "OutcomeMeasurementValue": "698.2",
                                                                            "OutcomeMeasurementLowerLimit": "307.74",
                                                                            "OutcomeMeasurementUpperLimit": "1583.97"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG003",
                                                                            "OutcomeMeasurementValue": "3615.6",
                                                                            "OutcomeMeasurementLowerLimit": "2033.96",
                                                                            "OutcomeMeasurementUpperLimit": "6427.30"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Day 1 - Hour 12",
                                                    "OutcomeClassDenomList": {
                                                        "OutcomeClassDenom": [
                                                            {
                                                                "OutcomeClassDenomUnits": "Participants",
                                                                "OutcomeClassDenomCountList": {
                                                                    "OutcomeClassDenomCount": [
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG000",
                                                                            "OutcomeClassDenomCountValue": "10"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG001",
                                                                            "OutcomeClassDenomCountValue": "13"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG002",
                                                                            "OutcomeClassDenomCountValue": "11"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG003",
                                                                            "OutcomeClassDenomCountValue": "14"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    },
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "903.8",
                                                                            "OutcomeMeasurementLowerLimit": "637.58",
                                                                            "OutcomeMeasurementUpperLimit": "1281.10"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "1531.3",
                                                                            "OutcomeMeasurementLowerLimit": "806.98",
                                                                            "OutcomeMeasurementUpperLimit": "2905.65"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG002",
                                                                            "OutcomeMeasurementValue": "675.1",
                                                                            "OutcomeMeasurementLowerLimit": "296.00",
                                                                            "OutcomeMeasurementUpperLimit": "1539.62"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG003",
                                                                            "OutcomeMeasurementValue": "3276.2",
                                                                            "OutcomeMeasurementLowerLimit": "1858.64",
                                                                            "OutcomeMeasurementUpperLimit": "5775.00"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Day 2 - Hour 24",
                                                    "OutcomeClassDenomList": {
                                                        "OutcomeClassDenom": [
                                                            {
                                                                "OutcomeClassDenomUnits": "Participants",
                                                                "OutcomeClassDenomCountList": {
                                                                    "OutcomeClassDenomCount": [
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG000",
                                                                            "OutcomeClassDenomCountValue": "12"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG001",
                                                                            "OutcomeClassDenomCountValue": "13"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG002",
                                                                            "OutcomeClassDenomCountValue": "11"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG003",
                                                                            "OutcomeClassDenomCountValue": "14"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    },
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "943.4",
                                                                            "OutcomeMeasurementLowerLimit": "690.74",
                                                                            "OutcomeMeasurementUpperLimit": "1288.35"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "1467.0",
                                                                            "OutcomeMeasurementLowerLimit": "884.10",
                                                                            "OutcomeMeasurementUpperLimit": "2434.35"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG002",
                                                                            "OutcomeMeasurementValue": "791.0",
                                                                            "OutcomeMeasurementLowerLimit": "340.46",
                                                                            "OutcomeMeasurementUpperLimit": "1837.60"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG003",
                                                                            "OutcomeMeasurementValue": "3218.8",
                                                                            "OutcomeMeasurementLowerLimit": "1965.24",
                                                                            "OutcomeMeasurementUpperLimit": "5272.05"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Day - 3",
                                                    "OutcomeClassDenomList": {
                                                        "OutcomeClassDenom": [
                                                            {
                                                                "OutcomeClassDenomUnits": "Participants",
                                                                "OutcomeClassDenomCountList": {
                                                                    "OutcomeClassDenomCount": [
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG000",
                                                                            "OutcomeClassDenomCountValue": "12"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG001",
                                                                            "OutcomeClassDenomCountValue": "13"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG002",
                                                                            "OutcomeClassDenomCountValue": "11"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG003",
                                                                            "OutcomeClassDenomCountValue": "14"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    },
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "903.4",
                                                                            "OutcomeMeasurementLowerLimit": "639.75",
                                                                            "OutcomeMeasurementUpperLimit": "1275.69"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "1413.1",
                                                                            "OutcomeMeasurementLowerLimit": "856.25",
                                                                            "OutcomeMeasurementUpperLimit": "2332.05"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG002",
                                                                            "OutcomeMeasurementValue": "682.1",
                                                                            "OutcomeMeasurementLowerLimit": "292.51",
                                                                            "OutcomeMeasurementUpperLimit": "1590.60"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG003",
                                                                            "OutcomeMeasurementValue": "1723.6",
                                                                            "OutcomeMeasurementLowerLimit": "1218.72",
                                                                            "OutcomeMeasurementUpperLimit": "2437.70"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Day - 5",
                                                    "OutcomeClassDenomList": {
                                                        "OutcomeClassDenom": [
                                                            {
                                                                "OutcomeClassDenomUnits": "Participants",
                                                                "OutcomeClassDenomCountList": {
                                                                    "OutcomeClassDenomCount": [
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG000",
                                                                            "OutcomeClassDenomCountValue": "11"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG001",
                                                                            "OutcomeClassDenomCountValue": "13"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG002",
                                                                            "OutcomeClassDenomCountValue": "11"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG003",
                                                                            "OutcomeClassDenomCountValue": "14"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    },
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "754.6",
                                                                            "OutcomeMeasurementLowerLimit": "536.22",
                                                                            "OutcomeMeasurementUpperLimit": "1061.93"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "1038.2",
                                                                            "OutcomeMeasurementLowerLimit": "724.11",
                                                                            "OutcomeMeasurementUpperLimit": "1488.44"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG002",
                                                                            "OutcomeMeasurementValue": "562.4",
                                                                            "OutcomeMeasurementLowerLimit": "242.23",
                                                                            "OutcomeMeasurementUpperLimit": "1305.93"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG003",
                                                                            "OutcomeMeasurementValue": "897.3",
                                                                            "OutcomeMeasurementLowerLimit": "644.77",
                                                                            "OutcomeMeasurementUpperLimit": "1248.66"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Day - 8",
                                                    "OutcomeClassDenomList": {
                                                        "OutcomeClassDenom": [
                                                            {
                                                                "OutcomeClassDenomUnits": "Participants",
                                                                "OutcomeClassDenomCountList": {
                                                                    "OutcomeClassDenomCount": [
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG000",
                                                                            "OutcomeClassDenomCountValue": "12"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG001",
                                                                            "OutcomeClassDenomCountValue": "13"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG002",
                                                                            "OutcomeClassDenomCountValue": "11"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG003",
                                                                            "OutcomeClassDenomCountValue": "14"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    },
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "678.1",
                                                                            "OutcomeMeasurementLowerLimit": "497.82",
                                                                            "OutcomeMeasurementUpperLimit": "923.66"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "857.8",
                                                                            "OutcomeMeasurementLowerLimit": "596.48",
                                                                            "OutcomeMeasurementUpperLimit": "1233.52"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG002",
                                                                            "OutcomeMeasurementValue": "472.3",
                                                                            "OutcomeMeasurementLowerLimit": "202.04",
                                                                            "OutcomeMeasurementUpperLimit": "1103.90"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG003",
                                                                            "OutcomeMeasurementValue": "525.3",
                                                                            "OutcomeMeasurementLowerLimit": "296.03",
                                                                            "OutcomeMeasurementUpperLimit": "932.01"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Day - 15",
                                                    "OutcomeClassDenomList": {
                                                        "OutcomeClassDenom": [
                                                            {
                                                                "OutcomeClassDenomUnits": "Participants",
                                                                "OutcomeClassDenomCountList": {
                                                                    "OutcomeClassDenomCount": [
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG000",
                                                                            "OutcomeClassDenomCountValue": "12"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG001",
                                                                            "OutcomeClassDenomCountValue": "12"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG002",
                                                                            "OutcomeClassDenomCountValue": "10"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG003",
                                                                            "OutcomeClassDenomCountValue": "14"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    },
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "397.6",
                                                                            "OutcomeMeasurementLowerLimit": "287.43",
                                                                            "OutcomeMeasurementUpperLimit": "549.88"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "722.7",
                                                                            "OutcomeMeasurementLowerLimit": "574.45",
                                                                            "OutcomeMeasurementUpperLimit": "909.25"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG002",
                                                                            "OutcomeMeasurementValue": "382.6",
                                                                            "OutcomeMeasurementLowerLimit": "270.89",
                                                                            "OutcomeMeasurementUpperLimit": "540.52"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG003",
                                                                            "OutcomeMeasurementValue": "444.7",
                                                                            "OutcomeMeasurementLowerLimit": "278.24",
                                                                            "OutcomeMeasurementUpperLimit": "710.85"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Day - 22",
                                                    "OutcomeClassDenomList": {
                                                        "OutcomeClassDenom": [
                                                            {
                                                                "OutcomeClassDenomUnits": "Participants",
                                                                "OutcomeClassDenomCountList": {
                                                                    "OutcomeClassDenomCount": [
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG000",
                                                                            "OutcomeClassDenomCountValue": "12"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG001",
                                                                            "OutcomeClassDenomCountValue": "13"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG002",
                                                                            "OutcomeClassDenomCountValue": "11"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG003",
                                                                            "OutcomeClassDenomCountValue": "14"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    },
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "268.3",
                                                                            "OutcomeMeasurementLowerLimit": "186.53",
                                                                            "OutcomeMeasurementUpperLimit": "385.82"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "476.7",
                                                                            "OutcomeMeasurementLowerLimit": "333.94",
                                                                            "OutcomeMeasurementUpperLimit": "680.44"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG002",
                                                                            "OutcomeMeasurementValue": "235.0",
                                                                            "OutcomeMeasurementLowerLimit": "170.80",
                                                                            "OutcomeMeasurementUpperLimit": "323.29"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG003",
                                                                            "OutcomeMeasurementValue": "331.6",
                                                                            "OutcomeMeasurementLowerLimit": "214.93",
                                                                            "OutcomeMeasurementUpperLimit": "511.48"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Day - 29",
                                                    "OutcomeClassDenomList": {
                                                        "OutcomeClassDenom": [
                                                            {
                                                                "OutcomeClassDenomUnits": "Participants",
                                                                "OutcomeClassDenomCountList": {
                                                                    "OutcomeClassDenomCount": [
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG000",
                                                                            "OutcomeClassDenomCountValue": "12"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG001",
                                                                            "OutcomeClassDenomCountValue": "13"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG002",
                                                                            "OutcomeClassDenomCountValue": "11"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG003",
                                                                            "OutcomeClassDenomCountValue": "14"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    },
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "201.0",
                                                                            "OutcomeMeasurementLowerLimit": "134.57",
                                                                            "OutcomeMeasurementUpperLimit": "300.21"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "418.7",
                                                                            "OutcomeMeasurementLowerLimit": "300.39",
                                                                            "OutcomeMeasurementUpperLimit": "583.66"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG002",
                                                                            "OutcomeMeasurementValue": "256.3",
                                                                            "OutcomeMeasurementLowerLimit": "173.31",
                                                                            "OutcomeMeasurementUpperLimit": "379.15"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG003",
                                                                            "OutcomeMeasurementValue": "281.8",
                                                                            "OutcomeMeasurementLowerLimit": "179.32",
                                                                            "OutcomeMeasurementUpperLimit": "442.91"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Day - 57",
                                                    "OutcomeClassDenomList": {
                                                        "OutcomeClassDenom": [
                                                            {
                                                                "OutcomeClassDenomUnits": "Participants",
                                                                "OutcomeClassDenomCountList": {
                                                                    "OutcomeClassDenomCount": [
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG000",
                                                                            "OutcomeClassDenomCountValue": "12"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG001",
                                                                            "OutcomeClassDenomCountValue": "13"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG002",
                                                                            "OutcomeClassDenomCountValue": "11"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG003",
                                                                            "OutcomeClassDenomCountValue": "13"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    },
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "151.8",
                                                                            "OutcomeMeasurementLowerLimit": "92.60",
                                                                            "OutcomeMeasurementUpperLimit": "248.73"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "200",
                                                                            "OutcomeMeasurementLowerLimit": "140.83",
                                                                            "OutcomeMeasurementUpperLimit": "284.08"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG002",
                                                                            "OutcomeMeasurementValue": "225.1",
                                                                            "OutcomeMeasurementLowerLimit": "156.31",
                                                                            "OutcomeMeasurementUpperLimit": "324.15"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG003",
                                                                            "OutcomeMeasurementValue": "133.1",
                                                                            "OutcomeMeasurementLowerLimit": "74.28",
                                                                            "OutcomeMeasurementUpperLimit": "238.50"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "Day - 85",
                                                    "OutcomeClassDenomList": {
                                                        "OutcomeClassDenom": [
                                                            {
                                                                "OutcomeClassDenomUnits": "Participants",
                                                                "OutcomeClassDenomCountList": {
                                                                    "OutcomeClassDenomCount": [
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG000",
                                                                            "OutcomeClassDenomCountValue": "12"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG001",
                                                                            "OutcomeClassDenomCountValue": "13"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG002",
                                                                            "OutcomeClassDenomCountValue": "11"
                                                                        },
                                                                        {
                                                                            "OutcomeClassDenomCountGroupId": "OG003",
                                                                            "OutcomeClassDenomCountValue": "14"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    },
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "100.1",
                                                                            "OutcomeMeasurementLowerLimit": "54.22",
                                                                            "OutcomeMeasurementUpperLimit": "184.86"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "131.4",
                                                                            "OutcomeMeasurementLowerLimit": "64.14",
                                                                            "OutcomeMeasurementUpperLimit": "269.25"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG002",
                                                                            "OutcomeMeasurementValue": "112.0",
                                                                            "OutcomeMeasurementLowerLimit": "58.14",
                                                                            "OutcomeMeasurementUpperLimit": "215.61"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG003",
                                                                            "OutcomeMeasurementValue": "92.5",
                                                                            "OutcomeMeasurementLowerLimit": "51.16",
                                                                            "OutcomeMeasurementUpperLimit": "167.11"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Primary",
                                        "OutcomeMeasureTitle": "Total Number of Treatment Emergent Adverse Events",
                                        "OutcomeMeasureDescription": "Analyses of adverse events (AE) were performed for events considered treatment-emergent (TE). TE was defined as any AE with onset after administration of the 1st dose of study drug or any event present at baseline but worsened in intensity through the study. Severity was graded by the PI using the Common Terminology Criteria for AEs Version 4.0. Grading went from Grade 1 (Mild) to Grade 5 (Death Related to AE).",
                                        "OutcomeMeasurePopulationDescription": "All patients randomized to receive either FX006 or TAcs in the hip or shoulder.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Number",
                                        "OutcomeMeasureUnitOfMeasure": "Events",
                                        "OutcomeMeasureTimeFrame": "12 Weeks",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "FX006 32 mg Shoulder",
                                                    "OutcomeGroupDescription": "Single intra-articular (IA) injection of FX006 32 mg in the Shoulder\n\nFX006 32 mg: Extended-release 32 mg FX006 IA injection"
                                                },
                                                {
                                                    "OutcomeGroupId": "OG001",
                                                    "OutcomeGroupTitle": "TAcs 40 mg Shoulder",
                                                    "OutcomeGroupDescription": "Single intra-articular (IA) injection of TAcs 40 mg in the Shoulder\n\nTAcs 40 mg: Immediate-release 40mg TAcs IA injection"
                                                },
                                                {
                                                    "OutcomeGroupId": "OG002",
                                                    "OutcomeGroupTitle": "FX006 32 mg Hip",
                                                    "OutcomeGroupDescription": "Single intra-articular (IA) injection of FX006 32 mg in the Hip\n\nFX006 32 mg: Extended-release 32 mg FX006 IA injection"
                                                },
                                                {
                                                    "OutcomeGroupId": "OG003",
                                                    "OutcomeGroupTitle": "TAcs 40 mg Hip",
                                                    "OutcomeGroupDescription": "Single intra-articular (IA) injection of TAcs 40 mg in the Hip\n\nTAcs 40 mg: Immediate-release 40mg TAcs IA injection"
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "12"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG001",
                                                                "OutcomeDenomCountValue": "13"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG002",
                                                                "OutcomeDenomCountValue": "15"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG003",
                                                                "OutcomeDenomCountValue": "15"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "10"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "7"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG002",
                                                                            "OutcomeMeasurementValue": "8"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG003",
                                                                            "OutcomeMeasurementValue": "17"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "AdverseEventsModule": {
                            "EventsFrequencyThreshold": "0",
                            "EventsTimeFrame": "Adverse events were collected following IA administration through the final study visit at 12 weeks.",
                            "EventGroupList": {
                                "EventGroup": [
                                    {
                                        "EventGroupId": "EG000",
                                        "EventGroupTitle": "FX006 32 mg Shoulder",
                                        "EventGroupDescription": "Single intra-articular (IA) injection of FX006 32 mg in the Shoulder\n\nFX006 32 mg: Extended-release 32 mg FX006 IA injection",
                                        "EventGroupDeathsNumAffected": "0",
                                        "EventGroupDeathsNumAtRisk": "12",
                                        "EventGroupSeriousNumAffected": "0",
                                        "EventGroupSeriousNumAtRisk": "12",
                                        "EventGroupOtherNumAffected": "4",
                                        "EventGroupOtherNumAtRisk": "12"
                                    },
                                    {
                                        "EventGroupId": "EG001",
                                        "EventGroupTitle": "TAcs 40 mg Shoulder",
                                        "EventGroupDescription": "Single intra-articular (IA) injection of TAcs 40 mg in the Shoulder\n\nTAcs 40 mg: Immediate-release 40mg TAcs IA injection",
                                        "EventGroupDeathsNumAffected": "0",
                                        "EventGroupDeathsNumAtRisk": "13",
                                        "EventGroupSeriousNumAffected": "0",
                                        "EventGroupSeriousNumAtRisk": "13",
                                        "EventGroupOtherNumAffected": "3",
                                        "EventGroupOtherNumAtRisk": "13"
                                    },
                                    {
                                        "EventGroupId": "EG002",
                                        "EventGroupTitle": "FX006 32 mg Hip",
                                        "EventGroupDescription": "Single intra-articular (IA) injection of FX006 32 mg in the Hip\n\nFX006 32 mg: Extended-release 32 mg FX006 IA injection",
                                        "EventGroupDeathsNumAffected": "0",
                                        "EventGroupDeathsNumAtRisk": "15",
                                        "EventGroupSeriousNumAffected": "0",
                                        "EventGroupSeriousNumAtRisk": "15",
                                        "EventGroupOtherNumAffected": "4",
                                        "EventGroupOtherNumAtRisk": "15"
                                    },
                                    {
                                        "EventGroupId": "EG003",
                                        "EventGroupTitle": "TAcs 40 mg Hip",
                                        "EventGroupDescription": "Single intra-articular (IA) injection of TAcs 40 mg in the Hip\n\nTAcs 40 mg: Immediate-release 40mg TAcs IA injection",
                                        "EventGroupDeathsNumAffected": "0",
                                        "EventGroupDeathsNumAtRisk": "15",
                                        "EventGroupSeriousNumAffected": "0",
                                        "EventGroupSeriousNumAtRisk": "15",
                                        "EventGroupOtherNumAffected": "7",
                                        "EventGroupOtherNumAtRisk": "15"
                                    }
                                ]
                            },
                            "OtherEventList": {
                                "OtherEvent": [
                                    {
                                        "OtherEventTerm": "Ear Pain",
                                        "OtherEventOrganSystem": "Ear and labyrinth disorders",
                                        "OtherEventSourceVocabulary": "MeDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "13"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Gastrooesophageal Reflux Disease",
                                        "OtherEventOrganSystem": "Gastrointestinal disorders",
                                        "OtherEventSourceVocabulary": "MeDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "13"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Nausea",
                                        "OtherEventOrganSystem": "Gastrointestinal disorders",
                                        "OtherEventSourceVocabulary": "MeDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "13"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Influenza Like Illness",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventSourceVocabulary": "MeDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "13"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Injection Site Hypoaesthesia",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventSourceVocabulary": "MeDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventNotes": "And Administrative Site Conditions",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "13"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Nasopharyngitis",
                                        "OtherEventOrganSystem": "Infections and infestations",
                                        "OtherEventSourceVocabulary": "MeDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "13"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Upper Respiratory Tract Infection",
                                        "OtherEventOrganSystem": "Infections and infestations",
                                        "OtherEventSourceVocabulary": "MeDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "13"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Urinary Tract Infection",
                                        "OtherEventOrganSystem": "Infections and infestations",
                                        "OtherEventSourceVocabulary": "MeDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "13"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Viral Upper Respiratory Tract Infection",
                                        "OtherEventOrganSystem": "Infections and infestations",
                                        "OtherEventSourceVocabulary": "MeDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "13"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Contusion",
                                        "OtherEventOrganSystem": "Injury, poisoning and procedural complications",
                                        "OtherEventSourceVocabulary": "MeDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "13"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Fall",
                                        "OtherEventOrganSystem": "Injury, poisoning and procedural complications",
                                        "OtherEventSourceVocabulary": "MeDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "13"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Incision Site Pain",
                                        "OtherEventOrganSystem": "Injury, poisoning and procedural complications",
                                        "OtherEventSourceVocabulary": "MeDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "13"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Periorbital Haemorrhage",
                                        "OtherEventOrganSystem": "Injury, poisoning and procedural complications",
                                        "OtherEventSourceVocabulary": "MeDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "13"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Road Traffic Accident",
                                        "OtherEventOrganSystem": "Injury, poisoning and procedural complications",
                                        "OtherEventSourceVocabulary": "MeDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "13"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Skin Abrasion",
                                        "OtherEventOrganSystem": "Injury, poisoning and procedural complications",
                                        "OtherEventSourceVocabulary": "MeDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "13"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Blood Pressure Increased",
                                        "OtherEventOrganSystem": "Investigations",
                                        "OtherEventSourceVocabulary": "MeDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "13"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Gout",
                                        "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                                        "OtherEventSourceVocabulary": "MeDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "13"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Arthralgia",
                                        "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                                        "OtherEventSourceVocabulary": "MeDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "13"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Back Pain",
                                        "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                                        "OtherEventSourceVocabulary": "MeDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "13"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Joint Range of Motion Decreased",
                                        "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                                        "OtherEventSourceVocabulary": "MeDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "13"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Muscular Weakness",
                                        "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                                        "OtherEventSourceVocabulary": "MeDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "13"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Musculoskeletal Discomfort",
                                        "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                                        "OtherEventSourceVocabulary": "MeDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "13"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Musculoskeletal Pain",
                                        "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                                        "OtherEventSourceVocabulary": "MeDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "13"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Osteoarthritis",
                                        "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                                        "OtherEventSourceVocabulary": "MeDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "13"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Pain In Extremity",
                                        "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                                        "OtherEventSourceVocabulary": "MeDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "13"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Headache",
                                        "OtherEventOrganSystem": "Nervous system disorders",
                                        "OtherEventSourceVocabulary": "MeDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "13"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Hypoaesthesia",
                                        "OtherEventOrganSystem": "Nervous system disorders",
                                        "OtherEventSourceVocabulary": "MeDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "13"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Testicular Pain",
                                        "OtherEventOrganSystem": "Reproductive system and breast disorders",
                                        "OtherEventSourceVocabulary": "MeDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "13"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Cough",
                                        "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                                        "OtherEventSourceVocabulary": "MeDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "13"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Respiratory Tract Congestion",
                                        "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                                        "OtherEventSourceVocabulary": "MeDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "13"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Melanocytic Hypoplasia",
                                        "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                                        "OtherEventSourceVocabulary": "MeDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "13"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Hot Flush",
                                        "OtherEventOrganSystem": "Vascular disorders",
                                        "OtherEventSourceVocabulary": "MeDRA 20.1",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "12"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "13"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "15"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "MoreInfoModule": {
                            "CertainAgreement": {
                                "AgreementPISponsorEmployee": "No",
                                "AgreementRestrictionType": "OTHER",
                                "AgreementRestrictiveAgreement": "Yes"
                            },
                            "PointOfContact": {
                                "PointOfContactTitle": "Scott Kelley MD, Chief Medical Officer",
                                "PointOfContactOrganization": "Flexion Therapeutics",
                                "PointOfContactEMail": "skelley@flexiontherapeutics.com",
                                "PointOfContactPhone": "781-305-7142"
                            }
                        }
                    },
                    "DocumentSection": {
                        "LargeDocumentModule": {
                            "LargeDocList": {
                                "LargeDoc": [
                                    {
                                        "LargeDocTypeAbbrev": "Prot",
                                        "LargeDocHasProtocol": "Yes",
                                        "LargeDocHasSAP": "No",
                                        "LargeDocHasICF": "No",
                                        "LargeDocLabel": "Study Protocol",
                                        "LargeDocDate": "April 5, 2018",
                                        "LargeDocUploadDate": "09/25/2019 16:26",
                                        "LargeDocFilename": "Prot_000.pdf"
                                    },
                                    {
                                        "LargeDocTypeAbbrev": "SAP",
                                        "LargeDocHasProtocol": "No",
                                        "LargeDocHasSAP": "Yes",
                                        "LargeDocHasICF": "No",
                                        "LargeDocLabel": "Statistical Analysis Plan",
                                        "LargeDocDate": "October 17, 2018",
                                        "LargeDocUploadDate": "09/25/2019 16:28",
                                        "LargeDocFilename": "SAP_001.pdf"
                                    }
                                ]
                            }
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000010003",
                                        "ConditionMeshTerm": "Osteoarthritis"
                                    },
                                    {
                                        "ConditionMeshId": "D000015207",
                                        "ConditionMeshTerm": "Osteoarthritis, Hip"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000001168",
                                        "ConditionAncestorTerm": "Arthritis"
                                    },
                                    {
                                        "ConditionAncestorId": "D000007592",
                                        "ConditionAncestorTerm": "Joint Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009140",
                                        "ConditionAncestorTerm": "Musculoskeletal Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000012216",
                                        "ConditionAncestorTerm": "Rheumatic Diseases"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M12078",
                                        "ConditionBrowseLeafName": "Osteoarthritis",
                                        "ConditionBrowseLeafAsFound": "Osteoarthritis",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M17064",
                                        "ConditionBrowseLeafName": "Osteoarthritis, Hip",
                                        "ConditionBrowseLeafAsFound": "Osteoarthritis of the Hip",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M12218",
                                        "ConditionBrowseLeafName": "Pain",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M3628",
                                        "ConditionBrowseLeafName": "Arthritis",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M9773",
                                        "ConditionBrowseLeafName": "Joint Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M11249",
                                        "ConditionBrowseLeafName": "Musculoskeletal Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M14197",
                                        "ConditionBrowseLeafName": "Rheumatic Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M5475",
                                        "ConditionBrowseLeafName": "Collagen Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC05",
                                        "ConditionBrowseBranchName": "Musculoskeletal Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC23",
                                        "ConditionBrowseBranchName": "Symptoms and General Pathology"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC17",
                                        "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionMeshList": {
                                "InterventionMesh": [
                                    {
                                        "InterventionMeshId": "D000014221",
                                        "InterventionMeshTerm": "Triamcinolone"
                                    },
                                    {
                                        "InterventionMeshId": "D000014222",
                                        "InterventionMeshTerm": "Triamcinolone Acetonide"
                                    },
                                    {
                                        "InterventionMeshId": "C000005900",
                                        "InterventionMeshTerm": "Triamcinolone hexacetonide"
                                    },
                                    {
                                        "InterventionMeshId": "C000631825",
                                        "InterventionMeshTerm": "FX006"
                                    },
                                    {
                                        "InterventionMeshId": "C000030262",
                                        "InterventionMeshTerm": "Triamcinolone diacetate"
                                    }
                                ]
                            },
                            "InterventionAncestorList": {
                                "InterventionAncestor": [
                                    {
                                        "InterventionAncestorId": "D000000893",
                                        "InterventionAncestorTerm": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000005938",
                                        "InterventionAncestorTerm": "Glucocorticoids"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006728",
                                        "InterventionAncestorTerm": "Hormones"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006730",
                                        "InterventionAncestorTerm": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045505",
                                        "InterventionAncestorTerm": "Physiological Effects of Drugs"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007166",
                                        "InterventionAncestorTerm": "Immunosuppressive Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007155",
                                        "InterventionAncestorTerm": "Immunologic Factors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000004791",
                                        "InterventionAncestorTerm": "Enzyme Inhibitors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045504",
                                        "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                                    }
                                ]
                            },
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafAsFound": "Deep",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M270065",
                                        "InterventionBrowseLeafName": "FX006",
                                        "InterventionBrowseLeafAsFound": "Stage III colon cancer",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M3369",
                                        "InterventionBrowseLeafName": "Anti-Inflammatory Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8199",
                                        "InterventionBrowseLeafName": "Glucocorticoids",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8941",
                                        "InterventionBrowseLeafName": "Hormones",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8940",
                                        "InterventionBrowseLeafName": "Hormone Antagonists",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9364",
                                        "InterventionBrowseLeafName": "Immunosuppressive Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9353",
                                        "InterventionBrowseLeafName": "Immunologic Factors",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 7,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT04043689",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "APHP 190051"
                            },
                            "SecondaryIdInfoList": {
                                "SecondaryIdInfo": [
                                    {
                                        "SecondaryId": "2019-A00501-56",
                                        "SecondaryIdType": "Other Identifier",
                                        "SecondaryIdDomain": "N°IDRCB"
                                    }
                                ]
                            },
                            "Organization": {
                                "OrgFullName": "Assistance Publique - Hôpitaux de Paris",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Therapeutic Effects of Transcranial Alternative Current Stimulation (tACS) in Chronic Post Stroke Hemianopia",
                            "OfficialTitle": "Therapeutic Effects of Transcranial Alternative Current Stimulation (tACS) in Chronic Post Stroke Hemianopia",
                            "Acronym": "HEMIANOTACS"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "July 2019",
                            "OverallStatus": "Unknown status",
                            "LastKnownStatus": "Not yet recruiting",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "October 1, 2019",
                                "StartDateType": "Anticipated"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "November 30, 2020",
                                "PrimaryCompletionDateType": "Anticipated"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "March 31, 2021",
                                "CompletionDateType": "Anticipated"
                            },
                            "StudyFirstSubmitDate": "July 25, 2019",
                            "StudyFirstSubmitQCDate": "August 1, 2019",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "August 2, 2019",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "August 1, 2019",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "August 2, 2019",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Sponsor"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Assistance Publique - Hôpitaux de Paris",
                                "LeadSponsorClass": "OTHER"
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "No",
                            "IsFDARegulatedDrug": "No",
                            "IsFDARegulatedDevice": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "Background: The most common visual field deficit after retro-chiasmatic lesions is homonymous hemianopia (HH), defined as the impossibility of seeing the contralesional visual hemisphere without ocular injury. HH affects between 90000 and 120 000 new cases per year in the United States and Europe HH was reported in 30% of patients after stroke (National Audit Office) (in France, with 130,000 strokes per year, 39,000 patients with HH). Despite the 30-year decline, the rehabilitation techniques have a low level of evidence of their effectiveness and few are used in routine clinical practice in France.\n\nTranscranial Alternate Current Stimulation (tACS) is a method of Alternative Current stimulation that can modulate neural activity by imposing local oscillatory activity.\n\nAn observational study of occipital tACS in patients with optic nerve lesions showed an increase in visual field size, power, and occipital alpha synchrony. Two transorbital tACS studies showed visual improvements , and compensations for abnormally weak oscillatory activity by temporal resynchronization. Our team has demonstrated a role of noninvasive brain stimulation in right hemisphere frontal eye fields on cortical beta-high (~ 30 Hz) oscillatory activity, improving the visual perception of both hemi-fields and the fronto-parietal synchrony of the right hemisphere.\n\nObjective:\n\nThis project aims to compare, on the same patient population, two tACS stimulation strategies, with the aim of increasing the attentional orientation towards the blind visual hemi-field and thus the visual detection of stimuli in this hemi-field. .\n\nFor this, The investigator team will evaluate on the one hand an occipital stimulation (V1-IPS) contralateral to the lesion, at a alfa frequency (10 Hz), which induces the desynchronization of the contralateral hemisphere with the aim of improving the visual perception of targets in the blind visual hemi-field. the study will compare this intervention to a stimulation of the frontal region (FEF) of the right hemisphere at a high-beta frequency (30 Hz), which showed effects of facilitation of endogenous and exogenous attentional orientation. The two previous strategies will be compared to a placebo tACS stimulation session.",
                            "DetailedDescription": "Background:\n\nFocusing on low-level perceptual activities, and robust, controlled explorations with medium-sized cohorts, several studies have shown tACS effects related to oscillatory activity and inter-regional synchrony.\n\nFor example, in healthy subjects, occipital tACS showed an increase in posterior alpha power following tACS alpha (10-14 Hz). At higher frequencies, the 60 Hz tACS showed a sustained reduction in visual contrast sensitivity threshold . Two studies in 2014 have also shown following 40 Hz tACS stimulation of occipital or parietal brain regions in healthy humans, sustained dependent on synchrony of posterior interhemispheric gamma band networks, and modulation effects of moving target perception Very recently, a 10 Hz occipital tACS stimulation study coupled with functional magnetic resonance Imaging recording (fMRI) showed diffuse effects likely to indicate occipito-parieto-temporal synchronization during the delayed phase of effects.\n\nAmong patients' trials, an observational study of uncontrolled occipital tACS in patients with optic nerve lesions showed improved visual acuity and visual field size, accompanied by an increase in power and of occipital alpha synchrony by targeting periorbital regions; More recently, a double-blind, multicenter, controlled trial in patients with optic nerve lesions showed, with daily transorbital tACS sessions lasting 10 weeks, a sustained (2.5%) increase in visual field size versus stimulation placebo.\n\nThis project aims to compare, on the same patient population, two tACS stimulation strategies, with the aim of increasing the attentional orientation towards the blind visual hemi-field and thus the visual detection of stimuli in this hemi-field. .\n\nFor this, the study will evaluate on the one hand an occipital stimulation (V1-IPS) contralateral to the lesion, at a alfa frequency (10 Hz), which induces the desynchronization of the contralateral hemisphere with the aim of improving the visual perception of targets in the blind visual hemi-field. This intervention will be compared to a stimulation of the frontal region (FEF) of the right hemisphere at a high-beta frequency (30 Hz), which showed effects of facilitation of endogenous and exogenous attentional orientation. The two previous strategies will be compared to a placebo tACS stimulation session.\n\nThe overall goal of this project is to modulate visual perception in patients with HH in the chronic phase using transcranial AC stimulation. The study aim is to evaluate the behavioral effects of tACS stimulation of the right fronto-parietal network (FEF-IPS) and the occipital and parieto-occipital region (V1-IPS), contralateral to the lesion, on visual perception in static and kinetic perimetry. The effects of stimulation of these two targets on brain activity by electrophysiology (EEG) will be quantified. The hypothesis is that the tACS, by increasing the functional connectivity (phase synchronism at the frequency delivered during the stimulation), will make it possible to modulate the threshold of visual perception.\n\nSpecifically, the hypothesis is that a single session of 30 Hz tACS stimulation of the right frontal cortex (around the right FEF) will increase fronto-parietal synchrony within the right hemisphere of patients with lesions acquired brain responsible for chronic HH, thus improving the static and kinetic visual field in the first 30 minutes post-stimulation. The investigator team also hypothesize that a single session of tACS stimulation on the occipital and posterior parietal cortex contralateral to the lesion (around the V1 region) of patients with acquired brain lesions responsible for chronic HH will improve the visual field in the first 30 minutes post-stimulation, but this improvement will be less compared to the improvement caused by the stimulation of the right FEF, which could be accompanied by a temporary decrease in the visual perception of the targets on the healthy visual hemi-field.\n\nMethods:\n\nMonocentric comparative randomized controlled, cross-over and blinded study, Major population (n = 18), acquired brain lesion responsible for homonymous hemianopia, chronic phase of cerebrovascular accident (between 3 months and 5 years of evolution) and cohort (n = 18) healthy subjects not treated with tACS to obtain normative data from visual fields, neuroimaging (MRI) and electroencephalography (EEG)\n\nEach patient or each healthy volunteer will have an inclusion visit including visual static and kinetic perimetry, EEG recordings, cognitive tests, questionnaire and brain MRI.\nThen, each patient will have 3 visits, including a first evaluation period (perimetry and EEG) then a stimulation session (right frontal active tACS or contralesional occipito-parietal active tACS, or placebo tACS) then a second evaluation time (EEG, perimetry , and reading tests)\n\nDiscussion:\n\nThe investigator team expect an immediate and significant increase in visual field size and improved visual detection capabilities of patients treated with active tACS stimulation on the right frontal region (FEF) and / or contralateral occipital region (V1-IPS) lesion\n\nThe project will contribute to the development of an innovative treatment to improve the quality of life of HH brain-injured patients, lacking effective treatment options to date.\n\nTACS is an easily accessible and easily applicable technique in large-scale clinical practice. Coupled with EEG monitoring, it is the only one that allows efficient and safe manipulation of oscillatory activity and interregional synchronicity.\n\nInterest in these new methods of non-invasive brain stimulation guiding brain plasticity, in stroke (130,000 new cases / year) or head trauma is very important. The scientific, clinical and technological implications are major."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Hemianopsia"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Not Applicable"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "Randomized",
                                "DesignInterventionModel": "Crossover Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "Triple",
                                    "DesignWhoMaskedList": {
                                        "DesignWhoMasked": [
                                            "Participant",
                                            "Investigator",
                                            "Outcomes Assessor"
                                        ]
                                    }
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "36",
                                "EnrollmentType": "Anticipated"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "tACS stimulation of the right frontal region",
                                        "ArmGroupType": "Active Comparator",
                                        "ArmGroupDescription": "Active tACS stimulation of the right frontal region (around the right FEF, EEG electrode FC2) at a high-beta frequency (30 Hz) with the goal of visibly training EEG recordings, frontal oscillatory activity and right fronto-parietal synchrony (FEF-IPS, or between FC2 and P4 electrodes) in the high-beta band (~ 30 Hz) which facilitates attentional orientation and visual perception in the two visual hemi-fields, but more particularly the targets present on the blind field of vision.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: tACS (transcranial Alternate Current Stimulation)"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "tACS stimulation of the occipito-parietal region",
                                        "ArmGroupType": "Active Comparator",
                                        "ArmGroupDescription": "Active tACS stimulation of the occipito-parietal posterior contralesional region(around the right IPS, EEG electrode P4), at an alpha frequency (10 Hz) which will induce on the EEG recordings an oscillatory drive in the alpha band ( ~ 10Hz) and an increase in synchrony at this frequency band on the stimulated posterior occipital and parietal lobe (EEG electrodes P4 and 02), but also, by transcallosal push-and-pull phenomena, a desynchronization effect of the contralateral posterior occipital and parietal area (EEG electrodes P3 and 01), which will facilitate attention orientation and target detection in the blind visual field of view.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: tACS (transcranial Alternate Current Stimulation)"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "TACS stimulation of the right frontal (FEF)",
                                        "ArmGroupType": "Sham Comparator",
                                        "ArmGroupDescription": ". Condition TACS stimulation of the right frontal (FEF) at a high-beta frequency (30 Hz) for half of the patients and unilateral occipital cortex (right / left) at an alfa frequency (10 Hz) for the other half . This condition will control the possible placebo effects of tACS stimulation and the potential effects of visual field enhancement with repetition of perimetry tests. This condition will also verify the lack of changes in cerebral rhythm activity in the case of an application without effective electrical current.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: tACS (transcranial Alternate Current Stimulation)"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "tACS (transcranial Alternate Current Stimulation)",
                                        "InterventionDescription": "This is a single-centric comparative randomized controlled blind and cross-over study.\n\nThe order of stimulation conditions will be randomized: (right frontal tACS / occipital tACS / tACS PLACEBO). The 3 stimulation conditions will be performed with a wash-out period of at least 1 week. In this study each patient will be his own control",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "TACS stimulation of the right frontal (FEF)",
                                                "tACS stimulation of the occipito-parietal region",
                                                "tACS stimulation of the right frontal region"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "To evaluate the immediate effect of a single tACS session on the static visual field size of patients with chronic phase HH",
                                        "PrimaryOutcomeDescription": "To evaluate the immediate effect of a single tACS session, under two different conditions of tACS stimulation (right frontal stimulation (FEF, Frontal Eye Fields) and contralateral occipito-parietal stimulation to the lesion (V1-IPS, primary visual cortex and intraparietal sulcus or intra-parietal furrow) on the static visual field size of patients with chronic phase HH",
                                        "PrimaryOutcomeTimeFrame": "Immediately after the intervention"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nPatient aged 18 and over\n\nPatient with homonymous lateral hemianopia with brain injury acquired for at least 3 months and at most 5 years after ischemic stroke, cerebral hematoma\nPatient able to understand French both orally and in writing\nPatient giving free, informed and written consent\nAbsence of a neurological disease interfering with the passing of tests\n\nNon-inclusion criteria :\n\nPatients subject to a legal protection measure (safeguarding of justice, guardianship and trusteeship, protected adults)\nPre-existing severe ophthalmological disorders (ophthalmic consultation before inclusion) pre-existing visual field defects, monocular visual acuity less than 5/10, severe oculomotor disorders\nContraindication of tACS and / or magnetic resonance imaging (pacemaker or implantable defibrillator, intracranial electrodes or other intracranial implant, cranial vault anomalies facing stimulation electrodes (plates, prostheses, uncovered skull)\nPregnant women and nursing mothers\nRecruitment in other interventional studies for the duration of the participation.\nNon-affiliation to a social security scheme (excluding AME) or non-beneficiary of such a scheme\n\nHealthy participants inclusion criteria are the following:\n\nHealthy Subject 18 years and older\nHealthy subject able to understand French both orally and in writing\nHealthy subject who has given free and informed consent and writes\n\nHealthy participants non-inclusion criteria are the following:\n\nSevere neurological, psychiatric, physical, or ophthalmological disorders that interfere with the normal performance of tests and study tasks\nContraindication to magnetic resonance imaging (pacemaker or implantable defibrillator, intracranial electrodes or other intracranial implant, abnormalities of the cranial vault opposite stimulation electrodes (plates, prostheses, uncovered skull)\nRecruitment in other interventional studies for the duration of the participation.\nPregnant women and nursing mothers\nNon-affiliation to a social security scheme (excluding AME) or non-beneficiary of such a scheme",
                            "HealthyVolunteers": "Accepts Healthy Volunteers",
                            "Gender": "All",
                            "MinimumAge": "18 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "CentralContactList": {
                                "CentralContact": [
                                    {
                                        "CentralContactName": "Alexia POTET, MD",
                                        "CentralContactRole": "Contact",
                                        "CentralContactPhone": "142161149",
                                        "CentralContactPhoneExt": "+33",
                                        "CentralContactEMail": "alexia.potet@aphp.fr"
                                    },
                                    {
                                        "CentralContactName": "Antoni VALERO-CABRÉ",
                                        "CentralContactRole": "Contact",
                                        "CentralContactPhone": "157274163",
                                        "CentralContactPhoneExt": "+33",
                                        "CentralContactEMail": "antoni.valerocabre@icm-institute.org"
                                    }
                                ]
                            }
                        },
                        "ReferencesModule": {
                            "ReferenceList": {
                                "Reference": [
                                    {
                                        "ReferencePMID": "17992086",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Sahraie A. Induced visual sensitivity changes in chronic hemianopia. Curr Opin Neurol. 2007 Dec;20(6):661-6. Review."
                                    },
                                    {
                                        "ReferencePMID": "20172510",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Schuett S, Dauner R, Zihl J. Line bisection in unilateral homonymous visual field defects. Cortex. 2011 Jan;47(1):47-52. doi: 10.1016/j.cortex.2010.01.008. Epub 2010 Jan 28."
                                    },
                                    {
                                        "ReferencePMID": "25414662",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Sergeeva EG, Henrich-Noack P, Bola M, Sabel BA. Brain-state-dependent non-invasive brain stimulation and functional priming: a hypothesis. Front Hum Neurosci. 2014 Nov 5;8:899. doi: 10.3389/fnhum.2014.00899. eCollection 2014."
                                    },
                                    {
                                        "ReferencePMID": "22124039",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Sabel BA, Fedorov AB, Naue N, Borrmann A, Herrmann C, Gall C. Non-invasive alternating current stimulation improves vision in optic neuropathy. Restor Neurol Neurosci. 2011;29(6):493-505. doi: 10.3233/RNN-2011-0624."
                                    },
                                    {
                                        "ReferencePMID": "21072168",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Zaehle T, Rach S, Herrmann CS. Transcranial alternating current stimulation enhances individual alpha activity in human EEG. PLoS One. 2010 Nov 1;5(11):e13766. doi: 10.1371/journal.pone.0013766."
                                    },
                                    {
                                        "ReferencePMID": "25549264",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Helfrich RF, Knepper H, Nolte G, Strüber D, Rach S, Herrmann CS, Schneider TR, Engel AK. Selective modulation of interhemispheric functional connectivity by HD-tACS shapes perception. PLoS Biol. 2014 Dec 30;12(12):e1002031. doi: 10.1371/journal.pbio.1002031. eCollection 2014 Dec."
                                    },
                                    {
                                        "ReferencePMID": "26608246",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Alekseichuk I, Diers K, Paulus W, Antal A. Transcranial electrical stimulation of the occipital cortex during visual perception modifies the magnitude of BOLD activity: A combined tES-fMRI approach. Neuroimage. 2016 Oct 15;140:110-7. doi: 10.1016/j.neuroimage.2015.11.034. Epub 2015 Nov 23."
                                    }
                                ]
                            }
                        },
                        "IPDSharingStatementModule": {
                            "IPDSharing": "Undecided"
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000006423",
                                        "ConditionMeshTerm": "Hemianopsia"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000014786",
                                        "ConditionAncestorTerm": "Vision Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000012678",
                                        "ConditionAncestorTerm": "Sensation Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009461",
                                        "ConditionAncestorTerm": "Neurologic Manifestations"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009422",
                                        "ConditionAncestorTerm": "Nervous System Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000001766",
                                        "ConditionAncestorTerm": "Blindness"
                                    },
                                    {
                                        "ConditionAncestorId": "D000005128",
                                        "ConditionAncestorTerm": "Eye Diseases"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M21459",
                                        "ConditionBrowseLeafName": "Stroke",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M8661",
                                        "ConditionBrowseLeafName": "Hemianopsia",
                                        "ConditionBrowseLeafAsFound": "Hemianopsia",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M16682",
                                        "ConditionBrowseLeafName": "Vision Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M14642",
                                        "ConditionBrowseLeafName": "Sensation Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M11556",
                                        "ConditionBrowseLeafName": "Neurologic Manifestations",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M4199",
                                        "ConditionBrowseLeafName": "Blindness",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M7423",
                                        "ConditionBrowseLeafName": "Eye Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC10",
                                        "ConditionBrowseBranchName": "Nervous System Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC14",
                                        "ConditionBrowseBranchName": "Heart and Blood Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC11",
                                        "ConditionBrowseBranchName": "Eye Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC23",
                                        "ConditionBrowseBranchName": "Symptoms and General Pathology"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 8,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT05282329",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "tACS-TJAH"
                            },
                            "Organization": {
                                "OrgFullName": "Tianjin Anding Hospital",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Efficacy of tACS for Treatment of Auditory Hallucinations in Refractory Schizophrenia",
                            "OfficialTitle": "Efficacy of Transcranial Alternating Current Stimulation (tACS) as an Add-on Treatment for Auditory Hallucinations in Refractory Schizophrenia: A Randomized, Double-blind, Sham-controlled Trial"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "February 2022",
                            "OverallStatus": "Recruiting",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "September 1, 2020",
                                "StartDateType": "Actual"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "July 31, 2022",
                                "PrimaryCompletionDateType": "Anticipated"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "December 31, 2022",
                                "CompletionDateType": "Anticipated"
                            },
                            "StudyFirstSubmitDate": "February 14, 2022",
                            "StudyFirstSubmitQCDate": "March 7, 2022",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "March 16, 2022",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "March 7, 2022",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "March 16, 2022",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Sponsor"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Tianjin Anding Hospital",
                                "LeadSponsorClass": "OTHER"
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "Yes",
                            "IsFDARegulatedDrug": "No",
                            "IsFDARegulatedDevice": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "The aim of this study is to evaluate the feasibility and efficacy of transcranial alternating current stimulation (tACS) as an add-on treatment for auditory hallucinations in refractory schizophrenia. Meanwhile, we aim to evaluate the effect of tACS on cognitive function of schizophrenia patients. we hypothesize tACS would improve refractory auditory hallucination symptoms in schizophrenia by regulating the alpha or gamma frequency band of temporal lobe。",
                            "DetailedDescription": "This is a randomized, double-blind, sham-controlled study to detect the effect of tACS for treatment of refractory auditory hallucinations in schizophrenia. 66 participants were randomly assigned 1:1 to tACS group or sham-control group. For both active and sham group, daily tACS sessions were scheduled in a 5-day sequence for four consecutive weeks, and each session lasted 20minutes. Based on the original and stable medication, active participants were administered 2 mA alternating current delivered with alpha frequency, delivered over the temporal lobe, while controls received sham stimulations with the same protocol. Scale assessments are performed at baseline, week 2, week 4 and week 6. Collection of blood took place at baseline, week 4 and week 6."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Schizophrenia"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Not Applicable"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "Randomized",
                                "DesignInterventionModel": "Parallel Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "Quadruple",
                                    "DesignWhoMaskedList": {
                                        "DesignWhoMasked": [
                                            "Participant",
                                            "Care Provider",
                                            "Investigator",
                                            "Outcomes Assessor"
                                        ]
                                    }
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "40",
                                "EnrollmentType": "Anticipated"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "tACS group",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "Participants receive tACS 20-min sessions in a 5-day sequence for four consecutive weeks,combined with original and stable medication. Active group participants were administered 2 mA alternating current delivered with alpha frequency, delivered over the temporal lobe.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: Transcranial alternating Current Stimulation (tACS)-active"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "Sham group",
                                        "ArmGroupType": "Sham Comparator",
                                        "ArmGroupDescription": "Controls received sham stimulation with the same protocol.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: Transcranial Alternating Current Stimulation (tACS)-sham"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "Transcranial alternating Current Stimulation (tACS)-active",
                                        "InterventionDescription": "Transcranial alternating current stimulation (tACS) employs a weak electric current for non-invasive brain stimulation with a sine-wave waveform, targeting brain oscillations in a frequency-specific manner. daily tACS sessions were scheduled in a 5-day sequence for four consecutive weeks, and each session lasted 20minutes. Participants were administered 2 mA alternating current delivered with alpha frequency, delivered over the temporal lobe.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "tACS group"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "Transcranial Alternating Current Stimulation (tACS)-sham",
                                        "InterventionDescription": "Transcranial alternating current stimulation (tACS) employs a weak electric current for non-invasive brain stimulation with a sine-wave waveform, targeting brain oscillations in a frequency-specific manner. Controls received sham stimulations with the same protocol.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Sham group"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "The change over time in the score of Psychotic Symptom Rating Scales (PSYRATS)",
                                        "PrimaryOutcomeDescription": "The main objective is to explore whether tACS combined with antipsychotics could improve refractory auditory hallucinations in schizophrenia after 4-week treatment. PSYRATS were assessed at baseline and week 2, 4, 6. Higher total score of the scale means more severe auditory hallucinations symptoms.",
                                        "PrimaryOutcomeTimeFrame": "baseline, week 2, week 4, week 6"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "The change over time in the score of Hamilton Depression Rating Scale (HAMD-17)",
                                        "SecondaryOutcomeDescription": "The change over time in the score of Hamilton Depression Rating Scale (HAMD-17)The aim is to explore whether tACS combined with antipsychotics could alleviate the severity of depressive symptoms as measured with HAMD-17 in refractory schizophrenia after 4-week treatment. Hamilton Depression Rating Scale (HAMD-17) was used to evaluate the severity of symptoms of depression. Higher total score of the scale means more severe depressive symptoms.",
                                        "SecondaryOutcomeTimeFrame": "baseline, week 2, week 4, week 6"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The change over time in the score of Hamilton Anxiety Rating Scale (HAMA)",
                                        "SecondaryOutcomeDescription": "The aim is to explore whether tACS combined with antipsychotics could alleviate the severity of anxious symptoms as measured with HAMA in refractory schizophrenia after 4-week treatment. Hamilton Anxiety Rating Scale (HAMA) was used to evaluate the severity of symptoms of anxiety. Higher total score of the scale means more severe anxious symptoms.",
                                        "SecondaryOutcomeTimeFrame": "baseline, week 2, week 4, week 6"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The change of scores in cognition",
                                        "SecondaryOutcomeDescription": "The aim is to observe whether active-stimuli in addition to regular treatment with antipsychotics will improve the cognitive function as measured with the MATRICS Consensus Cognitive Battery after 4 weeks of treatment compared to sham-stimuli, and investigators assess the scale at baseline and week 4.",
                                        "SecondaryOutcomeTimeFrame": "baseline, week 4"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The changes of levels of Brain Derived Neurotrophic Factor in peripheral blood from baseline to week 6",
                                        "SecondaryOutcomeDescription": "The aim is to investigate the change of Brain Derived Neurotrophic Factor level in peripheral blood as active stimuli in addition to regular medical treatment after 4 weeks of treatment compared to sham stimuli, and EDTA tubes were used to collect 5ml of peripheral blood at baseline, weeks 4, and 6 before feeding. The plasma was extracted after centrifugation, and the concentration of BDNF in plasma was detected by ELISA.",
                                        "SecondaryOutcomeTimeFrame": "baseline, week 4, week 6"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The change of scores of Adverse events scale from baseline to week 4",
                                        "SecondaryOutcomeDescription": "The aim is to evaluate the adverse effects during the treatment.",
                                        "SecondaryOutcomeTimeFrame": "week 1, week 2, week 3, week 4"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The change of Gamma band activity before and after intervention",
                                        "SecondaryOutcomeDescription": "The aim is to observe the changes in gamma band activity before and after intervention. EEG signals were recorded at baseline, 4 and 6 weeks. Gamma has been interpreted as an imbalance between excitation and inhibition, and is significantly associated with positive symptoms in schizophrenia. Changes in Gamma PSD before and after intervention were calculated by resting state EEG. In addition, 40hz - auditory homeostasis was collected to calculate whether the power of auditory evoked potentials changed before and after the intervention.",
                                        "SecondaryOutcomeTimeFrame": "baseline, week4, week 6"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nEligible participants aged 18-70 with DSM-5-defined schizophrenia or schizophrenia-like disorder.\nDuration of illness > 12 weeks.\nBeing clinically stable and on an adequate therapeutic dose of antipsychotics for at least 8 weeks prior to enrolment.\nJunior high school education or above\nAfter treatment with ≥ 2 different antipsychotics (greater than the equivalent dose of chlorpromazine 600mg), the curative effect was poor (CGI ≥ 4 points or the PANSS score reduction rate since this treatment was less than 20%)\nAgreement to participate in the study and provide the written informed consent.\n\nExclusion Criteria:\n\nHaving unstable medical conditions, current psychiatric comorbidity or active substance use disorder (in exception to caffeine and/or tobacco)\nHaving Serious physical diseases or nervous system diseases;\nHaving any brain device / implant, including cochlear implant and aneurysm clip;\nHaving a history or family history of autoimmune diseases or immune diseases;\nPregnancy or breastfeeding at enrollment;\nSkin lesions on scalp at the area of electrode application.",
                            "HealthyVolunteers": "No",
                            "Gender": "All",
                            "MinimumAge": "18 Years",
                            "MaximumAge": "70 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "CentralContactList": {
                                "CentralContact": [
                                    {
                                        "CentralContactName": "Jie Li, Doctor",
                                        "CentralContactRole": "Contact",
                                        "CentralContactPhone": "022-88188006",
                                        "CentralContactEMail": "jieli@tjmhc.com"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "Tianjin Anding Hospital",
                                        "LocationStatus": "Recruiting",
                                        "LocationCity": "Tianjin",
                                        "LocationState": "Tianjin",
                                        "LocationCountry": "China",
                                        "LocationContactList": {
                                            "LocationContact": [
                                                {
                                                    "LocationContactName": "Jie Li, doctor",
                                                    "LocationContactRole": "Contact",
                                                    "LocationContactPhone": "+86 022 88188006",
                                                    "LocationContactEMail": "jieli@tjmhc.com"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000006212",
                                        "ConditionMeshTerm": "Hallucinations"
                                    },
                                    {
                                        "ConditionMeshId": "D000012559",
                                        "ConditionMeshTerm": "Schizophrenia"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000019967",
                                        "ConditionAncestorTerm": "Schizophrenia Spectrum and Other Psychotic Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000001523",
                                        "ConditionAncestorTerm": "Mental Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000010468",
                                        "ConditionAncestorTerm": "Perceptual Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000019954",
                                        "ConditionAncestorTerm": "Neurobehavioral Manifestations"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009461",
                                        "ConditionAncestorTerm": "Neurologic Manifestations"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009422",
                                        "ConditionAncestorTerm": "Nervous System Diseases"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M14528",
                                        "ConditionBrowseLeafName": "Schizophrenia",
                                        "ConditionBrowseLeafAsFound": "Schizophrenia",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M8456",
                                        "ConditionBrowseLeafName": "Hallucinations",
                                        "ConditionBrowseLeafAsFound": "Hallucinations",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M3967",
                                        "ConditionBrowseLeafName": "Mental Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M13625",
                                        "ConditionBrowseLeafName": "Psychotic Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M20991",
                                        "ConditionBrowseLeafName": "Schizophrenia Spectrum and Other Psychotic Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M12531",
                                        "ConditionBrowseLeafName": "Perceptual Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M20979",
                                        "ConditionBrowseLeafName": "Neurobehavioral Manifestations",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M11556",
                                        "ConditionBrowseLeafName": "Neurologic Manifestations",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BXM",
                                        "ConditionBrowseBranchName": "Behaviors and Mental Disorders"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC10",
                                        "ConditionBrowseBranchName": "Nervous System Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC23",
                                        "ConditionBrowseBranchName": "Symptoms and General Pathology"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 9,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT04710719",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "Keloid_5FU/TAC"
                            },
                            "Organization": {
                                "OrgFullName": "Our Lady of the Lake Hospital",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Post-Surgical Injection With Triamcinolone Versus Triamcinolone/Fluorouracil in Treatment of Keloids",
                            "OfficialTitle": "Efficacy of Post-Surgical Intralesional Injection With Triamcinolone Versus Triamcinolone Plus Fluorouracil in the Treatment of Keloids"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "September 2021",
                            "OverallStatus": "Recruiting",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "February 1, 2021",
                                "StartDateType": "Actual"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "December 31, 2023",
                                "PrimaryCompletionDateType": "Anticipated"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "December 31, 2023",
                                "CompletionDateType": "Anticipated"
                            },
                            "StudyFirstSubmitDate": "January 12, 2021",
                            "StudyFirstSubmitQCDate": "January 13, 2021",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "January 15, 2021",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "September 8, 2021",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "September 16, 2021",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Sponsor"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Our Lady of the Lake Hospital",
                                "LeadSponsorClass": "OTHER"
                            },
                            "CollaboratorList": {
                                "Collaborator": [
                                    {
                                        "CollaboratorName": "Louisiana State University Health Sciences Center in New Orleans",
                                        "CollaboratorClass": "OTHER"
                                    }
                                ]
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "Yes",
                            "IsFDARegulatedDrug": "No",
                            "IsFDARegulatedDevice": "No",
                            "IsUSExport": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "There have been many modalities utilized in the treatment of keloids of the head and neck, however none have been universally successful. The most widely utilized non-surgical intervention is primary intralesional injection with triamcinolone (TAC) which inhibits the proliferation of fibroblasts, inhibits collagen synthesis, and increases collagenase production, or fluorouracil (5-FU), a potent inhibitor of fibroblast proliferation. Despite the abundance of studies evaluating primary intralesional injection for keloids, there are limited studies available regarding the efficacy of primary surgical excision followed by adjuvant intralesional injection. The proposed study herein would serve to improve the level of evidence and to establish the safety and efficacy of combined intralesional TAC+5FU for keloids following surgical excision.",
                            "DetailedDescription": "This is a single blinded, prospective randomized controlled trial of patients who elect for surgical treatment of keloids at the Center for Facial Plastic and Reconstructive Surgery at Our Lady of the Lake Regional Medical Center (OLOLRMC), a tertiary referral center affiliated with the Louisiana State University Health Sciences Center (LSUHSC) teaching system. Power analysis estimated approximately 134 patients total (67 per group) for 80% power to detect a difference at the 5% confidence level. This is based off of a prior group's study comparing primary intralesional injection with TAC vs TAC+5FU (no surgery). That study showed 39.2% recurrence with TAC vs 17.5% with TAC+5FU.\n\nThe patients enrolled in the study will be randomized to one of two arms: surgical excision+TAC or surgical excision+TAC+5FU. Randomization will be performed using a permuted block randomization algorithm (Ex. AABBABABABBABBAA, where A=TAC only group and B=TAC +5FU). All patients will undergo surgical excision of the keloid, either under general anesthesia in the operating room or local anesthesia in the clinic setting depending on patient age and preference. The goal of excision will be complete extra-lesional excision with primary closure. It will be noted if a patient requires intra-lesional excision or additional reconstructive techniques such as advancement flap, skin grafting, or allografting (i.e. Integra). Monofilament sutures will be used preferentially to prevent local inflammatory reaction which can precipitate keloid formation. In group 1 (surgical excision+TAC), all patients will be treated with adjuvant intralesional TAC 40mg/mL 7-10 days post-op and then every 4 weeks for a total of 3 injections. The triamcinolone vial will be obtained from pharmacy and drawn up by the physician prior to injection. In group 2 (surgical excision+TAC+5FU), all patients will be treated with adjuvant intralesional TAC and 5FU at a dose of 0.1mg TAC for every 0.9mg 5FU 7-10 days post-op then every 4 weeks for a total of 3 injections. The mixture of TAC+5FU will be prepared by the pharmacy and delivered to the physician prior to injection. The goal volume of injection for both arms of the study will be 0.1cc per cm2 of scar excised, though any deviations from this and the rationale will be noted.\n\nAssessments will be performed at 3, 6, 9, and 12 months after completion of treatment. At each time point, a member of the study team and patient will complete their respective portion of the Patient and Observer Scar Assessment Scale (POSAS) which has been proven as a reliable and valid method of assessing keloid scars (5). The observer portion of the survey to be completed by the study team assesses vascularity, pigmentation, thickness, pliability, and surface area of the lesion. The patient portion of the survey focuses on the overall cosmetic and functional sequela including pain, itching, color, stiffness, thickness, and irregularity. Patients will also be asked about any side effects experienced. Each portion of the POSAS will be blinded from the study team member and the participant until both have completed the survey at each visit, so that one set of answers will not bias the other. If a patient demonstrates signs of recurrence or return of symptoms, there will be the option for additional injections within the patient's originally designated study arm. However, if early analysis demonstrates the alternative study arm to have superior efficacy, there will be the option to continue injections with the alternative study arm injection.\n\nData collection will include demographic data such as age, gender, race, and Fitzpatrick skin type, as well as location of the keloid, etiology (trauma, post-surgical, etc.), and prior treatments if any. The size and thickness of each lesion, secondary defect size following adjacent tissue transfer, and amount of adjuvant medication injected during each adjuvant injection will be collected. Data analysis will include overall efficacy as well as stratification by variables such as the location of the lesion, size of the lesion, and prior treatment."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Keloid",
                                    "Keloid Scar Following Surgery"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Not Applicable"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "Randomized",
                                "DesignInterventionModel": "Parallel Assignment",
                                "DesignInterventionModelDescription": "2 cohort arms, single blinded; 1=TAC alone, 2=TAC+5FU",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "Single",
                                    "DesignMaskingDescription": "Participants will not be aware of which injection they will be receiving in follow up treatment for their keloid (TAC alone or TAC/5FU)",
                                    "DesignWhoMaskedList": {
                                        "DesignWhoMasked": [
                                            "Participant"
                                        ]
                                    }
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "134",
                                "EnrollmentType": "Anticipated"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "TAC only",
                                        "ArmGroupType": "Active Comparator",
                                        "ArmGroupDescription": "Participants will be treated with adjuvant intralesional TAC 40mg/mL 7-10 days post-op and then every 4 weeks for a total of 3 injections. Assessments will be performed at 3, 6, 9, and 12 months after completion of treatment. At each time point, a member of the study team and patient will complete their respective portion of the Patient and Observer Scar Assessment Scale (POSAS).",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: Triamcinolone Injection"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "TAC + 5FU",
                                        "ArmGroupType": "Active Comparator",
                                        "ArmGroupDescription": "Participants will be treated with adjuvant intralesional TAC and 5FU at a dose of 0.1mg TAC for every 0.9mg 5FU 7-10 days post-op then every 4 weeks for a total of 3 injections. Assessments will be performed at 3, 6, 9, and 12 months after completion of treatment. At each time point, a member of the study team and patient will complete their respective portion of the Patient and Observer Scar Assessment Scale (POSAS).",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: Triamcinolone Injection and 5-fluorouracil injection"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "Triamcinolone Injection",
                                        "InterventionDescription": "Post surgical injection at site of keloid with TAC for 3 injections",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "TAC only"
                                            ]
                                        },
                                        "InterventionOtherNameList": {
                                            "InterventionOtherName": [
                                                "TAC"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "Triamcinolone Injection and 5-fluorouracil injection",
                                        "InterventionDescription": "Post surgical injection at site of keloid with TAC and 5FU for 3 injections",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "TAC + 5FU"
                                            ]
                                        },
                                        "InterventionOtherNameList": {
                                            "InterventionOtherName": [
                                                "TAC + 5FU"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Keloid Recurrence by visual assessment meaning either there is or is not a keloid physically present (determined by number of keloids observed and rate of recurrence after treatment)",
                                        "PrimaryOutcomeDescription": "Treatment effective if no keloid recurrence is visible by 12 months post treatment",
                                        "PrimaryOutcomeTimeFrame": "12 months"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "Symptomatology-assessed by Patient and Observer Scar Assessment Scale",
                                        "SecondaryOutcomeDescription": "Effectiveness of treatment on symptoms (pruritus, pain, hyperpigmentation or other side effects) as determined by changes in the POSAS survey (1 being \"not observed\" to 10 being \"present always\" and also by visual assessment by the physician",
                                        "SecondaryOutcomeTimeFrame": "3 months"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nSubjects of any age\nSubjects with at least one keloid of any size located in the head and neck region\n\nExclusion Criteria:\n\nsubjects with comorbidities prohibiting local injection of either TAC or 5FU including pregnancy, lactation, or planning pregnancy.",
                            "HealthyVolunteers": "Accepts Healthy Volunteers",
                            "Gender": "All",
                            "StdAgeList": {
                                "StdAge": [
                                    "Child",
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "CentralContactList": {
                                "CentralContact": [
                                    {
                                        "CentralContactName": "Christine LeBoeuf, DNP",
                                        "CentralContactRole": "Contact",
                                        "CentralContactPhone": "225-765-5956",
                                        "CentralContactEMail": "christine.leboeuf@fmolhs.org"
                                    },
                                    {
                                        "CentralContactName": "Leslie Son, PhD",
                                        "CentralContactRole": "Contact",
                                        "CentralContactPhone": "225-757-4165",
                                        "CentralContactEMail": "Lson@lsuhsc.edu"
                                    }
                                ]
                            },
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Justin Sowder, MD",
                                        "OverallOfficialAffiliation": "Louisiana State University Health Sciences Center - New Orleans",
                                        "OverallOfficialRole": "Principal Investigator"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "Our Lady of the Lake Hospital",
                                        "LocationStatus": "Recruiting",
                                        "LocationCity": "Baton Rouge",
                                        "LocationState": "Louisiana",
                                        "LocationZip": "70808",
                                        "LocationCountry": "United States",
                                        "LocationContactList": {
                                            "LocationContact": [
                                                {
                                                    "LocationContactName": "Leslie Son, Ph.D.",
                                                    "LocationContactRole": "Contact",
                                                    "LocationContactPhone": "225-757-4165",
                                                    "LocationContactEMail": "lson@lsuhsc.edu"
                                                },
                                                {
                                                    "LocationContactName": "Christine LeBoeuf, DNP",
                                                    "LocationContactRole": "Contact",
                                                    "LocationContactPhone": "225-765-5956",
                                                    "LocationContactEMail": "christine.leboeuf@fmolhs.org"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "ReferencesModule": {
                            "ReferenceList": {
                                "Reference": [
                                    {
                                        "ReferencePMID": "27427423",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Ren Y, Zhou X, Wei Z, Lin W, Fan B, Feng S. Efficacy and safety of triamcinolone acetonide alone and in combination with 5-fluorouracil for treating hypertrophic scars and keloids: a systematic review and meta-analysis. Int Wound J. 2017 Jun;14(3):480-487. doi: 10.1111/iwj.12629. Epub 2016 Jul 18. Review."
                                    },
                                    {
                                        "ReferencePMID": "30340861",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Khalid FA, Mehrose MY, Saleem M, Yousaf MA, Mujahid AM, Rehman SU, Ahmad S, Tarar MN. Comparison of efficacy and safety of intralesional triamcinolone and combination of triamcinolone with 5-fluorouracil in the treatment of keloids and hypertrophic scars: Randomised control trial. Burns. 2019 Feb;45(1):69-75. doi: 10.1016/j.burns.2018.08.011. Epub 2018 Oct 16."
                                    },
                                    {
                                        "ReferencePMID": "16404281",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Al-Attar A, Mess S, Thomassen JM, Kauffman CL, Davison SP. Keloid pathogenesis and treatment. Plast Reconstr Surg. 2006 Jan;117(1):286-300. Review."
                                    },
                                    {
                                        "ReferencePMID": "19233005",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Davison SP, Dayan JH, Clemens MW, Sonni S, Wang A, Crane A. Efficacy of intralesional 5-fluorouracil and triamcinolone in the treatment of keloids. Aesthet Surg J. 2009 Jan-Feb;29(1):40-6. doi: 10.1016/j.asj.2008.11.006."
                                    },
                                    {
                                        "ReferencePMID": "19595138",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Wu XL, Gao Z, Song N, Liu W. [Clinical study of auricular keloid treatment with both surgical excision and intralesional injection of low-dose 5-fluorouracil and corticosteroids]. Zhonghua Yi Xue Za Zhi. 2009 Apr 28;89(16):1102-5. Chinese."
                                    },
                                    {
                                        "ReferencePMID": "22373972",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Nicholas RS, Falvey H, Lemonas P, Damodaran G, Ghannem A, Selim F, Navsaria H, Myers S. Patient-related keloid scar assessment and outcome measures. Plast Reconstr Surg. 2012 Mar;129(3):648-656. doi: 10.1097/PRS.0b013e3182402c51. Erratum in: Plast Reconstr Surg. 2012 May;129(5):1213. Ghannem, Ali [corrected to Ghanem, Ali M]."
                                    }
                                ]
                            }
                        },
                        "IPDSharingStatementModule": {
                            "IPDSharing": "No"
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000007627",
                                        "ConditionMeshTerm": "Keloid"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000003095",
                                        "ConditionAncestorTerm": "Collagen Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000003240",
                                        "ConditionAncestorTerm": "Connective Tissue Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000002921",
                                        "ConditionAncestorTerm": "Cicatrix"
                                    },
                                    {
                                        "ConditionAncestorId": "D000005355",
                                        "ConditionAncestorTerm": "Fibrosis"
                                    },
                                    {
                                        "ConditionAncestorId": "D000010335",
                                        "ConditionAncestorTerm": "Pathologic Processes"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M5312",
                                        "ConditionBrowseLeafName": "Cicatrix",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M9806",
                                        "ConditionBrowseLeafName": "Keloid",
                                        "ConditionBrowseLeafAsFound": "Keloid",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M14197",
                                        "ConditionBrowseLeafName": "Rheumatic Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M5475",
                                        "ConditionBrowseLeafName": "Collagen Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M5616",
                                        "ConditionBrowseLeafName": "Connective Tissue Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M7637",
                                        "ConditionBrowseLeafName": "Fibrosis",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC23",
                                        "ConditionBrowseBranchName": "Symptoms and General Pathology"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC17",
                                        "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC05",
                                        "ConditionBrowseBranchName": "Musculoskeletal Diseases"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionMeshList": {
                                "InterventionMesh": [
                                    {
                                        "InterventionMeshId": "D000014221",
                                        "InterventionMeshTerm": "Triamcinolone"
                                    },
                                    {
                                        "InterventionMeshId": "D000014222",
                                        "InterventionMeshTerm": "Triamcinolone Acetonide"
                                    },
                                    {
                                        "InterventionMeshId": "C000005900",
                                        "InterventionMeshTerm": "Triamcinolone hexacetonide"
                                    },
                                    {
                                        "InterventionMeshId": "D000005472",
                                        "InterventionMeshTerm": "Fluorouracil"
                                    },
                                    {
                                        "InterventionMeshId": "C000030262",
                                        "InterventionMeshTerm": "Triamcinolone diacetate"
                                    }
                                ]
                            },
                            "InterventionAncestorList": {
                                "InterventionAncestor": [
                                    {
                                        "InterventionAncestorId": "D000000963",
                                        "InterventionAncestorTerm": "Antimetabolites"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045504",
                                        "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                                    },
                                    {
                                        "InterventionAncestorId": "D000000964",
                                        "InterventionAncestorTerm": "Antimetabolites, Antineoplastic"
                                    },
                                    {
                                        "InterventionAncestorId": "D000000970",
                                        "InterventionAncestorTerm": "Antineoplastic Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007166",
                                        "InterventionAncestorTerm": "Immunosuppressive Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007155",
                                        "InterventionAncestorTerm": "Immunologic Factors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045505",
                                        "InterventionAncestorTerm": "Physiological Effects of Drugs"
                                    },
                                    {
                                        "InterventionAncestorId": "D000000893",
                                        "InterventionAncestorTerm": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000005938",
                                        "InterventionAncestorTerm": "Glucocorticoids"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006728",
                                        "InterventionAncestorTerm": "Hormones"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006730",
                                        "InterventionAncestorTerm": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                                    },
                                    {
                                        "InterventionAncestorId": "D000004791",
                                        "InterventionAncestorTerm": "Enzyme Inhibitors"
                                    }
                                ]
                            },
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M7752",
                                        "InterventionBrowseLeafName": "Fluorouracil",
                                        "InterventionBrowseLeafAsFound": "Acid",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafAsFound": "Deep",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafAsFound": "Deep",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafAsFound": "Deep",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafAsFound": "Deep",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M3433",
                                        "InterventionBrowseLeafName": "Antimetabolites",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9364",
                                        "InterventionBrowseLeafName": "Immunosuppressive Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9353",
                                        "InterventionBrowseLeafName": "Immunologic Factors",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M3369",
                                        "InterventionBrowseLeafName": "Anti-Inflammatory Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8199",
                                        "InterventionBrowseLeafName": "Glucocorticoids",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8941",
                                        "InterventionBrowseLeafName": "Hormones",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8940",
                                        "InterventionBrowseLeafName": "Hormone Antagonists",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "ANeo",
                                        "InterventionBrowseBranchName": "Antineoplastic Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 10,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT04524897",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "TIRBESC"
                            },
                            "Organization": {
                                "OrgFullName": "Assiut University",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "The Use of Triamcinolone Injection in Treatment of Refractory Benign Esophageal Stricture in Children",
                            "OfficialTitle": "The Use of Triamcinolone Injection in Treatment of Refractory Benign Esophageal Stricture in Children"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "August 2020",
                            "OverallStatus": "Not yet recruiting",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "December 1, 2020",
                                "StartDateType": "Anticipated"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "October 2021",
                                "PrimaryCompletionDateType": "Anticipated"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "March 2022",
                                "CompletionDateType": "Anticipated"
                            },
                            "StudyFirstSubmitDate": "August 16, 2020",
                            "StudyFirstSubmitQCDate": "August 21, 2020",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "August 24, 2020",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "October 25, 2020",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "October 27, 2020",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Principal Investigator",
                                "ResponsiblePartyInvestigatorFullName": "Ahmed Zuhry",
                                "ResponsiblePartyInvestigatorTitle": "assiut university children hospital, assistant lecturer ,gastroentrologyand hepatology and endoscopy unit.",
                                "ResponsiblePartyInvestigatorAffiliation": "Assiut University"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Assiut University",
                                "LeadSponsorClass": "OTHER"
                            }
                        },
                        "OversightModule": {
                            "IsFDARegulatedDrug": "No",
                            "IsFDARegulatedDevice": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "To evaluate the efficacy of Intra-lesional triamcinolone injection in the management of refractory benign esophageal Stricture in children.",
                            "DetailedDescription": "Oesophageal stricture is a commonly encountered clinical problem, especially in gastroenterology. It occurs due to narrowing of oesophagus, which results in swallowing difficulty. Oesophageal stricture has two major types: benign and malignant. Malignant type results from carcinoma but benign type has different causes.\n\nAmongst benign aetiologies, gastrointestinal reflux disease (GERD), peptic injury, oesophageal webs, radiation damage, caustic swallowing and anastomotic strictures are most common. Corrosive intake is an important public health issue in developed countries and its incidence is still increasing in developing countries. The problem is largely unreported and its exact prevalence cannot be figured out due to the insufficient reporting or personal experience.\n\nCorrosives materials can damage the bodies' tissues, as they come in contact with them. They are usually utilised to clean metals. It can cause severe health hazard, if swallowed accidentally or intentionally. Epidemiological studies have documented corrosive intake as the third most common cause of poisoning in adults.\n\nThe most common symptom of oesophageal stricture is progressive dysphagia to solids followed by inability to tolerate liquids. These strictures are diagnosed most commonly by using barium swallow, endoscopy and biopsy. Endoscopic dilatation is the most applicable method to treat oesophageal strictures, and proton pump inhibitors (PPIs) are also used to inhibit acid production.\n\nAccording to the Kochman criteria, refractory or recurrent strictures are defined as an anatomic restriction because of a cicatricial luminal compromise or fibrosis resulting in clinical symptoms of dysphagia in the absence of endoscopic evidence of inflammation. This may occur as the result of either an inability to successfully remediate the anatomic problem to a diameter of at least 14 mm over five sessions at two-week intervals (refractory); or as a result of an inability to maintain a satisfactory luminal diameter for four weeks once the target diameter of 14 mm has been achieved (recurrent). This definition is not meant to include patients with an inflammatory stricture (which will not resolve until the inflammation subsides), or those with a satisfactory diameter but having dysphagia on the basis of neuromuscular dysfunction (for example those with dysphagia due to postoperative and/or postradiation therapy).\n\nEsophageal rehabilitation has been carried out for many years with different techniques, depending on the experience of each physician, esophageal prostheses or splints, dilations with balloons or Savary-Gilliard plugs, Hurst dilators, etc., have been used, but in reality, there is no worldwide standardization for the management of these patients and even less so for the use of certain substances such as triamcinolone acetonide applied intralesionally, or more recently, topical mitomycin C.\n\nTriamcinolone acetonide is a synthetic corticosteroid with a preventive effect on collagen synthesis, fibrosis, and chronic cicatrization that has been used for many years, applied in intralesional injection after esophageal dilations for the purpose of delaying cicatrization and thus reducing the number of dilations.\n\nPresently, through many studies, it has been concluded that intralesional corticosteroid injections can be added to standard treatment for corrosive oesophageal stricture. International literature exhibited that intralesional steroid injections help in increasing the diameter because of its anti-inflammatory action."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Esophageal Stricture"
                                ]
                            },
                            "KeywordList": {
                                "Keyword": [
                                    "triamcinolole",
                                    "refractory esophageal stricture",
                                    "children"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Phase 4"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "N/A",
                                "DesignInterventionModel": "Single Group Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "None (Open Label)"
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "20",
                                "EnrollmentType": "Anticipated"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "The use of Triamcinolone Injection",
                                        "ArmGroupType": "Other",
                                        "ArmGroupDescription": "Triamcinolone acetate (40 mg/mL)",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: Triamcinolone Injection in treatment of refractory benign Esophageal Stricture in children"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "Triamcinolone Injection in treatment of refractory benign Esophageal Stricture in children",
                                        "InterventionDescription": "Triamcinolone Injection in treatment of refractory benign Esophageal Stricture with endoscopic dilatation",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "The use of Triamcinolone Injection"
                                            ]
                                        },
                                        "InterventionOtherNameList": {
                                            "InterventionOtherName": [
                                                "Triamcinolone Injection in treatment of refractory benign Esophageal Stricture with endoscopic dilatation"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "number of patients show improvement in dysphagia scale after five session of triamcinolone injection",
                                        "PrimaryOutcomeDescription": "number of patients show improvement in dysphagia scale after five session of triamcinolone injection",
                                        "PrimaryOutcomeTimeFrame": "2years"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "the number of patients who will show complete relieve of dysphagia after five sessions of triamcinolone injection",
                                        "SecondaryOutcomeDescription": "complete abscence of dysphagia after triamcinolone injection",
                                        "SecondaryOutcomeTimeFrame": "2years"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nAll patients admitted to Assiut University Children Hospital with:\nrefractory benign esophageal stricture(inability to successfully remediate the anatomic problem to a diameter of at least 14 mm over five sessions at two-week interval)\ninability to maintain a satisfactory luminal diameter for four weeks once the target diameter of 14 mm has been achieved\n\nExclusion Criteria:\n\nPharyngeal stenosis precluding endoscopic examination and dilatation\ntracheo-esophageal fistula,\ngastric cicatrization that precluded safe placement of aguidewire\nany patient who was unfit for general anesthesia.",
                            "HealthyVolunteers": "No",
                            "Gender": "All",
                            "MinimumAge": "6 Months",
                            "MaximumAge": "18 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Child",
                                    "Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "CentralContactList": {
                                "CentralContact": [
                                    {
                                        "CentralContactName": "ahmed osman, assistant lecturer",
                                        "CentralContactRole": "Contact",
                                        "CentralContactPhone": "01010168440",
                                        "CentralContactEMail": "ahmedzuhry3999@gmail.com"
                                    }
                                ]
                            },
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Nagla Abou Faddan, Professor",
                                        "OverallOfficialAffiliation": "Assiut University",
                                        "OverallOfficialRole": "Study Director"
                                    }
                                ]
                            }
                        },
                        "ReferencesModule": {
                            "ReferenceList": {
                                "Reference": [
                                    {
                                        "ReferencePMID": "18704454",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Morikawa N, Honna T, Kuroda T, Watanabe K, Tanaka H, Takayasu H, Fujino A, Tanemura H, Matsukubo M. High dose intravenous methylprednisolone resolves esophageal stricture resistant to balloon dilatation with intralesional injection of dexamethasone. Pediatr Surg Int. 2008 Oct;24(10):1161-4. doi: 10.1007/s00383-008-2224-7."
                                    },
                                    {
                                        "ReferencePMID": "23840136",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Contini S, Scarpignato C. Caustic injury of the upper gastrointestinal tract: a comprehensive review. World J Gastroenterol. 2013 Jul 7;19(25):3918-30. doi: 10.3748/wjg.v19.i25.3918. Review."
                                    },
                                    {
                                        "ReferencePMID": "25559822",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Mowry JB, Spyker DA, Cantilena LR Jr, McMillan N, Ford M. 2013 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 31st Annual Report. Clin Toxicol (Phila). 2014 Dec;52(10):1032-283. doi: 10.3109/15563650.2014.987397."
                                    },
                                    {
                                        "ReferencePMID": "25133115",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Park KS. Evaluation and management of caustic injuries from ingestion of Acid or alkaline substances. Clin Endosc. 2014 Jul;47(4):301-7. doi: 10.5946/ce.2014.47.4.301. Epub 2014 Jul 28. Review."
                                    },
                                    {
                                        "ReferencePMID": "16111985",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Kochman ML, McClave SA, Boyce HW. The refractory and the recurrent esophageal stricture: a definition. Gastrointest Endosc. 2005 Sep;62(3):474-5."
                                    },
                                    {
                                        "ReferencePMID": "22517516",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Berger M, Ure B, Lacher M. Mitomycin C in the therapy of recurrent esophageal strictures: hype or hope? Eur J Pediatr Surg. 2012 Apr;22(2):109-16. doi: 10.1055/s-0032-1311695. Epub 2012 Apr 19. Review."
                                    },
                                    {
                                        "ReferencePMID": "28840483",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Ravich WJ. Endoscopic Management of Benign Esophageal Strictures. Curr Gastroenterol Rep. 2017 Aug 24;19(10):50. doi: 10.1007/s11894-017-0591-8. Review."
                                    },
                                    {
                                        "ReferencePMID": "23796367",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Nagaich N, Nijhawan S, Katiyar P, Sharma R, Rathore M. Mitomycin-C: 'a ray of hope' in refractory corrosive esophageal strictures. Dis Esophagus. 2014 Apr;27(3):203-5. doi: 10.1111/dote.12092. Epub 2013 Jun 24."
                                    },
                                    {
                                        "ReferencePMID": "11577311",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Poddar U, Thapa BR. Benign esophageal strictures in infants and children: results of Savary-Gilliard bougie dilation in 107 Indian children. Gastrointest Endosc. 2001 Oct;54(4):480-4."
                                    }
                                ]
                            }
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000004940",
                                        "ConditionMeshTerm": "Esophageal Stenosis"
                                    },
                                    {
                                        "ConditionMeshId": "D000003251",
                                        "ConditionMeshTerm": "Constriction, Pathologic"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000020763",
                                        "ConditionAncestorTerm": "Pathological Conditions, Anatomical"
                                    },
                                    {
                                        "ConditionAncestorId": "D000004935",
                                        "ConditionAncestorTerm": "Esophageal Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000005767",
                                        "ConditionAncestorTerm": "Gastrointestinal Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000004066",
                                        "ConditionAncestorTerm": "Digestive System Diseases"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M5627",
                                        "ConditionBrowseLeafName": "Constriction, Pathologic",
                                        "ConditionBrowseLeafAsFound": "Stricture",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M7242",
                                        "ConditionBrowseLeafName": "Esophageal Stenosis",
                                        "ConditionBrowseLeafAsFound": "Esophageal Stricture",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M21672",
                                        "ConditionBrowseLeafName": "Pathological Conditions, Anatomical",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M7237",
                                        "ConditionBrowseLeafName": "Esophageal Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M8035",
                                        "ConditionBrowseLeafName": "Gastrointestinal Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M6407",
                                        "ConditionBrowseLeafName": "Digestive System Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC23",
                                        "ConditionBrowseBranchName": "Symptoms and General Pathology"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC06",
                                        "ConditionBrowseBranchName": "Digestive System Diseases"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionMeshList": {
                                "InterventionMesh": [
                                    {
                                        "InterventionMeshId": "D000014221",
                                        "InterventionMeshTerm": "Triamcinolone"
                                    },
                                    {
                                        "InterventionMeshId": "D000014222",
                                        "InterventionMeshTerm": "Triamcinolone Acetonide"
                                    },
                                    {
                                        "InterventionMeshId": "C000005900",
                                        "InterventionMeshTerm": "Triamcinolone hexacetonide"
                                    },
                                    {
                                        "InterventionMeshId": "C000030262",
                                        "InterventionMeshTerm": "Triamcinolone diacetate"
                                    }
                                ]
                            },
                            "InterventionAncestorList": {
                                "InterventionAncestor": [
                                    {
                                        "InterventionAncestorId": "D000000893",
                                        "InterventionAncestorTerm": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000005938",
                                        "InterventionAncestorTerm": "Glucocorticoids"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006728",
                                        "InterventionAncestorTerm": "Hormones"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006730",
                                        "InterventionAncestorTerm": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045505",
                                        "InterventionAncestorTerm": "Physiological Effects of Drugs"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007166",
                                        "InterventionAncestorTerm": "Immunosuppressive Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007155",
                                        "InterventionAncestorTerm": "Immunologic Factors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000004791",
                                        "InterventionAncestorTerm": "Enzyme Inhibitors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045504",
                                        "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                                    }
                                ]
                            },
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafAsFound": "Deep",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafAsFound": "Deep",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafAsFound": "Deep",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafAsFound": "Deep",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M3369",
                                        "InterventionBrowseLeafName": "Anti-Inflammatory Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8199",
                                        "InterventionBrowseLeafName": "Glucocorticoids",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8941",
                                        "InterventionBrowseLeafName": "Hormones",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8940",
                                        "InterventionBrowseLeafName": "Hormone Antagonists",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9364",
                                        "InterventionBrowseLeafName": "Immunosuppressive Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9353",
                                        "InterventionBrowseLeafName": "Immunologic Factors",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 11,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT04842955",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "NP4479"
                            },
                            "Organization": {
                                "OrgFullName": "Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Modulators of Gamma tACS in Alzheimer's Disease (Mod-GammAD)",
                            "OfficialTitle": "Interventional Cross-over Study to Evaluate the Modulators of Efficacy of Alternating Current Brain Stimulation (tACS) in Patients With Alzheimer's Disease",
                            "Acronym": "Mod-GammAD"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "November 2021",
                            "OverallStatus": "Completed",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "March 10, 2021",
                                "StartDateType": "Actual"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "April 30, 2021",
                                "PrimaryCompletionDateType": "Actual"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "April 30, 2021",
                                "CompletionDateType": "Actual"
                            },
                            "StudyFirstSubmitDate": "March 10, 2021",
                            "StudyFirstSubmitQCDate": "April 8, 2021",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "April 13, 2021",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "November 12, 2021",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "November 15, 2021",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Principal Investigator",
                                "ResponsiblePartyInvestigatorFullName": "Barbara Borroni",
                                "ResponsiblePartyInvestigatorTitle": "Professor",
                                "ResponsiblePartyInvestigatorAffiliation": "Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia",
                                "LeadSponsorClass": "OTHER"
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "No",
                            "IsFDARegulatedDrug": "No",
                            "IsFDARegulatedDevice": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "Brain oscillations are ubiquitous in the human brain and have been implicated in cognitive and behavioral states defined in precisely tuned neural networks. In neurodegenerative disorders, neurodegeneration is accompanied by changes in oscillatory activity leading to the emerging concept of neurological and psychiatric disorders as \"oscillopathies\". Alzheimer's disease, which accounts for the vast majority of age-related dementias, is characterised by a prominent disruption of oscillations in the gamma frequency band. The restoration of gamma oscillations by neural entrainment in animal models of Alzheimer's disease have shown a remarkable decrease in the pathological burden of amyloid and tau via increased microglial activity, resulting in a significant increase of cognitive performances.\n\nTranscranial alternating current brain stimulation (tACS), is a neurophysiological method of non-invasive modulation of the excitability of the central nervous system that is having an increasingly numerous spectrum of potential therapeutic applications. Recent studies have demonstrated the effectiveness of this method in modulating the natural frequencies of cerebral oscillation, underlying multiple cognitive processes such as verbal memory, perception and working memory. On the basis of these premises, the treatment with gamma tACS is proposed in patients affected by Alzheimer's disease.\n\nIn this randomized, double-blind, sham-controlled, cross-over study, the investigators will evaluate the modulators of response on cognitive measure to a single stimulation with gamma tACS on the posterior parietal cortex in patients with Mild Cognitive Impairment due to Alzheimer's disease.",
                            "DetailedDescription": "Brain oscillations are ubiquitous in the human brain and have been implicated in cognitive and behavioral states defined in precisely tuned neural networks. In neurodegenerative disorders, neurodegeneration is accompanied by changes in oscillatory activity leading to the emerging concept of neurological and psychiatric disorders as \"oscillopathies\". Alzheimer's disease, which accounts for the vast majority of age-related dementias, is characterised by a prominent disruption of oscillations in the gamma frequency band. The restoration of gamma oscillations by neural entrainment in animal models of Alzheimer's disease have shown a remarkable decrease in the pathological burden of amyloid and tau via increased microglial activity, resulting in a significant increase of cognitive performances.\n\nTranscranial alternating current brain stimulation (tACS), is a neurophysiological method of non-invasive modulation of the excitability of the central nervous system that is having an increasingly numerous spectrum of potential therapeutic applications. Recent studies have demonstrated the effectiveness of this method in modulating the natural frequencies of cerebral oscillation, underlying multiple cognitive processes such as verbal memory, perception and working memory.\n\nOn the basis of these premises, the treatment with gamma tACS is proposed in patients affected by Alzheimer's disease.\n\nIn this randomized, double-blind, sham-controlled, cross-over study, the investigators will evaluate the modulators of response on cognitive measure to a single stimulation with gamma tACS on the posterior parietal cortex in patients with Mild Cognitive Impairment due to Alzheimer's disease.\n\nSubjects will be randomized in two groups, one receiving a single treatment with gamma tACS (40 Hz) first and the other receiving sham stimulation. After one week the treatments will be exchanged. Patients will be evaluated with neuropsychological tests and neurophysiological measures of cholinergic transmission. Modulators of response, including cognitive reserve, baseline impairment, apo-E genotype, MRI measures of atrophy and connectivity, electric field modelling, will be considered."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Alzheimer Disease"
                                ]
                            },
                            "KeywordList": {
                                "Keyword": [
                                    "Alzheimer's disease",
                                    "transcranial Alternating Current Stimulation",
                                    "Gamma stimulation",
                                    "tACS"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Not Applicable"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "Randomized",
                                "DesignInterventionModel": "Crossover Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "Quadruple",
                                    "DesignWhoMaskedList": {
                                        "DesignWhoMasked": [
                                            "Participant",
                                            "Care Provider",
                                            "Investigator",
                                            "Outcomes Assessor"
                                        ]
                                    }
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "60",
                                "EnrollmentType": "Actual"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "real tACS",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "Single session of gamma tACS (40 Hz) at 3 mA over the superior parietal cortex (Precuneus)",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: Gamma tACS (40 Hz) over the superior parietal cortex"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "sham tACS",
                                        "ArmGroupType": "Sham Comparator",
                                        "ArmGroupDescription": "Single session of sham tACS over the superior parietal cortex (Precuneus)",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: Sham tACS over the superior parietal cortex"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "Gamma tACS (40 Hz) over the superior parietal cortex",
                                        "InterventionDescription": "Single session of gamma tACS (40 Hz) over the superior parietal cortex",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "real tACS"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "Sham tACS over the superior parietal cortex",
                                        "InterventionDescription": "Single session of sham tACS over the superior parietal cortex",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "sham tACS"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Changes in Rey Auditory Verbal Learning Test scores",
                                        "PrimaryOutcomeDescription": "Participants are given a list of 15 unrelated words repeated over five different trials and are asked to repeat. Another list of 15 unrelated words are given and the patient must again repeat the original list of 15 words and then again after 30 minutes.\n\nThe score ranges from 0 (worse performance) to 15 (best performance).",
                                        "PrimaryOutcomeTimeFrame": "Baseline (immediately before the intervention) - Immediately after the intervention"
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "Changes in Face-Name Associative Memory Test scores",
                                        "PrimaryOutcomeDescription": "The Face-Name Associative Memory Test is a cross-modal associative memory test, it includes 20 face-name pairs. The administration procedure starts with the presentation of 20 faces with each name and participants should read the name underneath the faces and try to learn each face-name pair. After 5 minutes, the faces are shown one by one and participants are asked to recall the associated names from 4 different names. The correct number of pairs recalled is recorded.\n\nThe score ranges from 0 (worse performance) to 20 (best performance).",
                                        "PrimaryOutcomeTimeFrame": "During the intervention compared to sham comparator"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "Change in SAI measurements",
                                        "SecondaryOutcomeDescription": "By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of gamma tACS on short latency afferent inhibition (SAI), which is a marker of cholinergic transmission.",
                                        "SecondaryOutcomeTimeFrame": "Baseline (immediately before the intervention) - Immediately after the intervention"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\n- Mild Cognitive Impairment due to Alzheimer's disease (according to Albert et al., Alzheimers Dement 2011).\n\nExclusion Criteria:\n\nCerebrovascular disorders, previous stroke, hydrocephalus, and intra-cranial mass documented by MRI.\nHistory of traumatic brain injury or other neurological diseases.\nSerious medical illness other than FTD\nHistory of seizures\nPregnancy\nMetal implants in the head (except dental fillings)\nElectronic implants (i.e. pace-maker, implanted medical pump)\nAge <18 years",
                            "HealthyVolunteers": "No",
                            "Gender": "All",
                            "MinimumAge": "18 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Barbara Borroni, MD",
                                        "OverallOfficialAffiliation": "Azienda Ospedaliera Spedali Civili, Brescia",
                                        "OverallOfficialRole": "Principal Investigator"
                                    },
                                    {
                                        "OverallOfficialName": "Alberto Benussi, MD",
                                        "OverallOfficialAffiliation": "Azienda Ospedaliera Spedali Civili, Brescia",
                                        "OverallOfficialRole": "Principal Investigator"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "AO Spedali Civili",
                                        "LocationCity": "Brescia",
                                        "LocationState": "BS",
                                        "LocationZip": "25100",
                                        "LocationCountry": "Italy"
                                    }
                                ]
                            }
                        },
                        "ReferencesModule": {
                            "ReferenceList": {
                                "Reference": [
                                    {
                                        "ReferencePMID": "19400723",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Fries P. Neuronal gamma-band synchronization as a fundamental process in cortical computation. Annu Rev Neurosci. 2009;32:209-24. doi: 10.1146/annurev.neuro.051508.135603. Review."
                                    },
                                    {
                                        "ReferencePMID": "27929004",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Iaccarino HF, Singer AC, Martorell AJ, Rudenko A, Gao F, Gillingham TZ, Mathys H, Seo J, Kritskiy O, Abdurrob F, Adaikkan C, Canter RG, Rueda R, Brown EN, Boyden ES, Tsai LH. Gamma frequency entrainment attenuates amyloid load and modifies microglia. Nature. 2016 Dec 7;540(7632):230-235. doi: 10.1038/nature20587. Erratum in: Nature. 2018 Oct;562(7725):E1."
                                    },
                                    {
                                        "ReferencePMID": "31076275",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Adaikkan C, Middleton SJ, Marco A, Pao PC, Mathys H, Kim DN, Gao F, Young JZ, Suk HJ, Boyden ES, McHugh TJ, Tsai LH. Gamma Entrainment Binds Higher-Order Brain Regions and Offers Neuroprotection. Neuron. 2019 Jun 5;102(5):929-943.e8. doi: 10.1016/j.neuron.2019.04.011. Epub 2019 May 7."
                                    },
                                    {
                                        "ReferencePMID": "30879788",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Martorell AJ, Paulson AL, Suk HJ, Abdurrob F, Drummond GT, Guan W, Young JZ, Kim DN, Kritskiy O, Barker SJ, Mangena V, Prince SM, Brown EN, Chung K, Boyden ES, Singer AC, Tsai LH. Multi-sensory Gamma Stimulation Ameliorates Alzheimer's-Associated Pathology and Improves Cognition. Cell. 2019 Apr 4;177(2):256-271.e22. doi: 10.1016/j.cell.2019.02.014. Epub 2019 Mar 14."
                                    },
                                    {
                                        "ReferencePMID": "23785325",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Herrmann CS, Rach S, Neuling T, Strüber D. Transcranial alternating current stimulation: a review of the underlying mechanisms and modulation of cognitive processes. Front Hum Neurosci. 2013 Jun 14;7:279. doi: 10.3389/fnhum.2013.00279. eCollection 2013."
                                    }
                                ]
                            }
                        },
                        "IPDSharingStatementModule": {
                            "IPDSharing": "Yes",
                            "IPDSharingDescription": "All data, including outcome measure results, study protocol and statistical analysis plan, will be shared upon reasonable request.",
                            "IPDSharingInfoTypeList": {
                                "IPDSharingInfoType": [
                                    "Study Protocol",
                                    "Statistical Analysis Plan (SAP)"
                                ]
                            },
                            "IPDSharingTimeFrame": "Data will be shared after the study completion indefinitely.",
                            "IPDSharingAccessCriteria": "Reasonable request"
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000000544",
                                        "ConditionMeshTerm": "Alzheimer Disease"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000003704",
                                        "ConditionAncestorTerm": "Dementia"
                                    },
                                    {
                                        "ConditionAncestorId": "D000001927",
                                        "ConditionAncestorTerm": "Brain Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000002493",
                                        "ConditionAncestorTerm": "Central Nervous System Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009422",
                                        "ConditionAncestorTerm": "Nervous System Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000024801",
                                        "ConditionAncestorTerm": "Tauopathies"
                                    },
                                    {
                                        "ConditionAncestorId": "D000019636",
                                        "ConditionAncestorTerm": "Neurodegenerative Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000019965",
                                        "ConditionAncestorTerm": "Neurocognitive Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000001523",
                                        "ConditionAncestorTerm": "Mental Disorders"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M3037",
                                        "ConditionBrowseLeafName": "Alzheimer Disease",
                                        "ConditionBrowseLeafAsFound": "Alzheimer's Disease",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M6056",
                                        "ConditionBrowseLeafName": "Dementia",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M4356",
                                        "ConditionBrowseLeafName": "Brain Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M4894",
                                        "ConditionBrowseLeafName": "Central Nervous System Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M22155",
                                        "ConditionBrowseLeafName": "Tauopathies",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M20711",
                                        "ConditionBrowseLeafName": "Neurodegenerative Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M20989",
                                        "ConditionBrowseLeafName": "Neurocognitive Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M3967",
                                        "ConditionBrowseLeafName": "Mental Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M13625",
                                        "ConditionBrowseLeafName": "Psychotic Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "T2192",
                                        "ConditionBrowseLeafName": "Familial Alzheimer Disease",
                                        "ConditionBrowseLeafAsFound": "Alzheimer's Disease",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "T4202",
                                        "ConditionBrowseLeafName": "Oculocerebral Syndrome With Hypopigmentation",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC10",
                                        "ConditionBrowseBranchName": "Nervous System Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BXM",
                                        "ConditionBrowseBranchName": "Behaviors and Mental Disorders"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "Rare",
                                        "ConditionBrowseBranchName": "Rare Diseases"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 12,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT04560959",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "LYS-[2020]-051"
                            },
                            "Organization": {
                                "OrgFullName": "Xuanwu Hospital, Beijing",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Atlas of Intracranial Recordings on Cortical Responses After Functional tACS",
                            "OfficialTitle": "An Atlas of Cerebral Responses to the Stimuli of the tACS Recorded by SEEG",
                            "Acronym": "AIRCRAFT"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "August 2020",
                            "OverallStatus": "Not yet recruiting",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "September 20, 2020",
                                "StartDateType": "Anticipated"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "May 1, 2021",
                                "PrimaryCompletionDateType": "Anticipated"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "December 1, 2021",
                                "CompletionDateType": "Anticipated"
                            },
                            "StudyFirstSubmitDate": "August 7, 2020",
                            "StudyFirstSubmitQCDate": "September 17, 2020",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "September 23, 2020",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "September 17, 2020",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "September 23, 2020",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Sponsor"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Xuanwu Hospital, Beijing",
                                "LeadSponsorClass": "OTHER"
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "No",
                            "IsFDARegulatedDrug": "No",
                            "IsFDARegulatedDevice": "Yes",
                            "IsUSExport": "Yes"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "By analyzing the SEEG recordings, we explore the range of cortical functional responses to strings of 77.5Hz stimulations delivered by tACS,"
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Transcranial Alternating Current Stimulation"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Phase 1",
                                    "Phase 2"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "N/A",
                                "DesignInterventionModel": "Single Group Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "None (Open Label)"
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "30",
                                "EnrollmentType": "Anticipated"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "tACS arm",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "The patient would receive strings of tACS stimulations in 77.5 HZ, each string would last for 1 second, followed by an interval of 5 seconds. A total of 600 strings would be sent out to the patients.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: tACS"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "tACS",
                                        "InterventionDescription": "tACS would be performed to epilepsy patients who have already received implantation of the SEEG electrodes",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "tACS arm"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Changes of intracranial activities",
                                        "PrimaryOutcomeDescription": "The change of the power in a band of 0-200 HZ according to the intracranial EEG recording.",
                                        "PrimaryOutcomeTimeFrame": "Within 250 ms immediately after the stimulation."
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "Frequency of the epileptic discharges",
                                        "SecondaryOutcomeDescription": "To count the numbers of epileptic discharges within the same duration before and when tACS intervention.",
                                        "SecondaryOutcomeTimeFrame": "50 minutes during the stimulation and 50 minutes of the interictal baseline before the intervention during the same hour of the day"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Event related potential (ERP)",
                                        "SecondaryOutcomeDescription": "ERP related to cognitive tasks before and immediately after the tACS intervention",
                                        "SecondaryOutcomeTimeFrame": "Baseline: 24 hours before the tACS intervention; Observation: Immediately after the end of the tACS intervention."
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nAll epileptic patients that would receive the implantation of SEEG electrodes, regardless of the seizure locations;\nThere was no metal implantation before;\nEligible for MRI examination;\nNo other lesional neurological disorders;\nCould be well informed by the study protocols.\n\nExclusion Criteria:\n\nSuffered from any other mental illnesses prior to the enrollment;\nThose suffering from the serious or unstable organic diseases;\nPregnant or lactation women, and those who have a plan of pregnant;\nPatients with central nervous system tumors, acute brain injury or infection;\nSkin injured, or allergic to the exposure of the conductive gel;\nThose with implanted devices;\nThose who received modified electrical convulsive therapy, or TMS within the recent one month;\nThe score of item 3 (suicidal item) in HAMD-17 equal or greater than 3;\nEnrolled in any other on going trials;\nOther situations evaluated by the researchers as inappropriate to the enrollment",
                            "HealthyVolunteers": "No",
                            "Gender": "All",
                            "MinimumAge": "14 Years",
                            "MaximumAge": "60 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Child",
                                    "Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "CentralContactList": {
                                "CentralContact": [
                                    {
                                        "CentralContactName": "P.H. Wei",
                                        "CentralContactRole": "Contact",
                                        "CentralContactPhone": "+86-010-83198252",
                                        "CentralContactEMail": "weipenghu@xwhosp.org"
                                    }
                                ]
                            },
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "G.G. Zhao",
                                        "OverallOfficialAffiliation": "Department of Neurosurgery, Capital Medical University",
                                        "OverallOfficialRole": "Principal Investigator"
                                    }
                                ]
                            }
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "InterventionBrowseModule": {
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 13,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT03135639",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "13-3918"
                            },
                            "Organization": {
                                "OrgFullName": "University of North Carolina, Chapel Hill",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Effects of Alpha tACS",
                            "OfficialTitle": "Evaluating Transcranial Alternating Current Stimulation (tACS) for Enhancing Creativity",
                            "Acronym": "PACS"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "April 2017",
                            "OverallStatus": "Completed",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "August 2016",
                                "StartDateType": "Actual"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "April 2017",
                                "PrimaryCompletionDateType": "Actual"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "April 2017",
                                "CompletionDateType": "Actual"
                            },
                            "StudyFirstSubmitDate": "April 20, 2017",
                            "StudyFirstSubmitQCDate": "April 28, 2017",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "May 1, 2017",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "August 14, 2019",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "August 19, 2019",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Sponsor"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "University of North Carolina, Chapel Hill",
                                "LeadSponsorClass": "OTHER"
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "No",
                            "IsFDARegulatedDrug": "No",
                            "IsFDARegulatedDevice": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "**Follow-up Control Study for Creativity Study\n\nPurpose: To investigate the effect of transcranial alternating current stimulation (tACS), a form of noninvasive brain stimulation, in healthy subjects. This experiment is a follow-up to previous tACS studies that used a creativity assessment.\n\nParticipants: 35 males and females, at least 18 years of age, without history of major psychiatric/neurological disease or associated medication use, or prior brain surgery/implants.\n\nProcedures (methods): This is a cross-over study design. Participants will undergo a control condition of stimulation (sham or individual alpha, 8-12 Hz, tACS) during electroencephalogram recordings. In addition, pupil diameter, heart rate, and respiration will be measured continuously. This is to study the physiological effects of stimulation.",
                            "DetailedDescription": "Participants will report for a study visit. They will review and sign a consent form.\n\nThey will first be fitted with two 5x7cm electrodes placed over occipital and parietal cortex (Cz and Oz). They will also be fitted with ECG electrodes as well as a respiration belt. In addition, they will have a 128-channel EEG net placed on their head and pupillometry glasses. Once the participant is fitted with this equipment, they will complete a 2-minute resting state EEG with their eyes closed to determine their individual alpha frequency. Following the individual alpha frequency determination, the participant will fill out an alertness questionnaire, followed by 3 EEG recordings:\n\n5 minute before stimulation recording\n20 minute recording during stimulation; either at their individual alpha frequency (between 8 and 12 Hz) or sham stimulation.\n5 minute after stimulation recording\n\nFollowing these three recordings, the participant will have a 20 minute break in which they will read neutral reading material or converse with the study staff, as well as provide a saliva sample to test for brain derived neurotropic factor (BDNF).\n\nAfter the 20 minute break, the participant will complete the alertness questionnaire, and the three recordings will be completed again. The participant will then be allowed to clean up, be paid, and leave.\n\n------------------------\n\nClarification for the Experimental Design:\n\nThis part of the study is a control condition that will consist of stimulation over occipital and parietal cortex with electrodes over Cz and Oz. Participants will then receive 2mA alternating current stimulation between 8Hz and 12Hz (based on their individual alpha frequency determined by a 2 min eyes closed recording) or sham stimulation for 20 minutes (approximately the duration of the TTCT test) in a resting condition where they will have to focus on a cross hair on a computer screen. EEG will be collected simultaneously during this.\n\nIn both conditions, the participants wear a Pupil eye tracking headset, which is commercially available. This allows to monitor eye movements and to obtain physiological relevant measures of the pupil.\n\nTo obtain a measure of the heart rate during both conditions, ECG electrodes as part of the EEG acquisition system are placed on the participant's body. Ideally one electrode below the left collarbone and a second below the right chest.\n\nRespiration Effort is measured in both conditions by a SleepSense sleep-lab sensor that is placed with an elastic band over the participants chest and connected to the EEG acquisition system.\n\nBefore each session, a questionnaire will be administered to the participant to assess the alertness state.\n\nThe entire procedure will be conducted by study personnel with documented training using brain stimulators and EEG."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Healthy"
                                ]
                            },
                            "KeywordList": {
                                "Keyword": [
                                    "tACS",
                                    "transcranial alternating current stimulation",
                                    "stimulation",
                                    "healthy control",
                                    "alpha oscillations",
                                    "heart rate variability"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Not Applicable"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "Randomized",
                                "DesignInterventionModel": "Crossover Assignment",
                                "DesignInterventionModelDescription": "Each participant will receive sham stimulation or stimulation at their individual alpha frequency (8-12 Hz) during a study visit. The order is randomized (i.e., half of participants will receive sham stimulation during the first stimulation session and half will receive sham stimulation during the second stimulation session).",
                                "DesignPrimaryPurpose": "Basic Science",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "Double",
                                    "DesignMaskingDescription": "This is a double-blind study, meaning that neither the participant nor the experimenter knows what kind of stimulation the participant is receiving. An unblinded monitor (separate from the staff that interacts with the participant) is responsible for creating the stimulation codes that run each session and for ensuring that these codes worked correctly.",
                                    "DesignWhoMaskedList": {
                                        "DesignWhoMasked": [
                                            "Participant",
                                            "Investigator"
                                        ]
                                    }
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "32",
                                "EnrollmentType": "Actual"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "Sham Stim followed by Alpha Stim",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "20 minutes of sham stimulation (sham stim) is followed by a washout period of 20 minutes. 20 minutes of alpha stimulation (alpha stim) is applied next.\n\nSham stimulation mimics the physical effects of stimulation, with up to 1 minute of stimulation during the session. Sham stimulation is delivered using the NeuroConn Plus Stimulator Sham.\n\nParticipants will receive 2 mA alternating current stimulation at their individual alpha frequency (8-12 Hz, as determined by the 2 minute resting state EEG) for 20 minutes. Alpha stimulation is delivered using the NeuroConn Plus Stimulator tACS.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Other: NeuroConn Plus Stimulator tACS",
                                                "Other: NeuroConn Plus Stimulator Sham"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "Alpha Stim followed by Sham Stim",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "20 minutes of alpha stimulation (alpha stim) is followed by a washout period of 20 minutes. 20 minutes of sham stimulation (sham stim) is applied next.\n\nParticipants will receive 2 mA alternating current stimulation at their individual alpha frequency (8-12 Hz, as determined by the 2 minute resting state EEG) for 20 minutes. Alpha stimulation is delivered using the NeuroConn Plus Stimulator tACS.\n\nSham stimulation mimics the physical effects of stimulation, with up to 1 minute of stimulation during the session. Sham stimulation is delivered using the NeuroConn Plus Stimulator Sham.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Other: NeuroConn Plus Stimulator tACS",
                                                "Other: NeuroConn Plus Stimulator Sham"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Other",
                                        "InterventionName": "NeuroConn Plus Stimulator tACS",
                                        "InterventionDescription": "Transcranial alternating current stimulation (tACS) is a novel, noninvasive brain stimulation approach in which weak electric currents are applied to the scalp. The electric currents that are applied to the scalp are in a sine-wave pattern.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Alpha Stim followed by Sham Stim",
                                                "Sham Stim followed by Alpha Stim"
                                            ]
                                        },
                                        "InterventionOtherNameList": {
                                            "InterventionOtherName": [
                                                "tACS"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Other",
                                        "InterventionName": "NeuroConn Plus Stimulator Sham",
                                        "InterventionDescription": "For sham stimulation, the participant receives up to 1 minute of tACS stimulation until the stimulation fades. This mimics the same skin sensations that a participant would experience during a tACS session.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Alpha Stim followed by Sham Stim",
                                                "Sham Stim followed by Alpha Stim"
                                            ]
                                        },
                                        "InterventionOtherNameList": {
                                            "InterventionOtherName": [
                                                "Sham tACS"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Electroencephalogram power in alpha band",
                                        "PrimaryOutcomeDescription": "Changes in the EEG power in the alpha (8-12 Hz) band before and after stimulation sessions.",
                                        "PrimaryOutcomeTimeFrame": "5 minute recordings before and after each 20 minute stimulation session during a single study visit."
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "Heart Rate Variability",
                                        "SecondaryOutcomeDescription": "Change in the ratio between the power in low frequency band and the power in high frequency band. As this outcome variable is a ratio between two items that are measured in microvolt^2, the ratio does not have a unit of measure.",
                                        "SecondaryOutcomeTimeFrame": "5 minute recordings before and after each 20 minute stimulation session during a single study visit."
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Pupil diameter",
                                        "SecondaryOutcomeDescription": "Pupil diameter is associated with arousal. We will look to see what the changes in arousal are before and after stimulation sessions.",
                                        "SecondaryOutcomeTimeFrame": "5 minute recordings before and after each 20 minute stimulation session during a single study visit."
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nMales and females at least 18 years of age\n\nExclusion Criteria:\n\nHistory of major neurological or psychiatric illness, including epilepsy\nMedication use associated with neurological or psychiatric illnesses\nCurrently undergoing counseling or psychotherapy treatment for depression, anxiety, eating disorders, PTSD, or other behavior conditions\nFirst degree relative (parent, sibling, child) with neurological or psychiatric illness (past and present)\nPrior brain surgery\nHead injury\nAny brain devices/implants (including cochlear implants and aneurysm clips)\nCardiovascular disease\nPregnancy",
                            "HealthyVolunteers": "Accepts Healthy Volunteers",
                            "Gender": "All",
                            "MinimumAge": "18 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Flavio Frohlich, PhD",
                                        "OverallOfficialAffiliation": "University of North Carolina, Chapel Hill",
                                        "OverallOfficialRole": "Principal Investigator"
                                    }
                                ]
                            }
                        },
                        "IPDSharingStatementModule": {
                            "IPDSharing": "Yes",
                            "IPDSharingDescription": "IPD will be shared upon request.",
                            "IPDSharingInfoTypeList": {
                                "IPDSharingInfoType": [
                                    "Study Protocol",
                                    "Informed Consent Form (ICF)",
                                    "Analytic Code"
                                ]
                            },
                            "IPDSharingTimeFrame": "Data will be available starting from 1 year after publication.",
                            "IPDSharingAccessCriteria": "Data will be available for other publications or other brain stimulation researchers. Sharing is at the discretion of the PI."
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "InterventionBrowseModule": {
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 14,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT05198726",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "UPT01"
                            },
                            "Organization": {
                                "OrgFullName": "Portucalense University",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Speed of Processing (SoP) Training Plus α-tACS",
                            "OfficialTitle": "Speed of Processing (SoP) Training Plus α-tACS in People With Mild Cognitive Impairment: a Double Blind, Parallel, Placebo Controlled Trial Study Protocol",
                            "Acronym": "aMCIUp"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "April 2022",
                            "OverallStatus": "Recruiting",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "April 19, 2022",
                                "StartDateType": "Actual"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "December 2024",
                                "PrimaryCompletionDateType": "Anticipated"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "June 2025",
                                "CompletionDateType": "Anticipated"
                            },
                            "StudyFirstSubmitDate": "December 20, 2021",
                            "StudyFirstSubmitQCDate": "January 6, 2022",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "January 20, 2022",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "April 19, 2022",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "April 20, 2022",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Sponsor"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Portucalense University",
                                "LeadSponsorClass": "OTHER"
                            },
                            "CollaboratorList": {
                                "Collaborator": [
                                    {
                                        "CollaboratorName": "Aveiro University",
                                        "CollaboratorClass": "OTHER"
                                    },
                                    {
                                        "CollaboratorName": "University of Coimbra",
                                        "CollaboratorClass": "OTHER"
                                    }
                                ]
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "No",
                            "IsFDARegulatedDrug": "No",
                            "IsFDARegulatedDevice": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "The current proposal aims to assess if the combination of Speed of Processing (SoP) training with alpha tACS (α-tACS) is able to increase brain speed of processing as assessed by the Useful Field of View (UFOV) when comparing to SoP training plus sham α-tACS. Moreover, a second aim is to assess if those changes in speed of processing transfer to other cognitive domains, such as memory, language and executive functioning. Furthermore, the mechanisms underlying these interventions will be tested, namely to assess brain connectivity and coherence as assessed by EEG. To that purpose, the aim of the current proposal is to conduct a double-blind, parallel randomized trial assessing the effects of combining SoP with alpha endogenous tACS (either active or sham) in participants with Mild Cognitive impairment (MCI).",
                            "DetailedDescription": "Dementia is thought to affect 6.3 million people across Europe and is especially prevalent in people over 85 years old (23.7%). In this sense, several cognitive training programs, alone or in combination with non-invasive brain stimulation have been used in order to ameliorate age-related cognitive impairments, and even to act in a prophylactic manner in order to prevent more extreme deficits, such as the ones presented in mild cognitive impairment, or even dementia.\n\nDespite all these efforts, the effects of CT - combined or not - with several forms of non-invasive brain stimulation have been modest at most.\n\nThe current proposal aims to assess if Speed of Processing (SoP) training combined with alpha tACS (α-tACS) increases speed of processing as assessed by the Useful Field of View (UFOV) when comparing to SoP training and sham α-tACS. Furthermore, association betweens changes in speed of processing and changes in other cognitive domains, such as memory, language and executive functioning will be assessed. Finnaly, the current proposal aims at probing the mechanisms underlying these interventions, namely to test brain connectivity and coherence as assessed by EEG."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Cognitive Dysfunction",
                                    "Mild Cognitive Impairment",
                                    "tACS",
                                    "Cognitive Training"
                                ]
                            },
                            "KeywordList": {
                                "Keyword": [
                                    "MCI",
                                    "tACS",
                                    "Cognitive training"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Not Applicable"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "Randomized",
                                "DesignInterventionModel": "Parallel Assignment",
                                "DesignInterventionModelDescription": "double-blinded, parallel randomized trial",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "Triple",
                                    "DesignMaskingDescription": "Sham tACS and cognitive training",
                                    "DesignWhoMaskedList": {
                                        "DesignWhoMasked": [
                                            "Participant",
                                            "Care Provider",
                                            "Outcomes Assessor"
                                        ]
                                    }
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "327",
                                "EnrollmentType": "Anticipated"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "Active tACS plus active SoP",
                                        "ArmGroupType": "Active Comparator",
                                        "ArmGroupDescription": "Active alpha range tACS plus Speed of Processing Training",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: alpha tACS",
                                                "Behavioral: Speed of Processing Training"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "Active tACS plus sham SoP",
                                        "ArmGroupType": "Active Comparator",
                                        "ArmGroupDescription": "Active alpha range tACS plus sham Speed of Processing Training",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: alpha tACS"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "Sham tACS plus active SoP",
                                        "ArmGroupType": "Active Comparator",
                                        "ArmGroupDescription": "Sham alpha range tACS plus Speed of Processing Training",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Behavioral: Speed of Processing Training"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "alpha tACS",
                                        "InterventionDescription": "2mA α-tACS (based on the IAF) over the prefrontal cortex (PFC)",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Active tACS plus active SoP",
                                                "Active tACS plus sham SoP"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Behavioral",
                                        "InterventionName": "Speed of Processing Training",
                                        "InterventionDescription": "SoP training will have a total of four conditions. In condition 1, participants will be asked to identity objects at increasingly brief exposures. For condition 2, identification of stimulus on the center of the screen will be requested from participants, while a second stimulus will appear somewhere in peripheral vision - stimulus duration, difficulty of the central localization task or the area in which targets may be located are used to change the level of difficulty. Condition 3 is similar to condition 2, but visual distractors are added. Finally, for condition 4, an auditory identification component is superimposed over the visual task (Jobe et al., 2001)",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Active tACS plus active SoP",
                                                "Sham tACS plus active SoP"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Useful Field of View Test (UFOV)",
                                        "PrimaryOutcomeDescription": "UFOV is a measure of the speed of visual processing for rapid detection and localization of targets under conditions of divided visual attention and in the presence and absence of visual clutter at an above chance level (i.e. 75%).",
                                        "PrimaryOutcomeTimeFrame": "Change from baseline to week 3"
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "Useful Field of View (UFOV)",
                                        "PrimaryOutcomeDescription": "UFOV is a measure of the speed of visual processing for rapid detection and localization of targets under conditions of divided visual attention and in the presence and absence of visual clutter at an above chance level (i.e. 75%).",
                                        "PrimaryOutcomeTimeFrame": "Change from baseline to week 6"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "Executive Composite Score from the Executive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research (NIH EXAMINER)",
                                        "SecondaryOutcomeDescription": "The NIH examiner executive composite comprises cognitive control, verbal fluency, and working memory assessments. Scores are based on the Item Response theory (IRT), which allows for the contribution of each item score is weighted by how effective that item measures that ability in any part of the continuum. Instead of a maximum or a minimum, higher scores, mean better performance.",
                                        "SecondaryOutcomeTimeFrame": "Change from baseline to week 3"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Executive Composite Score from the Executive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research (NIH EXAMINER)",
                                        "SecondaryOutcomeDescription": "The NIH examiner executive composite comprises cognitive control, verbal fluency, and working memory assessments. Scores are based on the Item Response theory (IRT), which allows for the contribution of each item score is weighted by how effective that item measures that ability in any part of the continuum. Instead of a maximum or a minimum, higher scores, mean better performance.",
                                        "SecondaryOutcomeTimeFrame": "Change from baseline to week 6"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "EEG power in the alpha band",
                                        "SecondaryOutcomeDescription": "Total Power",
                                        "SecondaryOutcomeTimeFrame": "Change from baseline to week 3"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "EEG power in the alpha band",
                                        "SecondaryOutcomeDescription": "Total Power",
                                        "SecondaryOutcomeTimeFrame": "Change from baseline to week 6"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "P300 Event related potential - A",
                                        "SecondaryOutcomeDescription": "Amplitude of the P300 potential",
                                        "SecondaryOutcomeTimeFrame": "Change from baseline to week 3"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "P300 Event related potential - L",
                                        "SecondaryOutcomeDescription": "Latency of the P300 potential",
                                        "SecondaryOutcomeTimeFrame": "Change from baseline to week 3"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "P300 Event related potential - A",
                                        "SecondaryOutcomeDescription": "Amplitude of the P300 potential",
                                        "SecondaryOutcomeTimeFrame": "Change from baseline to week 6"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "P300 Event related potential - L",
                                        "SecondaryOutcomeDescription": "Latency of the P300 potential",
                                        "SecondaryOutcomeTimeFrame": "Change from baseline to week 6"
                                    }
                                ]
                            },
                            "OtherOutcomeList": {
                                "OtherOutcome": [
                                    {
                                        "OtherOutcomeMeasure": "Useful Field of View (UFOV)",
                                        "OtherOutcomeDescription": "Measure of the speed of visual processing for rapid detection and localization of targets under conditions of divided visual attention and in the presence and absence of visual clutter at an above chance level (i.e. 75%).",
                                        "OtherOutcomeTimeFrame": "Change from baseline to 1 month follow-up (after intervention ended)"
                                    },
                                    {
                                        "OtherOutcomeMeasure": "Useful Field of View (UFOV)",
                                        "OtherOutcomeDescription": "Measure of the speed of visual processing for rapid detection and localization of targets under conditions of divided visual attention and in the presence and absence of visual clutter at an above chance level (i.e. 75%).",
                                        "OtherOutcomeTimeFrame": "Change from baseline to 3 months follow-up (after intervention ended)"
                                    },
                                    {
                                        "OtherOutcomeMeasure": "Useful Field of View (UFOV)",
                                        "OtherOutcomeDescription": "Measure of the speed of visual processing for rapid detection and localization of targets under conditions of divided visual attention and in the presence and absence of visual clutter at an above chance level (i.e. 75%).",
                                        "OtherOutcomeTimeFrame": "Change from baseline to 6 months follow-up (after intervention ended)"
                                    },
                                    {
                                        "OtherOutcomeMeasure": "Executive Composite Score from NIH EXAMINER",
                                        "OtherOutcomeDescription": "The NIH examiner comprises cognitive control, verbal fluency, and working memory assessments",
                                        "OtherOutcomeTimeFrame": "Change from baseline to 1 month follow-up (after intervention ended)"
                                    },
                                    {
                                        "OtherOutcomeMeasure": "Executive Composite Score from NIH EXAMINER",
                                        "OtherOutcomeDescription": "The NIH examiner comprises cognitive control, verbal fluency, and working memory assessments",
                                        "OtherOutcomeTimeFrame": "Change from baseline to 3 months follow-up (after intervention ended)"
                                    },
                                    {
                                        "OtherOutcomeMeasure": "Executive Composite Score from NIH EXAMINER",
                                        "OtherOutcomeDescription": "The NIH examiner comprises cognitive control, verbal fluency, and working memory assessments",
                                        "OtherOutcomeTimeFrame": "Change from baseline to 6 months follow-up (after intervention ended)"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nCommunity-dwelling adults aged 65 years and older, with cognitive complains in memory or other functions, which have declined over time\n\nExclusion Criteria:\n\nScore in the mini mental examination less than 23 (or over 28);\nDiagnosis of Alzheimer´s Disease, any other medical condition that may predispose participants for a forthcoming decline in function, or that may increase their risk of mortality during the duration of the study.\nAny contra-indication to tACS, severe sensory losses or communication difficulties that will prevent them from successfully complete the training.\nHad any cognitive training in the past.",
                            "HealthyVolunteers": "No",
                            "Gender": "All",
                            "MinimumAge": "65 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "CentralContactList": {
                                "CentralContact": [
                                    {
                                        "CentralContactName": "Jorge Leite, PhD",
                                        "CentralContactRole": "Contact",
                                        "CentralContactPhone": "+351225572685",
                                        "CentralContactEMail": "jorgel@upt.pt"
                                    },
                                    {
                                        "CentralContactName": "Reitoria UPT",
                                        "CentralContactRole": "Contact",
                                        "CentralContactPhone": "+351225572000",
                                        "CentralContactEMail": "reitoria@upt.pt"
                                    }
                                ]
                            },
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Jorge Leite, PhD",
                                        "OverallOfficialAffiliation": "Portucalense University",
                                        "OverallOfficialRole": "Principal Investigator"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "Portucalense University",
                                        "LocationStatus": "Recruiting",
                                        "LocationCity": "Porto",
                                        "LocationZip": "4200 - 072",
                                        "LocationCountry": "Portugal",
                                        "LocationContactList": {
                                            "LocationContact": [
                                                {
                                                    "LocationContactName": "Jorge Leite, PhD",
                                                    "LocationContactRole": "Contact",
                                                    "LocationContactPhone": "00351225572000",
                                                    "LocationContactEMail": "jorgel@upt.pt"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "ReferencesModule": {
                            "ReferenceList": {
                                "Reference": [
                                    {
                                        "ReferencePMID": "11514044",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Jobe JB, Smith DM, Ball K, Tennstedt SL, Marsiske M, Willis SL, Rebok GW, Morris JN, Helmers KF, Leveck MD, Kleinman K. ACTIVE: a cognitive intervention trial to promote independence in older adults. Control Clin Trials. 2001 Aug;22(4):453-79."
                                    }
                                ]
                            }
                        },
                        "IPDSharingStatementModule": {
                            "IPDSharing": "Yes",
                            "IPDSharingDescription": "Deidentified and coded data will be available to researchers upon request",
                            "IPDSharingInfoTypeList": {
                                "IPDSharingInfoType": [
                                    "Statistical Analysis Plan (SAP)"
                                ]
                            },
                            "IPDSharingTimeFrame": "Data will be available upon study completion.",
                            "IPDSharingAccessCriteria": "Upon request."
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000060825",
                                        "ConditionMeshTerm": "Cognitive Dysfunction"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000003072",
                                        "ConditionAncestorTerm": "Cognition Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000019965",
                                        "ConditionAncestorTerm": "Neurocognitive Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000001523",
                                        "ConditionAncestorTerm": "Mental Disorders"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M28858",
                                        "ConditionBrowseLeafName": "Cognitive Dysfunction",
                                        "ConditionBrowseLeafAsFound": "Mild Cognitive Impairment",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M5453",
                                        "ConditionBrowseLeafName": "Cognition Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M20989",
                                        "ConditionBrowseLeafName": "Neurocognitive Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M3967",
                                        "ConditionBrowseLeafName": "Mental Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M13625",
                                        "ConditionBrowseLeafName": "Psychotic Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BXM",
                                        "ConditionBrowseBranchName": "Behaviors and Mental Disorders"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 15,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT00687596",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "TAC101-202"
                            },
                            "Organization": {
                                "OrgFullName": "Taiho Oncology, Inc.",
                                "OrgClass": "INDUSTRY"
                            },
                            "BriefTitle": "Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy",
                            "OfficialTitle": "A Phase 2, Double-blind, Placebo-controlled, Randomized, International, Multicenter Study of Oral TAC 101 as Second Line Treatment in Patients With Advanced Hepatocellular Carcinoma Who Received Sorafenib as First Line Therapy"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "January 2022",
                            "OverallStatus": "Terminated",
                            "WhyStopped": "Terminated due to safety concerns",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "August 1, 2008",
                                "StartDateType": "Actual"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "May 10, 2010",
                                "PrimaryCompletionDateType": "Actual"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "May 10, 2010",
                                "CompletionDateType": "Actual"
                            },
                            "StudyFirstSubmitDate": "May 28, 2008",
                            "StudyFirstSubmitQCDate": "May 30, 2008",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "June 2, 2008",
                                "StudyFirstPostDateType": "Estimate"
                            },
                            "ResultsFirstSubmitDate": "November 9, 2021",
                            "ResultsFirstSubmitQCDate": "January 3, 2022",
                            "ResultsFirstPostDateStruct": {
                                "ResultsFirstPostDate": "February 1, 2022",
                                "ResultsFirstPostDateType": "Actual"
                            },
                            "DispFirstSubmitDate": "June 4, 2013",
                            "DispFirstSubmitQCDate": "June 4, 2013",
                            "DispFirstPostDateStruct": {
                                "DispFirstPostDate": "June 12, 2013",
                                "DispFirstPostDateType": "Estimate"
                            },
                            "LastUpdateSubmitDate": "January 3, 2022",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "February 1, 2022",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Sponsor"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Taiho Oncology, Inc.",
                                "LeadSponsorClass": "INDUSTRY"
                            },
                            "CollaboratorList": {
                                "Collaborator": [
                                    {
                                        "CollaboratorName": "Quintiles, Inc.",
                                        "CollaboratorClass": "INDUSTRY"
                                    }
                                ]
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "The purpose of this study is to determine whether TAC-101 as a second line therapy for participants who received Sorafenib as first line therapy is effective in slowing tumor activity in patients with advanced hepatocellular carcinoma. The study is also looking at the safety of TAC-101 following treatment with Sorafenib.",
                            "DetailedDescription": "Advanced metastatic hepatocellular carcinoma (HCC) is not treatable by surgical approaches or locoregional therapies such as hepatic artery hemoembolization or radiofrequency ablation (RFA) which are effective in controlling localized tumors. Currently marketed systemic chemotherapy agents, with the exception of sorafenib, provide marginal benefit. Despite the demonstrated survival benefit from sorafenib, it is still imperative to improve to the effectiveness of systemic therapy in this patient population. Studies of TAC-101, a synthetic retinoid, indicate that although TAC-101 may not induce tumor regression, it appears to have a stabilizing effect, prolonging survival over what was expected historically. This Phase 2, randomized, double-blind, placebo-controlled international, multicenter study is designed to evaluate the efficacy and safety of TAC 101 as second line treatment in patients with advanced HCC following treatment with sorafenib as first-line therapy. Sorafenib has recently been approved as first line treatment for HCC in the EU and the US and is expected to become the standard of care for the first-line treatment of advanced HCC. Aside from best supportive care, there is no second line therapy available for HCC. It is hypothesized that TAC 101 treatment can extend Overall Survival (OS) after discontinuation of sorafenib."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Hepatocellular Carcinoma"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Phase 2"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "Randomized",
                                "DesignInterventionModel": "Parallel Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "Double",
                                    "DesignWhoMaskedList": {
                                        "DesignWhoMasked": [
                                            "Participant",
                                            "Investigator"
                                        ]
                                    }
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "52",
                                "EnrollmentType": "Actual"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "TAC-101",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a dose of 20 milligram per day (mg/day) of TAC-101 (as second line treatment) oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period on Days 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: TAC-101"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "Placebo",
                                        "ArmGroupType": "Placebo Comparator",
                                        "ArmGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a matching placebo for TAC-101 oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period from on 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: Placebo"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "TAC-101",
                                        "InterventionDescription": "Participants were randomized to TAC 101 received TAC 101 20 mg (administered as 2 10 mg formulated tablets) PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) for 14 days followed by a 7 day recovery period. This cycle was repeated every 21 days.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "TAC-101"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "Placebo",
                                        "InterventionDescription": "Participants randomized to placebo received 2 placebo tablets (identical in appearance to the TAC 101 tablets) administered PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) in a regimen identical to that for TAC 101.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Placebo"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Overall Survival (OS)",
                                        "PrimaryOutcomeDescription": "OS was defined as the time from the date of randomization to the date of death. Participants who were still alive were censored at the date last known to be alive (last contact date or last follow-up visit).",
                                        "PrimaryOutcomeTimeFrame": "From the date of randomization to date of death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "Radiologic Progression-free Survival (PFS)",
                                        "SecondaryOutcomeDescription": "PFS was defined as the time from date of randomization to the date of tumor disease progression (ie, radiological only) or death due to any cause. Participants who were alive at the time of analysis and had no signs of tumor progression had their time of PFS censored at the date of the last tumor assessment, unless they received new antitumor therapy.",
                                        "SecondaryOutcomeTimeFrame": "From the date of randomization to date of tumor disease progression or death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Time To Progression (TTP)",
                                        "SecondaryOutcomeDescription": "TTP was defined as time from randomization to the date of tumor progression (radiological only). Participants who were alive with no tumor progression or who died prior to tumor progression had their TTP censored at the date of their last tumor assessment, unless they received new antitumor therapy.",
                                        "SecondaryOutcomeTimeFrame": "From the date of randomization to date of tumor disease progression or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)",
                                        "SecondaryOutcomeDescription": "Any untoward medical condition that occurs in a participants while participating in a clinical study and does not necessarily have a causal relationship with the use of the study treatment was considered an AE. A serious AE (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs were defined as AEs (both serious/non-serious) that occur from the initiation of any study medication administration, and do not necessarily have a causal relationship to the use of the study medication.",
                                        "SecondaryOutcomeTimeFrame": "From Baseline up to 30 days after the last dose (maximum duration: up to 7.2 months for Placebo and up to 7.9 months for TAC-101)"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Change From Baseline in Plasma Levels of the Tumor Marker Alpha-fetoprotein (AFP)",
                                        "SecondaryOutcomeDescription": "AFP is a tumor marker for hepatocellular carcinoma and elevations in AFP values could precede clinical deterioration and tumor recurrence in participants. Baseline was defined as the last value obtained within 72 hours prior to study treatment administration on Cycle 1 Day 1.",
                                        "SecondaryOutcomeTimeFrame": "From the date of randomization to date of tumor disease progression or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Percent Change From Baseline in Plasma Levels of the Tumor Marker Alpha Fetoprotein-L3 (AFP-L3)",
                                        "SecondaryOutcomeDescription": "AFP-L3 is a tumor marker for hepatocellular carcinoma and elevations in AFP-L3 values could precede clinical deterioration and tumor recurrence in participants. Baseline was defined as the last value obtained within 72 hours prior to study treatment administration on Cycle 1 Day 1.",
                                        "SecondaryOutcomeTimeFrame": "From the date of randomization to date of tumor disease progression or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Maximum Exposure-response Analysis: Maximum Plasma Concentration (Cmax) of TAC-101",
                                        "SecondaryOutcomeDescription": "Cmax: maximum plasma concentration; Pharmacokinetic (PK) blood samples were collected at 4 hours (± 1 hour), 8 hours (± 1 hour), and 24 hours (± 1 hour) post-dose on Day 1 of treatment Cycle 1. The 24-hour sample was collected prior to dosing on Day 2.",
                                        "SecondaryOutcomeTimeFrame": "Cycle 1-day 1: 4, 8, and 24 hours after the first dose of study drug"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Overall Exposure-response Analysis: Area Under Curve (AUC0-inf) of TAC-101",
                                        "SecondaryOutcomeDescription": "AUC(0-inf): Area under the curve from time zero extrapolated to infinity. PK blood samples were collected at 4 hours (± 1 hour), 8 hours (± 1 hour), and 24 hours (± 1 hour) post-dose on Day 1 of treatment Cycle 1. The 24-hour sample was collected prior to dosing on Day 2.",
                                        "SecondaryOutcomeTimeFrame": "Cycle 1-day 1: 4, 8, and 24 hours after the first dose of study drug"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Changes From Baseline in Plasma Insulin-like Growth Factor-2 (IGF-2)",
                                        "SecondaryOutcomeDescription": "RAR related factors are markers for disease progression in hepatocellular carcinoma participants. In hepatocellular carcinoma participants, IGF-2 is a characteristic biomarkers and its levels are higher in responder cells. The detection of IGF-2 levels showed the efficacy of TAC-101 in IGF-2 influenced malignancy.",
                                        "SecondaryOutcomeTimeFrame": "From Baseline up to end of study treatment or up to tumor disease progression or up to death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Changes From Baseline in Plasma Transforming Growth Factor-beta (TGFβ2)",
                                        "SecondaryOutcomeDescription": "TGF-β is responsible for tissue regeneration, cell differentiation, embryonic development, and regulation of the immune system. TGF-β2 levels are higher in non-responder cells hence helps in detection of such cells.",
                                        "SecondaryOutcomeTimeFrame": "From Baseline up to end of study treatment or up to tumor disease progression or up to death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Changes From Baseline in Plasma Insulin-like Growth Factor Binding Protein-3 (IGFBP-3)",
                                        "SecondaryOutcomeDescription": "IGFBP-3 acts as a mediator of antiproliferative signals in hepatocellular carcinoma cells. The inhibition of hepatocellular carcinoma cell proliferation is associated with upregulation of IGFBP-3. Retinoic acid response element (RARE) exists on the promoter region of the IGFBP-3.",
                                        "SecondaryOutcomeTimeFrame": "From Baseline up to end of study treatment or up to tumor disease progression or up to death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Changes From Baseline in Plasma Insulin-like Growth Factor Binding Protein-6 (IGFBP-6)",
                                        "SecondaryOutcomeDescription": "IGFBP-6 has an IGF-2 binding specificity and inhibits growth of a number of IGF-2-dependent cancers. RARE exists on the promoter region of the IGFBP-6.",
                                        "SecondaryOutcomeTimeFrame": "From Baseline up to end of study treatment or up to tumor disease progression or up to death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Changes From Baseline in Plasma Lactoferrin",
                                        "SecondaryOutcomeDescription": "RARE exists on the promoter region of the lactoferrin gene.",
                                        "SecondaryOutcomeTimeFrame": "From Baseline up to end of study treatment or up to tumor disease progression or up to death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Changes From Baseline in Plasma Vascular Endothelial Growth Factor-A (VEGF-A)",
                                        "SecondaryOutcomeDescription": "End of Treatment was defined as \"as soon as possible following the last dose of study medication\".",
                                        "SecondaryOutcomeTimeFrame": "From Baseline up to end of study treatment or up to tumor disease progression or up to death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Number of Participants With Antitumor Activity After Treatment Discontinuation",
                                        "SecondaryOutcomeDescription": "Antitumor activity after treatment discontinuation in participant was determined by images, computed tomography (CT), and magnetic resonance imaging (MRI). Tumor imaging was done at Baseline any time within 4 weeks prior to the first dose of study treatment on Cycle 1, Day 1 and every 6 weeks (±1 week) during treatment, regardless of a dose delay. If participant discontinued study treatment for a reason other than disease progression (PD), data collected every 6 weeks until PD and following PD, data collected optionally every 6 weeks until death or up to 1 year after the last participant was randomized.",
                                        "SecondaryOutcomeTimeFrame": "From the date of treatment discontinuation to date of tumor disease progression or death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Relationship Between Tumor Gene Expression of Messenger Ribonucleic Acid (mRNA) Ratio of Co-activators, Co-repressors and Efficacy Parameters",
                                        "SecondaryOutcomeDescription": "The assessment of correlative factors was to be conducted on tissue removed prior to the study, if available. Tumor tissue assessments included investigation of the relationship between tumor gene mRNA expression of co-activators and co-repressors and efficacy parameters.",
                                        "SecondaryOutcomeTimeFrame": "At Baseline (prior to treatment after consenting informed consent form [ICF]) up to last dose of study treatment, assessed every 6 weeks (maximum duration: up to 21.3 months)"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nProvide written informed consent prior to performance of any study procedures.\nIs at least 18 years of age.\nHave a diagnosis of advanced unresectable histologically confirmed HCC (excluding fibrolamellar carcinoma).\nHave discontinued from first line treatment with sorafenib monotherapy for any reason (ie, tumor disease progression, intolerance) at least 14 days prior to planned randomization but have not received any second line treatment for HCC.\nHave recovered from any significant sorafenib-related treatment toxicities prior to randomization (Grade 1).\nHave at least 1 target lesion that is viable (has vascularization) and can be accurately measured according to RECIST.\nPatients who have received local therapy prior to sorafenib administration (radiation, surgery, hepatic arterial embolization, chemoembolization, RFA, percutaneous ethanol injection [PEI] or cryoablation) are eligible. Local therapy must be completed at least 4 weeks prior to the baseline scan.\nHave ECOG score of 0, 1, or 2.\nChild-Pugh score <8.\n\nHave adequate organ function defined as:\n\nPlatelet count great than 50, less than 109/L;\nHemoglobin 8.0 g/dL;\nTotal bilirubin 3 mg/dL;\nAlanine transaminase (ALT) and aspartate aminotransferase (AST) less than or equal to 5 X ULN;\nSerum creatinine 1.5 X ULN;\nPT-international normalized ratio (INR) 2.3 or PT 6 seconds above control\nTotal white blood cell (WBC) count 2.0 109/L\nIs able to take medications orally (eg, no feeding tube).\nWomen of childbearing potential must have a negative pregnancy test (urine or serum) prior to randomization and within 2 days prior to starting the study drug. Females must agree to adequate non-estrogenic birth control if conception is possible during the study; and males must agree to adequate birth control during the study and up to 6 months after the discontinuation of study medication.\n\nExclusion Criteria:\n\nHistory of DVT, PE, myocardial infarction (MI), CVA, transitory ischemic attack (TIA), or any other significant TE during the last 3 years.\nHave clinically significant symptoms of hepatic encephalopathy or known brain metastasis.\nPatients who have had clinically significant acute gastrointestinal bleeding as a result of portal vein hypertension within 4 weeks prior to randomization are excluded; however, patients with a history of acute gastrointestinal bleeding that have received appropriate treatment, ie, ligation of varices, are eligible.\nAre receiving therapeutic regimens of anticoagulants, with the exception of prophylaxis care of indwelling venous access devices.\nHave received a liver transplant.\nAre taking prohibited medication.\nHave received a previous systemic therapy (including investigational agents) other than sorafenib (see Inclusion Criterion 4) for treatment of HCC. Patients participating in surveys or observational studies are eligible to participate in this study.\n\nHave had treatment with any of the following within the specified timeframe prior to randomization:\n\nAny sorafenib within the 14 days prior to randomization.\nMajor surgery within the 4 weeks prior to randomization.\nAny transfusion, treatment with blood component preparation, received. erythropoietin , albumin preparation, and granulocyte colony-stimulating factor (G CSF) within the 2 weeks prior to randomization.\n\nHas a serious illness or medical condition(s) including, but not limited to the following:\n\nKnown gastrointestinal disorder, including malabsorption, chronic nausea, vomiting, or diarrhea present to the extent that it might interfere with oral intake and absorption of the study medication.\nKnown human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness.\nPrevious or concurrent malignancy except for basal cell carcinoma and/or in situ carcinoma of the cervix, or other solid tumor treated curatively and without evidence of recurrence for at least 3 years prior to the study.\nUncontrolled metabolic disorders or other nonmalignant organ or systemic diseases or secondary effects of cancer that induce a high medical risk and/or make assessment of survival uncertain.\nHas active or uncontrolled clinically serious infection excluding chronic hepatitis.\nOther severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the Investigator would make the patient inappropriate for entry into this study (eg, active urinary tract infection).\nKnown allergy or hypersensitivity of TAC 101 and any other components used in the TAC 101 tablet.",
                            "HealthyVolunteers": "No",
                            "Gender": "All",
                            "MinimumAge": "18 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Taiho Central",
                                        "OverallOfficialAffiliation": "Taiho Oncology, Inc. USA",
                                        "OverallOfficialRole": "Study Director"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "I.R.C.C.S. San Matteo University Hospital, Golgi",
                                        "LocationCity": "Pavia",
                                        "LocationZip": "27100",
                                        "LocationCountry": "Italy"
                                    }
                                ]
                            }
                        }
                    },
                    "ResultsSection": {
                        "ParticipantFlowModule": {
                            "FlowPreAssignmentDetails": "The study was stopped after only 52 of the required 220 participants (26 of 110 participants in each treatment group) were randomized. Sponsor terminated the study due to safety concerns and thus, stopped enrollment and study treatment on 06-May-2009, but continued follow-up of all the treated participants for survival till 10 May 2010 and thus, the same was considered as study completion date.",
                            "FlowRecruitmentDetails": "The study was conducted at 17 study centers worldwide between 01-August-2008 to 10-May-2010.",
                            "FlowGroupList": {
                                "FlowGroup": [
                                    {
                                        "FlowGroupId": "FG000",
                                        "FlowGroupTitle": "TAC-101",
                                        "FlowGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a dose of 20 milligram per day (mg/day) of TAC-101 (as second line treatment) oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period on Days 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                    },
                                    {
                                        "FlowGroupId": "FG001",
                                        "FlowGroupTitle": "Placebo",
                                        "FlowGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a matching placebo for TAC-101 oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period from on 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                    }
                                ]
                            },
                            "FlowPeriodList": {
                                "FlowPeriod": [
                                    {
                                        "FlowPeriodTitle": "Overall Study",
                                        "FlowMilestoneList": {
                                            "FlowMilestone": [
                                                {
                                                    "FlowMilestoneType": "STARTED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "26"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG001",
                                                                "FlowAchievementNumSubjects": "26"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowMilestoneType": "COMPLETED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "0"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG001",
                                                                "FlowAchievementNumSubjects": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowMilestoneType": "NOT COMPLETED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "26"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG001",
                                                                "FlowAchievementNumSubjects": "26"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "FlowDropWithdrawList": {
                                            "FlowDropWithdraw": [
                                                {
                                                    "FlowDropWithdrawType": "Adverse Event (AE)",
                                                    "FlowReasonList": {
                                                        "FlowReason": [
                                                            {
                                                                "FlowReasonGroupId": "FG000",
                                                                "FlowReasonNumSubjects": "10"
                                                            },
                                                            {
                                                                "FlowReasonGroupId": "FG001",
                                                                "FlowReasonNumSubjects": "3"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowDropWithdrawType": "Radiological Disease Progression",
                                                    "FlowReasonList": {
                                                        "FlowReason": [
                                                            {
                                                                "FlowReasonGroupId": "FG000",
                                                                "FlowReasonNumSubjects": "6"
                                                            },
                                                            {
                                                                "FlowReasonGroupId": "FG001",
                                                                "FlowReasonNumSubjects": "2"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowDropWithdrawType": "Clinical Disease Progression",
                                                    "FlowReasonList": {
                                                        "FlowReason": [
                                                            {
                                                                "FlowReasonGroupId": "FG000",
                                                                "FlowReasonNumSubjects": "1"
                                                            },
                                                            {
                                                                "FlowReasonGroupId": "FG001",
                                                                "FlowReasonNumSubjects": "3"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowDropWithdrawType": "Investigator Discretion",
                                                    "FlowReasonList": {
                                                        "FlowReason": [
                                                            {
                                                                "FlowReasonGroupId": "FG000",
                                                                "FlowReasonNumSubjects": "3"
                                                            },
                                                            {
                                                                "FlowReasonGroupId": "FG001",
                                                                "FlowReasonNumSubjects": "1"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowDropWithdrawType": "Sponsor Terminated Study",
                                                    "FlowReasonList": {
                                                        "FlowReason": [
                                                            {
                                                                "FlowReasonGroupId": "FG000",
                                                                "FlowReasonNumSubjects": "6"
                                                            },
                                                            {
                                                                "FlowReasonGroupId": "FG001",
                                                                "FlowReasonNumSubjects": "17"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "BaselineCharacteristicsModule": {
                            "BaselinePopulationDescription": "Baseline analysis included all randomized participants who received any dose of study medication and analyzed by the treatment received.",
                            "BaselineGroupList": {
                                "BaselineGroup": [
                                    {
                                        "BaselineGroupId": "BG000",
                                        "BaselineGroupTitle": "TAC-101",
                                        "BaselineGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a dose of 20 mg/day of TAC-101 (as second line treatment) oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period on Days 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                    },
                                    {
                                        "BaselineGroupId": "BG001",
                                        "BaselineGroupTitle": "Placebo",
                                        "BaselineGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a matching placebo for TAC-101 oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period from on 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                    },
                                    {
                                        "BaselineGroupId": "BG002",
                                        "BaselineGroupTitle": "Total",
                                        "BaselineGroupDescription": "Total of all reporting groups"
                                    }
                                ]
                            },
                            "BaselineDenomList": {
                                "BaselineDenom": [
                                    {
                                        "BaselineDenomUnits": "Participants",
                                        "BaselineDenomCountList": {
                                            "BaselineDenomCount": [
                                                {
                                                    "BaselineDenomCountGroupId": "BG000",
                                                    "BaselineDenomCountValue": "26"
                                                },
                                                {
                                                    "BaselineDenomCountGroupId": "BG001",
                                                    "BaselineDenomCountValue": "26"
                                                },
                                                {
                                                    "BaselineDenomCountGroupId": "BG002",
                                                    "BaselineDenomCountValue": "52"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "BaselineMeasureList": {
                                "BaselineMeasure": [
                                    {
                                        "BaselineMeasureTitle": "Age, Continuous",
                                        "BaselineMeasureParamType": "Mean",
                                        "BaselineMeasureDispersionType": "Standard Deviation",
                                        "BaselineMeasureUnitOfMeasure": "years",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "71.1",
                                                                            "BaselineMeasurementSpread": "6.93"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "68.2",
                                                                            "BaselineMeasurementSpread": "6.38"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "69.7",
                                                                            "BaselineMeasurementSpread": "6.75"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Sex: Female, Male",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineCategoryTitle": "Female",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "3"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "4"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "7"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Male",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "23"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "22"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "45"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Race/Ethnicity, Customized",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineClassTitle": "White",
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "23"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "24"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "47"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineClassTitle": "Black, of African Heritage",
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "2"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "2"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineClassTitle": "Asian",
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "1"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "1"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineClassTitle": "Other: Unspecified",
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "2"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "2"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomeMeasuresModule": {
                            "OutcomeMeasureList": {
                                "OutcomeMeasure": [
                                    {
                                        "OutcomeMeasureType": "Primary",
                                        "OutcomeMeasureTitle": "Overall Survival (OS)",
                                        "OutcomeMeasureDescription": "OS was defined as the time from the date of randomization to the date of death. Participants who were still alive were censored at the date last known to be alive (last contact date or last follow-up visit).",
                                        "OutcomeMeasurePopulationDescription": "Analysis was performed on safety population that included all randomized participants who received at least one dose of double-blind study medication and was summarized by the treatment received.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Mean",
                                        "OutcomeMeasureDispersionType": "Standard Deviation",
                                        "OutcomeMeasureUnitOfMeasure": "months",
                                        "OutcomeMeasureTimeFrame": "From the date of randomization to date of death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "TAC-101",
                                                    "OutcomeGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a dose of 20 mg/day of TAC-101 (as second line treatment) oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period on Days 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                                },
                                                {
                                                    "OutcomeGroupId": "OG001",
                                                    "OutcomeGroupTitle": "Placebo",
                                                    "OutcomeGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a matching placebo for TAC-101 oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period from on 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "26"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG001",
                                                                "OutcomeDenomCountValue": "26"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "8.23",
                                                                            "OutcomeMeasurementSpread": "5.406"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "8.35",
                                                                            "OutcomeMeasurementSpread": "5.351"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Secondary",
                                        "OutcomeMeasureTitle": "Radiologic Progression-free Survival (PFS)",
                                        "OutcomeMeasureDescription": "PFS was defined as the time from date of randomization to the date of tumor disease progression (ie, radiological only) or death due to any cause. Participants who were alive at the time of analysis and had no signs of tumor progression had their time of PFS censored at the date of the last tumor assessment, unless they received new antitumor therapy.",
                                        "OutcomeMeasurePopulationDescription": "Analysis was performed on safety population that included all randomized participants who received at least one dose of double-blind study medication and was summarized by the treatment received. Here, 'Overall number of participants analyzed' signifies participants with valid assessment at specified timepoint.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Mean",
                                        "OutcomeMeasureDispersionType": "Standard Deviation",
                                        "OutcomeMeasureUnitOfMeasure": "months",
                                        "OutcomeMeasureTimeFrame": "From the date of randomization to date of tumor disease progression or death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "TAC-101",
                                                    "OutcomeGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a dose of 20 mg/day of TAC-101 (as second line treatment) oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period on Days 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                                },
                                                {
                                                    "OutcomeGroupId": "OG001",
                                                    "OutcomeGroupTitle": "Placebo",
                                                    "OutcomeGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a matching placebo for TAC-101 oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period from on 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "21"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG001",
                                                                "OutcomeDenomCountValue": "22"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "4.95",
                                                                            "OutcomeMeasurementSpread": "4.904"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "4.82",
                                                                            "OutcomeMeasurementSpread": "3.647"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Secondary",
                                        "OutcomeMeasureTitle": "Time To Progression (TTP)",
                                        "OutcomeMeasureDescription": "TTP was defined as time from randomization to the date of tumor progression (radiological only). Participants who were alive with no tumor progression or who died prior to tumor progression had their TTP censored at the date of their last tumor assessment, unless they received new antitumor therapy.",
                                        "OutcomeMeasurePopulationDescription": "Analysis was performed on safety population that included all randomized participants who received at least one dose of double-blind study medication and was summarized by the treatment received. Here, 'Overall number of participants analyzed' signifies participants with valid assessment at specified timepoint.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Mean",
                                        "OutcomeMeasureDispersionType": "Standard Deviation",
                                        "OutcomeMeasureUnitOfMeasure": "months",
                                        "OutcomeMeasureTimeFrame": "From the date of randomization to date of tumor disease progression or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "TAC-101",
                                                    "OutcomeGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a dose of 20 mg/day of TAC-101 (as second line treatment) oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period on Days 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                                },
                                                {
                                                    "OutcomeGroupId": "OG001",
                                                    "OutcomeGroupTitle": "Placebo",
                                                    "OutcomeGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a matching placebo for TAC-101 oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period from on 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "21"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG001",
                                                                "OutcomeDenomCountValue": "22"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "4.14",
                                                                            "OutcomeMeasurementSpread": "4.430"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "4.09",
                                                                            "OutcomeMeasurementSpread": "3.146"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Secondary",
                                        "OutcomeMeasureTitle": "Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)",
                                        "OutcomeMeasureDescription": "Any untoward medical condition that occurs in a participants while participating in a clinical study and does not necessarily have a causal relationship with the use of the study treatment was considered an AE. A serious AE (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs were defined as AEs (both serious/non-serious) that occur from the initiation of any study medication administration, and do not necessarily have a causal relationship to the use of the study medication.",
                                        "OutcomeMeasurePopulationDescription": "Analysis was performed on safety population that included all randomized participants who received at least one dose of double-blind study medication and was summarized by the treatment received.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Count of Participants",
                                        "OutcomeMeasureUnitOfMeasure": "Participants",
                                        "OutcomeMeasureTimeFrame": "From Baseline up to 30 days after the last dose (maximum duration: up to 7.2 months for Placebo and up to 7.9 months for TAC-101)",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "TAC-101",
                                                    "OutcomeGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a dose of 20 mg/day of TAC-101 (as second line treatment) oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period on Days 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                                },
                                                {
                                                    "OutcomeGroupId": "OG001",
                                                    "OutcomeGroupTitle": "Placebo",
                                                    "OutcomeGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a matching placebo for TAC-101 oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period from on 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "26"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG001",
                                                                "OutcomeDenomCountValue": "26"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeClassTitle": "TEAE",
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "26"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "25"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "TESAE",
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "12"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "11"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Secondary",
                                        "OutcomeMeasureTitle": "Change From Baseline in Plasma Levels of the Tumor Marker Alpha-fetoprotein (AFP)",
                                        "OutcomeMeasureDescription": "AFP is a tumor marker for hepatocellular carcinoma and elevations in AFP values could precede clinical deterioration and tumor recurrence in participants. Baseline was defined as the last value obtained within 72 hours prior to study treatment administration on Cycle 1 Day 1.",
                                        "OutcomeMeasurePopulationDescription": "Analysis was performed on safety population that included all randomized participants who received at least 1 dose of double-blind study medication and was summarized by the treatment received. Here, 'Overall number of participants analyzed' signifies participants with valid assessment at specified timepoint.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Mean",
                                        "OutcomeMeasureDispersionType": "Standard Deviation",
                                        "OutcomeMeasureUnitOfMeasure": "nanogram per milliliter (ng/mL)",
                                        "OutcomeMeasureTimeFrame": "From the date of randomization to date of tumor disease progression or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "TAC-101",
                                                    "OutcomeGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a dose of 20 mg/day of TAC-101 (as second line treatment) oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period on Days 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                                },
                                                {
                                                    "OutcomeGroupId": "OG001",
                                                    "OutcomeGroupTitle": "Placebo",
                                                    "OutcomeGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a matching placebo for TAC-101 oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period from on 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "21"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG001",
                                                                "OutcomeDenomCountValue": "23"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "2779.3",
                                                                            "OutcomeMeasurementSpread": "16314.87"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "571.7",
                                                                            "OutcomeMeasurementSpread": "14301.08"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Secondary",
                                        "OutcomeMeasureTitle": "Percent Change From Baseline in Plasma Levels of the Tumor Marker Alpha Fetoprotein-L3 (AFP-L3)",
                                        "OutcomeMeasureDescription": "AFP-L3 is a tumor marker for hepatocellular carcinoma and elevations in AFP-L3 values could precede clinical deterioration and tumor recurrence in participants. Baseline was defined as the last value obtained within 72 hours prior to study treatment administration on Cycle 1 Day 1.",
                                        "OutcomeMeasurePopulationDescription": "Analysis was performed on safety population that included all randomized participants who received at least 1 dose of double-blind study medication and was summarized by the treatment received. Here, 'Overall number of participants analyzed' signifies participants with valid assessment at specified timepoint.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Mean",
                                        "OutcomeMeasureDispersionType": "Standard Deviation",
                                        "OutcomeMeasureUnitOfMeasure": "percent change",
                                        "OutcomeMeasureTimeFrame": "From the date of randomization to date of tumor disease progression or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "TAC-101",
                                                    "OutcomeGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a dose of 20 mg/day of TAC-101 (as second line treatment) oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period on Days 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                                },
                                                {
                                                    "OutcomeGroupId": "OG001",
                                                    "OutcomeGroupTitle": "Placebo",
                                                    "OutcomeGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a matching placebo for TAC-101 oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period from on 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "20"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG001",
                                                                "OutcomeDenomCountValue": "22"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "2.27",
                                                                            "OutcomeMeasurementSpread": "12.107"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "3.20",
                                                                            "OutcomeMeasurementSpread": "8.129"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Secondary",
                                        "OutcomeMeasureTitle": "Maximum Exposure-response Analysis: Maximum Plasma Concentration (Cmax) of TAC-101",
                                        "OutcomeMeasureDescription": "Cmax: maximum plasma concentration; Pharmacokinetic (PK) blood samples were collected at 4 hours (± 1 hour), 8 hours (± 1 hour), and 24 hours (± 1 hour) post-dose on Day 1 of treatment Cycle 1. The 24-hour sample was collected prior to dosing on Day 2.",
                                        "OutcomeMeasurePopulationDescription": "PK population included all participants in safety population participating in this sub-study and treated with active study treatment. Due to limited number of participants with evaluable PK data, no data was collected and analyzed for the conclusion of maximum exposure. Here, 'Overall number of participants analyzed' signifies participants with valid assessment at specified timepoint.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureTimeFrame": "Cycle 1-day 1: 4, 8, and 24 hours after the first dose of study drug",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "TAC-101",
                                                    "OutcomeGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a dose of 20 mg/day of TAC-101 (as second line treatment) oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period on Days 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                                },
                                                {
                                                    "OutcomeGroupId": "OG001",
                                                    "OutcomeGroupTitle": "Placebo",
                                                    "OutcomeGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a matching placebo for TAC-101 oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period from on 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "0"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG001",
                                                                "OutcomeDenomCountValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Secondary",
                                        "OutcomeMeasureTitle": "Overall Exposure-response Analysis: Area Under Curve (AUC0-inf) of TAC-101",
                                        "OutcomeMeasureDescription": "AUC(0-inf): Area under the curve from time zero extrapolated to infinity. PK blood samples were collected at 4 hours (± 1 hour), 8 hours (± 1 hour), and 24 hours (± 1 hour) post-dose on Day 1 of treatment Cycle 1. The 24-hour sample was collected prior to dosing on Day 2.",
                                        "OutcomeMeasurePopulationDescription": "PK population included all participants in safety population participating in this sub-study and treated with active study treatment. Due to limited number of participants with evaluable PK data, no data was collected and analyzed for conclusion of maximum exposure. Here, 'Overall number of participants analyzed' signifies participants with valid assessment at specified timepoint.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureTimeFrame": "Cycle 1-day 1: 4, 8, and 24 hours after the first dose of study drug",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "TAC-101",
                                                    "OutcomeGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a dose of 20 mg/day of TAC-101 (as second line treatment) oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period on Days 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                                },
                                                {
                                                    "OutcomeGroupId": "OG001",
                                                    "OutcomeGroupTitle": "Placebo",
                                                    "OutcomeGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a matching placebo for TAC-101 oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period from on 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "0"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG001",
                                                                "OutcomeDenomCountValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Secondary",
                                        "OutcomeMeasureTitle": "Changes From Baseline in Plasma Insulin-like Growth Factor-2 (IGF-2)",
                                        "OutcomeMeasureDescription": "RAR related factors are markers for disease progression in hepatocellular carcinoma participants. In hepatocellular carcinoma participants, IGF-2 is a characteristic biomarkers and its levels are higher in responder cells. The detection of IGF-2 levels showed the efficacy of TAC-101 in IGF-2 influenced malignancy.",
                                        "OutcomeMeasurePopulationDescription": "Analysis was performed on safety population that included all randomized participants who received at least 1 dose of double-blind study medication and was summarized by the treatment received. Here, 'Overall number of participants analyzed' signifies participants with valid assessment at specified timepoint.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Mean",
                                        "OutcomeMeasureDispersionType": "Standard Deviation",
                                        "OutcomeMeasureUnitOfMeasure": "ng/mL",
                                        "OutcomeMeasureTimeFrame": "From Baseline up to end of study treatment or up to tumor disease progression or up to death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "TAC-101",
                                                    "OutcomeGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a dose of 20 mg/day of TAC-101 (as second line treatment) oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period on Days 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                                },
                                                {
                                                    "OutcomeGroupId": "OG001",
                                                    "OutcomeGroupTitle": "Placebo",
                                                    "OutcomeGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a matching placebo for TAC-101 oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period from on 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "3"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG001",
                                                                "OutcomeDenomCountValue": "7"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "330.8",
                                                                            "OutcomeMeasurementSpread": "87.82"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "115.6",
                                                                            "OutcomeMeasurementSpread": "181.59"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Secondary",
                                        "OutcomeMeasureTitle": "Changes From Baseline in Plasma Transforming Growth Factor-beta (TGFβ2)",
                                        "OutcomeMeasureDescription": "TGF-β is responsible for tissue regeneration, cell differentiation, embryonic development, and regulation of the immune system. TGF-β2 levels are higher in non-responder cells hence helps in detection of such cells.",
                                        "OutcomeMeasurePopulationDescription": "Analysis was performed on safety population that included all randomized participants who received at least 1 dose of double-blind study medication and was summarized by the treatment received. Here, 'Overall number of participants analyzed' signifies participants with valid assessment at specified timepoint.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Mean",
                                        "OutcomeMeasureDispersionType": "Standard Deviation",
                                        "OutcomeMeasureUnitOfMeasure": "picograms per milliliter (pg/mL)",
                                        "OutcomeMeasureTimeFrame": "From Baseline up to end of study treatment or up to tumor disease progression or up to death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "TAC-101",
                                                    "OutcomeGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a dose of 20 mg/day of TAC-101 (as second line treatment) oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period on Days 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                                },
                                                {
                                                    "OutcomeGroupId": "OG001",
                                                    "OutcomeGroupTitle": "Placebo",
                                                    "OutcomeGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a matching placebo for TAC-101 oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period from on 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "2"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG001",
                                                                "OutcomeDenomCountValue": "7"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "-3.51",
                                                                            "OutcomeMeasurementSpread": "4.957"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "0.92",
                                                                            "OutcomeMeasurementSpread": "2.427"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Secondary",
                                        "OutcomeMeasureTitle": "Changes From Baseline in Plasma Insulin-like Growth Factor Binding Protein-3 (IGFBP-3)",
                                        "OutcomeMeasureDescription": "IGFBP-3 acts as a mediator of antiproliferative signals in hepatocellular carcinoma cells. The inhibition of hepatocellular carcinoma cell proliferation is associated with upregulation of IGFBP-3. Retinoic acid response element (RARE) exists on the promoter region of the IGFBP-3.",
                                        "OutcomeMeasurePopulationDescription": "Analysis was performed on safety population that included all randomized participants who received at least 1 dose of double-blind study medication and was summarized by the treatment received. Here, 'Overall number of participants analyzed' signifies participants with valid assessment at specified timepoint.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Mean",
                                        "OutcomeMeasureDispersionType": "Standard Deviation",
                                        "OutcomeMeasureUnitOfMeasure": "ng/mL",
                                        "OutcomeMeasureTimeFrame": "From Baseline up to end of study treatment or up to tumor disease progression or up to death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "TAC-101",
                                                    "OutcomeGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a dose of 20 mg/day of TAC-101 (as second line treatment) oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period on Days 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                                },
                                                {
                                                    "OutcomeGroupId": "OG001",
                                                    "OutcomeGroupTitle": "Placebo",
                                                    "OutcomeGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a matching placebo for TAC-101 oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period from on 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "3"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG001",
                                                                "OutcomeDenomCountValue": "7"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "370.6",
                                                                            "OutcomeMeasurementSpread": "242.97"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "-112.4",
                                                                            "OutcomeMeasurementSpread": "179.64"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Secondary",
                                        "OutcomeMeasureTitle": "Changes From Baseline in Plasma Insulin-like Growth Factor Binding Protein-6 (IGFBP-6)",
                                        "OutcomeMeasureDescription": "IGFBP-6 has an IGF-2 binding specificity and inhibits growth of a number of IGF-2-dependent cancers. RARE exists on the promoter region of the IGFBP-6.",
                                        "OutcomeMeasurePopulationDescription": "Analysis was performed on safety population that included all randomized participants who received at least 1 dose of double-blind study medication and was summarized by the treatment received. Here, 'Overall number of participants analyzed' signifies participants with valid assessment at specified timepoint.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Mean",
                                        "OutcomeMeasureDispersionType": "Standard Deviation",
                                        "OutcomeMeasureUnitOfMeasure": "ng/mL",
                                        "OutcomeMeasureTimeFrame": "From Baseline up to end of study treatment or up to tumor disease progression or up to death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "TAC-101",
                                                    "OutcomeGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a dose of 20 mg/day of TAC-101 (as second line treatment) oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period on Days 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                                },
                                                {
                                                    "OutcomeGroupId": "OG001",
                                                    "OutcomeGroupTitle": "Placebo",
                                                    "OutcomeGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a matching placebo for TAC-101 oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period from on 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "3"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG001",
                                                                "OutcomeDenomCountValue": "7"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "-40.7",
                                                                            "OutcomeMeasurementSpread": "82.08"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "-86.9",
                                                                            "OutcomeMeasurementSpread": "72.82"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Secondary",
                                        "OutcomeMeasureTitle": "Changes From Baseline in Plasma Lactoferrin",
                                        "OutcomeMeasureDescription": "RARE exists on the promoter region of the lactoferrin gene.",
                                        "OutcomeMeasurePopulationDescription": "Analysis was performed on safety population that included all randomized participants who received at least 1 dose of double-blind study medication and was summarized by the treatment received. Here, 'Overall number of participants analyzed' signifies participants with valid assessment at specified timepoint.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Mean",
                                        "OutcomeMeasureDispersionType": "Standard Deviation",
                                        "OutcomeMeasureUnitOfMeasure": "ng/mL",
                                        "OutcomeMeasureTimeFrame": "From Baseline up to end of study treatment or up to tumor disease progression or up to death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "TAC-101",
                                                    "OutcomeGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a dose of 20 mg/day of TAC-101 (as second line treatment) oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period on Days 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                                },
                                                {
                                                    "OutcomeGroupId": "OG001",
                                                    "OutcomeGroupTitle": "Placebo",
                                                    "OutcomeGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a matching placebo for TAC-101 oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period from on 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "3"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG001",
                                                                "OutcomeDenomCountValue": "6"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "-133.3",
                                                                            "OutcomeMeasurementSpread": "177.20"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "-25.5",
                                                                            "OutcomeMeasurementSpread": "25.83"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Secondary",
                                        "OutcomeMeasureTitle": "Changes From Baseline in Plasma Vascular Endothelial Growth Factor-A (VEGF-A)",
                                        "OutcomeMeasureDescription": "End of Treatment was defined as \"as soon as possible following the last dose of study medication\".",
                                        "OutcomeMeasurePopulationDescription": "Analysis was performed on safety population that included all randomized participants who received at least 1 dose of double-blind study medication and was summarized by the treatment received. Here, 'Overall number of participants analyzed' signifies participants with valid assessment at specified timepoint.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Mean",
                                        "OutcomeMeasureDispersionType": "Standard Deviation",
                                        "OutcomeMeasureUnitOfMeasure": "pg/mL",
                                        "OutcomeMeasureTimeFrame": "From Baseline up to end of study treatment or up to tumor disease progression or up to death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "TAC-101",
                                                    "OutcomeGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a dose of 20 mg/day of TAC-101 (as second line treatment) oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period on Days 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                                },
                                                {
                                                    "OutcomeGroupId": "OG001",
                                                    "OutcomeGroupTitle": "Placebo",
                                                    "OutcomeGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a matching placebo for TAC-101 oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period from on 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "3"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG001",
                                                                "OutcomeDenomCountValue": "7"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "-29.50",
                                                                            "OutcomeMeasurementSpread": "51.859"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "11.40",
                                                                            "OutcomeMeasurementSpread": "83.141"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Secondary",
                                        "OutcomeMeasureTitle": "Number of Participants With Antitumor Activity After Treatment Discontinuation",
                                        "OutcomeMeasureDescription": "Antitumor activity after treatment discontinuation in participant was determined by images, computed tomography (CT), and magnetic resonance imaging (MRI). Tumor imaging was done at Baseline any time within 4 weeks prior to the first dose of study treatment on Cycle 1, Day 1 and every 6 weeks (±1 week) during treatment, regardless of a dose delay. If participant discontinued study treatment for a reason other than disease progression (PD), data collected every 6 weeks until PD and following PD, data collected optionally every 6 weeks until death or up to 1 year after the last participant was randomized.",
                                        "OutcomeMeasurePopulationDescription": "The data were not collected and analyzed for this outcome measure due to low enrollment of participants.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureTimeFrame": "From the date of treatment discontinuation to date of tumor disease progression or death or up to 1 year post last participant was randomized, whichever was earlier (maximum duration: up to 21.3 months)",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "TAC-101",
                                                    "OutcomeGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a dose of 20 mg/day of TAC-101 (as second line treatment) oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period on Days 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                                },
                                                {
                                                    "OutcomeGroupId": "OG001",
                                                    "OutcomeGroupTitle": "Placebo",
                                                    "OutcomeGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a matching placebo for TAC-101 oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period from on 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "0"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG001",
                                                                "OutcomeDenomCountValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Secondary",
                                        "OutcomeMeasureTitle": "Relationship Between Tumor Gene Expression of Messenger Ribonucleic Acid (mRNA) Ratio of Co-activators, Co-repressors and Efficacy Parameters",
                                        "OutcomeMeasureDescription": "The assessment of correlative factors was to be conducted on tissue removed prior to the study, if available. Tumor tissue assessments included investigation of the relationship between tumor gene mRNA expression of co-activators and co-repressors and efficacy parameters.",
                                        "OutcomeMeasurePopulationDescription": "The data were not collected and analyzed for this outcome measure due to low enrollment of participants.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureTimeFrame": "At Baseline (prior to treatment after consenting informed consent form [ICF]) up to last dose of study treatment, assessed every 6 weeks (maximum duration: up to 21.3 months)",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "TAC-101",
                                                    "OutcomeGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a dose of 20 mg/day of TAC-101 (as second line treatment) oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period on Days 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                                },
                                                {
                                                    "OutcomeGroupId": "OG001",
                                                    "OutcomeGroupTitle": "Placebo",
                                                    "OutcomeGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a matching placebo for TAC-101 oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period from on 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "0"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG001",
                                                                "OutcomeDenomCountValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "AdverseEventsModule": {
                            "EventsFrequencyThreshold": "5",
                            "EventsTimeFrame": "From Baseline up to 30 days after the last dose (maximum duration: up to 7.2 months for Placebo and up to 7.9 months for TAC-101)",
                            "EventsDescription": "Analysis was performed on safety population.",
                            "EventGroupList": {
                                "EventGroup": [
                                    {
                                        "EventGroupId": "EG000",
                                        "EventGroupTitle": "TAC-101",
                                        "EventGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a dose of 20 mg/day of TAC-101 (as second line treatment) oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period on Days 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion.",
                                        "EventGroupDeathsNumAffected": "2",
                                        "EventGroupDeathsNumAtRisk": "26",
                                        "EventGroupSeriousNumAffected": "12",
                                        "EventGroupSeriousNumAtRisk": "26",
                                        "EventGroupOtherNumAffected": "25",
                                        "EventGroupOtherNumAtRisk": "26"
                                    },
                                    {
                                        "EventGroupId": "EG001",
                                        "EventGroupTitle": "Placebo",
                                        "EventGroupDescription": "Participants with advanced hepatocellular carcinoma who had previously received Sorafenib (as first line therapy) were administered a matching placebo for TAC-101 oral tablets within 1 hour post morning meals on Days 1 to 14 followed by a recovery period from on 15 to 21 in 21-day cycle until disease progression or participant met a treatment discontinuation criterion.",
                                        "EventGroupDeathsNumAffected": "6",
                                        "EventGroupDeathsNumAtRisk": "26",
                                        "EventGroupSeriousNumAffected": "11",
                                        "EventGroupSeriousNumAtRisk": "26",
                                        "EventGroupOtherNumAffected": "24",
                                        "EventGroupOtherNumAtRisk": "26"
                                    }
                                ]
                            },
                            "SeriousEventList": {
                                "SeriousEvent": [
                                    {
                                        "SeriousEventTerm": "Atrial thrombosis",
                                        "SeriousEventOrganSystem": "Cardiac disorders",
                                        "SeriousEventSourceVocabulary": "MedDRA 10.0",
                                        "SeriousEventAssessmentType": "Systematic Assessment",
                                        "SeriousEventStatsList": {
                                            "SeriousEventStats": [
                                                {
                                                    "SeriousEventStatsGroupId": "EG000",
                                                    "SeriousEventStatsNumEvents": "2",
                                                    "SeriousEventStatsNumAffected": "2",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "SeriousEventStatsGroupId": "EG001",
                                                    "SeriousEventStatsNumEvents": "0",
                                                    "SeriousEventStatsNumAffected": "0",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "SeriousEventTerm": "Cardiac arrest",
                                        "SeriousEventOrganSystem": "Cardiac disorders",
                                        "SeriousEventSourceVocabulary": "MedDRA 10.0",
                                        "SeriousEventAssessmentType": "Systematic Assessment",
                                        "SeriousEventStatsList": {
                                            "SeriousEventStats": [
                                                {
                                                    "SeriousEventStatsGroupId": "EG000",
                                                    "SeriousEventStatsNumEvents": "0",
                                                    "SeriousEventStatsNumAffected": "0",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "SeriousEventStatsGroupId": "EG001",
                                                    "SeriousEventStatsNumEvents": "1",
                                                    "SeriousEventStatsNumAffected": "1",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "SeriousEventTerm": "Left ventricular failure",
                                        "SeriousEventOrganSystem": "Cardiac disorders",
                                        "SeriousEventSourceVocabulary": "MedDRA 10.0",
                                        "SeriousEventAssessmentType": "Systematic Assessment",
                                        "SeriousEventStatsList": {
                                            "SeriousEventStats": [
                                                {
                                                    "SeriousEventStatsGroupId": "EG000",
                                                    "SeriousEventStatsNumEvents": "0",
                                                    "SeriousEventStatsNumAffected": "0",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "SeriousEventStatsGroupId": "EG001",
                                                    "SeriousEventStatsNumEvents": "1",
                                                    "SeriousEventStatsNumAffected": "1",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "SeriousEventTerm": "Abdominal pain",
                                        "SeriousEventOrganSystem": "Gastrointestinal disorders",
                                        "SeriousEventSourceVocabulary": "MedDRA 10.0",
                                        "SeriousEventAssessmentType": "Systematic Assessment",
                                        "SeriousEventStatsList": {
                                            "SeriousEventStats": [
                                                {
                                                    "SeriousEventStatsGroupId": "EG000",
                                                    "SeriousEventStatsNumEvents": "1",
                                                    "SeriousEventStatsNumAffected": "1",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "SeriousEventStatsGroupId": "EG001",
                                                    "SeriousEventStatsNumEvents": "0",
                                                    "SeriousEventStatsNumAffected": "0",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "SeriousEventTerm": "Gastrointestinal haemorrhage",
                                        "SeriousEventOrganSystem": "Gastrointestinal disorders",
                                        "SeriousEventSourceVocabulary": "MedDRA 10.0",
                                        "SeriousEventAssessmentType": "Systematic Assessment",
                                        "SeriousEventStatsList": {
                                            "SeriousEventStats": [
                                                {
                                                    "SeriousEventStatsGroupId": "EG000",
                                                    "SeriousEventStatsNumEvents": "0",
                                                    "SeriousEventStatsNumAffected": "0",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "SeriousEventStatsGroupId": "EG001",
                                                    "SeriousEventStatsNumEvents": "2",
                                                    "SeriousEventStatsNumAffected": "2",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "SeriousEventTerm": "Oesophageal varices haemorrhage",
                                        "SeriousEventOrganSystem": "Gastrointestinal disorders",
                                        "SeriousEventSourceVocabulary": "MedDRA 10.0",
                                        "SeriousEventAssessmentType": "Systematic Assessment",
                                        "SeriousEventStatsList": {
                                            "SeriousEventStats": [
                                                {
                                                    "SeriousEventStatsGroupId": "EG000",
                                                    "SeriousEventStatsNumEvents": "0",
                                                    "SeriousEventStatsNumAffected": "0",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "SeriousEventStatsGroupId": "EG001",
                                                    "SeriousEventStatsNumEvents": "1",
                                                    "SeriousEventStatsNumAffected": "1",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "SeriousEventTerm": "Disease progression",
                                        "SeriousEventOrganSystem": "General disorders",
                                        "SeriousEventSourceVocabulary": "MedDRA 10.0",
                                        "SeriousEventAssessmentType": "Systematic Assessment",
                                        "SeriousEventStatsList": {
                                            "SeriousEventStats": [
                                                {
                                                    "SeriousEventStatsGroupId": "EG000",
                                                    "SeriousEventStatsNumEvents": "0",
                                                    "SeriousEventStatsNumAffected": "0",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "SeriousEventStatsGroupId": "EG001",
                                                    "SeriousEventStatsNumEvents": "1",
                                                    "SeriousEventStatsNumAffected": "1",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "SeriousEventTerm": "Fatigue",
                                        "SeriousEventOrganSystem": "General disorders",
                                        "SeriousEventSourceVocabulary": "MedDRA 10.0",
                                        "SeriousEventAssessmentType": "Systematic Assessment",
                                        "SeriousEventStatsList": {
                                            "SeriousEventStats": [
                                                {
                                                    "SeriousEventStatsGroupId": "EG000",
                                                    "SeriousEventStatsNumEvents": "0",
                                                    "SeriousEventStatsNumAffected": "0",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "SeriousEventStatsGroupId": "EG001",
                                                    "SeriousEventStatsNumEvents": "2",
                                                    "SeriousEventStatsNumAffected": "2",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "SeriousEventTerm": "General physical health deterioration",
                                        "SeriousEventOrganSystem": "General disorders",
                                        "SeriousEventSourceVocabulary": "MedDRA 10.0",
                                        "SeriousEventAssessmentType": "Systematic Assessment",
                                        "SeriousEventStatsList": {
                                            "SeriousEventStats": [
                                                {
                                                    "SeriousEventStatsGroupId": "EG000",
                                                    "SeriousEventStatsNumEvents": "0",
                                                    "SeriousEventStatsNumAffected": "0",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "SeriousEventStatsGroupId": "EG001",
                                                    "SeriousEventStatsNumEvents": "1",
                                                    "SeriousEventStatsNumAffected": "1",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "SeriousEventTerm": "Oedema due to hepatic disease",
                                        "SeriousEventOrganSystem": "General disorders",
                                        "SeriousEventSourceVocabulary": "MedDRA 10.0",
                                        "SeriousEventAssessmentType": "Systematic Assessment",
                                        "SeriousEventStatsList": {
                                            "SeriousEventStats": [
                                                {
                                                    "SeriousEventStatsGroupId": "EG000",
                                                    "SeriousEventStatsNumEvents": "1",
                                                    "SeriousEventStatsNumAffected": "1",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "SeriousEventStatsGroupId": "EG001",
                                                    "SeriousEventStatsNumEvents": "0",
                                                    "SeriousEventStatsNumAffected": "0",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "SeriousEventTerm": "Cytolytic hepatitis",
                                        "SeriousEventOrganSystem": "Hepatobiliary disorders",
                                        "SeriousEventSourceVocabulary": "MedDRA 10.0",
                                        "SeriousEventAssessmentType": "Systematic Assessment",
                                        "SeriousEventStatsList": {
                                            "SeriousEventStats": [
                                                {
                                                    "SeriousEventStatsGroupId": "EG000",
                                                    "SeriousEventStatsNumEvents": "0",
                                                    "SeriousEventStatsNumAffected": "0",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "SeriousEventStatsGroupId": "EG001",
                                                    "SeriousEventStatsNumEvents": "1",
                                                    "SeriousEventStatsNumAffected": "1",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "SeriousEventTerm": "Hepatic failure",
                                        "SeriousEventOrganSystem": "Hepatobiliary disorders",
                                        "SeriousEventSourceVocabulary": "MedDRA 10.0",
                                        "SeriousEventAssessmentType": "Systematic Assessment",
                                        "SeriousEventStatsList": {
                                            "SeriousEventStats": [
                                                {
                                                    "SeriousEventStatsGroupId": "EG000",
                                                    "SeriousEventStatsNumEvents": "1",
                                                    "SeriousEventStatsNumAffected": "1",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "SeriousEventStatsGroupId": "EG001",
                                                    "SeriousEventStatsNumEvents": "1",
                                                    "SeriousEventStatsNumAffected": "1",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "SeriousEventTerm": "Hyperbilirubinaemia",
                                        "SeriousEventOrganSystem": "Hepatobiliary disorders",
                                        "SeriousEventSourceVocabulary": "MedDRA 10.0",
                                        "SeriousEventAssessmentType": "Systematic Assessment",
                                        "SeriousEventStatsList": {
                                            "SeriousEventStats": [
                                                {
                                                    "SeriousEventStatsGroupId": "EG000",
                                                    "SeriousEventStatsNumEvents": "0",
                                                    "SeriousEventStatsNumAffected": "0",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "SeriousEventStatsGroupId": "EG001",
                                                    "SeriousEventStatsNumEvents": "1",
                                                    "SeriousEventStatsNumAffected": "1",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "SeriousEventTerm": "Pneumonia",
                                        "SeriousEventOrganSystem": "Infections and infestations",
                                        "SeriousEventSourceVocabulary": "MedDRA 10.0",
                                        "SeriousEventAssessmentType": "Systematic Assessment",
                                        "SeriousEventStatsList": {
                                            "SeriousEventStats": [
                                                {
                                                    "SeriousEventStatsGroupId": "EG000",
                                                    "SeriousEventStatsNumEvents": "1",
                                                    "SeriousEventStatsNumAffected": "1",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "SeriousEventStatsGroupId": "EG001",
                                                    "SeriousEventStatsNumEvents": "0",
                                                    "SeriousEventStatsNumAffected": "0",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "SeriousEventTerm": "Weight decreased",
                                        "SeriousEventOrganSystem": "Investigations",
                                        "SeriousEventSourceVocabulary": "MedDRA 10.0",
                                        "SeriousEventAssessmentType": "Systematic Assessment",
                                        "SeriousEventStatsList": {
                                            "SeriousEventStats": [
                                                {
                                                    "SeriousEventStatsGroupId": "EG000",
                                                    "SeriousEventStatsNumEvents": "0",
                                                    "SeriousEventStatsNumAffected": "0",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "SeriousEventStatsGroupId": "EG001",
                                                    "SeriousEventStatsNumEvents": "1",
                                                    "SeriousEventStatsNumAffected": "1",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "SeriousEventTerm": "Epilepsy",
                                        "SeriousEventOrganSystem": "Nervous system disorders",
                                        "SeriousEventSourceVocabulary": "MedDRA 10.0",
                                        "SeriousEventAssessmentType": "Systematic Assessment",
                                        "SeriousEventStatsList": {
                                            "SeriousEventStats": [
                                                {
                                                    "SeriousEventStatsGroupId": "EG000",
                                                    "SeriousEventStatsNumEvents": "1",
                                                    "SeriousEventStatsNumAffected": "1",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "SeriousEventStatsGroupId": "EG001",
                                                    "SeriousEventStatsNumEvents": "0",
                                                    "SeriousEventStatsNumAffected": "0",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "SeriousEventTerm": "Hepatic encephalopathy",
                                        "SeriousEventOrganSystem": "Nervous system disorders",
                                        "SeriousEventSourceVocabulary": "MedDRA 10.0",
                                        "SeriousEventAssessmentType": "Systematic Assessment",
                                        "SeriousEventStatsList": {
                                            "SeriousEventStats": [
                                                {
                                                    "SeriousEventStatsGroupId": "EG000",
                                                    "SeriousEventStatsNumEvents": "0",
                                                    "SeriousEventStatsNumAffected": "0",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "SeriousEventStatsGroupId": "EG001",
                                                    "SeriousEventStatsNumEvents": "1",
                                                    "SeriousEventStatsNumAffected": "1",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "SeriousEventTerm": "Dyspnoea",
                                        "SeriousEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                                        "SeriousEventSourceVocabulary": "MedDRA 10.0",
                                        "SeriousEventAssessmentType": "Systematic Assessment",
                                        "SeriousEventStatsList": {
                                            "SeriousEventStats": [
                                                {
                                                    "SeriousEventStatsGroupId": "EG000",
                                                    "SeriousEventStatsNumEvents": "2",
                                                    "SeriousEventStatsNumAffected": "1",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "SeriousEventStatsGroupId": "EG001",
                                                    "SeriousEventStatsNumEvents": "1",
                                                    "SeriousEventStatsNumAffected": "1",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "SeriousEventTerm": "Pulmonary embolism",
                                        "SeriousEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                                        "SeriousEventSourceVocabulary": "MedDRA 10.0",
                                        "SeriousEventAssessmentType": "Systematic Assessment",
                                        "SeriousEventStatsList": {
                                            "SeriousEventStats": [
                                                {
                                                    "SeriousEventStatsGroupId": "EG000",
                                                    "SeriousEventStatsNumEvents": "1",
                                                    "SeriousEventStatsNumAffected": "1",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "SeriousEventStatsGroupId": "EG001",
                                                    "SeriousEventStatsNumEvents": "0",
                                                    "SeriousEventStatsNumAffected": "0",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "SeriousEventTerm": "Deep vein thrombosis",
                                        "SeriousEventOrganSystem": "Vascular disorders",
                                        "SeriousEventSourceVocabulary": "MedDRA 10.0",
                                        "SeriousEventAssessmentType": "Systematic Assessment",
                                        "SeriousEventStatsList": {
                                            "SeriousEventStats": [
                                                {
                                                    "SeriousEventStatsGroupId": "EG000",
                                                    "SeriousEventStatsNumEvents": "4",
                                                    "SeriousEventStatsNumAffected": "4",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "SeriousEventStatsGroupId": "EG001",
                                                    "SeriousEventStatsNumEvents": "0",
                                                    "SeriousEventStatsNumAffected": "0",
                                                    "SeriousEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OtherEventList": {
                                "OtherEvent": [
                                    {
                                        "OtherEventTerm": "Anaemia",
                                        "OtherEventOrganSystem": "Blood and lymphatic system disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Abdominal pain",
                                        "OtherEventOrganSystem": "Gastrointestinal disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "3",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "4",
                                                    "OtherEventStatsNumAffected": "4",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Abdominal pain upper",
                                        "OtherEventOrganSystem": "Gastrointestinal disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Ascites",
                                        "OtherEventOrganSystem": "Gastrointestinal disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "4",
                                                    "OtherEventStatsNumAffected": "4",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Constipation",
                                        "OtherEventOrganSystem": "Gastrointestinal disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Diarrhoea",
                                        "OtherEventOrganSystem": "Gastrointestinal disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "4",
                                                    "OtherEventStatsNumAffected": "4",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "5",
                                                    "OtherEventStatsNumAffected": "5",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Dry mouth",
                                        "OtherEventOrganSystem": "Gastrointestinal disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Nausea",
                                        "OtherEventOrganSystem": "Gastrointestinal disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Vomiting",
                                        "OtherEventOrganSystem": "Gastrointestinal disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "3",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Asthenia",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "7",
                                                    "OtherEventStatsNumAffected": "7",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Fatigue",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "8",
                                                    "OtherEventStatsNumAffected": "6",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "7",
                                                    "OtherEventStatsNumAffected": "5",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "General physical health deterioration",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Oedema peripheral",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "6",
                                                    "OtherEventStatsNumAffected": "6",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "5",
                                                    "OtherEventStatsNumAffected": "5",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Performance status decreased",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "3",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Hyperbilirubinaemia",
                                        "OtherEventOrganSystem": "Hepatobiliary disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "3",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Bronchitis",
                                        "OtherEventOrganSystem": "Infections and infestations",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "3",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Fall",
                                        "OtherEventOrganSystem": "Injury, poisoning and procedural complications",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Blood bilirubin increased",
                                        "OtherEventOrganSystem": "Investigations",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Anorexia",
                                        "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "7",
                                                    "OtherEventStatsNumAffected": "5",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Arthralgia",
                                        "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "5",
                                                    "OtherEventStatsNumAffected": "5",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "3",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Back pain",
                                        "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Musculoskeletal pain",
                                        "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "4",
                                                    "OtherEventStatsNumAffected": "4",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Myalgia",
                                        "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Dizziness",
                                        "OtherEventOrganSystem": "Nervous system disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "3",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Headache",
                                        "OtherEventOrganSystem": "Nervous system disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "3",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Insomnia",
                                        "OtherEventOrganSystem": "Psychiatric disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Cough",
                                        "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "3",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Dyspnoea",
                                        "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Epistaxis",
                                        "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "3",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Dry skin",
                                        "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Palmar-plantar erythrodysaesthesia syndrome",
                                        "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "4",
                                                    "OtherEventStatsNumAffected": "3",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Pruritus",
                                        "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "4",
                                                    "OtherEventStatsNumAffected": "4",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Rash",
                                        "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "3",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Hypertension",
                                        "OtherEventOrganSystem": "Vascular disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "4",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Hypotension",
                                        "OtherEventOrganSystem": "Vascular disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "26"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "MoreInfoModule": {
                            "CertainAgreement": {
                                "AgreementPISponsorEmployee": "No",
                                "AgreementRestrictionType": "OTHER",
                                "AgreementRestrictiveAgreement": "Yes"
                            },
                            "PointOfContact": {
                                "PointOfContactTitle": "Taiho Central",
                                "PointOfContactOrganization": "Taiho Oncology, Inc.",
                                "PointOfContactEMail": "clinicaltrialinfo@taihooncology.com",
                                "PointOfContactPhone": "609-250-7336"
                            }
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000002277",
                                        "ConditionMeshTerm": "Carcinoma"
                                    },
                                    {
                                        "ConditionMeshId": "D000006528",
                                        "ConditionMeshTerm": "Carcinoma, Hepatocellular"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000009375",
                                        "ConditionAncestorTerm": "Neoplasms, Glandular and Epithelial"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009370",
                                        "ConditionAncestorTerm": "Neoplasms by Histologic Type"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009369",
                                        "ConditionAncestorTerm": "Neoplasms"
                                    },
                                    {
                                        "ConditionAncestorId": "D000000230",
                                        "ConditionAncestorTerm": "Adenocarcinoma"
                                    },
                                    {
                                        "ConditionAncestorId": "D000008113",
                                        "ConditionAncestorTerm": "Liver Neoplasms"
                                    },
                                    {
                                        "ConditionAncestorId": "D000004067",
                                        "ConditionAncestorTerm": "Digestive System Neoplasms"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009371",
                                        "ConditionAncestorTerm": "Neoplasms by Site"
                                    },
                                    {
                                        "ConditionAncestorId": "D000004066",
                                        "ConditionAncestorTerm": "Digestive System Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000008107",
                                        "ConditionAncestorTerm": "Liver Diseases"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M4686",
                                        "ConditionBrowseLeafName": "Carcinoma",
                                        "ConditionBrowseLeafAsFound": "Carcinoma",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M8765",
                                        "ConditionBrowseLeafName": "Carcinoma, Hepatocellular",
                                        "ConditionBrowseLeafAsFound": "Hepatocellular Carcinoma",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M11472",
                                        "ConditionBrowseLeafName": "Neoplasms, Glandular and Epithelial",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M11467",
                                        "ConditionBrowseLeafName": "Neoplasms by Histologic Type",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M2737",
                                        "ConditionBrowseLeafName": "Adenocarcinoma",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M10265",
                                        "ConditionBrowseLeafName": "Liver Neoplasms",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M8038",
                                        "ConditionBrowseLeafName": "Gastrointestinal Neoplasms",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M6408",
                                        "ConditionBrowseLeafName": "Digestive System Neoplasms",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M8035",
                                        "ConditionBrowseLeafName": "Gastrointestinal Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M6407",
                                        "ConditionBrowseLeafName": "Digestive System Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M10259",
                                        "ConditionBrowseLeafName": "Liver Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC04",
                                        "ConditionBrowseBranchName": "Neoplasms"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC06",
                                        "ConditionBrowseBranchName": "Digestive System Diseases"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M1680",
                                        "InterventionBrowseLeafName": "Sorafenib",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "ANeo",
                                        "InterventionBrowseBranchName": "Antineoplastic Agents"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 16,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT02362191",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "14-0600"
                            },
                            "Organization": {
                                "OrgFullName": "University of North Carolina, Chapel Hill",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Targeting Inter-Hemispheric Alpha Coherence With tACS To Treat PMDD",
                            "OfficialTitle": "Targeting Inter-Hemispheric Alpha Coherence With tACS To Treat PMDD"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "June 2020",
                            "OverallStatus": "Terminated",
                            "WhyStopped": "The study was terminated because the dense treatment schedule precluded successful recruitment of study participants.",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "March 2015"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "March 2020",
                                "PrimaryCompletionDateType": "Actual"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "March 2020",
                                "CompletionDateType": "Actual"
                            },
                            "StudyFirstSubmitDate": "September 27, 2014",
                            "StudyFirstSubmitQCDate": "February 7, 2015",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "February 12, 2015",
                                "StudyFirstPostDateType": "Estimate"
                            },
                            "ResultsFirstSubmitDate": "September 16, 2020",
                            "ResultsFirstSubmitQCDate": "September 16, 2020",
                            "ResultsFirstPostDateStruct": {
                                "ResultsFirstPostDate": "October 9, 2020",
                                "ResultsFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "September 16, 2020",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "October 9, 2020",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Sponsor"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "University of North Carolina, Chapel Hill",
                                "LeadSponsorClass": "OTHER"
                            },
                            "CollaboratorList": {
                                "Collaborator": [
                                    {
                                        "CollaboratorName": "Foundation of Hope, North Carolina",
                                        "CollaboratorClass": "OTHER"
                                    }
                                ]
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "Purpose: Using transcranial alternating current stimulation (tACS), we will study whether tACS induces changes in prefrontal alpha oscillatory frequencies in women with premenstrual dysphoric disorder (PMDD) and whether tACS effects on alpha oscillations varies by menstrual cycle phase. An exploratory objective is to assess whether there are any changes in symptom severity during the menstrual cycle phase in which tACS is delivered relative to their baseline symptom levels (determined in a diagnostic feeder study, see below).\n\nParticipants: Women between ages 18-52 with a diagnosis of PMDD confirmed by participation in a PMDD diagnostic study (IRB# 05-3000).\n\nProcedures (methods): After a re-screening and consent appointment, eligible participants will alert the study staff when they begin menstruating. Participants will have their first session in either the follicular phase or luteal phase (determined by ovulation testing) of their menstrual cycle and the second session in the other cycle phase. The order of phase at first testing will be counterbalanced across participants. Each session will consist of 40 minutes of tACS with by an EEG recording before and after stimulation. Patients' symptoms will be assessed at the end of each session and with the daily mood ratings collected throughout the menstrual cycle that coincides with tACS sessions (approximately 26 - 32 days).",
                            "DetailedDescription": "Premenstrual Dysphoric Disorder (PMDD) describes the cyclic appearance of affective symptoms and resultant impairment during the luteal phase of the menstrual cycle. The objective of the experiment is to determine if transcranial alternating current electrical stimulation (tACS) will alter prefrontal alpha oscillatory frequencies in women with PMDD, disruption of which has been implicated in other mood disorders. A secondary objective is to determine if menstrual cycle phase will influence the effects of tACS on alpha oscillations. Demonstration of 'target engagement' (alterations in left prefrontal alpha oscillatory frequencies with tACS) is a necessary first step before moving forward with subsequent research that would test whether tACS is a potential treatment for this disorder - promising research in other mood disorders suggests that it may be.\n\nThe cause of PMDD is unknown, the morbidity substantial, and the identified treatments limited in their effectiveness, since 40% of PMDD women are non-responders to SSRIs and many additional women are intolerant of antidepressant induced side effects. PMDD is prevalent (6-8% of women of reproductive age), attended by substantial morbidity, and hence a significant public health problem. Indeed, by World Health Calculations, PMDD is associated with 4.5 million Disability Adjusted Life Years in the US alone. The rationale for testing whether tACS differentially alters target engagement in the follicular versus luteal phases of the menstrual cycle is described below.\n\nDifferential Effects on Cortical Activity: The rationale for testing whether tACS differentially alters target engagement in the follicular versus luteal phases of the menstrual cycle is as follows: 1) Role of Hormones: While there is little evidence for ovarian dysfunction in PMDD a role for the reproductive hormones is clearly implicated, since our own work and that of others has shown that suppression of ovarian function results in a complete remission of symptoms in a majority of women with PMDD, while adding back gonadal hormones results in the return of symptoms in women with PMDD, with no symptoms seen in controls. Both estradiol and progesterone appear capable of precipitating mood destabilization in this paradigm. Recently completed studies from our group further demonstrate that continuous administration of hormones for longer than one-month results in a sustained symptom remission subsequent to the initial precipitated episode. Thus, dysphoric mood states in PMDD appear to be induced by normal changes in gonadal hormones rather than by exposure to elevated hormone levels (i.e., women with PMDD are differentially sensitive to the mood dysregulatory effects of reproductive steroids).\n\nAlthough there is substantial literature demonstrating the effects of reproductive steroids and, by extension, the menstrual cycle on cortical activity, the usually described effects are disturbed in women with PMDD. Examples include the following: 1) in normal women, activation of the medial orbitofrontal cortex is diminished during the luteal phase and the affective valence of the stimulus to which it responds is reversed (i.e., it responds only to negative stimuli rather than to positive stimuli, as occurs during the follicular phase). These changes are absent in women with PMDD. 2) in normal women during the luteal phase, there is an increase in cortical inhibition - a presumed effect of the GABA receptor activating effects of the progesterone metabolite allopregnanolone. This effect is absent in women with PMDD. Both animal and human data further suggest the role of a disturbed cortical response to progesterone-derived neurosteroids in PMDD. Thus, sudden changes in the levels of allopregnanolone (as occurs at the start of the luteal phase with increasing levels of progesterone) result in subcortical excitability and irritability in rodents, while elimination of changes in progesterone-derived neurosteroids (with neurosteroid synthesis inhibition) successfully prevents the emergence of the dysphoric state in PMDD.\n\nDifferential Network Activation: Psychiatric disorders characterized by dysregulation of affective state -depression and PMDD - are increasingly recognized as are \"network disorders\" in which aberrant electric signaling in large-scale neuronal networks mediates the clinical symptoms. Recent studies have documented impaired balance in activation between left and right prefrontal cortex in patients with PMDD. In particular, similar to major depressive disorder, the balance between alpha oscillation power in the left and the right hemisphere is shifted towards the left in patients with PMDD. The presence of alpha oscillations corresponds to a relative decrease in neuronal activity (inverse relationship). Therefore, such a left-shifted alpha asymmetry is indicative of hypoactivation of the left hemisphere - a common finding in imaging studies of patients with MDD. Since this asymmetry is exacerbated during the luteal but not the follicular phase (corresponding to the time course of symptom presentation in PMDD, we hypothesize that successful normalization of alpha oscillations in women with PMDD would be a plausible approach to symptom remediation. This network level intervention can be accomplished with brain stimulation by application of weak electric currents, a non-invasive approach to modulating intrinsic cortical network dynamics. The advantage of this approach is twofold: it is non-pharmacologic and thus avoids the otherwise attendant side effects; and it will provide systems level insights into the pathophysiology underlying mood state dysregulation.\n\nBrain stimulation by constant electric currents applied to the scalp (tDCs) modulates neuronal excitability in humans. Transcranial current stimulation with sine-wave stimulation waveforms (transcranial alternating current stimulation, tACS) likely enhances cortical oscillations in a frequency specific manner. The mechanisms of weak electric fields generated by tDCS and tACS previously have been demonstrated to interact with cortical network activity by altering the temporal activity structure of electric signaling in cortex. In this study, we will assess whether tACS will decrease left frontal alpha power (8-12 Hz) and whether the extent of the decrease varies by menstrual cycle phase. An exploratory objective will be to examine the severity of the PMDD symptoms collected daily during the stimulation cycle and compare that severity with baseline symptoms ratings collected during the PMDD diagnostic study from which these participants will be recruited. The rationale for this stimulation is the known deficits in the overall structure of cortical activity in this frequency band in patients with mood disorders and the previously demonstrate clinical benefits of tDCS in the treatment of mood disorders. In this study, we will use more targeted stimulation waveforms by employing bilateral tACS instead of tDCS. We hypothesize that this choice of a more sophisticated waveform that directly enhances synchronization between the two hemispheres may be more effective in engaging the target. tDCS modulates overall activity levels of the targeted cortical area in a non-specific manner. Here, however, we propose to evaluate a more specific stimulation modality, tACS, (10 Hz stimulation frequency) that has been shown to selectively enhance cortical alpha rhythms. Since the selected patient population reportedly exhibits specific deficits in the alpha frequency band, our stimulation approach will provide a more targeted and therefore possibly a more effective manipulation.\n\nProtocol History: This protocol was originally designed to test the therapeutic efficacy of tACS in PMDD in a double blind, randomized, sham controlled, cross-over study of 5 tACS sessions. We were unable to recruit subjects, largely consequent to the many daily treatment sessions required. We subsequently changed the primary focus of the study to that of determining whether a single session of tACS engaged left prefrontal cortical alpha oscillations and, by reducing them, reduced alpha asymmetry. We further asked whether this effect was menstrual cycle phase-dependent."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Premenstrual Dysphoric Disorder"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Not Applicable"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "N/A",
                                "DesignInterventionModel": "Single Group Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "None (Open Label)"
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "5",
                                "EnrollmentType": "Actual"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "Single Session tACS Across Menstrual Cycle",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "Participants assigned to receive a single session of tACS during the follicular and luteal phase of their menstrual cycle.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: Alternating Current Stimulator"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "Alternating Current Stimulator",
                                        "InterventionDescription": "Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Single Session tACS Across Menstrual Cycle"
                                            ]
                                        },
                                        "InterventionOtherNameList": {
                                            "InterventionOtherName": [
                                                "XCSITE 100 Stimulator"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Change in Alpha Frequency Electrical Activity in Left Frontal Cortex Following Stimulation",
                                        "PrimaryOutcomeDescription": "Fast Fourier transform is applied to 8 minutes of EEG data before and after tACS. Primary outcome is the difference in alpha frequency amplitude (8-12 Hz) in the left frontal cortex from baseline as a result of intervention.",
                                        "PrimaryOutcomeTimeFrame": "8-minute recording before vs after intervention"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "Difference in Magnitude of Effect of tACS on Left Prefrontal Alpha in Follicular vs Luteal Phase",
                                        "SecondaryOutcomeDescription": "Comparison of the change in EEG left prefrontal activity following tACS in luteal vs. follicular phases measured by the luteal pre to post change in EEG compared with the follicular pre to post change in EEG. Pre-post EEG recordings will occur during the follicular phase (5-9 days after menstruation) and in the luteal, premenstrual phase (9-13 days after ovulation).",
                                        "SecondaryOutcomeTimeFrame": "Over the course of 2 menstrual cycles, pre-post EEG recordings will occur, one during the follicular phase (5-9 days after menstruation) and one in the luteal, premenstrual phase (9-13 days after ovulation)"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nAge 18-52;\nHave participated in our PMDD diagnostic study (IRB# 05-3000);\nRegularly menstruating without hormonal contraceptives (e.g., birth control pills, injections, implants, progestin IUDs);\nMedication free or regularly taking medication that has no effect on the nervous system;\nNot currently pregnant or planning to become pregnant;\nWith sufficient resources to prevent pregnancy\n\nExclusion Criteria included:\n\nBrain surgery or brain implants, including cochlear implants or aneurysm clips\nNeurological disease, like epilepsy or a brain tumor\nTraumatic brain injury\nPregnant or nursing\nAn unstable medical illness, like congestive heart failure or end stage kidney disease\nHistory of severe or recurrent substance abuse, or any substance abuse within 2 years of study enrollment\n\nHistory of suicidal behavior within 5 years of study enrollment\n\nDepartment of Psychiatry Faculty, Employee, or Trainee",
                            "HealthyVolunteers": "No",
                            "Gender": "Female",
                            "MinimumAge": "18 Years",
                            "MaximumAge": "52 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "David R Rubinow, MD",
                                        "OverallOfficialAffiliation": "Dept of Psychiatry, UNC School of Medicine",
                                        "OverallOfficialRole": "Principal Investigator"
                                    }
                                ]
                            }
                        },
                        "IPDSharingStatementModule": {
                            "IPDSharing": "No"
                        }
                    },
                    "ResultsSection": {
                        "ParticipantFlowModule": {
                            "FlowGroupList": {
                                "FlowGroup": [
                                    {
                                        "FlowGroupId": "FG000",
                                        "FlowGroupTitle": "Single Session tACS Across Menstrual Cycle",
                                        "FlowGroupDescription": "Participants assigned to receive a single session of tACS during the follicular and luteal phase of their menstrual cycle.\n\nAlternating Current Stimulator: Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied."
                                    }
                                ]
                            },
                            "FlowPeriodList": {
                                "FlowPeriod": [
                                    {
                                        "FlowPeriodTitle": "Overall Study",
                                        "FlowMilestoneList": {
                                            "FlowMilestone": [
                                                {
                                                    "FlowMilestoneType": "STARTED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "5"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowMilestoneType": "COMPLETED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "3"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowMilestoneType": "NOT COMPLETED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "2"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "BaselineCharacteristicsModule": {
                            "BaselineGroupList": {
                                "BaselineGroup": [
                                    {
                                        "BaselineGroupId": "BG000",
                                        "BaselineGroupTitle": "Single Session tACS Across Menstrual Cycle",
                                        "BaselineGroupDescription": "Participants assigned to receive a single session of tACS during the follicular and luteal phase of their menstrual cycle.\n\nAlternating Current Stimulator: Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied."
                                    }
                                ]
                            },
                            "BaselineDenomList": {
                                "BaselineDenom": [
                                    {
                                        "BaselineDenomUnits": "Participants",
                                        "BaselineDenomCountList": {
                                            "BaselineDenomCount": [
                                                {
                                                    "BaselineDenomCountGroupId": "BG000",
                                                    "BaselineDenomCountValue": "5"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "BaselineMeasureList": {
                                "BaselineMeasure": [
                                    {
                                        "BaselineMeasureTitle": "Age, Continuous",
                                        "BaselineMeasureParamType": "Mean",
                                        "BaselineMeasureDispersionType": "Standard Deviation",
                                        "BaselineMeasureUnitOfMeasure": "years",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "28.8",
                                                                            "BaselineMeasurementSpread": "7.3"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Sex: Female, Male",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineCategoryTitle": "Female",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "5"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Male",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Ethnicity (NIH/OMB)",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineCategoryTitle": "Hispanic or Latino",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Not Hispanic or Latino",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "5"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Unknown or Not Reported",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Race (NIH/OMB)",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineCategoryTitle": "American Indian or Alaska Native",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Asian",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Native Hawaiian or Other Pacific Islander",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Black or African American",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "1"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "White",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "4"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "More than one race",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Unknown or Not Reported",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Region of Enrollment",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineClassTitle": "United States",
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "5"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomeMeasuresModule": {
                            "OutcomeMeasureList": {
                                "OutcomeMeasure": [
                                    {
                                        "OutcomeMeasureType": "Primary",
                                        "OutcomeMeasureTitle": "Change in Alpha Frequency Electrical Activity in Left Frontal Cortex Following Stimulation",
                                        "OutcomeMeasureDescription": "Fast Fourier transform is applied to 8 minutes of EEG data before and after tACS. Primary outcome is the difference in alpha frequency amplitude (8-12 Hz) in the left frontal cortex from baseline as a result of intervention.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Mean",
                                        "OutcomeMeasureDispersionType": "Standard Deviation",
                                        "OutcomeMeasureUnitOfMeasure": "microvolts",
                                        "OutcomeMeasureTimeFrame": "8-minute recording before vs after intervention",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "Single Session tACS Across Menstrual Cycle",
                                                    "OutcomeGroupDescription": "Participants assigned to receive a single session of tACS during the follicular and luteal phase of their menstrual cycle.\n\nAlternating Current Stimulator: Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "3"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "0.044",
                                                                            "OutcomeMeasurementSpread": "0.218"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeAnalysisList": {
                                            "OutcomeAnalysis": [
                                                {
                                                    "OutcomeAnalysisGroupIdList": {
                                                        "OutcomeAnalysisGroupId": [
                                                            "OG000"
                                                        ]
                                                    },
                                                    "OutcomeAnalysisNonInferiorityType": "Other",
                                                    "OutcomeAnalysisPValue": "0.758",
                                                    "OutcomeAnalysisPValueComment": "The threshold for statistical significance is 0.05.",
                                                    "OutcomeAnalysisStatisticalMethod": "t-test, 2 sided"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Secondary",
                                        "OutcomeMeasureTitle": "Difference in Magnitude of Effect of tACS on Left Prefrontal Alpha in Follicular vs Luteal Phase",
                                        "OutcomeMeasureDescription": "Comparison of the change in EEG left prefrontal activity following tACS in luteal vs. follicular phases measured by the luteal pre to post change in EEG compared with the follicular pre to post change in EEG. Pre-post EEG recordings will occur during the follicular phase (5-9 days after menstruation) and in the luteal, premenstrual phase (9-13 days after ovulation).",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Mean",
                                        "OutcomeMeasureDispersionType": "Standard Deviation",
                                        "OutcomeMeasureUnitOfMeasure": "microvolts",
                                        "OutcomeMeasureTimeFrame": "Over the course of 2 menstrual cycles, pre-post EEG recordings will occur, one during the follicular phase (5-9 days after menstruation) and one in the luteal, premenstrual phase (9-13 days after ovulation)",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "Single Session tACS Across Menstrual Cycle",
                                                    "OutcomeGroupDescription": "Participants assigned to receive a single session of tACS during the follicular and luteal phase of their menstrual cycle.\n\nAlternating Current Stimulator: Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "3"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "-0.191",
                                                                            "OutcomeMeasurementSpread": "0.313"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeAnalysisList": {
                                            "OutcomeAnalysis": [
                                                {
                                                    "OutcomeAnalysisGroupIdList": {
                                                        "OutcomeAnalysisGroupId": [
                                                            "OG000"
                                                        ]
                                                    },
                                                    "OutcomeAnalysisNonInferiorityType": "Other",
                                                    "OutcomeAnalysisPValue": "0.40",
                                                    "OutcomeAnalysisPValueComment": "The threshold for statistical significance is 0.05.",
                                                    "OutcomeAnalysisStatisticalMethod": "t-test, 2 sided"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "AdverseEventsModule": {
                            "EventsFrequencyThreshold": "0",
                            "EventsTimeFrame": "Adverse events were collected starting at Baseline through the onset of menses after the second tACS session, an approximate total duration of up to 2 months",
                            "EventGroupList": {
                                "EventGroup": [
                                    {
                                        "EventGroupId": "EG000",
                                        "EventGroupTitle": "Single Session tACS Across Menstrual Cycle",
                                        "EventGroupDescription": "Participants assigned to receive a single session of tACS during the follicular and luteal phase of their menstrual cycle.\n\nAlternating Current Stimulator: Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.",
                                        "EventGroupDeathsNumAffected": "0",
                                        "EventGroupDeathsNumAtRisk": "5",
                                        "EventGroupSeriousNumAffected": "0",
                                        "EventGroupSeriousNumAtRisk": "5",
                                        "EventGroupOtherNumAffected": "0",
                                        "EventGroupOtherNumAtRisk": "5"
                                    }
                                ]
                            }
                        },
                        "MoreInfoModule": {
                            "CertainAgreement": {
                                "AgreementPISponsorEmployee": "Yes"
                            },
                            "PointOfContact": {
                                "PointOfContactTitle": "David Rubinow, MD",
                                "PointOfContactOrganization": "University of North Carolina at Chapel Hill",
                                "PointOfContactEMail": "drubinow@med.unc.edu",
                                "PointOfContactPhone": "919-445-0220"
                            }
                        }
                    },
                    "DocumentSection": {
                        "LargeDocumentModule": {
                            "LargeDocList": {
                                "LargeDoc": [
                                    {
                                        "LargeDocTypeAbbrev": "Prot_SAP",
                                        "LargeDocHasProtocol": "Yes",
                                        "LargeDocHasSAP": "Yes",
                                        "LargeDocHasICF": "No",
                                        "LargeDocLabel": "Study Protocol and Statistical Analysis Plan",
                                        "LargeDocDate": "August 14, 2020",
                                        "LargeDocUploadDate": "09/16/2020 11:53",
                                        "LargeDocFilename": "Prot_SAP_000.pdf"
                                    }
                                ]
                            }
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000065446",
                                        "ConditionMeshTerm": "Premenstrual Dysphoric Disorder"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000011293",
                                        "ConditionAncestorTerm": "Premenstrual Syndrome"
                                    },
                                    {
                                        "ConditionAncestorId": "D000008599",
                                        "ConditionAncestorTerm": "Menstruation Disturbances"
                                    },
                                    {
                                        "ConditionAncestorId": "D000010335",
                                        "ConditionAncestorTerm": "Pathologic Processes"
                                    },
                                    {
                                        "ConditionAncestorId": "D000003866",
                                        "ConditionAncestorTerm": "Depressive Disorder"
                                    },
                                    {
                                        "ConditionAncestorId": "D000019964",
                                        "ConditionAncestorTerm": "Mood Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000001523",
                                        "ConditionAncestorTerm": "Mental Disorders"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M29667",
                                        "ConditionBrowseLeafName": "Premenstrual Dysphoric Disorder",
                                        "ConditionBrowseLeafAsFound": "Premenstrual Dysphoric Disorder",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M15507",
                                        "ConditionBrowseLeafName": "Syndrome",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M13319",
                                        "ConditionBrowseLeafName": "Premenstrual Syndrome",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M10734",
                                        "ConditionBrowseLeafName": "Menstruation Disturbances",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M6210",
                                        "ConditionBrowseLeafName": "Depression",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M6213",
                                        "ConditionBrowseLeafName": "Depressive Disorder",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M20988",
                                        "ConditionBrowseLeafName": "Mood Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M3967",
                                        "ConditionBrowseLeafName": "Mental Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M13625",
                                        "ConditionBrowseLeafName": "Psychotic Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC23",
                                        "ConditionBrowseBranchName": "Symptoms and General Pathology"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BXM",
                                        "ConditionBrowseBranchName": "Behaviors and Mental Disorders"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 17,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT03178344",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "16-1911a"
                            },
                            "SecondaryIdInfoList": {
                                "SecondaryIdInfo": [
                                    {
                                        "SecondaryId": "R01MH111889-01",
                                        "SecondaryIdType": "U.S. NIH Grant/Contract",
                                        "SecondaryIdLink": "https://reporter.nih.gov/quickSearch/R01MH111889-01"
                                    }
                                ]
                            },
                            "Organization": {
                                "OrgFullName": "University of North Carolina, Chapel Hill",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Effect of tACS Stimulation on Alpha Oscillations",
                            "OfficialTitle": "Rational Optimization of tACS for Targeting Thalamo-Cortical Oscillations (Experiment 2)",
                            "Acronym": "AIMS1"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "February 2018",
                            "OverallStatus": "Completed",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "August 1, 2017",
                                "StartDateType": "Actual"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "November 4, 2017",
                                "PrimaryCompletionDateType": "Actual"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "November 4, 2017",
                                "CompletionDateType": "Actual"
                            },
                            "StudyFirstSubmitDate": "June 2, 2017",
                            "StudyFirstSubmitQCDate": "June 2, 2017",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "June 6, 2017",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "ResultsFirstSubmitDate": "November 7, 2018",
                            "ResultsFirstSubmitQCDate": "November 7, 2018",
                            "ResultsFirstPostDateStruct": {
                                "ResultsFirstPostDate": "December 7, 2018",
                                "ResultsFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "February 7, 2019",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "February 26, 2019",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Sponsor"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "University of North Carolina, Chapel Hill",
                                "LeadSponsorClass": "OTHER"
                            },
                            "CollaboratorList": {
                                "Collaborator": [
                                    {
                                        "CollaboratorName": "National Institutes of Health (NIH)",
                                        "CollaboratorClass": "NIH"
                                    },
                                    {
                                        "CollaboratorName": "National Institute of Mental Health (NIMH)",
                                        "CollaboratorClass": "NIH"
                                    }
                                ]
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "No",
                            "IsFDARegulatedDrug": "No",
                            "IsFDARegulatedDevice": "Yes",
                            "IsUnapprovedDevice": "Yes",
                            "IsUSExport": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "Transcranial Alternating Current Stimulation (tACS) is one method that has been demonstrated to enhance alpha oscillations in healthy participants by applying weak electrical currents to the scalp to modulate rhythmic brain activity patterns. This study will involve tACS-induced frontal alpha oscillations, EEG recordings, and other physiological and biological measures."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Healthy"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Not Applicable"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "Randomized",
                                "DesignInterventionModel": "Crossover Assignment",
                                "DesignInterventionModelDescription": "Each participant will receive sham stimulation or 10 Hz tACS stimulation at two separate sessions. The order will be randomized (ie, half the participants will receive sham stimulation at the first session and 10 Hz tACS stimulation at the second session, and the other half will receive 10 Hz tACS stimulation at the first session and sham stimulation at the second session).",
                                "DesignPrimaryPurpose": "Basic Science",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "Double",
                                    "DesignMaskingDescription": "This study will follow a double-blind experimental design, so neither the participant nor the experimenter will know what kind of stimulation the participant is receiving at what session. A separate unblinded monitor, who will not interact with the participants, will be responsible for creating the stimulation codes for each session.",
                                    "DesignWhoMaskedList": {
                                        "DesignWhoMasked": [
                                            "Participant",
                                            "Investigator"
                                        ]
                                    }
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "20",
                                "EnrollmentType": "Actual"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "Sham Stimulation, then Alpha Stimulation",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "Participants receive sham stimulation at the first session, followed by a 5-9 day washout period and alpha stimulation at the second session.\n\nSham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham.\n\nParticipants will receive 2 mA of alternating current stimulation at a frequency of 10 Hz for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: XCSITE100 Stimulator tACS",
                                                "Device: XCSITE100 Stimulator Sham"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "Alpha Stimulation, then Sham Stimulation",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "Participants receive alpha stimulation at the first session, followed by a 5-9 day washout period and sham stimulation at the second session.\n\nParticipants will receive 2 mA of alternating current stimulation at a frequency of 10 Hz for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.\n\nSham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: XCSITE100 Stimulator tACS",
                                                "Device: XCSITE100 Stimulator Sham"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "XCSITE100 Stimulator tACS",
                                        "InterventionDescription": "Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Alpha Stimulation, then Sham Stimulation",
                                                "Sham Stimulation, then Alpha Stimulation"
                                            ]
                                        },
                                        "InterventionOtherNameList": {
                                            "InterventionOtherName": [
                                                "tACS"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "XCSITE100 Stimulator Sham",
                                        "InterventionDescription": "The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Alpha Stimulation, then Sham Stimulation",
                                                "Sham Stimulation, then Alpha Stimulation"
                                            ]
                                        },
                                        "InterventionOtherNameList": {
                                            "InterventionOtherName": [
                                                "Sham tACS"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Salivary Alpha Amylase",
                                        "PrimaryOutcomeDescription": "Change after stimulation",
                                        "PrimaryOutcomeTimeFrame": "Before and after 40-minute stimulation at each session."
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "Salivary Cortisol",
                                        "PrimaryOutcomeDescription": "Change before and after stimulation",
                                        "PrimaryOutcomeTimeFrame": "Before and after 40 minutes of stimulation"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "Heart Rate Variability",
                                        "SecondaryOutcomeDescription": "Change in the ratio between the power in low frequency band and the power in high frequency band. As this outcome variable is a ratio between two items that are measured in microvolt^2, the ratio does not have a unit of measure.",
                                        "SecondaryOutcomeTimeFrame": "Before and after 40-minute stimulation at each session."
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Percent Change in Respiration",
                                        "SecondaryOutcomeDescription": "Respiration rate, measured via a belt placed around the participant's abdomen as breaths per second.",
                                        "SecondaryOutcomeTimeFrame": "Before and after 40-minute stimulation at each session."
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Electroencephalogram (EEG)",
                                        "SecondaryOutcomeDescription": "The investigators will compare alpha oscillation power from resting-state EEG recordings before and after stimulation/sham at each session.",
                                        "SecondaryOutcomeTimeFrame": "Before and after 40-minute stimulation at each session."
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nAges 18-65\nCapacity to understand all relevant risks and potential benefits of the study (informed consent)\nNegative pregnancy test for female participants\n\nExclusion Criteria:\n\nHistory of major neurological or psychiatric illness, including epilepsy\nMedication use associated with neurological or psychiatric illnesses\nCurrently undergoing counseling or psychotherapy treatment for depression, anxiety, eating disorders, PTSD or other behavioral conditions\nFirst degree relative (parent, sibling, child) with major neurological or psychiatric illness\nPrior brain surgery\nMajor head injury\nAny brain devices/implants (including cochlear implants and aneurysm clips)\nBraids or other hair styling that prevents direct access to the scalp (if removal not possible)\nSkin allergies or very sensitive skin\nPregnant or nursing females\nFailure to pass a urinary drug test at the first session\nUse of hormonal birth control or supplements in the past two weeks\nNon English speakers\nCardiovascular disease",
                            "HealthyVolunteers": "Accepts Healthy Volunteers",
                            "Gender": "All",
                            "MinimumAge": "18 Years",
                            "MaximumAge": "65 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Flavio Frohlich, PhD",
                                        "OverallOfficialAffiliation": "University of North Carolina, Chapel Hill",
                                        "OverallOfficialRole": "Principal Investigator"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "University of North Carolina Chapel Hill",
                                        "LocationCity": "Chapel Hill",
                                        "LocationState": "North Carolina",
                                        "LocationZip": "27514",
                                        "LocationCountry": "United States"
                                    }
                                ]
                            }
                        },
                        "IPDSharingStatementModule": {
                            "IPDSharing": "No",
                            "IPDSharingDescription": "IPD will not be shared with other researchers."
                        }
                    },
                    "ResultsSection": {
                        "ParticipantFlowModule": {
                            "FlowGroupList": {
                                "FlowGroup": [
                                    {
                                        "FlowGroupId": "FG000",
                                        "FlowGroupTitle": "Sham Stimulation, Then Alpha Stimulation",
                                        "FlowGroupDescription": "Participants will receive sham stimulation at the first session. Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham. Then, participants will receive 2 mA of alternating current stimulation at a frequency of 10 Hz for 40 minutes at the first session. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.\n\nXCSITE100 Stimulator Sham: The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session."
                                    },
                                    {
                                        "FlowGroupId": "FG001",
                                        "FlowGroupTitle": "Alpha Stimulation, Then Sham Stimulation",
                                        "FlowGroupDescription": "Participants will receive 2 mA of alternating current stimulation at a frequency of 10 Hz for 40 minutes at the first session. tACS stimulation is delivered using the XCSITE100 Stimulator tACS. Then, participants will receive sham stimulation at the second session. Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham.\n\nXCSITE100 Stimulator tACS: Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied."
                                    }
                                ]
                            },
                            "FlowPeriodList": {
                                "FlowPeriod": [
                                    {
                                        "FlowPeriodTitle": "First Session",
                                        "FlowMilestoneList": {
                                            "FlowMilestone": [
                                                {
                                                    "FlowMilestoneType": "STARTED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "10"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG001",
                                                                "FlowAchievementNumSubjects": "10"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowMilestoneType": "COMPLETED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "10"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG001",
                                                                "FlowAchievementNumSubjects": "10"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowMilestoneType": "NOT COMPLETED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "0"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG001",
                                                                "FlowAchievementNumSubjects": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowPeriodTitle": "Washout Period (5-9 Days)",
                                        "FlowMilestoneList": {
                                            "FlowMilestone": [
                                                {
                                                    "FlowMilestoneType": "STARTED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "10"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG001",
                                                                "FlowAchievementNumSubjects": "10"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowMilestoneType": "COMPLETED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "10"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG001",
                                                                "FlowAchievementNumSubjects": "10"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowMilestoneType": "NOT COMPLETED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "0"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG001",
                                                                "FlowAchievementNumSubjects": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "FlowPeriodTitle": "Second Session",
                                        "FlowMilestoneList": {
                                            "FlowMilestone": [
                                                {
                                                    "FlowMilestoneType": "STARTED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "10"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG001",
                                                                "FlowAchievementNumSubjects": "10"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowMilestoneType": "COMPLETED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "10"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG001",
                                                                "FlowAchievementNumSubjects": "10"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowMilestoneType": "NOT COMPLETED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "0"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG001",
                                                                "FlowAchievementNumSubjects": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "BaselineCharacteristicsModule": {
                            "BaselineGroupList": {
                                "BaselineGroup": [
                                    {
                                        "BaselineGroupId": "BG000",
                                        "BaselineGroupTitle": "Overall Group (Both Sham and Alpha Stimulation)",
                                        "BaselineGroupDescription": "Participants received sham stimulation at one session and alpha stimulation at the other in a randomized order. Sessions were separated by 5-9 days."
                                    }
                                ]
                            },
                            "BaselineDenomList": {
                                "BaselineDenom": [
                                    {
                                        "BaselineDenomUnits": "Participants",
                                        "BaselineDenomCountList": {
                                            "BaselineDenomCount": [
                                                {
                                                    "BaselineDenomCountGroupId": "BG000",
                                                    "BaselineDenomCountValue": "20"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "BaselineMeasureList": {
                                "BaselineMeasure": [
                                    {
                                        "BaselineMeasureTitle": "Age, Categorical",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineCategoryTitle": "<=18 years",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Between 18 and 65 years",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "20"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": ">=65 years",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Sex: Female, Male",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineCategoryTitle": "Female",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "5"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Male",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "15"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Race (NIH/OMB)",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineCategoryTitle": "American Indian or Alaska Native",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Asian",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "4"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Native Hawaiian or Other Pacific Islander",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Black or African American",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "4"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "White",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "11"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "More than one race",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "1"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Unknown or Not Reported",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomeMeasuresModule": {
                            "OutcomeMeasureList": {
                                "OutcomeMeasure": [
                                    {
                                        "OutcomeMeasureType": "Primary",
                                        "OutcomeMeasureTitle": "Salivary Alpha Amylase",
                                        "OutcomeMeasureDescription": "Change after stimulation",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Mean",
                                        "OutcomeMeasureDispersionType": "Standard Deviation",
                                        "OutcomeMeasureUnitOfMeasure": "log-normalized percent change of U/mL",
                                        "OutcomeMeasureTimeFrame": "Before and after 40-minute stimulation at each session.",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "Sham Stimulation",
                                                    "OutcomeGroupDescription": "Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham.\n\nXCSITE100 Stimulator Sham: The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session."
                                                },
                                                {
                                                    "OutcomeGroupId": "OG001",
                                                    "OutcomeGroupTitle": "Alpha Stimulation",
                                                    "OutcomeGroupDescription": "Participants will receive 2 mA of alternating current stimulation at a frequency of 10 Hz for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.\n\nXCSITE100 Stimulator tACS: Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "20"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG001",
                                                                "OutcomeDenomCountValue": "20"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "0.00695",
                                                                            "OutcomeMeasurementSpread": "0.196"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "0.03055",
                                                                            "OutcomeMeasurementSpread": "0.188"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeAnalysisList": {
                                            "OutcomeAnalysis": [
                                                {
                                                    "OutcomeAnalysisGroupIdList": {
                                                        "OutcomeAnalysisGroupId": [
                                                            "OG000",
                                                            "OG001"
                                                        ]
                                                    },
                                                    "OutcomeAnalysisNonInferiorityType": "Equivalence",
                                                    "OutcomeAnalysisNonInferiorityComment": "ANOVA",
                                                    "OutcomeAnalysisPValue": "0.70",
                                                    "OutcomeAnalysisPValueComment": "P value threshold is 0.05",
                                                    "OutcomeAnalysisStatisticalMethod": "ANOVA"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Primary",
                                        "OutcomeMeasureTitle": "Salivary Cortisol",
                                        "OutcomeMeasureDescription": "Change before and after stimulation",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Mean",
                                        "OutcomeMeasureDispersionType": "Standard Deviation",
                                        "OutcomeMeasureUnitOfMeasure": "log-normalized percent change µg/dL",
                                        "OutcomeMeasureTimeFrame": "Before and after 40 minutes of stimulation",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "Sham Stimulation",
                                                    "OutcomeGroupDescription": "Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham.\n\nXCSITE100 Stimulator Sham: The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session."
                                                },
                                                {
                                                    "OutcomeGroupId": "OG001",
                                                    "OutcomeGroupTitle": "Alpha Stimulation",
                                                    "OutcomeGroupDescription": "Participants will receive 2 mA of alternating current stimulation at a frequency of 10 Hz for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.\n\nXCSITE100 Stimulator tACS: Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "20"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG001",
                                                                "OutcomeDenomCountValue": "20"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "-0.0551",
                                                                            "OutcomeMeasurementSpread": "0.168"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "-0.0702",
                                                                            "OutcomeMeasurementSpread": "0.164"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeAnalysisList": {
                                            "OutcomeAnalysis": [
                                                {
                                                    "OutcomeAnalysisGroupIdList": {
                                                        "OutcomeAnalysisGroupId": [
                                                            "OG000",
                                                            "OG001"
                                                        ]
                                                    },
                                                    "OutcomeAnalysisNonInferiorityType": "Equivalence",
                                                    "OutcomeAnalysisNonInferiorityComment": "ANOVA",
                                                    "OutcomeAnalysisPValue": "0.71",
                                                    "OutcomeAnalysisPValueComment": "P value threshold is 0.05.",
                                                    "OutcomeAnalysisStatisticalMethod": "ANOVA"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Secondary",
                                        "OutcomeMeasureTitle": "Heart Rate Variability",
                                        "OutcomeMeasureDescription": "Change in the ratio between the power in low frequency band and the power in high frequency band. As this outcome variable is a ratio between two items that are measured in microvolt^2, the ratio does not have a unit of measure.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Mean",
                                        "OutcomeMeasureDispersionType": "Standard Deviation",
                                        "OutcomeMeasureUnitOfMeasure": "log-normalized percent change",
                                        "OutcomeMeasureTimeFrame": "Before and after 40-minute stimulation at each session.",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "Sham Stimulation",
                                                    "OutcomeGroupDescription": "Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham.\n\nXCSITE100 Stimulator Sham: The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session."
                                                },
                                                {
                                                    "OutcomeGroupId": "OG001",
                                                    "OutcomeGroupTitle": "Alpha Stimulation",
                                                    "OutcomeGroupDescription": "Participants will receive 2 mA of alternating current stimulation at a frequency of 10 Hz for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.\n\nXCSITE100 Stimulator tACS: Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "20"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG001",
                                                                "OutcomeDenomCountValue": "20"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "1.599",
                                                                            "OutcomeMeasurementSpread": "3.33"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "0.308",
                                                                            "OutcomeMeasurementSpread": "3.70"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Secondary",
                                        "OutcomeMeasureTitle": "Percent Change in Respiration",
                                        "OutcomeMeasureDescription": "Respiration rate, measured via a belt placed around the participant's abdomen as breaths per second.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Mean",
                                        "OutcomeMeasureDispersionType": "Standard Deviation",
                                        "OutcomeMeasureUnitOfMeasure": "Percent change in breaths per second",
                                        "OutcomeMeasureTimeFrame": "Before and after 40-minute stimulation at each session.",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "Sham Stimulation",
                                                    "OutcomeGroupDescription": "Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham.\n\nXCSITE100 Stimulator Sham: The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session."
                                                },
                                                {
                                                    "OutcomeGroupId": "OG001",
                                                    "OutcomeGroupTitle": "Alpha Stimulation",
                                                    "OutcomeGroupDescription": "Participants will receive 2 mA of alternating current stimulation at a frequency of 10 Hz for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.\n\nXCSITE100 Stimulator tACS: Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "20"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG001",
                                                                "OutcomeDenomCountValue": "20"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "-0.0075",
                                                                            "OutcomeMeasurementSpread": "0.076"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "0.0325",
                                                                            "OutcomeMeasurementSpread": "0.093"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Secondary",
                                        "OutcomeMeasureTitle": "Electroencephalogram (EEG)",
                                        "OutcomeMeasureDescription": "The investigators will compare alpha oscillation power from resting-state EEG recordings before and after stimulation/sham at each session.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Mean",
                                        "OutcomeMeasureDispersionType": "Standard Deviation",
                                        "OutcomeMeasureUnitOfMeasure": "percent change of uV^2/Hz",
                                        "OutcomeMeasureTimeFrame": "Before and after 40-minute stimulation at each session.",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "Sham Stimulation",
                                                    "OutcomeGroupDescription": "Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham.\n\nXCSITE100 Stimulator Sham: The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session."
                                                },
                                                {
                                                    "OutcomeGroupId": "OG001",
                                                    "OutcomeGroupTitle": "Alpha Stimulation",
                                                    "OutcomeGroupDescription": "Participants will receive 2 mA of alternating current stimulation at a frequency of 10 Hz for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.\n\nXCSITE100 Stimulator tACS: Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "20"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG001",
                                                                "OutcomeDenomCountValue": "20"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "-0.0087",
                                                                            "OutcomeMeasurementSpread": "0.0360"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "0.0114",
                                                                            "OutcomeMeasurementSpread": "0.0752"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "AdverseEventsModule": {
                            "EventsFrequencyThreshold": "0",
                            "EventsTimeFrame": "From first session until completion of second session for each participant, for a total of 7-11 days (including both session days and 5-9 days of washout).",
                            "EventGroupList": {
                                "EventGroup": [
                                    {
                                        "EventGroupId": "EG000",
                                        "EventGroupTitle": "Sham Stimulation",
                                        "EventGroupDescription": "Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation is delivered using the XCSITE100 Stimulator Sham.\n\nXCSITE100 Stimulator Sham: The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session.",
                                        "EventGroupDeathsNumAffected": "0",
                                        "EventGroupDeathsNumAtRisk": "20",
                                        "EventGroupSeriousNumAffected": "0",
                                        "EventGroupSeriousNumAtRisk": "20",
                                        "EventGroupOtherNumAffected": "0",
                                        "EventGroupOtherNumAtRisk": "20"
                                    },
                                    {
                                        "EventGroupId": "EG001",
                                        "EventGroupTitle": "Alpha Stimulation",
                                        "EventGroupDescription": "Participants will receive 2 mA of alternating current stimulation at a frequency of 10 Hz for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.\n\nXCSITE100 Stimulator tACS: Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.",
                                        "EventGroupDeathsNumAffected": "0",
                                        "EventGroupDeathsNumAtRisk": "20",
                                        "EventGroupSeriousNumAffected": "0",
                                        "EventGroupSeriousNumAtRisk": "20",
                                        "EventGroupOtherNumAffected": "0",
                                        "EventGroupOtherNumAtRisk": "20"
                                    }
                                ]
                            }
                        },
                        "MoreInfoModule": {
                            "CertainAgreement": {
                                "AgreementPISponsorEmployee": "Yes",
                                "AgreementRestrictiveAgreement": "No"
                            },
                            "PointOfContact": {
                                "PointOfContactTitle": "Jhana Parikh",
                                "PointOfContactOrganization": "Department of Psychiatry, UNC Chapel Hill",
                                "PointOfContactEMail": "jhana_parikh@med.unc.edu",
                                "PointOfContactPhone": "919-966-9929"
                            }
                        }
                    },
                    "DocumentSection": {
                        "LargeDocumentModule": {
                            "LargeDocList": {
                                "LargeDoc": [
                                    {
                                        "LargeDocTypeAbbrev": "Prot_SAP",
                                        "LargeDocHasProtocol": "Yes",
                                        "LargeDocHasSAP": "Yes",
                                        "LargeDocHasICF": "No",
                                        "LargeDocLabel": "Study Protocol and Statistical Analysis Plan",
                                        "LargeDocDate": "April 11, 2017",
                                        "LargeDocUploadDate": "11/07/2018 13:26",
                                        "LargeDocFilename": "Prot_SAP_000.pdf"
                                    }
                                ]
                            }
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "InterventionBrowseModule": {
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 18,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT03449979",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "16-1911b"
                            },
                            "SecondaryIdInfoList": {
                                "SecondaryIdInfo": [
                                    {
                                        "SecondaryId": "R01MH101547",
                                        "SecondaryIdType": "U.S. NIH Grant/Contract",
                                        "SecondaryIdLink": "https://reporter.nih.gov/quickSearch/R01MH101547"
                                    }
                                ]
                            },
                            "Organization": {
                                "OrgFullName": "University of North Carolina, Chapel Hill",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Single Session of tACS in a Depressive Episode",
                            "OfficialTitle": "Rational Optimization of tACS for Targeting Thalamo-Cortical Oscillations (Experiment 3)",
                            "Acronym": "SSDE"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "September 2019",
                            "OverallStatus": "Completed",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "September 19, 2018",
                                "StartDateType": "Actual"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "August 16, 2019",
                                "PrimaryCompletionDateType": "Actual"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "August 16, 2019",
                                "CompletionDateType": "Actual"
                            },
                            "StudyFirstSubmitDate": "February 15, 2018",
                            "StudyFirstSubmitQCDate": "February 22, 2018",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "February 28, 2018",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "ResultsFirstSubmitDate": "May 18, 2020",
                            "ResultsFirstSubmitQCDate": "May 18, 2020",
                            "ResultsFirstPostDateStruct": {
                                "ResultsFirstPostDate": "June 4, 2020",
                                "ResultsFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "May 18, 2020",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "June 4, 2020",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Sponsor"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "University of North Carolina, Chapel Hill",
                                "LeadSponsorClass": "OTHER"
                            },
                            "CollaboratorList": {
                                "Collaborator": [
                                    {
                                        "CollaboratorName": "National Institute of Mental Health (NIMH)",
                                        "CollaboratorClass": "NIH"
                                    }
                                ]
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "No",
                            "IsFDARegulatedDrug": "No",
                            "IsFDARegulatedDevice": "Yes",
                            "IsUnapprovedDevice": "Yes"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "Purpose: Investigating the effects of non-invasive transcranial alternating current stimulation (tACS) on healthy participants and participants with mood disorders.\n\nParticipants: 40 males and females, ages 18-65, with depressed mood; 40 healthy males and females, ages 18-65, free of neurological or psychiatric conditions.\n\nProcedures: This is a single visit study with two stimulation conditions (tACS and sham tACS). The session will begin with clinical assessments (including confirmation of diagnosis), followed by an interactive EEG task, then a 7 minute resting state EEG (2 minutes eyes closed, 5 minutes eyes open), followed by the stimulation session (40 minutes of tACS or sham tACS), followed by an additional 5 minute resting state EEG. The stimulation will involved 40 minutes of transcranial alternating current stimulation, 2 mA in amplitude and at individualized alpha frequency (determined by the 2 minutes eyes closed EEG recording; between 8 and 12Hz).",
                            "DetailedDescription": "Participants will report for a study visit and will review and sign a consent form.\n\nParticipants will complete several clinical assessments and also take a urine drug test and urine pregnancy test (if applicable). Eligibility will be re-assessed by the investigators before the participant moves on to the next phase.\n\nIf the participant still qualifies, the participant will first be fitted with two 5x5cm electrodes placed over F3/F4 (10-20 measurement system) and one 5x7cm electrode placed over Cz. In addition, the participant will have a 128-channel EEG net placed on their head. Participants will provide a saliva sample to assess for brain-derived neurotrophic factor (BDNF), which may affect how the participant's brain responds to stimulation. Once the participant is fitted with this equipment, the participant will complete two interactive EEG tasks, then 2-minute resting state EEG with the participant's eyes closed, then a 5-minute resting state EEG with the participant's eyes open.\n\nFollowing these recordings, participants will respond to additional questionnaires. Immediately following this, the participant will receive 40 minutes of stimulation (tACS or sham tACS). During this stimulation, participants will sit comfortably upright and awake.\n\nAfter stimulation has completed, participants will respond to additional questionnaires. Once completed, participants will then complete an additional 5-minute resting state EEG with the participant's eyes open, as well as complete one of the additional interactive EEG tasks.\n\nFinally, participants will respond to a blinding questionnaire to assess if the participant thought that the participant received stimulation. Once complete, the participant will leave. This session is estimated to last about 4 hours."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Depression",
                                    "Major Depressive Disorder",
                                    "Premenstrual Dysphoric Disorder",
                                    "Depressive Episode"
                                ]
                            },
                            "KeywordList": {
                                "Keyword": [
                                    "tACS",
                                    "transcranial alternating current stimulation",
                                    "stimulation",
                                    "heart rate variability",
                                    "electroencephalogram",
                                    "EEG"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Not Applicable"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "Randomized",
                                "DesignInterventionModel": "Parallel Assignment",
                                "DesignInterventionModelDescription": "This study recruits both participants currently experiencing a depressive episode (regardless of diagnosis) and those with no history of neurological or psychiatric illness. Randomization will occur in a 1:1 ratio for both of these groups, with half of each group receiving transcranial alternating current stimulation (tACS) at 10 Hz and the other half receiving placebo (or sham) stimulation.",
                                "DesignPrimaryPurpose": "Basic Science",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "Double",
                                    "DesignMaskingDescription": "This is a double-blind study, meaning that neither the participant nor the experimenter knows what kind of stimulation the participant is receiving. An unblinded monitor (separate from the staff that interacts with the participant) is responsible for creating the stimulation codes that run each session and for ensuring that these codes worked correctly.",
                                    "DesignWhoMaskedList": {
                                        "DesignWhoMasked": [
                                            "Participant",
                                            "Investigator"
                                        ]
                                    }
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "84",
                                "EnrollmentType": "Actual"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "alpha stimulation in participants in a depressive episode",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "Participants in a depressive episode will receive 2 mA of alternating current stimulation at individualized alpha stimulation (between 8 and 12Hz; determined by an EEG recording prior to stimulation) for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: XCSITE100 Stimulator tACS"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "sham stimulation in participants in a depressive episode",
                                        "ArmGroupType": "Placebo Comparator",
                                        "ArmGroupDescription": "Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation to participants in a depressive episode is delivered using the XCSITE100 Stimulator Sham.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: XCSITE100 Stimulator Sham"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "alpha stimulation in healthy participants",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "Healthy participants will receive 2 mA of alternating current stimulation at individualized alpha stimulation (between 8 and 12Hz; determined by an EEG recording prior to stimulation) for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: XCSITE100 Stimulator tACS"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "sham stimulation in healthy participants",
                                        "ArmGroupType": "Placebo Comparator",
                                        "ArmGroupDescription": "Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation to healthy participants is delivered using the XCSITE100 Stimulator Sham.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: XCSITE100 Stimulator Sham"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "XCSITE100 Stimulator Sham",
                                        "InterventionDescription": "The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "sham stimulation in healthy participants",
                                                "sham stimulation in participants in a depressive episode"
                                            ]
                                        },
                                        "InterventionOtherNameList": {
                                            "InterventionOtherName": [
                                                "Sham tACS"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "XCSITE100 Stimulator tACS",
                                        "InterventionDescription": "Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "alpha stimulation in healthy participants",
                                                "alpha stimulation in participants in a depressive episode"
                                            ]
                                        },
                                        "InterventionOtherNameList": {
                                            "InterventionOtherName": [
                                                "tACS"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Change in Alpha Frequency Electrical Activity in Left Frontal Cortex From Stimulation",
                                        "PrimaryOutcomeDescription": "Fast Fourier transform is applied to 5 minutes of EEG data before and after intervention. Primary outcome is the difference in alpha frequency amplitude (8-12 Hz) in the left frontal cortex from baseline as a result of intervention.",
                                        "PrimaryOutcomeTimeFrame": "5 minute recording before and after intervention"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria for individuals with depressed mood:\n\nAges 18-65 years\nHamilton Depression Rating Scale score >8\nCapacity to understand all relevant risks and potential benefits of the study (informed consent)\nLow suicide risk which will be determined through the use of both the Structured Clinical Interview for the DSM-5 and by scoring less than 3 (0,1, or 2) in the Hamilton rating depression scale.\nNegative pregnancy test for female participants\n\nExclusion Criteria for individuals with depressed mood:\n\nDSM-5 diagnosis of alcohol of substance abuse (other than nicotine) within the 12 months\nDSM-5 diagnosis of alcohol or substance dependence (other than nicotine) within the last 12 months\nDSM-5 diagnosis of personality disorder\nEating disorder (current or within the past 3 months)\nAnything that, in the opinion of the investigator, would place the participant at increased risk or preclude the participant's full compliance with or completion of the study\nNeurological disorders, including but not limited to history of seizures (except childhood febrile seizures and electro-convulsive therapy (ECT) induced seizures), dementia, history of stroke, Parkinson's disease, multiple sclerosis, cerebral aneurysm.\nMedical or neurological illness (unstable cardiac disease, AIDS, malignancy, liver or renal impairment) or treatment for a medical disorder that could interfere with study participation\nHistory of traumatic brain injury, reoccurring seizures or later cognitive rehabilitation or causing cognitive sequelae\nHistory of childhood trauma (determined by the Childhood Trauma Questionnaire)\nPrior brain surgery\nAny brain devices/implants, including cochlear implants and aneurysm clips\nCo-morbid neurological condition (i.e. seizure disorder, brain tumor)\nUse of illicit drugs, confirmed by a drug test\nNon English speakers\nPregnant or nursing females\nCurrent use of benzodiazepines or anti-epileptic drugs\n\nInclusion Criteria for healthy controls:\n\nAges 18-65 years\nHamilton Depression Rating Scale score ≤8\nCapacity to understand all relevant risks and potential benefits of the study (informed consent)\nNegative pregnancy test for female participants\n\nExclusion Criteria for healthy controls:\n\nHistory of major neurological or psychiatric illness, including epilepsy\nMedication use associated with neurological or psychiatric illnesses\nCurrently undergoing counseling or psychotherapy treatment for depression, anxiety, eating disorders, PTSD or other behavioral conditions\nDSM-5 diagnosis of personality disorder\nFirst degree relative (parent, sibling, child) with major neurological or psychiatric illness\nPrior brain surgery\nMajor head injury\nAny brain devices/implants (including cochlear implants and aneurysm clips)\nHistory of childhood trauma (determined by the Childhood Trauma Questionnaire)\nUse of illicit drugs, confirmed by a drug test\nBraids or other hair styling that prevents direct access to the scalp (if removal not possible)\nSkin allergies or very sensitive skin\nNon English speakers\nPregnant or nursing females",
                            "HealthyVolunteers": "Accepts Healthy Volunteers",
                            "Gender": "All",
                            "MinimumAge": "18 Years",
                            "MaximumAge": "65 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Flavio Frohlich, PhD",
                                        "OverallOfficialAffiliation": "UNC Chapel Hill",
                                        "OverallOfficialRole": "Principal Investigator"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "University of North Carolina Chapel Hill",
                                        "LocationCity": "Chapel Hill",
                                        "LocationState": "North Carolina",
                                        "LocationZip": "27599",
                                        "LocationCountry": "United States"
                                    }
                                ]
                            }
                        },
                        "IPDSharingStatementModule": {
                            "IPDSharing": "No"
                        }
                    },
                    "ResultsSection": {
                        "ParticipantFlowModule": {
                            "FlowGroupList": {
                                "FlowGroup": [
                                    {
                                        "FlowGroupId": "FG000",
                                        "FlowGroupTitle": "Alpha Stimulation in Participants in a Depressive Episode",
                                        "FlowGroupDescription": "Participants in a depressive episode will receive 2 mA of alternating current stimulation at individualized alpha stimulation (between 8 and 12 Hz; determined by an EEG recording prior to stimulation) for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.\n\nXCSITE100 Stimulator tACS: Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied."
                                    },
                                    {
                                        "FlowGroupId": "FG001",
                                        "FlowGroupTitle": "Sham Stimulation in Participants in a Depressive Episode",
                                        "FlowGroupDescription": "Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation to participants in a depressive episode is delivered using the XCSITE100 Stimulator Sham.\n\nXCSITE100 Stimulator Sham: The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session."
                                    },
                                    {
                                        "FlowGroupId": "FG002",
                                        "FlowGroupTitle": "Alpha Stimulation in Healthy Participants",
                                        "FlowGroupDescription": "Healthy participants will receive 2 mA of alternating current stimulation at individualized alpha stimulation (between 8 and 12 Hz; determined by an EEG recording prior to stimulation) for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.\n\nXCSITE100 Stimulator tACS: Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied."
                                    },
                                    {
                                        "FlowGroupId": "FG003",
                                        "FlowGroupTitle": "Sham Stimulation in Healthy Participants",
                                        "FlowGroupDescription": "Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation to healthy participants is delivered using the XCSITE100 Stimulator Sham.\n\nXCSITE100 Stimulator Sham: The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session."
                                    }
                                ]
                            },
                            "FlowPeriodList": {
                                "FlowPeriod": [
                                    {
                                        "FlowPeriodTitle": "Overall Study",
                                        "FlowMilestoneList": {
                                            "FlowMilestone": [
                                                {
                                                    "FlowMilestoneType": "STARTED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "21"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG001",
                                                                "FlowAchievementNumSubjects": "20"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG002",
                                                                "FlowAchievementNumSubjects": "21"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG003",
                                                                "FlowAchievementNumSubjects": "22"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowMilestoneType": "COMPLETED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "21"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG001",
                                                                "FlowAchievementNumSubjects": "20"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG002",
                                                                "FlowAchievementNumSubjects": "21"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG003",
                                                                "FlowAchievementNumSubjects": "21"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowMilestoneType": "NOT COMPLETED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "0"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG001",
                                                                "FlowAchievementNumSubjects": "0"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG002",
                                                                "FlowAchievementNumSubjects": "0"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG003",
                                                                "FlowAchievementNumSubjects": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "FlowDropWithdrawList": {
                                            "FlowDropWithdraw": [
                                                {
                                                    "FlowDropWithdrawType": "Technical difficulty",
                                                    "FlowReasonList": {
                                                        "FlowReason": [
                                                            {
                                                                "FlowReasonGroupId": "FG000",
                                                                "FlowReasonNumSubjects": "0"
                                                            },
                                                            {
                                                                "FlowReasonGroupId": "FG001",
                                                                "FlowReasonNumSubjects": "0"
                                                            },
                                                            {
                                                                "FlowReasonGroupId": "FG002",
                                                                "FlowReasonNumSubjects": "0"
                                                            },
                                                            {
                                                                "FlowReasonGroupId": "FG003",
                                                                "FlowReasonNumSubjects": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "BaselineCharacteristicsModule": {
                            "BaselinePopulationDescription": "One healthy control participant that received sham stimulation was excluded from analysis as we were unable to find an age and sex matched participant. One healthy control participant that received sham stimulation did not complete the study due to technical difficulties.",
                            "BaselineGroupList": {
                                "BaselineGroup": [
                                    {
                                        "BaselineGroupId": "BG000",
                                        "BaselineGroupTitle": "Alpha Stimulation in Participants in a Depressive Episode",
                                        "BaselineGroupDescription": "Participants in a depressive episode will receive 2 mA of alternating current stimulation at individualized alpha stimulation (between 8 and 12 Hz; determined by an EEG recording prior to stimulation) for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.\n\nXCSITE100 Stimulator tACS: Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied."
                                    },
                                    {
                                        "BaselineGroupId": "BG001",
                                        "BaselineGroupTitle": "Sham Stimulation in Participants in a Depressive Episode",
                                        "BaselineGroupDescription": "Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation to participants in a depressive episode is delivered using the XCSITE100 Stimulator Sham.\n\nXCSITE100 Stimulator Sham: The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session."
                                    },
                                    {
                                        "BaselineGroupId": "BG002",
                                        "BaselineGroupTitle": "Alpha Stimulation in Healthy Participants",
                                        "BaselineGroupDescription": "Healthy participants will receive 2 mA of alternating current stimulation at individualized alpha stimulation (between 8 and 12 Hz; determined by an EEG recording prior to stimulation) for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.\n\nXCSITE100 Stimulator tACS: Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied."
                                    },
                                    {
                                        "BaselineGroupId": "BG003",
                                        "BaselineGroupTitle": "Sham Stimulation in Healthy Participants",
                                        "BaselineGroupDescription": "Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation to healthy participants is delivered using the XCSITE100 Stimulator Sham.\n\nXCSITE100 Stimulator Sham: The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session."
                                    },
                                    {
                                        "BaselineGroupId": "BG004",
                                        "BaselineGroupTitle": "Total",
                                        "BaselineGroupDescription": "Total of all reporting groups"
                                    }
                                ]
                            },
                            "BaselineDenomList": {
                                "BaselineDenom": [
                                    {
                                        "BaselineDenomUnits": "Participants",
                                        "BaselineDenomCountList": {
                                            "BaselineDenomCount": [
                                                {
                                                    "BaselineDenomCountGroupId": "BG000",
                                                    "BaselineDenomCountValue": "21"
                                                },
                                                {
                                                    "BaselineDenomCountGroupId": "BG001",
                                                    "BaselineDenomCountValue": "20"
                                                },
                                                {
                                                    "BaselineDenomCountGroupId": "BG002",
                                                    "BaselineDenomCountValue": "21"
                                                },
                                                {
                                                    "BaselineDenomCountGroupId": "BG003",
                                                    "BaselineDenomCountValue": "22"
                                                },
                                                {
                                                    "BaselineDenomCountGroupId": "BG004",
                                                    "BaselineDenomCountValue": "84"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "BaselineMeasureList": {
                                "BaselineMeasure": [
                                    {
                                        "BaselineMeasureTitle": "Age, Continuous",
                                        "BaselineMeasureParamType": "Mean",
                                        "BaselineMeasureDispersionType": "Standard Deviation",
                                        "BaselineMeasureUnitOfMeasure": "years",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineClassDenomList": {
                                                        "BaselineClassDenom": [
                                                            {
                                                                "BaselineClassDenomUnits": "Participants",
                                                                "BaselineClassDenomCountList": {
                                                                    "BaselineClassDenomCount": [
                                                                        {
                                                                            "BaselineClassDenomCountGroupId": "BG000",
                                                                            "BaselineClassDenomCountValue": "21"
                                                                        },
                                                                        {
                                                                            "BaselineClassDenomCountGroupId": "BG001",
                                                                            "BaselineClassDenomCountValue": "20"
                                                                        },
                                                                        {
                                                                            "BaselineClassDenomCountGroupId": "BG002",
                                                                            "BaselineClassDenomCountValue": "21"
                                                                        },
                                                                        {
                                                                            "BaselineClassDenomCountGroupId": "BG003",
                                                                            "BaselineClassDenomCountValue": "22"
                                                                        },
                                                                        {
                                                                            "BaselineClassDenomCountGroupId": "BG004",
                                                                            "BaselineClassDenomCountValue": "84"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    },
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "28.429",
                                                                            "BaselineMeasurementSpread": "11.902"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "27.65",
                                                                            "BaselineMeasurementSpread": "12.227"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "28.095",
                                                                            "BaselineMeasurementSpread": "11.432"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG003",
                                                                            "BaselineMeasurementValue": "27.182",
                                                                            "BaselineMeasurementSpread": "12.133"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG004",
                                                                            "BaselineMeasurementValue": "27.796",
                                                                            "BaselineMeasurementSpread": "11.831"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Sex: Female, Male",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineClassDenomList": {
                                                        "BaselineClassDenom": [
                                                            {
                                                                "BaselineClassDenomUnits": "Participants",
                                                                "BaselineClassDenomCountList": {
                                                                    "BaselineClassDenomCount": [
                                                                        {
                                                                            "BaselineClassDenomCountGroupId": "BG000",
                                                                            "BaselineClassDenomCountValue": "21"
                                                                        },
                                                                        {
                                                                            "BaselineClassDenomCountGroupId": "BG001",
                                                                            "BaselineClassDenomCountValue": "20"
                                                                        },
                                                                        {
                                                                            "BaselineClassDenomCountGroupId": "BG002",
                                                                            "BaselineClassDenomCountValue": "21"
                                                                        },
                                                                        {
                                                                            "BaselineClassDenomCountGroupId": "BG003",
                                                                            "BaselineClassDenomCountValue": "22"
                                                                        },
                                                                        {
                                                                            "BaselineClassDenomCountGroupId": "BG004",
                                                                            "BaselineClassDenomCountValue": "84"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    },
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineCategoryTitle": "Female",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "17"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "16"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "17"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG003",
                                                                            "BaselineMeasurementValue": "17"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG004",
                                                                            "BaselineMeasurementValue": "67"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Male",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "4"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "4"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "4"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG003",
                                                                            "BaselineMeasurementValue": "5"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG004",
                                                                            "BaselineMeasurementValue": "17"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Ethnicity (NIH/OMB)",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineClassDenomList": {
                                                        "BaselineClassDenom": [
                                                            {
                                                                "BaselineClassDenomUnits": "Participants",
                                                                "BaselineClassDenomCountList": {
                                                                    "BaselineClassDenomCount": [
                                                                        {
                                                                            "BaselineClassDenomCountGroupId": "BG000",
                                                                            "BaselineClassDenomCountValue": "21"
                                                                        },
                                                                        {
                                                                            "BaselineClassDenomCountGroupId": "BG001",
                                                                            "BaselineClassDenomCountValue": "20"
                                                                        },
                                                                        {
                                                                            "BaselineClassDenomCountGroupId": "BG002",
                                                                            "BaselineClassDenomCountValue": "21"
                                                                        },
                                                                        {
                                                                            "BaselineClassDenomCountGroupId": "BG003",
                                                                            "BaselineClassDenomCountValue": "22"
                                                                        },
                                                                        {
                                                                            "BaselineClassDenomCountGroupId": "BG004",
                                                                            "BaselineClassDenomCountValue": "84"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    },
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineCategoryTitle": "Hispanic or Latino",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "1"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "6"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG003",
                                                                            "BaselineMeasurementValue": "2"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG004",
                                                                            "BaselineMeasurementValue": "9"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Not Hispanic or Latino",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "20"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "19"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "14"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG003",
                                                                            "BaselineMeasurementValue": "17"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG004",
                                                                            "BaselineMeasurementValue": "70"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Unknown or Not Reported",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "1"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "1"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG003",
                                                                            "BaselineMeasurementValue": "3"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG004",
                                                                            "BaselineMeasurementValue": "5"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Race (NIH/OMB)",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineClassDenomList": {
                                                        "BaselineClassDenom": [
                                                            {
                                                                "BaselineClassDenomUnits": "Participants",
                                                                "BaselineClassDenomCountList": {
                                                                    "BaselineClassDenomCount": [
                                                                        {
                                                                            "BaselineClassDenomCountGroupId": "BG000",
                                                                            "BaselineClassDenomCountValue": "21"
                                                                        },
                                                                        {
                                                                            "BaselineClassDenomCountGroupId": "BG001",
                                                                            "BaselineClassDenomCountValue": "20"
                                                                        },
                                                                        {
                                                                            "BaselineClassDenomCountGroupId": "BG002",
                                                                            "BaselineClassDenomCountValue": "21"
                                                                        },
                                                                        {
                                                                            "BaselineClassDenomCountGroupId": "BG003",
                                                                            "BaselineClassDenomCountValue": "22"
                                                                        },
                                                                        {
                                                                            "BaselineClassDenomCountGroupId": "BG004",
                                                                            "BaselineClassDenomCountValue": "84"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    },
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineCategoryTitle": "American Indian or Alaska Native",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG003",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG004",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Asian",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "1"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "1"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "4"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG003",
                                                                            "BaselineMeasurementValue": "7"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG004",
                                                                            "BaselineMeasurementValue": "13"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Native Hawaiian or Other Pacific Islander",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG003",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG004",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Black or African American",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "4"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "2"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "2"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG003",
                                                                            "BaselineMeasurementValue": "4"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG004",
                                                                            "BaselineMeasurementValue": "12"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "White",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "15"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "16"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "13"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG003",
                                                                            "BaselineMeasurementValue": "10"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG004",
                                                                            "BaselineMeasurementValue": "54"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "More than one race",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "1"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "1"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "2"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG003",
                                                                            "BaselineMeasurementValue": "1"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG004",
                                                                            "BaselineMeasurementValue": "5"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Unknown or Not Reported",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG003",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG004",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Region of Enrollment",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineClassTitle": "United States",
                                                    "BaselineClassDenomList": {
                                                        "BaselineClassDenom": [
                                                            {
                                                                "BaselineClassDenomUnits": "Participants",
                                                                "BaselineClassDenomCountList": {
                                                                    "BaselineClassDenomCount": [
                                                                        {
                                                                            "BaselineClassDenomCountGroupId": "BG000",
                                                                            "BaselineClassDenomCountValue": "21"
                                                                        },
                                                                        {
                                                                            "BaselineClassDenomCountGroupId": "BG001",
                                                                            "BaselineClassDenomCountValue": "20"
                                                                        },
                                                                        {
                                                                            "BaselineClassDenomCountGroupId": "BG002",
                                                                            "BaselineClassDenomCountValue": "21"
                                                                        },
                                                                        {
                                                                            "BaselineClassDenomCountGroupId": "BG003",
                                                                            "BaselineClassDenomCountValue": "22"
                                                                        },
                                                                        {
                                                                            "BaselineClassDenomCountGroupId": "BG004",
                                                                            "BaselineClassDenomCountValue": "84"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    },
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "21"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "20"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "21"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG003",
                                                                            "BaselineMeasurementValue": "22"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG004",
                                                                            "BaselineMeasurementValue": "84"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Alpha oscillations in left frontal cortex before stimulation",
                                        "BaselineMeasurePopulationDescription": "One healthy control participant that received sham stimulation was excluded from analysis as we were unable to find an age and sex matched participant. One healthy control participant that received sham stimulation did not complete the study due to technical difficulties.",
                                        "BaselineMeasureParamType": "Mean",
                                        "BaselineMeasureDispersionType": "Standard Deviation",
                                        "BaselineMeasureUnitOfMeasure": "microvolts",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineClassDenomList": {
                                                        "BaselineClassDenom": [
                                                            {
                                                                "BaselineClassDenomUnits": "Participants",
                                                                "BaselineClassDenomCountList": {
                                                                    "BaselineClassDenomCount": [
                                                                        {
                                                                            "BaselineClassDenomCountGroupId": "BG000",
                                                                            "BaselineClassDenomCountValue": "21"
                                                                        },
                                                                        {
                                                                            "BaselineClassDenomCountGroupId": "BG001",
                                                                            "BaselineClassDenomCountValue": "20"
                                                                        },
                                                                        {
                                                                            "BaselineClassDenomCountGroupId": "BG002",
                                                                            "BaselineClassDenomCountValue": "21"
                                                                        },
                                                                        {
                                                                            "BaselineClassDenomCountGroupId": "BG003",
                                                                            "BaselineClassDenomCountValue": "20"
                                                                        },
                                                                        {
                                                                            "BaselineClassDenomCountGroupId": "BG004",
                                                                            "BaselineClassDenomCountValue": "82"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    },
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0.789",
                                                                            "BaselineMeasurementSpread": "0.088"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "0.812",
                                                                            "BaselineMeasurementSpread": "0.056"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "0.826",
                                                                            "BaselineMeasurementSpread": "0.076"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG003",
                                                                            "BaselineMeasurementValue": "0.845",
                                                                            "BaselineMeasurementSpread": "0.095"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG004",
                                                                            "BaselineMeasurementValue": "0.818",
                                                                            "BaselineMeasurementSpread": "0.081"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomeMeasuresModule": {
                            "OutcomeMeasureList": {
                                "OutcomeMeasure": [
                                    {
                                        "OutcomeMeasureType": "Primary",
                                        "OutcomeMeasureTitle": "Change in Alpha Frequency Electrical Activity in Left Frontal Cortex From Stimulation",
                                        "OutcomeMeasureDescription": "Fast Fourier transform is applied to 5 minutes of EEG data before and after intervention. Primary outcome is the difference in alpha frequency amplitude (8-12 Hz) in the left frontal cortex from baseline as a result of intervention.",
                                        "OutcomeMeasurePopulationDescription": "One of the healthy participants that received sham stimulation could not be age and sex matched, therefore, we did not analyze this participant.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Mean",
                                        "OutcomeMeasureDispersionType": "Standard Deviation",
                                        "OutcomeMeasureUnitOfMeasure": "microvolts",
                                        "OutcomeMeasureTimeFrame": "5 minute recording before and after intervention",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "Alpha Stimulation in Participants in a Depressive Episode",
                                                    "OutcomeGroupDescription": "Participants in a depressive episode will receive 2 mA of alternating current stimulation at individualized alpha stimulation (between 8 and 12 Hz; determined by an EEG recording prior to stimulation) for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.\n\nXCSITE100 Stimulator tACS: Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied."
                                                },
                                                {
                                                    "OutcomeGroupId": "OG001",
                                                    "OutcomeGroupTitle": "Sham Stimulation in Participants in a Depressive Episode",
                                                    "OutcomeGroupDescription": "Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation to participants in a depressive episode is delivered using the XCSITE100 Stimulator Sham.\n\nXCSITE100 Stimulator Sham: The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session."
                                                },
                                                {
                                                    "OutcomeGroupId": "OG002",
                                                    "OutcomeGroupTitle": "Alpha Stimulation in Healthy Participants",
                                                    "OutcomeGroupDescription": "Healthy participants will receive 2 mA of alternating current stimulation at individualized alpha stimulation (between 8 and 12 Hz; determined by an EEG recording prior to stimulation) for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.\n\nXCSITE100 Stimulator tACS: Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied."
                                                },
                                                {
                                                    "OutcomeGroupId": "OG003",
                                                    "OutcomeGroupTitle": "Sham Stimulation in Healthy Participants",
                                                    "OutcomeGroupDescription": "Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation to healthy participants is delivered using the XCSITE100 Stimulator Sham.\n\nXCSITE100 Stimulator Sham: The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "21"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG001",
                                                                "OutcomeDenomCountValue": "20"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG002",
                                                                "OutcomeDenomCountValue": "21"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG003",
                                                                "OutcomeDenomCountValue": "20"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "-0.005",
                                                                            "OutcomeMeasurementSpread": "0.022"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "0.008",
                                                                            "OutcomeMeasurementSpread": "0.023"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG002",
                                                                            "OutcomeMeasurementValue": "0.004",
                                                                            "OutcomeMeasurementSpread": "0.017"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG003",
                                                                            "OutcomeMeasurementValue": "0.007",
                                                                            "OutcomeMeasurementSpread": "0.022"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeAnalysisList": {
                                            "OutcomeAnalysis": [
                                                {
                                                    "OutcomeAnalysisGroupIdList": {
                                                        "OutcomeAnalysisGroupId": [
                                                            "OG000",
                                                            "OG001"
                                                        ]
                                                    },
                                                    "OutcomeAnalysisGroupDescription": "Interaction in the effect of tACS on left frontal alpha oscillation in the depressed group. Two-way interaction of within-participant factor of before/after tACS and between-participant factor of alpha-tACS/placebo.",
                                                    "OutcomeAnalysisNonInferiorityType": "Superiority",
                                                    "OutcomeAnalysisPValue": "0.0852",
                                                    "OutcomeAnalysisStatisticalMethod": "ANOVA",
                                                    "OutcomeAnalysisStatisticalComment": "degrees of freedom = (1,39); F-statistic = 3.119"
                                                },
                                                {
                                                    "OutcomeAnalysisGroupIdList": {
                                                        "OutcomeAnalysisGroupId": [
                                                            "OG002",
                                                            "OG003"
                                                        ]
                                                    },
                                                    "OutcomeAnalysisGroupDescription": "Interaction in the effect of tACS on left frontal alpha oscillation in the healthy group. Two-way interaction of within-participant factor of before/after tACS and between-participant factor of alpha-tACS/placebo.",
                                                    "OutcomeAnalysisNonInferiorityType": "Superiority",
                                                    "OutcomeAnalysisPValue": "0.6676",
                                                    "OutcomeAnalysisStatisticalMethod": "ANOVA",
                                                    "OutcomeAnalysisStatisticalComment": "degrees of freedom = (1,39); F-statistic = 0.187"
                                                },
                                                {
                                                    "OutcomeAnalysisGroupIdList": {
                                                        "OutcomeAnalysisGroupId": [
                                                            "OG000",
                                                            "OG002"
                                                        ]
                                                    },
                                                    "OutcomeAnalysisGroupDescription": "Main effect of alpha-tACS on session (before and after) on left frontal alpha oscillations across both groups (healthy and patient).",
                                                    "OutcomeAnalysisNonInferiorityType": "Superiority",
                                                    "OutcomeAnalysisPValue": "0.929",
                                                    "OutcomeAnalysisPValueComment": "degrees of freedom = (1,41); F-statistic = 0.008",
                                                    "OutcomeAnalysisStatisticalMethod": "ANOVA"
                                                },
                                                {
                                                    "OutcomeAnalysisGroupIdList": {
                                                        "OutcomeAnalysisGroupId": [
                                                            "OG000"
                                                        ]
                                                    },
                                                    "OutcomeAnalysisGroupDescription": "Difference in alpha oscillations after versus before in the depressed cohort (one-tailed Student's t-test) with the hypothesis to decrease pathologically elevate left frontal alpha oscillations",
                                                    "OutcomeAnalysisNonInferiorityType": "Superiority",
                                                    "OutcomeAnalysisPValue": "0.1950",
                                                    "OutcomeAnalysisStatisticalMethod": "t-test, 1 sided",
                                                    "OutcomeAnalysisStatisticalComment": "degrees of freedom = 20; t-statistic = -0.08789"
                                                },
                                                {
                                                    "OutcomeAnalysisGroupIdList": {
                                                        "OutcomeAnalysisGroupId": [
                                                            "OG002"
                                                        ]
                                                    },
                                                    "OutcomeAnalysisGroupDescription": "Difference in alpha oscillations after versus before in the healthy cohort (one-tailed Student's t-test) run as a control analysis",
                                                    "OutcomeAnalysisNonInferiorityType": "Superiority",
                                                    "OutcomeAnalysisPValue": "0.8603",
                                                    "OutcomeAnalysisStatisticalMethod": "t-test, 1 sided",
                                                    "OutcomeAnalysisStatisticalComment": "degrees of freedom = 20; t-statistic = 1.1117"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "AdverseEventsModule": {
                            "EventsFrequencyThreshold": "0",
                            "EventsTimeFrame": "Adverse events were collected over the 5 hours of the single session experiment",
                            "EventGroupList": {
                                "EventGroup": [
                                    {
                                        "EventGroupId": "EG000",
                                        "EventGroupTitle": "Alpha Stimulation in Patients in a Depressive Episode",
                                        "EventGroupDescription": "Participants in a depressive episode will receive 2 mA of alternating current stimulation at individualized alpha stimulation (between 8 and 12 Hz; determined by an EEG recording prior to stimulation) for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.\n\nXCSITE100 Stimulator tACS: Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.",
                                        "EventGroupDeathsNumAffected": "0",
                                        "EventGroupDeathsNumAtRisk": "21",
                                        "EventGroupSeriousNumAffected": "0",
                                        "EventGroupSeriousNumAtRisk": "21",
                                        "EventGroupOtherNumAffected": "12",
                                        "EventGroupOtherNumAtRisk": "21"
                                    },
                                    {
                                        "EventGroupId": "EG001",
                                        "EventGroupTitle": "Sham Stimulation in Patients in a Depressive Episode",
                                        "EventGroupDescription": "Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation to participants in a depressive episode is delivered using the XCSITE100 Stimulator Sham.\n\nXCSITE100 Stimulator Sham: The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session.",
                                        "EventGroupDeathsNumAffected": "0",
                                        "EventGroupDeathsNumAtRisk": "20",
                                        "EventGroupSeriousNumAffected": "0",
                                        "EventGroupSeriousNumAtRisk": "20",
                                        "EventGroupOtherNumAffected": "7",
                                        "EventGroupOtherNumAtRisk": "20"
                                    },
                                    {
                                        "EventGroupId": "EG002",
                                        "EventGroupTitle": "Alpha Stimulation in Healthy Participants",
                                        "EventGroupDescription": "Healthy participants will receive 2 mA of alternating current stimulation at individualized alpha stimulation (between 8 and 12 Hz; determined by an EEG recording prior to stimulation) for 40 minutes. tACS stimulation is delivered using the XCSITE100 Stimulator tACS.\n\nXCSITE100 Stimulator tACS: Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.",
                                        "EventGroupDeathsNumAffected": "0",
                                        "EventGroupDeathsNumAtRisk": "21",
                                        "EventGroupSeriousNumAffected": "0",
                                        "EventGroupSeriousNumAtRisk": "21",
                                        "EventGroupOtherNumAffected": "9",
                                        "EventGroupOtherNumAtRisk": "21"
                                    },
                                    {
                                        "EventGroupId": "EG003",
                                        "EventGroupTitle": "Sham Stimulation in Healthy Participants",
                                        "EventGroupDescription": "Sham Stimulation mimics the physical effects of stimulation, with up to one minute of stimulation during the session. Sham stimulation to healthy participants is delivered using the XCSITE100 Stimulator Sham.\n\nXCSITE100 Stimulator Sham: The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session.",
                                        "EventGroupDeathsNumAffected": "0",
                                        "EventGroupDeathsNumAtRisk": "22",
                                        "EventGroupSeriousNumAffected": "0",
                                        "EventGroupSeriousNumAtRisk": "22",
                                        "EventGroupOtherNumAffected": "5",
                                        "EventGroupOtherNumAtRisk": "22"
                                    }
                                ]
                            },
                            "OtherEventList": {
                                "OtherEvent": [
                                    {
                                        "OtherEventTerm": "Tingling",
                                        "OtherEventOrganSystem": "Investigations",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "7",
                                                    "OtherEventStatsNumAffected": "7",
                                                    "OtherEventStatsNumAtRisk": "21"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "20"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "7",
                                                    "OtherEventStatsNumAffected": "7",
                                                    "OtherEventStatsNumAtRisk": "21"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "4",
                                                    "OtherEventStatsNumAffected": "4",
                                                    "OtherEventStatsNumAtRisk": "22"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Flickering Lights",
                                        "OtherEventOrganSystem": "Investigations",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "3",
                                                    "OtherEventStatsNumAtRisk": "21"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "20"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "3",
                                                    "OtherEventStatsNumAtRisk": "21"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "22"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Itching",
                                        "OtherEventOrganSystem": "Investigations",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "3",
                                                    "OtherEventStatsNumAtRisk": "21"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "20"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "21"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "22"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Burning sensation",
                                        "OtherEventOrganSystem": "Investigations",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "7",
                                                    "OtherEventStatsNumAffected": "7",
                                                    "OtherEventStatsNumAtRisk": "21"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "3",
                                                    "OtherEventStatsNumAtRisk": "20"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "3",
                                                    "OtherEventStatsNumAtRisk": "21"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "3",
                                                    "OtherEventStatsNumAtRisk": "22"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Scalp pain",
                                        "OtherEventOrganSystem": "Investigations",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "3",
                                                    "OtherEventStatsNumAtRisk": "21"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "20"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "21"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "22"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Neck pain",
                                        "OtherEventOrganSystem": "Investigations",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "21"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "20"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "21"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "22"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Headache",
                                        "OtherEventOrganSystem": "Investigations",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "21"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "20"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG002",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "21"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG003",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "22"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "MoreInfoModule": {
                            "CertainAgreement": {
                                "AgreementPISponsorEmployee": "Yes"
                            },
                            "PointOfContact": {
                                "PointOfContactTitle": "Justin Riddle, PhD",
                                "PointOfContactOrganization": "University of North Carolina at Chapel Hill",
                                "PointOfContactEMail": "justin_riddle@med.unc.edu",
                                "PointOfContactPhone": "6617131602"
                            }
                        }
                    },
                    "DocumentSection": {
                        "LargeDocumentModule": {
                            "LargeDocList": {
                                "LargeDoc": [
                                    {
                                        "LargeDocTypeAbbrev": "Prot_SAP",
                                        "LargeDocHasProtocol": "Yes",
                                        "LargeDocHasSAP": "Yes",
                                        "LargeDocHasICF": "No",
                                        "LargeDocLabel": "Study Protocol and Statistical Analysis Plan",
                                        "LargeDocDate": "April 29, 2019",
                                        "LargeDocUploadDate": "01/14/2020 13:30",
                                        "LargeDocFilename": "Prot_SAP_000.pdf"
                                    }
                                ]
                            }
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000004194",
                                        "ConditionMeshTerm": "Disease"
                                    },
                                    {
                                        "ConditionMeshId": "D000065446",
                                        "ConditionMeshTerm": "Premenstrual Dysphoric Disorder"
                                    },
                                    {
                                        "ConditionMeshId": "D000003863",
                                        "ConditionMeshTerm": "Depression"
                                    },
                                    {
                                        "ConditionMeshId": "D000003866",
                                        "ConditionMeshTerm": "Depressive Disorder"
                                    },
                                    {
                                        "ConditionMeshId": "D000003865",
                                        "ConditionMeshTerm": "Depressive Disorder, Major"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000010335",
                                        "ConditionAncestorTerm": "Pathologic Processes"
                                    },
                                    {
                                        "ConditionAncestorId": "D000001526",
                                        "ConditionAncestorTerm": "Behavioral Symptoms"
                                    },
                                    {
                                        "ConditionAncestorId": "D000019964",
                                        "ConditionAncestorTerm": "Mood Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000001523",
                                        "ConditionAncestorTerm": "Mental Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000011293",
                                        "ConditionAncestorTerm": "Premenstrual Syndrome"
                                    },
                                    {
                                        "ConditionAncestorId": "D000008599",
                                        "ConditionAncestorTerm": "Menstruation Disturbances"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M6210",
                                        "ConditionBrowseLeafName": "Depression",
                                        "ConditionBrowseLeafAsFound": "Depressive Episode",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M6213",
                                        "ConditionBrowseLeafName": "Depressive Disorder",
                                        "ConditionBrowseLeafAsFound": "Depressive Disorder",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M6212",
                                        "ConditionBrowseLeafName": "Depressive Disorder, Major",
                                        "ConditionBrowseLeafAsFound": "Major Depressive Disorder",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M29667",
                                        "ConditionBrowseLeafName": "Premenstrual Dysphoric Disorder",
                                        "ConditionBrowseLeafAsFound": "Premenstrual Dysphoric Disorder",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M3970",
                                        "ConditionBrowseLeafName": "Behavioral Symptoms",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M20988",
                                        "ConditionBrowseLeafName": "Mood Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M3967",
                                        "ConditionBrowseLeafName": "Mental Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M13625",
                                        "ConditionBrowseLeafName": "Psychotic Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M15507",
                                        "ConditionBrowseLeafName": "Syndrome",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M13319",
                                        "ConditionBrowseLeafName": "Premenstrual Syndrome",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M10734",
                                        "ConditionBrowseLeafName": "Menstruation Disturbances",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BXM",
                                        "ConditionBrowseBranchName": "Behaviors and Mental Disorders"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC23",
                                        "ConditionBrowseBranchName": "Symptoms and General Pathology"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 19,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT03880279",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "TAC01-CD19-01"
                            },
                            "Organization": {
                                "OrgFullName": "Triumvira Immunologics, Inc.",
                                "OrgClass": "INDUSTRY"
                            },
                            "BriefTitle": "Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma",
                            "OfficialTitle": "A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC T Cells Targeting CD19 in Relapsed or Refractory Large B-Cell Lymphoma",
                            "Acronym": "TACTIC-19"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "February 2022",
                            "OverallStatus": "Withdrawn",
                            "WhyStopped": "Following a change in company governance, Triumvira terminated the study prior to enrolling any subjects due to a challenging competitive landscape.",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "May 2020",
                                "StartDateType": "Anticipated"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "April 2022",
                                "PrimaryCompletionDateType": "Anticipated"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "April 2024",
                                "CompletionDateType": "Anticipated"
                            },
                            "StudyFirstSubmitDate": "March 13, 2019",
                            "StudyFirstSubmitQCDate": "March 18, 2019",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "March 19, 2019",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "February 7, 2022",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "February 23, 2022",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Sponsor"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Triumvira Immunologics, Inc.",
                                "LeadSponsorClass": "INDUSTRY"
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "Yes",
                            "IsFDARegulatedDrug": "Yes",
                            "IsFDARegulatedDevice": "No",
                            "IsUSExport": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "Phase I/II study to evaluate TAC01-CD19 in subjects with relapsed or refractory B-cell lymphomas. TAC technology is a novel way to genetically modify T cells and to redirect these T cells to target cancer antigens by co-opting the natural T cell receptor. The dose finding portion of this study will evaluate the safety and tolerability of increasing dose levels of TAC01-CD19 to identify a Maximal Tolerated Dose (MTD) or Recommended Phase II Dose (RP2D). The dose expansion portion of the study will further evaluate the safety, efficacy and pharmacokinetics of TAC01-CD19 at the RP2D."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Lymphoma, B-Cell"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Phase 1",
                                    "Phase 2"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "N/A",
                                "DesignInterventionModel": "Single Group Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "None (Open Label)"
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "0",
                                "EnrollmentType": "Actual"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "TAC01-CD19",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "TAC01-CD19, Autologous TAC (T cell antigen coupler) T cells, single infusion, multiple dosage levels.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Biological: TAC01-CD19"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Biological",
                                        "InterventionName": "TAC01-CD19",
                                        "InterventionDescription": "Dose-escalating cohorts plus expansion groups",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "TAC01-CD19"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Incidence of dose-limiting toxicities (DLTs)",
                                        "PrimaryOutcomeDescription": "Measurement of occurrence of study-defined DLTs",
                                        "PrimaryOutcomeTimeFrame": "First 28 days after dosing"
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "Incidence of adverse events (AEs)",
                                        "PrimaryOutcomeDescription": "Type, frequency, and severity of adverse events (AEs) and laboratory abnormalities",
                                        "PrimaryOutcomeTimeFrame": "Informed consent through 2 years after dosing"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nHistologically confirmed CD19+ Large B-Cell Lymphoma including Diffuse Large B-cell Lymphoma (DLBCL) not otherwise specified (including de novo and transformed lymphoma), Primary Mediastinal Large B-cell Lymphoma, High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 rearrangement per WHO 2016 classification.\nRelapsed or refractory disease after greater than 2 lines of therapy including anthracycline and anti-CD20 therapy and either having failed autologous stem cell transplant (ASCT) or being ineligible for ASCT.\nECOG 0-1.\nAdequate organ function.\n\nExclusion Criteria:\n\nPrior treatment with any of the following: allogeneic bone marrow transplantation, gene therapy, adoptive cell transfer of any kind, including CAR T cells.\nActive central nervous system (CNS) lymphoma involvement.\nHistory or presence of clinically relevant CNS pathology.\nActive inflammatory neurological disorders, autoimmune disease, or infections.",
                            "HealthyVolunteers": "No",
                            "Gender": "All",
                            "MinimumAge": "18 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "IPDSharingStatementModule": {
                            "IPDSharing": "No"
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000008223",
                                        "ConditionMeshTerm": "Lymphoma"
                                    },
                                    {
                                        "ConditionMeshId": "D000016393",
                                        "ConditionMeshTerm": "Lymphoma, B-Cell"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000009370",
                                        "ConditionAncestorTerm": "Neoplasms by Histologic Type"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009369",
                                        "ConditionAncestorTerm": "Neoplasms"
                                    },
                                    {
                                        "ConditionAncestorId": "D000008232",
                                        "ConditionAncestorTerm": "Lymphoproliferative Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000008206",
                                        "ConditionAncestorTerm": "Lymphatic Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000007160",
                                        "ConditionAncestorTerm": "Immunoproliferative Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000007154",
                                        "ConditionAncestorTerm": "Immune System Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000008228",
                                        "ConditionAncestorTerm": "Lymphoma, Non-Hodgkin"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M10372",
                                        "ConditionBrowseLeafName": "Lymphoma",
                                        "ConditionBrowseLeafAsFound": "Lymphoma",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M17980",
                                        "ConditionBrowseLeafName": "Lymphoma, B-Cell",
                                        "ConditionBrowseLeafAsFound": "Lymphoma, B-Cell",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M11467",
                                        "ConditionBrowseLeafName": "Neoplasms by Histologic Type",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M10377",
                                        "ConditionBrowseLeafName": "Lymphoproliferative Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M10355",
                                        "ConditionBrowseLeafName": "Lymphatic Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M9358",
                                        "ConditionBrowseLeafName": "Immunoproliferative Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M9352",
                                        "ConditionBrowseLeafName": "Immune System Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M10374",
                                        "ConditionBrowseLeafName": "Lymphoma, Non-Hodgkin",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "T3543",
                                        "ConditionBrowseLeafName": "Lymphosarcoma",
                                        "ConditionBrowseLeafAsFound": "Lymphoma",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "T640",
                                        "ConditionBrowseLeafName": "B-cell Lymphoma",
                                        "ConditionBrowseLeafAsFound": "B-cell Lymphoma",
                                        "ConditionBrowseLeafRelevance": "high"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC04",
                                        "ConditionBrowseBranchName": "Neoplasms"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC15",
                                        "ConditionBrowseBranchName": "Blood and Lymph Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC20",
                                        "ConditionBrowseBranchName": "Immune System Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "Rare",
                                        "ConditionBrowseBranchName": "Rare Diseases"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 20,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT04375722",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "36878"
                            },
                            "Organization": {
                                "OrgFullName": "Medical College of Wisconsin",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Transcranial Alternating Current Stimulation (tACS) in Aphasia",
                            "OfficialTitle": "Exogenous Tuning of Neural Oscillations as a Mode of Treatment in Post-stroke Aphasia"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "November 2021",
                            "OverallStatus": "Recruiting",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "January 4, 2020",
                                "StartDateType": "Actual"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "January 2025",
                                "PrimaryCompletionDateType": "Anticipated"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "January 2025",
                                "CompletionDateType": "Anticipated"
                            },
                            "StudyFirstSubmitDate": "May 1, 2020",
                            "StudyFirstSubmitQCDate": "May 1, 2020",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "May 5, 2020",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "November 18, 2021",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "November 30, 2021",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Principal Investigator",
                                "ResponsiblePartyInvestigatorFullName": "Priyanka Shah-Basak, PhD",
                                "ResponsiblePartyInvestigatorTitle": "Priyanka Shah-Basak, PhD",
                                "ResponsiblePartyInvestigatorAffiliation": "Medical College of Wisconsin"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Medical College of Wisconsin",
                                "LeadSponsorClass": "OTHER"
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "No",
                            "IsFDARegulatedDrug": "No",
                            "IsFDARegulatedDevice": "Yes",
                            "IsUnapprovedDevice": "Yes",
                            "IsUSExport": "Yes"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "This study will assess the effects of transcranial alternating current stimulation (tACS) on language recovery after stroke as well as healthy language functions.",
                            "DetailedDescription": "Aphasia is a debilitating disorder, typically resulting from damage to the left hemisphere, that can impair a range of communication abilities, including language production and comprehension, reading, and writing. Approximately 180,000 new cases of aphasia are identified per year, and approximately 1 million or 1 in 250 are living with aphasia in the United States (NIH-NIDCD, 2015). Treatments are limited and provide modest benefits at best. The current emphasis in aphasia rehabilitation is to formulate intensive speech and language therapies and augment therapeutic benefits by providing brain stimulation concurrent with therapies. Transcranial direct current stimulation (tDCS) is one of the most widely used such technique. While tDCS has had relative success in chronic aphasia (>6 months after stroke), it has not been efficacious during subacute stages (<3 months after stroke). But enhancing language recovery early after stroke is desirable because of its potential impact on long-term language outcomes and quality-of-life.\n\nThe current study will investigate the efficacy of high-definition tACS (HD-tACS) to help restore neural oscillatory activity in aphasia. TACS differs from tDCS in that sinusoidal, alternating currents are delivered rather than constant currents. TACS can manipulate the ongoing oscillatory neuronal activity and potentially increase functional synchronization (or connectivity) between targeted areas. This feature of tACS is quite attractive, given the new body of evidence suggesting that language impairments stem from diminished functional connectivity and disruptions in the language network due to stroke. The selection of tACS frequencies in this study is guided by our preliminary work examining pathological neural oscillations found near stroke-lesioned areas (or perilesional) in aphasia. By exogenously tuning the perilesional oscillations with tACS, the investigators hope to up-regulate communication across these areas and other connected areas to improve language outcome. If successful, tACS will be a powerful and novel treatment approach with reverberating positive impact on long-term recovery.\n\nThe study will employ HD-tACS in a within-subject and sham-controlled design, using two frequencies (alpha/10 Hz and low-gamma/40 Hz) combined with language tasks and electroencephalography (EEG) to evaluate subsequent behavioral and neurophysiological changes. Investigators plan to recruit 50 participants: 25 stroke survivors with aphasia at lease 1 month after stroke, and 25 healthy controls.\n\nParticipants will complete language testing that covers a broad range of language functions, medical history, and MRI. Eligible participants will undergo active tACS at 10 Hz or 40 Hz, or sham-tACS. All participants will receive all three stimulation types during separate visits. The tACS administrator and participants will be blinded to the stimulation type. The order of stimulation type will be counterbalanced across participants. Washout period between visits will be at least 48 hours to minimize potential carryover effects. EEG will be acquired before and after tACS during periods of rest (resting-state) and during language tasks. Participants will complete a questionnaire at the end of stimulation visits to assess potential side effects of tACS. Total time enrolled in the study is expected to be 2-3 weeks, which may be longer depending on participant's availability."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Aphasia",
                                    "Stroke"
                                ]
                            },
                            "KeywordList": {
                                "Keyword": [
                                    "language",
                                    "language impairment",
                                    "transcranial alternating current stimulation",
                                    "tACS"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Not Applicable"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "Randomized",
                                "DesignInterventionModel": "Single Group Assignment",
                                "DesignInterventionModelDescription": "In the within-subject design healthy participants and stroke survivors will receive tACS stimulation at 10 Hz, 40 Hz, and sham settings in a randomized order with >48 hours washout period in between stimulation sessions.",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "Quadruple",
                                    "DesignMaskingDescription": "Participant, care provider, investigator and outcomes assessor are all blinded. One study team member will be designated as unblinded.",
                                    "DesignWhoMaskedList": {
                                        "DesignWhoMasked": [
                                            "Participant",
                                            "Care Provider",
                                            "Investigator",
                                            "Outcomes Assessor"
                                        ]
                                    }
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "50",
                                "EnrollmentType": "Anticipated"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "tACS 10 Hz low frequency",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "High-Definition-tACS will be delivered via a battery operated alternating current stimulator (Soterix) using two 3x1 center-surround montages. Targets of stimulation will be localized based on the 10-10 International EEG system with center electrodes placed at a frontal and a temporoparietal site. The current is turned on and increased in a ramplike fashion over approximately 30 seconds. Participants will undergo tACS with 10-Hz stimulation for 20-minutes with 1 milliampere (mA) peak-to-peak intensity. Stimulation will be maintained no longer than 20 minutes.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: tACS 10-Hz"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "tACS 40 Hz high frequency",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "High-Definition-tACS will be delivered via a battery operated alternating current stimulator (Soterix) using two 3x1 center-surround montages. Targets of stimulation will be localized based on the 10-10 International EEG system with center electrodes placed at a frontal and a temporoparietal site. The current is turned on and increased in a ramplike fashion over approximately 30 seconds. Participants will undergo tACS with 40-Hz stimulation for 20-minutes with 1 milliampere (mA) peak-to-peak intensity. Stimulation will be maintained no longer than 20 minutes.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: tACS 40-Hz"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "tACS sham",
                                        "ArmGroupType": "Sham Comparator",
                                        "ArmGroupDescription": "High-Definition-tACS will be delivered via a battery operated alternating current stimulator (Soterix) using two 3x1 center-surround montages. Targets of stimulation will be localized based on the 10-10 International EEG system with center electrodes placed at a frontal and a temporoparietal site. The current is turned on and increased in a ramplike fashion for 10 to 30 seconds and then ramped down. In this way, the participants experience the same initial sensations (mild tingling) as the active tACS groups.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: tACS sham"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "tACS 10-Hz",
                                        "InterventionDescription": "Low frequency alternating current will be applied.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "tACS 10 Hz low frequency"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "tACS 40-Hz",
                                        "InterventionDescription": "High frequency alternating current will be applied.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "tACS 40 Hz high frequency"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "tACS sham",
                                        "InterventionDescription": "Sham stimulation setting will be applied.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "tACS sham"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "tACS frequency-dependent changes in language performance on object and action naming tasks",
                                        "PrimaryOutcomeDescription": "Improvement on noun and verb retrieval performance as determined by increases in accuracy and decreases in reaction time.",
                                        "PrimaryOutcomeTimeFrame": "Immediate changes monitored after 20 minutes of tACS of each type"
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "tACS frequency-dependent neurophysiological changes",
                                        "PrimaryOutcomeDescription": "Concomitant frequency-specific EEG changes in spectral power and phase synchronization are expected.",
                                        "PrimaryOutcomeTimeFrame": "Immediate changes monitored after 20 minutes of tACS of each type"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "Individual differences in tACS responsiveness",
                                        "SecondaryOutcomeDescription": "tACS responsiveness depending on language impairment types, stroke lesion and language lateralization characteristics will be explored.",
                                        "SecondaryOutcomeTimeFrame": "Based on immediate changes monitored after 20 minutes of tACS of each type"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nHealthy Controls\n\n18 years of age or older\nFluent in English\nNo history of neurological or psychiatric disorders\n\nStroke Patients\n\nDiagnosed with post-stroke aphasia by referring physician/neuropsychologist\nConsent date >=1 months after stroke onset\nRight-handed\nFluent in English\n18 years of age or older\n\nExclusion Criteria:\n\nSevere cognitive, auditory or visual impairments that would preclude cognitive and language testing\nPresence of major untreated or unstable psychiatric disease\nA chronic medical condition that is not treated or is unstable\nThe presence of cardiac stimulators or pacemakers\nAny metal implants in the skull\nContraindications to MRI or tACS\nHistory of seizures\nHistory of dyslexia or other developmental learning disabilities",
                            "HealthyVolunteers": "Accepts Healthy Volunteers",
                            "Gender": "All",
                            "MinimumAge": "18 Years",
                            "MaximumAge": "85 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "CentralContactList": {
                                "CentralContact": [
                                    {
                                        "CentralContactName": "Samantha Drane, MS",
                                        "CentralContactRole": "Contact",
                                        "CentralContactPhone": "414-955-5891",
                                        "CentralContactPhoneExt": "4149555894",
                                        "CentralContactEMail": "sdrane@mcw.edu"
                                    }
                                ]
                            },
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Priyanka Shah-Basak, PhD",
                                        "OverallOfficialAffiliation": "Medical College of Wisconsin",
                                        "OverallOfficialRole": "Principal Investigator"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "Medical College of Wisconsin",
                                        "LocationStatus": "Recruiting",
                                        "LocationCity": "Milwaukee",
                                        "LocationState": "Wisconsin",
                                        "LocationZip": "53226",
                                        "LocationCountry": "United States",
                                        "LocationContactList": {
                                            "LocationContact": [
                                                {
                                                    "LocationContactName": "Samantha Drane, MS",
                                                    "LocationContactRole": "Contact",
                                                    "LocationContactPhone": "414-955-5891",
                                                    "LocationContactEMail": "sdrane@mcw.edu"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "ReferencesModule": {
                            "ReferenceList": {
                                "Reference": [
                                    {
                                        "ReferencePMID": "28709880",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Antal A, Alekseichuk I, Bikson M, Brockmöller J, Brunoni AR, Chen R, Cohen LG, Dowthwaite G, Ellrich J, Flöel A, Fregni F, George MS, Hamilton R, Haueisen J, Herrmann CS, Hummel FC, Lefaucheur JP, Liebetanz D, Loo CK, McCaig CD, Miniussi C, Miranda PC, Moliadze V, Nitsche MA, Nowak R, Padberg F, Pascual-Leone A, Poppendieck W, Priori A, Rossi S, Rossini PM, Rothwell J, Rueger MA, Ruffini G, Schellhorn K, Siebner HR, Ugawa Y, Wexler A, Ziemann U, Hallett M, Paulus W. Low intensity transcranial electric stimulation: Safety, ethical, legal regulatory and application guidelines. Clin Neurophysiol. 2017 Sep;128(9):1774-1809. doi: 10.1016/j.clinph.2017.06.001. Epub 2017 Jun 19. Review."
                                    },
                                    {
                                        "ReferencePMID": "31077693",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Bucur M, Papagno C. Are transcranial brain stimulation effects long-lasting in post-stroke aphasia? A comparative systematic review and meta-analysis on naming performance. Neurosci Biobehav Rev. 2019 Jul;102:264-289. doi: 10.1016/j.neubiorev.2019.04.019. Epub 2019 May 8."
                                    },
                                    {
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Buzsaki, G. (2006). Rhythms of the brain. New York: Oxford."
                                    },
                                    {
                                        "ReferencePMID": "26106540",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Chu RK, Braun AR, Meltzer JA. MEG-based detection and localization of perilesional dysfunction in chronic stroke. Neuroimage Clin. 2015 Apr 8;8:157-69. doi: 10.1016/j.nicl.2015.03.019. eCollection 2015."
                                    },
                                    {
                                        "ReferencePMID": "22713421",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Dubovik S, Ptak R, Aboulafia T, Magnin C, Gillabert N, Allet L, Pignat JM, Schnider A, Guggisberg AG. EEG alpha band synchrony predicts cognitive and motor performance in patients with ischemic stroke. Behav Neurol. 2013;26(3):187-9. doi: 10.3233/BEN-2012-129007."
                                    },
                                    {
                                        "ReferencePMID": "22858178",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Finnigan S, van Putten MJ. EEG in ischaemic stroke: quantitative EEG can uniquely inform (sub-)acute prognoses and clinical management. Clin Neurophysiol. 2013 Jan;124(1):10-9. doi: 10.1016/j.clinph.2012.07.003. Epub 2012 Aug 2. Review."
                                    },
                                    {
                                        "ReferencePMID": "17889600",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Finnigan SP, Walsh M, Rose SE, Chalk JB. Quantitative EEG indices of sub-acute ischaemic stroke correlate with clinical outcomes. Clin Neurophysiol. 2007 Nov;118(11):2525-32. Epub 2007 Sep 21."
                                    },
                                    {
                                        "ReferencePMID": "30128538",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Fridriksson J, Rorden C, Elm J, Sen S, George MS, Bonilha L. Transcranial Direct Current Stimulation vs Sham Stimulation to Treat Aphasia After Stroke: A Randomized Clinical Trial. JAMA Neurol. 2018 Dec 1;75(12):1470-1476. doi: 10.1001/jamaneurol.2018.2287."
                                    },
                                    {
                                        "ReferencePMID": "26447583",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Fries P. Rhythms for Cognition: Communication through Coherence. Neuron. 2015 Oct 7;88(1):220-35. doi: 10.1016/j.neuron.2015.09.034. Review."
                                    },
                                    {
                                        "ReferencePMID": "21414995",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Grefkes C, Fink GR. Reorganization of cerebral networks after stroke: new insights from neuroimaging with connectivity approaches. Brain. 2011 May;134(Pt 5):1264-76. doi: 10.1093/brain/awr033. Epub 2011 Mar 16. Review."
                                    },
                                    {
                                        "ReferencePMID": "24461998",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Helfrich RF, Schneider TR, Rach S, Trautmann-Lengsfeld SA, Engel AK, Herrmann CS. Entrainment of brain oscillations by transcranial alternating current stimulation. Curr Biol. 2014 Feb 3;24(3):333-9. doi: 10.1016/j.cub.2013.12.041. Epub 2014 Jan 23."
                                    },
                                    {
                                        "ReferencePMID": "23785325",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Herrmann CS, Rach S, Neuling T, Strüber D. Transcranial alternating current stimulation: a review of the underlying mechanisms and modulation of cognitive processes. Front Hum Neurosci. 2013 Jun 14;7:279. doi: 10.3389/fnhum.2013.00279. eCollection 2013."
                                    },
                                    {
                                        "ReferencePMID": "26973515",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Kielar A, Deschamps T, Chu RK, Jokel R, Khatamian YB, Chen JJ, Meltzer JA. Identifying Dysfunctional Cortex: Dissociable Effects of Stroke and Aging on Resting State Dynamics in MEG and fMRI. Front Aging Neurosci. 2016 Mar 3;8:40. doi: 10.3389/fnagi.2016.00040. eCollection 2016."
                                    },
                                    {
                                        "ReferencePMID": "27163249",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Shah-Basak PP, Wurzman R, Purcell JB, Gervits F, Hamilton R. Fields or flows? A comparative metaanalysis of transcranial magnetic and direct current stimulation to treat post-stroke aphasia. Restor Neurol Neurosci. 2016 May 2;34(4):537-58. doi: 10.3233/RNN-150616. Review."
                                    },
                                    {
                                        "ReferencePMID": "30421472",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Shah-Basak PP, Kielar A, Deschamps T, Verhoeff NP, Jokel R, Meltzer J. Spontaneous oscillatory markers of cognitive status in two forms of dementia. Hum Brain Mapp. 2019 Apr 1;40(5):1594-1607. doi: 10.1002/hbm.24470. Epub 2018 Nov 12."
                                    },
                                    {
                                        "ReferencePMID": "25954178",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Shah-Basak PP, Norise C, Garcia G, Torres J, Faseyitan O, Hamilton RH. Individualized treatment with transcranial direct current stimulation in patients with chronic non-fluent aphasia due to stroke. Front Hum Neurosci. 2015 Apr 21;9:201. doi: 10.3389/fnhum.2015.00201. eCollection 2015."
                                    }
                                ]
                            }
                        },
                        "IPDSharingStatementModule": {
                            "IPDSharing": "No"
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000001037",
                                        "ConditionMeshTerm": "Aphasia"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000009422",
                                        "ConditionAncestorTerm": "Nervous System Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000013064",
                                        "ConditionAncestorTerm": "Speech Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000007806",
                                        "ConditionAncestorTerm": "Language Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000003147",
                                        "ConditionAncestorTerm": "Communication Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000019954",
                                        "ConditionAncestorTerm": "Neurobehavioral Manifestations"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009461",
                                        "ConditionAncestorTerm": "Neurologic Manifestations"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M21459",
                                        "ConditionBrowseLeafName": "Stroke",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M3504",
                                        "ConditionBrowseLeafName": "Aphasia",
                                        "ConditionBrowseLeafAsFound": "Aphasia",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M9975",
                                        "ConditionBrowseLeafName": "Language Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M15016",
                                        "ConditionBrowseLeafName": "Speech Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M5526",
                                        "ConditionBrowseLeafName": "Communication Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M20979",
                                        "ConditionBrowseLeafName": "Neurobehavioral Manifestations",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M11556",
                                        "ConditionBrowseLeafName": "Neurologic Manifestations",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC10",
                                        "ConditionBrowseBranchName": "Nervous System Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC14",
                                        "ConditionBrowseBranchName": "Heart and Blood Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC23",
                                        "ConditionBrowseBranchName": "Symptoms and General Pathology"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BXM",
                                        "ConditionBrowseBranchName": "Behaviors and Mental Disorders"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 21,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT05188105",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "NP4758"
                            },
                            "Organization": {
                                "OrgFullName": "Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Alpha tACS in Dementia With Lewy Bodies",
                            "OfficialTitle": "Interventional Cross-over Study to Evaluate the Efficacy of Transcranial Alternating Current Stimulation (tACS) on Cognitive Performance in Patients With Dementia With Lewy Bodies",
                            "Acronym": "Alpha-DLB"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "January 2022",
                            "OverallStatus": "Recruiting",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "October 18, 2021",
                                "StartDateType": "Actual"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "June 30, 2022",
                                "PrimaryCompletionDateType": "Anticipated"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "June 30, 2022",
                                "CompletionDateType": "Anticipated"
                            },
                            "StudyFirstSubmitDate": "November 14, 2021",
                            "StudyFirstSubmitQCDate": "January 11, 2022",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "January 12, 2022",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "January 11, 2022",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "January 12, 2022",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Principal Investigator",
                                "ResponsiblePartyInvestigatorFullName": "Barbara Borroni",
                                "ResponsiblePartyInvestigatorTitle": "Clinical Professor",
                                "ResponsiblePartyInvestigatorAffiliation": "Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia",
                                "LeadSponsorClass": "OTHER"
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "No",
                            "IsFDARegulatedDrug": "No",
                            "IsFDARegulatedDevice": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "Brain oscillations are ubiquitous in the human brain and have been implicated in cognitive and behavioral states defined in precisely tuned neural networks. In neurodegenerative disorders, neurodegeneration is accompanied by changes in oscillatory activity leading to the emerging concept of neurological and psychiatric disorders as \"oscillopathies\".\n\nDementia with Lewy bodies (DLB), which is the second most frequent cause of neurodegenerative dementia, is characterized by an important alteration of brain oscillations. The restoration of oscillations by neuronal entrainment in animal models of neurodegenerative disease has shown a significant reduction in the neuropathological load of toxic proteins, with a consequent significant increase in cognitive performance.\n\nTranscranial alternating current brain stimulation (tACS), is a neurophysiological method of non-invasive modulation of the excitability of the central nervous system that is having an increasingly numerous spectrum of potential therapeutic applications. Recent studies have demonstrated the effectiveness of this method in modulating the natural frequencies of cerebral oscillation, underlying multiple cognitive processes such as verbal memory, perception and working memory.\n\nOn the basis of these premises, the treatment with alpha tACS is proposed in patients with DLB.\n\nIn this randomized, double-blind, sham-controlled, cross-over study, the investigators will evaluate whether a single stimulation with alpha tACS on the occipital lobes can improve symptoms in patients with DLB.",
                            "DetailedDescription": "Brain oscillations are ubiquitous in the human brain and have been implicated in cognitive and behavioral states defined in precisely tuned neural networks. In neurodegenerative disorders, neurodegeneration is accompanied by changes in oscillatory activity leading to the emerging concept of neurological and psychiatric disorders as \"oscillopathies\".\n\nDementia with Lewy bodies (DLB), which is the second most frequent cause of neurodegenerative dementia, is characterized by an important alteration of brain oscillations. The restoration of oscillations by neuronal entrainment in animal models of neurodegenerative disease has shown a significant reduction in the neuropathological load of toxic proteins, with a consequent significant increase in cognitive performance.\n\nTranscranial alternating current brain stimulation (tACS), is a neurophysiological method of non-invasive modulation of the excitability of the central nervous system that is having an increasingly numerous spectrum of potential therapeutic applications. Recent studies have demonstrated the effectiveness of this method in modulating the natural frequencies of cerebral oscillation, underlying multiple cognitive processes such as verbal memory, perception and working memory.\n\nOn the basis of these premises, the treatment with alpha tACS is proposed in patients with DLB.\n\nIn this randomized, double-blind, sham-controlled, cross-over study, the investigators will evaluate whether a single stimulation with alpha tACS on the occipital lobes can improve symptoms in patients with DLB.\n\nSubjects will be randomized in two groups, one receiving a single treatment with alpha tACS (12 Hz) first and the other receiving sham stimulation. After one week the treatments will be exchanged. Patients will be evaluated with neuropsychological tests and neurophysiological measures of cholinergic transmission."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Dementia With Lewy Bodies",
                                    "Lewy Body Disease"
                                ]
                            },
                            "KeywordList": {
                                "Keyword": [
                                    "Dementia with Lewy bodies",
                                    "Lewy Body Disease",
                                    "Alpha stimulation",
                                    "transcranial alternating current stimulation"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Not Applicable"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "Randomized",
                                "DesignInterventionModel": "Crossover Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "Quadruple",
                                    "DesignWhoMaskedList": {
                                        "DesignWhoMasked": [
                                            "Participant",
                                            "Care Provider",
                                            "Investigator",
                                            "Outcomes Assessor"
                                        ]
                                    }
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "20",
                                "EnrollmentType": "Anticipated"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "real tACS",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "Single session of alpha tACS (12 Hz) at 3 mA over the occipital cortex.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: Alpha tACS (12 Hz) over the occipital cortex"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "sham tACS",
                                        "ArmGroupType": "Placebo Comparator",
                                        "ArmGroupDescription": "Single session of sham tACS over the occipital cortex.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: Alpha tACS (12 Hz) over the occipital cortex"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "Alpha tACS (12 Hz) over the occipital cortex",
                                        "InterventionDescription": "Single session of alpha tACS (12 Hz) over the occipital cortex",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "real tACS",
                                                "sham tACS"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Changes in Visual Search Task Test scores",
                                        "PrimaryOutcomeDescription": "The visual search task requires participants to determine whether a target (such as a particular letter, shape, or image) is present in an array of other stimuli. The task consists of two parts, each with 64 stimuli, for a total of 128 stimuli. Participants are asked to look at the screen and press a button if the target stimulus is present or another button if the target stimulus is absent. After pressing the chosen button, a feedback will appear on the screen that will tell the subject if his answer is correct or incorrect. Subjects must respond as quickly as possible, otherwise the answer will be considered missed and they will proceed to the next screen.\n\nThe score ranges from 0 (worse performance) to 128 (best performance).",
                                        "PrimaryOutcomeTimeFrame": "40 minutes after the start of the intervention"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "Changes in Rey Auditory Verbal Learning Test scores",
                                        "SecondaryOutcomeDescription": "Participants are given a list of 15 unrelated words repeated over five different trials and are asked to repeat. Another list of 15 unrelated words are given and the patient must again repeat the original list of 15 words and then again after 30 minutes.\n\nThe score ranges from 0 (worse performance) to 15 (best performance).",
                                        "SecondaryOutcomeTimeFrame": "Baseline (immediately before the intervention) - Immediately after the intervention"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Changes in Trail Making Test Part A",
                                        "SecondaryOutcomeDescription": "The Trail Making Test Part A consists of 25 circles on a piece of paper with the numbers 1-25 written randomly in the circles. The test taker's task is to start with number one and draw a line from that circle to the circle with the number two in it to the circle with the three in it, etc. The person continues to connect the circles in numerical order until they reach number 25.\n\nScoring is based on time taken to complete the test with lower scores being better.",
                                        "SecondaryOutcomeTimeFrame": "Baseline (immediately before the intervention) - Immediately after the intervention"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Changes in Trail Making Test Part B",
                                        "SecondaryOutcomeDescription": "The Trail Making Test Part B consists of 24 circles on a piece of paper, but rather than all of the circles containing numbers, half of the circles have the numbers 1-12 in them and the other half (12) contain the letters A-L. The person taking the test has to draw a line from one circle to the next in ascending order; however, he must alternate the circles with numbers in them (1-13) with circles with letters in them (A-L). In other words, he is to connect the circles in order like this: 1-A-2-B-3-C-4-D-5-E and so on.\n\nScoring is based on time taken to complete the test with lower scores being better.",
                                        "SecondaryOutcomeTimeFrame": "Baseline (immediately before the intervention) - Immediately after the intervention"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Changes in relative alpha power in occipital EEG leads",
                                        "SecondaryOutcomeDescription": "By using electroencephalography (EEG), the investigators will evaluate the effects of alpha tACS on relative alpha power in occipital EEG leads.",
                                        "SecondaryOutcomeTimeFrame": "Baseline (immediately before the intervention) - Immediately after the intervention"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Change in SAI measurements",
                                        "SecondaryOutcomeDescription": "By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of alpha tACS on short latency afferent inhibition (SAI), which is a marker of cholinergic transmission.",
                                        "SecondaryOutcomeTimeFrame": "Baseline (immediately before the intervention) - Immediately after the intervention"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Change in SICI measurements",
                                        "SecondaryOutcomeDescription": "By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of alpha tACS on short interval intracortical inhibition (SICI), which is a marker of GABAergic transmission.",
                                        "SecondaryOutcomeTimeFrame": "Baseline (immediately before the intervention) - Immediately after the intervention"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Change in ICF measurements",
                                        "SecondaryOutcomeDescription": "By using transcranial magnetic stimulation (TMS), the investigators will evaluate the effects of alpha tACS on intracortical facilitation (ICF), which is a marker of glutamatergic transmission.",
                                        "SecondaryOutcomeTimeFrame": "Baseline (immediately before the intervention) - Immediately after the intervention"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nDementia with Lewy bodies (criteria according to McKeith, Neurology 2017).\n\nExclusion Criteria:\n\nCerebrovascular disorders, previous stroke, hydrocephalus, and intra-cranial mass documented by MRI.\nHistory of traumatic brain injury or other neurological diseases.\nSerious medical illness other than DLB\nHistory of seizures\nPregnancy\nMetal implants in the head (except dental fillings)\nElectronic implants (i.e. pace-maker, implanted medical pump)\nAge <18 years",
                            "HealthyVolunteers": "No",
                            "Gender": "All",
                            "MinimumAge": "18 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "CentralContactList": {
                                "CentralContact": [
                                    {
                                        "CentralContactName": "Barbara Borroni, MD",
                                        "CentralContactRole": "Contact",
                                        "CentralContactPhone": "+39 030 3995631",
                                        "CentralContactEMail": "bborroni@inwind.it"
                                    },
                                    {
                                        "CentralContactName": "Alberto Benussi, MD",
                                        "CentralContactRole": "Contact",
                                        "CentralContactPhone": "+39 030 3995631",
                                        "CentralContactEMail": "benussialberto@gmail.com"
                                    }
                                ]
                            },
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Barbara Borroni, MD",
                                        "OverallOfficialAffiliation": "ASST Spedali Civili di Brescia",
                                        "OverallOfficialRole": "Principal Investigator"
                                    },
                                    {
                                        "OverallOfficialName": "Alberto Benussi, MD",
                                        "OverallOfficialAffiliation": "ASST Spedali Civili di Brescia",
                                        "OverallOfficialRole": "Principal Investigator"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "ASST Spedali Civili di Brescia",
                                        "LocationStatus": "Recruiting",
                                        "LocationCity": "Brescia",
                                        "LocationState": "BS",
                                        "LocationZip": "25123",
                                        "LocationCountry": "Italy",
                                        "LocationContactList": {
                                            "LocationContact": [
                                                {
                                                    "LocationContactName": "Barbara Borroni, MD",
                                                    "LocationContactRole": "Contact",
                                                    "LocationContactPhone": "+39 030 3995631",
                                                    "LocationContactEMail": "bborroni@inwind.it"
                                                },
                                                {
                                                    "LocationContactName": "Alberto Benussi, MD",
                                                    "LocationContactRole": "Contact",
                                                    "LocationContactPhone": "+39 030 3995631",
                                                    "LocationContactEMail": "benussialberto@gmail.com"
                                                },
                                                {
                                                    "LocationContactName": "Barbara Borroni, MD",
                                                    "LocationContactRole": "Principal Investigator"
                                                },
                                                {
                                                    "LocationContactName": "Alberto Benussi, MD",
                                                    "LocationContactRole": "Principal Investigator"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "ReferencesModule": {
                            "ReferenceList": {
                                "Reference": [
                                    {
                                        "ReferencePMID": "28592453",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, Aarsland D, Galvin J, Attems J, Ballard CG, Bayston A, Beach TG, Blanc F, Bohnen N, Bonanni L, Bras J, Brundin P, Burn D, Chen-Plotkin A, Duda JE, El-Agnaf O, Feldman H, Ferman TJ, Ffytche D, Fujishiro H, Galasko D, Goldman JG, Gomperts SN, Graff-Radford NR, Honig LS, Iranzo A, Kantarci K, Kaufer D, Kukull W, Lee VMY, Leverenz JB, Lewis S, Lippa C, Lunde A, Masellis M, Masliah E, McLean P, Mollenhauer B, Montine TJ, Moreno E, Mori E, Murray M, O'Brien JT, Orimo S, Postuma RB, Ramaswamy S, Ross OA, Salmon DP, Singleton A, Taylor A, Thomas A, Tiraboschi P, Toledo JB, Trojanowski JQ, Tsuang D, Walker Z, Yamada M, Kosaka K. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017 Jul 4;89(1):88-100. doi: 10.1212/WNL.0000000000004058. Epub 2017 Jun 7. Review."
                                    },
                                    {
                                        "ReferencePMID": "32450445",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Franciotti R, Pilotto A, Moretti DV, Falasca NW, Arnaldi D, Taylor JP, Nobili F, Kramberger M, Ptacek SG, Padovani A, Aarlsand D, Onofrj M, Bonanni L; E-DLB consortium. Anterior EEG slowing in dementia with Lewy bodies: a multicenter European cohort study. Neurobiol Aging. 2020 Sep;93:55-60. doi: 10.1016/j.neurobiolaging.2020.04.023. Epub 2020 Apr 29."
                                    },
                                    {
                                        "ReferencePMID": "30654367",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Aoki Y, Kazui H, Pascal-Marqui RD, Ishii R, Yoshiyama K, Kanemoto H, Suzuki Y, Sato S, Hata M, Canuet L, Iwase M, Ikeda M. EEG Resting-State Networks in Dementia with Lewy Bodies Associated with Clinical Symptoms. Neuropsychobiology. 2019;77(4):206-218. doi: 10.1159/000495620. Epub 2019 Jan 17."
                                    },
                                    {
                                        "ReferencePMID": "32321573",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Schumacher J, Thomas AJ, Peraza LR, Firbank M, Cromarty R, Hamilton CA, Donaghy PC, O'Brien JT, Taylor JP. EEG alpha reactivity and cholinergic system integrity in Lewy body dementia and Alzheimer's disease. Alzheimers Res Ther. 2020 Apr 22;12(1):46. doi: 10.1186/s13195-020-00613-6."
                                    },
                                    {
                                        "ReferencePMID": "32641111",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Schumacher J, Taylor JP, Hamilton CA, Firbank M, Cromarty RA, Donaghy PC, Roberts G, Allan L, Lloyd J, Durcan R, Barnett N, O'Brien JT, Thomas AJ. Quantitative EEG as a biomarker in mild cognitive impairment with Lewy bodies. Alzheimers Res Ther. 2020 Jul 8;12(1):82. doi: 10.1186/s13195-020-00650-1."
                                    },
                                    {
                                        "ReferencePMID": "27589528",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Bonanni L, Franciotti R, Nobili F, Kramberger MG, Taylor JP, Garcia-Ptacek S, Falasca NW, Famá F, Cromarty R, Onofrj M, Aarsland D; E-DLB study group. EEG Markers of Dementia with Lewy Bodies: A Multicenter Cohort Study. J Alzheimers Dis. 2016 Oct 18;54(4):1649-1657."
                                    },
                                    {
                                        "ReferencePMID": "33039748",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Pascarelli MT, Del Percio C, De Pandis MF, Ferri R, Lizio R, Noce G, Lopez S, Rizzo M, Soricelli A, Nobili F, Arnaldi D, Famà F, Orzi F, Buttinelli C, Giubilei F, Salvetti M, Cipollini V, Franciotti R, Onofri M, Fuhr P, Gschwandtner U, Ransmayr G, Aarsland D, Parnetti L, Farotti L, Marizzoni M, D'Antonio F, De Lena C, Güntekin B, Hanoğlu L, Yener G, Emek-Savaş DD, Triggiani AI, Paul Taylor J, McKeith I, Stocchi F, Vacca L, Hampel H, Frisoni GB, Bonanni L, Babiloni C. Abnormalities of resting-state EEG in patients with prodromal and overt dementia with Lewy bodies: Relation to clinical symptoms. Clin Neurophysiol. 2020 Nov;131(11):2716-2731. doi: 10.1016/j.clinph.2020.09.004. Epub 2020 Sep 23."
                                    },
                                    {
                                        "ReferencePMID": "26179663",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "van Dellen E, de Waal H, van der Flier WM, Lemstra AW, Slooter AJ, Smits LL, van Straaten EC, Stam CJ, Scheltens P. Loss of EEG Network Efficiency Is Related to Cognitive Impairment in Dementia With Lewy Bodies. Mov Disord. 2015 Nov;30(13):1785-93. doi: 10.1002/mds.26309. Epub 2015 Jul 16."
                                    },
                                    {
                                        "ReferencePMID": "10084544",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Briel RC, McKeith IG, Barker WA, Hewitt Y, Perry RH, Ince PG, Fairbairn AF. EEG findings in dementia with Lewy bodies and Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1999 Mar;66(3):401-3."
                                    },
                                    {
                                        "ReferencePMID": "18202105",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Bonanni L, Thomas A, Tiraboschi P, Perfetti B, Varanese S, Onofrj M. EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. Brain. 2008 Mar;131(Pt 3):690-705. doi: 10.1093/brain/awm322. Epub 2008 Jan 17."
                                    },
                                    {
                                        "ReferencePMID": "32480310",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Massa F, Meli R, Grazzini M, Famà F, De Carli F, Filippi L, Arnaldi D, Pardini M, Morbelli S, Nobili F. Utility of quantitative EEG in early Lewy body disease. Parkinsonism Relat Disord. 2020 Jun;75:70-75. doi: 10.1016/j.parkreldis.2020.05.007. Epub 2020 May 24."
                                    },
                                    {
                                        "ReferencePMID": "27103525",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Dauwan M, van Dellen E, van Boxtel L, van Straaten ECW, de Waal H, Lemstra AW, Gouw AA, van der Flier WM, Scheltens P, Sommer IE, Stam CJ. EEG-directed connectivity from posterior brain regions is decreased in dementia with Lewy bodies: a comparison with Alzheimer's disease and controls. Neurobiol Aging. 2016 May;41:122-129. doi: 10.1016/j.neurobiolaging.2016.02.017. Epub 2016 Feb 21."
                                    },
                                    {
                                        "ReferencePMID": "29407464",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Babiloni C, Del Percio C, Lizio R, Noce G, Lopez S, Soricelli A, Ferri R, Nobili F, Arnaldi D, Famà F, Aarsland D, Orzi F, Buttinelli C, Giubilei F, Onofrj M, Stocchi F, Stirpe P, Fuhr P, Gschwandtner U, Ransmayr G, Garn H, Fraioli L, Pievani M, Frisoni GB, D'Antonio F, De Lena C, Güntekin B, Hanoğlu L, Başar E, Yener G, Emek-Savaş DD, Triggiani AI, Franciotti R, Taylor JP, Vacca L, De Pandis MF, Bonanni L. Abnormalities of resting-state functional cortical connectivity in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study. Neurobiol Aging. 2018 May;65:18-40. doi: 10.1016/j.neurobiolaging.2017.12.023. Epub 2017 Dec 30."
                                    },
                                    {
                                        "ReferencePMID": "28454845",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Babiloni C, Del Percio C, Lizio R, Noce G, Cordone S, Lopez S, Soricelli A, Ferri R, Pascarelli MT, Nobili F, Arnaldi D, Aarsland D, Orzi F, Buttinelli C, Giubilei F, Onofrj M, Stocchi F, Stirpe P, Fuhr P, Gschwandtner U, Ransmayr G, Caravias G, Garn H, Sorpresi F, Pievani M, Frisoni GB, D'Antonio F, De Lena C, Güntekin B, Hanoğlu L, Başar E, Yener G, Emek-Savaş DD, Triggiani AI, Franciotti R, De Pandis MF, Bonanni L. Abnormalities of cortical neural synchronization mechanisms in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study. Neurobiol Aging. 2017 Jul;55:143-158. doi: 10.1016/j.neurobiolaging.2017.03.030. Epub 2017 Apr 5."
                                    },
                                    {
                                        "ReferencePMID": "28928634",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Tavakoli AV, Yun K. Transcranial Alternating Current Stimulation (tACS) Mechanisms and Protocols. Front Cell Neurosci. 2017 Sep 1;11:214. doi: 10.3389/fncel.2017.00214. eCollection 2017. Review."
                                    },
                                    {
                                        "ReferencePMID": "33276533",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Klink K, Paßmann S, Kasten FH, Peter J. The Modulation of Cognitive Performance with Transcranial Alternating Current Stimulation: A Systematic Review of Frequency-Specific Effects. Brain Sci. 2020 Dec 2;10(12). pii: E932. doi: 10.3390/brainsci10120932. Review."
                                    }
                                ]
                            }
                        },
                        "IPDSharingStatementModule": {
                            "IPDSharing": "Yes",
                            "IPDSharingDescription": "All data, including outcome measure results, study protocol and statistical analysis plan, will be shared upon reasonable request.",
                            "IPDSharingInfoTypeList": {
                                "IPDSharingInfoType": [
                                    "Study Protocol",
                                    "Statistical Analysis Plan (SAP)"
                                ]
                            },
                            "IPDSharingTimeFrame": "Data will be shared after the study completion indefinitely.",
                            "IPDSharingAccessCriteria": "Reasonable request"
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000003704",
                                        "ConditionMeshTerm": "Dementia"
                                    },
                                    {
                                        "ConditionMeshId": "D000020961",
                                        "ConditionMeshTerm": "Lewy Body Disease"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000001927",
                                        "ConditionAncestorTerm": "Brain Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000002493",
                                        "ConditionAncestorTerm": "Central Nervous System Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009422",
                                        "ConditionAncestorTerm": "Nervous System Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000019965",
                                        "ConditionAncestorTerm": "Neurocognitive Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000001523",
                                        "ConditionAncestorTerm": "Mental Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000019636",
                                        "ConditionAncestorTerm": "Neurodegenerative Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000020734",
                                        "ConditionAncestorTerm": "Parkinsonian Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000001480",
                                        "ConditionAncestorTerm": "Basal Ganglia Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009069",
                                        "ConditionAncestorTerm": "Movement Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000080874",
                                        "ConditionAncestorTerm": "Synucleinopathies"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M6056",
                                        "ConditionBrowseLeafName": "Dementia",
                                        "ConditionBrowseLeafAsFound": "Dementia",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M21846",
                                        "ConditionBrowseLeafName": "Lewy Body Disease",
                                        "ConditionBrowseLeafAsFound": "Dementia With Lewy Bodies",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M4356",
                                        "ConditionBrowseLeafName": "Brain Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M4894",
                                        "ConditionBrowseLeafName": "Central Nervous System Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M20989",
                                        "ConditionBrowseLeafName": "Neurocognitive Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M3967",
                                        "ConditionBrowseLeafName": "Mental Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M13625",
                                        "ConditionBrowseLeafName": "Psychotic Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M20711",
                                        "ConditionBrowseLeafName": "Neurodegenerative Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M21647",
                                        "ConditionBrowseLeafName": "Parkinsonian Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M24756",
                                        "ConditionBrowseLeafName": "Ganglion Cysts",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M15510",
                                        "ConditionBrowseLeafName": "Synovial Cyst",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M3926",
                                        "ConditionBrowseLeafName": "Basal Ganglia Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M11181",
                                        "ConditionBrowseLeafName": "Movement Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M2217",
                                        "ConditionBrowseLeafName": "Synucleinopathies",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "T4202",
                                        "ConditionBrowseLeafName": "Oculocerebral Syndrome With Hypopigmentation",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC10",
                                        "ConditionBrowseBranchName": "Nervous System Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BXM",
                                        "ConditionBrowseBranchName": "Behaviors and Mental Disorders"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC04",
                                        "ConditionBrowseBranchName": "Neoplasms"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC17",
                                        "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC18",
                                        "ConditionBrowseBranchName": "Nutritional and Metabolic Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "Rare",
                                        "ConditionBrowseBranchName": "Rare Diseases"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 22,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT02221453",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "PersDMEcytokineTA"
                            },
                            "Organization": {
                                "OrgFullName": "Unity Health Toronto",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Cytokine Levels in Patients With Persistent Diabetic Macular Edema Treated With Triamcinolone Acetonide",
                            "OfficialTitle": "Cytokine Levels in Patients With Persistent Diabetic Macular Edema Treated With Triamcinolone Acetonide: an Interventional Prospective Study"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "September 2019",
                            "OverallStatus": "Completed",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "September 2015",
                                "StartDateType": "Actual"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "December 2016",
                                "PrimaryCompletionDateType": "Actual"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "December 2016",
                                "CompletionDateType": "Actual"
                            },
                            "StudyFirstSubmitDate": "August 18, 2014",
                            "StudyFirstSubmitQCDate": "August 18, 2014",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "August 20, 2014",
                                "StudyFirstPostDateType": "Estimate"
                            },
                            "LastUpdateSubmitDate": "September 17, 2019",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "September 19, 2019",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Sponsor"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Unity Health Toronto",
                                "LeadSponsorClass": "OTHER"
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "Diabetic macular edema refers to swelling (fluid accumulation) in the center of the retina. The retina is like the film of a camera and is located in the back of the eye. This condition can develop in diabetics where swelling results from leaking of fluid from the blood vessels of the eye, into the center of the retina, the macula. If left untreated, this can affect central vision. The current standard treatment for diabetic macular edema includes medications injected directly into the eye (intravitreal injections) and laser eye treatment. The drugs that are injected directly into the eye are known as anti-Vascular Endothelial Growth Factor (anti-VEGF) agents which help to reduce the leaking. This includes bevacizumab (Avastin®) and ranibizumab (Lucentis®).\n\nHowever, some patients do not respond well to these anti-VEGF treatments will be given the option of switching to an another class of medications, called steroids. Triamcinolone acetonide is one of these steroids and is also injected directly into the eye. These steroids will help reduce inflammation and possibly as a consequence, reduce swelling in the eye.\n\nThe purpose of this study is to determine what cellular factors affect a patient's treatment response (amount of swelling reduction) following triamcinolone acetonide intravitreal injections for diabetic macular edema."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Diabetic Macular Edema"
                                ]
                            },
                            "KeywordList": {
                                "Keyword": [
                                    "Diabetic Macular Edema",
                                    "Ocular Cytokines",
                                    "Triamcinolone Acetonide"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Phase 2"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "N/A",
                                "DesignInterventionModel": "Single Group Assignment",
                                "DesignPrimaryPurpose": "Basic Science",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "None (Open Label)"
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "3",
                                "EnrollmentType": "Actual"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "Triamcinolone Acetonide Treatment",
                                        "ArmGroupType": "Other",
                                        "ArmGroupDescription": "Triamcinolone Acetonide Injectable Suspension 40 mg/mL intravitreal injection",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: Triamcinolone Acetonide"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "Triamcinolone Acetonide",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Triamcinolone Acetonide Treatment"
                                            ]
                                        },
                                        "InterventionOtherNameList": {
                                            "InterventionOtherName": [
                                                "Triesence"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Change in cytokine levels (picograms per mL) between baseline triamcinolone acetonide injection and 3 months",
                                        "PrimaryOutcomeDescription": "The study involves the measurement of ocular cytokines in the anterior chamber fluid including: EGF, VEGF, PlGF, IL-2, IL-3, IL-6, IL-17, TGF-B2, IL-8, VCAM, TGF-B, MMP-9, MIG, ICAM-1 and MCP-1.",
                                        "PrimaryOutcomeTimeFrame": "3 months after baseline triamcinolone acetonide injection"
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "Change in cytokine levels (picograms per mL) 3 months after 2nd triamcinolone acetonide injection",
                                        "PrimaryOutcomeDescription": "Note that the 2nd triamcinolone acetonide injection occurs 3 months after baseline injection. The study involves the measurement of ocular cytokines in the anterior chamber fluid including: EGF, VEGF, PlGF, IL-2, IL-3, IL-6, IL-17, TGF-B2, IL-8, VCAM, TGF-B, MMP-9, MIG, ICAM-1 and MCP-1.",
                                        "PrimaryOutcomeTimeFrame": "3 months after 2nd triamcinolone acetonide injection"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "Change in ocular cytokine levels (picograms per mL) in relation to change in Early Treatment of Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) in response to steroid treatment",
                                        "SecondaryOutcomeDescription": "The study involves the measurement of ocular cytokines in the anterior chamber fluid including: EGF, VEGF, PlGF, IL-2, IL-3, IL-6, IL-17, TGF-B2, IL-8, VCAM, TGF-B, MMP-9, MIG, ICAM-1 and MCP-1. Change in ETDRS BCVA is in ETDRS letters.",
                                        "SecondaryOutcomeTimeFrame": "3 months after baseline injection"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Change in ocular cytokine levels (picograms per mL) in relation to change in Early Treatment of Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) in response to steroid treatment",
                                        "SecondaryOutcomeDescription": "The study involves the measurement of ocular cytokines in the anterior chamber fluid including: EGF, VEGF, PlGF, IL-2, IL-3, IL-6, IL-17, TGF-B2, IL-8, VCAM, TGF-B, MMP-9, MIG, ICAM-1 and MCP-1. Change in ETDRS BCVA is in ETDRS letters.",
                                        "SecondaryOutcomeTimeFrame": "3 months after 2nd triamcinolone acetonide injection"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Change in ocular cytokine levels (picograms per mL) in relation to change in central macular thickness (CMT) measured in micrometers (um) from optical coherence tomography",
                                        "SecondaryOutcomeDescription": "The study involves the measurement of ocular cytokines in the anterior chamber fluid including: EGF, VEGF, PlGF, IL-2, IL-3, IL-6, IL-17, TGF-B2, IL-8, VCAM, TGF-B, MMP-9, MIG, ICAM-1 and MCP-1. Change in CMT is in micrometers (um).",
                                        "SecondaryOutcomeTimeFrame": "3 months after baseline injection"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Change in ocular cytokine levels (picograms per mL) in relation to change in central macular thickness (CMT) measured in micrometers (um) from optical coherence tomography",
                                        "SecondaryOutcomeDescription": "The study involves the measurement of ocular cytokines in the anterior chamber fluid including: EGF, VEGF, PlGF, IL-2, IL-3, IL-6, IL-17, TGF-B2, IL-8, VCAM, TGF-B, MMP-9, MIG, ICAM-1 and MCP-1. Change in CMT is in micrometers (um).",
                                        "SecondaryOutcomeTimeFrame": "3 months after 2nd triamcinolone acetonide injection"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nPresence of Non Proliferative Diabetic Retinopathy (NDPR) or Proliferative Diabetic Retinopathy as confirmed by IntraVenous Fluorescein Angiography (IVFA)\nPrior treatment with ≥ 6 intravitreal anti-VEGF injections but no treatment in last 4 weeks\nLess than 10% improvement in Central Macular Thickness on OCT scan and less than 1 line improvement in vision from baseline\nLess than 10% reduction in macular volume\nAge 18 years or older\nSubjects with Type I or II diabetes mellitus\nsnellen Acuity 20/40 to 20/400 and its ETDRS equivalent\nAbility to provide signed informed consent\nCapable of complying with study protocol.\n\nExclusion Criteria:\n\nPrevious intraocular injection of steroid medication.\nConcurrent ocular disease (wet Age-Related Macular Degeneration, significant Epiretinal Membrane, vitreomacular traction etc) that would limit visual acuity in the opinion of the treating physician\nProliferative diabetic retinopathy in the study eye or PanRetinal Photocoagulation within the last 12 months\nPoor glycemic control HbA1c >9%\nPrior vitrectomy surgery.\nPrior intraocular surgery within 3 months in study eye\nLaser treatment within 3 months of study eye\nUse of systemic steroids (eg, oral, intravenous, intramuscular, epidural, rectal, or extensive dermal) within 1 month prior to study enrollment.\nKnown history of Intraocular Pressure (IOP) elevation in response to steroid treatment in either eye that resulted in any of the following: a) = 10 mm Hg increase in IOP in response to steroid injection, or b) IOP = 25 mm Hg and required 2 or more anti-glaucoma medications to keep IOP below 21 mm Hg.\nKnown allergies to study drug or fluorescein\nHistory of stroke or acute Myocardial Infarction within 6 months of enrolment\nPatients receiving dialysis for renal failure\nPatients currently on systemic immunosuppression\nPatients with glaucoma\nPatients who are pregnant.\nUnwilling or unable to follow or comply with all study related procedures",
                            "HealthyVolunteers": "No",
                            "Gender": "All",
                            "MinimumAge": "18 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Rajeev Muni, MD MSc FRCSC",
                                        "OverallOfficialAffiliation": "Unity Health Toronto",
                                        "OverallOfficialRole": "Principal Investigator"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "St. Michael's Hospital Eye Clinic",
                                        "LocationCity": "Toronto",
                                        "LocationState": "Ontario",
                                        "LocationZip": "M5C2T2",
                                        "LocationCountry": "Canada"
                                    }
                                ]
                            }
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000008269",
                                        "ConditionMeshTerm": "Macular Edema"
                                    },
                                    {
                                        "ConditionMeshId": "D000004487",
                                        "ConditionMeshTerm": "Edema"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000008268",
                                        "ConditionAncestorTerm": "Macular Degeneration"
                                    },
                                    {
                                        "ConditionAncestorId": "D000012162",
                                        "ConditionAncestorTerm": "Retinal Degeneration"
                                    },
                                    {
                                        "ConditionAncestorId": "D000012164",
                                        "ConditionAncestorTerm": "Retinal Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000005128",
                                        "ConditionAncestorTerm": "Eye Diseases"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M10413",
                                        "ConditionBrowseLeafName": "Macular Edema",
                                        "ConditionBrowseLeafAsFound": "Macular Edema",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M6809",
                                        "ConditionBrowseLeafName": "Edema",
                                        "ConditionBrowseLeafAsFound": "Edema",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M10412",
                                        "ConditionBrowseLeafName": "Macular Degeneration",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M14149",
                                        "ConditionBrowseLeafName": "Retinal Degeneration",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M14151",
                                        "ConditionBrowseLeafName": "Retinal Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M7423",
                                        "ConditionBrowseLeafName": "Eye Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC11",
                                        "ConditionBrowseBranchName": "Eye Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC23",
                                        "ConditionBrowseBranchName": "Symptoms and General Pathology"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionMeshList": {
                                "InterventionMesh": [
                                    {
                                        "InterventionMeshId": "D000014221",
                                        "InterventionMeshTerm": "Triamcinolone"
                                    },
                                    {
                                        "InterventionMeshId": "D000014222",
                                        "InterventionMeshTerm": "Triamcinolone Acetonide"
                                    },
                                    {
                                        "InterventionMeshId": "C000005900",
                                        "InterventionMeshTerm": "Triamcinolone hexacetonide"
                                    },
                                    {
                                        "InterventionMeshId": "C000030262",
                                        "InterventionMeshTerm": "Triamcinolone diacetate"
                                    }
                                ]
                            },
                            "InterventionAncestorList": {
                                "InterventionAncestor": [
                                    {
                                        "InterventionAncestorId": "D000000893",
                                        "InterventionAncestorTerm": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000005938",
                                        "InterventionAncestorTerm": "Glucocorticoids"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006728",
                                        "InterventionAncestorTerm": "Hormones"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006730",
                                        "InterventionAncestorTerm": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045505",
                                        "InterventionAncestorTerm": "Physiological Effects of Drugs"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007166",
                                        "InterventionAncestorTerm": "Immunosuppressive Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007155",
                                        "InterventionAncestorTerm": "Immunologic Factors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000004791",
                                        "InterventionAncestorTerm": "Enzyme Inhibitors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045504",
                                        "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                                    }
                                ]
                            },
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafAsFound": "Deep",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M3369",
                                        "InterventionBrowseLeafName": "Anti-Inflammatory Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8199",
                                        "InterventionBrowseLeafName": "Glucocorticoids",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8941",
                                        "InterventionBrowseLeafName": "Hormones",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8940",
                                        "InterventionBrowseLeafName": "Hormone Antagonists",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9364",
                                        "InterventionBrowseLeafName": "Immunosuppressive Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9353",
                                        "InterventionBrowseLeafName": "Immunologic Factors",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 23,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT00667628",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "TAC101-203"
                            },
                            "Organization": {
                                "OrgFullName": "Taiho Oncology, Inc.",
                                "OrgClass": "INDUSTRY"
                            },
                            "BriefTitle": "Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular Carcinoma",
                            "OfficialTitle": "A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of TAC-101 in Combination With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Japanese Patients With Advanced Hepatocellular Carcinoma"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "April 2022",
                            "OverallStatus": "Terminated",
                            "WhyStopped": "Terminated due to safety concerns.",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "April 24, 2008",
                                "StartDateType": "Actual"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "December 22, 2009",
                                "PrimaryCompletionDateType": "Actual"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "December 22, 2009",
                                "CompletionDateType": "Actual"
                            },
                            "StudyFirstSubmitDate": "April 24, 2008",
                            "StudyFirstSubmitQCDate": "April 25, 2008",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "April 28, 2008",
                                "StudyFirstPostDateType": "Estimate"
                            },
                            "ResultsFirstSubmitDate": "December 8, 2021",
                            "ResultsFirstSubmitQCDate": "April 14, 2022",
                            "ResultsFirstPostDateStruct": {
                                "ResultsFirstPostDate": "April 15, 2022",
                                "ResultsFirstPostDateType": "Actual"
                            },
                            "DispFirstSubmitDate": "June 4, 2013",
                            "DispFirstSubmitQCDate": "June 4, 2013",
                            "DispFirstPostDateStruct": {
                                "DispFirstPostDate": "June 12, 2013",
                                "DispFirstPostDateType": "Estimate"
                            },
                            "LastUpdateSubmitDate": "April 14, 2022",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "April 15, 2022",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Sponsor"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Taiho Oncology, Inc.",
                                "LeadSponsorClass": "INDUSTRY"
                            },
                            "CollaboratorList": {
                                "Collaborator": [
                                    {
                                        "CollaboratorName": "Quintiles, Inc.",
                                        "CollaboratorClass": "INDUSTRY"
                                    }
                                ]
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "The purpose of this study is to determine whether TAC-101 combined with Transcatheter Arterial Chemoembolization (TACE) is more effective than TACE alone in slowing tumor activity in patients with advanced hepatocellular carcinoma. The study is also looking at the safety of TAC-101 in combination with TACE.",
                            "DetailedDescription": "Advanced metastatic hepatocellular carcinoma (HCC) is not treatable by surgical approaches or locoregional therapies such as hepatic artery hemoembolization or radiofrequency ablation (RFA) which are effective in controlling localized tumors. Transcatheter arterial chemoembolization (TACE) is the most commonly performed procedure in the treatment of unresectable liver tumors for selected patients. The TACE procedure delivers highly concentrated drugs to the tumor itself and arrests blood flow. Most patients will have intrahepatic recurrence of their tumors following TACE. Studies of TAC-101, a synthetic retinoid, indicate that although TAC-101 may not induce tumor regression, it appears to have a stabilizing effect, prolonging survival over what was expected historically. This study is designed as a randomized, double-blind, placebo-controlled, parallel-group, phase 2 study in patients with advanced HCC who have undergone a TACE procedure, which will be conducted at multiple sites in Japan, to determine if administration of TAC-101 will enhance the benefits of the TACE procedure."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Advanced Hepatocellular Carcinoma"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Phase 2"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "Randomized",
                                "DesignInterventionModel": "Parallel Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "Double",
                                    "DesignWhoMaskedList": {
                                        "DesignWhoMasked": [
                                            "Participant",
                                            "Investigator"
                                        ]
                                    }
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "54",
                                "EnrollmentType": "Actual"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "Placebo",
                                        "ArmGroupType": "Placebo Comparator",
                                        "ArmGroupDescription": "Participants were administered with placebo tablets matching to TAC-101 orally, every day on the first 14 days (Days 1 to 14) followed by a 7-day (Days 15 to 21) treatment recovery period. Repeated every 21 days cycle up to new lesions were observed or the participant met a treatment discontinuation criterion.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: Placebo"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "TAC-101",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "Participants were administered with TAC-101 tablets, 20 milligram per day (mg/day) orally for every day on the first 14 days (Days 1 to 14) followed by a 7-day (Days 15 to 21) recovery period (21-day Cycle). Repeated every 21 days cycle up to new lesions were observed or the participant met a treatment discontinuation criterion.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: TAC-101"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "TAC-101",
                                        "InterventionDescription": "Participants received TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "TAC-101"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "Placebo",
                                        "InterventionDescription": "Participants received placebo (two matching tablets) at same frequency and duration of active treatment.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Placebo"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Time to Appearance of New Lesions (TTNL)",
                                        "PrimaryOutcomeDescription": "TTNL was defined as the time from the date of randomization to the date of appearance of a new lesion. Participants who had no appearance of new lesions had their TTNL censored at the date of their last tumor assessment.",
                                        "PrimaryOutcomeTimeFrame": "From randomization (within 14 days prior to first TACE) assessed every 9 weeks after first TACE to date of appearance of a new lesion or until cut-off date (22-Dec-2009) (up to approximately 20 months)"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "Overall Survival (OS)",
                                        "SecondaryOutcomeDescription": "OS was defined as the time from date of randomization to date of death. Participants who were still alive at the time of analysis had their survival time censored at the last date known to be alive.",
                                        "SecondaryOutcomeTimeFrame": "From randomization (within 14 days prior to first TACE) assessed every 9 weeks after first TACE until cut-off date of 22 Dec 2009 (up to approximately 20 months)"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Progression-Free Survival (PFS)",
                                        "SecondaryOutcomeDescription": "PFS was defined as the time from date of randomization to the date of disease progression (radiological, only).",
                                        "SecondaryOutcomeTimeFrame": "From randomization (within 14 days prior to first TACE) assessed every 9 weeks after first TACE until cut-off date of 22 Dec 2009 (up to approximately 20 months)"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Objective Tumor Response Rate (ORR)",
                                        "SecondaryOutcomeDescription": "ORR was defined as the percentage of participants with objective evidence of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to less than (<)10 millimeters (mm). PR was defined as at least a 30 percent decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters.",
                                        "SecondaryOutcomeTimeFrame": "From randomization (within 14 days prior to first TACE) assessed every 9 weeks after first TACE until cut-off date of 22 Dec 2009 (up to approximately 20 months)"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Change From Baseline in Plasma Levels of Tumor Marker Alpha-fetoprotein (AFP)",
                                        "SecondaryOutcomeDescription": "AFP was known as a tumor marker for advanced hepatocellular carcinoma (HCC) and was recognized as useful for following the course of HCC. Changes in serum AFP parallel the clinical course of HCC, where elevations can precede clinical deterioration and tumor recurrence.",
                                        "SecondaryOutcomeTimeFrame": "Baseline, End of treatment (last dose of study medication, i.e., approximately 7 months)"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)",
                                        "SecondaryOutcomeDescription": "Any untoward medical condition that occurs in a participants while participating in a clinical study and does not necessarily have a causal relationship with the use of the study drug was considered an adverse event (AE). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs: AEs that occur from the initiation of any study treatment administration, and do not necessarily have a causal relationship to the use of the study drug.",
                                        "SecondaryOutcomeTimeFrame": "From first dose of study drug up to 30 days after last dose of study drug or until the start of new anti-tumor therapy, whichever was earlier (up to approximately 8.5 months)"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\n- A patient must meet all of the following inclusion criteria to be eligible for enrollment in this study and before undergoing the first TACE procedure of this study:\n\nHas an HCC diagnosis by histology or by the following non-invasive criteria observed either at enrollment or in the past.\n\nOne imaging technique (CT scan or magnetic resonance imaging [MRI] both with unenhanced plus hepatic arterial phase and portal venous phases) showing characteristic features in a focal lesion > 20 mm with arterial vascularization.\nTwo dynamic imaging techniques (CT scan, MRI with unenhanced plus hepatic arterial phase and portal venous phases) showing characteristic features coincidentally in a focal lesion 10-20 mm with arterial vascularization.\nIs TACE naïve or has received the most recent TACE procedure at least 120 days before signing ICF.\nEligible to receive TACE and being scheduled to receive TACE.\nMust be ≥ 20 years of age.\nIs not amenable to treatment with curative surgery, transplant, or percutaneous ablation, including RFA, percutaneous ethanol injection therapy (PEIT) and percutaneous microwave coagulation therapy (PMCT).\n\nMust have lesions in the liver that are confirmed nodular type with demonstrated substantial hypervascularity by CT scan or MRI both with unenhanced plus hepatic arterial phase and portal venous phases performed prior to first TACE in this study with the following tumor features:\n\nIf there are ≥ 4 intrahepatic lesions, all lesions can be < 30 mm. or, regardless of the number of lesions, the longest diameter of at least one intrahepatic lesion is ≥ 30 mm).\nNo vascular invasion in main trunk and first order branch of portal vein.\nNo extrahepatic tumor spread. The absence of extrahepatic abdominal tumors must be confirmed.\nHas adequate organ function as defined by the following criteria: White blood cell (WBC) count > 3,000/mm3; Platelet count > 60,000/mm3; Hemoglobin > 8.0 grams (g)/deciliter (dL); Aspartate transaminase (AST) < 5 x upper limit of normal (ULN); Alanine transaminase (ALT) < 5 x ULN; Total bilirubin < 2.0 mg/dL; Albumin ≥ 2.8 g/dL; Serum creatinine ≤ 1.5 mg/dL; International normalized ratio (INR) ≤ 2.0; Triglyceride ≤ 2.5 x ULN.\nMust have a Child-Pugh classification of ≤ 8.\nMust have a Cancer of the Liver Italian Program (CLIP)60 score of 0, 1, 2 or 3 (Appendix B).\nMust have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\nMust be willing and able to comply with schedule visits, treatment plans, laboratory tests, and other study procedures.\nMust provide written informed consent prior to the implementation of any study assessment or procedures.\n\nExclusion Criteria:\n\nPatients will be excluded from participation in the study if any of the following conditions are observed before undergoing the first TACE procedure:\n\nPatient has longest diameter of intrahepatic lesion ≥ 100 mm.\nPatient has only infiltration type of HCC.\nPatient has extrahepatic metastasis of HCC including regional lymph node metastases (including in lymph nodes and organs).\nPatient had systemic chemotherapy (eg, sorafenib, doxorubicin), immunotherapy, or biologic therapy or radiotherapy for HCC, or treatment with TAC-101.\nPatient received treatment with any of the following within the specified time frame: Any major surgical procedure within 28 days prior to signing the ICF; Any transfusion, treatment with blood component preparation, albumin preparation, and granulocyte colony stimulating factor (G-CSF) within 14 days prior to signing the ICF; Any local therapy such as alcohol injection, radiofrequency/ultrasound ablation, intraarterial chemotherapy (transcatheter arterial injection) for HCC performed within 28 days prior to signing the ICF; Any investigational agent within 28 days prior to signing the ICF.\nPatient has ascites, pleural effusions or pericardial fluid refractory to diuretic therapy.\nPatient has clinical symptoms of hepatic encephalopathy.\nPatient has active or uncontrolled clinically serious infection excluding chronic hepatitis.\nPatient has a history of gastrointestinal (GI) bleeding in last 3 months.\nPatient has previous or concurrent malignancy except for in situ carcinoma of the cervix, or other solid tumor treated curatively and without evidence of recurrence for at least 3 years prior to the study.\nPatient has uncontrolled metabolic disorders or other nonmalignant organ or systemic diseases or secondary effects of cancer that induce a high medical risk and/or make assessment of survival uncertain.\nPatient has any history of deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction (MI), cerebrovascular accident (CVA), transient ischemic attack (TIA), unstable angina pectoris, or any other significant thromboembolic event (TE) during the last 3 years.\nPatient has clinically significant electrocardiogram (ECG) abnormality.\nPatient has GI disease resulting in an inability to take oral medication.\nPatient has known allergy or hypersensitivity to TAC-101, doxorubicin, epirubicin, other anthracyclines, anthracenediones or any of the components used in the study drug formulations.\nPatient has known hypersensitivity to iodinated contrast medium.\nPatient is receiving therapeutic regimens of anticoagulants. However, use of low dose anticoagulants for prophylactic care of indwelling venous access device is permitted.\nPatient is taking medication known or suspected to predispose patient to an increased risk of VTE (eg, oral contraceptives, hormone replacement therapy, megestrol acetate).\nPatient is taking azoles or tetracyclines, because of the potential for drug interactions.\nWomen who intend to become pregnant or are pregnant or lactating and men able to procreate that refuse to use a highly effective method of birth control during treatment with study medication and up to 6 months thereafter.",
                            "HealthyVolunteers": "No",
                            "MinimumAge": "20 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Taiho Central, MD",
                                        "OverallOfficialAffiliation": "Taiho Oncology, Inc.",
                                        "OverallOfficialRole": "Study Director"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "Aichi Cancer Center Hospital",
                                        "LocationCity": "Nagoya",
                                        "LocationState": "Aichi",
                                        "LocationZip": "464-8681",
                                        "LocationCountry": "Japan"
                                    },
                                    {
                                        "LocationFacility": "National hospital organization Shikoku Cancer Center",
                                        "LocationCity": "Matsuyama",
                                        "LocationState": "Ehime",
                                        "LocationZip": "791-0280",
                                        "LocationCountry": "Japan"
                                    },
                                    {
                                        "LocationFacility": "Fukuoka University Hospital",
                                        "LocationCity": "Jonan-ku",
                                        "LocationState": "Fukuoka",
                                        "LocationZip": "814-0180",
                                        "LocationCountry": "Japan"
                                    },
                                    {
                                        "LocationFacility": "Kurume University Hospital",
                                        "LocationCity": "Kurume",
                                        "LocationState": "Fukuoka",
                                        "LocationZip": "831-0011",
                                        "LocationCountry": "Japan"
                                    },
                                    {
                                        "LocationFacility": "Ogaki Municipal Hospital",
                                        "LocationCity": "Oogaki",
                                        "LocationState": "Gifu",
                                        "LocationZip": "503-8502",
                                        "LocationCountry": "Japan"
                                    },
                                    {
                                        "LocationFacility": "Fukuyama City Hospital",
                                        "LocationCity": "Fukuyama",
                                        "LocationState": "Hiroshima",
                                        "LocationZip": "721-8511",
                                        "LocationCountry": "Japan"
                                    },
                                    {
                                        "LocationFacility": "Asahikawa-Kosei General Hospital",
                                        "LocationCity": "Asahikawa",
                                        "LocationState": "Hokkaido",
                                        "LocationZip": "078-8211",
                                        "LocationCountry": "Japan"
                                    },
                                    {
                                        "LocationFacility": "Hokkaido University Hospital",
                                        "LocationCity": "Sapporo",
                                        "LocationState": "Hokkaido",
                                        "LocationZip": "060-8648",
                                        "LocationCountry": "Japan"
                                    },
                                    {
                                        "LocationFacility": "The Hospital of Hyogo College of Medicine",
                                        "LocationCity": "Hishinomiya",
                                        "LocationState": "Hyogo",
                                        "LocationZip": "663-8501",
                                        "LocationCountry": "Japan"
                                    },
                                    {
                                        "LocationFacility": "Kanazawa University Hospital",
                                        "LocationCity": "Kanazawa",
                                        "LocationState": "Ishikawa",
                                        "LocationZip": "920-8641",
                                        "LocationCountry": "Japan"
                                    },
                                    {
                                        "LocationFacility": "Iwate Medical University Hospital",
                                        "LocationCity": "Morioka",
                                        "LocationState": "Iwate",
                                        "LocationZip": "020-8505",
                                        "LocationCountry": "Japan"
                                    },
                                    {
                                        "LocationFacility": "Yokohama City University Medical Center",
                                        "LocationCity": "Yokohama",
                                        "LocationState": "Kanagawa",
                                        "LocationZip": "232-0024",
                                        "LocationCountry": "Japan"
                                    },
                                    {
                                        "LocationFacility": "Mie University Hospital",
                                        "LocationCity": "Tsu",
                                        "LocationState": "Mie",
                                        "LocationZip": "514-8507",
                                        "LocationCountry": "Japan"
                                    },
                                    {
                                        "LocationFacility": "Nara Medical University Hospital",
                                        "LocationCity": "Kashihara",
                                        "LocationState": "Nara",
                                        "LocationZip": "634-8522",
                                        "LocationCountry": "Japan"
                                    },
                                    {
                                        "LocationFacility": "Okayama University Hospital",
                                        "LocationCity": "Shikata-cho",
                                        "LocationState": "Okayama",
                                        "LocationZip": "700-8558",
                                        "LocationCountry": "Japan"
                                    },
                                    {
                                        "LocationFacility": "Osaka City University Hospital",
                                        "LocationCity": "Abeno-ku",
                                        "LocationState": "Osaka",
                                        "LocationZip": "545-8586",
                                        "LocationCountry": "Japan"
                                    },
                                    {
                                        "LocationFacility": "Osaka medical Center for Cancer and Cardiovascular Diseases",
                                        "LocationCity": "Higashinari-ku",
                                        "LocationState": "Osaka",
                                        "LocationZip": "537-8511",
                                        "LocationCountry": "Japan"
                                    },
                                    {
                                        "LocationFacility": "Osaka City General Hospital",
                                        "LocationCity": "Miyakojima-ku",
                                        "LocationState": "Osaka",
                                        "LocationZip": "534-0021",
                                        "LocationCountry": "Japan"
                                    },
                                    {
                                        "LocationFacility": "Kansai Medical Univesity Takii Hospital",
                                        "LocationCity": "Moriguchi",
                                        "LocationState": "Osaka",
                                        "LocationZip": "570-8507",
                                        "LocationCountry": "Japan"
                                    },
                                    {
                                        "LocationFacility": "Kinki University Hospital",
                                        "LocationCity": "Osaka-sayama",
                                        "LocationState": "Osaka",
                                        "LocationZip": "589-8511",
                                        "LocationCountry": "Japan"
                                    },
                                    {
                                        "LocationFacility": "Osaka Red Cross Hospital",
                                        "LocationCity": "Tennoji-ku",
                                        "LocationState": "Osaka",
                                        "LocationZip": "543-8555",
                                        "LocationCountry": "Japan"
                                    },
                                    {
                                        "LocationFacility": "Shizuoka Cancer Center Hospital",
                                        "LocationCity": "Sunto-gun",
                                        "LocationState": "Shizuoka",
                                        "LocationZip": "411-8777",
                                        "LocationCountry": "Japan"
                                    },
                                    {
                                        "LocationFacility": "The University of Tokyo Hospital",
                                        "LocationCity": "Bunkyo-ku",
                                        "LocationState": "Tokyo",
                                        "LocationZip": "113-8655",
                                        "LocationCountry": "Japan"
                                    },
                                    {
                                        "LocationFacility": "Tochigi Cancer Center",
                                        "LocationCity": "Chiyoda-ku",
                                        "LocationState": "Tokyo",
                                        "LocationZip": "101-0047",
                                        "LocationCountry": "Japan"
                                    },
                                    {
                                        "LocationFacility": "Kyoundo Hospital",
                                        "LocationCity": "Chiyoda",
                                        "LocationState": "Tokyo",
                                        "LocationZip": "101-0062",
                                        "LocationCountry": "Japan"
                                    },
                                    {
                                        "LocationFacility": "National Cancer Center Hospital",
                                        "LocationCity": "Chuo-ku",
                                        "LocationState": "Tokyo",
                                        "LocationZip": "104-0045",
                                        "LocationCountry": "Japan"
                                    },
                                    {
                                        "LocationFacility": "Wakayama Medical University Hospital",
                                        "LocationCity": "Kimidera",
                                        "LocationState": "Wakayama",
                                        "LocationZip": "641-8510",
                                        "LocationCountry": "Japan"
                                    },
                                    {
                                        "LocationFacility": "Kochi Health Science Center",
                                        "LocationCity": "Kochi",
                                        "LocationZip": "781-8555",
                                        "LocationCountry": "Japan"
                                    },
                                    {
                                        "LocationFacility": "Kumamoto University Hospital",
                                        "LocationCity": "Kumamoto",
                                        "LocationZip": "860-8556",
                                        "LocationCountry": "Japan"
                                    }
                                ]
                            }
                        }
                    },
                    "ResultsSection": {
                        "ParticipantFlowModule": {
                            "FlowPreAssignmentDetails": "Randomization was balanced between treatment arms according to the stratification factors of number of lesions (less than [<] 5 versus greater than equal to [>=] 5) and baseline alpha-fetoprotein (AFP) level (<400 nanograms per milliliters [ng/mL] versus >=400 ng/mL).",
                            "FlowRecruitmentDetails": "A total of 67 participants were screened, of which 54 participants received the first transcatheter arterial chemoembolization (TACE) prior to randomization. Two participants discontinued prior to randomization due to adverse event and thus, a total of 52 participants were randomized in the study and received study drug in the double-blind period. The study was prematurely terminated by the Sponsor due to safety concerns.",
                            "FlowGroupList": {
                                "FlowGroup": [
                                    {
                                        "FlowGroupId": "FG000",
                                        "FlowGroupTitle": "Placebo",
                                        "FlowGroupDescription": "Participants were administered with placebo tablets matching to TAC-101 orally, every day on the first 14 days (Days 1 to 14) followed by a 7-day (Days 15 to 21) treatment recovery period (21-day Cycle). Repeated every 21 days up to new lesions were observed or the participant met a treatment discontinuation criterion."
                                    },
                                    {
                                        "FlowGroupId": "FG001",
                                        "FlowGroupTitle": "TAC-101",
                                        "FlowGroupDescription": "Participants were administered with TAC-101 tablets, 20 milligrams per day (mg/day) orally for every day on the first 14 days (Days 1 to 14) followed by a 7-day (Days 15 to 21) recovery period (21-day Cycle). Repeated every 21 days up to new lesions were observed or the participant met a treatment discontinuation criterion."
                                    }
                                ]
                            },
                            "FlowPeriodList": {
                                "FlowPeriod": [
                                    {
                                        "FlowPeriodTitle": "Overall Study",
                                        "FlowMilestoneList": {
                                            "FlowMilestone": [
                                                {
                                                    "FlowMilestoneType": "STARTED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "25"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG001",
                                                                "FlowAchievementNumSubjects": "27"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowMilestoneType": "COMPLETED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "0"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG001",
                                                                "FlowAchievementNumSubjects": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowMilestoneType": "NOT COMPLETED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "25"
                                                            },
                                                            {
                                                                "FlowAchievementGroupId": "FG001",
                                                                "FlowAchievementNumSubjects": "27"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "FlowDropWithdrawList": {
                                            "FlowDropWithdraw": [
                                                {
                                                    "FlowDropWithdrawType": "Lost to Follow-up",
                                                    "FlowReasonList": {
                                                        "FlowReason": [
                                                            {
                                                                "FlowReasonGroupId": "FG000",
                                                                "FlowReasonNumSubjects": "1"
                                                            },
                                                            {
                                                                "FlowReasonGroupId": "FG001",
                                                                "FlowReasonNumSubjects": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowDropWithdrawType": "Death",
                                                    "FlowReasonList": {
                                                        "FlowReason": [
                                                            {
                                                                "FlowReasonGroupId": "FG000",
                                                                "FlowReasonNumSubjects": "6"
                                                            },
                                                            {
                                                                "FlowReasonGroupId": "FG001",
                                                                "FlowReasonNumSubjects": "6"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowDropWithdrawType": "Investigator Considers in Best Interest",
                                                    "FlowReasonList": {
                                                        "FlowReason": [
                                                            {
                                                                "FlowReasonGroupId": "FG000",
                                                                "FlowReasonNumSubjects": "1"
                                                            },
                                                            {
                                                                "FlowReasonGroupId": "FG001",
                                                                "FlowReasonNumSubjects": "0"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowDropWithdrawType": "Sponsor Terminated Study",
                                                    "FlowReasonList": {
                                                        "FlowReason": [
                                                            {
                                                                "FlowReasonGroupId": "FG000",
                                                                "FlowReasonNumSubjects": "17"
                                                            },
                                                            {
                                                                "FlowReasonGroupId": "FG001",
                                                                "FlowReasonNumSubjects": "21"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "BaselineCharacteristicsModule": {
                            "BaselinePopulationDescription": "Safety population included all participants who underwent a first combination with transcatheter arterial chemoembolization (TACE) procedure prior to randomization in this study, who were randomized and received at least one dose of double-blind medication.",
                            "BaselineGroupList": {
                                "BaselineGroup": [
                                    {
                                        "BaselineGroupId": "BG000",
                                        "BaselineGroupTitle": "Placebo",
                                        "BaselineGroupDescription": "Participants were administered with placebo tablets matching to TAC-101 orally, every day on the first 14 days (Days 1 to 14) followed by a 7-day (Days 15 to 21) treatment recovery period. Repeated every 21 days cycle up to new lesions were observed or the participant met a treatment discontinuation criterion."
                                    },
                                    {
                                        "BaselineGroupId": "BG001",
                                        "BaselineGroupTitle": "TAC-101",
                                        "BaselineGroupDescription": "Participants were administered with TAC-101 tablets, 20 mg/day orally for every day on the first 14 days (Days 1 to 14) followed by a 7-day (Days 15 to 21) recovery period (21-day Cycle). Repeated every 21 days cycle up to new lesions were observed or the participant met a treatment discontinuation criterion."
                                    },
                                    {
                                        "BaselineGroupId": "BG002",
                                        "BaselineGroupTitle": "Total",
                                        "BaselineGroupDescription": "Total of all reporting groups"
                                    }
                                ]
                            },
                            "BaselineDenomList": {
                                "BaselineDenom": [
                                    {
                                        "BaselineDenomUnits": "Participants",
                                        "BaselineDenomCountList": {
                                            "BaselineDenomCount": [
                                                {
                                                    "BaselineDenomCountGroupId": "BG000",
                                                    "BaselineDenomCountValue": "25"
                                                },
                                                {
                                                    "BaselineDenomCountGroupId": "BG001",
                                                    "BaselineDenomCountValue": "27"
                                                },
                                                {
                                                    "BaselineDenomCountGroupId": "BG002",
                                                    "BaselineDenomCountValue": "52"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "BaselineMeasureList": {
                                "BaselineMeasure": [
                                    {
                                        "BaselineMeasureTitle": "Age, Continuous",
                                        "BaselineMeasureParamType": "Mean",
                                        "BaselineMeasureDispersionType": "Standard Deviation",
                                        "BaselineMeasureUnitOfMeasure": "years",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "68.6",
                                                                            "BaselineMeasurementSpread": "9.77"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "69.4",
                                                                            "BaselineMeasurementSpread": "8.31"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "69.1",
                                                                            "BaselineMeasurementSpread": "8.96"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Sex: Female, Male",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineCategoryTitle": "Female",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "3"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "4"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "7"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Male",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "22"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "23"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "45"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Race (NIH/OMB)",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineCategoryTitle": "American Indian or Alaska Native",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Asian",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "25"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "27"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "52"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Native Hawaiian or Other Pacific Islander",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Black or African American",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "White",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "More than one race",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Unknown or Not Reported",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG001",
                                                                            "BaselineMeasurementValue": "0"
                                                                        },
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG002",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomeMeasuresModule": {
                            "OutcomeMeasureList": {
                                "OutcomeMeasure": [
                                    {
                                        "OutcomeMeasureType": "Primary",
                                        "OutcomeMeasureTitle": "Time to Appearance of New Lesions (TTNL)",
                                        "OutcomeMeasureDescription": "TTNL was defined as the time from the date of randomization to the date of appearance of a new lesion. Participants who had no appearance of new lesions had their TTNL censored at the date of their last tumor assessment.",
                                        "OutcomeMeasurePopulationDescription": "Safety population included all participants who underwent a first combination with TACE procedure prior to randomization in this study, who were randomized and who received at least one dose of double-blind medication. Here, overall number of participants analyzed' signifies participants with available data for the outcome measure.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Mean",
                                        "OutcomeMeasureDispersionType": "Standard Deviation",
                                        "OutcomeMeasureUnitOfMeasure": "months",
                                        "OutcomeMeasureTimeFrame": "From randomization (within 14 days prior to first TACE) assessed every 9 weeks after first TACE to date of appearance of a new lesion or until cut-off date (22-Dec-2009) (up to approximately 20 months)",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "Placebo",
                                                    "OutcomeGroupDescription": "Participants were administered with placebo tablets matching to TAC-101 orally, every day on the first 14 days (Days 1 to 14) followed by a 7-day (Days 15 to 21) treatment recovery period (21-day Cycle). Repeated every 21 days up to new lesions were observed or the participant met a treatment discontinuation criterion."
                                                },
                                                {
                                                    "OutcomeGroupId": "OG001",
                                                    "OutcomeGroupTitle": "TAC-101",
                                                    "OutcomeGroupDescription": "Participants were administered with TAC-101 tablets, 20 mg/day orally for every day on the first 14 days (Days 1 to 14) followed by a 7-day (Days 15 to 21) recovery period (21-day Cycle). Repeated every 21 days up to new lesions were observed or the participant met a treatment discontinuation criterion."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "24"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG001",
                                                                "OutcomeDenomCountValue": "26"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "8.4",
                                                                            "OutcomeMeasurementSpread": "4.00"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "7.0",
                                                                            "OutcomeMeasurementSpread": "4.07"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Secondary",
                                        "OutcomeMeasureTitle": "Overall Survival (OS)",
                                        "OutcomeMeasureDescription": "OS was defined as the time from date of randomization to date of death. Participants who were still alive at the time of analysis had their survival time censored at the last date known to be alive.",
                                        "OutcomeMeasurePopulationDescription": "Safety population included all participants who underwent a first combination with TACE procedure prior to randomization in this study, who were randomized and who received at least one dose of double-blind medication.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Mean",
                                        "OutcomeMeasureDispersionType": "Standard Deviation",
                                        "OutcomeMeasureUnitOfMeasure": "months",
                                        "OutcomeMeasureTimeFrame": "From randomization (within 14 days prior to first TACE) assessed every 9 weeks after first TACE until cut-off date of 22 Dec 2009 (up to approximately 20 months)",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "Placebo",
                                                    "OutcomeGroupDescription": "Participants were administered with placebo tablets matching to TAC-101 orally, every day on the first 14 days (Days 1 to 14) followed by a 7-day (Days 15 to 21) treatment recovery period (21-day Cycle). Repeated every 21 days up to new lesions were observed or the participant met a treatment discontinuation criterion."
                                                },
                                                {
                                                    "OutcomeGroupId": "OG001",
                                                    "OutcomeGroupTitle": "TAC-101",
                                                    "OutcomeGroupDescription": "Participants were administered with TAC-101 tablets, 20 mg/day orally for every day on the first 14 days (Days 1 to 14) followed by a 7-day (Days 15 to 21) recovery period (21-day Cycle). Repeated every 21 days up to new lesions were observed or the participant met a treatment discontinuation criterion."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "25"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG001",
                                                                "OutcomeDenomCountValue": "27"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "13.9",
                                                                            "OutcomeMeasurementSpread": "2.87"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "13.2",
                                                                            "OutcomeMeasurementSpread": "4.18"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Secondary",
                                        "OutcomeMeasureTitle": "Progression-Free Survival (PFS)",
                                        "OutcomeMeasureDescription": "PFS was defined as the time from date of randomization to the date of disease progression (radiological, only).",
                                        "OutcomeMeasurePopulationDescription": "The safety population was planned, with an independent review of tumor response. However, the independent reviews were deferred. Hence, the data was not collected and not evaluated.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureTimeFrame": "From randomization (within 14 days prior to first TACE) assessed every 9 weeks after first TACE until cut-off date of 22 Dec 2009 (up to approximately 20 months)",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "Placebo",
                                                    "OutcomeGroupDescription": "Participants were administered with placebo tablets matching to TAC-101 orally, every day on the first 14 days (Days 1 to 14) followed by a 7-day (Days 15 to 21) treatment recovery period (21-day Cycle). Repeated every 21 days up to new lesions were observed or the participant met a treatment discontinuation criterion."
                                                },
                                                {
                                                    "OutcomeGroupId": "OG001",
                                                    "OutcomeGroupTitle": "TAC-101",
                                                    "OutcomeGroupDescription": "Participants were administered with TAC-101 tablets, 20 mg/day orally for every day on the first 14 days (Days 1 to 14) followed by a 7-day (Days 15 to 21) recovery period (21-day Cycle). Repeated every 21 days up to new lesions were observed or the participant met a treatment discontinuation criterion."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "0"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG001",
                                                                "OutcomeDenomCountValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Secondary",
                                        "OutcomeMeasureTitle": "Objective Tumor Response Rate (ORR)",
                                        "OutcomeMeasureDescription": "ORR was defined as the percentage of participants with objective evidence of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR was defined as the disappearance of all target lesions. Any pathological lymph nodes must have reduction in short axis to less than (<)10 millimeters (mm). PR was defined as at least a 30 percent decrease in the sum of diameters of the target lesions, taking as a reference the baseline sum diameters.",
                                        "OutcomeMeasurePopulationDescription": "The safety population was planned, with an independent review of tumor response. However, the independent reviews were deferred. Hence, the data were not collected and not evaluated.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureTimeFrame": "From randomization (within 14 days prior to first TACE) assessed every 9 weeks after first TACE until cut-off date of 22 Dec 2009 (up to approximately 20 months)",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "Placebo",
                                                    "OutcomeGroupDescription": "Participants were administered with placebo tablets matching to TAC-101 orally, every day on the first 14 days (Days 1 to 14) followed by a 7-day (Days 15 to 21) treatment recovery period (21-day Cycle). Repeated every 21 days up to new lesions were observed or the participant met a treatment discontinuation criterion."
                                                },
                                                {
                                                    "OutcomeGroupId": "OG001",
                                                    "OutcomeGroupTitle": "TAC-101",
                                                    "OutcomeGroupDescription": "Participants were administered with TAC-101 tablets, 20 mg/day orally for every day on the first 14 days (Days 1 to 14) followed by a 7-day (Days 15 to 21) recovery period (21-day Cycle). Repeated every 21 days up to new lesions were observed or the participant met a treatment discontinuation criterion."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "0"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG001",
                                                                "OutcomeDenomCountValue": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Secondary",
                                        "OutcomeMeasureTitle": "Change From Baseline in Plasma Levels of Tumor Marker Alpha-fetoprotein (AFP)",
                                        "OutcomeMeasureDescription": "AFP was known as a tumor marker for advanced hepatocellular carcinoma (HCC) and was recognized as useful for following the course of HCC. Changes in serum AFP parallel the clinical course of HCC, where elevations can precede clinical deterioration and tumor recurrence.",
                                        "OutcomeMeasurePopulationDescription": "Safety population included all participants who underwent a first combination with TACE procedure prior to randomization in this study, who were randomized and who received at least one dose of double-blind drug. Here, 'overall number of participants analyzed' signifies participants with available data for the outcome measure.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Mean",
                                        "OutcomeMeasureDispersionType": "Standard Deviation",
                                        "OutcomeMeasureUnitOfMeasure": "nanogram per milliliter (ng/mL)",
                                        "OutcomeMeasureTimeFrame": "Baseline, End of treatment (last dose of study medication, i.e., approximately 7 months)",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "Placebo",
                                                    "OutcomeGroupDescription": "Participants were administered with placebo tablets matching to TAC-101 orally, every day on the first 14 days (Days 1 to 14) followed by a 7-day (Days 15 to 21) treatment recovery period (21-day Cycle). Repeated every 21 days up to new lesions were observed or the participant met a treatment discontinuation criterion."
                                                },
                                                {
                                                    "OutcomeGroupId": "OG001",
                                                    "OutcomeGroupTitle": "TAC-101",
                                                    "OutcomeGroupDescription": "Participants were administered with TAC-101 tablets, 20 mg/day orally for every day on the first 14 days (Days 1 to 14) followed by a 7-day (Days 15 to 21) recovery period (21-day Cycle). Repeated every 21 days up to new lesions were observed or the participant met a treatment discontinuation criterion."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "24"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG001",
                                                                "OutcomeDenomCountValue": "24"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "-324.0",
                                                                            "OutcomeMeasurementSpread": "1903.05"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "8147.9",
                                                                            "OutcomeMeasurementSpread": "37555.15"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Secondary",
                                        "OutcomeMeasureTitle": "Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)",
                                        "OutcomeMeasureDescription": "Any untoward medical condition that occurs in a participants while participating in a clinical study and does not necessarily have a causal relationship with the use of the study drug was considered an adverse event (AE). A serious adverse event (SAE) was defined as any untoward medical occurrence that resulted in any of the following outcomes: death, life-threatening, required initial or prolonged in-patient hospitalization, persistent or significant disability/incapacity, congenital anomaly/birth defect, or considered as medically important event. TEAEs: AEs that occur from the initiation of any study treatment administration, and do not necessarily have a causal relationship to the use of the study drug.",
                                        "OutcomeMeasurePopulationDescription": "Safety population included all participants who had underwent a first combination with TACE procedure prior to randomization in this study, who were randomized and who had received at least one dose of double-blind medication.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Number",
                                        "OutcomeMeasureUnitOfMeasure": "participants",
                                        "OutcomeMeasureTimeFrame": "From first dose of study drug up to 30 days after last dose of study drug or until the start of new anti-tumor therapy, whichever was earlier (up to approximately 8.5 months)",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "Placebo",
                                                    "OutcomeGroupDescription": "Participants were administered with placebo tablets matching to TAC-101 orally, every day on the first 14 days (Days 1 to 14) followed by a 7-day (Days 15 to 21) treatment recovery period (21-day Cycle). Repeated every 21 days up to new lesions were observed or the participant met a treatment discontinuation criterion."
                                                },
                                                {
                                                    "OutcomeGroupId": "OG001",
                                                    "OutcomeGroupTitle": "TAC-101",
                                                    "OutcomeGroupDescription": "Participants were administered with TAC-101 tablets, 20 mg/day orally for every day on the first 14 days (Days 1 to 14) followed by a 7-day (Days 15 to 21) recovery period (21-day Cycle). Repeated every 21 days up to new lesions were observed or the participant met a treatment discontinuation criterion."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "25"
                                                            },
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG001",
                                                                "OutcomeDenomCountValue": "27"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeClassTitle": "TEAEs",
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "22"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "25"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "OutcomeClassTitle": "TESAEs",
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "2"
                                                                        },
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG001",
                                                                            "OutcomeMeasurementValue": "5"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "AdverseEventsModule": {
                            "EventsFrequencyThreshold": "5",
                            "EventsTimeFrame": "AEs were collected from first dose (i.e., Day 1) of study drug to last dose of study drug + 30 days (up to approximately 8.5 months). Deaths were collected from Baseline up to end of study (up to approximately 20 months).",
                            "EventsDescription": "Reported AEs were TEAEs that developed/worsened in grade or became serious during TEAE period (defined as the time from the first dose of study drug to the last dose of study drug + 30 days) and was assessed on safety population. All-Cause Mortality data collected during the study was assessed for all randomized participants.",
                            "EventGroupList": {
                                "EventGroup": [
                                    {
                                        "EventGroupId": "EG000",
                                        "EventGroupTitle": "Placebo",
                                        "EventGroupDescription": "Participants were administered with placebo tablets matching to TAC-101 orally, every day on the first 14 days (Days 1 to 14) followed by a 7-day (Days 15 to 21) treatment recovery period (21-day Cycle). Repeated every 21 days up to new lesions were observed or the participant met a treatment discontinuation criterion.",
                                        "EventGroupDeathsNumAffected": "6",
                                        "EventGroupDeathsNumAtRisk": "25",
                                        "EventGroupSeriousNumAffected": "2",
                                        "EventGroupSeriousNumAtRisk": "25",
                                        "EventGroupOtherNumAffected": "22",
                                        "EventGroupOtherNumAtRisk": "25"
                                    },
                                    {
                                        "EventGroupId": "EG001",
                                        "EventGroupTitle": "TAC-101",
                                        "EventGroupDescription": "Participants were administered with TAC-101 tablets, 20 mg/day orally for every day on the first 14 days (Days 1 to 14) followed by a 7-day (Days 15 to 21) recovery period (21-day Cycle). Repeated every 21 days up to new lesions were observed or the participant met a treatment discontinuation criterion.",
                                        "EventGroupDeathsNumAffected": "6",
                                        "EventGroupDeathsNumAtRisk": "27",
                                        "EventGroupSeriousNumAffected": "5",
                                        "EventGroupSeriousNumAtRisk": "27",
                                        "EventGroupOtherNumAffected": "25",
                                        "EventGroupOtherNumAtRisk": "27"
                                    }
                                ]
                            },
                            "SeriousEventList": {
                                "SeriousEvent": [
                                    {
                                        "SeriousEventTerm": "Oesophageal varices haemorrhage",
                                        "SeriousEventOrganSystem": "Gastrointestinal disorders",
                                        "SeriousEventSourceVocabulary": "MedDRA 10.0",
                                        "SeriousEventAssessmentType": "Systematic Assessment",
                                        "SeriousEventStatsList": {
                                            "SeriousEventStats": [
                                                {
                                                    "SeriousEventStatsGroupId": "EG000",
                                                    "SeriousEventStatsNumEvents": "1",
                                                    "SeriousEventStatsNumAffected": "1",
                                                    "SeriousEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "SeriousEventStatsGroupId": "EG001",
                                                    "SeriousEventStatsNumEvents": "0",
                                                    "SeriousEventStatsNumAffected": "0",
                                                    "SeriousEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "SeriousEventTerm": "Disease progression",
                                        "SeriousEventOrganSystem": "General disorders",
                                        "SeriousEventSourceVocabulary": "MedDRA 10.0",
                                        "SeriousEventAssessmentType": "Systematic Assessment",
                                        "SeriousEventStatsList": {
                                            "SeriousEventStats": [
                                                {
                                                    "SeriousEventStatsGroupId": "EG000",
                                                    "SeriousEventStatsNumEvents": "0",
                                                    "SeriousEventStatsNumAffected": "0",
                                                    "SeriousEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "SeriousEventStatsGroupId": "EG001",
                                                    "SeriousEventStatsNumEvents": "1",
                                                    "SeriousEventStatsNumAffected": "1",
                                                    "SeriousEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "SeriousEventTerm": "Cholecystitis",
                                        "SeriousEventOrganSystem": "Hepatobiliary disorders",
                                        "SeriousEventSourceVocabulary": "MedDRA 10.0",
                                        "SeriousEventAssessmentType": "Systematic Assessment",
                                        "SeriousEventStatsList": {
                                            "SeriousEventStats": [
                                                {
                                                    "SeriousEventStatsGroupId": "EG000",
                                                    "SeriousEventStatsNumEvents": "0",
                                                    "SeriousEventStatsNumAffected": "0",
                                                    "SeriousEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "SeriousEventStatsGroupId": "EG001",
                                                    "SeriousEventStatsNumEvents": "1",
                                                    "SeriousEventStatsNumAffected": "1",
                                                    "SeriousEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "SeriousEventTerm": "Portal vein thrombosis",
                                        "SeriousEventOrganSystem": "Hepatobiliary disorders",
                                        "SeriousEventSourceVocabulary": "MedDRA 10.0",
                                        "SeriousEventAssessmentType": "Systematic Assessment",
                                        "SeriousEventStatsList": {
                                            "SeriousEventStats": [
                                                {
                                                    "SeriousEventStatsGroupId": "EG000",
                                                    "SeriousEventStatsNumEvents": "0",
                                                    "SeriousEventStatsNumAffected": "0",
                                                    "SeriousEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "SeriousEventStatsGroupId": "EG001",
                                                    "SeriousEventStatsNumEvents": "1",
                                                    "SeriousEventStatsNumAffected": "1",
                                                    "SeriousEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "SeriousEventTerm": "Cervical vertebral fracture",
                                        "SeriousEventOrganSystem": "Injury, poisoning and procedural complications",
                                        "SeriousEventSourceVocabulary": "MedDRA 10.0",
                                        "SeriousEventAssessmentType": "Systematic Assessment",
                                        "SeriousEventStatsList": {
                                            "SeriousEventStats": [
                                                {
                                                    "SeriousEventStatsGroupId": "EG000",
                                                    "SeriousEventStatsNumEvents": "0",
                                                    "SeriousEventStatsNumAffected": "0",
                                                    "SeriousEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "SeriousEventStatsGroupId": "EG001",
                                                    "SeriousEventStatsNumEvents": "1",
                                                    "SeriousEventStatsNumAffected": "1",
                                                    "SeriousEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "SeriousEventTerm": "Forearm fracture",
                                        "SeriousEventOrganSystem": "Injury, poisoning and procedural complications",
                                        "SeriousEventSourceVocabulary": "MedDRA 10.0",
                                        "SeriousEventAssessmentType": "Systematic Assessment",
                                        "SeriousEventStatsList": {
                                            "SeriousEventStats": [
                                                {
                                                    "SeriousEventStatsGroupId": "EG000",
                                                    "SeriousEventStatsNumEvents": "0",
                                                    "SeriousEventStatsNumAffected": "0",
                                                    "SeriousEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "SeriousEventStatsGroupId": "EG001",
                                                    "SeriousEventStatsNumEvents": "1",
                                                    "SeriousEventStatsNumAffected": "1",
                                                    "SeriousEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "SeriousEventTerm": "Anorexia",
                                        "SeriousEventOrganSystem": "Metabolism and nutrition disorders",
                                        "SeriousEventSourceVocabulary": "MedDRA 10.0",
                                        "SeriousEventAssessmentType": "Systematic Assessment",
                                        "SeriousEventStatsList": {
                                            "SeriousEventStats": [
                                                {
                                                    "SeriousEventStatsGroupId": "EG000",
                                                    "SeriousEventStatsNumEvents": "0",
                                                    "SeriousEventStatsNumAffected": "0",
                                                    "SeriousEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "SeriousEventStatsGroupId": "EG001",
                                                    "SeriousEventStatsNumEvents": "1",
                                                    "SeriousEventStatsNumAffected": "1",
                                                    "SeriousEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "SeriousEventTerm": "Contralateral breast cancer",
                                        "SeriousEventOrganSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                                        "SeriousEventSourceVocabulary": "MedDRA 10.0",
                                        "SeriousEventAssessmentType": "Systematic Assessment",
                                        "SeriousEventStatsList": {
                                            "SeriousEventStats": [
                                                {
                                                    "SeriousEventStatsGroupId": "EG000",
                                                    "SeriousEventStatsNumEvents": "0",
                                                    "SeriousEventStatsNumAffected": "0",
                                                    "SeriousEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "SeriousEventStatsGroupId": "EG001",
                                                    "SeriousEventStatsNumEvents": "1",
                                                    "SeriousEventStatsNumAffected": "1",
                                                    "SeriousEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "SeriousEventTerm": "Cerebral infarction",
                                        "SeriousEventOrganSystem": "Nervous system disorders",
                                        "SeriousEventSourceVocabulary": "MedDRA 10.0",
                                        "SeriousEventAssessmentType": "Systematic Assessment",
                                        "SeriousEventStatsList": {
                                            "SeriousEventStats": [
                                                {
                                                    "SeriousEventStatsGroupId": "EG000",
                                                    "SeriousEventStatsNumEvents": "0",
                                                    "SeriousEventStatsNumAffected": "0",
                                                    "SeriousEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "SeriousEventStatsGroupId": "EG001",
                                                    "SeriousEventStatsNumEvents": "1",
                                                    "SeriousEventStatsNumAffected": "1",
                                                    "SeriousEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "SeriousEventTerm": "Platelet count decreased",
                                        "SeriousEventOrganSystem": "Investigations",
                                        "SeriousEventSourceVocabulary": "MedDRA 10.0",
                                        "SeriousEventAssessmentType": "Systematic Assessment",
                                        "SeriousEventStatsList": {
                                            "SeriousEventStats": [
                                                {
                                                    "SeriousEventStatsGroupId": "EG000",
                                                    "SeriousEventStatsNumEvents": "1",
                                                    "SeriousEventStatsNumAffected": "1",
                                                    "SeriousEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "SeriousEventStatsGroupId": "EG001",
                                                    "SeriousEventStatsNumEvents": "0",
                                                    "SeriousEventStatsNumAffected": "0",
                                                    "SeriousEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OtherEventList": {
                                "OtherEvent": [
                                    {
                                        "OtherEventTerm": "Palpitations",
                                        "OtherEventOrganSystem": "Cardiac disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Abdominal pain",
                                        "OtherEventOrganSystem": "Gastrointestinal disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "6",
                                                    "OtherEventStatsNumAffected": "5",
                                                    "OtherEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Abdominal pain upper",
                                        "OtherEventOrganSystem": "Gastrointestinal disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Constipation",
                                        "OtherEventOrganSystem": "Gastrointestinal disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "5",
                                                    "OtherEventStatsNumAffected": "5",
                                                    "OtherEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Nausea",
                                        "OtherEventOrganSystem": "Gastrointestinal disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "5",
                                                    "OtherEventStatsNumAffected": "5",
                                                    "OtherEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "3",
                                                    "OtherEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Chills",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Fatigue",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "9",
                                                    "OtherEventStatsNumAffected": "6",
                                                    "OtherEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "10",
                                                    "OtherEventStatsNumAffected": "7",
                                                    "OtherEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Oedema peripheral",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Pyrexia",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "8",
                                                    "OtherEventStatsNumAffected": "6",
                                                    "OtherEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "8",
                                                    "OtherEventStatsNumAffected": "5",
                                                    "OtherEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Hepatic function abnormal",
                                        "OtherEventOrganSystem": "Hepatobiliary disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "3",
                                                    "OtherEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Nasopharyngitis",
                                        "OtherEventOrganSystem": "Infections and infestations",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Aspartate aminotransferase increased",
                                        "OtherEventOrganSystem": "Investigations",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Blood bilirubin increased",
                                        "OtherEventOrganSystem": "Investigations",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Blood sodium decreased",
                                        "OtherEventOrganSystem": "Investigations",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Fibrin d dimer increased",
                                        "OtherEventOrganSystem": "Investigations",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "3",
                                                    "OtherEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Thrombin-antithrombin iii complex increased",
                                        "OtherEventOrganSystem": "Investigations",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "4",
                                                    "OtherEventStatsNumAffected": "4",
                                                    "OtherEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Anorexia",
                                        "OtherEventOrganSystem": "Metabolism and nutrition disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "3",
                                                    "OtherEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Arthralgia",
                                        "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "7",
                                                    "OtherEventStatsNumAffected": "6",
                                                    "OtherEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Arthritis",
                                        "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Back pain",
                                        "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "3",
                                                    "OtherEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "3",
                                                    "OtherEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Myalgia",
                                        "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "3",
                                                    "OtherEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Pain in extremity",
                                        "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "4",
                                                    "OtherEventStatsNumAffected": "3",
                                                    "OtherEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Dizziness",
                                        "OtherEventOrganSystem": "Nervous system disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Insomnia",
                                        "OtherEventOrganSystem": "Psychiatric disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Alopecia",
                                        "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Pruritus",
                                        "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Rash",
                                        "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "12",
                                                    "OtherEventStatsNumAffected": "10",
                                                    "OtherEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Skin exfoliation",
                                        "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "0",
                                                    "OtherEventStatsNumAffected": "0",
                                                    "OtherEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "3",
                                                    "OtherEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Deep vein thrombosis",
                                        "OtherEventOrganSystem": "Vascular disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Diarrhoea",
                                        "OtherEventOrganSystem": "Gastrointestinal disorders",
                                        "OtherEventSourceVocabulary": "MedDRA 10.0",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "25"
                                                },
                                                {
                                                    "OtherEventStatsGroupId": "EG001",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "27"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "MoreInfoModule": {
                            "CertainAgreement": {
                                "AgreementPISponsorEmployee": "No",
                                "AgreementRestrictiveAgreement": "Yes"
                            },
                            "PointOfContact": {
                                "PointOfContactTitle": "Taiho Central",
                                "PointOfContactOrganization": "Taiho Oncology, Inc.",
                                "PointOfContactEMail": "clinicaltrialinfo@taihooncology.com",
                                "PointOfContactPhone": "609-250-7336"
                            }
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000002277",
                                        "ConditionMeshTerm": "Carcinoma"
                                    },
                                    {
                                        "ConditionMeshId": "D000006528",
                                        "ConditionMeshTerm": "Carcinoma, Hepatocellular"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000009375",
                                        "ConditionAncestorTerm": "Neoplasms, Glandular and Epithelial"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009370",
                                        "ConditionAncestorTerm": "Neoplasms by Histologic Type"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009369",
                                        "ConditionAncestorTerm": "Neoplasms"
                                    },
                                    {
                                        "ConditionAncestorId": "D000000230",
                                        "ConditionAncestorTerm": "Adenocarcinoma"
                                    },
                                    {
                                        "ConditionAncestorId": "D000008113",
                                        "ConditionAncestorTerm": "Liver Neoplasms"
                                    },
                                    {
                                        "ConditionAncestorId": "D000004067",
                                        "ConditionAncestorTerm": "Digestive System Neoplasms"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009371",
                                        "ConditionAncestorTerm": "Neoplasms by Site"
                                    },
                                    {
                                        "ConditionAncestorId": "D000004066",
                                        "ConditionAncestorTerm": "Digestive System Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000008107",
                                        "ConditionAncestorTerm": "Liver Diseases"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M4686",
                                        "ConditionBrowseLeafName": "Carcinoma",
                                        "ConditionBrowseLeafAsFound": "Carcinoma",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M8765",
                                        "ConditionBrowseLeafName": "Carcinoma, Hepatocellular",
                                        "ConditionBrowseLeafAsFound": "Hepatocellular Carcinoma",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M11472",
                                        "ConditionBrowseLeafName": "Neoplasms, Glandular and Epithelial",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M11467",
                                        "ConditionBrowseLeafName": "Neoplasms by Histologic Type",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M2737",
                                        "ConditionBrowseLeafName": "Adenocarcinoma",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M10265",
                                        "ConditionBrowseLeafName": "Liver Neoplasms",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M8038",
                                        "ConditionBrowseLeafName": "Gastrointestinal Neoplasms",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M6408",
                                        "ConditionBrowseLeafName": "Digestive System Neoplasms",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M8035",
                                        "ConditionBrowseLeafName": "Gastrointestinal Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M6407",
                                        "ConditionBrowseLeafName": "Digestive System Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M10259",
                                        "ConditionBrowseLeafName": "Liver Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC04",
                                        "ConditionBrowseBranchName": "Neoplasms"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC06",
                                        "ConditionBrowseBranchName": "Digestive System Diseases"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M5134",
                                        "InterventionBrowseLeafName": "Chlorotrianisene",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "ANeo",
                                        "InterventionBrowseBranchName": "Antineoplastic Agents"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 24,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT03636126",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "018-181"
                            },
                            "Organization": {
                                "OrgFullName": "Baylor Research Institute",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Virtual Reality and tACS for Performance Enhancement",
                            "OfficialTitle": "Virtual Reality and tACS for Performance Enhancement"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "July 2021",
                            "OverallStatus": "Completed",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "January 3, 2019",
                                "StartDateType": "Actual"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "October 14, 2020",
                                "PrimaryCompletionDateType": "Actual"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "October 14, 2020",
                                "CompletionDateType": "Actual"
                            },
                            "StudyFirstSubmitDate": "August 13, 2018",
                            "StudyFirstSubmitQCDate": "August 15, 2018",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "August 17, 2018",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "July 22, 2021",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "July 26, 2021",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Sponsor"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Baylor Research Institute",
                                "LeadSponsorClass": "OTHER"
                            }
                        },
                        "OversightModule": {
                            "IsFDARegulatedDrug": "No",
                            "IsFDARegulatedDevice": "Yes",
                            "IsUSExport": "Yes"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "The chronic stress of police work may reduce human performance through increases in anxiety, depression, pain, and insomnia. Land's End VR may teach mindful meditation that is associated with reduced anxiety, depression, pain, and insomnia. tACS may produce similar effects to Selective Serotonin Reuptake Inhibitors (SSRIs) without the side effect risks of SSRIs by stimulating neurotransmitter production and modulating the default mode network, resulting in reduced anxiety, depression, pain, and insomnia. These two technologies have not been investigated as interventions among police officers. Therefore, we propose a pilot randomized waitlist-controlled crossover trial of the feasibility and efficacy of Land's End VR and tACS among police officers."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Law Enforcement Officers"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Not Applicable"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "Randomized",
                                "DesignInterventionModel": "Crossover Assignment",
                                "DesignInterventionModelDescription": "The total study time will be 4 weeks. Participants will be asked to use the VR and tACS for two of these four weeks. Participants will be randomly assigned to one of two groups: A) a group that uses the tACS+VR for weeks 1 & 2 or B) a group that uses the tACS+VR for weeks 3 & 4.",
                                "DesignPrimaryPurpose": "Diagnostic",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "None (Open Label)"
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "45",
                                "EnrollmentType": "Actual"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "VR + TACS",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "Complete one chapter of the virtual reality game \"Land's End\" while simultaneously using the tACS system (chapters range in length from approximately 5-20 minutes) after waking up each day (or prior to beginning a work shift).\nUse the tACS system without the VR for 20 minutes just before sleep (or at the end of a work shift, whichever time point is most convenient). Table 1. Timeline of Study Treatment",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: VR + TACS"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "No Intervention for 2 Weeks",
                                        "ArmGroupType": "No Intervention",
                                        "ArmGroupDescription": "For 2 weeks of the 4 week study, each group (Group A and Group B) will continue work shifts as usual with no intervention."
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "VR + TACS",
                                        "InterventionDescription": "TACS- A regulated class of transcranial alternating current stimulation (tACS), called Cranial Electrotherapy Stimulation (CES) by Fisher Wallace Laboratories (FWL) is FDA-Cleared to treat depression, anxiety, and insomnia (Proof of FDA clearance and 510k provided in the appendix). FWL tACS delivers weak non-invasive electrical stimulation (1-4 milliamps at 15, 500, and 15,000 Hz) to the frontal/temporal brain regions by electrodes placed above the temples. Land's End Virtual Reality Game Meta-analyses show Virtual Reality (VR) is an effective non-pharmacological method that reduces obstacles to human performance such as pain, insomnia, anxiety, sleep deprivation, and a variety of other stress responses.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "VR + TACS"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Numeric Rating Scale (NRS)",
                                        "PrimaryOutcomeDescription": "The Numerical Rating Scale (NRS) has been validated as a measure of pain intensity and is one of the most commonly used measures in assessing pain. The NRS asks patients to rate their pain severity on a 0 to 10 scale, with 0 being \"no pain\" to 10 being \"so severe that you can't stand it.\"",
                                        "PrimaryOutcomeTimeFrame": "Change in score Assessed at Baseline, 2 weeks and 4 weeks."
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "Insomnia Severity Index (ISI)",
                                        "PrimaryOutcomeDescription": "The Insomnia Severity Index (ISI) is a 7-item, self-report instrument that assesses the severity of insomnia. The ISI has adequate reliability and validity and is frequently used in randomized controlled trials of sleep interventions. A 5-point Likert scale is used to rate each item (e.g., 0 = no problem; 4 = very severe problem), yielding a total score ranging from 0 to 28. The total score is interpreted as follows: absence of insomnia (0-7); sub-threshold insomnia (8-14); moderate insomnia (15-21); and severe insomnia (22-28).",
                                        "PrimaryOutcomeTimeFrame": "Change in score Assessed at Baseline, 2 weeks and 4 weeks."
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "The Patient Health Questionnaire 8 (PHQ-8)",
                                        "PrimaryOutcomeDescription": "The PHQ-8 is a brief self-report measure of major depressive disorder. The PHQ-8 is considered to be valid measure of depression for population-based studies and clinical populations with a cut off score of equal or greater than 10 as the diagnostic for current depression. The PHQ-8 is derived from the PHQ-9 by removing the last question regarding suicide assessment.",
                                        "PrimaryOutcomeTimeFrame": "Change in score Assessed at Baseline, 2 weeks and 4 weeks."
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "Primary Care Posttraumatic Stress Disorder Screen (PC-PTSD)",
                                        "PrimaryOutcomeDescription": "The PC-PTSD is a 4-item\"yes\" or \"no\" screen designed for use in medical settings and is the current screening instrument used in the VA system to screen for PTSD. This is considered a psychometrically sound screen for determining the presence and absence of PTSD in the VA setting and has also been used in the civilian primary care population. With a cut-off score of 3, the PC-PTSD has shown 85% diagnostic efficiency, 78% sensitivity, and 87% specificity.",
                                        "PrimaryOutcomeTimeFrame": "Change in score Assessed at Baseline, 2 weeks and 4 weeks."
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "Generalized Anxiety Disorder (GAD7)",
                                        "PrimaryOutcomeDescription": "The GAD7 is a 7-item questionnaire that measures severity of anxiety. Response options are \"not at all,\" \"several days,\" \"more than half the days,\" and \"nearly every day,\" scored as 0, 1, 2, and 3, respectively. Therefore, GAD-7 scores range from 0 to 21, with scores of 5, 10, and 15 representing mild, moderate, and severe anxiety symptom levels, respectively",
                                        "PrimaryOutcomeTimeFrame": "Change in score Assessed at Baseline, 2 weeks and 4 weeks."
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "Demographics Questionnaire",
                                        "SecondaryOutcomeDescription": "Participants will be asked to provide standard demographic information (i.e., age, gender, race/ethnicity, level of education, etc.). Participants will also be asked about hearing and visual impairment as well as any history of motion sickness.",
                                        "SecondaryOutcomeTimeFrame": "Assessed at Baseline"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Alcohol Use Disorder Identification Test-Consumption (AUDIT-C)",
                                        "SecondaryOutcomeDescription": "Alcohol Use Disorder Identification Test-Consumption (AUDIT-C) is a 3-item alcohol screen that can identify problem alcohol use. The AUDIT-C is scored o a scale of 0-12, each question has 5 answer choices with \"a\" being 0 points and \"e\" being 4 points.",
                                        "SecondaryOutcomeTimeFrame": "Assessed at Baseline, 2 weeks and 4 weeks."
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Attitudes Toward the Experience Survey",
                                        "SecondaryOutcomeDescription": "The Attitudes Toward the Experience Survey is an 8-item NRS that will be used to measure the participant's attitude toward the VR experience. Participants rate the degree to which they agree with the statements on a 1-10 scale, with 0 being \"strongly disagree\" and 10 being \"strongly agree.\"",
                                        "SecondaryOutcomeTimeFrame": "Assessed at 4 weeks"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\n18 years of age and older\nEnglish-Speaking (The measures have not been validated in other languages).\nWilling and able to provide informed consent and participate in the study visit and study follow-up questionnaires\nAble to position head completely upright (90 degrees from the ground) in order to view the entirety of the Virtual Reality video\n\nExclusion Criteria:\n\nHearing or visually impaired where they cannot use the Samsung Gear VR\nHistory of motion sickness or cyber sickness and unwilling to watch a 10-minute virtual reality video because of it\nUnable to position head completely upright (90 degrees from the ground)\nHistory of seizures\nLesions, rashes, or open wounds on face, head, neck, or ears\nMedical device implanted in the head or neck\nParticipants with pacemakers\nParticipants with known or suspected heart disease",
                            "HealthyVolunteers": "Accepts Healthy Volunteers",
                            "Gender": "All",
                            "MinimumAge": "18 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "Garland PD",
                                        "LocationCity": "Garland",
                                        "LocationState": "Texas",
                                        "LocationZip": "75042",
                                        "LocationCountry": "United States"
                                    }
                                ]
                            }
                        },
                        "IPDSharingStatementModule": {
                            "IPDSharing": "Undecided"
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "InterventionBrowseModule": {
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 25,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT02598869",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "00011584"
                            },
                            "Organization": {
                                "OrgFullName": "Oregon Health and Science University",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema",
                            "OfficialTitle": "Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema (CME)"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "February 2019",
                            "OverallStatus": "Withdrawn",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "November 30, 2015",
                                "StartDateType": "Actual"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "May 15, 2016",
                                "PrimaryCompletionDateType": "Actual"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "May 15, 2016",
                                "CompletionDateType": "Actual"
                            },
                            "StudyFirstSubmitDate": "August 31, 2015",
                            "StudyFirstSubmitQCDate": "November 4, 2015",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "November 6, 2015",
                                "StudyFirstPostDateType": "Estimate"
                            },
                            "LastUpdateSubmitDate": "February 5, 2019",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "February 7, 2019",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Principal Investigator",
                                "ResponsiblePartyInvestigatorFullName": "Phoebe Lin, MD,PhD",
                                "ResponsiblePartyInvestigatorTitle": "Assistant professor of Ophthalmology",
                                "ResponsiblePartyInvestigatorAffiliation": "Oregon Health and Science University"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Oregon Health and Science University",
                                "LeadSponsorClass": "OTHER"
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "Yes"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "Macular edema is the most common sight threatening complication of uveitis which can lead to permanent loss of central vision. Triamcinolone acetonide ( the study drug)injection for treatment of cystoid macular edema(CME) is well established. The purpose of this study is to compare the safety and efficacy of injecting the study drug inside the eye(intravitreal injection) and behind the eye(subtenon injection)",
                            "DetailedDescription": "The study is randomized interventional non inferiority study that will enroll 30 adults aged 18 or older with the diagnosis of cystoid macular edema secondary to non-infectious uveitis. Potential subjects will be recruited from the retina and uveitis clinics at the Casey Eye Institute, Oregon health and science University(OHSU). Potential recruits will be asked to sign and date the informed consent and a copy will be given to subject prior to any study procedure. Subjects will have a screening visit before the injection procedure so that the study doctor can decide if they meet the criteria to be in the study. This study requires 6 visits to the clinic and will take 6 months to complete. During the screening visit, medical/ surgical/ ocular history and will be collected from the subject and medical records. Laboratory tests will be performed to rule out infectious uveitis if the subject has not already had infectious types of uveitis ruled out since the time of diagnosis of uveitis. Urine collection for pregnancy test for females of childbearing potential will be done. Examination of subjects will include measurement of visual acuity, examination of the front and back part of the eye, measurement of the eye pressure . A scan of the retina will be obtained by spectral domain optical coherence tomography (SD-OCT). During the injection visit, history, examination, and pregnancy tests will be repeated in addition to receiving the injection. Subjects will be randomized to either injecting the study drug by intravitreal or subtenon routes. Examination after injection will be performed to rule out immediate complications. Then subjects will have 4 follow-up visits (2 weeks, 1 month, 3 months and 6 months). During each visit, subjects will be asked about adverse events, concomitant medications, how their eyes feel in addition to obtaining a clinical examination and OCT."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Uveitis",
                                    "Cystoid Macular Edema"
                                ]
                            },
                            "KeywordList": {
                                "Keyword": [
                                    "Triamcinolone acetonide"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Phase 4"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "Randomized",
                                "DesignInterventionModel": "Parallel Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "Single",
                                    "DesignWhoMaskedList": {
                                        "DesignWhoMasked": [
                                            "Participant"
                                        ]
                                    }
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "0",
                                "EnrollmentType": "Actual"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "Intravitreal triamcinolone",
                                        "ArmGroupType": "Active Comparator",
                                        "ArmGroupDescription": "subjects will receive intravitreal injection of 2mg /0.05 ml of preservative free triamcinolone acetonide ( otherwise known as triesence)",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: Triamcinolone Acetonide"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "posterior subtenon triamcinolone",
                                        "ArmGroupType": "Active Comparator",
                                        "ArmGroupDescription": "subjects will receive posterior subtenon injection of 40mg /1 ml of preserved triamcinolone acetonide ( otherwise known as kenalog)",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: Triamcinolone Acetonide"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "Triamcinolone Acetonide",
                                        "InterventionDescription": "injection of triamcinolone acetonide",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Intravitreal triamcinolone",
                                                "posterior subtenon triamcinolone"
                                            ]
                                        },
                                        "InterventionOtherNameList": {
                                            "InterventionOtherName": [
                                                "triesence",
                                                "kenalog"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Mean change in best corrected visual acuity( BCVA)",
                                        "PrimaryOutcomeDescription": "Best corrected visual acuity will be assessed using the Snellen chart",
                                        "PrimaryOutcomeTimeFrame": "at 1,3 and 6 months after intervention"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "Change in central macular thickness in micrometers",
                                        "SecondaryOutcomeDescription": "A spectral domain optical coherence tomography device will be used to capture central macular thickness",
                                        "SecondaryOutcomeTimeFrame": "at 1,3 and 6 months after intervention"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Percentage of eyes that develop side effects",
                                        "SecondaryOutcomeTimeFrame": "at 1,3 and 6 months after intervention"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nMale or non-pregnant female at least 18 years of age at the time of consent\nOne or both eyes having CME associated with non-infectious uveitis\nSubject has the ability to understand and sign the Informed Consent Form\nSubject is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures\n\nExclusion Criteria:\n\nAllergy to triamcinolone acetonide\nHistory of any type of non-infectious uveitis without macular edema\nVitreous hemorrhage\nUveitis with infectious etiology\nCME due to non-uveitis causes\nPrevious viral retinitis or uveitis\nToxoplasmosis scar in study eye or scar related to viral retinitis\nMedia opacity interfering with optical coherence tomography (OCT) or evaluation of the retina and vitreous\nPatient may not have had prior treatment for CME within the past 3 months including anti-VEGF (vascular endothelial growth factor), periocular or intravitreal steroid\nPregnant or nursing women; females of childbearing potential who are unwilling or unable to use an acceptable method of contraception\nSubjects unwilling to comply with the study protocol or who are likely to be lost to follow-up within 6 months",
                            "HealthyVolunteers": "No",
                            "Gender": "All",
                            "MinimumAge": "18 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ReferencesModule": {
                            "ReferenceList": {
                                "Reference": [
                                    {
                                        "ReferencePMID": "10896343",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Guex-Crosier Y. The pathogenesis and clinical presentation of macular edema in inflammatory diseases. Doc Ophthalmol. 1999;97(3-4):297-309. Review."
                                    },
                                    {
                                        "ReferencePMID": "17083528",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Sivaprasad S, McCluskey P, Lightman S. Intravitreal steroids in the management of macular oedema. Acta Ophthalmol Scand. 2006 Dec;84(6):722-33. Review."
                                    },
                                    {
                                        "ReferencePMID": "21652023",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Leder HA, Jabs DA, Galor A, Dunn JP, Thorne JE. Periocular triamcinolone acetonide injections for cystoid macular edema complicating noninfectious uveitis. Am J Ophthalmol. 2011 Sep;152(3):441-448.e2. doi: 10.1016/j.ajo.2011.02.009. Epub 2011 Jun 8."
                                    }
                                ]
                            }
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000008269",
                                        "ConditionMeshTerm": "Macular Edema"
                                    },
                                    {
                                        "ConditionMeshId": "D000014605",
                                        "ConditionMeshTerm": "Uveitis"
                                    },
                                    {
                                        "ConditionMeshId": "D000004487",
                                        "ConditionMeshTerm": "Edema"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000008268",
                                        "ConditionAncestorTerm": "Macular Degeneration"
                                    },
                                    {
                                        "ConditionAncestorId": "D000012162",
                                        "ConditionAncestorTerm": "Retinal Degeneration"
                                    },
                                    {
                                        "ConditionAncestorId": "D000012164",
                                        "ConditionAncestorTerm": "Retinal Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000005128",
                                        "ConditionAncestorTerm": "Eye Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000014603",
                                        "ConditionAncestorTerm": "Uveal Diseases"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M16505",
                                        "ConditionBrowseLeafName": "Uveitis",
                                        "ConditionBrowseLeafAsFound": "Uveitis",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M10413",
                                        "ConditionBrowseLeafName": "Macular Edema",
                                        "ConditionBrowseLeafAsFound": "Macular Edema",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M6809",
                                        "ConditionBrowseLeafName": "Edema",
                                        "ConditionBrowseLeafAsFound": "Edema",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M10412",
                                        "ConditionBrowseLeafName": "Macular Degeneration",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M14149",
                                        "ConditionBrowseLeafName": "Retinal Degeneration",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M14151",
                                        "ConditionBrowseLeafName": "Retinal Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M7423",
                                        "ConditionBrowseLeafName": "Eye Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M16503",
                                        "ConditionBrowseLeafName": "Uveal Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "T5824",
                                        "ConditionBrowseLeafName": "Uveal Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC11",
                                        "ConditionBrowseBranchName": "Eye Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC23",
                                        "ConditionBrowseBranchName": "Symptoms and General Pathology"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "Rare",
                                        "ConditionBrowseBranchName": "Rare Diseases"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionMeshList": {
                                "InterventionMesh": [
                                    {
                                        "InterventionMeshId": "D000014221",
                                        "InterventionMeshTerm": "Triamcinolone"
                                    },
                                    {
                                        "InterventionMeshId": "D000014222",
                                        "InterventionMeshTerm": "Triamcinolone Acetonide"
                                    },
                                    {
                                        "InterventionMeshId": "C000005900",
                                        "InterventionMeshTerm": "Triamcinolone hexacetonide"
                                    },
                                    {
                                        "InterventionMeshId": "C000030262",
                                        "InterventionMeshTerm": "Triamcinolone diacetate"
                                    }
                                ]
                            },
                            "InterventionAncestorList": {
                                "InterventionAncestor": [
                                    {
                                        "InterventionAncestorId": "D000000893",
                                        "InterventionAncestorTerm": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000005938",
                                        "InterventionAncestorTerm": "Glucocorticoids"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006728",
                                        "InterventionAncestorTerm": "Hormones"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006730",
                                        "InterventionAncestorTerm": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045505",
                                        "InterventionAncestorTerm": "Physiological Effects of Drugs"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007166",
                                        "InterventionAncestorTerm": "Immunosuppressive Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007155",
                                        "InterventionAncestorTerm": "Immunologic Factors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000004791",
                                        "InterventionAncestorTerm": "Enzyme Inhibitors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045504",
                                        "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                                    }
                                ]
                            },
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafAsFound": "Deep",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M3369",
                                        "InterventionBrowseLeafName": "Anti-Inflammatory Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8199",
                                        "InterventionBrowseLeafName": "Glucocorticoids",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8941",
                                        "InterventionBrowseLeafName": "Hormones",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8940",
                                        "InterventionBrowseLeafName": "Hormone Antagonists",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9364",
                                        "InterventionBrowseLeafName": "Immunosuppressive Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9353",
                                        "InterventionBrowseLeafName": "Immunologic Factors",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 26,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT03241563",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "ATX-TRIAM-2016"
                            },
                            "Organization": {
                                "OrgFullName": "Goldman, Butterwick, Fitzpatrick and Groff",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Subcutaneous Sodium Deoxycholate Injections With or Without Triamcinolone for Reduction of Submental Fat",
                            "OfficialTitle": "A Randomized, Double-blind Comparison Trial of Subcutaneous Sodium Deoxycholate Injections With or Without Triamcinolone for Reduction of Submental Fat"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "August 2017",
                            "OverallStatus": "Completed",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "April 2016"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "February 2017",
                                "PrimaryCompletionDateType": "Actual"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "February 2017",
                                "CompletionDateType": "Actual"
                            },
                            "StudyFirstSubmitDate": "March 2, 2017",
                            "StudyFirstSubmitQCDate": "August 4, 2017",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "August 7, 2017",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "August 4, 2017",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "August 7, 2017",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Sponsor"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Goldman, Butterwick, Fitzpatrick and Groff",
                                "LeadSponsorClass": "OTHER"
                            },
                            "CollaboratorList": {
                                "Collaborator": [
                                    {
                                        "CollaboratorName": "Allergan",
                                        "CollaboratorClass": "INDUSTRY"
                                    }
                                ]
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "The subjects and evaluating investigator will be blinded to the treatment, thus maintaining double-blind status. By nature of the varying volumes of injection, the treating investigator will be unblinded to the treatment. A series of 3 injection sessions will be performed spaced 4 weeks apart.\n\nCanfield Vectra 3D imaging will be performed at baseline and at each follow up visit. Follow up visits will be performed 3 and 5 days after each injection session to assess for side effect and tolerability profile. After the final injection session, additional follow up visits will be performed at days 90 and 180 to assess for efficacy. Subject weight will be recorded at baseline and at end of study.",
                            "DetailedDescription": "This is a Single-site randomized, double-blind comparison trial of Kybella injections with or without triamcinolone acetate for the reduction of submental fat. 20 subjects will be enrolled into the trial. Of these 20 subjects, 5 will be randomized to receive Kybella injections alone whereas 15 will receive Kybella plus triamcinolone acetate in the following way:\n\nKybella alone: 2 mg/cm2 of Kybella will be delivered in up to 50 injections spaced 1.0 cm apart at 0.2 mL/injection for a total dose of up to 100 mg of sodium deoxycholate.\nKybella plus triamcinolone: 0.2 mL of 2 mg/cm2 of Kybella will be mixed with 0.05 mL of 40 mg/mL of triamcinolone acetate and then delivered in up to 50 injections spaced 1.0 cm apart at 0.25 mL/injection for a total dose of up to 100 mg of sodium deoxycholate using a 30 gauge (or smaller) 0.5-inch needle.\n\nThe treatment area will be bounded superiorly by a line 1 cm inferior to the mandibular margin, laterally by the sternocleidomastoid muscles, and inferiorly by the hyoid bone. The subjects and evaluating investigator will be blinded to the treatment, thus maintaining double-blind status. By nature of the varying volumes of injection, the treating investigator will be unblinded to the treatment. A series of 3 injection sessions will be performed spaced 4 weeks apart.\n\nCanfield Vectra 3D imaging will be performed at baseline and at each follow up visit. Follow up visits will be performed 3 and 5 days after each injection session to assess for side effect and tolerability profile. After the final injection session, additional follow up visits will be performed at days 90 and 180 to assess for efficacy. Subject weight will be recorded at baseline and at end of study."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Fat Reduction"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Phase 4"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "Randomized",
                                "DesignInterventionModel": "Parallel Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "Double",
                                    "DesignWhoMaskedList": {
                                        "DesignWhoMasked": [
                                            "Participant",
                                            "Outcomes Assessor"
                                        ]
                                    }
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "20",
                                "EnrollmentType": "Actual"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "without triamcinolone",
                                        "ArmGroupType": "Active Comparator",
                                        "ArmGroupDescription": "sodium Deoxycholate without triamcinolone",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: Sodium Deoxycholate"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "with triamcinolone",
                                        "ArmGroupType": "Active Comparator",
                                        "ArmGroupDescription": "sodium Deoxycholate with triamcinolone",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: Sodium Deoxycholate",
                                                "Drug: Triamcinolone"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "Sodium Deoxycholate",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "with triamcinolone",
                                                "without triamcinolone"
                                            ]
                                        },
                                        "InterventionOtherNameList": {
                                            "InterventionOtherName": [
                                                "Kybella"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "Triamcinolone",
                                        "InterventionDescription": "Triamcinolone 40mg/ml",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "with triamcinolone"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Evaluation of Efficacy of Kybella with Triamcinolone in the Reduction of Submental Fat",
                                        "PrimaryOutcomeDescription": "evaluate the efficacy associated with Kybella injections for the reduction of fat of the upper neck in the treatment of submental fat with and without added triamcinolone acetonide. An evaluator blinded to the study will grade the level of improvement of the submental fat using the Clinician Graded Submental Fat Rating Scale.",
                                        "PrimaryOutcomeTimeFrame": "6 Months"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "Evaluation of Safety of Kybella with Triamcinolone for Reduction of Submental Fat",
                                        "SecondaryOutcomeDescription": "Differences in rates of edema, erythema, tenderness, and erosion/ulceration, based on blinded evaluator assessment, will be compared between subjects treated with Kybella with and without triamcinolone",
                                        "SecondaryOutcomeTimeFrame": "6 months"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\n1. Females or Males in good general health age 18 - 65 years of age\n2. Fitzpatrick skin types I-VI\n3. Must be willing to give and sign a HIPPA form and informed consent form\n4. Must be willing and able to comply with all study protocols and schedules\n5. Must have submental fat graded by the investigator as 2 or 3 using the Clinician-Reported Submental Fat Rating Scale (PR-SMFRS)\n6. Negative urine pregnancy test prior to each treatment (if applicable)\n7. Female patients will be either of non-childbearing potential defined as: 7.1 Having no uterus 7.2 No menses for at least 12 months. Or; (WOCBP) women of childbearing potential must agree to use an effective method of birth control during the course of the study, such as: 7.3 Oral contraceptive pill, injection, implant, patch, vaginal ring, intrauterine device 7.4 Intrauterine coil 7.5 Bilateral tubal ligation 7.6 Barrier method used with an additional form of contraception (e.g., sponge, spermicide or condom) 7.7 Abstinence (If practicing abstinence must agree to use barrier method described above (7.6) if becomes sexually active) 7.8 Vasectomized partner (must agree to use barrier method described above (7.6) if becomes sexually active with unvasectomized partner)\n8. Males must be willing to be clean shaven for all study visits\n9. The patient must have had a stable weight (no fluctuation of >15 pounds in a year), diet, and physical activity for the previous 6 months\n\nExclusion Criteria:\n\n1. Pregnancy, currently breast feeding or planning pregnancy for the duration of the trial\n2. Any UNCONTROLLED systemic disease -a potential patient in whom therapy for a systemic disease is not yet stabilized will not be considered for entry into the study\n3. Treatment with botulinum toxin injections in the neck or chin area within 6 months before randomization\n4. Any Scars, unshaven hair, tattoos or jewelry on or near the proposed treatment area\n5. Significant history or current evidence of a medical, psychological or other disorder that, in the investigator's opinion, would preclude enrollment into the study\n6. An active dermatitis or open wound in the proposed treatment area\n7. An active bacterial, fungal, or viral infection in the proposed treatment area\n8. Pre-existing skin condition to the submental region that may confound evaluation or analysis, at investigator discretion\n9. Previously treated with subcutaneous sodium deoxycholate to the submental region\n10. Previously treated with focused ultrasound, radiofrequency, cryolipolysis or liposuction to the submental region within the previous 6 months\n11. Any other laser, light energy device, or chemical peel treatment to the submental region within the previous 3 months\n12. Pre-existing neurological or gastrointestinal condition leading to dysphagia, dysphonia or facial nerve palsy\n13. Pre-existing medical condition other than increased submental fat that may result in increased submental fullness such as but not limited to thyroid enlargement, goiter, cervical lymphadenopathy etc., at investigator discretion\n14. Must not have a planned fat reduction procedure of any variety to the submental region for the duration of the study\n15. Must not have planned significant alterations in diet or physical activity that may result in significant fluctuations in weight\n16. Current participation or participation within 30 days prior to the start of this study in a drug or other investigational research study.",
                            "HealthyVolunteers": "Accepts Healthy Volunteers",
                            "Gender": "All",
                            "MinimumAge": "18 Years",
                            "MaximumAge": "65 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Mitchel P Goldman, MD",
                                        "OverallOfficialAffiliation": "DCLA",
                                        "OverallOfficialRole": "Principal Investigator"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "Dermatology Cosmetic Laser Medical Associates of La Jolla, Inc.",
                                        "LocationCity": "San Diego",
                                        "LocationState": "California",
                                        "LocationZip": "92121",
                                        "LocationCountry": "United States"
                                    }
                                ]
                            }
                        },
                        "IPDSharingStatementModule": {
                            "IPDSharing": "No"
                        }
                    },
                    "AnnotationSection": {
                        "AnnotationModule": {
                            "UnpostedAnnotation": {
                                "UnpostedResponsibleParty": "Goldman, Butterwick, Fitzpatrick and Groff",
                                "UnpostedEventList": {
                                    "UnpostedEvent": [
                                        {
                                            "UnpostedEventType": "Release",
                                            "UnpostedEventDate": "October 24, 2017"
                                        },
                                        {
                                            "UnpostedEventType": "Reset",
                                            "UnpostedEventDate": "November 28, 2017"
                                        },
                                        {
                                            "UnpostedEventType": "Release",
                                            "UnpostedEventDate": "February 12, 2019"
                                        },
                                        {
                                            "UnpostedEventType": "Reset",
                                            "UnpostedEventDate": "March 5, 2019"
                                        },
                                        {
                                            "UnpostedEventType": "Release",
                                            "UnpostedEventDate": "April 30, 2019"
                                        },
                                        {
                                            "UnpostedEventType": "Reset",
                                            "UnpostedEventDate": "May 21, 2019"
                                        },
                                        {
                                            "UnpostedEventType": "Release",
                                            "UnpostedEventDate": "August 15, 2019"
                                        },
                                        {
                                            "UnpostedEventType": "Reset",
                                            "UnpostedEventDate": "September 4, 2019"
                                        }
                                    ]
                                }
                            }
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022",
                            "SubmissionTracking": {
                                "SubmissionInfoList": {
                                    "SubmissionInfo": [
                                        {
                                            "SubmissionReleaseDate": "October 24, 2017",
                                            "SubmissionResetDate": "November 28, 2017"
                                        },
                                        {
                                            "SubmissionReleaseDate": "February 12, 2019",
                                            "SubmissionResetDate": "March 5, 2019"
                                        },
                                        {
                                            "SubmissionReleaseDate": "April 30, 2019",
                                            "SubmissionResetDate": "May 21, 2019"
                                        },
                                        {
                                            "SubmissionReleaseDate": "August 15, 2019",
                                            "SubmissionResetDate": "September 4, 2019"
                                        }
                                    ]
                                }
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionMeshList": {
                                "InterventionMesh": [
                                    {
                                        "InterventionMeshId": "D000014221",
                                        "InterventionMeshTerm": "Triamcinolone"
                                    },
                                    {
                                        "InterventionMeshId": "D000003840",
                                        "InterventionMeshTerm": "Deoxycholic Acid"
                                    }
                                ]
                            },
                            "InterventionAncestorList": {
                                "InterventionAncestor": [
                                    {
                                        "InterventionAncestorId": "D000000893",
                                        "InterventionAncestorTerm": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000005938",
                                        "InterventionAncestorTerm": "Glucocorticoids"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006728",
                                        "InterventionAncestorTerm": "Hormones"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006730",
                                        "InterventionAncestorTerm": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045505",
                                        "InterventionAncestorTerm": "Physiological Effects of Drugs"
                                    },
                                    {
                                        "InterventionAncestorId": "D000002756",
                                        "InterventionAncestorTerm": "Cholagogues and Choleretics"
                                    },
                                    {
                                        "InterventionAncestorId": "D000005765",
                                        "InterventionAncestorTerm": "Gastrointestinal Agents"
                                    }
                                ]
                            },
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafAsFound": "Deep",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M6188",
                                        "InterventionBrowseLeafName": "Deoxycholic Acid",
                                        "InterventionBrowseLeafAsFound": "Holmium Laser",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M3369",
                                        "InterventionBrowseLeafName": "Anti-Inflammatory Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8199",
                                        "InterventionBrowseLeafName": "Glucocorticoids",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8941",
                                        "InterventionBrowseLeafName": "Hormones",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8940",
                                        "InterventionBrowseLeafName": "Hormone Antagonists",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8033",
                                        "InterventionBrowseLeafName": "Gastrointestinal Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "Gast",
                                        "InterventionBrowseBranchName": "Gastrointestinal Agents"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 27,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT03412604",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "2017P000648"
                            },
                            "Organization": {
                                "OrgFullName": "Massachusetts General Hospital",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Effect of Modulating Gamma Oscillations Using tACS",
                            "OfficialTitle": "Effect of Modulating Gamma Oscillations by Transcranial Alternating Current Stimulation on Brain Structure and Function in Humans"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "February 2022",
                            "OverallStatus": "Completed",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "August 2, 2018",
                                "StartDateType": "Actual"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "May 7, 2019",
                                "PrimaryCompletionDateType": "Actual"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "September 15, 2019",
                                "CompletionDateType": "Actual"
                            },
                            "StudyFirstSubmitDate": "January 22, 2018",
                            "StudyFirstSubmitQCDate": "January 22, 2018",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "January 26, 2018",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "ResultsFirstSubmitDate": "July 10, 2020",
                            "ResultsFirstSubmitQCDate": "May 18, 2021",
                            "ResultsFirstPostDateStruct": {
                                "ResultsFirstPostDate": "May 21, 2021",
                                "ResultsFirstPostDateType": "Actual"
                            },
                            "ResultsFirstPostedQCCommentsDateStruct": {
                                "ResultsFirstPostedQCCommentsDate": "July 28, 2020",
                                "ResultsFirstPostedQCCommentsDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "February 2, 2022",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "February 8, 2022",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Principal Investigator",
                                "ResponsiblePartyInvestigatorFullName": "Emiliano Santarnecchi",
                                "ResponsiblePartyInvestigatorTitle": "Associate Professor of Radiology",
                                "ResponsiblePartyInvestigatorAffiliation": "Massachusetts General Hospital"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Massachusetts General Hospital",
                                "LeadSponsorClass": "OTHER"
                            },
                            "CollaboratorList": {
                                "Collaborator": [
                                    {
                                        "CollaboratorName": "Defense Advanced Research Projects Agency",
                                        "CollaboratorClass": "FED"
                                    }
                                ]
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "Yes",
                            "IsFDARegulatedDrug": "No",
                            "IsFDARegulatedDevice": "Yes",
                            "IsUnapprovedDevice": "Yes",
                            "IsUSExport": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "This study aims to implement an intervention based on multiple, individualized multifocal tACS stimulation sessions based on individual PET and MRI information in patients with amyloid-positive PET with the hope that this leads to microglia activation and decrease in cerebral amyloid and tau depositions in human patients with AD.",
                            "DetailedDescription": "This study will leverage all this accumulated knowledge by implementing an intervention based on multiple, individualized multifocal tACS stimulation sessions based on individual PET and MRI information in patients with amyloid-positive PET with the hope that this leads to microglia activation and decrease in cerebral amyloid and tau depositions in human patients with AD.This would have immense translational impact, as gamma tACS is an intervention that is portable, does not require expensive hardware, can be widely applied to large numbers of patients with AD, as well as, given its favorable side effect profile, even to patients at earlier stages of the disease who have cerebral amyloid/tau without clinical symptoms.\n\nThe investigators aim to enroll 10 individuals with AD with evidence of increased cerebral amyloid burden on amyloid PET imaging. This would allow for a final sample size of 5-6 fully evaluable subjects. Each subject's participation in this study will consist of approximately 31-35 visits: 1 day for consent and screening procedures, 5-7 days of baseline procedures (this includes the PET scans), 20 tACS study visits, and 5-7 days of follow-up assessments. Subjects will undergo baseline cognitive assessment, structural and functional MRI characterization, PET imaging to assess amyloid burden, tau deposition and level of microglia activation, and resting-state EEG measurement. Additionally, subjects will undergo a TMS-EEG and a tACS-EEG recording session to assess brain plasticity levels and identify markers of response to stimulation. All subjects will subsequently undergo 20 sessions of gamma-frequency (40 Hz) tACS. At the end of the 20 sessions, subjects will then repeat the baseline assessments over 5-7 visits, including repeat PET imaging to assess for changes in amyloid burden, tau deposition, and microglia activation."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Alzheimer Disease"
                                ]
                            },
                            "KeywordList": {
                                "Keyword": [
                                    "Alzheimer Disease"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Not Applicable"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "N/A",
                                "DesignInterventionModel": "Single Group Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "None (Open Label)"
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "5",
                                "EnrollmentType": "Actual"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "tACS",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "Transcranial alternating current stimulation (tACS) tuned at the frequency of 40Hz (gamma frequency) will be applied for 1 hour in 20 sessions on consecutive weekdays. The tACS intervention (20 sessions) will be preceded and followed by amyloid, microglia and tau PET imaging as well as a clinical/cognitive evaluation. The assessment of the effect of stimulation on microglia activation, amyloid deposition and tau deposition will constitute a primary outcome measure. Assessment of adverse effects will be also evaluated as a secondary outcome. The effect of brain stimulation on brain connectivity will be assessed by EEG and MRI and cognitive function.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: Transcranial Alternating Current Stimulation (tACS)"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "Transcranial Alternating Current Stimulation (tACS)",
                                        "InterventionDescription": "tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "tACS"
                                            ]
                                        },
                                        "InterventionOtherNameList": {
                                            "InterventionOtherName": [
                                                "Non-invasive Brain Stimulation"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "PET Amyloid Burden",
                                        "PrimaryOutcomeDescription": "Changes in the amyloid load observed via PET imaging will be evaluated by comparing PET data acquired before and after the 20 tACS sessions. The metric used is standardized uptake value ratio (SUVR), a measure of the amount of proteins in the brain identified at the PET exam. We will calculate the difference between pre and post tACS SUVR for the entire brain and report the average value (and standard deviation) for the entire group of patients. A negative value express a decrease in the amount of proteins in the brain post tACS intervention.",
                                        "PrimaryOutcomeTimeFrame": "baseline and up to 12 weeks"
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "PET Tau Deposition",
                                        "PrimaryOutcomeDescription": "Changes in the tau deposition observed via PET imaging will be evaluated by comparing PET data acquired before and after the 20 tACS sessions. The metric used is SUVR, a measure of the amount of proteins in the brain identified at the PET exam. We will calculate the difference between pre and post tACS SUVR (dSUVR) for the entire brain and report the average value (and standard deviation) for the entire group of patients. A negative value express a decrease in the amount of proteins in the brain post tACS intervention.",
                                        "PrimaryOutcomeTimeFrame": "up to 12 weeks"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "PET Microglia Activation",
                                        "SecondaryOutcomeDescription": "Changes in the microglia activation observed via PET imaging will be evaluated by comparing PET data acquired before and after the 20 tACS sessions. The metric used is SUVR, a measure of the amount of proteins in the brain identified at the PET exam. We will calculate the difference between pre and post tACS SUVR (dSUVR) for the entire brain and report the average value (and standard deviation) for the entire group of patients. A negative value express a decrease in the amount of proteins in the brain post tACS intervention.",
                                        "SecondaryOutcomeTimeFrame": "up to 12 weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Changes in Brain Perfusion as Measured by Arterial Spin Labeling",
                                        "SecondaryOutcomeDescription": "Patients underwent a comprehensive MRI exam before and after the tACS intervention, including measures of brain perfusion via Arterial Spin Labeling (ASL) sequences. The outcome measure represent the average change in perfusion (i.e. blood flow) recorded in regions targeted by tACS. Since Alzheimer's Disease is also characterized by a decrease of brain metabolism, an increased of blood flow after treatment would constitute a very promising sign of tACS efficacy in reducing Alzheimer's pathology in the brain.\n\nWe will report the change in blood flow (mean, standard deviation) after tACS treatment.",
                                        "SecondaryOutcomeTimeFrame": "6 weeks (pre-post tACS intervention)"
                                    }
                                ]
                            },
                            "OtherOutcomeList": {
                                "OtherOutcome": [
                                    {
                                        "OtherOutcomeMeasure": "Alzheimer's Disease Assessment Scale -Cog Score",
                                        "OtherOutcomeDescription": "Change in Adas-Cog score will be reported, to document a potential clinical benefit of tACS. The scale ranges from 0-70 with higher score indicating greater cognitive impairment.",
                                        "OtherOutcomeTimeFrame": "up to 12 weeks"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nClinical Diagnosis of mild to moderate AD*\nMini Mental State Examination (MMSE) > 18\nMild AD ≥ 21\nModerate AD 18-20\n\nDemonstration or history of memory impairments.\n\n* Confirmation of diagnosis will be made by the study MD based on a holistic consideration of the participant's cognitive evaluation and history.\n\nAmyloid positive PET imaging\nAt least 45 years old\nOn a stable dose of medications for memory loss including cholinesterase inhibitors (e.g. donepezil, rivastigmine or memantine) as defined as 6 consecutive weeks of treatment at an unchanging dose\nMinimum of completed 8th grade education\nIQ> 85 as determined by the WTAR and no history of intellectual disability\n\nExclusion Criteria:\n\nCurrent history of poorly controlled migraines including chronic medication for migraine prevention\nCurrent or past history of any neurological disorder other than dementia, such as epilepsy, stroke, progressive neurologic disease (e.g. multiple sclerosis) or intracranial brain lesions; and history of previous neurosurgery or head trauma that resulted in residual neurologic impairment.\nPast or current history of major depression, bipolar disorder or psychotic disorders, or any other major psychiatric condition.\nContraindication for undergoing MRI or receiving TMS or tACS,\n>50 mSv of radiation exposure for research within the past year (PET imaging exclusion)\nPresence of the Thr/Thr polymorphism in the TSPO gene (rs6971) due to low affinity binding for the PBR 28 (microlgia) PET scan\nHistory of fainting spells of unknown or undetermined etiology that might constitute seizures.\nHistory of seizures, diagnosis of epilepsy, history of abnormal (epileptiform) EEG or immediate (1st degree relative) family history of epilepsy; with the exception of a single seizure of benign etiology (e.g. febrile seizure) in the judgment of the investigator.\nChronic (particularly) uncontrolled medical conditions that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.).\nMetal implants (excluding dental fillings) or devices such as pacemaker, medication pump, nerve stimulator, TENS unit, ventriculo-peritoneal shunt, cochlear implant, unless cleared by the study MD.\nSubstance abuse or dependence within the past six months.\nMedications will be reviewed by the responsible MD and a decision about inclusion will be made based on the following: The patient's past medical history, drug dose, history of recent medication changes or duration of treatment, and combination of CNS active drugs.\nAll female participants that are pre-menopausal will be required to have a pregnancy test; any participant who is pregnant or breastfeeding will not be enrolled in the study.\nSubjects who, in the investigator's opinion, might not be suitable for the study\nA hair style or head dress that prevents electrode contact with the scalp or would interfere with the stimulation (for example: thick braids, hair weave, afro, wig)",
                            "HealthyVolunteers": "No",
                            "Gender": "All",
                            "MinimumAge": "45 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "Beth Israel Deaconess Medical Center",
                                        "LocationCity": "Boston",
                                        "LocationState": "Massachusetts",
                                        "LocationZip": "02215",
                                        "LocationCountry": "United States"
                                    }
                                ]
                            }
                        },
                        "ReferencesModule": {
                            "ReferenceList": {
                                "Reference": [
                                    {
                                        "ReferencePMID": "34930421",
                                        "ReferenceType": "derived",
                                        "ReferenceCitation": "Sprugnoli G, Munsch F, Cappon D, Paciorek R, Macone J, Connor A, El Fakhri G, Salvador R, Ruffini G, Donohoe K, Shafi MM, Press D, Alsop DC, Pascual Leone A, Santarnecchi E. Impact of multisession 40Hz tACS on hippocampal perfusion in patients with Alzheimer's disease. Alzheimers Res Ther. 2021 Dec 20;13(1):203. doi: 10.1186/s13195-021-00922-4."
                                    }
                                ]
                            }
                        }
                    },
                    "ResultsSection": {
                        "ParticipantFlowModule": {
                            "FlowRecruitmentDetails": "5 participants were enrolled in the study. 4 out of 5 participants completed the study. 1 study subject did not complete the follow-up amyloid and tau PET scans.",
                            "FlowGroupList": {
                                "FlowGroup": [
                                    {
                                        "FlowGroupId": "FG000",
                                        "FlowGroupTitle": "tACS",
                                        "FlowGroupDescription": "Transcranial alternating current stimulation (tACS) tuned at the frequency of 40Hz (gamma frequency) will be applied for 1 hour in 20 sessions on consecutive weekdays. The tACS intervention (20 sessions) will be preceded and followed by amyloid, microglia and tau PET imaging as well as a clinical/cognitive evaluation. The assessment of the effect of stimulation on microglia activation, amyloid deposition and tau deposition will constitute a primary outcome measure. Assessment of adverse effects will be also evaluated as a secondary outcome. The effect of brain stimulation on brain connectivity will be assessed by EEG and MRI and cognitive function.\n\nTranscranial Alternating Current Stimulation (tACS): tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region."
                                    }
                                ]
                            },
                            "FlowPeriodList": {
                                "FlowPeriod": [
                                    {
                                        "FlowPeriodTitle": "Overall Study",
                                        "FlowMilestoneList": {
                                            "FlowMilestone": [
                                                {
                                                    "FlowMilestoneType": "STARTED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "5"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowMilestoneType": "COMPLETED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "4"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowMilestoneType": "NOT COMPLETED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "FlowDropWithdrawList": {
                                            "FlowDropWithdraw": [
                                                {
                                                    "FlowDropWithdrawType": "Withdrawal by Subject",
                                                    "FlowReasonList": {
                                                        "FlowReason": [
                                                            {
                                                                "FlowReasonGroupId": "FG000",
                                                                "FlowReasonNumSubjects": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "BaselineCharacteristicsModule": {
                            "BaselineGroupList": {
                                "BaselineGroup": [
                                    {
                                        "BaselineGroupId": "BG000",
                                        "BaselineGroupTitle": "tACS",
                                        "BaselineGroupDescription": "Transcranial alternating current stimulation (tACS) tuned at the frequency of 40Hz (gamma frequency) will be applied for 1 hour in 20 sessions on consecutive weekdays. The tACS intervention (20 sessions) will be preceded and followed by amyloid, microglia and tau PET imaging as well as a clinical/cognitive evaluation. The assessment of the effect of stimulation on microglia activation, amyloid deposition and tau deposition will constitute a primary outcome measure. Assessment of adverse effects will be also evaluated as a secondary outcome. The effect of brain stimulation on brain connectivity will be assessed by EEG and MRI and cognitive function.\n\nTranscranial Alternating Current Stimulation (tACS): tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region."
                                    }
                                ]
                            },
                            "BaselineDenomList": {
                                "BaselineDenom": [
                                    {
                                        "BaselineDenomUnits": "Participants",
                                        "BaselineDenomCountList": {
                                            "BaselineDenomCount": [
                                                {
                                                    "BaselineDenomCountGroupId": "BG000",
                                                    "BaselineDenomCountValue": "5"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "BaselineMeasureList": {
                                "BaselineMeasure": [
                                    {
                                        "BaselineMeasureTitle": "Age, Customized",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineClassTitle": "56",
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "1"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineClassTitle": "64",
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "1"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineClassTitle": "73",
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "1"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "BaselineClassTitle": "84",
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "2"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Sex: Female, Male",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineCategoryTitle": "Female",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "1"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Male",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "4"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Ethnicity (NIH/OMB)",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineCategoryTitle": "Hispanic or Latino",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Not Hispanic or Latino",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "5"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Unknown or Not Reported",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Race (NIH/OMB)",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineCategoryTitle": "American Indian or Alaska Native",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Asian",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Native Hawaiian or Other Pacific Islander",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Black or African American",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "White",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "5"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "More than one race",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Unknown or Not Reported",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Region of Enrollment",
                                        "BaselineMeasureParamType": "Number",
                                        "BaselineMeasureUnitOfMeasure": "participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineClassTitle": "United States",
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "5"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomeMeasuresModule": {
                            "OutcomeMeasureList": {
                                "OutcomeMeasure": [
                                    {
                                        "OutcomeMeasureType": "Primary",
                                        "OutcomeMeasureTitle": "PET Amyloid Burden",
                                        "OutcomeMeasureDescription": "Changes in the amyloid load observed via PET imaging will be evaluated by comparing PET data acquired before and after the 20 tACS sessions. The metric used is standardized uptake value ratio (SUVR), a measure of the amount of proteins in the brain identified at the PET exam. We will calculate the difference between pre and post tACS SUVR for the entire brain and report the average value (and standard deviation) for the entire group of patients. A negative value express a decrease in the amount of proteins in the brain post tACS intervention.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Mean",
                                        "OutcomeMeasureDispersionType": "Standard Deviation",
                                        "OutcomeMeasureUnitOfMeasure": "SUVR",
                                        "OutcomeMeasureTimeFrame": "baseline and up to 12 weeks",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "tACS",
                                                    "OutcomeGroupDescription": "Transcranial alternating current stimulation (tACS) tuned at the frequency of 40Hz (gamma frequency) will be applied for 1 hour in 20 sessions on consecutive weekdays. The tACS intervention (20 sessions) will be preceded and followed by amyloid, microglia and tau PET imaging as well as a clinical/cognitive evaluation. The assessment of the effect of stimulation on microglia activation, amyloid deposition and tau deposition will constitute a primary outcome measure. Assessment of adverse effects will be also evaluated as a secondary outcome. The effect of brain stimulation on brain connectivity will be assessed by EEG and MRI and cognitive function.\n\nTranscranial Alternating Current Stimulation (tACS): tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "5"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "-1.11",
                                                                            "OutcomeMeasurementSpread": "0.76"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Primary",
                                        "OutcomeMeasureTitle": "PET Tau Deposition",
                                        "OutcomeMeasureDescription": "Changes in the tau deposition observed via PET imaging will be evaluated by comparing PET data acquired before and after the 20 tACS sessions. The metric used is SUVR, a measure of the amount of proteins in the brain identified at the PET exam. We will calculate the difference between pre and post tACS SUVR (dSUVR) for the entire brain and report the average value (and standard deviation) for the entire group of patients. A negative value express a decrease in the amount of proteins in the brain post tACS intervention.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Mean",
                                        "OutcomeMeasureDispersionType": "Standard Deviation",
                                        "OutcomeMeasureUnitOfMeasure": "SUVR",
                                        "OutcomeMeasureTimeFrame": "up to 12 weeks",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "tACS",
                                                    "OutcomeGroupDescription": "Transcranial alternating current stimulation (tACS) tuned at the frequency of 40Hz (gamma frequency) will be applied for 1 hour in 20 sessions on consecutive weekdays. The tACS intervention (20 sessions) will be preceded and followed by amyloid, microglia and tau PET imaging as well as a clinical/cognitive evaluation. The assessment of the effect of stimulation on microglia activation, amyloid deposition and tau deposition will constitute a primary outcome measure. Assessment of adverse effects will be also evaluated as a secondary outcome. The effect of brain stimulation on brain connectivity will be assessed by EEG and MRI and cognitive function.\n\nTranscranial Alternating Current Stimulation (tACS): tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "5"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "-2.85",
                                                                            "OutcomeMeasurementSpread": "1.20"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Secondary",
                                        "OutcomeMeasureTitle": "PET Microglia Activation",
                                        "OutcomeMeasureDescription": "Changes in the microglia activation observed via PET imaging will be evaluated by comparing PET data acquired before and after the 20 tACS sessions. The metric used is SUVR, a measure of the amount of proteins in the brain identified at the PET exam. We will calculate the difference between pre and post tACS SUVR (dSUVR) for the entire brain and report the average value (and standard deviation) for the entire group of patients. A negative value express a decrease in the amount of proteins in the brain post tACS intervention.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Mean",
                                        "OutcomeMeasureDispersionType": "Standard Deviation",
                                        "OutcomeMeasureUnitOfMeasure": "SUVR",
                                        "OutcomeMeasureTimeFrame": "up to 12 weeks",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "tACS",
                                                    "OutcomeGroupDescription": "Transcranial alternating current stimulation (tACS) tuned at the frequency of 40Hz (gamma frequency) will be applied for 1 hour in 20 sessions on consecutive weekdays. The tACS intervention (20 sessions) will be preceded and followed by amyloid, microglia and tau PET imaging as well as a clinical/cognitive evaluation. The assessment of the effect of stimulation on microglia activation, amyloid deposition and tau deposition will constitute a primary outcome measure. Assessment of adverse effects will be also evaluated as a secondary outcome. The effect of brain stimulation on brain connectivity will be assessed by EEG and MRI and cognitive function.\n\nTranscranial Alternating Current Stimulation (tACS): tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "5"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "-0.56",
                                                                            "OutcomeMeasurementSpread": "1.08"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Secondary",
                                        "OutcomeMeasureTitle": "Changes in Brain Perfusion as Measured by Arterial Spin Labeling",
                                        "OutcomeMeasureDescription": "Patients underwent a comprehensive MRI exam before and after the tACS intervention, including measures of brain perfusion via Arterial Spin Labeling (ASL) sequences. The outcome measure represent the average change in perfusion (i.e. blood flow) recorded in regions targeted by tACS. Since Alzheimer's Disease is also characterized by a decrease of brain metabolism, an increased of blood flow after treatment would constitute a very promising sign of tACS efficacy in reducing Alzheimer's pathology in the brain.\n\nWe will report the change in blood flow (mean, standard deviation) after tACS treatment.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Mean",
                                        "OutcomeMeasureDispersionType": "Standard Deviation",
                                        "OutcomeMeasureUnitOfMeasure": "mg/min/100gr",
                                        "OutcomeMeasureTimeFrame": "6 weeks (pre-post tACS intervention)",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "tACS",
                                                    "OutcomeGroupDescription": "Transcranial alternating current stimulation (tACS) tuned at the frequency of 40Hz (gamma frequency) will be applied for 1 hour in 20 sessions on consecutive weekdays. The tACS intervention (20 sessions) will be preceded and followed by amyloid, microglia and tau PET imaging as well as a clinical/cognitive evaluation. The assessment of the effect of stimulation on microglia activation, amyloid deposition and tau deposition will constitute a primary outcome measure. Assessment of adverse effects will be also evaluated as a secondary outcome. The effect of brain stimulation on brain connectivity will be assessed by EEG and MRI and cognitive function.\n\nTranscranial Alternating Current Stimulation (tACS): tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "5"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "1.2",
                                                                            "OutcomeMeasurementSpread": "0.6"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Other Pre-specified",
                                        "OutcomeMeasureTitle": "Alzheimer's Disease Assessment Scale -Cog Score",
                                        "OutcomeMeasureDescription": "Change in Adas-Cog score will be reported, to document a potential clinical benefit of tACS. The scale ranges from 0-70 with higher score indicating greater cognitive impairment.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Mean",
                                        "OutcomeMeasureDispersionType": "Standard Deviation",
                                        "OutcomeMeasureUnitOfMeasure": "Scores on a scale",
                                        "OutcomeMeasureTimeFrame": "up to 12 weeks",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "tACS",
                                                    "OutcomeGroupDescription": "Transcranial alternating current stimulation (tACS) tuned at the frequency of 40Hz (gamma frequency) will be applied for 1 hour in 20 sessions on consecutive weekdays. The tACS intervention (20 sessions) will be preceded and followed by amyloid, microglia and tau PET imaging as well as a clinical/cognitive evaluation. The assessment of the effect of stimulation on microglia activation, amyloid deposition and tau deposition will constitute a primary outcome measure. Assessment of adverse effects will be also evaluated as a secondary outcome. The effect of brain stimulation on brain connectivity will be assessed by EEG and MRI and cognitive function.\n\nTranscranial Alternating Current Stimulation (tACS): tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "5"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "1.5",
                                                                            "OutcomeMeasurementSpread": "2.9"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "AdverseEventsModule": {
                            "EventsFrequencyThreshold": "0",
                            "EventsTimeFrame": "1 year",
                            "EventGroupList": {
                                "EventGroup": [
                                    {
                                        "EventGroupId": "EG000",
                                        "EventGroupTitle": "tACS",
                                        "EventGroupDescription": "Transcranial alternating current stimulation (tACS) tuned at the frequency of 40Hz (gamma frequency) will be applied for 1 hour in 20 sessions on consecutive weekdays. The tACS intervention (20 sessions) will be preceded and followed by amyloid, microglia and tau PET imaging as well as a clinical/cognitive evaluation. The assessment of the effect of stimulation on microglia activation, amyloid deposition and tau deposition will constitute a primary outcome measure. Assessment of adverse effects will be also evaluated as a secondary outcome. The effect of brain stimulation on brain connectivity will be assessed by EEG and MRI and cognitive function.\n\nTranscranial Alternating Current Stimulation (tACS): tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.",
                                        "EventGroupDeathsNumAffected": "0",
                                        "EventGroupDeathsNumAtRisk": "5",
                                        "EventGroupSeriousNumAffected": "1",
                                        "EventGroupSeriousNumAtRisk": "5",
                                        "EventGroupOtherNumAffected": "5",
                                        "EventGroupOtherNumAtRisk": "5"
                                    }
                                ]
                            },
                            "SeriousEventList": {
                                "SeriousEvent": [
                                    {
                                        "SeriousEventTerm": "Sensation Under Electrodes",
                                        "SeriousEventOrganSystem": "General disorders",
                                        "SeriousEventAssessmentType": "Systematic Assessment",
                                        "SeriousEventStatsList": {
                                            "SeriousEventStats": [
                                                {
                                                    "SeriousEventStatsGroupId": "EG000",
                                                    "SeriousEventStatsNumEvents": "1",
                                                    "SeriousEventStatsNumAffected": "1",
                                                    "SeriousEventStatsNumAtRisk": "5"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "OtherEventList": {
                                "OtherEvent": [
                                    {
                                        "OtherEventTerm": "Headache",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "5"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Scalp Pain",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "5"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Neck Pain",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "5"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Skin Irritation",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumAffected": "3",
                                                    "OtherEventStatsNumAtRisk": "5"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Sensations Under Electrodes",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventNotes": "tingling, itching, burning",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumAffected": "5",
                                                    "OtherEventStatsNumAtRisk": "5"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Visual Changes",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventNotes": "flashing lights in peripheral vision",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumAffected": "3",
                                                    "OtherEventStatsNumAtRisk": "5"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Mood Change",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventNotes": "positive mood change",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "5"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "MoreInfoModule": {
                            "CertainAgreement": {
                                "AgreementPISponsorEmployee": "No",
                                "AgreementRestrictiveAgreement": "No"
                            },
                            "PointOfContact": {
                                "PointOfContactTitle": "Emiliano Santarnecchi",
                                "PointOfContactOrganization": "Massachusetts General Hospital",
                                "PointOfContactEMail": "esantarnecchi@mgh.harvard.edu",
                                "PointOfContactPhone": "617-667-0326"
                            }
                        }
                    },
                    "DocumentSection": {
                        "LargeDocumentModule": {
                            "LargeDocList": {
                                "LargeDoc": [
                                    {
                                        "LargeDocTypeAbbrev": "Prot_SAP",
                                        "LargeDocHasProtocol": "Yes",
                                        "LargeDocHasSAP": "Yes",
                                        "LargeDocHasICF": "No",
                                        "LargeDocLabel": "Study Protocol and Statistical Analysis Plan",
                                        "LargeDocDate": "December 10, 2018",
                                        "LargeDocUploadDate": "05/05/2020 17:02",
                                        "LargeDocFilename": "Prot_SAP_000.pdf"
                                    }
                                ]
                            }
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022",
                            "SubmissionTracking": {}
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000000544",
                                        "ConditionMeshTerm": "Alzheimer Disease"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000003704",
                                        "ConditionAncestorTerm": "Dementia"
                                    },
                                    {
                                        "ConditionAncestorId": "D000001927",
                                        "ConditionAncestorTerm": "Brain Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000002493",
                                        "ConditionAncestorTerm": "Central Nervous System Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009422",
                                        "ConditionAncestorTerm": "Nervous System Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000024801",
                                        "ConditionAncestorTerm": "Tauopathies"
                                    },
                                    {
                                        "ConditionAncestorId": "D000019636",
                                        "ConditionAncestorTerm": "Neurodegenerative Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000019965",
                                        "ConditionAncestorTerm": "Neurocognitive Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000001523",
                                        "ConditionAncestorTerm": "Mental Disorders"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M3037",
                                        "ConditionBrowseLeafName": "Alzheimer Disease",
                                        "ConditionBrowseLeafAsFound": "Alzheimer's Disease",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M6056",
                                        "ConditionBrowseLeafName": "Dementia",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M4356",
                                        "ConditionBrowseLeafName": "Brain Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M4894",
                                        "ConditionBrowseLeafName": "Central Nervous System Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M22155",
                                        "ConditionBrowseLeafName": "Tauopathies",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M20711",
                                        "ConditionBrowseLeafName": "Neurodegenerative Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M20989",
                                        "ConditionBrowseLeafName": "Neurocognitive Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M3967",
                                        "ConditionBrowseLeafName": "Mental Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M13625",
                                        "ConditionBrowseLeafName": "Psychotic Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "T2192",
                                        "ConditionBrowseLeafName": "Familial Alzheimer Disease",
                                        "ConditionBrowseLeafAsFound": "Alzheimer's Disease",
                                        "ConditionBrowseLeafRelevance": "high"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC10",
                                        "ConditionBrowseBranchName": "Nervous System Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BXM",
                                        "ConditionBrowseBranchName": "Behaviors and Mental Disorders"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "Rare",
                                        "ConditionBrowseBranchName": "Rare Diseases"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 28,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT03805854",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "01/2019"
                            },
                            "Organization": {
                                "OrgFullName": "Technische Universität München",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Modulating Pain Using Transcranial Alternating Stimulation (tACS) in Healthy Human Subjects",
                            "OfficialTitle": "Modulating Pain Using Transcranial Alternating Stimulation (tACS) in Healthy Human Subjects"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "June 2020",
                            "OverallStatus": "Completed",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "April 15, 2019",
                                "StartDateType": "Actual"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "October 23, 2019",
                                "PrimaryCompletionDateType": "Actual"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "October 23, 2019",
                                "CompletionDateType": "Actual"
                            },
                            "StudyFirstSubmitDate": "January 10, 2019",
                            "StudyFirstSubmitQCDate": "January 15, 2019",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "January 16, 2019",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "June 2, 2020",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "June 4, 2020",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Principal Investigator",
                                "ResponsiblePartyInvestigatorFullName": "Markus Ploner",
                                "ResponsiblePartyInvestigatorTitle": "Heisenberg Professor of Human Pain Research",
                                "ResponsiblePartyInvestigatorAffiliation": "Technische Universität München"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Technische Universität München",
                                "LeadSponsorClass": "OTHER"
                            },
                            "CollaboratorList": {
                                "Collaborator": [
                                    {
                                        "CollaboratorName": "German Research Foundation",
                                        "CollaboratorClass": "OTHER"
                                    }
                                ]
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "No",
                            "IsFDARegulatedDrug": "No",
                            "IsFDARegulatedDevice": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "Pain is a highly complex and subjective phenomenon which results from the dynamic integration of sensory and contextual (i.e. cognitive, emotional, and motivational) processes. Recent evidence suggests that neural oscillations and their synchronization between different brain areas might form the basis of these integrative functions. When investigating tonic experimental pain lasting for several minutes, for example, objective stimulus intensity is inversely related to alpha (8-13 Hz) and beta (13-30 Hz) oscillations in early somatosensory areas, while subjective pain intensity is positively associated with gamma (30-100 Hz) oscillations in prefrontal cortex. Yet, with a few exemptions, reported links between oscillatory brain activity and pain have mostly been established by correlative approaches which do not allow to infer causality. The current project aims at comprehensively investigating the causal role of neural oscillations for tonic experimental pain in healthy human subjects. To this end, transcranial alternating current stimulation (tACS) will be employed to modulate oscillatory brain activity in alpha and gamma frequency bands and investigate effects of this manipulation on pain perception and pain-related autonomic responses. Using an established tonic pain stimulation protocol and a double-blind, sham-controlled design, effects of tACS of somatosensory as well as prefrontal brain areas will be investigated. Results promise to elucidate the neural mechanisms underlying tonic experimental pain by testing the mechanistic role of neural oscillations in different aspects of pain processing. Furthermore, they might contribute to the development of urgently needed new treatment approaches for chronic pain using neuromodulatory methods."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Experimental Pain in Healthy Human Subjects"
                                ]
                            },
                            "KeywordList": {
                                "Keyword": [
                                    "pain",
                                    "tACS",
                                    "alpha",
                                    "gamma",
                                    "neural oscillations",
                                    "brain"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Not Applicable"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "N/A",
                                "DesignInterventionModel": "Single Group Assignment",
                                "DesignInterventionModelDescription": "Each participant will participate in 6 experimental conditions aimed at studying the effect of different tACS protocols on pain processing: (1) 10 Hz tACS of the bilateral somatosensory cortex, (2) 10 Hz tACS of the prefrontal cortex, (3) 80 Hz tACS of the bilateral somatosensory cortex, (4) 80 Hz tACS of the prefrontal cortex, (5) sham stimulation of the bilateral somatosensory cortex, and (6) sham stimulation of the prefrontal cortex. Each condition will be administered in an individual session. Sessions will be conducted in pseudo-randomized order and separated by at least 24 hours to avoid any carry-over effects of the stimulation. During each tACS administration, pain will be induced by means of an established tonic thermal stimulation paradigm lasting for several minutes (TSA-II; Medoc, Ramat Yishai, Israel) while pain ratings and autonomic responses will be recorded (Nickel et al., 2017a; Nickel et al., 2017b).",
                                "DesignPrimaryPurpose": "Basic Science",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "None (Open Label)",
                                    "DesignMaskingDescription": "Neither participants nor the conducting investigator will be informed about the administered tACS protocol (10 Hz tACS, 80 Hz tACS or sham stimulation) (= double-blind study). Blinding of participants will be achieved by using tACS intensities which should not evoke perceivable stimulation side effects like skin or visual sensations. Blinding of participants will be controlled using post-hoc questionnaires. An unblinded research assistant who does not interact with the participants will be responsible for initiating and monitoring the appropriate tACS protocol and, thus, enable the blinding of the conducting investigator."
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "39",
                                "EnrollmentType": "Actual"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "Transcranial alternating current stimulation (tACS)",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: 10 Hz tACS of the bilateral somatosensory cortex",
                                                "Device: 10 Hz tACS of the prefrontal cortex",
                                                "Device: 80 Hz tACS of the bilateral somatosensory cortex",
                                                "Device: 80 Hz tACS of the prefrontal cortex",
                                                "Device: Sham stimulation of the bilateral somatosensory cortex",
                                                "Device: Sham stimulation of the prefrontal cortex"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "10 Hz tACS of the bilateral somatosensory cortex",
                                        "InterventionDescription": "10 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Transcranial alternating current stimulation (tACS)"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "10 Hz tACS of the prefrontal cortex",
                                        "InterventionDescription": "10 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5*5 cm rubber electrodes placed at electrode positions F3 and F4 according to the international 10-20 system.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Transcranial alternating current stimulation (tACS)"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "80 Hz tACS of the bilateral somatosensory cortex",
                                        "InterventionDescription": "80 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Transcranial alternating current stimulation (tACS)"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "80 Hz tACS of the prefrontal cortex",
                                        "InterventionDescription": "80 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 minutes using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5*5 cm rubber electrodes placed at electrode positions F3 and F4 according to the international 10-20 system.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Transcranial alternating current stimulation (tACS)"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "Sham stimulation of the bilateral somatosensory cortex",
                                        "InterventionDescription": "10 Hz tACS at 1 mA will be applied over the bilateral somatosensory cortex for 10 seconds at the beginning of the experimental session using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5*5 cm rubber electrodes placed at electrode positions CP3 and CP4 according to the international 10-20 system.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Transcranial alternating current stimulation (tACS)"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "Sham stimulation of the prefrontal cortex",
                                        "InterventionDescription": "10 Hz tACS at 1 mA will be applied over the prefrontal cortex for 10 seconds at the beginning of the experimental session using a Neuroconn stimulator (DC-Stimulator MR; Neuroconn, Ilmenau, Germany) and 2 5*5 cm rubber placed at electrode positions F3 and F4 according to the international 10-20 system.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Transcranial alternating current stimulation (tACS)"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Changes in pain rating on visual analogue scale (VAS; 0: 'no pain' to 10: 'maximal tolerable pain') between sessions",
                                        "PrimaryOutcomeDescription": "During thermal stimulation, participants will be instructed to continuously rate the currently perceived pain intensity using a finger-span device.",
                                        "PrimaryOutcomeTimeFrame": "During 10 min thermal stimulation in each of six interventions (10 Hz tACS/80 Hz tACS/sham stimulation of the somatosensory/prefrontal cortex), which are separated by at least 24 hrs."
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "Changes in skin conductance responses (µS) between sessions",
                                        "PrimaryOutcomeDescription": "Skin conductance responses will be recorded using two electrodes attached to the index and middle finger of the left hand.",
                                        "PrimaryOutcomeTimeFrame": "During 10 min thermal stimulation in each of six interventions (10 Hz tACS/80 Hz tACS/sham stimulation of the somatosensory/prefrontal cortex), which are separated by at least 24 hrs."
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "Changes in heart rate (BPM, beats per minute) between sessions",
                                        "PrimaryOutcomeDescription": "The electrocardiogram (ECG) will be recorded using two electrodes placed under the right clavicle and below the sternum, respectively.",
                                        "PrimaryOutcomeTimeFrame": "During 10 min thermal stimulation in each of six interventions (10 Hz tACS/80 Hz tACS/sham stimulation of the somatosensory/prefrontal cortex), which are separated by at least 24 hrs."
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "Changes in oscillatory brain activity before and after tACS application within each session",
                                        "PrimaryOutcomeDescription": "5-minute resting state electroencephalogram (EEG) will be recorded with two electrodes placed at the same electrode positions used for the respective tACS protocol. Power of oscillatory brain activity will be quantified in the alpha (8-12 Hz) and gamma (30-100 Hz) bands.",
                                        "PrimaryOutcomeTimeFrame": "Measured immediately before and after the tACS protocol in each of six interventions (10 Hz tACS/80 Hz tACS/sham stimulation of the somatosensory/prefrontal cortex), which are separated by at least 24 hrs."
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "Perception of tACS induced visual and skin sensations measured by numerical rating scale (NRS; 0: 'no sensation' to 10: 'very strong sensation')",
                                        "SecondaryOutcomeDescription": "The perception of visual and skin sensations induced by the tACS protocols will be assessed using a custom questionnaire.",
                                        "SecondaryOutcomeTimeFrame": "Measured immediately after the EEG measurement following each of six interventions (10 Hz tACS/80 Hz tACS/sham stimulation of the somatosensory/prefrontal cortex), which are separated by at least 24 hrs."
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\naged 18-65 years\nRight-handedness\nWritten informed consent\n\nExclusion Criteria:\n\nPregnancy\nNeurological or psychiatric diseases (e.g. epilepsy, stroke, depression, anxiety disorders)\nSevere general illnesses (e.g. tumors, diabetes)\nSkin diseases (e.g. dermatitis, psoriasis or eczema)\nCurrent or recurrent pain\nRegular intake of medication\nSurgical procedures involving the head or spinal cord\nHead trauma followed by impairment of consciousness\nPast fainting spells or syncopes\nMetal (except titanium) or electronic implants\nSide-effects following previous electrical or magnetic stimulation\nSide-effects following previous thermal stimulation",
                            "HealthyVolunteers": "Accepts Healthy Volunteers",
                            "Gender": "All",
                            "MinimumAge": "18 Years",
                            "MaximumAge": "65 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Markus Ploner, Prof. Dr. med.",
                                        "OverallOfficialAffiliation": "Department of Neurology, Klinikum rechts der Isar, Technische Universität München",
                                        "OverallOfficialRole": "Principal Investigator"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "Department of Neurology, Klinikum rechts der Isar, Technische Universität München",
                                        "LocationCity": "Munich",
                                        "LocationState": "Bavaria",
                                        "LocationZip": "81675",
                                        "LocationCountry": "Germany"
                                    }
                                ]
                            }
                        },
                        "ReferencesModule": {
                            "ReferenceList": {
                                "Reference": [
                                    {
                                        "ReferencePMID": "30268803",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Ahn S, Prim JH, Alexander ML, McCulloch KL, Fröhlich F. Identifying and Engaging Neuronal Oscillations by Transcranial Alternating Current Stimulation in Patients With Chronic Low Back Pain: A Randomized, Crossover, Double-Blind, Sham-Controlled Pilot Study. J Pain. 2019 Mar;20(3):277.e1-277.e11. doi: 10.1016/j.jpain.2018.09.004. Epub 2018 Sep 27."
                                    },
                                    {
                                        "ReferencePMID": "29551661",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Arendsen LJ, Hugh-Jones S, Lloyd DM. Transcranial Alternating Current Stimulation at Alpha Frequency Reduces Pain When the Intensity of Pain is Uncertain. J Pain. 2018 Jul;19(7):807-818. doi: 10.1016/j.jpain.2018.02.014. Epub 2018 Mar 15."
                                    },
                                    {
                                        "ReferencePMID": "23785325",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Herrmann CS, Rach S, Neuling T, Strüber D. Transcranial alternating current stimulation: a review of the underlying mechanisms and modulation of cognitive processes. Front Hum Neurosci. 2013 Jun 14;7:279. doi: 10.3389/fnhum.2013.00279. eCollection 2013."
                                    },
                                    {
                                        "ReferencePMID": "24535464",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Jensen MP, Day MA, Miró J. Neuromodulatory treatments for chronic pain: efficacy and mechanisms. Nat Rev Neurol. 2014 Mar;10(3):167-78. doi: 10.1038/nrneurol.2014.12. Epub 2014 Feb 18. Review."
                                    },
                                    {
                                        "ReferencePMID": "28700538",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Nickel MM, May ES, Tiemann L, Postorino M, Ta Dinh S, Ploner M. Autonomic responses to tonic pain are more closely related to stimulus intensity than to pain intensity. Pain. 2017 Nov;158(11):2129-2136. doi: 10.1097/j.pain.0000000000001010."
                                    },
                                    {
                                        "ReferencePMID": "28069543",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Nickel MM, May ES, Tiemann L, Schmidt P, Postorino M, Ta Dinh S, Gross J, Ploner M. Brain oscillations differentially encode noxious stimulus intensity and pain intensity. Neuroimage. 2017 Mar 1;148:141-147. doi: 10.1016/j.neuroimage.2017.01.011. Epub 2017 Jan 7."
                                    },
                                    {
                                        "ReferencePMID": "28025007",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Ploner M, Sorg C, Gross J. Brain Rhythms of Pain. Trends Cogn Sci. 2017 Feb;21(2):100-110. doi: 10.1016/j.tics.2016.12.001. Epub 2016 Dec 23. Review."
                                    },
                                    {
                                        "ReferencePMID": "29311747",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Polanía R, Nitsche MA, Ruff CC. Studying and modifying brain function with non-invasive brain stimulation. Nat Neurosci. 2018 Feb;21(2):174-187. doi: 10.1038/s41593-017-0054-4. Epub 2018 Jan 8. Review."
                                    },
                                    {
                                        "ReferencePMID": "25754338",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Schulz E, May ES, Postorino M, Tiemann L, Nickel MM, Witkovsky V, Schmidt P, Gross J, Ploner M. Prefrontal Gamma Oscillations Encode Tonic Pain in Humans. Cereb Cortex. 2015 Nov;25(11):4407-14. doi: 10.1093/cercor/bhv043. Epub 2015 Mar 8."
                                    },
                                    {
                                        "ReferencePMID": "28003656",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Sitaram R, Ros T, Stoeckel L, Haller S, Scharnowski F, Lewis-Peacock J, Weiskopf N, Blefari ML, Rana M, Oblak E, Birbaumer N, Sulzer J. Closed-loop brain training: the science of neurofeedback. Nat Rev Neurosci. 2017 Feb;18(2):86-100. doi: 10.1038/nrn.2016.164. Epub 2016 Dec 22. Review. Erratum in: Nat Rev Neurosci. 2019 May;20(5):314."
                                    },
                                    {
                                        "ReferencePMID": "29887799",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Vosskuhl J, Strüber D, Herrmann CS. Non-invasive Brain Stimulation: A Paradigm Shift in Understanding Brain Oscillations. Front Hum Neurosci. 2018 May 25;12:211. doi: 10.3389/fnhum.2018.00211. eCollection 2018. Review."
                                    },
                                    {
                                        "ReferencePMID": "33845173",
                                        "ReferenceType": "derived",
                                        "ReferenceCitation": "May ES, Hohn VD, Nickel MM, Tiemann L, Gil Ávila C, Heitmann H, Sauseng P, Ploner M. Modulating Brain Rhythms of Pain Using Transcranial Alternating Current Stimulation (tACS) - A Sham-Controlled Study in Healthy Human Participants. J Pain. 2021 Oct;22(10):1256-1272. doi: 10.1016/j.jpain.2021.03.150. Epub 2021 Jun 12."
                                    }
                                ]
                            }
                        },
                        "IPDSharingStatementModule": {
                            "IPDSharing": "Yes",
                            "IPDSharingDescription": "Pseudonymized individual participant data sets will be made available at the OSF online repository [https://osf.io/] upon publication.",
                            "IPDSharingURL": "https://osf.io/pnd6g/"
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M12218",
                                        "ConditionBrowseLeafName": "Pain",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC23",
                                        "ConditionBrowseBranchName": "Symptoms and General Pathology"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 29,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT00203372",
                            "NCTIdAliasList": {
                                "NCTIdAlias": [
                                    "NCT00128674"
                                ]
                            },
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "TORI B-02"
                            },
                            "SecondaryIdInfoList": {
                                "SecondaryIdInfo": [
                                    {
                                        "SecondaryId": "10-001419",
                                        "SecondaryIdType": "Other Identifier",
                                        "SecondaryIdDomain": "JCCC IRB"
                                    }
                                ]
                            },
                            "Organization": {
                                "OrgFullName": "Translational Oncology Research International",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Neoadjuvant TAC Plus or Minus Bevacizumab(AVF3299)",
                            "OfficialTitle": "A Multicenter, Placebo-Controlled, Double-Blind Randomized Phase II Trial of Neoadjuvant Treatment With Single-Agent Bevacizumab or Placebo, Followed by Six Cycles of Docetaxel, Doxorubicin, and Cyclophosphamide (TAC), With or Without Bevacizumab in Patients With Stage II or Stage III Breast Cancer"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "February 2011",
                            "OverallStatus": "Completed",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "May 2005"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "June 2012",
                                "PrimaryCompletionDateType": "Actual"
                            },
                            "StudyFirstSubmitDate": "September 12, 2005",
                            "StudyFirstSubmitQCDate": "September 12, 2005",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "September 20, 2005",
                                "StudyFirstPostDateType": "Estimate"
                            },
                            "LastUpdateSubmitDate": "October 9, 2015",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "October 12, 2015",
                                "LastUpdatePostDateType": "Estimate"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Sponsor"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Translational Oncology Research International",
                                "LeadSponsorClass": "OTHER"
                            },
                            "CollaboratorList": {
                                "Collaborator": [
                                    {
                                        "CollaboratorName": "Genentech, Inc.",
                                        "CollaboratorClass": "INDUSTRY"
                                    }
                                ]
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "Yes"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "The purpose of this study is to evaluate the safety of the TAC-bevacizumab combination and investigate whether changes in gene expression, or the expression of specific biomarkers, are either predictive of response to bevacizumab or indicative of response.",
                            "DetailedDescription": "The study combines bevacizumab with a very efficacious combination chemotherapy regimen for the treatment of stage II or stage III primary breast cancer. Safety of the TAC-bevacizumab combination will be evaluated. In addition, the study design incorporates an initial cycle of bevacizumab or placebo alone. Assessing the isolated effects of bevacizumab in a setting where pre- and post-treatment tissue specimens can be obtained will provide essential information about the mechanisms by which VEGF inhibition affects tumor growth, and represents an ideal opportunity to evaluate the molecular effects of bevacizumab on breast tumor tissue."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Breast Cancer"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Phase 2"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "Randomized",
                                "DesignInterventionModel": "Parallel Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "Double",
                                    "DesignWhoMaskedList": {
                                        "DesignWhoMasked": [
                                            "Participant",
                                            "Investigator"
                                        ]
                                    }
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "6",
                                "EnrollmentType": "Actual"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "Bevacizumab 7.5 and TAC",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "one dose of Bevacizumab (7.5mg/kg) will be administered intravenously every 3 weeks followed by TAC.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: Bevacizumab 7.5 and TAC"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "Placebo 7.5 and TAC",
                                        "ArmGroupType": "Placebo Comparator",
                                        "ArmGroupDescription": "Placebo7.5 will be administered intravenously every 3 weeks followed by TAC.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "Bevacizumab 15 and TAC",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "one dose of Bevacizumab (15mg/kg) will be administered intravenously every 3 weeks followed by TAC.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: Bevacizumab 15 and TAC"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "Placebo 15 and TAC",
                                        "ArmGroupType": "Placebo Comparator",
                                        "ArmGroupDescription": "Placebo 15mg/kg will be administered intravenously every 3 weeks followed by TAC.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: Placebo 15 and TAC"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "Bevacizumab 7.5 and TAC",
                                        "InterventionDescription": "Bevacizumab given intravenously at a dose of 7.5mg/kg every 3 weeks, followed by docetaxel, doxorubicin and cyclophosphamide (TAC).",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Bevacizumab 7.5 and TAC"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)",
                                        "InterventionDescription": "placebo 7.5 will be adminitered intravenously every 3 weeks followed by TAC",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Placebo 7.5 and TAC"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "Bevacizumab 15 and TAC",
                                        "InterventionDescription": "one dose of Bevacizumab (15 mg/kg) will be administered intravenously every 3 weeks followed by TAC.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Bevacizumab 15 and TAC"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "Placebo 15 and TAC",
                                        "InterventionDescription": "one dose of placebo 15 will be administered intravenously every 3 weeks followed by TAC.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Placebo 15 and TAC"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "•To evaluate the safety and toxicity of the TAC regimen with the addition of bevacizumab given as preoperative therapy to patients with Stage II or Stage III breast cancer",
                                        "PrimaryOutcomeDescription": "Patients will be evaluated for adverse events (all grades) at each study visit for the duration of their participation in the study. All AEs should be graded using the NCI--CTCAE, Version 3.0. Patients discontinued from the treatment phase of the study for any reason will be evaluated within 30 days after the decision to discontinue treatment.",
                                        "PrimaryOutcomeTimeFrame": "4 years"
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "•To estimate change from baseline expression of HIF1α as a measure of tumor angiogenesis, after a single dose of bevacizumab as compared to placebo",
                                        "PrimaryOutcomeTimeFrame": "4 years"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "•To estimate the rate of CHF in patients receiving TAC with or without bevacizumab",
                                        "SecondaryOutcomeTimeFrame": "4 years"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "•To estimate the rates of left ventricular ejection fraction (LVEF) changes as measured by either a decrease of > 15% from baseline, or > 10% to a value below the lower limit of normal (for the institution), in patients receiving TAC or TAC + bevacizumab",
                                        "SecondaryOutcomeTimeFrame": "4 years"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "•To investigate the clinical efficacy of TAC and TAC plus bevacizumab by estimating the clinical objective response rate (CR + PR), pathologic complete response rate (pCR), and rate of breast-conserving surgery (BCS)",
                                        "SecondaryOutcomeTimeFrame": "4 years"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "•To estimate the rate of post-surgical wound healing complications in patients who receive surgery after TAC or TAC plus bevacizumab",
                                        "SecondaryOutcomeTimeFrame": "4 years"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nHistologically or cytologically proven adenocarcinoma of the breast\nStage II (T > 3 cm) or Stage III disease (except inflammatory breast cancer), according to the AJCC Staging Manual, 6th Edition, 2002\nHER2-negative disease (as defined by fluorescence in situ hybridization [FISH])\nECOG performance status 0-1\nNo prior chemotherapy, radiotherapy, or endocrine therapy for invasive or noninvasive breast cancer\nNormal cardiac function (ejection fraction > lower limit of normal) as determined by MUGA or echocardiogram\nAdequate organ function\n\nExclusion Criteria:\n\nPrior chemotherapy or radiotherapy for Stage II or Stage III breast cancer\nInflammatory Breast Cancer, clinically defined as the presence of erythema or induration involving one-third or more of the breast\nPrior treatment with an anti-angiogenic agent\nPrior ipsilateral radiation therapy for invasive or non-invasive breast cancer\nBilateral invasive breast cancer\nConcurrent therapy with any other non-protocol anti-cancer therapy\nCurrent therapy with hormone replacement therapy, or any hormonal agent such as raloxifene, tamoxifen, or other selective estrogen receptor modulators (agents must be stopped prior to randomization)\nPresence of neuropathy > grade 2 (NCI-CTC version 3.0) at baseline\nPresence of any non-healing wound, bone fracture, or ulcer, or the presence of clinically significant (> grade 2) peripheral vascular disease\nHistory of any other malignancy within the past 5 years, with the exception of non-melanoma skin cancer or carcinoma-in-situ of the cervix\nClinically significant cardiovascular disease (e.g., hypertension [BP > 150/100], myocardial infarction or stroke within 6 months, unstable angina), New York Heart Association (NYHA) Grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication\nActive peptic ulcer disease, inflammatory bowel disease, or other gastrointestinal condition increasing the risk of perforation; history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to beginning therapy\nActive, uncontrolled infection requiring parenteral antimicrobials\nThe presence of any other medical or psychiatric disorder that, in the opinion of the treating physician, would contraindicate the use of the drugs in this protocol or place the subject at undue risk for treatment complications\nPregnancy or lactation\nA history of a severe hypersensitivity reaction to bevacizumab, or docetaxel or other drugs formulated with polysorbate 80\nEvidence of bleeding diathesis or coagulopathy\nMajor surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to beginning therapy, or anticipation of the need for a major surgical procedure during the course of the study; minor surgical procedure, fine needle aspiration, or core biopsy within 7 days prior to beginning therapy\nUrine protein:creatinine ratio of > 1.0 at screening",
                            "HealthyVolunteers": "No",
                            "Gender": "Female",
                            "MinimumAge": "18 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Fairooz Kabbinavar, MD",
                                        "OverallOfficialAffiliation": "Chief Medical Officer",
                                        "OverallOfficialRole": "Study Chair"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "UCLA Medical Center",
                                        "LocationCity": "Los Angeles",
                                        "LocationState": "California",
                                        "LocationZip": "90095",
                                        "LocationCountry": "United States"
                                    },
                                    {
                                        "LocationFacility": "Wilshire Oncology Medical Group, Inc.",
                                        "LocationCity": "Pomona",
                                        "LocationState": "California",
                                        "LocationZip": "91767",
                                        "LocationCountry": "United States"
                                    },
                                    {
                                        "LocationFacility": "Cancer Institute of Florida, P.A.",
                                        "LocationCity": "Orlando",
                                        "LocationState": "Florida",
                                        "LocationZip": "32804",
                                        "LocationCountry": "United States"
                                    },
                                    {
                                        "LocationFacility": "Northwest Georgia Oncology Centers, P.C.",
                                        "LocationCity": "Marietta",
                                        "LocationState": "Georgia",
                                        "LocationZip": "30060",
                                        "LocationCountry": "United States"
                                    },
                                    {
                                        "LocationFacility": "South Texas Oncology and Hematology, P.A.",
                                        "LocationCity": "San Antonio",
                                        "LocationState": "Texas",
                                        "LocationZip": "78207",
                                        "LocationCountry": "United States"
                                    },
                                    {
                                        "LocationFacility": "Cross Cancer Institute",
                                        "LocationCity": "Edmonton",
                                        "LocationState": "Alberta",
                                        "LocationZip": "T6G 1Z2",
                                        "LocationCountry": "Canada"
                                    },
                                    {
                                        "LocationFacility": "McGill University",
                                        "LocationCity": "Montreal",
                                        "LocationState": "Quebec",
                                        "LocationZip": "H2W 1S6",
                                        "LocationCountry": "Canada"
                                    },
                                    {
                                        "LocationFacility": "St. Vincent's University Hospital",
                                        "LocationCity": "Dublin",
                                        "LocationZip": "4",
                                        "LocationCountry": "Ireland"
                                    },
                                    {
                                        "LocationFacility": "St. James's Hospital",
                                        "LocationCity": "Dublin",
                                        "LocationZip": "8",
                                        "LocationCountry": "Ireland"
                                    }
                                ]
                            }
                        }
                    },
                    "AnnotationSection": {
                        "AnnotationModule": {
                            "UnpostedAnnotation": {
                                "UnpostedResponsibleParty": "Translational Oncology Research International",
                                "UnpostedEventList": {
                                    "UnpostedEvent": [
                                        {
                                            "UnpostedEventType": "Release",
                                            "UnpostedEventDate": "January 28, 2016"
                                        },
                                        {
                                            "UnpostedEventType": "Reset",
                                            "UnpostedEventDate": "February 25, 2016"
                                        },
                                        {
                                            "UnpostedEventType": "Release",
                                            "UnpostedEventDate": "October 17, 2016"
                                        },
                                        {
                                            "UnpostedEventType": "Reset",
                                            "UnpostedEventDate": "December 9, 2016"
                                        },
                                        {
                                            "UnpostedEventType": "Release",
                                            "UnpostedEventDate": "January 24, 2022"
                                        },
                                        {
                                            "UnpostedEventType": "Reset",
                                            "UnpostedEventDate": "February 15, 2022"
                                        }
                                    ]
                                }
                            }
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022",
                            "SubmissionTracking": {
                                "SubmissionInfoList": {
                                    "SubmissionInfo": [
                                        {
                                            "SubmissionReleaseDate": "January 28, 2016",
                                            "SubmissionResetDate": "February 25, 2016"
                                        },
                                        {
                                            "SubmissionReleaseDate": "October 17, 2016",
                                            "SubmissionResetDate": "December 9, 2016"
                                        },
                                        {
                                            "SubmissionReleaseDate": "January 24, 2022",
                                            "SubmissionResetDate": "February 15, 2022"
                                        }
                                    ]
                                }
                            }
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000001943",
                                        "ConditionMeshTerm": "Breast Neoplasms"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000009371",
                                        "ConditionAncestorTerm": "Neoplasms by Site"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009369",
                                        "ConditionAncestorTerm": "Neoplasms"
                                    },
                                    {
                                        "ConditionAncestorId": "D000001941",
                                        "ConditionAncestorTerm": "Breast Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000012871",
                                        "ConditionAncestorTerm": "Skin Diseases"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M4372",
                                        "ConditionBrowseLeafName": "Breast Neoplasms",
                                        "ConditionBrowseLeafAsFound": "Breast Cancer",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M4370",
                                        "ConditionBrowseLeafName": "Breast Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M14826",
                                        "ConditionBrowseLeafName": "Skin Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC04",
                                        "ConditionBrowseBranchName": "Neoplasms"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC17",
                                        "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionMeshList": {
                                "InterventionMesh": [
                                    {
                                        "InterventionMeshId": "D000003520",
                                        "InterventionMeshTerm": "Cyclophosphamide"
                                    },
                                    {
                                        "InterventionMeshId": "D000068258",
                                        "InterventionMeshTerm": "Bevacizumab"
                                    },
                                    {
                                        "InterventionMeshId": "D000077143",
                                        "InterventionMeshTerm": "Docetaxel"
                                    },
                                    {
                                        "InterventionMeshId": "D000004317",
                                        "InterventionMeshTerm": "Doxorubicin"
                                    }
                                ]
                            },
                            "InterventionAncestorList": {
                                "InterventionAncestor": [
                                    {
                                        "InterventionAncestorId": "D000007166",
                                        "InterventionAncestorTerm": "Immunosuppressive Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007155",
                                        "InterventionAncestorTerm": "Immunologic Factors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045505",
                                        "InterventionAncestorTerm": "Physiological Effects of Drugs"
                                    },
                                    {
                                        "InterventionAncestorId": "D000018501",
                                        "InterventionAncestorTerm": "Antirheumatic Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000018906",
                                        "InterventionAncestorTerm": "Antineoplastic Agents, Alkylating"
                                    },
                                    {
                                        "InterventionAncestorId": "D000000477",
                                        "InterventionAncestorTerm": "Alkylating Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045504",
                                        "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                                    },
                                    {
                                        "InterventionAncestorId": "D000000970",
                                        "InterventionAncestorTerm": "Antineoplastic Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000019653",
                                        "InterventionAncestorTerm": "Myeloablative Agonists"
                                    },
                                    {
                                        "InterventionAncestorId": "D000074322",
                                        "InterventionAncestorTerm": "Antineoplastic Agents, Immunological"
                                    },
                                    {
                                        "InterventionAncestorId": "D000020533",
                                        "InterventionAncestorTerm": "Angiogenesis Inhibitors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000043924",
                                        "InterventionAncestorTerm": "Angiogenesis Modulating Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006133",
                                        "InterventionAncestorTerm": "Growth Substances"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006131",
                                        "InterventionAncestorTerm": "Growth Inhibitors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000050257",
                                        "InterventionAncestorTerm": "Tubulin Modulators"
                                    },
                                    {
                                        "InterventionAncestorId": "D000050256",
                                        "InterventionAncestorTerm": "Antimitotic Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000050258",
                                        "InterventionAncestorTerm": "Mitosis Modulators"
                                    },
                                    {
                                        "InterventionAncestorId": "D000000903",
                                        "InterventionAncestorTerm": "Antibiotics, Antineoplastic"
                                    },
                                    {
                                        "InterventionAncestorId": "D000059005",
                                        "InterventionAncestorTerm": "Topoisomerase II Inhibitors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000059003",
                                        "InterventionAncestorTerm": "Topoisomerase Inhibitors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000004791",
                                        "InterventionAncestorTerm": "Enzyme Inhibitors"
                                    }
                                ]
                            },
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M6644",
                                        "InterventionBrowseLeafName": "Doxorubicin",
                                        "InterventionBrowseLeafAsFound": "Used",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M227311",
                                        "InterventionBrowseLeafName": "Liposomal doxorubicin",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M5879",
                                        "InterventionBrowseLeafName": "Cyclophosphamide",
                                        "InterventionBrowseLeafAsFound": "Tablet",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M1668",
                                        "InterventionBrowseLeafName": "Docetaxel",
                                        "InterventionBrowseLeafAsFound": "Activity",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M246",
                                        "InterventionBrowseLeafName": "Bevacizumab",
                                        "InterventionBrowseLeafAsFound": "Hours",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9364",
                                        "InterventionBrowseLeafName": "Immunosuppressive Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9353",
                                        "InterventionBrowseLeafName": "Immunologic Factors",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M19757",
                                        "InterventionBrowseLeafName": "Antirheumatic Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M20095",
                                        "InterventionBrowseLeafName": "Antineoplastic Agents, Alkylating",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M2972",
                                        "InterventionBrowseLeafName": "Alkylating Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M1346",
                                        "InterventionBrowseLeafName": "Antineoplastic Agents, Immunological",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M21471",
                                        "InterventionBrowseLeafName": "Angiogenesis Inhibitors",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M25350",
                                        "InterventionBrowseLeafName": "Tubulin Modulators",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M25349",
                                        "InterventionBrowseLeafName": "Antimitotic Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M3374",
                                        "InterventionBrowseLeafName": "Anti-Bacterial Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M3376",
                                        "InterventionBrowseLeafName": "Antibiotics, Antitubercular",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "ANeo",
                                        "InterventionBrowseBranchName": "Antineoplastic Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "ARhu",
                                        "InterventionBrowseBranchName": "Antirheumatic Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infe",
                                        "InterventionBrowseBranchName": "Anti-Infective Agents"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 30,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT03994081",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "20-1822"
                            },
                            "Organization": {
                                "OrgFullName": "University of North Carolina, Chapel Hill",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Mechanism of Action of tACS for the Treatment of MDD",
                            "OfficialTitle": "Mechanism of Action for Transcranial Alternating Current (tACS) Stimulation for the Treatment of Major Depressive Disorder (MDD)",
                            "Acronym": "GLADIATOR2"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "June 2021",
                            "OverallStatus": "Recruiting",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "June 9, 2021",
                                "StartDateType": "Actual"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "July 2023",
                                "PrimaryCompletionDateType": "Anticipated"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "July 2024",
                                "CompletionDateType": "Anticipated"
                            },
                            "StudyFirstSubmitDate": "June 10, 2019",
                            "StudyFirstSubmitQCDate": "June 19, 2019",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "June 21, 2019",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "June 22, 2021",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "June 28, 2021",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Sponsor"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "University of North Carolina, Chapel Hill",
                                "LeadSponsorClass": "OTHER"
                            },
                            "CollaboratorList": {
                                "Collaborator": [
                                    {
                                        "CollaboratorName": "Foundation of Hope for Research and Treatment of Mental Illness",
                                        "CollaboratorClass": "UNKNOWN"
                                    },
                                    {
                                        "CollaboratorName": "National Alliance for Research on Schizophrenia and Depression",
                                        "CollaboratorClass": "OTHER"
                                    }
                                ]
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "Yes",
                            "IsFDARegulatedDrug": "No",
                            "IsFDARegulatedDevice": "Yes",
                            "IsUnapprovedDevice": "Yes",
                            "IsUSExport": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "The purpose of this research study is to use a specific type of non-invasive brain stimulation known as transcranial alternating current stimulation (tACS) to determine its effects on brain activity (measured with electroencephalogram, or EEG, a type of non-invasive brain recording) and mood in patients with Major Depressive Disorder (MDD).",
                            "DetailedDescription": "The device used for non-invasive brain stimulation is investigational and has not been approved by the FDA, though it has been designated as a nonsignificant risk (NSR) device study by the FDA. Half of the participants will receive tACS and half will receive sham stimulation, an inactive control procedure for comparison use only. Participation in this study includes up to nine appointments, each one lasting from 30 minutes to six hours over the course of 3 weeks. The first two appointments will be remote interviews to determine eligibility. If you qualify, the next five appointments will be scheduled as consecutive stimulation sessions in the Carolina Center for Neurostimulation at the Vilcom office. An optional MRI at UNC may be scheduled afterwards. The follow-up appointment will be in our center two weeks after you complete the final stimulation session. We estimate the total time needed to complete study participation to be about 28 hours. This study is not designed to benefit participants and there is little chance that you will benefit from being in this research study. There is a small chance that you may experience a reduction in the severity of symptoms associated with MDD. Transcranial current stimulation (the application of a very weak electric current across your brain) has been used without reports of any serious side-effects."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Major Depressive Disorder",
                                    "MDD"
                                ]
                            },
                            "KeywordList": {
                                "Keyword": [
                                    "tACS",
                                    "Major Depressive Disorder",
                                    "MDD",
                                    "mood symptoms",
                                    "sham"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Not Applicable"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "Randomized",
                                "DesignInterventionModel": "Parallel Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "Quadruple",
                                    "DesignWhoMaskedList": {
                                        "DesignWhoMasked": [
                                            "Participant",
                                            "Care Provider",
                                            "Investigator",
                                            "Outcomes Assessor"
                                        ]
                                    }
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "20",
                                "EnrollmentType": "Anticipated"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "transcranial alternating current stimulation (tACS) at alpha",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "10 Hz tACS with an amplitude of 1 mA for 40 minutes. Uses tACS device.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: tACS"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "sham stimulation",
                                        "ArmGroupType": "Sham Comparator",
                                        "ArmGroupDescription": "Will include 20 seconds of ramp-up, 40 seconds of 10 Hz tACS at 1 mA, and 20 seconds of ramp-down for a total of 80 seconds of stimulation. Uses sham tACS device.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: Sham tACS"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "tACS",
                                        "InterventionDescription": "XCSITE100",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "transcranial alternating current stimulation (tACS) at alpha"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "Sham tACS",
                                        "InterventionDescription": "XCSITE100",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "sham stimulation"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Change in the amplitude of left frontal alpha oscillations measured in eyes-open resting-state EEG recordings from baseline to day 5 of stimulation.",
                                        "PrimaryOutcomeDescription": "Fourier transform is applied to 2 second epochs of resting-state eyes-open EEG data and averaged across epochs. The amplitude of alpha oscillations is calculated and averaged across left frontal electrodes. The difference between the baseline recording on the first day of stimulation is compared to the recording on the fifth day of the intervention prior to stimulation.",
                                        "PrimaryOutcomeTimeFrame": "Baseline, Day 5"
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "Change in the amplitude of left frontal alpha oscillations measured in eyes-open resting-state EEG recordings from baseline to two-week follow-up of stimulation.",
                                        "PrimaryOutcomeDescription": "Fourier transform is applied to 2 second epochs of resting-state eyes-open EEG data and averaged across epochs. The amplitude of alpha oscillations is calculated and averaged across left frontal electrodes. The difference between the baseline recording on the first day of stimulation is compared to the recording on the two-week follow-up after intervention.",
                                        "PrimaryOutcomeTimeFrame": "Baseline, two-week follow-up visit"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "Correlation between changes in the amplitude of left frontal alpha oscillations from baseline to day 5 of intervention and changes in symptoms of depression from baseline to two-week follow-up",
                                        "SecondaryOutcomeDescription": "Correlation Coefficient (r) will be used to determine if there is a relationship between the change in Hamilton Depression Rating Scale (HDRS) scores from baseline to two-week follow up and change in the amplitude of left frontal alpha oscillations before stimulation at baseline and Day 5 of stimulation. The HDRS is a clinician-rated measure of depression severity where higher scores indicate greater depression severity. To calculate the amplitude of left frontal alpha oscillations, Fourier transform is applied to 2 second epochs of resting-state eyes-open EEG data and averaged across epochs. The amplitude of alpha oscillations is calculated and averaged across left frontal electrodes.",
                                        "SecondaryOutcomeTimeFrame": "Baseline, Day 5"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Correlation between changes in the amplitude of left frontal alpha oscillations from baseline to two-week follow-up",
                                        "SecondaryOutcomeDescription": "Correlation Coefficient (r) will be used to determine if there is a relationship between the change in Hamilton Depression Rating Scale (HDRS) scores from baseline to two-week follow up and change in the amplitude of left frontal alpha oscillations before stimulation at baseline and Day 5 of stimulation. The HDRS is a clinician-rated measure of depression severity where higher scores indicate greater depression severity. To calculate the amplitude of left frontal alpha oscillations, Fourier transform is applied to 2 second epochs of resting-state eyes-open EEG data and averaged across epochs. The amplitude of alpha oscillations is calculated and averaged across left frontal electrodes.",
                                        "SecondaryOutcomeTimeFrame": "Baseline, two-week follow-up visit"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Correlation between changes in the amplitude of left frontal alpha oscillations and changes in symptoms of depression from baseline to two-week follow-up",
                                        "SecondaryOutcomeDescription": "Correlation Coefficient (r) will be used to determine if there is a relationship between the change in Hamilton Depression Rating Scale (HDRS) scores from baseline to two-week follow up and change in the amplitude of left frontal alpha oscillations before stimulation at baseline and two-week follow-up. The HDRS is a clinician-rated measure of depression severity where higher scores indicate greater depression severity. To calculate the amplitude of left frontal alpha oscillations, Fourier transform is applied to 2 second epochs of resting-state eyes-open EEG data and averaged across epochs. The amplitude of alpha oscillations is calculated and averaged across left frontal electrodes.",
                                        "SecondaryOutcomeTimeFrame": "Baseline, two-week follow-up visit"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nAges 18-65 years\nDSM-V diagnosis of MDD; unipolar, non-psychotic\nHamilton Rating Depression Rating Scale score >8\nCapacity to understand all relevant risks and potential benefits of the study (informed consent)\nLow suicide risk\n\nExclusion Criteria:\n\nDSM-V diagnosis of alcohol of substance abuse (other than nicotine) within the last month or a DSM-IV diagnosis of alcohol or substance dependence (other than nicotine) within the last 6 months\nCurrent axis I mood, or psychotic disorder other than major depressive disorder.\nLifetime comorbid psychiatric bipolar or psychotic disorder.\nEating disorder (current or within the past 6 months)\nObsessive-compulsive disorder (lifetime)\nPost traumatic stress disorder (PTSD, current or within the last 6 months)\nAttention Deficit Hyperactivity Disorder (ADHD, currently under treatment)\nAnything that, in the opinion of the investigator, would place the participant at increased risk or preclude the participant's full compliance with or completion of the study\nNeurological disorders, including but not limited to history of seizures (except childhood febrile seizures and electroconvulsive therapy (ECT) induced seizures), dementia, history of stroke, Parkinson's disease, multiple sclerosis, cerebral aneurysm.\nMedical or neurological illness (unstable cardiac disease, AIDS, malignancy, liver or renal impairment) or treatment for a medical disorder that could interfere with study participation\nHistory of traumatic brain injury, reoccurring seizures or later cognitive rehabilitation or causing cognitive sequelae\nPrior brain surgery\nAny brain devices/implants, including cochlear implants and aneurysm clips\nCo-morbid neurological condition (i.e. seizure disorder, brain tumor)\nNon English speakers\nPregnancy, nursing, or if female and fertile, unwilling to use appropriate birth control measures during study participation\nCurrent use of benzodiazepines or anti-epileptic drugs",
                            "HealthyVolunteers": "No",
                            "Gender": "All",
                            "MinimumAge": "18 Years",
                            "MaximumAge": "65 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "CentralContactList": {
                                "CentralContact": [
                                    {
                                        "CentralContactName": "Rachel Force, PhD",
                                        "CentralContactRole": "Contact",
                                        "CentralContactPhone": "984-974-6239",
                                        "CentralContactEMail": "rachel_force@med.unc.edu"
                                    }
                                ]
                            },
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "David Rubinow, MD",
                                        "OverallOfficialAffiliation": "University of North Carolina at Chapel Hill - Department of Psychiatry",
                                        "OverallOfficialRole": "Principal Investigator"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "UNC at Vilcom Center",
                                        "LocationStatus": "Recruiting",
                                        "LocationCity": "Chapel Hill",
                                        "LocationState": "North Carolina",
                                        "LocationZip": "27514",
                                        "LocationCountry": "United States",
                                        "LocationContactList": {
                                            "LocationContact": [
                                                {
                                                    "LocationContactName": "Rachel B Force",
                                                    "LocationContactRole": "Contact",
                                                    "LocationContactPhone": "984-974-6239",
                                                    "LocationContactEMail": "GLAD2study@unc.edu"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "IPDSharingStatementModule": {
                            "IPDSharing": "Yes",
                            "IPDSharingDescription": "IPD will be shared upon request.",
                            "IPDSharingInfoTypeList": {
                                "IPDSharingInfoType": [
                                    "Study Protocol",
                                    "Informed Consent Form (ICF)",
                                    "Analytic Code"
                                ]
                            },
                            "IPDSharingTimeFrame": "Data will be available starting from 9 to 36 months following publication.",
                            "IPDSharingAccessCriteria": "Deidentified individual data that supports the results will be shared beginning 9 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC."
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000003866",
                                        "ConditionMeshTerm": "Depressive Disorder"
                                    },
                                    {
                                        "ConditionMeshId": "D000003863",
                                        "ConditionMeshTerm": "Depression"
                                    },
                                    {
                                        "ConditionMeshId": "D000003865",
                                        "ConditionMeshTerm": "Depressive Disorder, Major"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000019964",
                                        "ConditionAncestorTerm": "Mood Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000001523",
                                        "ConditionAncestorTerm": "Mental Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000001526",
                                        "ConditionAncestorTerm": "Behavioral Symptoms"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M6210",
                                        "ConditionBrowseLeafName": "Depression",
                                        "ConditionBrowseLeafAsFound": "Depressive Disorder",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M6213",
                                        "ConditionBrowseLeafName": "Depressive Disorder",
                                        "ConditionBrowseLeafAsFound": "Depressive Disorder",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M6212",
                                        "ConditionBrowseLeafName": "Depressive Disorder, Major",
                                        "ConditionBrowseLeafAsFound": "Major Depressive Disorder",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M20988",
                                        "ConditionBrowseLeafName": "Mood Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M3967",
                                        "ConditionBrowseLeafName": "Mental Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M13625",
                                        "ConditionBrowseLeafName": "Psychotic Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M3970",
                                        "ConditionBrowseLeafName": "Behavioral Symptoms",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BXM",
                                        "ConditionBrowseBranchName": "Behaviors and Mental Disorders"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 31,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT04545294",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "2-106-05-123"
                            },
                            "Organization": {
                                "OrgFullName": "Tri-Service General Hospital",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Theta tACS During Working Memory Training: A Pilot Study of the Effects on Negative Symptoms of Schizophrenia",
                            "OfficialTitle": "Online Left-hemispheric Frontoparietal Theta In-phase tACS During Working Memory Training in Schizophrenia Patients: A Pilot Randomized Double-blind, Sham-controlled Study of the Effects on Negative Symptoms"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "September 2020",
                            "OverallStatus": "Completed",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "August 14, 2019",
                                "StartDateType": "Actual"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "April 10, 2020",
                                "PrimaryCompletionDateType": "Actual"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "April 10, 2020",
                                "CompletionDateType": "Actual"
                            },
                            "StudyFirstSubmitDate": "September 3, 2020",
                            "StudyFirstSubmitQCDate": "September 3, 2020",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "September 11, 2020",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "September 20, 2020",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "September 23, 2020",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Principal Investigator",
                                "ResponsiblePartyInvestigatorFullName": "Hsin-An Chang, MD",
                                "ResponsiblePartyInvestigatorTitle": "Attending Psychiatrist, Department of Psychiatry, Principal Investigator, Associate Professor",
                                "ResponsiblePartyInvestigatorAffiliation": "Tri-Service General Hospital"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Tri-Service General Hospital",
                                "LeadSponsorClass": "OTHER"
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "No",
                            "IsFDARegulatedDrug": "No",
                            "IsFDARegulatedDevice": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "In this randomized double-blind trial, we investigated whether externally induced left-hemispheric frontoparietal theta synchronization by multi-electrode online theta (6Hz) transcranial alternating current stimulation (tACS) would enhance the influence of a working memory training on negative symptoms of schizophrenia.",
                            "DetailedDescription": "Negative symptoms have a negative impact on the prognosis of schizophrenia, but effective treatment for this symptom dimension is still under investigation. Identifying a treatment target that has a close link to negative symptoms or highly impacts negative symptoms may help to develop an effective therapy to counteract negative symptoms of schizophrenia. Recent theoretical and empirical work linking negative symptoms and cognitive impairment in schizophrenia has identified a potential treatment target: cognitive deficits. Evidence has indicated that cognitive remediation (CR) has a positive effect on improving negative symptoms of schizophrenia, in particular behavioural negative symptoms.\n\nAlthough it is still debated which active components of CR contribute to the improvements in negative symptoms. The framework proposed by Gold and colleagues may be a candidate to explain how CR improves negative symptoms (i.e., possible through improving working memory). Anhedonia (i.e., the diminished ability to experience pleasure and reduced reactivity to pleasurable stimuli) represents a challenging negative symptom in schizophrenia.The impairment in hedonic processing has been associated with reduced motivation to engage in potentially rewarding events. Working memory (WM) plays an important role in the formation, maintenance, and retrieval of affective and value representations, all of which are essential for anticipatory pleasure. Individuals represent events and forecast pleasure by using WM in order to recruit motivational resources. It has been suggested that there is a hedonic detector system within the WM model and that WM serves as a potential underlying cognitive mechanism for anticipatory pleasure and goal-related behaviours. Problems in WM may reduce the ability to retrieve and manipulate information to motivate and guide future behaviour, thereby contributing to diminished motivation and the pleasure experience. It is known that the recruitment of the prefrontal-striatal system (including dorsolateral prefrontal cortex, cingulate cortex, insula, and ventral striatum) implicates in hedonic processing. It is also known that the same brain regions can be viewed as core brain regions of the WM network because they are activated during WM load. The overlap in activation of the prefrontal-striatal system during hedonic processing and WM provides robust evidence supporting the relationship between hedonic capacity and WM. Evidence indicated a correlation between the activity in WM brain networks and the improvement in negative symptoms following antipsychotic treatment, suggesting a mediating effect of WM on negative symptoms improvement in the context of a pharmacological intervention. More recently, studies indicated that 20 sessions of WM training (dual n-back task training) showed neural transfer effect to enhance hedonic processing in individuals with high social anhedonia and ameliorate hedonic dysfunction in schizophrenia patients with prominent negative symptoms.\n\nIn addition to WM training, non-invasive brain stimulation (NIBS) is also a non-pharmacological method to improve brain neural plasticity. For example, repetitive transcranial magnetic stimulation (rTMS) can change the activity of cortical nerve temporarily or continuously and enhance neural plasticity. However, the ability of rTMS alone to improve cognitive function in schizophrenia is frequently limited to some extent, necessitating a combination with WM training to boost cognitive functions.\n\nTranscranial alternating current stimulation (tACS), a safe NIBS technique that applies low-intensity alternating current, is also a potential therapeutic option in treating the cognitive impairment in schizophrenia. The stimulation frequency of tACS is usually set to coincide with the targeted brain endogenous rhythms. It would synchronize the neural oscillations in the stimulated cortical regions to the applied stimulation frequency. Different tACS current intensity (0.5 to 4 mA), stimulation frequency (0.1 to 80 Hz), electrode montages, phase difference across the stimulation site, with/without DC offset, and the states (e.g., at rest or concurrently under the tasks) during stimulation contribute to its different effects. If both the target electrode and the reference electrode are in the same phase of the cycle of the current at any given time, the phase difference will be 0 degree (i.e., in-phase). The phase difference will be 180 degrees (i.e., anti-phase) if the electrodes are in the opposite phase. In-phase and anti-phase tACS over brain regions elicits synchronization and desynchronization of neuronal activity across the brain regions, respectively.\n\nThe state-dependent tACS effects indicate that the effects of tACS are enhanced when the state of the targeted brain regions is active. Specifically, synchronization of frontoparietal regions at theta frequencies dominates during an executive task. tACS at the frequency close to the theta oscillation activated by an executive task would elicit more resonance and may, in turn, help to enhance executive function. tACS applied when an individual is concurrently engaged in a specific cognitive task is defined as online tACS. In healthy subjects, online theta (6Hz) in-phase tACS facilitated frontoparietal phase coupling (synchronization) resulting in improved WM performance, whereas online theta (6Hz) anti-phase tACS disrupted theta phase-coupling (desynchonization) resulting in impaired WM performance.\n\nThe prolonged after-effects of tACS may be related to a phenomenon called spike-timing-dependent plasticity (STDP), a process that modifies the connection strengths based on the relative timing of the input and output spikes (or action potentials) of a neuron. STDP means that synapse will be strengthened if input action potentials occur immediately before the output action potentials, and synapse will be made weaker if an input action potentials occur immediately after an output action potentials. The STDP process is known to explain in part long-term depression (LTD) and long-term potentiation (LTP) of nervous systems. To sum up, tACS at a frequency close to that of resonance frequency during tACS may intensify the synapses across the stimulated regions through the mechanism of STDP. Repetitive (multiple-session) tACS during specific time intervals may consolidate the neuroplasticity effects, and may, in turn, elicit a long-lasting effect for further clinical application in treating neuropsychiatric disorders. In schizophrenia patients, a few case reports indicated 1-5 sessions of online theta in-phase tACS over left frontoparietal regions improved the performance of WM and several other cognitive domains.\n\nSo far, there is no relevant research report exploring whether and how the joint intervention (i.e., online theta (6Hz) in-phase tACS over the left frontoparietal regions plus WM training) will have a combined effect on improving the performance of WM and other cognitive domains in schizophrenic patients. Neither is any research investigating whether online theta (6Hz) in-phase tACS over the left frontoparietal regions can potentiate the effects of WM training on improving negative symptoms of schizophrenia. To sum up, we hypothesize that the combination training mode of active online theta tACS plus WM training would have a greater ability to reduce negative symptoms of schizophrenia compared to the training mode of sham online theta tACS plus WM training. The study aims to test the efficacy of \"active online theta tACS plus WM\" versus \"sham online theta tACS plus WM training\" in improving negative symptoms, WM performance, and other cognitive domains performance of schizophrenia using a double-blinded, randomized sham-controlled trial design. In order to evaluate the efficacy of the interventions, we will use behavioral outcomes (e.g., negative symptoms assessment and neurocognitive assessment) and neurophysiological outcomes (e.g., EEG and heart rate variability).\n\nMethods\n\nDual N back training\n\nThe study will use a dual n-back task for WM training. In this task, squares at 8 different locations will show up sequentially (stimulus length, 500 ms; inter-stimulus interval, 2,500 ms) on a computer screen every 3 seconds. Simultaneously with the presentation of the squares, one of eight consonants will show up sequentially through a speaker. Participants will have to judge whether the location of a square and the consonant they heard matches the one n-back before (the same n value for both visual and auditory targets). Each training session has 20 blocks consisting of 20 + n trials and takes around 25 min. Each block includes six auditory and six visual targets (four appearing in only one modality, and two appearing in both modalities simultaneously) whose locations are random. Participants will have to make responses manually by pressing the mouse left-click button for visual targets and the right-click button for auditory targets. No responses were required for non-targets. If a target is correctly detected, a green flash will be given, which constitutes a positive feedback. If a target is falsely detected, a blue flash will be given, which constitutes a negative feedback. The dual N back training is designed to continuously vary its difficulty by modifying the WM load (i.e., the level of n) and thereby track the participants' performance. Each training session begins at n = 1. Participants' performance will be analyzed after each block and the level of n for the next block will be adapted according to the following principle. The level of n increases by 1 in the next block if the mistakes per modality made by the participant are<3. Conversely, n would decrease by 1 if the mistakes per modality made by the participant are>5. In all other cases, the n is kept unchanged. Participants will come to the laboratory and take part in the WM training sessions twice daily for 5 weekdays (total 10 sessions), with each session lasting for approximately 25 minutes. The time interval between twice-daily sessions will be >3 hours.\n\nOnline left-hemispheric frontoparietal theta (6Hz) in-phase tACS\n\nθ tACS will be administered during the dual n-back task, starting at the beginning of each task and lasting for 20 min. In the active θ tACS condition, sinusoidal tACS will be delivered by two battery-operated devices connected with two 4 × 1 wire adaptors (Equalizer Box, NeuroConn, Ilmenau, Germany). The electrode montages used for θ tACS will be positioned at left frontoparietal locations. The stimulation electrodes of the 1st stimulator will be placed at the International 10-10 electrode position F1, F5, AF3, and FC3 (stimulation electrodes) and CPz (return electrode) to cover the left frontal cortex. For the 2nd stimulator, the stimulation electrodes will be placed at P1, P5, CP3, and PO3 (stimulation electrodes) and FCz (return electrode) to cover the left parietal cortex. A NeuroConn digital to analog converter (DAQ) will control the two stimulators and create an in-phase (synchronous) setup (0° relative phase difference between the output signals of the two tACS-stimulators)."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Schizophrenia",
                                    "Schizoaffective Disorder",
                                    "Negative Symptoms",
                                    "Working Memory Training",
                                    "Psychosocial Impairment",
                                    "Autonomic Imbalance",
                                    "EEG"
                                ]
                            },
                            "KeywordList": {
                                "Keyword": [
                                    "Schizophrenia",
                                    "Schizoaffective Disorder",
                                    "Transcranial alternating current stimulation",
                                    "Theta oscillatory rhythm",
                                    "Theta Phase-Coupling",
                                    "Negative symptoms",
                                    "Working memory training"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Not Applicable"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "Randomized",
                                "DesignInterventionModel": "Parallel Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "Quadruple",
                                    "DesignMaskingDescription": "The allocation concealment was further ensured by the administration of tACS using \"study mode of the device\" in which a five-digit numerical code specific to individual participant was entered into the device (Eldith DC stimulator Plus, NeuroConn, Ilmenau, Germany) that resulted in either active or sham stimulation, i.e., the researcher got the randomization code and a unique five-digit numerical code for an individual participant from the study coordinator while tACS administrator entered the code for study mode into the device. The study coordinator had continuous access to the randomization list and unblinded the study after the final visit of the last participant. Not until the unblinding of the trial did the participants, tACS administrators, researchers and clinical raters know the actual stimulation types.",
                                    "DesignWhoMaskedList": {
                                        "DesignWhoMasked": [
                                            "Participant",
                                            "Care Provider",
                                            "Investigator",
                                            "Outcomes Assessor"
                                        ]
                                    }
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "36",
                                "EnrollmentType": "Actual"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "Active theta (6Hz) in-phase tACS",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "θ tACS will be administered during the dual n-back task, starting at the beginning of each task and lasting for 20 min. In the active θ tACS condition, sinusoidal tACS will be delivered by two battery-operated devices (Eldith DC stimulator Plus, neuroConn, Ilmenau, Germany) connected with two 4 × 1 wire adaptors (Equalizer Box, NeuroConn, Ilmenau, Germany), via 10 carbon rubber electrodes (1 cm radius, high-definition 4 × 1 rings configuration with a gel layer of 2.0 mm), at 6 Hz frequency, 2 mA current intensity without DC offset, with 100 cycles ramp-up/ramp-down and a 0° relative phase, for 20 min, twice-daily on 5 consecutive weekdays.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: Theta tACS"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "Sham tACS",
                                        "ArmGroupType": "Sham Comparator",
                                        "ArmGroupDescription": "During sham sessions, tACS will be applied in the synchronous condition for 30 s of 2 mA normal-like stimulation at the beginning of each dual n-back task. After that, only a tiny current pulse (110 μA over 15 ms) for impedance control took place every 550 ms during the remaining time.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: Theta tACS"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "Theta tACS",
                                        "InterventionDescription": "See detail in arm/group descriptions regarding the intervention.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Active theta (6Hz) in-phase tACS",
                                                "Sham tACS"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "The change over time in the negative symptoms subscale score of the Chinese version of the Positive and Negative Syndrome Scale (PANSS) (from baseline to the timepoints immediately after intervention, at one-week and one-month follow-ups).",
                                        "PrimaryOutcomeDescription": "A clinician-administered rating scale to measure the severity of psychopathological symptoms of the patients with schizophrenia spectrum disorder. The patient is rated from 1 to 7 on 30 different symptom items. All items scores are summed up to yield a total PANSS score, which ranges from 30 to 210. A higher score indicates greater psychopathological symptom severity. There are 7 items for positive symptoms subscale (score 7-49), 7 items for negative symptoms subscale (score 7-49), 16 items for general symptoms subscale (score 16-112).",
                                        "PrimaryOutcomeTimeFrame": "Five weeks"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "The change over time in the Chinese version of the Positive and Negative Syndrome Scale Factor Score for Negative Symptoms (PANSS-FSNS) (from baseline to the timepoints immediately after intervention, at one-week and one-month follow-ups).",
                                        "SecondaryOutcomeDescription": "A clinician-administered rating scale to measure the severity of psychopathological symptoms of the patients with schizophrenia spectrum disorder. The patient is rated from 1 to 7 on 30 different symptom items. All items scores are summed up to yield a total PANSS score, which ranges from 30 to 210. A higher score indicates greater psychopathological symptom severity. The five-factor PANSS model can be obtained by calculating from 26 of 30 items of PANSS: positive (5 items, P1+P3+P5+P6+G9,score 5-35) , negative (7 items, N1+N2+N3+N4+N6+G7+G16, score 7-49), grandiosity/excitement (4 items, score 4-28), disorganization (5 items, score 5-35), and depression (4 items, score 4-28) factor scores. The cognitive component of the PANSS can be obtained as well (3 items, P2+N5+G11, score 3-21).",
                                        "SecondaryOutcomeTimeFrame": "Five weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The change over time in the score of the Chinese version of the Scale for the Assessment of Negative Symptoms (SANS) (from baseline to the timepoints immediately after intervention, at one-week and one-month follow-ups).",
                                        "SecondaryOutcomeDescription": "The Scale for the Assessment of Negative Symptoms (SANS) is used to assess negative symptoms in schizophrenia on a 25 item, 6-point scale. The SANS measures five domains of the negative symptoms including affective flattening or blunting, alogia, avolition - apathy, anhedonia - Asociality, Attention. In each domain, separate symptoms are rated from 0 (absent) to 5 (severe). A total SANS score ranges from 0 to 125.",
                                        "SecondaryOutcomeTimeFrame": "Five weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The change over time in the score of the Chinese version of the Personal and Social Performance scale (PSP) (from baseline to the timepoints immediately after intervention, at one-week and one-month follow-ups).",
                                        "SecondaryOutcomeDescription": "A clinician-administered rating scale to measure the psychosocial functioning of the patients with schizophrenia spectrum disorder. The PSP scale measures psychosocial functioning within four domains: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior.The patient is rated from 1 to 6 on each item of the four domains. A higher score indicates greater psychosocial functioning in any of the four domains. The final global score is defined according to a summary instruction table. This scale provides a single, overall rating from 1 to 100, where a higher score represents better personal and social function.",
                                        "SecondaryOutcomeTimeFrame": "Five weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The change over time in the score of the self-reported version of the graphic personal and social performance scale (SRG-PSP) (from baseline to the timepoints immediately after intervention and at one-week follow-up)",
                                        "SecondaryOutcomeDescription": "The SRG-PSP is a self-rating scale of proven validity and reliability, comprising both male and female versions of cartoon-like pictures that are derived from the narrative text of the four domains of Personal and Social Performance (PSP) scale including the sub-items of socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behaviour.",
                                        "SecondaryOutcomeTimeFrame": "Two weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The change over time in the score of the abbreviated version of the Scale to Assess Unawareness in Mental Disorder in schizophrenia (SUMD) (from baseline to the timepoints immediately after intervention, at one-week and one-month follow-ups).",
                                        "SecondaryOutcomeDescription": "An expert-rating scale based on a patient interview to measure patients' clinical insight. The abbreviated version of SUMD comprises 9 items measuring current states of awareness as follows: (1) a mental disorder, (2) consequences of a mental disorder, (3) effects of drugs, (4) hallucinatory experiences, (5) delusional ideas, (6) disorganized thoughts, (7) blunted affect, (8) anhedonia, and (9) lack of sociability. Scores on each item range from 0 to 3. A score of 0 indicates 'not applicable'; 1, 'aware'; 2, 'somewhat aware/unaware' and 3, 'severely unaware.' Based on the 3 dimensions approach of the abbreviated version of SUMD, the scores on the items 1-3, 4-6 and 7-9 were averaged to obtain the dimension score of 'awareness of the disease', 'awareness of positive symptoms', and 'awareness of negative symptoms', respectively. All dimension scores were linearized on a 0-100 scale, with 0 and 100 indicating the lowest and highest level of unawareness, respectively.",
                                        "SecondaryOutcomeTimeFrame": "Five weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The change over time in the score of the Taiwanese version of the Beck Cognitive Insight Scale (BCIS) (from baseline to the timepoints immediately after intervention and at one-week follow-up)",
                                        "SecondaryOutcomeDescription": "Cognitive insight was measured by the Taiwanese version of the Beck Cognitive Insight Scale (BCIS), a self-reported instrument comprising 15 items.The Taiwanese BCIS is composed of 2 subscales including reflective attitude (9 items) and certain attitude (6 items). We obtained a R-C (reflective attitude minus certain attitude) index of the Taiwanese BCIS, representing the measurement of cognitive insight by subtracting the score of the certain attitude subscale from that of the reflective attitude subscale. Lower R-C index scores indicate poorer cognitive insight.",
                                        "SecondaryOutcomeTimeFrame": "Two weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The change over time in the score of the Taiwanese version of the Self-Appraisal of Illness Questionnaire (SAIQ) (from baseline to the timepoints immediately after intervention and at one-week follow-up)",
                                        "SecondaryOutcomeDescription": "The Taiwanese version of the Self-Appraisal of Illness Questionnaire (SAIQ) was used to assess attitudes toward mental illness and experience of psychiatric treatment.This self-administered tool was composed of 17 items. The patients rated the extent to which they agreed with each statement of the item by using a four-point Likert scale, ranging from 1, ''do not agree at all'', to 4, ''completely agree''. Whether the scale score is in order from least to most or from the most to least depends on the content of the item statement. The total score of SAIQ ranges from 17 to 68.",
                                        "SecondaryOutcomeTimeFrame": "Two weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The change over time in the negative symptoms subscale score of the Chinese version of the Schizophrenia Quality of Life Scale Revision Four (from baseline to the timepoints immediately after intervention and at one-week follow-up)",
                                        "SecondaryOutcomeDescription": "The Chinese version of the Schizophrenia Quality of Life Scale Revision Four is a self-administered questionnaire of 33 items in two domains: psychosocial and vitality. All but four items are coded on a scale of 0-4 according to the frequency of occurrence during the previous 7 days (0 = always, 4 = never; the four exceptions are coded 0 = never, 4 = always). A higher score indicates higher health-related QoL.",
                                        "SecondaryOutcomeTimeFrame": "Two weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The changes over time in the results of Digit span (forward and backward) (from baseline to the timepoints immediately after intervention and at one-week follow-up)",
                                        "SecondaryOutcomeDescription": "A test to measure the capacity of working memory of the patients",
                                        "SecondaryOutcomeTimeFrame": "Two weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The changes over time in the results of Finger tapping test (from baseline to the timepoints immediately after intervention and at one-week follow-up)",
                                        "SecondaryOutcomeDescription": "A neuropsychological test that examines motor functioning, specifically, motor speed and lateralized coordination.",
                                        "SecondaryOutcomeTimeFrame": "Two weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The changes over time in the results of Continuous Performance (CPT, version 2.0) (from baseline to the timepoints immediately after intervention and at one-week follow-up)",
                                        "SecondaryOutcomeDescription": "A neuropsychological test that examines the performance of prefrontal-mediated task",
                                        "SecondaryOutcomeTimeFrame": "Two weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The changes over time in the results of Wisconsin Card Sorting Test (WCST) (from baseline to the timepoints immediately after intervention and at one-week follow-up)",
                                        "SecondaryOutcomeDescription": "A neuropsychological test of \"set-shifting\", i.e. the ability to display flexibility in the face of changing schedules of reinforcement.",
                                        "SecondaryOutcomeTimeFrame": "Two weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The changes over time in the results of Tower of London test (from baseline to the timepoints immediately after intervention and at one-week follow-up)",
                                        "SecondaryOutcomeDescription": "A neuropsychological test for the assessment of executive functioning specifically to detect deficits in planning, which may occur due to a variety of medical and neuropsychiatric conditions.",
                                        "SecondaryOutcomeTimeFrame": "Two weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The changes over time in the results of Color Trails Test (CTT) (from baseline to the timepoints immediately after intervention and at one-week follow-up)",
                                        "SecondaryOutcomeDescription": "The CTT, a culture-neutral version of the Trail Making Test, was selected to measure sustained visual attention. The CTT consists of two parts (CTT-1 and CTT-2). The CTT-1 requires participants to connect a series of numbered circles that are randomly printed on a sheet of paper. In the CTT-2, numbered circles of 1 to 25 are shown twice (printed in pink and in yellow) randomly on a sheet of paper. Participants are asked to connect the numbers from 1 to 25 alternating between the two colors.",
                                        "SecondaryOutcomeTimeFrame": "Two weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The changes over time in the results of Stroop Color Word Test (SCWT) (from baseline to the timepoints immediately after intervention and at one-week follow-up)",
                                        "SecondaryOutcomeDescription": "Stroop Color Word Test (SCWT), Chinese version; was administered to measure selective attention and cognitive flexibility. SCWT is composed of three parts, each lasting for 45 seconds.",
                                        "SecondaryOutcomeTimeFrame": "Two weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The changes over time in the results of the dual 2-back task (from baseline to the timepoints immediately after intervention, at one-week and one-month follow-ups).",
                                        "SecondaryOutcomeDescription": "In the dual 2-back task, squares at 8 different locations will show up sequentially (stimulus length, 500 ms; inter-stimulus interval, 2,500 ms) on a computer screen every 3 seconds. Simultaneously with the presentation of the squares, one of eight consonants will show up sequentially through a speaker. Participants will have to judge whether the location of a square and the consonant they heard matches the one 2-back before (the same for both visual and auditory targets). Each experimental condition was presented with 100+n trials, resulting in a task time of 5 min. Each task includes 30 auditory and 30 visual targets (four appearing in only one modality, and two appearing in both modalities simultaneously) whose locations are random. Participants will have to make responses manually by pressing the mouse left-click button for visual targets and the right-click button for auditory targets. No responses were required for non-targets.",
                                        "SecondaryOutcomeTimeFrame": "Five weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The changes over time in indices of heart rate variability (HRV) measured at baseline, during the first session of tACS, after 10-session tACS, at 1-week and 1-month follow-ups.",
                                        "SecondaryOutcomeDescription": "HRV indices represent autonomic functioning. ECG electrodes were placed on bilateral arms just below the elbows, with a ground electrode placed just above the right wrist bone. Lead I electrocardiogram of each patient was taken for 5 min after sitting and having a rest for 20 min in a soundproof, dim-lighted room with thermostatic control. At the four timepoints (baseline, after 10-session tACS, at 1-week and 1-month follow-ups), HRV will be collected during resting and during a dual 2-back task. The ECG signals were acquired, stored, pre-processed according to the recommended procedures and processed by an HRV analyser (LR8Z11, Yangyin Corp., Taipei, Taiwan). The time domain of HRV is obtained: Standard deviation of NN intervals (SDNN). Power spectrum of HRV is quantified into the standard frequency-domain measurements including low-frequency power (LF, 0.04-0.15 Hz), high-frequency power (HF, 0.15-0.40 Hz).",
                                        "SecondaryOutcomeTimeFrame": "Five weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The changes over time in EEG absolute power and coherence in the frontoparietal electrode pairs in the alpha and theta range (from baseline to the timepoints after intervention, at one-week and one-month follow-ups)",
                                        "SecondaryOutcomeDescription": "In a recliner in a dimly lit, electrically shielded room, patients' EEGs were recorded at 4 timepoints (baseline, after 10-session tACS, at 1-week and 1-month follow-ups) by using the Neuro Prax® TMS/tDCS full-band DC-EEG system with 32 EEG Ag/AgCl electrodes in the standard 10-20 International placement. EEG will be collected during resting, eye-opened (5min) and during a dual 2-back task (5min). Signals will be amplified in the dynamic input range of ± 140 mV at a resolution of 0.5 μV by using EEG amplifiers and stored for offline analyses. Eye or muscle artifacts were automatically detected and removed using NeuroPrax's built-in software.",
                                        "SecondaryOutcomeTimeFrame": "Five weeks"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nEligible participants aged 20-65 with DSM-V-defined schizophrenia or schizoaffective disorder.\nDuration of illness > 2 years.\nBeing clinically stable and on an adequate therapeutic dose of antipsychotics for at least 8 weeks prior to enrolment.\nAgreement to participate in the study and provide the written informed consent.\n\nExclusion Criteria:\n\nHaving unstable medical conditions, current psychiatric comorbidity or active substance use disorder (in exception to caffeine and/or tobacco).\nHaving a history of seizures, meningitis or encephalitis.\nHaving contraindications for transcranial electrical stimulation or transcranial magnetic stimulation, e.g., pacemakers, metallic or magnetic pieces in the head/brain, ear implants and other implantible brain medical devices.\nHaving a history of intracranial neoplasms or surgery, or a history of severe head injuries or cerebrovascular diseases.\nPregnancy or breastfeeding at enrollment.\nSkin lesions on scalp at the area of electrode application",
                            "HealthyVolunteers": "No",
                            "Gender": "All",
                            "MinimumAge": "20 Years",
                            "MaximumAge": "65 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Hsin-An Chang, M.D.",
                                        "OverallOfficialAffiliation": "Tri-Service General Hospital",
                                        "OverallOfficialRole": "Principal Investigator"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "Tri-service general hospital",
                                        "LocationCity": "Taipei",
                                        "LocationZip": "114",
                                        "LocationCountry": "Taiwan"
                                    }
                                ]
                            }
                        },
                        "ReferencesModule": {
                            "ReferenceList": {
                                "Reference": [
                                    {
                                        "ReferencePMID": "27023427",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Alagapan S, Schmidt SL, Lefebvre J, Hadar E, Shin HW, Frӧhlich F. Modulation of Cortical Oscillations by Low-Frequency Direct Cortical Stimulation Is State-Dependent. PLoS Biol. 2016 Mar 29;14(3):e1002424. doi: 10.1371/journal.pbio.1002424. eCollection 2016 Mar."
                                    },
                                    {
                                        "ReferencePMID": "25477826",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Battleday RM, Muller T, Clayton MS, Cohen Kadosh R. Mapping the mechanisms of transcranial alternating current stimulation: a pathway from network effects to cognition. Front Psychiatry. 2014 Nov 20;5:162. doi: 10.3389/fpsyt.2014.00162. eCollection 2014. Review."
                                    },
                                    {
                                        "ReferencePMID": "27930934",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Cella M, Preti A, Edwards C, Dow T, Wykes T. Cognitive remediation for negative symptoms of schizophrenia: A network meta-analysis. Clin Psychol Rev. 2017 Mar;52:43-51. doi: 10.1016/j.cpr.2016.11.009. Epub 2016 Nov 28. Review."
                                    },
                                    {
                                        "ReferencePMID": "23993864",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Farreny A, Aguado J, Ochoa S, Haro JM, Usall J. The role of negative symptoms in the context of cognitive remediation for schizophrenia. Schizophr Res. 2013 Oct;150(1):58-63. doi: 10.1016/j.schres.2013.08.008. Epub 2013 Aug 29."
                                    },
                                    {
                                        "ReferencePMID": "25528757",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Fusar-Poli P, Papanastasiou E, Stahl D, Rocchetti M, Carpenter W, Shergill S, McGuire P. Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials. Schizophr Bull. 2015 Jul;41(4):892-9. doi: 10.1093/schbul/sbu170. Epub 2014 Dec 20."
                                    },
                                    {
                                        "ReferencePMID": "22101961",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Gold JM, Barch DM, Carter CS, Dakin S, Luck SJ, MacDonald AW 3rd, Ragland JD, Ranganath C, Kovacs I, Silverstein SM, Strauss M. Clinical, functional, and intertask correlations of measures developed by the Cognitive Neuroscience Test Reliability and Clinical Applications for Schizophrenia Consortium. Schizophr Bull. 2012 Jan;38(1):144-52. doi: 10.1093/schbul/sbr142. Epub 2011 Nov 17."
                                    },
                                    {
                                        "ReferencePMID": "18591195",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Gold JM, Waltz JA, Prentice KJ, Morris SE, Heerey EA. Reward processing in schizophrenia: a deficit in the representation of value. Schizophr Bull. 2008 Sep;34(5):835-47. doi: 10.1093/schbul/sbn068. Epub 2008 Jun 30. Review."
                                    },
                                    {
                                        "ReferencePMID": "18443283",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Jaeggi SM, Buschkuehl M, Jonides J, Perrig WJ. Improving fluid intelligence with training on working memory. Proc Natl Acad Sci U S A. 2008 May 13;105(19):6829-33. doi: 10.1073/pnas.0801268105. Epub 2008 Apr 28."
                                    },
                                    {
                                        "ReferencePMID": "10209231",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Klimesch W. EEG alpha and theta oscillations reflect cognitive and memory performance: a review and analysis. Brain Res Brain Res Rev. 1999 Apr;29(2-3):169-95. Review."
                                    },
                                    {
                                        "ReferencePMID": "19782634",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Kringelbach ML, Berridge KC. Towards a functional neuroanatomy of pleasure and happiness. Trends Cogn Sci. 2009 Nov;13(11):479-87. doi: 10.1016/j.tics.2009.08.006. Epub 2009 Sep 24. Review."
                                    },
                                    {
                                        "ReferencePMID": "24011822",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Lett TA, Voineskos AN, Kennedy JL, Levine B, Daskalakis ZJ. Treating working memory deficits in schizophrenia: a review of the neurobiology. Biol Psychiatry. 2014 Mar 1;75(5):361-70. doi: 10.1016/j.biopsych.2013.07.026. Epub 2013 Sep 5. Review."
                                    },
                                    {
                                        "ReferencePMID": "31583951",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Li X, Chu MY, Lv QY, Hu HX, Li Z, Yi ZH, Wang JH, Zhang JY, Lui SSY, Cheung EFC, Shum DHK, Chan RCK. The remediation effects of working memory training in schizophrenia patients with prominent negative symptoms. Cogn Neuropsychiatry. 2019 Nov;24(6):434-453. doi: 10.1080/13546805.2019.1674644. Epub 2019 Oct 4."
                                    },
                                    {
                                        "ReferencePMID": "27752140",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Li X, Li Z, Li K, Zeng YW, Shi HS, Xie WL, Yang ZY, Lui SS, Cheung EF, Leung AW, Chan RC. The neural transfer effect of working memory training to enhance hedonic processing in individuals with social anhedonia. Sci Rep. 2016 Oct 18;6:35481. doi: 10.1038/srep35481."
                                    },
                                    {
                                        "ReferencePMID": "27639163",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Li X, Xiao YH, Zou LQ, Li HH, Yang ZY, Shi HS, Lui SS, Cheung EF, Chan RC. The effects of working memory training on enhancing hedonic processing to affective rewards in individuals with high social anhedonia. Psychiatry Res. 2016 Nov 30;245:482-490. doi: 10.1016/j.psychres.2016.09.006. Epub 2016 Sep 8."
                                    },
                                    {
                                        "ReferencePMID": "23164479",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Nejad AB, Madsen KH, Ebdrup BH, Siebner HR, Rasmussen H, Aggernæs B, Glenthøj BY, Baaré WF. Neural markers of negative symptom outcomes in distributed working memory brain activity of antipsychotic-naive schizophrenia patients. Int J Neuropsychopharmacol. 2013 Jul;16(6):1195-204. doi: 10.1017/S1461145712001253. Epub 2012 Nov 20."
                                    },
                                    {
                                        "ReferencePMID": "22683259",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Polanía R, Nitsche MA, Korman C, Batsikadze G, Paulus W. The importance of timing in segregated theta phase-coupling for cognitive performance. Curr Biol. 2012 Jul 24;22(14):1314-8. doi: 10.1016/j.cub.2012.05.021. Epub 2012 Jun 7."
                                    },
                                    {
                                        "ReferencePMID": "22178808",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Rottschy C, Langner R, Dogan I, Reetz K, Laird AR, Schulz JB, Fox PT, Eickhoff SB. Modelling neural correlates of working memory: a coordinate-based meta-analysis. Neuroimage. 2012 Mar;60(1):830-46. doi: 10.1016/j.neuroimage.2011.11.050. Epub 2011 Dec 1."
                                    },
                                    {
                                        "ReferencePMID": "28250567",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Sreeraj VS, Shanbhag V, Nawani H, Shivakumar V, Damodharan D, Bose A, Narayanaswamy JC, Venkatasubramanian G. Feasibility of Online Neuromodulation Using Transcranial Alternating Current Stimulation in Schizophrenia. Indian J Psychol Med. 2017 Jan-Feb;39(1):92-95. doi: 10.4103/0253-7176.198937."
                                    },
                                    {
                                        "ReferencePMID": "30024457",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Sreeraj VS, Shivakumar V, Sowmya S, Bose A, Nawani H, Narayanaswamy JC, Venkatasubramanian G. Online Theta Frequency Transcranial Alternating Current Stimulation for Cognitive Remediation in Schizophrenia: A Case Report and Review of Literature. J ECT. 2019 Jun;35(2):139-143. doi: 10.1097/YCT.0000000000000523. Review."
                                    },
                                    {
                                        "ReferencePMID": "23709387",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Strauss GP. Translating basic emotion research into novel psychosocial interventions for anhedonia. Schizophr Bull. 2013 Jul;39(4):737-9. doi: 10.1093/schbul/sbt082. Epub 2013 May 24."
                                    },
                                    {
                                        "ReferencePMID": "31913979",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Vinograd M, Craske MG. Using Neuroscience to Augment Behavioral Interventions for Depression. Harv Rev Psychiatry. 2020 Jan/Feb;28(1):14-25. doi: 10.1097/HRP.0000000000000241. Review."
                                    },
                                    {
                                        "ReferencePMID": "25648377",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Vossen A, Gross J, Thut G. Alpha Power Increase After Transcranial Alternating Current Stimulation at Alpha Frequency (α-tACS) Reflects Plastic Changes Rather Than Entrainment. Brain Stimul. 2015 May-Jun;8(3):499-508. doi: 10.1016/j.brs.2014.12.004. Epub 2014 Dec 20."
                                    },
                                    {
                                        "ReferencePMID": "21072168",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Zaehle T, Rach S, Herrmann CS. Transcranial alternating current stimulation enhances individual alpha activity in human EEG. PLoS One. 2010 Nov 1;5(11):e13766. doi: 10.1371/journal.pone.0013766."
                                    }
                                ]
                            }
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000012559",
                                        "ConditionMeshTerm": "Schizophrenia"
                                    },
                                    {
                                        "ConditionMeshId": "D000011618",
                                        "ConditionMeshTerm": "Psychotic Disorders"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000019967",
                                        "ConditionAncestorTerm": "Schizophrenia Spectrum and Other Psychotic Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000001523",
                                        "ConditionAncestorTerm": "Mental Disorders"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M14528",
                                        "ConditionBrowseLeafName": "Schizophrenia",
                                        "ConditionBrowseLeafAsFound": "Schizophrenia",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M3967",
                                        "ConditionBrowseLeafName": "Mental Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M13625",
                                        "ConditionBrowseLeafName": "Psychotic Disorders",
                                        "ConditionBrowseLeafAsFound": "Schizoaffective Disorder",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M20991",
                                        "ConditionBrowseLeafName": "Schizophrenia Spectrum and Other Psychotic Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BXM",
                                        "ConditionBrowseBranchName": "Behaviors and Mental Disorders"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 32,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT01797432",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "0907M69801"
                            },
                            "Organization": {
                                "OrgFullName": "University of Minnesota",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata",
                            "OfficialTitle": "Safety and Efficacy of Combined Restylane and Triamcinolone Acetonide Injections for the Treatment of Alopecia Areata"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "December 2020",
                            "OverallStatus": "Completed",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "March 2009"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "November 2014",
                                "PrimaryCompletionDateType": "Actual"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "December 2015",
                                "CompletionDateType": "Actual"
                            },
                            "StudyFirstSubmitDate": "July 6, 2012",
                            "StudyFirstSubmitQCDate": "February 20, 2013",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "February 22, 2013",
                                "StudyFirstPostDateType": "Estimate"
                            },
                            "ResultsFirstSubmitDate": "October 30, 2020",
                            "ResultsFirstSubmitQCDate": "December 17, 2020",
                            "ResultsFirstPostDateStruct": {
                                "ResultsFirstPostDate": "January 12, 2021",
                                "ResultsFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "December 17, 2020",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "January 12, 2021",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Sponsor"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "University of Minnesota",
                                "LeadSponsorClass": "OTHER"
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "Yes",
                            "IsFDARegulatedDrug": "Yes",
                            "IsFDARegulatedDevice": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "The investigators hypothesize that Restylane® could serve as a repair matrix which also maintains IL triamcinolone acetonide concentrations at higher levels for a longer period of time in the skin, giving a more sustained local anti-inflammatory effect and thus, arresting the AA process and promoting hair regrowth. Furthermore, the combination of Restylane® with IL triamcinolone acetonide injections may prevent a common side effect, atrophy. With the prevention of scalp atrophy and the preservation of higher concentrations of triamcinolone acetonide for longer periods of time, patients may see a better clinical response for a longer period of time. Quality of life may improve as the number of clinic visits decreases as would the number of IL corticosteroid injections."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Alopecia Areata"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Phase 2"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "N/A",
                                "DesignInterventionModel": "Single Group Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "None (Open Label)"
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "14",
                                "EnrollmentType": "Actual"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "Combined IL Kenalog and Restylane",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "Injection of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on whole scalp and Restylane on half of scalp",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10)",
                                                "Device: Restylane"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10)",
                                        "InterventionDescription": "Intralesional injections of 4mLs Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on the whole scalp",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Combined IL Kenalog and Restylane"
                                            ]
                                        },
                                        "InterventionOtherNameList": {
                                            "InterventionOtherName": [
                                                "Kenalog-10"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "Restylane",
                                        "InterventionDescription": "Intralesional injections of 2mLs of Restylane on one side of the scalp",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Combined IL Kenalog and Restylane"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Change in Alopecia Areata Half Head Severity Score (AAHHSS) at 12 Weeks Compared to Baseline",
                                        "PrimaryOutcomeDescription": "The primary endpoint of evaluating the efficacy of administration of IL triamcinolone acetonide 10 mg/cc and Restylane® in the management of AA is the alopecia areata half head severity score (AAHHSS) comparing week 12 with baseline hair loss. Four discreet areas of the scalp are examined. The percent of terminal hair loss in each area is measured by visual estimation. Those percent figures are multiplied by the total area on one half of the scalp represented by the four respective areas. 1) Left parietal scalp (18% of area), right parietal scalp (18% of area), frontal scalp (40% of area), and occipital scalp (24% of area). Scores range from 0 to 50, with higher scores indicating more hair loss.",
                                        "PrimaryOutcomeTimeFrame": "12 weeks"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "Number of Adverse Events Reported by Subjects",
                                        "SecondaryOutcomeDescription": "To assess the safety of IL triamcinolone acetonide 10 mg/cc and Restylane® in the management of AA.",
                                        "SecondaryOutcomeTimeFrame": "12 weeks"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nMen and women ages 18 and greater.\nAlopecia areata diagnosis in the last two years with extensive scalp involvement, between 74% and 99%, alopecia areata must involve the left and right hemispheres of the scalp.\nWilling to abstain from use of over the counter products and prescription products, other than study medications, which may promote hair growth.\nWilling to abstain from the use of non-steroidal anti-inflammatory medications, aspirin, St. Johns Wart, and high doses of Vitamin E supplementation.\nSubjects are capable of giving informed consent.\nWilling to adhere to protocol, including scalp examinations and photography.\n\nExclusion Criteria:\n\nAllergy or intolerance to Restylane® or hyaluronate preparations\nAllergy or intolerance to triamcinolone acetonide, 10 mg/cc.\nUnderlying disease that might be adversely affected by Restylane® or triamcinolone (ex. patients with bleeding disorders).\nImmunosuppressed patients (history of transplantation, cancer, chemotherapy, splenectomy, HIV).\nPregnant or lactating female.\nApplication of topical immunomodulatory or immunosuppressive agent in the preceding 6 weeks.\nSystemic administration of corticosteroid or other systemic treatment (i.e. prednisone) that has immunomodulatory or other immunosuppressive mechanism of action, in the preceding 8 weeks.\nClinical evidence of secondary skin infection (i.e., folliculitis).\nOther inflammatory or infectious skin disease that might interfere with evaluations during the study.\nInvestigational medications within the past 30 days.\nPatients with susceptibility to keloid formation.\nSevere allergies manifested by a history of anaphylaxis, or history or presence of multiple severe allergies\nPatients with allergies to gram positive bacterial proteins\nUnable to give consent.",
                            "HealthyVolunteers": "No",
                            "Gender": "All",
                            "MinimumAge": "18 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Maria Hordinsky, MD",
                                        "OverallOfficialAffiliation": "University of Minnesota - Department of Dermatology",
                                        "OverallOfficialRole": "Principal Investigator"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "University of Minnesota Department of Dermatology",
                                        "LocationCity": "Minneapolis",
                                        "LocationState": "Minnesota",
                                        "LocationZip": "55455",
                                        "LocationCountry": "United States"
                                    }
                                ]
                            }
                        }
                    },
                    "ResultsSection": {
                        "ParticipantFlowModule": {
                            "FlowGroupList": {
                                "FlowGroup": [
                                    {
                                        "FlowGroupId": "FG000",
                                        "FlowGroupTitle": "Combined IL Kenalog and Restylane",
                                        "FlowGroupDescription": "Injection of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on whole scalp and Restylane on half of scalp\n\nIntralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10): Intralesional injections of 4mLs Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on the whole scalp\n\nRestylane: Intralesional injections of 2mLs of Restylane on one side of the scalp"
                                    }
                                ]
                            },
                            "FlowPeriodList": {
                                "FlowPeriod": [
                                    {
                                        "FlowPeriodTitle": "Overall Study",
                                        "FlowMilestoneList": {
                                            "FlowMilestone": [
                                                {
                                                    "FlowMilestoneType": "STARTED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "14"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowMilestoneType": "COMPLETED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "10"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowMilestoneType": "NOT COMPLETED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "4"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "FlowDropWithdrawList": {
                                            "FlowDropWithdraw": [
                                                {
                                                    "FlowDropWithdrawType": "Lost to Follow-up",
                                                    "FlowReasonList": {
                                                        "FlowReason": [
                                                            {
                                                                "FlowReasonGroupId": "FG000",
                                                                "FlowReasonNumSubjects": "1"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowDropWithdrawType": "Adverse Event",
                                                    "FlowReasonList": {
                                                        "FlowReason": [
                                                            {
                                                                "FlowReasonGroupId": "FG000",
                                                                "FlowReasonNumSubjects": "1"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowDropWithdrawType": "Withdrawal by Subject",
                                                    "FlowReasonList": {
                                                        "FlowReason": [
                                                            {
                                                                "FlowReasonGroupId": "FG000",
                                                                "FlowReasonNumSubjects": "1"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowDropWithdrawType": "lived too far from study site",
                                                    "FlowReasonList": {
                                                        "FlowReason": [
                                                            {
                                                                "FlowReasonGroupId": "FG000",
                                                                "FlowReasonNumSubjects": "1"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "BaselineCharacteristicsModule": {
                            "BaselineGroupList": {
                                "BaselineGroup": [
                                    {
                                        "BaselineGroupId": "BG000",
                                        "BaselineGroupTitle": "Combined IL Kenalog and Restylane",
                                        "BaselineGroupDescription": "Injection of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on whole scalp and Restylane on half of scalp\n\nIntralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10): Intralesional injections of 4mLs Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on the whole scalp\n\nRestylane: Intralesional injections of 2mLs of Restylane on one side of the scalp"
                                    }
                                ]
                            },
                            "BaselineDenomList": {
                                "BaselineDenom": [
                                    {
                                        "BaselineDenomUnits": "Participants",
                                        "BaselineDenomCountList": {
                                            "BaselineDenomCount": [
                                                {
                                                    "BaselineDenomCountGroupId": "BG000",
                                                    "BaselineDenomCountValue": "14"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "BaselineMeasureList": {
                                "BaselineMeasure": [
                                    {
                                        "BaselineMeasureTitle": "Age, Categorical",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineCategoryTitle": "<=18 years",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Between 18 and 65 years",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "13"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": ">=65 years",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "1"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Age, Continuous",
                                        "BaselineMeasureParamType": "Mean",
                                        "BaselineMeasureDispersionType": "Standard Deviation",
                                        "BaselineMeasureUnitOfMeasure": "years",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "41.43",
                                                                            "BaselineMeasurementSpread": "18.98"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Sex: Female, Male",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineCategoryTitle": "Female",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "12"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Male",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "2"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Race (NIH/OMB)",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineCategoryTitle": "American Indian or Alaska Native",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "1"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Asian",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Native Hawaiian or Other Pacific Islander",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Black or African American",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "White",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "13"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "More than one race",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Unknown or Not Reported",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Region of Enrollment",
                                        "BaselineMeasureParamType": "Number",
                                        "BaselineMeasureUnitOfMeasure": "participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineClassTitle": "United States",
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "14"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomeMeasuresModule": {
                            "OutcomeMeasureList": {
                                "OutcomeMeasure": [
                                    {
                                        "OutcomeMeasureType": "Primary",
                                        "OutcomeMeasureTitle": "Change in Alopecia Areata Half Head Severity Score (AAHHSS) at 12 Weeks Compared to Baseline",
                                        "OutcomeMeasureDescription": "The primary endpoint of evaluating the efficacy of administration of IL triamcinolone acetonide 10 mg/cc and Restylane® in the management of AA is the alopecia areata half head severity score (AAHHSS) comparing week 12 with baseline hair loss. Four discreet areas of the scalp are examined. The percent of terminal hair loss in each area is measured by visual estimation. Those percent figures are multiplied by the total area on one half of the scalp represented by the four respective areas. 1) Left parietal scalp (18% of area), right parietal scalp (18% of area), frontal scalp (40% of area), and occipital scalp (24% of area). Scores range from 0 to 50, with higher scores indicating more hair loss.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Mean",
                                        "OutcomeMeasureDispersionType": "Standard Deviation",
                                        "OutcomeMeasureUnitOfMeasure": "score on a scale",
                                        "OutcomeMeasureTimeFrame": "12 weeks",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "Combined IL Kenalog and Restylane",
                                                    "OutcomeGroupDescription": "Injection of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on whole scalp and Restylane on half of scalp\n\nIntralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10): Intralesional injections of 4mLs Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on the whole scalp\n\nRestylane: Intralesional injections of 2mLs of Restylane on one side of the scalp"
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "10"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "-17.75",
                                                                            "OutcomeMeasurementSpread": "23.36"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Secondary",
                                        "OutcomeMeasureTitle": "Number of Adverse Events Reported by Subjects",
                                        "OutcomeMeasureDescription": "To assess the safety of IL triamcinolone acetonide 10 mg/cc and Restylane® in the management of AA.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Number",
                                        "OutcomeMeasureUnitOfMeasure": "adverse events",
                                        "OutcomeMeasureTimeFrame": "12 weeks",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "Combined IL Kenalog and Restylane",
                                                    "OutcomeGroupDescription": "Injection of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on whole scalp and Restylane on half of scalp\n\nIntralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10): Intralesional injections of 4mLs Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on the whole scalp\n\nRestylane: Intralesional injections of 2mLs of Restylane on one side of the scalp"
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "14"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "25"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "AdverseEventsModule": {
                            "EventsFrequencyThreshold": "0",
                            "EventGroupList": {
                                "EventGroup": [
                                    {
                                        "EventGroupId": "EG000",
                                        "EventGroupTitle": "Combined IL Kenalog and Restylane",
                                        "EventGroupDescription": "Injection of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on whole scalp and Restylane on half of scalp\n\nIntralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10): Intralesional injections of 4mLs Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on the whole scalp\n\nRestylane: Intralesional injections of 2mLs of Restylane on one side of the scalp",
                                        "EventGroupDeathsNumAffected": "0",
                                        "EventGroupDeathsNumAtRisk": "14",
                                        "EventGroupSeriousNumAffected": "0",
                                        "EventGroupSeriousNumAtRisk": "14",
                                        "EventGroupOtherNumAffected": "11",
                                        "EventGroupOtherNumAtRisk": "14"
                                    }
                                ]
                            },
                            "OtherEventList": {
                                "OtherEvent": [
                                    {
                                        "OtherEventTerm": "Bronchial Infection",
                                        "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "14"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Shingles",
                                        "OtherEventOrganSystem": "Infections and infestations",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "14"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Bladder Infection",
                                        "OtherEventOrganSystem": "Renal and urinary disorders",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "14"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Migraine Headache",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "14"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Cold Sore",
                                        "OtherEventOrganSystem": "Immune system disorders",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "14"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Fatigue",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "14"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Allergic Reaction",
                                        "OtherEventOrganSystem": "Immune system disorders",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "14"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Upper Respiratory Infection",
                                        "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "14"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Pain at Injection Site",
                                        "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "14"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Irregular Menstrual Cycle",
                                        "OtherEventOrganSystem": "Reproductive system and breast disorders",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "14"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Cold/flu",
                                        "OtherEventOrganSystem": "Infections and infestations",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "14"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Headache",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "14"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Difficulty Concentrating",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "14"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Traveler's Diarrhea",
                                        "OtherEventOrganSystem": "Gastrointestinal disorders",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "14"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Acne",
                                        "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "14"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Vomiting",
                                        "OtherEventOrganSystem": "Gastrointestinal disorders",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "14"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Eczema",
                                        "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "14"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Hives",
                                        "OtherEventOrganSystem": "Immune system disorders",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "14"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Bump on Head",
                                        "OtherEventOrganSystem": "Injury, poisoning and procedural complications",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "14"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "MoreInfoModule": {
                            "CertainAgreement": {
                                "AgreementPISponsorEmployee": "Yes"
                            },
                            "PointOfContact": {
                                "PointOfContactTitle": "Maria Hordinsky, MD",
                                "PointOfContactOrganization": "University of Minnesota",
                                "PointOfContactEMail": "hordi001@umn.edu",
                                "PointOfContactPhone": "612-625-6118"
                            }
                        }
                    },
                    "DocumentSection": {
                        "LargeDocumentModule": {
                            "LargeDocList": {
                                "LargeDoc": [
                                    {
                                        "LargeDocTypeAbbrev": "Prot_SAP",
                                        "LargeDocHasProtocol": "Yes",
                                        "LargeDocHasSAP": "Yes",
                                        "LargeDocHasICF": "No",
                                        "LargeDocLabel": "Study Protocol and Statistical Analysis Plan",
                                        "LargeDocDate": "April 3, 2013",
                                        "LargeDocUploadDate": "10/30/2020 11:55",
                                        "LargeDocFilename": "Prot_SAP_000.pdf"
                                    },
                                    {
                                        "LargeDocTypeAbbrev": "ICF",
                                        "LargeDocHasProtocol": "No",
                                        "LargeDocHasSAP": "No",
                                        "LargeDocHasICF": "Yes",
                                        "LargeDocLabel": "Informed Consent Form",
                                        "LargeDocDate": "November 17, 2014",
                                        "LargeDocUploadDate": "10/30/2020 11:55",
                                        "LargeDocFilename": "ICF_001.pdf"
                                    }
                                ]
                            }
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000000505",
                                        "ConditionMeshTerm": "Alopecia"
                                    },
                                    {
                                        "ConditionMeshId": "D000000506",
                                        "ConditionMeshTerm": "Alopecia Areata"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000007039",
                                        "ConditionAncestorTerm": "Hypotrichosis"
                                    },
                                    {
                                        "ConditionAncestorId": "D000006201",
                                        "ConditionAncestorTerm": "Hair Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000012871",
                                        "ConditionAncestorTerm": "Skin Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000020763",
                                        "ConditionAncestorTerm": "Pathological Conditions, Anatomical"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M2998",
                                        "ConditionBrowseLeafName": "Alopecia",
                                        "ConditionBrowseLeafAsFound": "Alopecia",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M2999",
                                        "ConditionBrowseLeafName": "Alopecia Areata",
                                        "ConditionBrowseLeafAsFound": "Alopecia Areata",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M9241",
                                        "ConditionBrowseLeafName": "Hypotrichosis",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M8445",
                                        "ConditionBrowseLeafName": "Hair Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M14826",
                                        "ConditionBrowseLeafName": "Skin Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M21672",
                                        "ConditionBrowseLeafName": "Pathological Conditions, Anatomical",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC17",
                                        "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC23",
                                        "ConditionBrowseBranchName": "Symptoms and General Pathology"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionMeshList": {
                                "InterventionMesh": [
                                    {
                                        "InterventionMeshId": "D000014221",
                                        "InterventionMeshTerm": "Triamcinolone"
                                    },
                                    {
                                        "InterventionMeshId": "D000014222",
                                        "InterventionMeshTerm": "Triamcinolone Acetonide"
                                    },
                                    {
                                        "InterventionMeshId": "C000005900",
                                        "InterventionMeshTerm": "Triamcinolone hexacetonide"
                                    },
                                    {
                                        "InterventionMeshId": "C000030262",
                                        "InterventionMeshTerm": "Triamcinolone diacetate"
                                    }
                                ]
                            },
                            "InterventionAncestorList": {
                                "InterventionAncestor": [
                                    {
                                        "InterventionAncestorId": "D000000893",
                                        "InterventionAncestorTerm": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000005938",
                                        "InterventionAncestorTerm": "Glucocorticoids"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006728",
                                        "InterventionAncestorTerm": "Hormones"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006730",
                                        "InterventionAncestorTerm": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045505",
                                        "InterventionAncestorTerm": "Physiological Effects of Drugs"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007166",
                                        "InterventionAncestorTerm": "Immunosuppressive Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007155",
                                        "InterventionAncestorTerm": "Immunologic Factors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000004791",
                                        "InterventionAncestorTerm": "Enzyme Inhibitors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045504",
                                        "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                                    }
                                ]
                            },
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafAsFound": "Cross-sectional Survey",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafAsFound": "Laryngoscope",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafAsFound": "Cross-sectional Survey",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafAsFound": "Cross-sectional Survey",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M3369",
                                        "InterventionBrowseLeafName": "Anti-Inflammatory Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8199",
                                        "InterventionBrowseLeafName": "Glucocorticoids",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8941",
                                        "InterventionBrowseLeafName": "Hormones",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8940",
                                        "InterventionBrowseLeafName": "Hormone Antagonists",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9364",
                                        "InterventionBrowseLeafName": "Immunosuppressive Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9353",
                                        "InterventionBrowseLeafName": "Immunologic Factors",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 33,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT00756782",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "TAC101-204"
                            },
                            "Organization": {
                                "OrgFullName": "Taiho Oncology, Inc.",
                                "OrgClass": "INDUSTRY"
                            },
                            "BriefTitle": "A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma",
                            "OfficialTitle": "Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of TAC-101 in Combination With Transcatheter Arterial Chemoembolization (TACE) Versus TACE Alone in Asian Patients With Advanced Hepatocellular Carcinoma"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "March 2012",
                            "OverallStatus": "Withdrawn",
                            "WhyStopped": "Terminated due to safety concerns.",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "October 2008"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "December 2008",
                                "PrimaryCompletionDateType": "Actual"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "December 2008",
                                "CompletionDateType": "Actual"
                            },
                            "StudyFirstSubmitDate": "September 19, 2008",
                            "StudyFirstSubmitQCDate": "September 19, 2008",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "September 22, 2008",
                                "StudyFirstPostDateType": "Estimate"
                            },
                            "LastUpdateSubmitDate": "March 1, 2012",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "March 5, 2012",
                                "LastUpdatePostDateType": "Estimate"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Sponsor"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Taiho Oncology, Inc.",
                                "LeadSponsorClass": "INDUSTRY"
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "The purpose of this study is to evaluate the efficacy and safety of TAC-101 after Transcatheter Arterial Chemoembolization (TACE) in patients with advanced, unresectable hepatocellular carcinoma (HCC) who are being scheduled for TACE.",
                            "DetailedDescription": "Transcatheter arterial chemoembolization (TACE) is a commonly performed procedure in the treatment of unresectable liver tumors for selected patients. TACE is a major palliative treatment for these patients. Most patients will have intrahepatic recurrence of their tumors following TACE. In this study, which will be conducted in Asian countries excluding Japan, TAC-101 will be administered as maintenance therapy after TACE compared with placebo therapy after TACE to patients with advanced HCC who are being scheduled for TACE and who either have not had any previous TACE procedures or who received their most recent TACE at least 120 days before signing the Informed Consent Form (ICF) and the TACE procedure resulted in complete necrosis, to determine if TAC-101 will enhance the benefits of TACE."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Advanced Hepatocellular Carcinoma"
                                ]
                            },
                            "KeywordList": {
                                "Keyword": [
                                    "hepatocellular carcinoma"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Phase 2"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "Randomized",
                                "DesignInterventionModel": "Parallel Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "Double",
                                    "DesignWhoMaskedList": {
                                        "DesignWhoMasked": [
                                            "Participant",
                                            "Investigator"
                                        ]
                                    }
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "0",
                                "EnrollmentType": "Actual"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "A",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "Patients will receive TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: TAC-101"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "B",
                                        "ArmGroupType": "Placebo Comparator",
                                        "ArmGroupDescription": "Patients will receive placebo (two matching tablets) at same frequency and duration of active treatment",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: Placebo"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "TAC-101",
                                        "InterventionDescription": "Patients will receive TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "A"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "Placebo",
                                        "InterventionDescription": "Patients will receive placebo (two matching tablets) at same frequency and duration of active treatment",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "B"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "radiologically proven progression-free survival (PFS)",
                                        "PrimaryOutcomeTimeFrame": "Tumor Imaging assessments will be conducted at screening/baseline within 14 days prior to first TACE; every 8 weeks during treatment within 14 days prior to first TACE and every 8 weeks during follow-up period within 14 days prior to first TACE."
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "Overall survival (OS)",
                                        "SecondaryOutcomeTimeFrame": "Survival status obtained every 8 weeks during imaging follow-up period, from first TACE, patients contacted every 12 weeks until death or for at least 3 yrs after randomization of the last patient."
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Time to appearance of remote new lesions (TTNLr)",
                                        "SecondaryOutcomeTimeFrame": "Tumor Imaging assessments will be conducted at screening/baseline within 14 days prior to first TACE; every 8 weeks during treatment within 14 days prior to first TACE and every 8 weeks during follow-up period within 14 days prior to first TACE."
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Objective tumor response rate (ORR) according to RECIST criteria (CR + PR)",
                                        "SecondaryOutcomeTimeFrame": "Tumor Imaging assessments will be conducted at screening/baseline within 14 days prior to first TACE; every 8 weeks during treatment within 14 days prior to first TACE and every 8 weeks during follow-up period within 14 days prior to first TACE."
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Effects on the plasma levels of alpha-fetoprotein (AFP and AFP-L3)",
                                        "SecondaryOutcomeTimeFrame": "Blood samples for AFP and AFP-L3assessment obtained at Screening/ Baseline; every 8 weeks after first TACE during the treatment period; at the end of the treatment period; and every 8 weeks (± 2 weeks) from first TACE during imaging f/up period."
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Number of post-randomization TACE procedures",
                                        "SecondaryOutcomeTimeFrame": "The number of post-randomization TACE procedures per patient in the double-blind treatment period patient will be counted every 8 weeks during treatment from first TACE."
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The adverse event (AE) profile and tolerability of TAC-101 therapy with TACE versus placebo therapy with TACE",
                                        "SecondaryOutcomeTimeFrame": "AEs will be reported from the time a patient signs ICF through the period of patient follow-up (30 days after the last dose of study medication)."
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The relationship between the PK of TAC-101 and its metabolites and safety and efficacy parameters, including hepatic function",
                                        "SecondaryOutcomeTimeFrame": "Pharmacokinetic blood samples will be collected (optional) at 4 hours (± 1 hour), 8 hours (± 1 hour), and 24 hours (± 1 hour) post-dose on Day 1 of treatment Cycle 1. The 24-hour sample must be collected prior to dosing on Day 2."
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The biological effects of TAC-101 on selected RAR-related factors and growth factor VEGF-A",
                                        "SecondaryOutcomeTimeFrame": "Blood samples collected at Screening/Baseline; every 8 weeks (± 2 weeks) after first TACE during the treatment period; at the end of the treatment period; at the Safety Follow-up visit (30 days after the end of study treatment)."
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The relationship between tumor gene expression (mRNA expression) of co-activators and co-repressors and efficacy parameters",
                                        "SecondaryOutcomeTimeFrame": "Tissue samples collected at Screening/Baseline."
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\n-A patient must meet all of the following inclusion criteria to be eligible for enrollment in this study and before undergoing the first TACE procedure of this study:\n\nHas an HCC diagnosis by histology (can not have a mixed tumor type such as HCC and cholangiocarcinoma) OR by the following non-invasive criteria observed either within 14 days prior to first TACE or in the past.\n\nOne imaging technique (CT scan or magnetic resonance imaging [MRI] both with unenhanced plus hepatic arterial phase and portal venous phases) showing characteristic features in a focal lesion > 20 mm with arterial vascularization, or\nTwo dynamic imaging techniques (CT scan, MRI with unenhanced plus hepatic arterial phase and portal venous phases) showing characteristic features coincidentally in a focal lesion 10-20 mm with arterial vascularization.\nIs TACE naïve or has received the most recent TACE procedure, which showed complete necrosis after treatment, at least 120 days before signing ICF.\nEligible to receive TACE and being scheduled to receive TACE.\nIs ≥ 18 years of age.\nIs not amenable to treatment with curative surgery, transplant, or percutaneous ablation, including RFA, percutaneous ethanol injection therapy (PEIT) and percutaneous microwave coagulation therapy (PMCT).\n\nHave at least 1 measurable lesion that is ≥10 mm in size. Measurable lesions must be confirmed nodular type (not including only infiltration type) which demonstrated substantial hypervascularity by CT scan or MRI both with unenhanced plus hepatic arterial phase and portal venous phases. All measurable lesions must be targeted by the first TACE in this study\n\nIf there are ≥ 4 intrahepatic lesions, at least 1 must be ≥10 mm and all lesions must be <100 mm.\nIf there are < 4 intrahepatic lesions, at least one must be ≥ 30 mm and all lesions must be <100 mm.\nNo vascular invasion in main trunk and first order branch of portal vein or other large vessels (hepatic vein or inferior vena cava).\nNo extrahepatic tumor spread\nAbsence of extrahepatic abdominal tumors must be confirmed.\n\nHas adequate organ function as defined by the following criteria:\n\nWhite blood cell (WBC) count > 3,000/mm3\nPlatelet count > 60,000/mm3\nHemoglobin > 8.0 grams (g)/deciliter (dL)\nAspartate transaminase (AST) < 5 x ULN\nAlanine transaminase (ALT) < 5 x ULN\nTotal bilirubin < 2.0 mg/dL\nAlbumin > 2.8 g/dL\nSerum creatinine < 1.5 mg/dL\nInternational normalized ratio (INR) ≤ 2.0\nTriglyceride ≤ 2.5 x ULN.\nHas a Child-Pugh classification of ≤ 8.\nHas a Cancer of the Liver Italian Program (CLIP)68 score of 0, 1, 2 or 3.\nHas an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.\nIs willing and able to comply with schedule visits, treatment plans, laboratory tests, and other study procedures.\nProvides written informed consent prior to the implementation of any study assessment or procedures.\n\nExclusion Criteria:\n\n- Patients will be excluded from participation in the study if any of the following conditions are observed before undergoing the first TACE procedure:\n\nHas only infiltration type of HCC.\nHas extrahepatic metastasis of HCC including regional lymph node metastases.\nHas had systemic chemotherapy (eg, sorafenib, doxorubicin), immunotherapy, or biologic therapy or radiotherapy for HCC, or treatment with TAC-101.\n\nReceived treatment with any of the following within the specified time frame:\n\nAny major surgical procedure within 28 days prior to signing the ICF\nAny red blood cell or thrombocyte transfusion, treatment with blood component preparation, albumin preparation, Granulocyte-Colony Stimulating Factor (G-CSF), or erythropoietin within 14 days prior to signing the ICF\nAny intra-arterial chemotherapy (transcatheter injection) using lipiodol for HCC performed within 119 days prior to signing ICF.\nAny local therapy such as alcohol injection, radiofrequency/ultrasound ablation, intraarterial chemotherapy (transcatheter arterial injection) for HCC performed within 28 days prior to signing the ICF\nAny investigational agent within 28 days prior to signing the ICF\nHas ascites, pleural effusions or pericardial fluid refractory to diuretic therapy.\nHas clinical symptoms of hepatic encephalopathy.\nHas active or uncontrolled clinically serious infection excluding chronic hepatitis.\nHas a history of gastrointestinal (GI) bleeding in last 3 months.\nHas previous or concurrent malignancy except for in situ carcinoma of the cervix, or other solid tumor treated curatively and without evidence of recurrence for at least 3 years prior to the study.\nHas uncontrolled metabolic disorders or other nonmalignant organ or systemic diseases or secondary effects of cancer that induce a high medical risk and/or make assessment of survival uncertain.\nHas any history during the last 3 years of deep vein thrombosis (DVT), pulmonary embolism (PE), myocardial infarction (MI), cerebrovascular accident (CVA), transient ischemic attack (TIA), unstable angina pectoris, or any other significant thromboembolic event (TE).\nHas ejection fraction (EF) by echocardiogram (ECHO) or multi-gate acquisition (MUGA) that is outside of the normal range according to the site's institutional standard.\nHas GI disease resulting in an inability to take oral medication.\nHas had a liver transplant.\nHas known allergy or hypersensitivity to TAC-101, doxorubicin, epirubicin, other anthracyclines, anthracenediones or any of the components used in the study drug formulations.\nHas known hypersensitivity to iodinated contrast medium.\nIs receiving therapeutic regimens of anticoagulants. However, use of low dose anticoagulants for prophylactic care of indwelling venous access device and use of low dose aspirin for prophylaxis are permitted.\nIs taking medication known or suspected to predispose patient to an increased risk of VTE (eg, oral contraceptives, hormone replacement therapy, megestrol acetate).",
                            "HealthyVolunteers": "No",
                            "Gender": "All",
                            "MinimumAge": "18 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Fabio Benedetti, MD",
                                        "OverallOfficialAffiliation": "Taiho Oncology, Inc.",
                                        "OverallOfficialRole": "Study Director"
                                    }
                                ]
                            }
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000002277",
                                        "ConditionMeshTerm": "Carcinoma"
                                    },
                                    {
                                        "ConditionMeshId": "D000006528",
                                        "ConditionMeshTerm": "Carcinoma, Hepatocellular"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000009375",
                                        "ConditionAncestorTerm": "Neoplasms, Glandular and Epithelial"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009370",
                                        "ConditionAncestorTerm": "Neoplasms by Histologic Type"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009369",
                                        "ConditionAncestorTerm": "Neoplasms"
                                    },
                                    {
                                        "ConditionAncestorId": "D000000230",
                                        "ConditionAncestorTerm": "Adenocarcinoma"
                                    },
                                    {
                                        "ConditionAncestorId": "D000008113",
                                        "ConditionAncestorTerm": "Liver Neoplasms"
                                    },
                                    {
                                        "ConditionAncestorId": "D000004067",
                                        "ConditionAncestorTerm": "Digestive System Neoplasms"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009371",
                                        "ConditionAncestorTerm": "Neoplasms by Site"
                                    },
                                    {
                                        "ConditionAncestorId": "D000004066",
                                        "ConditionAncestorTerm": "Digestive System Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000008107",
                                        "ConditionAncestorTerm": "Liver Diseases"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M4686",
                                        "ConditionBrowseLeafName": "Carcinoma",
                                        "ConditionBrowseLeafAsFound": "Carcinoma",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M8765",
                                        "ConditionBrowseLeafName": "Carcinoma, Hepatocellular",
                                        "ConditionBrowseLeafAsFound": "Hepatocellular Carcinoma",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M11472",
                                        "ConditionBrowseLeafName": "Neoplasms, Glandular and Epithelial",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M11467",
                                        "ConditionBrowseLeafName": "Neoplasms by Histologic Type",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M2737",
                                        "ConditionBrowseLeafName": "Adenocarcinoma",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M10265",
                                        "ConditionBrowseLeafName": "Liver Neoplasms",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M8038",
                                        "ConditionBrowseLeafName": "Gastrointestinal Neoplasms",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M6408",
                                        "ConditionBrowseLeafName": "Digestive System Neoplasms",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M8035",
                                        "ConditionBrowseLeafName": "Gastrointestinal Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M6407",
                                        "ConditionBrowseLeafName": "Digestive System Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M10259",
                                        "ConditionBrowseLeafName": "Liver Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC04",
                                        "ConditionBrowseBranchName": "Neoplasms"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC06",
                                        "ConditionBrowseBranchName": "Digestive System Diseases"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M5134",
                                        "InterventionBrowseLeafName": "Chlorotrianisene",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "ANeo",
                                        "InterventionBrowseBranchName": "Antineoplastic Agents"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 34,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT00846690",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "HSC-DB-08-0484"
                            },
                            "Organization": {
                                "OrgFullName": "The University of Texas Health Science Center, Houston",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Comparative Efficacy of 20% Benzocaine Versus TAC Alternate Gel",
                            "OfficialTitle": "Comparative Efficacy of 20% Benzocaine Versus TAC Alternate Gel for Control of Pain of Dental Needle Insertion in the Palate"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "February 2009",
                            "OverallStatus": "Unknown status",
                            "LastKnownStatus": "Recruiting",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "January 2009"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "March 2009",
                                "PrimaryCompletionDateType": "Anticipated"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "May 2009",
                                "CompletionDateType": "Anticipated"
                            },
                            "StudyFirstSubmitDate": "February 18, 2009",
                            "StudyFirstSubmitQCDate": "February 18, 2009",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "February 19, 2009",
                                "StudyFirstPostDateType": "Estimate"
                            },
                            "LastUpdateSubmitDate": "February 18, 2009",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "February 19, 2009",
                                "LastUpdatePostDateType": "Estimate"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyOldNameTitle": "Femme Ambrosio",
                                "ResponsiblePartyOldOrganization": "University of Texas Health Science Center Houston"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "The University of Texas Health Science Center, Houston",
                                "LeadSponsorClass": "OTHER"
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "The project is a study comparing the effectiveness of two topical anesthetics for control of pain associated with dental needle insertion in the palatal mucosa. A standard dental topical anesthetic (20% benzocaine) will serve as an \"active\" control and will be compared to a combination topical anesthetic, consisting of 20% lidocaine, 4% tetracaine and 2% phenylephrine (TAC Alternate Gel, Compounding Arts Pharmacy, Lafayette, LA)."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Dental Pain",
                                    "Postoperative Pain"
                                ]
                            },
                            "KeywordList": {
                                "Keyword": [
                                    "topical anesthetics",
                                    "topical anesthesia",
                                    "20% benzocaine",
                                    "TAC alternate gel",
                                    "combination topical anesthetics",
                                    "dental anesthesia"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Phase 4"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "Randomized",
                                "DesignInterventionModel": "Crossover Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "Double",
                                    "DesignWhoMaskedList": {
                                        "DesignWhoMasked": [
                                            "Participant",
                                            "Care Provider"
                                        ]
                                    }
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "20",
                                "EnrollmentType": "Anticipated"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "Benzocaine",
                                        "ArmGroupType": "Active Comparator",
                                        "ArmGroupDescription": "serves as \"active\" control",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: benzocaine"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "TAC",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "serves as comparator",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: TAC alternate gel"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "benzocaine",
                                        "InterventionDescription": "20% benzocaine., topical placement onto site, minimal amount, for 1 minute",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Benzocaine"
                                            ]
                                        },
                                        "InterventionOtherNameList": {
                                            "InterventionOtherName": [
                                                "Hurricaine"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "TAC alternate gel",
                                        "InterventionDescription": "use 1 pump, place topically onto site, leave for 1-3 minutes",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "TAC"
                                            ]
                                        },
                                        "InterventionOtherNameList": {
                                            "InterventionOtherName": [
                                                "20% TAC alternate gel"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "visual analogue scale score",
                                        "PrimaryOutcomeTimeFrame": "pre-op, insertion, every minute post-op for 10 minutes"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "blood pressure",
                                        "SecondaryOutcomeTimeFrame": "three times pre-op, insertion, ten times post-op"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "oxygen saturation",
                                        "SecondaryOutcomeTimeFrame": "three times pre-op, insertion, ten times post-op"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "heart rate",
                                        "SecondaryOutcomeTimeFrame": "three times pre-op, insertion, ten times post-op"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nVolunteers 18 years or older\nAbility to consent to participate in the research\nAbility to communicate a VAS score\nGenerally healthy, ASA I and ASA II\nNo known drug allergies\nAbility to tolerate pulse oximeter and blood pressure cuff without psychological, or physiological consequence\n\nExclusion Criteria:\n\nAllergy or other contraindications to the topical anesthetics\nInability to consent to participation in the study\nUse of analgesics prior to the procedure\nVulnerable populations",
                            "HealthyVolunteers": "Accepts Healthy Volunteers",
                            "Gender": "All",
                            "StdAgeList": {
                                "StdAge": [
                                    "Child",
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "CentralContactList": {
                                "CentralContact": [
                                    {
                                        "CentralContactName": "Femme L Ambrosio, DDS",
                                        "CentralContactRole": "Contact",
                                        "CentralContactPhone": "858 603-6345",
                                        "CentralContactEMail": "femme.l.ambrosio@uth.tmc.edu"
                                    },
                                    {
                                        "CentralContactName": "Arthur H Jeske, DDS, PhD",
                                        "CentralContactRole": "Contact",
                                        "CentralContactPhone": "713 500 4506",
                                        "CentralContactEMail": "arthur.h.jeske@uth.tmc.edu"
                                    }
                                ]
                            },
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Femme L Ambrosio, DDS",
                                        "OverallOfficialAffiliation": "UT Health Science Center Houston",
                                        "OverallOfficialRole": "Principal Investigator"
                                    },
                                    {
                                        "OverallOfficialName": "Arthur H Jeske, DDS, PhD",
                                        "OverallOfficialAffiliation": "UT Health Science Center Houston",
                                        "OverallOfficialRole": "Study Chair"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "UT Pediatric Dentistry Clinic Houston Medical Center",
                                        "LocationStatus": "Recruiting",
                                        "LocationCity": "6655 Travis Suite 460",
                                        "LocationState": "Texas",
                                        "LocationZip": "77030",
                                        "LocationCountry": "United States",
                                        "LocationContactList": {
                                            "LocationContact": [
                                                {
                                                    "LocationContactName": "Femme L Ambrosio, DDS",
                                                    "LocationContactRole": "Contact",
                                                    "LocationContactPhone": "858-603-6345",
                                                    "LocationContactEMail": "femme.l.ambrosio@uth.tmc.edu"
                                                },
                                                {
                                                    "LocationContactName": "Arthur H Jeske, DDS PhD",
                                                    "LocationContactRole": "Contact",
                                                    "LocationContactPhone": "7135004506",
                                                    "LocationContactEMail": "arthur.h.jeske@uth.tmc.edu"
                                                },
                                                {
                                                    "LocationContactName": "Robert Tate, DDS MS",
                                                    "LocationContactRole": "Sub-Investigator"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        }
                    },
                    "AnnotationSection": {
                        "AnnotationModule": {
                            "UnpostedAnnotation": {
                                "UnpostedResponsibleParty": "Femme Ambrosio, Professor, The University of Texas Health Science Center, Houston",
                                "UnpostedEventList": {
                                    "UnpostedEvent": [
                                        {
                                            "UnpostedEventType": "Release",
                                            "UnpostedEventDate": "June 15, 2011"
                                        },
                                        {
                                            "UnpostedEventType": "Reset",
                                            "UnpostedEventDate": "July 14, 2011"
                                        }
                                    ]
                                }
                            }
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022",
                            "SubmissionTracking": {
                                "SubmissionInfoList": {
                                    "SubmissionInfo": [
                                        {
                                            "SubmissionReleaseDate": "June 15, 2011",
                                            "SubmissionResetDate": "July 14, 2011"
                                        }
                                    ]
                                }
                            }
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000014098",
                                        "ConditionMeshTerm": "Toothache"
                                    },
                                    {
                                        "ConditionMeshId": "D000010149",
                                        "ConditionMeshTerm": "Pain, Postoperative"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000011183",
                                        "ConditionAncestorTerm": "Postoperative Complications"
                                    },
                                    {
                                        "ConditionAncestorId": "D000010335",
                                        "ConditionAncestorTerm": "Pathologic Processes"
                                    },
                                    {
                                        "ConditionAncestorId": "D000010146",
                                        "ConditionAncestorTerm": "Pain"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009461",
                                        "ConditionAncestorTerm": "Neurologic Manifestations"
                                    },
                                    {
                                        "ConditionAncestorId": "D000014076",
                                        "ConditionAncestorTerm": "Tooth Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009057",
                                        "ConditionAncestorTerm": "Stomatognathic Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000005157",
                                        "ConditionAncestorTerm": "Facial Pain"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M12221",
                                        "ConditionBrowseLeafName": "Pain, Postoperative",
                                        "ConditionBrowseLeafAsFound": "Postoperative Pain",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M16005",
                                        "ConditionBrowseLeafName": "Toothache",
                                        "ConditionBrowseLeafAsFound": "Dental Pain",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M12218",
                                        "ConditionBrowseLeafName": "Pain",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M13217",
                                        "ConditionBrowseLeafName": "Postoperative Complications",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M11556",
                                        "ConditionBrowseLeafName": "Neurologic Manifestations",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M15983",
                                        "ConditionBrowseLeafName": "Tooth Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M11169",
                                        "ConditionBrowseLeafName": "Stomatognathic Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M20242",
                                        "ConditionBrowseLeafName": "Facies",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M7452",
                                        "ConditionBrowseLeafName": "Facial Pain",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC23",
                                        "ConditionBrowseBranchName": "Symptoms and General Pathology"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC07",
                                        "ConditionBrowseBranchName": "Mouth and Tooth Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC10",
                                        "ConditionBrowseBranchName": "Nervous System Diseases"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionMeshList": {
                                "InterventionMesh": [
                                    {
                                        "InterventionMeshId": "D000008012",
                                        "InterventionMeshTerm": "Lidocaine"
                                    },
                                    {
                                        "InterventionMeshId": "D000010656",
                                        "InterventionMeshTerm": "Phenylephrine"
                                    },
                                    {
                                        "InterventionMeshId": "D000001566",
                                        "InterventionMeshTerm": "Benzocaine"
                                    },
                                    {
                                        "InterventionMeshId": "D000013748",
                                        "InterventionMeshTerm": "Tetracaine"
                                    }
                                ]
                            },
                            "InterventionAncestorList": {
                                "InterventionAncestor": [
                                    {
                                        "InterventionAncestorId": "D000000779",
                                        "InterventionAncestorTerm": "Anesthetics, Local"
                                    },
                                    {
                                        "InterventionAncestorId": "D000000777",
                                        "InterventionAncestorTerm": "Anesthetics"
                                    },
                                    {
                                        "InterventionAncestorId": "D000002492",
                                        "InterventionAncestorTerm": "Central Nervous System Depressants"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045505",
                                        "InterventionAncestorTerm": "Physiological Effects of Drugs"
                                    },
                                    {
                                        "InterventionAncestorId": "D000018689",
                                        "InterventionAncestorTerm": "Sensory System Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000018373",
                                        "InterventionAncestorTerm": "Peripheral Nervous System Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000000889",
                                        "InterventionAncestorTerm": "Anti-Arrhythmia Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000061567",
                                        "InterventionAncestorTerm": "Voltage-Gated Sodium Channel Blockers"
                                    },
                                    {
                                        "InterventionAncestorId": "D000026941",
                                        "InterventionAncestorTerm": "Sodium Channel Blockers"
                                    },
                                    {
                                        "InterventionAncestorId": "D000049990",
                                        "InterventionAncestorTerm": "Membrane Transport Modulators"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045504",
                                        "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                                    },
                                    {
                                        "InterventionAncestorId": "D000002316",
                                        "InterventionAncestorTerm": "Cardiotonic Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000009184",
                                        "InterventionAncestorTerm": "Mydriatics"
                                    },
                                    {
                                        "InterventionAncestorId": "D000001337",
                                        "InterventionAncestorTerm": "Autonomic Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000013566",
                                        "InterventionAncestorTerm": "Sympathomimetics"
                                    },
                                    {
                                        "InterventionAncestorId": "D000014662",
                                        "InterventionAncestorTerm": "Vasoconstrictor Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000014663",
                                        "InterventionAncestorTerm": "Nasal Decongestants"
                                    },
                                    {
                                        "InterventionAncestorId": "D000019141",
                                        "InterventionAncestorTerm": "Respiratory System Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000058646",
                                        "InterventionAncestorTerm": "Adrenergic alpha-1 Receptor Agonists"
                                    },
                                    {
                                        "InterventionAncestorId": "D000000316",
                                        "InterventionAncestorTerm": "Adrenergic alpha-Agonists"
                                    },
                                    {
                                        "InterventionAncestorId": "D000000322",
                                        "InterventionAncestorTerm": "Adrenergic Agonists"
                                    },
                                    {
                                        "InterventionAncestorId": "D000018663",
                                        "InterventionAncestorTerm": "Adrenergic Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000018377",
                                        "InterventionAncestorTerm": "Neurotransmitter Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000020011",
                                        "InterventionAncestorTerm": "Protective Agents"
                                    }
                                ]
                            },
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M3259",
                                        "InterventionBrowseLeafName": "Anesthetics",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M4006",
                                        "InterventionBrowseLeafName": "Benzocaine",
                                        "InterventionBrowseLeafAsFound": "Employees",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M10166",
                                        "InterventionBrowseLeafName": "Lidocaine",
                                        "InterventionBrowseLeafAsFound": "Low potassium",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M12713",
                                        "InterventionBrowseLeafName": "Phenylephrine",
                                        "InterventionBrowseLeafAsFound": "Low potassium",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M12183",
                                        "InterventionBrowseLeafName": "Oxymetazoline",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M15669",
                                        "InterventionBrowseLeafName": "Tetracaine",
                                        "InterventionBrowseLeafAsFound": "Low potassium",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M3261",
                                        "InterventionBrowseLeafName": "Anesthetics, Local",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M3365",
                                        "InterventionBrowseLeafName": "Anti-Arrhythmia Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M22330",
                                        "InterventionBrowseLeafName": "Sodium Channel Blockers",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M29178",
                                        "InterventionBrowseLeafName": "Diuretics, Potassium Sparing",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M4724",
                                        "InterventionBrowseLeafName": "Cardiotonic Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M11291",
                                        "InterventionBrowseLeafName": "Mydriatics",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M15497",
                                        "InterventionBrowseLeafName": "Sympathomimetics",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16561",
                                        "InterventionBrowseLeafName": "Vasoconstrictor Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M7118",
                                        "InterventionBrowseLeafName": "Ephedrine",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M26739",
                                        "InterventionBrowseLeafName": "Pseudoephedrine",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16562",
                                        "InterventionBrowseLeafName": "Nasal Decongestants",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M20290",
                                        "InterventionBrowseLeafName": "Respiratory System Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M19899",
                                        "InterventionBrowseLeafName": "Adrenergic Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M2820",
                                        "InterventionBrowseLeafName": "Adrenergic alpha-Agonists",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M2825",
                                        "InterventionBrowseLeafName": "Adrenergic Agonists",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M19657",
                                        "InterventionBrowseLeafName": "Neurotransmitter Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M21022",
                                        "InterventionBrowseLeafName": "Protective Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "T433",
                                        "InterventionBrowseLeafName": "Tannic Acid",
                                        "InterventionBrowseLeafAsFound": "Employees",
                                        "InterventionBrowseLeafRelevance": "high"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "CNSDep",
                                        "InterventionBrowseBranchName": "Central Nervous System Depressants"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "AnArAg",
                                        "InterventionBrowseBranchName": "Anti-Arrhythmia Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "ChanBlk",
                                        "InterventionBrowseBranchName": "Channel Blockers"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "CaAg",
                                        "InterventionBrowseBranchName": "Cardiotonic Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "VaCoAg",
                                        "InterventionBrowseBranchName": "Vasoconstrictor Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "Resp",
                                        "InterventionBrowseBranchName": "Respiratory System Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "CNSSti",
                                        "InterventionBrowseBranchName": "Central Nervous System Stimulants"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "Ot",
                                        "InterventionBrowseBranchName": "Other Dietary Supplements"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 35,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT03756610",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "2018-24"
                            },
                            "Organization": {
                                "OrgFullName": "Shanghai Mental Health Center",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Transcranial Alternating Current Stimulation (tACS) for Cognitive Impairments in Patients With Schizophrenia",
                            "OfficialTitle": "Transcranial Alternating Current Stimulation (tACS) for Cognitive Impairments in Patients With Schizophrenia: a Randomized Controlled Trial"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "October 2018",
                            "OverallStatus": "Unknown status",
                            "LastKnownStatus": "Recruiting",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "November 2018",
                                "StartDateType": "Anticipated"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "December 2019",
                                "PrimaryCompletionDateType": "Anticipated"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "March 2020",
                                "CompletionDateType": "Anticipated"
                            },
                            "StudyFirstSubmitDate": "October 27, 2018",
                            "StudyFirstSubmitQCDate": "November 26, 2018",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "November 28, 2018",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "November 26, 2018",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "November 28, 2018",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Sponsor"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Shanghai Mental Health Center",
                                "LeadSponsorClass": "OTHER"
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "Yes",
                            "IsFDARegulatedDrug": "No",
                            "IsFDARegulatedDevice": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "This trial attempts to investigate whether 10 sessions of tACS improves cognitive function, especially which domains of cognitive function are most improved and to investigate whether 10 sessions of tACS affecting brain activation during a working memory task and changes patterns of brain connectivity networks.Subjects will be divided into 2 groups 2:1, active and sham tACS. 50 subjects will be in the active group, and 25 subjects in the sham group (specific numbers to be decided on later).",
                            "DetailedDescription": "Schizophrenia patients (SZ) show profound and persistent cognitive deficits in attention, executive processing, and verbal and visuospatial memory, which persist even after psychotic symptoms are ameliorated. Cognitive deficits may be more important in preventing functional, occupational, and social recovery in SZ than other symptom domains and are not effectively treated by current pharmacological approaches. Alternating current stimulation (tACS) is less expensive than other modalities (e.g. repetitive transcranial magnetic stimulation; rTMS), easily available, and has a good safety profile in healthy controls (HC) and SZ. The ability to entrain γ oscillations with 40Hz tACS, might compensate more specifically for this deficit in γ oscillations in schizophrenia, and, may therefore, produce more robust behavioral improvements in working memory and other aspects of cognition.However, no studies have looked at the effects of multiple daily tACS stimulation at a 40HZ γ frequency on cognitive function and symptoms in schizophrenia. This provides a rationale for the current study, which proposes to investigate the effects of 10 sessions of 40HZ tACS on cognitive functions, symptoms in schizophrenia.\n\nActive vs. sham treatment will be randomly assigned in a 2:1 fashion (A:S) in groups using computer generated lists. Subjects and tDCS testers or evaluators will be blind to treatment. Subjects will be evaluated with cognitive, symptom and functional measures at baseline, within 1 day ( or 2 days fro some measures) after 10 sessions, 2 weeks after 10 sessions, 1 month after 10 sessions, and 2 months after 10 sessions.After the 1 month evaluation, subjects in the initial active tACS group will be randomly assigned to receive either 5 booster sessions of either active or sham tACS ( 25 subjects each), following parameters used in the initial treatment. Subjects in the initial Sham group will receive 5 booster session Sham tACS. Participants will be scanned once prior to tACS sessions, and within 3 days after the 10th tACS session, using our Siemens 3T Tim Verio MRI scanner with a standard 32-channel phased-array head coil."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Schizophrenia"
                                ]
                            },
                            "KeywordList": {
                                "Keyword": [
                                    "tACS",
                                    "schizophrenia",
                                    "cognition",
                                    "fMRI"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Not Applicable"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "Randomized",
                                "DesignInterventionModel": "Parallel Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "Quadruple",
                                    "DesignWhoMaskedList": {
                                        "DesignWhoMasked": [
                                            "Participant",
                                            "Care Provider",
                                            "Investigator",
                                            "Outcomes Assessor"
                                        ]
                                    }
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "90",
                                "EnrollmentType": "Anticipated"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "Active tACS & active boosting group",
                                        "ArmGroupType": "Active Comparator",
                                        "ArmGroupDescription": "The active tACS & active boosting group will be stimulated with 10 sessions of active alternating current stimulation (tACS) and 5 booster sessions of active tACS.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: Active tACS",
                                                "Device: Active boosting"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "Active tACS & sham boosting group",
                                        "ArmGroupType": "Other",
                                        "ArmGroupDescription": "The active tACS & sham boosting group will be stimulated with 10 sessions of active alternating current stimulation (tACS) and 5 booster sessions of sham tACS.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: Active tACS",
                                                "Device: Sham boosting"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "Sham tACS & sham boosting group",
                                        "ArmGroupType": "Sham Comparator",
                                        "ArmGroupDescription": "The sham tACS & sham boosting group will be stimulated with 10 sessions of sham alternating current stimulation (tACS) and 5 booster sessions of sham tACS.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: Sham tACS",
                                                "Device: Sham boosting"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "Active tACS",
                                        "InterventionDescription": "Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded). Each subject will have 10 active tACS sessions.The active tACS group will be stimulated with a 2 mA current for 20 minutes.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Active tACS & active boosting group",
                                                "Active tACS & sham boosting group"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "Sham tACS",
                                        "InterventionDescription": "Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded). Each subject will have 10 sham tACS sessions.The sham tACS group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Sham tACS & sham boosting group"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "Active boosting",
                                        "InterventionDescription": "Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded).One month later after initial treatment, each subject will have 5 booster sessions of active tACS.The active boosting group will be stimulated with a 2 mA current for 20 minutes.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Active tACS & active boosting group"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "Sham boosting",
                                        "InterventionDescription": "Placement of stimuli electrodes will be: a) active electrode over the left DLPFC (F3), and b) reference electrode over the right parietal region (P2). The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tACS sessions on consecutive days (weekends and holidays excluded).One month later after initial treatment, each subject will have 5 booster sessions of sham tACS.The sham boosting group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Active tACS & sham boosting group",
                                                "Sham tACS & sham boosting group"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "changes in The MATRICS Consensus Cognitive Battery (MCCB)",
                                        "PrimaryOutcomeTimeFrame": "Change from Baseline MCCB at 2 weeks."
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "changes in Neuroimage changes in Magnetic Resonance Imaging (MRI)",
                                        "PrimaryOutcomeDescription": "Including T1, resting state functional MRI, task based functional MRI and Diffusion Tensor Imaging(DTI)",
                                        "PrimaryOutcomeTimeFrame": "Change from Baseline at 2 weeks."
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "changes in Gamma oscillation intensity ( 40-80 Hz) over the left and right frontal lobe",
                                        "PrimaryOutcomeDescription": "measured by electroencephalogram (EEG)",
                                        "PrimaryOutcomeTimeFrame": "Change from Baseline at 2 weeks."
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "N-back task",
                                        "SecondaryOutcomeDescription": "to test working memory",
                                        "SecondaryOutcomeTimeFrame": "At baseline,1-week, 2-week, 4-week, and 8-week follow-up."
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The Paced Auditory Serial Addition Task (PASAT)",
                                        "SecondaryOutcomeDescription": "to test Verbal Working memory",
                                        "SecondaryOutcomeTimeFrame": "At baseline,2-week, 4-week, and 8-week follow-up."
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The Positive and Negative Syndrome Scale (PANSS)",
                                        "SecondaryOutcomeDescription": "PANSS was assessed using 30 basic items to form three subscales: positive, negative, and general psychopathological scales.The value of each item is ranging from 1 to 7, higher values represent more serious symptoms of schizophrenia.",
                                        "SecondaryOutcomeTimeFrame": "At baseline,2-week, 4-week, and 8-week follow-up."
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The USCD Performance- Based Skills Assessment Battery (UPSA)",
                                        "SecondaryOutcomeTimeFrame": "At baseline,2-week, 4-week, and 8-week follow-up."
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Side-effects of tACS",
                                        "SecondaryOutcomeTimeFrame": "At each stimulation session,up to 2 weeks."
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The MATRICS Consensus Cognitive Battery (MCCB)",
                                        "SecondaryOutcomeTimeFrame": "At 4-week and 8-week follow-up."
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nSubjects who have cognitive deficits as indicated by a score of < 85 on RBANS, and meet criteria for DSM-5 diagnosis of chronic SZ, schizoaffective disorder (SA), or schizophreniform disorder (SZF), and who are stably treated with antipsychotic medications and are not in acute exacerbation of illness symptoms.\n\nExclusion Criteria:\n\nPatients with risk factors for an MRI scan, seizure disorder, and for women of childbearing age who are pregnant or regularly engaging in sexual activity and not regularly using an acceptable birth control method (systemic or double-barrier).",
                            "HealthyVolunteers": "No",
                            "Gender": "All",
                            "MinimumAge": "18 Years",
                            "MaximumAge": "60 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "CentralContactList": {
                                "CentralContact": [
                                    {
                                        "CentralContactName": "Chunbo Li, Ph.D.",
                                        "CentralContactRole": "Contact",
                                        "CentralContactPhone": "86-21-34773243",
                                        "CentralContactEMail": "chunbo_li@163.com"
                                    }
                                ]
                            },
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Chunbo Li, Ph.D.",
                                        "OverallOfficialAffiliation": "Shanghai Mental Health Center",
                                        "OverallOfficialRole": "Principal Investigator"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "Shanghai Mental Health Center",
                                        "LocationStatus": "Recruiting",
                                        "LocationCity": "Shanghai",
                                        "LocationState": "Shanghai",
                                        "LocationZip": "200030",
                                        "LocationCountry": "China",
                                        "LocationContactList": {
                                            "LocationContact": [
                                                {
                                                    "LocationContactName": "Chunbo Li, PHD",
                                                    "LocationContactRole": "Contact",
                                                    "LocationContactPhone": "86-21-34773243",
                                                    "LocationContactEMail": "chunbo_li@163.com"
                                                },
                                                {
                                                    "LocationContactName": "Chunbo Li, PHD",
                                                    "LocationContactRole": "Principal Investigator"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "IPDSharingStatementModule": {
                            "IPDSharing": "No"
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000012559",
                                        "ConditionMeshTerm": "Schizophrenia"
                                    },
                                    {
                                        "ConditionMeshId": "D000060825",
                                        "ConditionMeshTerm": "Cognitive Dysfunction"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000019967",
                                        "ConditionAncestorTerm": "Schizophrenia Spectrum and Other Psychotic Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000001523",
                                        "ConditionAncestorTerm": "Mental Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000003072",
                                        "ConditionAncestorTerm": "Cognition Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000019965",
                                        "ConditionAncestorTerm": "Neurocognitive Disorders"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M14528",
                                        "ConditionBrowseLeafName": "Schizophrenia",
                                        "ConditionBrowseLeafAsFound": "Schizophrenia",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M28858",
                                        "ConditionBrowseLeafName": "Cognitive Dysfunction",
                                        "ConditionBrowseLeafAsFound": "Cognitive Impairment",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M3967",
                                        "ConditionBrowseLeafName": "Mental Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M13625",
                                        "ConditionBrowseLeafName": "Psychotic Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M20991",
                                        "ConditionBrowseLeafName": "Schizophrenia Spectrum and Other Psychotic Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M5453",
                                        "ConditionBrowseLeafName": "Cognition Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M20989",
                                        "ConditionBrowseLeafName": "Neurocognitive Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BXM",
                                        "ConditionBrowseBranchName": "Behaviors and Mental Disorders"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 36,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT01280214",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "EMC119710ctil"
                            },
                            "Organization": {
                                "OrgFullName": "HaEmek Medical Center, Israel",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Local Triamcinolone Injection in Active Thyroid Orbitopathy",
                            "OfficialTitle": "Peribulbar and Subconjunctival Kenalog Injection for Thyroid Orbitopathy"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "January 2011",
                            "OverallStatus": "Unknown status",
                            "LastKnownStatus": "Not yet recruiting",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "February 2011"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "February 2013",
                                "PrimaryCompletionDateType": "Anticipated"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "February 2013",
                                "CompletionDateType": "Anticipated"
                            },
                            "StudyFirstSubmitDate": "January 15, 2011",
                            "StudyFirstSubmitQCDate": "January 19, 2011",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "January 20, 2011",
                                "StudyFirstPostDateType": "Estimate"
                            },
                            "LastUpdateSubmitDate": "January 19, 2011",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "January 20, 2011",
                                "LastUpdatePostDateType": "Estimate"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyOldNameTitle": "Dr Daniel Briscoe",
                                "ResponsiblePartyOldOrganization": "Haemek Medical center"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "HaEmek Medical Center, Israel",
                                "LeadSponsorClass": "OTHER"
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "Yes"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "Comparing the effectiveness of subconjunctival and peribulbar Triamcinolone injection to systemic Steroid therapy for patients with active thyroid orbitopathy.",
                            "DetailedDescription": "Local Steroid treatment may help in active thyroid orbitopathy. till today, systemic Steroids are the treatment for active thyroid orbitopathy which is associated with systemic adverse effects.\n\nIn this study the investigators want to compare the effectiveness of local Triamcinolone therapy for active thyroid orbitopathy."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Thyroid Disease"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Not Applicable"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "N/A",
                                "DesignInterventionModel": "Single Group Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "None (Open Label)"
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "30",
                                "EnrollmentType": "Anticipated"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "Triamcinolone",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: Triamcinolone"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "Triamcinolone",
                                        "InterventionDescription": "Subconjunctival and peribulbar, 40 mg/ml, 3 monthly injection",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Triamcinolone"
                                            ]
                                        },
                                        "InterventionOtherNameList": {
                                            "InterventionOtherName": [
                                                "kenalog"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Comparing the effectiveness of subconjunctival and peribulbar Triamcinolone injection to systemic Steroid therapy for patients with active thyroid orbitopathy .",
                                        "PrimaryOutcomeDescription": "Every month, each participant will undergo several tests : blood sugar, full ocular examination, color test, visual field and ultrasound test for measuring the thickness of extraocular muscles.Clinical activity score for thyroid orbitopathy will be assesed too. The results of the clinical and ultrasonogrophic findings will determine the effectiveness of the treatment.\n\nA patient with deterioration of thyroid orbitopathy during the research, will be treated by systemic Steroids in addition to the local injections.",
                                        "PrimaryOutcomeTimeFrame": "6 months"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "To check if the level of TSH Receptor antibodies are affected by the local injection.",
                                        "SecondaryOutcomeDescription": "A blood test for TSH Receptor antibodies will be taken for every patient at the beginnig of the research and after 4 months.",
                                        "SecondaryOutcomeTimeFrame": "4 months"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nAge>18 years.\nActive thyroid orbitopathy according to clinical activity score>=3.\n\nExclusion Criteria:\n\nIntraorbital or active infections.\nTuberculosis.\nOther orbital disease.\nPregnancy.\nCompressive optic neuropathy.\nSystemic steroid therapy within 6 months of study start.",
                            "HealthyVolunteers": "No",
                            "Gender": "All",
                            "MinimumAge": "18 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "CentralContactList": {
                                "CentralContact": [
                                    {
                                        "CentralContactName": "Daniel Briscoe, MD",
                                        "CentralContactRole": "Contact",
                                        "CentralContactPhone": "972-4-6494344",
                                        "CentralContactEMail": "daniel_br@clalit.org.il"
                                    }
                                ]
                            },
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Daniel Briscoe, MD",
                                        "OverallOfficialAffiliation": "haemek medical center",
                                        "OverallOfficialRole": "Study Chair"
                                    }
                                ]
                            }
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000049970",
                                        "ConditionMeshTerm": "Graves Ophthalmopathy"
                                    },
                                    {
                                        "ConditionMeshId": "D000013959",
                                        "ConditionMeshTerm": "Thyroid Diseases"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000004700",
                                        "ConditionAncestorTerm": "Endocrine System Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000015785",
                                        "ConditionAncestorTerm": "Eye Diseases, Hereditary"
                                    },
                                    {
                                        "ConditionAncestorId": "D000005128",
                                        "ConditionAncestorTerm": "Eye Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000006111",
                                        "ConditionAncestorTerm": "Graves Disease"
                                    },
                                    {
                                        "ConditionAncestorId": "D000005094",
                                        "ConditionAncestorTerm": "Exophthalmos"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009916",
                                        "ConditionAncestorTerm": "Orbital Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000030342",
                                        "ConditionAncestorTerm": "Genetic Diseases, Inborn"
                                    },
                                    {
                                        "ConditionAncestorId": "D000006042",
                                        "ConditionAncestorTerm": "Goiter"
                                    },
                                    {
                                        "ConditionAncestorId": "D000006980",
                                        "ConditionAncestorTerm": "Hyperthyroidism"
                                    },
                                    {
                                        "ConditionAncestorId": "D000001327",
                                        "ConditionAncestorTerm": "Autoimmune Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000007154",
                                        "ConditionAncestorTerm": "Immune System Diseases"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M25301",
                                        "ConditionBrowseLeafName": "Graves Ophthalmopathy",
                                        "ConditionBrowseLeafAsFound": "Thyroid Orbitopathy",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M15870",
                                        "ConditionBrowseLeafName": "Thyroid Diseases",
                                        "ConditionBrowseLeafAsFound": "Thyroid Disease",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M7423",
                                        "ConditionBrowseLeafName": "Eye Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M7014",
                                        "ConditionBrowseLeafName": "Endocrine System Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M17491",
                                        "ConditionBrowseLeafName": "Eye Diseases, Hereditary",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M8366",
                                        "ConditionBrowseLeafName": "Graves Disease",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M7389",
                                        "ConditionBrowseLeafName": "Exophthalmos",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M11997",
                                        "ConditionBrowseLeafName": "Orbital Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M22839",
                                        "ConditionBrowseLeafName": "Genetic Diseases, Inborn",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M8299",
                                        "ConditionBrowseLeafName": "Goiter",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M9183",
                                        "ConditionBrowseLeafName": "Hyperthyroidism",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M3781",
                                        "ConditionBrowseLeafName": "Autoimmune Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M9352",
                                        "ConditionBrowseLeafName": "Immune System Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC11",
                                        "ConditionBrowseBranchName": "Eye Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC16",
                                        "ConditionBrowseBranchName": "Diseases and Abnormalities at or Before Birth"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC19",
                                        "ConditionBrowseBranchName": "Gland and Hormone Related Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC20",
                                        "ConditionBrowseBranchName": "Immune System Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionMeshList": {
                                "InterventionMesh": [
                                    {
                                        "InterventionMeshId": "D000014221",
                                        "InterventionMeshTerm": "Triamcinolone"
                                    }
                                ]
                            },
                            "InterventionAncestorList": {
                                "InterventionAncestor": [
                                    {
                                        "InterventionAncestorId": "D000000893",
                                        "InterventionAncestorTerm": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000005938",
                                        "InterventionAncestorTerm": "Glucocorticoids"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006728",
                                        "InterventionAncestorTerm": "Hormones"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006730",
                                        "InterventionAncestorTerm": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045505",
                                        "InterventionAncestorTerm": "Physiological Effects of Drugs"
                                    }
                                ]
                            },
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafAsFound": "Deep",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M3369",
                                        "InterventionBrowseLeafName": "Anti-Inflammatory Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8199",
                                        "InterventionBrowseLeafName": "Glucocorticoids",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8941",
                                        "InterventionBrowseLeafName": "Hormones",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8940",
                                        "InterventionBrowseLeafName": "Hormone Antagonists",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 37,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT00148330",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "NHMRC project 402573"
                            },
                            "Organization": {
                                "OrgFullName": "University of Sydney",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Open Label Extension of a Clinical Trial of Intravitreal Triamcinolone for Diabetic Macular Oedema-TDMX Study",
                            "OfficialTitle": "An Open Label Extension of the Phase II/III Clinical Trial of Intravitreal Triamcinolone on the Effects and Safety of Clinically Significant Diabetic Macular Oedema That Persists After Laser Treatment"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "May 2005",
                            "OverallStatus": "Completed",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "May 2005"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "July 2008",
                                "PrimaryCompletionDateType": "Actual"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "July 2008",
                                "CompletionDateType": "Actual"
                            },
                            "StudyFirstSubmitDate": "September 6, 2005",
                            "StudyFirstSubmitQCDate": "September 6, 2005",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "September 7, 2005",
                                "StudyFirstPostDateType": "Estimate"
                            },
                            "LastUpdateSubmitDate": "June 29, 2010",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "June 30, 2010",
                                "LastUpdatePostDateType": "Estimate"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyOldNameTitle": "Professor Mark Gillies",
                                "ResponsiblePartyOldOrganization": "Save Sight Institute, The University of Sudyney"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "University of Sydney",
                                "LeadSponsorClass": "OTHER"
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "Yes"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "This open label extension will treat all the eyes of study participants with active study medication (intravitreal triamcinolone) as well as standard laser treatment where appropriate.\n\nThe specific aims will be to test the following hypotheses:\n\nThat intravitreal triamcinolone for diabetic macular oedema that persists or recurs after laser treatment remains efficacious over five years\nThat intravitreal triamcinolone for diabetic macular oedema that persists or recurs after laser treatment retains a manageable and acceptable safety profile over five years",
                            "DetailedDescription": "A 25 fold increase in the risk of going blind on diagnosis of diabetes is one of the most daunting threats that patients face. People using insulin are particularly challenged because they are unable accurately to draw up their dose of drug. Most cases of vision impairment in diabetes are due to macular oedema that persists or recurs after laser treatment. There are now a number of uncontrolled, anecdotal reports that intravitreal triamcinolone (IVTA) is highly effective for the treatment of diabetic macular edema which is refractory to conventional laser treatment. We commenced the first placebo-controlled, double masked clinical trial of IVTA for refractory macular oedema in 2002. The 3 month results from this study provide the first scientific proof of principle that IVTA reduces macular thickness and improves vision. The two year results will be available in March 2005, but confidential interim analysis of efficacy data in September 2004 suggested that the beneficial effect of triamcinolone treatment persisted. Thus it appears that treatment with IVTA may be the most significant development for the prevention of blindness in people with diabetes since the introduction of laser treatment. It would also be a highly cost-effective intervention that could be administered by general ophthalmologists. The treatment cannot be recommended for routine use, however, until its long term efficacy and safety have been established. Since we already have a well studied group of patients who have received treatment for 2 years, we are in a unique position to extend the study in order to provide the long-term (5-year) safety and efficacy data that does not appear to be forthcoming from any other source. The completion of this study will have a direct and immediate effect on the risk of blindness in people with diabetes by allowing doctors to predict more accurately the long term effects of this promising new treatment."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Diabetic Macular Oedema"
                                ]
                            },
                            "KeywordList": {
                                "Keyword": [
                                    "Diabetic macular oedema",
                                    "Triamcinolone acetate",
                                    "Intravitreal injection",
                                    "Clinical trial",
                                    "Laser treatment"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Phase 2",
                                    "Phase 3"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "Non-Randomized",
                                "DesignInterventionModel": "Single Group Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "None (Open Label)"
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "64",
                                "EnrollmentType": "Actual"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "Triamcinolone acetate",
                                        "InterventionDescription": "When indicated, intravitreal triamcinolone (0.1 ml of Kenacort 40© [40mg/ml triamcinolone acetonide, Bristol-Myers Squibb pharmaceuticals, Australia]) was injected into the vitreous under sterile conditions in a minor procedures area.",
                                        "InterventionOtherNameList": {
                                            "InterventionOtherName": [
                                                "Kenacort 40©"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Increase of ≥5 letters at the 5-year study visit on a LogMAR chart compared with (a) the initial baseline level and (b) the level at the 2-year study visit.",
                                        "PrimaryOutcomeDescription": "Changes from Baseline to 5 years: Improvement of ≥5 letters after 5 years was found in 14/33 (42%) eyes initially treated with triamcinolone compared with 11/34 (32%) eyes initially treated with placebo (zGEE=0.81, P=0.4).\n\nChanges from 2 to 5 years (open-label extension):Improvement of ≥5 letters of best-corrected visual acuity was found in 8/29 (28%) eyes initial-triamcinolone compared with 7/28 (25%) initial-placebo eyes (zGEE=0.20, P=0.8).",
                                        "PrimaryOutcomeTimeFrame": "3 year extension, total 5 years study from baseline"
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "Incidence of moderate or severe adverse events over the 3 years of the open-label extension",
                                        "PrimaryOutcomeDescription": "The incidence of cataract surgery declined in the third year: 5/11 (45%) eyes from the initial-triamcinolone group that were phakic at the beginning of the 3rd year required cataract surgery.",
                                        "PrimaryOutcomeTimeFrame": "3 year extension study, total 5 year study from baseline"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "Change in macular thickness by OCT",
                                        "SecondaryOutcomeDescription": "Changes from Baseline to 5 years: Foveal thickness had decreased by 30µm (95% confidence interval, -47 to 107µm) less in the initial-triamcinolone group than in the initial-placebo group at 5 years (zGEE=0.76, P=0.45).\n\nChanges from 2 to 5 years (open-label extension):Foveal thickness had actually increased slightly on average in the initial-triamcinolone group, but decreased in initial-placebo eyes. Overall it had decreased by 70µm (95% confidence interval, -1 to 140µm) more in the placebo group than in the treatment group between 2 and 5 years (zGEE=1.93, P=0.05).",
                                        "SecondaryOutcomeTimeFrame": "3 year extension, total 5 year study from the baseline"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Any change in visual acuity",
                                        "SecondaryOutcomeDescription": "Loss of ten or more letters was found in 6/33 (18%) initial-triamcinolone eyes compared with 8/34 (24%) initial-placebo eyes.",
                                        "SecondaryOutcomeTimeFrame": "3 year extension, total 5 year study from the baseline"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Number of laser treatments required.",
                                        "SecondaryOutcomeDescription": "During the third to fifth years of the study, a similar proportion of eyes from the 2 groups had macular edema that warranted laser treatment: initial-triamcinolone, 5/29 (17%); initial-placebo, 6/28 (21%).",
                                        "SecondaryOutcomeTimeFrame": "3 year extension study, total 5 year study from baseline"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nParticipation in the study will be offered to all patients at the conclusion of the TDMO study. Currently we are still following 64 of the 69 (93%) eyes that were initially entered into the study that had reduced vision from diabetic macular oedema at baseline.\n\nExclusion Criteria:\n\nUncontrolled glaucoma\nLoss of vision due to other causes (e.g. age related macular degeneration, myopic macular degeneration)\nknown allergies to triamcinolone acetate, patient is already receiving systemic steroid treatment, intercurrent severe disease such as septicemia, any condition which would affect follow-up or photographic documentation (e.g. geographical, psycho-social, media opacities)",
                            "HealthyVolunteers": "No",
                            "Gender": "All",
                            "MinimumAge": "18 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Mark C Gillies, MBBS, PhD",
                                        "OverallOfficialAffiliation": "Save Sight Institute, Deaprtment of Clinical Ophthalmology, University of Sydney",
                                        "OverallOfficialRole": "Principal Investigator"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "Save Sight Institute, Sydney/Sydney Eye Hospital Campus, University of Sydney",
                                        "LocationCity": "Sydney",
                                        "LocationState": "New South Wales",
                                        "LocationZip": "2000",
                                        "LocationCountry": "Australia"
                                    }
                                ]
                            }
                        },
                        "ReferencesModule": {
                            "ReferenceList": {
                                "Reference": [
                                    {
                                        "ReferencePMID": "15522370",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Sutter FK, Simpson JM, Gillies MC. Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment: three-month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology. 2004 Nov;111(11):2044-9."
                                    },
                                    {
                                        "ReferencePMID": "15860283",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Larsson J, Zhu M, Sutter F, Gillies MC. Relation between reduction of foveal thickness and visual acuity in diabetic macular edema treated with intravitreal triamcinolone. Am J Ophthalmol. 2005 May;139(5):802-6."
                                    },
                                    {
                                        "ReferencePMID": "19349792",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Kuo CH, Gillies MC. Role of steroids in the treatment of diabetic macular edema. Int Ophthalmol Clin. 2009 Spring;49(2):121-34. doi: 10.1097/IIO.0b013e31819fcce8. Review."
                                    },
                                    {
                                        "ReferencePMID": "19796823",
                                        "ReferenceType": "result",
                                        "ReferenceCitation": "Gillies MC, Simpson JM, Gaston C, Hunt G, Ali H, Zhu M, Sutter F. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology. 2009 Nov;116(11):2182-7. doi: 10.1016/j.ophtha.2009.04.049. Epub 2009 Oct 1."
                                    },
                                    {
                                        "ReferencePMID": "19264220",
                                        "ReferenceType": "result",
                                        "ReferenceCitation": "Gillies M. Diabetic macular edema. Ophthalmology. 2009 Mar;116(3):595; author reply 596-7. doi: 10.1016/j.ophtha.2008.12.016."
                                    },
                                    {
                                        "ReferencePMID": "19264215",
                                        "ReferenceType": "result",
                                        "ReferenceCitation": "Gillies MC, Simpson JM, Zhu M, Hunt G, Ali H, Gaston C. Intravitreal triamcinolone. Ophthalmology. 2009 Mar;116(3):591. doi: 10.1016/j.ophtha.2008.09.044."
                                    },
                                    {
                                        "ReferencePMID": "16828501",
                                        "ReferenceType": "result",
                                        "ReferenceCitation": "Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology. 2006 Sep;113(9):1533-8. Epub 2006 Jul 7."
                                    },
                                    {
                                        "ReferencePMID": "18785964",
                                        "ReferenceType": "result",
                                        "ReferenceCitation": "Larsson J, Kifley A, Zhu M, Wang JJ, Mitchell P, Sutter FK, Gillies MC. Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo-controlled, clinical trial. Acta Ophthalmol. 2009 May;87(3):275-80. doi: 10.1111/j.1755-3768.2008.01245.x. Epub 2008 Sep 10."
                                    },
                                    {
                                        "ReferencePMID": "18599569",
                                        "ReferenceType": "derived",
                                        "ReferenceCitation": "Wickremasinghe SS, Rogers SL, Gillies MC, Zhu M, Wong TY. Retinal vascular caliber changes after intravitreal triamcinolone treatment for diabetic macular edema. Invest Ophthalmol Vis Sci. 2008 Nov;49(11):4707-11. doi: 10.1167/iovs.08-1678. Epub 2008 Jul 3."
                                    }
                                ]
                            }
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000008269",
                                        "ConditionMeshTerm": "Macular Edema"
                                    },
                                    {
                                        "ConditionMeshId": "D000004487",
                                        "ConditionMeshTerm": "Edema"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000008268",
                                        "ConditionAncestorTerm": "Macular Degeneration"
                                    },
                                    {
                                        "ConditionAncestorId": "D000012162",
                                        "ConditionAncestorTerm": "Retinal Degeneration"
                                    },
                                    {
                                        "ConditionAncestorId": "D000012164",
                                        "ConditionAncestorTerm": "Retinal Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000005128",
                                        "ConditionAncestorTerm": "Eye Diseases"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M10413",
                                        "ConditionBrowseLeafName": "Macular Edema",
                                        "ConditionBrowseLeafAsFound": "Macular Edema",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M6809",
                                        "ConditionBrowseLeafName": "Edema",
                                        "ConditionBrowseLeafAsFound": "Edema",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M10412",
                                        "ConditionBrowseLeafName": "Macular Degeneration",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M14149",
                                        "ConditionBrowseLeafName": "Retinal Degeneration",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M14151",
                                        "ConditionBrowseLeafName": "Retinal Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M7423",
                                        "ConditionBrowseLeafName": "Eye Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC11",
                                        "ConditionBrowseBranchName": "Eye Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC23",
                                        "ConditionBrowseBranchName": "Symptoms and General Pathology"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionMeshList": {
                                "InterventionMesh": [
                                    {
                                        "InterventionMeshId": "D000014221",
                                        "InterventionMeshTerm": "Triamcinolone"
                                    }
                                ]
                            },
                            "InterventionAncestorList": {
                                "InterventionAncestor": [
                                    {
                                        "InterventionAncestorId": "D000000893",
                                        "InterventionAncestorTerm": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000005938",
                                        "InterventionAncestorTerm": "Glucocorticoids"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006728",
                                        "InterventionAncestorTerm": "Hormones"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006730",
                                        "InterventionAncestorTerm": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045505",
                                        "InterventionAncestorTerm": "Physiological Effects of Drugs"
                                    }
                                ]
                            },
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafAsFound": "Deep",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M3369",
                                        "InterventionBrowseLeafName": "Anti-Inflammatory Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8199",
                                        "InterventionBrowseLeafName": "Glucocorticoids",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8941",
                                        "InterventionBrowseLeafName": "Hormones",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8940",
                                        "InterventionBrowseLeafName": "Hormone Antagonists",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 38,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT01051648",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "Triam1"
                            },
                            "Organization": {
                                "OrgFullName": "Cairo University",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Triamcinolone Assisted Anterior Vitrectomy",
                            "OfficialTitle": "Triamcinolone Assisted Anterior Vitrectomy in Complicated Cataract Surgery and Anterior Segment Reconstruction"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "February 2008",
                            "OverallStatus": "Completed",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "December 2007"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "February 2008",
                                "PrimaryCompletionDateType": "Actual"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "June 2008",
                                "CompletionDateType": "Actual"
                            },
                            "StudyFirstSubmitDate": "January 15, 2010",
                            "StudyFirstSubmitQCDate": "January 15, 2010",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "January 18, 2010",
                                "StudyFirstPostDateType": "Estimate"
                            },
                            "LastUpdateSubmitDate": "January 15, 2010",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "January 18, 2010",
                                "LastUpdatePostDateType": "Estimate"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyOldNameTitle": "Dr.Mostafa A EL-Helw,assistant. professor of Ophthalmology Cairo university",
                                "ResponsiblePartyOldOrganization": "Cairo university medical school. EL-Nour Eye hospital"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Cairo University",
                                "LeadSponsorClass": "OTHER"
                            },
                            "CollaboratorList": {
                                "Collaborator": [
                                    {
                                        "CollaboratorName": "AL-Nour Eye Hospital",
                                        "CollaboratorClass": "OTHER"
                                    },
                                    {
                                        "CollaboratorName": "Kasr El Aini Hospital",
                                        "CollaboratorClass": "OTHER"
                                    }
                                ]
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "Yes"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "Injecting Triamcinolone acetenoide for visualizing and removing vitreous from the anterior chamber.",
                            "DetailedDescription": "The research followed the tenets of the Declaration of Helsinki, ;informed consent were obtained from patients where all details of the procedure were explained with emphasis on the intended outcome. The research was approved by the institutional review board.\n\nTen eyes of 10 patients were divided into 2 groups. Group A included 6 eyes of 6 patients with accidental rupture of posterior capsule during cataract surgery (5 eyes underwent phacoemulsification technique and one underwent ECCE). Group B included four eyes of 4 patients undergoing anterior segment reconstruction (anterior vitrectomy, secondary IOL Implantation and iris repair by direct approximation using 10/0 prolene sutures). In group A the mean age was 68.1 ± 10.93 years (range 47 to 79 years), 3 were males and 3 were females. In group B the mean age was 14 ± 5.6 years (range 9 to 22 years), 3 were males and one female. Demographic data and pre-operative Information are presented in table 1 and 2.\n\nIn all patients triamcinolone acetonide was prepared by keeping the bottle vertical to allow sedimentation of crystals thus removing the vehicle. It was then injected into the anterior chamber (2 ml with concentration 20 mg/ml) just prior to anterior vitrectomy. The direction of the tip of the needle was kept away from the corneal endothelium to minimize endothelial toxicity. Triamcinolone was removed as quickly & completely as possible after finishing anterior vitrectomy.\n\nPostoperative regimen included topical steroids and antibiotics for about 4-6 weeks. Topical anti-glaucoma drugs were used in cases of high postoperative IOP for few days until stabilization of IOP. Follow up period ranged from 2 months up to 27 months."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Vitrectomy",
                                    "Cataract"
                                ]
                            },
                            "KeywordList": {
                                "Keyword": [
                                    "Triamcinolone acetenoide",
                                    "anterior vitrectomy",
                                    "presence of vitreous in the anterior chamber.",
                                    "effect of triamcinolone injection on IOP,intraocular infection"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Phase 2"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "N/A",
                                "DesignInterventionModel": "Single Group Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "None (Open Label)"
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "10",
                                "EnrollmentType": "Actual"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "Triamcinolone acetenoide",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "Intra ocular injection of triamcinolone acetonide to visualize vitreous strands in the anterior chamber of the eye in complicated cataract surgery",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: Intra ocular injection of triamcinolone acetonide"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "Intra ocular injection of triamcinolone acetonide",
                                        "InterventionDescription": "In all patients triamcinolone acetonide was prepared by keeping the bottle vertical to allow sedimentation of crystals thus removing the vehicle. It was then injected into the anterior chamber (2 ml with concentration 20 mg/ml) just prior to anterior vitrectomy. The direction of the tip of the needle was kept away from the corneal endothelium to minimize endothelial toxicity. Triamcinolone was removed as quickly & completely as possible after finishing anterior vitrectomy",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Triamcinolone acetenoide"
                                            ]
                                        },
                                        "InterventionOtherNameList": {
                                            "InterventionOtherName": [
                                                "kena cort"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Proper visualization of vitreous strands in the anterior chamber of the eye",
                                        "PrimaryOutcomeTimeFrame": "immediately"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "intraocular pressure rise",
                                        "SecondaryOutcomeTimeFrame": "2-3 weeks"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nPatients with vitreous in the anterior chamber whether in\n\ncomplicated cataract surgery\ndisorganized anterior segment structures\n\nExclusion Criteria:\n\nGlaucoma patients\nIntra ocular infections\nBacterial or fungal",
                            "HealthyVolunteers": "No",
                            "Gender": "All",
                            "MinimumAge": "47 Years",
                            "MaximumAge": "79 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Mostafa A EL-Helw, M.D.",
                                        "OverallOfficialAffiliation": "Cairo unuversity & EL-Nour eye hospital",
                                        "OverallOfficialRole": "Principal Investigator"
                                    },
                                    {
                                        "OverallOfficialName": "Ahmed M Emarah, M.D.",
                                        "OverallOfficialAffiliation": "Cairo university & EL-Nour eye hospital",
                                        "OverallOfficialRole": "Principal Investigator"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "El-Nour Eye hospital",
                                        "LocationCity": "Cairo",
                                        "LocationZip": "11371",
                                        "LocationCountry": "Egypt"
                                    },
                                    {
                                        "LocationFacility": "Kasr Al-Ainy Hospital Cairo university",
                                        "LocationCity": "Cairo",
                                        "LocationZip": "11451",
                                        "LocationCountry": "Egypt"
                                    }
                                ]
                            }
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000002386",
                                        "ConditionMeshTerm": "Cataract"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000007905",
                                        "ConditionAncestorTerm": "Lens Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000005128",
                                        "ConditionAncestorTerm": "Eye Diseases"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M9435",
                                        "ConditionBrowseLeafName": "Infections",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M5520",
                                        "ConditionBrowseLeafName": "Communicable Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M4790",
                                        "ConditionBrowseLeafName": "Cataract",
                                        "ConditionBrowseLeafAsFound": "Cataract",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M10069",
                                        "ConditionBrowseLeafName": "Lens Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M7423",
                                        "ConditionBrowseLeafName": "Eye Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC01",
                                        "ConditionBrowseBranchName": "Infections"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC23",
                                        "ConditionBrowseBranchName": "Symptoms and General Pathology"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC11",
                                        "ConditionBrowseBranchName": "Eye Diseases"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionMeshList": {
                                "InterventionMesh": [
                                    {
                                        "InterventionMeshId": "D000014221",
                                        "InterventionMeshTerm": "Triamcinolone"
                                    },
                                    {
                                        "InterventionMeshId": "D000014222",
                                        "InterventionMeshTerm": "Triamcinolone Acetonide"
                                    },
                                    {
                                        "InterventionMeshId": "C000005900",
                                        "InterventionMeshTerm": "Triamcinolone hexacetonide"
                                    },
                                    {
                                        "InterventionMeshId": "C000030262",
                                        "InterventionMeshTerm": "Triamcinolone diacetate"
                                    }
                                ]
                            },
                            "InterventionAncestorList": {
                                "InterventionAncestor": [
                                    {
                                        "InterventionAncestorId": "D000000893",
                                        "InterventionAncestorTerm": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000005938",
                                        "InterventionAncestorTerm": "Glucocorticoids"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006728",
                                        "InterventionAncestorTerm": "Hormones"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006730",
                                        "InterventionAncestorTerm": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045505",
                                        "InterventionAncestorTerm": "Physiological Effects of Drugs"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007166",
                                        "InterventionAncestorTerm": "Immunosuppressive Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007155",
                                        "InterventionAncestorTerm": "Immunologic Factors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000004791",
                                        "InterventionAncestorTerm": "Enzyme Inhibitors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045504",
                                        "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                                    }
                                ]
                            },
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafAsFound": "Deep",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M3369",
                                        "InterventionBrowseLeafName": "Anti-Inflammatory Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8199",
                                        "InterventionBrowseLeafName": "Glucocorticoids",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8941",
                                        "InterventionBrowseLeafName": "Hormones",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8940",
                                        "InterventionBrowseLeafName": "Hormone Antagonists",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9364",
                                        "InterventionBrowseLeafName": "Immunosuppressive Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9353",
                                        "InterventionBrowseLeafName": "Immunologic Factors",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 39,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT03248856",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "1456/2017"
                            },
                            "SecondaryIdInfoList": {
                                "SecondaryIdInfo": [
                                    {
                                        "SecondaryId": "2017-002377-19",
                                        "SecondaryIdType": "EudraCT Number"
                                    }
                                ]
                            },
                            "Organization": {
                                "OrgFullName": "Medical University of Vienna",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Triamcinolone Levels in Cochlear Perilymph",
                            "OfficialTitle": "Triamcinolone Levels in Cochlear Perilymph"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "September 2021",
                            "OverallStatus": "Completed",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "October 2, 2017",
                                "StartDateType": "Actual"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "December 31, 2020",
                                "PrimaryCompletionDateType": "Actual"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "May 31, 2021",
                                "CompletionDateType": "Actual"
                            },
                            "StudyFirstSubmitDate": "August 9, 2017",
                            "StudyFirstSubmitQCDate": "August 9, 2017",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "August 14, 2017",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "September 25, 2021",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "September 28, 2021",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Sponsor-Investigator",
                                "ResponsiblePartyInvestigatorFullName": "Christoph Arnoldner",
                                "ResponsiblePartyInvestigatorTitle": "Assoc Prof PD Dr.",
                                "ResponsiblePartyInvestigatorAffiliation": "Medical University of Vienna"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Christoph Arnoldner",
                                "LeadSponsorClass": "OTHER"
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "Yes",
                            "IsFDARegulatedDrug": "No",
                            "IsFDARegulatedDevice": "No",
                            "IsUSExport": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "In this study Triamcinolone acetonide will be applied intratympanically before cochlear implant surgery. After round window exposure, a perilymph sample and simultaneously a blood sample will be drawn. Triamcinolone levels will then be analyzed in the samples.",
                            "DetailedDescription": "At the ENT department of the university hospital Vienna (AKH Wien) patients are treated with intratympanic triamcinolone acetonide before cochlea implantation to reduce inflammation and in some cases to protect residual hearing. Triamcinolone acetonide levels in cochlear perilymph will be evaluated in an open prospective clinical study. Patients scheduled for cochlear implant surgery between 18 and 90 years will be included. Patients who are treated with steroids preoperatively will be excluded from the study. Patients will be randomized after inclusion to one of four groups. The randomization is carried out to generate hypothesis for the needed dose and best time of application in the future. Triamcinolone acetonide will then be applied 20-24h before surgery or at the beginning of the surgery, depending on randomization (see below). About 20 µl of perilymph will be sampled simultaneously to a blood sample during cochlear implant surgery.\n\nThe probes will be stored at -80°C. Triamcinolone acetonide levels of the blood and perilymph will be determined by the pharmaceutical laboratory (Department of Pharmaceutical Technology and Biopharmaceutics, University of Vienna).\n\nThe patients will be randomized to 4 groups. Group 1 - Volon A 10mg administration 20 - 24 hours before sampling. Group 2 - Volon A 40mg administration 20 - 24 hours before sampling. Group 3 Volon A 10mg - administration 1 to 2 hours before sampling. Group 4 - Volon A 40mg administration 1 to 2 hours before sampling.\n\nThe time interval of application (1 to 2 hours and 20 to 24 hours before sampling) are a result of varying time of surgery depending on surgeons and patient anatomy as well as day to day clinical organization. Patients can withdraw consent at any time of the study.\n\nThe active phase of each patient will be between 6 and 9 days depending on time of follow-up visit."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Cochlear Hearing Loss"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Phase 1"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "Randomized",
                                "DesignInterventionModel": "Parallel Assignment",
                                "DesignPrimaryPurpose": "Basic Science",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "None (Open Label)"
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "40",
                                "EnrollmentType": "Actual"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "Group 1",
                                        "ArmGroupType": "Other",
                                        "ArmGroupDescription": "Group 1 will receive triamcinolone acetonide 10mg 20 to 24hours before sampling.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: Triamcinolone Acetonide"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "Group 2",
                                        "ArmGroupType": "Other",
                                        "ArmGroupDescription": "Group 2 will receive triamcinolone acetonide 40mg 20 to 24hours before sampling.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: Triamcinolone Acetonide"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "Group 3",
                                        "ArmGroupType": "Other",
                                        "ArmGroupDescription": "Group 3 will receive triamcinolone acetonide 10mg 1 to 2 hours before sampling.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: Triamcinolone Acetonide"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "Group 4",
                                        "ArmGroupType": "Other",
                                        "ArmGroupDescription": "Group 3 will receive triamcinolone acetonide 40mg 1 to 2 hours before sampling.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: Triamcinolone Acetonide"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "Triamcinolone Acetonide",
                                        "InterventionDescription": "Intratympanic administration",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Group 1",
                                                "Group 2",
                                                "Group 3",
                                                "Group 4"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Triamcinolone levels in comparison",
                                        "PrimaryOutcomeDescription": "Absorption of Triamcinolone acetonide in cochlear perilymph in comparison to dissemination to the blood circulation",
                                        "PrimaryOutcomeTimeFrame": "2 years"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "Triamcinolone stability",
                                        "SecondaryOutcomeDescription": "The stability of triamcinolone acetonide levels in the cochlear perilymph",
                                        "SecondaryOutcomeTimeFrame": "2 years"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Triamcinolone concentrations",
                                        "SecondaryOutcomeDescription": "Perilymph concentrations and blood concentrations of triamcinolone acetonide after administration of different Triamcinolone acetonide doses.",
                                        "SecondaryOutcomeTimeFrame": "2 years"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Impedances",
                                        "SecondaryOutcomeDescription": "Difference of impedances of patients receiving different doses at different timepoints",
                                        "SecondaryOutcomeTimeFrame": "2 years"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nPatients between 18 and 90 years will be included in the study, who will undergo a cochlear implantation and are willing to participate in the study\n\nExclusion Criteria:\n\nPatients younger than 18 years\nPatients who receive cortisone on a regular basis or receive cortisone i.v. or p.o. preoperatively\nPatients with contraindications against the administration of Volon A",
                            "HealthyVolunteers": "No",
                            "Gender": "All",
                            "MinimumAge": "18 Years",
                            "MaximumAge": "90 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "Medical University of Vienna (AKH)",
                                        "LocationCity": "Vienna",
                                        "LocationZip": "1090",
                                        "LocationCountry": "Austria"
                                    }
                                ]
                            }
                        },
                        "ReferencesModule": {
                            "ReferenceList": {
                                "Reference": [
                                    {
                                        "ReferencePMID": "34591079",
                                        "ReferenceType": "derived",
                                        "ReferenceCitation": "Dahm V, Gausterer JC, Auinger AB, Honeder C, Gabor F, Reznicek G, Kaider A, Riss D, Arnoldner C. Evaluation of Levels of Triamcinolone Acetonide in Human Perilymph and Plasma After Intratympanic Application in Patients Receiving Cochlear Implants: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2021 Nov 1;147(11):974-980. doi: 10.1001/jamaoto.2021.2492."
                                    }
                                ]
                            }
                        },
                        "IPDSharingStatementModule": {
                            "IPDSharing": "Yes",
                            "IPDSharingInfoTypeList": {
                                "IPDSharingInfoType": [
                                    "Study Protocol"
                                ]
                            },
                            "IPDSharingTimeFrame": "January 2020"
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000034381",
                                        "ConditionMeshTerm": "Hearing Loss"
                                    },
                                    {
                                        "ConditionMeshId": "D000006319",
                                        "ConditionMeshTerm": "Hearing Loss, Sensorineural"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000006311",
                                        "ConditionAncestorTerm": "Hearing Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000004427",
                                        "ConditionAncestorTerm": "Ear Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000010038",
                                        "ConditionAncestorTerm": "Otorhinolaryngologic Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000012678",
                                        "ConditionAncestorTerm": "Sensation Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009461",
                                        "ConditionAncestorTerm": "Neurologic Manifestations"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009422",
                                        "ConditionAncestorTerm": "Nervous System Diseases"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M23573",
                                        "ConditionBrowseLeafName": "Hearing Loss",
                                        "ConditionBrowseLeafAsFound": "Hearing Loss",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M5992",
                                        "ConditionBrowseLeafName": "Deafness",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M8559",
                                        "ConditionBrowseLeafName": "Hearing Loss, Sensorineural",
                                        "ConditionBrowseLeafAsFound": "Cochlear Hearing Loss",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M8552",
                                        "ConditionBrowseLeafName": "Hearing Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M6753",
                                        "ConditionBrowseLeafName": "Ear Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M12113",
                                        "ConditionBrowseLeafName": "Otorhinolaryngologic Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M14642",
                                        "ConditionBrowseLeafName": "Sensation Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M11556",
                                        "ConditionBrowseLeafName": "Neurologic Manifestations",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC09",
                                        "ConditionBrowseBranchName": "Ear, Nose, and Throat Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC10",
                                        "ConditionBrowseBranchName": "Nervous System Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC23",
                                        "ConditionBrowseBranchName": "Symptoms and General Pathology"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionMeshList": {
                                "InterventionMesh": [
                                    {
                                        "InterventionMeshId": "D000014221",
                                        "InterventionMeshTerm": "Triamcinolone"
                                    },
                                    {
                                        "InterventionMeshId": "D000014222",
                                        "InterventionMeshTerm": "Triamcinolone Acetonide"
                                    },
                                    {
                                        "InterventionMeshId": "C000005900",
                                        "InterventionMeshTerm": "Triamcinolone hexacetonide"
                                    },
                                    {
                                        "InterventionMeshId": "C000030262",
                                        "InterventionMeshTerm": "Triamcinolone diacetate"
                                    }
                                ]
                            },
                            "InterventionAncestorList": {
                                "InterventionAncestor": [
                                    {
                                        "InterventionAncestorId": "D000000893",
                                        "InterventionAncestorTerm": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000005938",
                                        "InterventionAncestorTerm": "Glucocorticoids"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006728",
                                        "InterventionAncestorTerm": "Hormones"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006730",
                                        "InterventionAncestorTerm": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045505",
                                        "InterventionAncestorTerm": "Physiological Effects of Drugs"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007166",
                                        "InterventionAncestorTerm": "Immunosuppressive Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007155",
                                        "InterventionAncestorTerm": "Immunologic Factors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000004791",
                                        "InterventionAncestorTerm": "Enzyme Inhibitors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045504",
                                        "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                                    }
                                ]
                            },
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafAsFound": "Deep",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M3369",
                                        "InterventionBrowseLeafName": "Anti-Inflammatory Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8199",
                                        "InterventionBrowseLeafName": "Glucocorticoids",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8941",
                                        "InterventionBrowseLeafName": "Hormones",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8940",
                                        "InterventionBrowseLeafName": "Hormone Antagonists",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9364",
                                        "InterventionBrowseLeafName": "Immunosuppressive Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9353",
                                        "InterventionBrowseLeafName": "Immunologic Factors",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 40,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT04831255",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "21584"
                            },
                            "Organization": {
                                "OrgFullName": "University of Virginia",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "ZILRETTA™ for Treatment of Idiopathic Adhesive Capsulitis",
                            "OfficialTitle": "A Stratified Investigation of a Single Injection of ZILRETTA™ (Triamcinolone Acetonide Extended-release Injectable Suspension) for Symptomatic Relief in Patients With Idiopathic Adhesive Capsulitis of the Shoulder"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "April 2021",
                            "OverallStatus": "Recruiting",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "June 21, 2019",
                                "StartDateType": "Actual"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "July 31, 2023",
                                "PrimaryCompletionDateType": "Anticipated"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "December 31, 2023",
                                "CompletionDateType": "Anticipated"
                            },
                            "StudyFirstSubmitDate": "March 31, 2021",
                            "StudyFirstSubmitQCDate": "March 31, 2021",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "April 5, 2021",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "April 5, 2021",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "April 8, 2021",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Principal Investigator",
                                "ResponsiblePartyInvestigatorFullName": "Brian Werner, MD",
                                "ResponsiblePartyInvestigatorTitle": "Assistant Professor, Department of Orthopaedic Surgery",
                                "ResponsiblePartyInvestigatorAffiliation": "University of Virginia"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "University of Virginia",
                                "LeadSponsorClass": "OTHER"
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "No",
                            "IsFDARegulatedDrug": "Yes",
                            "IsFDARegulatedDevice": "No",
                            "IsUSExport": "Yes"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "Adhesive capsulitis is a fairly common orthopedic condition that causes pain and loss of range of motion. There are a variety of ways to treat adhesive capsulitis, one of them being an intra-articular steroid injection. This is done to help decrease the inflammatory response caused by adhesive capsulitis. In this study, all participants will receive an intra-articular glenohumeral injection of ZILRETTA and will be followed up with at four time points over 1 year to observe pain, function and range of motion following the injection.",
                            "DetailedDescription": "Adhesive capsulitis is a painful shoulder condition characterized by a gradual loss of both passive and active range of motion due to inflammatory changes and eventual fibrosis and contracture of the shoulder joint capsule. It occurs in about 2% to 5% of the population, and a majority of patients are female. The true cause of the condition remains unclear, however, it has been proposed that the initial synovitis stimulates the development of a fibrotic cascade. The development of adhesive capsulitis has been associated with diabetes mellitus, thyroid dysfunction, Dupuytrens contractures, autoimmune diseases and treatments for certain cancers. Adhesive capsulitis progresses through four predictable phases, defined by symptoms, physical examination, arthroscopic appearance and biopsies.\n\nRegardless of stage, the mainstay of treatment for adhesive capsulitis of the shoulder is conservative, focused mainly on physical therapy combined with a home exercise program, regardless of stage. Pharmacologic agents are often used as adjuncts to physical therapy, and include nonsteroidal anti-inflammatory medications (NSAIDs), oral corticosteroids and intra-articular injections of corticosteroids. Although a large percentage of patients in the early stages of disease respond well to conservative treatments, those who fail therapy and injections may require surgical intervention, including arthroscopy with lysis of adhesions and/or manipulation under anesthesia.\n\nNumerous studies have investigated the effect and success of injections combined with standard physical therapy for adhesive capsulitis of the shoulder. In general, intra-articular injection of corticosteroids has been found to be superior to administration of oral cortisone and at least equivalent to manipulation under anesthesia alone. Injections have been shown to reduce pain quicker and result in earlier return of range of motion. Low doses of steroid appear equally as effective as higher doses. Image-guided injections, whether ultrasound or fluoroscopic guided injections, have also been shown to be more effective than blinded injections.\n\nFailure of an injection and therapy to provide relief either results in a repeat image-guided injection or surgical intervention, both of which have significant associated cost and potential morbidity. Thus, there would be significant potential value to a long-acting, sustained release intra-articular steroid injection for the treatment of adhesive capsulitis of the shoulder. Zilretta®, triamcinolone acetonide extended release suspension 32 mg, is a microsphere formulation of injectable steroid which is FDA-approved for and has shown significant promise for the treatment of knee osteoarthritis. This long-acting steroid could have several important advantages in the treatment of shoulder adhesive capsulitis. It may potentiate and prolong the anti-inflammatory effect of the steroid, and potentially avoid the need for costly additional image-guided injections or expensive and potentially morbid surgery. An additional potential benefit is less elevation of peripheral blood glucose in diabetics, a known complication of traditional steroid injections that has been demonstrated to be mitigated using a sustained release formulation.\n\nOut primary aim in this study is to assess patient reported pain and outcomes in patients with idiopathic adhesive capsulitis of the shoulder at 3, 6 and 12 months following single, image guided ZILRETTA injection."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Adhesive Capsulitis",
                                    "Frozen Shoulder",
                                    "Adhesive Capsulitis of Shoulder"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Phase 1"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "N/A",
                                "DesignInterventionModel": "Single Group Assignment",
                                "DesignInterventionModelDescription": "All subjects receive the ZILRETTA injection",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "None (Open Label)"
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "50",
                                "EnrollmentType": "Anticipated"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "ZILRETTA",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "Single injection of triamcinolone acetonide extended-release injectable suspension, injected in the glenohumeral joint under ultrasound guidance.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: triamcinolone acetonide extended-release injectable suspension"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "triamcinolone acetonide extended-release injectable suspension",
                                        "InterventionDescription": "ZILRETTA (triamcinolone acetonide extended-release injectable suspension) injection in the glenohumeral joint administered under ultrasound guidance.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "ZILRETTA"
                                            ]
                                        },
                                        "InterventionOtherNameList": {
                                            "InterventionOtherName": [
                                                "ZILRETTA"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Visual Analog Scale Score",
                                        "PrimaryOutcomeDescription": "Pain rating on a scale of 0-10, higher numbers indicating a worse outcome",
                                        "PrimaryOutcomeTimeFrame": "6 months after injection"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "American Shoulder and Elbow Society Score",
                                        "SecondaryOutcomeDescription": "Pain and function patient reported outcome for the shoulder. Scores range from 0 to 100 with a score of 0 indicating a worse shoulder condition and 100 indicating a better shoulder condition.",
                                        "SecondaryOutcomeTimeFrame": "6 months after injection"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "American Shoulder and Elbow Society Score",
                                        "SecondaryOutcomeDescription": "Pain and function patient reported outcome for the shoulder. Scores range from 0 to 100 with a score of 0 indicating a worse shoulder condition and 100 indicating a better shoulder condition.",
                                        "SecondaryOutcomeTimeFrame": "12 months after injection"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "PROMIS Physical Function Score",
                                        "SecondaryOutcomeDescription": "Patient reported outcome measuring physical function level measured by T scores and standard deviations. The average is 50, so a T score lower than 50 indicates a worse outcome.",
                                        "SecondaryOutcomeTimeFrame": "6 months after injection"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "PROMIS Physical Function Score",
                                        "SecondaryOutcomeDescription": "Patient reported outcome measuring physical function level measured by T scores and standard deviations. The average is 50, so a T score lower than 50 indicates a worse outcome.",
                                        "SecondaryOutcomeTimeFrame": "12 months after injection"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Triplanar Range of Motion",
                                        "SecondaryOutcomeDescription": "Shoulder range of motion",
                                        "SecondaryOutcomeTimeFrame": "1 month after injection"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Triplanar Range of Motion",
                                        "SecondaryOutcomeDescription": "Shoulder range of motion",
                                        "SecondaryOutcomeTimeFrame": "3 months after injection"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Triplanar Range of Motion",
                                        "SecondaryOutcomeDescription": "Shoulder range of motion",
                                        "SecondaryOutcomeTimeFrame": "6 months after injection"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Triplanar Range of Motion",
                                        "SecondaryOutcomeDescription": "Shoulder range of motion",
                                        "SecondaryOutcomeTimeFrame": "12 months after injection"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Need for another injection",
                                        "SecondaryOutcomeDescription": "Yes or no answer if the patient needed another corticosteroid injection during their time enrolled in the study",
                                        "SecondaryOutcomeTimeFrame": "12 months after injection"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Time to second injection (if applicable)",
                                        "SecondaryOutcomeDescription": "how long after the ZILRETTA injection the patient needed another corticosteroid injection",
                                        "SecondaryOutcomeTimeFrame": "12 months after injection"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nDiagnosis of idiopathic adhesive capsulitis (onset <6 months prior)\nPain rating of 5 or greater out of 10 on 0-10 scale at time of enrollment\nWilling to come on site for follow up evaluations at 1 month, 3 months, 6 months, and 12 months after the injection\n\nExclusion Criteria:\n\nActive workers compensation case\nKnown psychiatric disorders under active treatment\nUncontrolled diabetes (defined as diabetic ketoacidosis, severe peripheral neuropathy, ophthalmologic or renal manifestations)\nDiagnosed osteoarthritis of the ipsilateral or contralateral shoulder\nPainful joint condition in another part of the body affecting perceived pain",
                            "HealthyVolunteers": "No",
                            "Gender": "All",
                            "MinimumAge": "18 Years",
                            "MaximumAge": "80 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "CentralContactList": {
                                "CentralContact": [
                                    {
                                        "CentralContactName": "Kaitlyn Shank, MEd, ATC",
                                        "CentralContactRole": "Contact",
                                        "CentralContactPhone": "434-243-5653",
                                        "CentralContactEMail": "kshank@virginia.edu"
                                    },
                                    {
                                        "CentralContactName": "Lizzie Leitch, MEd, ATC",
                                        "CentralContactRole": "Contact",
                                        "CentralContactPhone": "434-243-0256",
                                        "CentralContactEMail": "ebl7nu@hscmail.mcc.virginia.edu"
                                    }
                                ]
                            },
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Brian Werner, MD",
                                        "OverallOfficialAffiliation": "University of Virginia",
                                        "OverallOfficialRole": "Principal Investigator"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "University of Virginia",
                                        "LocationStatus": "Recruiting",
                                        "LocationCity": "Charlottesville",
                                        "LocationState": "Virginia",
                                        "LocationZip": "22908",
                                        "LocationCountry": "United States",
                                        "LocationContactList": {
                                            "LocationContact": [
                                                {
                                                    "LocationContactName": "Kaitlyn Shank, MEd, ATC",
                                                    "LocationContactRole": "Contact",
                                                    "LocationContactPhone": "434-243-5653",
                                                    "LocationContactEMail": "kshank@virginia.edu"
                                                },
                                                {
                                                    "LocationContactName": "Lizzie Leitch, MEd, ATC",
                                                    "LocationContactRole": "Contact",
                                                    "LocationContactPhone": "434-243-0256",
                                                    "LocationContactEMail": "ebl7nu@hscmail.mcc.virginia.edu"
                                                },
                                                {
                                                    "LocationContactName": "Brian Werner, MD",
                                                    "LocationContactRole": "Principal Investigator"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "IPDSharingStatementModule": {
                            "IPDSharing": "No"
                        }
                    },
                    "DocumentSection": {
                        "LargeDocumentModule": {
                            "LargeDocList": {
                                "LargeDoc": [
                                    {
                                        "LargeDocTypeAbbrev": "ICF",
                                        "LargeDocHasProtocol": "No",
                                        "LargeDocHasSAP": "No",
                                        "LargeDocHasICF": "Yes",
                                        "LargeDocLabel": "Informed Consent Form",
                                        "LargeDocDate": "June 21, 2019",
                                        "LargeDocUploadDate": "03/19/2021 08:54",
                                        "LargeDocFilename": "ICF_000.pdf"
                                    }
                                ]
                            }
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000002062",
                                        "ConditionMeshTerm": "Bursitis"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000007592",
                                        "ConditionAncestorTerm": "Joint Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009140",
                                        "ConditionAncestorTerm": "Musculoskeletal Diseases"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M4484",
                                        "ConditionBrowseLeafName": "Bursitis",
                                        "ConditionBrowseLeafAsFound": "Adhesive Capsulitis",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M9773",
                                        "ConditionBrowseLeafName": "Joint Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M11249",
                                        "ConditionBrowseLeafName": "Musculoskeletal Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC05",
                                        "ConditionBrowseBranchName": "Musculoskeletal Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionMeshList": {
                                "InterventionMesh": [
                                    {
                                        "InterventionMeshId": "D000014221",
                                        "InterventionMeshTerm": "Triamcinolone"
                                    },
                                    {
                                        "InterventionMeshId": "D000014222",
                                        "InterventionMeshTerm": "Triamcinolone Acetonide"
                                    },
                                    {
                                        "InterventionMeshId": "C000005900",
                                        "InterventionMeshTerm": "Triamcinolone hexacetonide"
                                    },
                                    {
                                        "InterventionMeshId": "C000030262",
                                        "InterventionMeshTerm": "Triamcinolone diacetate"
                                    }
                                ]
                            },
                            "InterventionAncestorList": {
                                "InterventionAncestor": [
                                    {
                                        "InterventionAncestorId": "D000000893",
                                        "InterventionAncestorTerm": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000005938",
                                        "InterventionAncestorTerm": "Glucocorticoids"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006728",
                                        "InterventionAncestorTerm": "Hormones"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006730",
                                        "InterventionAncestorTerm": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045505",
                                        "InterventionAncestorTerm": "Physiological Effects of Drugs"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007166",
                                        "InterventionAncestorTerm": "Immunosuppressive Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007155",
                                        "InterventionAncestorTerm": "Immunologic Factors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000004791",
                                        "InterventionAncestorTerm": "Enzyme Inhibitors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045504",
                                        "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                                    }
                                ]
                            },
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafAsFound": "Deep",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M3369",
                                        "InterventionBrowseLeafName": "Anti-Inflammatory Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8199",
                                        "InterventionBrowseLeafName": "Glucocorticoids",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8941",
                                        "InterventionBrowseLeafName": "Hormones",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8940",
                                        "InterventionBrowseLeafName": "Hormone Antagonists",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9364",
                                        "InterventionBrowseLeafName": "Immunosuppressive Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9353",
                                        "InterventionBrowseLeafName": "Immunologic Factors",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 41,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT04701593",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "19-377"
                            },
                            "Organization": {
                                "OrgFullName": "Virginia Polytechnic Institute and State University",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Using Triamcinolone Acetonide to Reduce Pain After Scleral Buckle Surgery",
                            "OfficialTitle": "Using Intraoperative Triamcinolone Acetonide Irrigation to Reduce Post-Operative Pain From Scleral Buckle Surgery"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "February 2022",
                            "OverallStatus": "Recruiting",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "January 3, 2020",
                                "StartDateType": "Actual"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "January 3, 2023",
                                "PrimaryCompletionDateType": "Anticipated"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "July 3, 2023",
                                "CompletionDateType": "Anticipated"
                            },
                            "StudyFirstSubmitDate": "January 5, 2021",
                            "StudyFirstSubmitQCDate": "January 5, 2021",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "January 8, 2021",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "February 15, 2022",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "February 17, 2022",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Sponsor"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Virginia Polytechnic Institute and State University",
                                "LeadSponsorClass": "OTHER"
                            }
                        },
                        "OversightModule": {
                            "IsFDARegulatedDrug": "Yes",
                            "IsFDARegulatedDevice": "No",
                            "IsUSExport": "Yes"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "PURPOSE: Scleral buckle surgery is a widely used ophthalmic surgery for the correction of rhegmatogenous retinal detachment. Studies suggest that eye pain is a common and underestimated occurrence after scleral buckle surgery, but as of yet, there is no definitive management method for reducing pain following scleral buckle surgery. The investigators aim to control pain following scleral buckle surgery with sub-tenon's irrigation with triamcinolone acetonide at the time of surgery. Using a randomized prospective clinical study, the investigators test if this technique will reduce the pain, nausea/vomiting, and analgesic use caused by scleral buckle surgery.\n\nMETHODS: Forty-eight patients undergoing scleral buckle surgery will be randomized into two groups. The experimental group receives a sub-tenon irrigation of 1 cc 40mg/mL triamcinolone acetonide around the base of the scleral buckle (0.25 cc in each quadrant) at time of operation. The control group does not receive any triamcinolone irrigation. Pain scores are measured 1 day post-operatively via 11-pt numerical rating scale as the primary outcome. The nausea/vomiting score is measured 1 day post-operatively via standard 6-pt scale. Patients track pain medication use via pill count. Values will be measured again at 1-2-week and 6 months post-op."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Retinal Detachment"
                                ]
                            },
                            "KeywordList": {
                                "Keyword": [
                                    "Scleral Buckle",
                                    "Triamcinolone Acetonide"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Phase 4"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "Randomized",
                                "DesignInterventionModel": "Parallel Assignment",
                                "DesignPrimaryPurpose": "Supportive Care",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "Double",
                                    "DesignWhoMaskedList": {
                                        "DesignWhoMasked": [
                                            "Participant",
                                            "Outcomes Assessor"
                                        ]
                                    }
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "24",
                                "EnrollmentType": "Anticipated"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "Control",
                                        "ArmGroupType": "No Intervention",
                                        "ArmGroupDescription": "No additional drug given"
                                    },
                                    {
                                        "ArmGroupLabel": "Experimental (Triamcinolone Acetonide)",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "receives a sub-tenon irrigation of 1 cc 40mg/mL triamcinolone acetonide around the base of the scleral buckle (0.25 cc in each quadrant) at time of operation",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: Triamcinolone Acetonide 40mg/mL"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "Triamcinolone Acetonide 40mg/mL",
                                        "InterventionDescription": "Sub-tenon irrigation 1cc",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Experimental (Triamcinolone Acetonide)"
                                            ]
                                        },
                                        "InterventionOtherNameList": {
                                            "InterventionOtherName": [
                                                "Kenalog"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Post Operative Pain Day 1",
                                        "PrimaryOutcomeDescription": "11-point Numerical Rating Scale (0-10, 10 being highest level of pain)",
                                        "PrimaryOutcomeTimeFrame": "1 Day Post-Op"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "Post Operative Pain Week 1",
                                        "SecondaryOutcomeDescription": "11-point Numerical Rating Scale (0-10, 10 being highest level of pain)",
                                        "SecondaryOutcomeTimeFrame": "1 Week Post-Op"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Post Operative Pain Month 6",
                                        "SecondaryOutcomeDescription": "11-point Numerical Rating Scale (0-10, 10 being highest level of pain)",
                                        "SecondaryOutcomeTimeFrame": "6 Months Post-Op"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Nausea/Vomiting Score Day 1",
                                        "SecondaryOutcomeDescription": "Standard 7-pt scale for nausea and vomiting (0-6, 6 being most nausea/vomiting)",
                                        "SecondaryOutcomeTimeFrame": "1 Day Post-Op"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Nausea/Vomiting Score Week 1",
                                        "SecondaryOutcomeDescription": "Standard 7-pt scale for nausea and vomiting (0-6, 6 being most nausea/vomiting)",
                                        "SecondaryOutcomeTimeFrame": "1 Week Post-Op"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Pain Medication Use Day 1",
                                        "SecondaryOutcomeDescription": "Pill-Count",
                                        "SecondaryOutcomeTimeFrame": "1 Day Post-Op"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Pain Medication Use Week 1",
                                        "SecondaryOutcomeDescription": "Pill-Count",
                                        "SecondaryOutcomeTimeFrame": "1 Week Post-Op"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nPatient must have rhegmatogenous retinal detachment and be scheduled to undergo scleral buckle surgery for correction\n\nExclusion Criteria:\n\nAdvanced Glaucoma\nHistory of corticosteroid responsive elevation in IOP\nAllergy to Triamcinolone Acetonide or other corticosteroids\nPre-existing chronic pain disorders\nHerpes zoster\nPrior corneal allograft\nAllergy to local anesthetic or penicillin\nPatients unable to consent on own behalf\nPatients unable to communicate pain and nausea levels\nPregnancy\nIncarceration",
                            "HealthyVolunteers": "No",
                            "Gender": "All",
                            "MinimumAge": "19 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "CentralContactList": {
                                "CentralContact": [
                                    {
                                        "CentralContactName": "Parth R Vaidya",
                                        "CentralContactRole": "Contact",
                                        "CentralContactPhone": "3363911953",
                                        "CentralContactEMail": "vaidpr14@vt.edu"
                                    },
                                    {
                                        "CentralContactName": "Vishak J John, MD",
                                        "CentralContactRole": "Contact",
                                        "CentralContactPhone": "(336) 703-7429",
                                        "CentralContactEMail": "Vishakjohn@vistareye.com"
                                    }
                                ]
                            },
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Vishak J John, MD",
                                        "OverallOfficialAffiliation": "Virginia Tech, Vistar Eye Center",
                                        "OverallOfficialRole": "Principal Investigator"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "Vistar Eye Centers",
                                        "LocationStatus": "Recruiting",
                                        "LocationCity": "Roanoke",
                                        "LocationState": "Virginia",
                                        "LocationZip": "24019",
                                        "LocationCountry": "United States",
                                        "LocationContactList": {
                                            "LocationContact": [
                                                {
                                                    "LocationContactName": "Vishak J John, MD",
                                                    "LocationContactRole": "Contact",
                                                    "LocationContactPhone": "336-703-7429",
                                                    "LocationContactEMail": "Vishakjohn@vistareye.com"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "IPDSharingStatementModule": {
                            "IPDSharing": "No"
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000012163",
                                        "ConditionMeshTerm": "Retinal Detachment"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000012164",
                                        "ConditionAncestorTerm": "Retinal Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000005128",
                                        "ConditionAncestorTerm": "Eye Diseases"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M12221",
                                        "ConditionBrowseLeafName": "Pain, Postoperative",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M14150",
                                        "ConditionBrowseLeafName": "Retinal Detachment",
                                        "ConditionBrowseLeafAsFound": "Retinal Detachment",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M12218",
                                        "ConditionBrowseLeafName": "Pain",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M14151",
                                        "ConditionBrowseLeafName": "Retinal Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M7423",
                                        "ConditionBrowseLeafName": "Eye Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC23",
                                        "ConditionBrowseBranchName": "Symptoms and General Pathology"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC11",
                                        "ConditionBrowseBranchName": "Eye Diseases"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionMeshList": {
                                "InterventionMesh": [
                                    {
                                        "InterventionMeshId": "D000014221",
                                        "InterventionMeshTerm": "Triamcinolone"
                                    },
                                    {
                                        "InterventionMeshId": "D000014222",
                                        "InterventionMeshTerm": "Triamcinolone Acetonide"
                                    },
                                    {
                                        "InterventionMeshId": "C000005900",
                                        "InterventionMeshTerm": "Triamcinolone hexacetonide"
                                    },
                                    {
                                        "InterventionMeshId": "C000030262",
                                        "InterventionMeshTerm": "Triamcinolone diacetate"
                                    }
                                ]
                            },
                            "InterventionAncestorList": {
                                "InterventionAncestor": [
                                    {
                                        "InterventionAncestorId": "D000000893",
                                        "InterventionAncestorTerm": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000005938",
                                        "InterventionAncestorTerm": "Glucocorticoids"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006728",
                                        "InterventionAncestorTerm": "Hormones"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006730",
                                        "InterventionAncestorTerm": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045505",
                                        "InterventionAncestorTerm": "Physiological Effects of Drugs"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007166",
                                        "InterventionAncestorTerm": "Immunosuppressive Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007155",
                                        "InterventionAncestorTerm": "Immunologic Factors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000004791",
                                        "InterventionAncestorTerm": "Enzyme Inhibitors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045504",
                                        "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                                    }
                                ]
                            },
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafAsFound": "Deep",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M3369",
                                        "InterventionBrowseLeafName": "Anti-Inflammatory Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8199",
                                        "InterventionBrowseLeafName": "Glucocorticoids",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8941",
                                        "InterventionBrowseLeafName": "Hormones",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8940",
                                        "InterventionBrowseLeafName": "Hormone Antagonists",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9364",
                                        "InterventionBrowseLeafName": "Immunosuppressive Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9353",
                                        "InterventionBrowseLeafName": "Immunologic Factors",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 42,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT03627741",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "17-008766"
                            },
                            "Organization": {
                                "OrgFullName": "Mayo Clinic",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors",
                            "OfficialTitle": "A Pilot Study of Intralesional Injection of Triamcinolone Acetonide for Desmoid Tumors"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "May 2021",
                            "OverallStatus": "Active, not recruiting",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "June 7, 2018",
                                "StartDateType": "Actual"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "May 2022",
                                "PrimaryCompletionDateType": "Anticipated"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "July 2022",
                                "CompletionDateType": "Anticipated"
                            },
                            "StudyFirstSubmitDate": "July 26, 2018",
                            "StudyFirstSubmitQCDate": "August 8, 2018",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "August 13, 2018",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "May 4, 2021",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "May 5, 2021",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Principal Investigator",
                                "ResponsiblePartyInvestigatorFullName": "Benjamin K. Wilke",
                                "ResponsiblePartyInvestigatorTitle": "Principal Investigator",
                                "ResponsiblePartyInvestigatorAffiliation": "Mayo Clinic"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Mayo Clinic",
                                "LeadSponsorClass": "OTHER"
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "Yes",
                            "IsFDARegulatedDrug": "Yes",
                            "IsFDARegulatedDevice": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "There is research supporting treatment of superficial fibromatoses (palmar fibromatosis and keloids) with triamcinolone acetonide injections. These lesions are histologically similar to deep fibromatoses (desmoid tumors). Currently there is little literature evaluating the response of desmoid tumors to injections of triamcinolone acetonide. The investigators aim to perform a pilot study evaluating the response of desmoid tumors to intralesional triamcinolone. If positive results are observed (based on RECIST criteria), then a phase II study will be initiated.",
                            "DetailedDescription": "Desmoid tumors are proliferations of fibroblasts and myofibroblasts, intermixed with abundant dense collagen. Histologically they are similar to superficial fibromatoses such as palmar (Dupuytren's disease) and plantar fibromatoses, as well as keloids. Unlike the superficial fibromatoses, desmoid tumors are located in the deep tissue and stratified based on an abdominal or extra-abdominal location.\n\nThere are currently many treatment options for desmoid tumors. Historically, wide surgical resection was the treatment of choice. This often resulted in a disfiguring appearance and recurrence was common, with rates between 30 - 40% following resection. Additionally, radiation and systemic therapies are performed, with an approximate 26% rate of objective response, based on RECIST. These therapies are however not without side effects. Observation initially is also a reasonable approach as a recent study reported up to 60% of desmoids demonstrating stable disease and 18% spontaneously regressing over a five year period. Longer follow-up studies are needed to determine the true natural history of desmoid tumors, but there currently is a need for an alternative treatment strategy with increased efficacy and fewer side-effects once observation has failed.\n\nCorticosteroids, such as triamcinolone acetonide, have long been used in the treatment of hypertrophic scars and keloids in order to decrease the size of the lesion. Proposed mechanisms of action of corticosteroids on keloids and hypertrophic scars include a decrease in the production of collagen, dissolution of insoluble collagen (collagenolysis), a decrease in the local inflammatory process, and an increased rate of apoptosis of fibroblast and inflammatory cells. Recently, reports have evaluated the use of triamcinolone acetonide in Dupuytren's disease, a superficial fibromatosis. A randomized controlled trial evaluated range of motion in patients following needle aponeurotomy alone and in combination with serial triamcinolone injections. They found improved range of motion in the triamcinolone cohort up to 24 months following treatment. Similarly, Ketchum et al reported that 97% of Dupuytren's nodules showed clinical regression following an average of 3.2 intralesional injections with triamcinolone acetonide, although half of these patients did experience reactivation of the disease at 1-3 years following treatment.\n\nCurrently there is limited reported experience with treatment of desmoid tumors by steroid therapy. Rhee et al reported a case of a chest wall desmoid tumor that recurred after two surgical resections and postoperative radiation therapy. They treated the lesion with weekly intralesional injections of 120 mg of triamcinolone acetonide for 4 weeks. At six months they noted a reduction in the size of the lesion. Similarly, Umemoto et al. reported a case of a 37 year old male with familial polyposis coli and intra-abdominal desmoid tumors. He was treated with oral prednisolone therapy with gradual regression of the lesions. At one year and six months following his last operation, the patient had no signs of recurrence of the desmoid tumors.\n\nBased on this background information we aim to perform a pilot study of 10 patients with a histologically confirmed diagnosis of extra-abdominal aggressive fibromatosis (desmoid tumor) in order to determine the response rate of intralesional injections of triamcinolone acetonide. Response will be evaluated using the World Health Organization (WHO) response criteria, total volume of the tumor, T2 signal hyperintensity, and RECIST."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Fibromatosis"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Phase 1"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "N/A",
                                "DesignInterventionModel": "Single Group Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "None (Open Label)"
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "10",
                                "EnrollmentType": "Actual"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "Triamcinolone arm",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "A concentration of 40 mg/ml of Triamcinolone Acetonide will be used for injections with a total dose of 120 mg of Triamcinolone given per injection. The injections will be performed under ultrasound guidance by a fellowship-trained musculoskeletal radiologist. The injection locations will be left to the discretion of the radiologist with the request to attempt to distribute the drug throughout the tumor. A total of three injections will be performed at six week intervals.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: Triamcinolone Acetonide"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "Triamcinolone Acetonide",
                                        "InterventionDescription": "A concentration of 40 mg/ml of Triamcinolone Acetonide will be used for injections with a total dose of 120 mg of Triamcinolone given per injection. The injections will be performed under ultrasound guidance by a fellowship-trained musculoskeletal radiologist. The injection locations will be left to the discretion of the radiologist with the request to attempt to distribute the drug throughout the tumor. A total of three injections will be performed at six week intervals.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Triamcinolone arm"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Response rate of desmoid tumors to serial triamcinolone injections based on WHO criteria.",
                                        "PrimaryOutcomeDescription": "Based on MRI imaging",
                                        "PrimaryOutcomeTimeFrame": "2 years"
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "Response rate of desmoid tumors to serial triamcinolone injections based on change in tumor volume.",
                                        "PrimaryOutcomeDescription": "Based on MRI imaging",
                                        "PrimaryOutcomeTimeFrame": "2 years"
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "Response rate of desmoid tumors to serial triamcinolone injections based on change in T2 signaling hyperintensity.",
                                        "PrimaryOutcomeDescription": "Based on MRI imaging",
                                        "PrimaryOutcomeTimeFrame": "2 years"
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "Response rate of desmoid tumors to serial triamcinolone injections based on RECIST.",
                                        "PrimaryOutcomeDescription": "Based on MRI imaging",
                                        "PrimaryOutcomeTimeFrame": "2 years"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "Number patients experiencing a non-serious adverse event following triamcinolone injections.",
                                        "SecondaryOutcomeDescription": "Defined as any untoward or undesirable experience associated with the use of a medical product.",
                                        "SecondaryOutcomeTimeFrame": "6 months following initial administration of triamcinolone injections"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Number of patients experiencing a serious adverse event following triamcinolone injections.",
                                        "SecondaryOutcomeDescription": "Including hospitalization, prolonged disability/incapacity, life-threatening adverse experience, birth defect, and death.",
                                        "SecondaryOutcomeTimeFrame": "6 months following initial adminstration of triamcinolone injections."
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria\n\nPatients with histologically confirmed diagnosis of extra-abdominal aggressive fibromatosis (desmoid tumor).\nAt least one of the following: Desmoid tumor that has shown stability in size over consecutive axial imaging (CT or MRI) at least 3 months apart AND presence of any tumor-related symptoms OR an increase in size based on consecutive axial imaging (CT or MRI). Additionally, for patients with a desmoid tumor which has been irradiated, at least a 10% increase in size by volume since receiving radiotherapy is required.\nECOG Performance status of < 1.\nAble to participate in three guided injection procedures.\nAble to undergo a MRI with and without contrast of the tumor site.\nAge > 18 years and ≤ 89 years.\nWilling to sign an informed consent form.\nWilling to comply with protocol procedures including required 21 month follow up after last injection.\n\nExclusion Criteria\n\nAllergy to the test drug or a component of its formulation\nPatients with a desmoid tumor which has been stable in size and without symptoms or decreased in size over the prior three months utilizing axial imaging according to the following criteria; (a) 10% when comparing a prior CT scan to a current MRI, or (b) more than 5% when comparing a prior MRI to a current MRI.\nThe patient must not be on anticoagulation (Aspirin okay)\nThe patient should not be pregnant or trying to become pregnant, and willing to use adequate contraception during study participation to avoid pregnancy\nThe patient should not be breastfeeding\nActive infection that in the opinion of the investigator compromises the patient's participation (i.e., a UTI is ok)\nA diagnosis of idiopathic thrombocytopenia purpura\nUndergoing concomitant treatment (including radiation, systemic treatment, surgery, or other tumor directed therapy). The patient must be off of the systemic therapy for a period of at least 5 drug half-lives prior to enrolling in the study.\nUncontrolled or poorly controlled diabetes mellitus\nHas an uncontrolled illness including, but not limited to, uncontrolled infection, or psychiatric illness/social situations that in the opinion of the investigator would limit compliance with study requirements",
                            "HealthyVolunteers": "Accepts Healthy Volunteers",
                            "Gender": "All",
                            "MinimumAge": "18 Years",
                            "MaximumAge": "89 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Benjamin K Wilke, MD",
                                        "OverallOfficialAffiliation": "Mayo Clinic",
                                        "OverallOfficialRole": "Principal Investigator"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "Mayo Clinic in Florida",
                                        "LocationCity": "Jacksonville",
                                        "LocationState": "Florida",
                                        "LocationZip": "32224",
                                        "LocationCountry": "United States"
                                    }
                                ]
                            }
                        },
                        "ReferencesModule": {
                            "SeeAlsoLinkList": {
                                "SeeAlsoLink": [
                                    {
                                        "SeeAlsoLinkLabel": "Mayo Clinic Clinical Trials",
                                        "SeeAlsoLinkURL": "https://www.mayo.edu/research/clinical-trials"
                                    }
                                ]
                            }
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000018222",
                                        "ConditionMeshTerm": "Fibromatosis, Aggressive"
                                    },
                                    {
                                        "ConditionMeshId": "D000005350",
                                        "ConditionMeshTerm": "Fibroma"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000018218",
                                        "ConditionAncestorTerm": "Neoplasms, Fibrous Tissue"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009372",
                                        "ConditionAncestorTerm": "Neoplasms, Connective Tissue"
                                    },
                                    {
                                        "ConditionAncestorId": "D000018204",
                                        "ConditionAncestorTerm": "Neoplasms, Connective and Soft Tissue"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009370",
                                        "ConditionAncestorTerm": "Neoplasms by Histologic Type"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009369",
                                        "ConditionAncestorTerm": "Neoplasms"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M19520",
                                        "ConditionBrowseLeafName": "Fibromatosis, Aggressive",
                                        "ConditionBrowseLeafAsFound": "Desmoid Tumor",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M2876",
                                        "ConditionBrowseLeafName": "Aggression",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M7632",
                                        "ConditionBrowseLeafName": "Fibroma",
                                        "ConditionBrowseLeafAsFound": "Fibromatosis",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M19516",
                                        "ConditionBrowseLeafName": "Neoplasms, Fibrous Tissue",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M11469",
                                        "ConditionBrowseLeafName": "Neoplasms, Connective Tissue",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M19502",
                                        "ConditionBrowseLeafName": "Neoplasms, Connective and Soft Tissue",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M11467",
                                        "ConditionBrowseLeafName": "Neoplasms by Histologic Type",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "T1822",
                                        "ConditionBrowseLeafName": "Desmoid Tumor",
                                        "ConditionBrowseLeafAsFound": "Desmoid Tumor",
                                        "ConditionBrowseLeafRelevance": "high"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC04",
                                        "ConditionBrowseBranchName": "Neoplasms"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BXM",
                                        "ConditionBrowseBranchName": "Behaviors and Mental Disorders"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC17",
                                        "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "Rare",
                                        "ConditionBrowseBranchName": "Rare Diseases"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionMeshList": {
                                "InterventionMesh": [
                                    {
                                        "InterventionMeshId": "D000014221",
                                        "InterventionMeshTerm": "Triamcinolone"
                                    },
                                    {
                                        "InterventionMeshId": "D000014222",
                                        "InterventionMeshTerm": "Triamcinolone Acetonide"
                                    },
                                    {
                                        "InterventionMeshId": "C000005900",
                                        "InterventionMeshTerm": "Triamcinolone hexacetonide"
                                    },
                                    {
                                        "InterventionMeshId": "C000030262",
                                        "InterventionMeshTerm": "Triamcinolone diacetate"
                                    }
                                ]
                            },
                            "InterventionAncestorList": {
                                "InterventionAncestor": [
                                    {
                                        "InterventionAncestorId": "D000000893",
                                        "InterventionAncestorTerm": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000005938",
                                        "InterventionAncestorTerm": "Glucocorticoids"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006728",
                                        "InterventionAncestorTerm": "Hormones"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006730",
                                        "InterventionAncestorTerm": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045505",
                                        "InterventionAncestorTerm": "Physiological Effects of Drugs"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007166",
                                        "InterventionAncestorTerm": "Immunosuppressive Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007155",
                                        "InterventionAncestorTerm": "Immunologic Factors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000004791",
                                        "InterventionAncestorTerm": "Enzyme Inhibitors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045504",
                                        "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                                    }
                                ]
                            },
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafAsFound": "Deep",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M3369",
                                        "InterventionBrowseLeafName": "Anti-Inflammatory Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8199",
                                        "InterventionBrowseLeafName": "Glucocorticoids",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8941",
                                        "InterventionBrowseLeafName": "Hormones",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8940",
                                        "InterventionBrowseLeafName": "Hormone Antagonists",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9364",
                                        "InterventionBrowseLeafName": "Immunosuppressive Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9353",
                                        "InterventionBrowseLeafName": "Immunologic Factors",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 43,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT04261049",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "19-3562"
                            },
                            "Organization": {
                                "OrgFullName": "University of North Carolina, Chapel Hill",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Effect of Zilretta Injection",
                            "OfficialTitle": "Effect of ZILRETTA Injection on Neuromuscular Function, Gait Biomechanics and Physical Performance"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "March 2020",
                            "OverallStatus": "Recruiting",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "August 1, 2020",
                                "StartDateType": "Actual"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "September 2023",
                                "PrimaryCompletionDateType": "Anticipated"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "September 2023",
                                "CompletionDateType": "Anticipated"
                            },
                            "StudyFirstSubmitDate": "February 5, 2020",
                            "StudyFirstSubmitQCDate": "February 5, 2020",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "February 7, 2020",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "September 21, 2020",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "September 23, 2020",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Sponsor"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "University of North Carolina, Chapel Hill",
                                "LeadSponsorClass": "OTHER"
                            },
                            "CollaboratorList": {
                                "Collaborator": [
                                    {
                                        "CollaboratorName": "Flexion Therapeutics, Inc.",
                                        "CollaboratorClass": "INDUSTRY"
                                    }
                                ]
                            }
                        },
                        "OversightModule": {
                            "IsFDARegulatedDrug": "Yes",
                            "IsFDARegulatedDevice": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "The purpose of this study is to examine the pre-post effects of a single ZILRETTA knee injection on physiological measures of self-reported pain and disability, physical performance, and physical activity in individuals with knee osteoarthritis (OA). The investigators will recruit 35 symptomatic knee OA patients for this study. All data will be collected prior to injection (baseline), as well as at 4 (post 1) and 8-week follow-ups (post 2).",
                            "DetailedDescription": "Individuals with knee osteoarthritis (OA) demonstrate significant physical disability which leads to diminished physical activity, a lesser quality of life, as well as a higher risk of inactivity related comorbidities including mortality. This is thought to be caused by an inability to voluntarily activate your quadriceps muscle due, in part, to knee joint swelling and joint-related pain. Incomplete muscle activation causes quadriceps weakness.\n\nIndividuals with quadriceps weakness exhibit changes in their walking biomechanics which is associated with diminished physical function and lesser physical activity in those with knee OA. Therefore, it is critical to develop interventions that target mechanisms causing decreased quadriceps activation in order to restore optimal walking biomechanics and improve physical activity.\n\nThe ZILRETTA knee injection is an FDA approved, extended release corticosteroid for in patients with knee osteoarthritis and has been shown to reduced knee pain for 3 months in approximately 70% of patients. Currently, there are no studies that have examined ZILRETTA's objective effectiveness on physical activity, biomechanics, and performance tests in patients who have received an injection.\n\nThe overall purpose of the current study is to examine the effect of a ZILRETTA knee injection on functional and performance tests including quadriceps neuromuscular activation, quadriceps strength, walking gait biomechanics, and a battery of physical performance outcomes at 4 and 8-weeks following injection in 35 individuals with knee OA."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Osteoarthritis, Knee"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Phase 1"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "N/A",
                                "DesignInterventionModel": "Single Group Assignment",
                                "DesignPrimaryPurpose": "Basic Science",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "None (Open Label)"
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "35",
                                "EnrollmentType": "Anticipated"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "ZILRETTA Injection",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "All patients upon enrolling in the study will receive a single 5 mL injection of 32 mg ZILRETTA into the affected knee joint.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: Triamcinolone Acetonide Extended-Release Injectable Suspension"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "Triamcinolone Acetonide Extended-Release Injectable Suspension",
                                        "InterventionDescription": "A single ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) intra-articular knee injection.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "ZILRETTA Injection"
                                            ]
                                        },
                                        "InterventionOtherNameList": {
                                            "InterventionOtherName": [
                                                "Zilretta Injectable Product"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Percentage Change in Mean Maximal Quadriceps Strength as Measured by the Maximal Isometric Voluntary Contractions Normalized to Body Weight from Baseline to the 8-week follow-up.",
                                        "PrimaryOutcomeDescription": "Quadriceps strength was measured in Newton Meters normalized to body weight of the individuals. Strength was assessed in 90 degrees of knee flexion.",
                                        "PrimaryOutcomeTimeFrame": "Baseline and 8-week follow-up"
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "Percentage Change in Mean Voluntary Quadriceps Activation as Measured by the Central Activation Ratio Expressed as a Percent of Full Activation from Baseline to the 8-week follow-up.",
                                        "PrimaryOutcomeDescription": "The investigators assessed voluntary quadriceps central activation ratio as a representative variable of lower extremity neuromuscular activation using the supra imposition technique. Quadriceps central activation ratio has been demonstrated to be significantly decreased in knee osteoarthritis (OA) compared to healthy, matched controls, and the investigators have reported acceptable measurement reliability (ICC2,k = 0.85)",
                                        "PrimaryOutcomeTimeFrame": "Baseline and 8-week follow-up"
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "Percentage Change in Mean Knee Flexion Angle During Walking Gait Measured in Degrees of Knee Flexion from Baseline to the 8-week follow-up.",
                                        "PrimaryOutcomeDescription": "The peak Knee Flexion Angle was calculated using using inverse dynamics calculations in the first 50% of the stance phase of gait and during self selected gait speed.",
                                        "PrimaryOutcomeTimeFrame": "Baseline and 8-week follow-up"
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "Percentage Change in Mean Internal Knee Extension Moment During Walking Gait Measured in Nm/ Body Weight*m from Baseline to the 8-week follow-up.",
                                        "PrimaryOutcomeDescription": "The peak internal knee extension moment was calculated using using inverse dynamics calculations in the first 50% of the stance phase of gait and normalized to the Body Weight* height (m) of the individual during self selected gait speed.",
                                        "PrimaryOutcomeTimeFrame": "Baseline and 8-week follow-up"
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "Percentage Change in Mean of Self-reported Disability Score as Measured by the Western Ontario and McMasters Universities Index from Baseline to the 8-week follow-up.",
                                        "PrimaryOutcomeDescription": "The Western Ontario and McMasters Universities Index is reliable and valid measure of self reported disability. The physical function consists of 17 items and asks about the magnitude of difficulty when ascending and descending stairs, rising from sitting, standing, bending, walking, getting in / out of a car, shopping, putting on and taking off socks, rising from bed, lying in bed, getting in and out of the bath, sitting, getting on and off the toilet, completing heavy household duties, and completing light household duties. Each item is presented in a 5 point Likert-type format and uses the following descriptors for possible answer choices none, mild moderate, severe, and extreme. Each descriptor corresponds to an ordinal scale of 0-4. The scores are summed for the items in each subscale, with total possible ranges as 0-68. Higher scores on the WOMAC indicate greater amounts of functional limitations.",
                                        "PrimaryOutcomeTimeFrame": "Baseline and 8-week follow-up"
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "Percentage Change in mean of self-reported Disability Score as Measured by the Knee Injury and Osteoarthritis Outcome Score from Baseline to the 8-week follow-up.",
                                        "PrimaryOutcomeDescription": "The Knee Injury and Osteoarthritis Outcomes Score (KOOS) consists of five subscales: Pain (9 items), Symptoms (7 items), Function in Activities of Daily Living (17 items), Function in Sport and Recreation (5 items) and Knee Related Quality of Life (4 items). Each item is presented in a 5 point Likert-type format that ranges from 0 (no problems) to 4 (extreme problems). Totals from each subscale are transformed to a 0-100 score. Lower scores on the KOOS indicate greater amounts of functional limitations.",
                                        "PrimaryOutcomeTimeFrame": "Baseline and 8-week follow-up"
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "Percentage Change in Physical Activity Scale for the Elderly from baseline to the 8-week follow-up.",
                                        "PrimaryOutcomeDescription": "Physical Activity Scale for the Elderly (PASE) scores are calculated from weights and frequency values for each of 12 types of activity. Responses to the first question about sitting activities are not scored. The scale is continuous with higher scores indicating greater physical activity.",
                                        "PrimaryOutcomeTimeFrame": "Baseline and 8-week follow-up"
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "Percentage Change in 30-s chair-stand test from Baseline to the 8-week follow-up.",
                                        "PrimaryOutcomeDescription": "The number of times that an individual can sit and stand in 30 seconds.",
                                        "PrimaryOutcomeTimeFrame": "Baseline and 8-week follow-up"
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "Percentage Change in 20 meter fast-paced walk test from Baseline to the 8-week follow-up.",
                                        "PrimaryOutcomeDescription": "The investigators will time the amount of seconds it takes to walk 20 meters.",
                                        "PrimaryOutcomeTimeFrame": "Baseline and 8-week follow-up"
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "Percentage Change in Stair-climb test from Baseline to the 8-week follow-up.",
                                        "PrimaryOutcomeDescription": "The investigators will time the amount of seconds it takes to walk up and down a flight of stairs.",
                                        "PrimaryOutcomeTimeFrame": "Baseline and 8-week follow-up"
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "The percentage change in steps per day from Baseline to the 8-week follow-up.",
                                        "PrimaryOutcomeDescription": "Physical activity will be measured in the form of steps per day using an ActiGraph accelerometer. Participants will wear the ActiGraph for 7 days following each testing session.",
                                        "PrimaryOutcomeTimeFrame": "Baseline and 8-week follow-up"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Full Inclusion Criteria:\n\nMale or female between the ages of 40 and 75 years old who:\nExhibit symptomatic knee OA, defined as a normalized WOMAC function subscale score >31(out of 100 points, indicating highest degree of dysfunction)\nHave radiographic evidence of tibiofemoral OA (2-4 on the Kellgren-Lawrence scale)\nProvide written informed consent and the ability to comply with the requirements of the study.\n\nBe willing to abstain from use of the following protocol-restricted medications during the study:\n\nCorticosteroid injections into the knee or any lower extremity joint will be restricted for 3 months prior to the screening visit (based on the drug half-life) and throughout the entirety of the study period including the 8-week follow-up test. Information about when the latest corticosteroid injection occurred for each participant prior to screening in order to determine when each participant can attend the screening visit.\nHyaluronic acid injections into the knee or any lower extremity joint will be restricted for 6 months prior to the screening visit (based on the drug half-life) and throughout the entirety of the study period including the 8-week follow-up test. Information about when the latest hyaluronic acid injection occurred for each participant prior to screening in order to determine when each participant can attend the screening visit.\nPrescription Depressants (Examples: opiates and opioids, barbiturates, tranquilizers and benzodiazepines) will be restricted 4-weeks prior to screening and throughout the study period as these medications may affect the neuromuscular function.\nPrescription Stimulants (Example: amphetamines) will be restricted 4-weeks prior to screening and throughout the study period as these medications may affect the neuromuscular function\nNon-steroidal anti-inflammatory drugs (NSAIDs) will be restricted 24 hours prior to screening or follow-up testing sessions. NSAID use will be tracked and patients instructed not to change their NSAIDs usage during the 8-weeks of the study.\nAcetaminophen will be restricted 24 hours prior to screening or follow-up testing sessions. Acetaminophen use will be tracked and patients instructed not to change their Acetaminophen usage during the 8-weeks of the study.\n\nFull Exclusion Criteria:\n\nPotential participants meeting any of the following criteria (based on the electronic medical record or in laboratory screening) will be excluded if they:\n\nAre hypersensitive to triamcinolone acetonide, corticosteroids or any components of the product\nHave other intra-articular investigational drug/biologic use in the previous 6-months\nHave been diagnosed with a cardiovascular condition restricting exercise\nHave had a corticosteroid injection in the involved knee in the previous 3-months or hyaluronic acid injection in the involved knee in the previous 6-months\nHave a pacemaker\nHave a neurodegenerative condition\nHave rheumatoid arthritis\nHave diabetes\nHave cancer\nHave a neural sensory dysfunction over the knee\nHave a body mass index (BMI) over 35\nHave a history of lower extremity orthopaedic surgery in the past year\nHave a history of a traumatic knee injury in the past 6 months\nHave any history of total knee arthroplasty in either extremity\nHave a diagnosed, non-reconstructed knee ligament tear\nNeed an assistive device to walk\nAre currently pregnant or planning to become pregnant while enrolled in the study\nAre taking medications that can react harmfully with injected corticosteroids\n\nNOTE: Individuals that have bilateral knee OA will not be excluded unless they meet another exclusion criteria. In case a patient needs an injection in both knees, they will be excluded. Only one knee will be injected for this study.",
                            "HealthyVolunteers": "No",
                            "Gender": "All",
                            "MinimumAge": "40 Years",
                            "MaximumAge": "75 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "CentralContactList": {
                                "CentralContact": [
                                    {
                                        "CentralContactName": "Brian Pietrosimone, PhD, ATC",
                                        "CentralContactRole": "Contact",
                                        "CentralContactPhone": "9199623617",
                                        "CentralContactEMail": "pietrosi@email.unc.edu"
                                    }
                                ]
                            },
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Brian Pietrosimone, PhD, ATC",
                                        "OverallOfficialAffiliation": "University of North Carolina, Chapel Hill",
                                        "OverallOfficialRole": "Principal Investigator"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "MOTION Science Institute",
                                        "LocationStatus": "Recruiting",
                                        "LocationCity": "Chapel Hill",
                                        "LocationState": "North Carolina",
                                        "LocationZip": "27516",
                                        "LocationCountry": "United States",
                                        "LocationContactList": {
                                            "LocationContact": [
                                                {
                                                    "LocationContactName": "Brian Pietrosimone, PhD",
                                                    "LocationContactRole": "Contact",
                                                    "LocationContactPhone": "919-962-3617",
                                                    "LocationContactEMail": "brian@unc.edu"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "ReferencesModule": {
                            "ReferenceList": {
                                "Reference": [
                                    {
                                        "ReferencePMID": "23680877",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Dobson F, Hinman RS, Roos EM, Abbott JH, Stratford P, Davis AM, Buchbinder R, Snyder-Mackler L, Henrotin Y, Thumboo J, Hansen P, Bennell KL. OARSI recommended performance-based tests to assess physical function in people diagnosed with hip or knee osteoarthritis. Osteoarthritis Cartilage. 2013 Aug;21(8):1042-52. doi: 10.1016/j.joca.2013.05.002. Epub 2013 May 13."
                                    },
                                    {
                                        "ReferencePMID": "15996138",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Elliott P, Hawthorne G. Imputing missing repeated measures data: how should we proceed? Aust N Z J Psychiatry. 2005 Jul;39(7):575-82."
                                    },
                                    {
                                        "ReferencePMID": "24490843",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Harkey MS, Gribble PA, Pietrosimone BG. Disinhibitory interventions and voluntary quadriceps activation: a systematic review. J Athl Train. 2014 May-Jun;49(3):411-21. doi: 10.4085/1062-6050-49.1.04. Epub 2014 Feb 3. Review."
                                    },
                                    {
                                        "ReferencePMID": "10987162",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Hopkins JT, Ingersoll CD, Edwards JE, Cordova ML. Changes in soleus motoneuron pool excitability after artificial knee joint effusion. Arch Phys Med Rehabil. 2000 Sep;81(9):1199-203."
                                    },
                                    {
                                        "ReferencePMID": "12937440",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Hopkins J, Ingersoll CD, Edwards J, Klootwyk TE. Cryotherapy and Transcutaneous Electric Neuromuscular Stimulation Decrease Arthrogenic Muscle Inhibition of the Vastus Medialis After Knee Joint Effusion. J Athl Train. 2002 Mar;37(1):25-31."
                                    },
                                    {
                                        "ReferencePMID": "11194097",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Hopkins JT, Ingersoll CD, Krause BA, Edwards JE, Cordova ML. Effect of knee joint effusion on quadriceps and soleus motoneuron pool excitability. Med Sci Sports Exerc. 2001 Jan;33(1):123-6."
                                    },
                                    {
                                        "ReferencePMID": "10380242",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Jones CJ, Rikli RE, Beam WC. A 30-s chair-stand test as a measure of lower body strength in community-residing older adults. Res Q Exerc Sport. 1999 Jun;70(2):113-9."
                                    },
                                    {
                                        "ReferencePMID": "13498604",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "KELLGREN JH, LAWRENCE JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 1957 Dec;16(4):494-502."
                                    },
                                    {
                                        "ReferencePMID": "15679884",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Kennedy DM, Stratford PW, Wessel J, Gollish JD, Penney D. Assessing stability and change of four performance measures: a longitudinal study evaluating outcome following total hip and knee arthroplasty. BMC Musculoskelet Disord. 2005 Jan 28;6:3."
                                    },
                                    {
                                        "ReferencePMID": "11779647",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Lewek M, Rudolph K, Axe M, Snyder-Mackler L. The effect of insufficient quadriceps strength on gait after anterior cruciate ligament reconstruction. Clin Biomech (Bristol, Avon). 2002 Jan;17(1):56-63."
                                    },
                                    {
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Leyland KM, Gates LS, Sanchez-Santos MT, Prieto Alhambra D, Judge A, Collins G, Cleveland R, Felson D, Jordon JM, Callahan LF, Nevitt M, Saberi Hosnijeh F, van Meurs JB, Jones G, Newton J, Batt M, Altman D, Cooper C, Arden N, Committee PC. Knee osteoarthritis and the risk of premature mortality in the community: an international individual patient level meta-analysis in 9889 subjects. Osteoarthritis and Cartilage. 2017;25:S29-S30."
                                    },
                                    {
                                        "ReferencePMID": "17451958",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Liikavainio T, Isolehto J, Helminen HJ, Perttunen J, Lepola V, Kiviranta I, Arokoski JP, Komi PV. Loading and gait symmetry during level and stair walking in asymptomatic subjects with knee osteoarthritis: importance of quadriceps femoris in reducing impact force during heel strike? Knee. 2007 Jun;14(3):231-8. Epub 2007 Apr 23."
                                    },
                                    {
                                        "ReferencePMID": "18996249",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Liikavainio T, Lyytinen T, Tyrväinen E, Sipilä S, Arokoski JP. Physical function and properties of quadriceps femoris muscle in men with knee osteoarthritis. Arch Phys Med Rehabil. 2008 Nov;89(11):2185-94. doi: 10.1016/j.apmr.2008.04.012."
                                    },
                                    {
                                        "ReferencePMID": "24084315",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Luc BA, Lepley AS, Tevald MA, Gribble PA, White DB, Pietrosimone BG. Reliability of corticomotor excitability in leg and thigh musculature at 14 and 28 days. J Sport Rehabil. 2014 Nov;23(4):330-8. doi: 10.1123/jsr.2013-0069. Epub 2013 Oct 1."
                                    },
                                    {
                                        "ReferencePMID": "26597088",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Luc BA, Harkey MH, Arguelles GD, Blackburn JT, Ryan ED, Pietrosimone B. Measuring voluntary quadriceps activation: Effect of visual feedback and stimulus delivery. J Electromyogr Kinesiol. 2016 Feb;26:73-81. doi: 10.1016/j.jelekin.2015.10.006. Epub 2015 Nov 2."
                                    },
                                    {
                                        "ReferencePMID": "29787693",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Luc-Harkey BA, Blackburn JT, Ryan ED, Harkey MS, Davis HC, Gaynor BR, Nissman DB, Spang JT, Pietrosimone B. Quadriceps Rate of Torque Development and Disability in Persons With Tibiofemoral Osteoarthritis. J Orthop Sports Phys Ther. 2018 Sep;48(9):694-703. doi: 10.2519/jospt.2018.7898. Epub 2018 May 22."
                                    },
                                    {
                                        "ReferencePMID": "1574662",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Marcus BH, Selby VC, Niaura RS, Rossi JS. Self-efficacy and the stages of exercise behavior change. Res Q Exerc Sport. 1992 Mar;63(1):60-6."
                                    },
                                    {
                                        "ReferencePMID": "21385807",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Nüesch E, Dieppe P, Reichenbach S, Williams S, Iff S, Jüni P. All cause and disease specific mortality in patients with knee or hip osteoarthritis: population based cohort study. BMJ. 2011 Mar 8;342:d1165. doi: 10.1136/bmj.d1165."
                                    },
                                    {
                                        "ReferencePMID": "19550206",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Palmieri-Smith RM, Thomas AC. A neuromuscular mechanism of posttraumatic osteoarthritis associated with ACL injury. Exerc Sport Sci Rev. 2009 Jul;37(3):147-53. doi: 10.1097/JES.0b013e3181aa6669. Review."
                                    },
                                    {
                                        "ReferencePMID": "25062605",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Pietrosimone B, Lepley AS, Murray AM, Thomas AC, Bahhur NO, Schwartz TA. Changes in voluntary quadriceps activation predict changes in muscle strength and gait biomechanics following knee joint effusion. Clin Biomech (Bristol, Avon). 2014 Sep;29(8):923-9. doi: 10.1016/j.clinbiomech.2014.06.014. Epub 2014 Jul 4."
                                    },
                                    {
                                        "ReferencePMID": "23016066",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Pietrosimone BG, McLeod MM, Lepley AS. A theoretical framework for understanding neuromuscular response to lower extremity joint injury. Sports Health. 2012 Jan;4(1):31-5."
                                    },
                                    {
                                        "ReferencePMID": "24944850",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Pietrosimone B, Thomas AC, Saliba SA, Ingersoll CD. Association between quadriceps strength and self-reported physical activity in people with knee osteoarthritis. Int J Sports Phys Ther. 2014 May;9(3):320-8."
                                    },
                                    {
                                        "ReferencePMID": "21333954",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Pietrosimone BG, Hertel J, Ingersoll CD, Hart JM, Saliba SA. Voluntary quadriceps activation deficits in patients with tibiofemoral osteoarthritis: a meta-analysis. PM R. 2011 Feb;3(2):153-62; quiz 162. doi: 10.1016/j.pmrj.2010.07.485. Review."
                                    },
                                    {
                                        "ReferencePMID": "22503429",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Pietrosimone BG, Saliba SA. Changes in voluntary quadriceps activation predict changes in quadriceps strength after therapeutic exercise in patients with knee osteoarthritis. Knee. 2012 Dec;19(6):939-43. doi: 10.1016/j.knee.2012.03.002. Epub 2012 Apr 13."
                                    },
                                    {
                                        "ReferencePMID": "20713439",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Pietrosimone BG, Saliba SA, Hart JM, Hertel J, Kerrigan DC, Ingersoll CD. Effects of disinhibitory transcutaneous electrical nerve stimulation and therapeutic exercise on sagittal plane peak knee kinematics and kinetics in people with knee osteoarthritis during gait: a randomized controlled trial. Clin Rehabil. 2010 Dec;24(12):1091-101. doi: 10.1177/0269215510375903. Epub 2010 Aug 16."
                                    },
                                    {
                                        "ReferencePMID": "10503556",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Roos EM, Klässbo M, Lohmander LS. WOMAC osteoarthritis index. Reliability, validity, and responsiveness in patients with arthroscopically assessed osteoarthritis. Western Ontario and MacMaster Universities. Scand J Rheumatol. 1999;28(4):210-5."
                                    },
                                    {
                                        "ReferencePMID": "23675793",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Seeley MK, Park J, King D, Hopkins JT. A novel experimental knee-pain model affects perceived pain and movement biomechanics. J Athl Train. 2013 May-Jun;48(3):337-45. doi: 10.4085/1062-6050-48.2.02. Epub 2013 Feb 20."
                                    },
                                    {
                                        "ReferencePMID": "11073346",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Simonsick EM, Gardner AW, Poehlman ET. Assessment of physical function and exercise tolerance in older adults: reproducibility and comparability of five measures. Aging (Milano). 2000 Aug;12(4):274-80."
                                    },
                                    {
                                        "ReferencePMID": "15130902",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Tubach F, Ravaud P, Baron G, Falissard B, Logeart I, Bellamy N, Bombardier C, Felson D, Hochberg M, van der Heijde D, Dougados M. Evaluation of clinically relevant states in patient reported outcomes in knee and hip osteoarthritis: the patient acceptable symptom state. Ann Rheum Dis. 2005 Jan;64(1):34-7. Epub 2004 May 6."
                                    },
                                    {
                                        "ReferencePMID": "8437031",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Washburn RA, Smith KW, Jette AM, Janney CA. The Physical Activity Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol. 1993 Feb;46(2):153-62."
                                    }
                                ]
                            }
                        },
                        "IPDSharingStatementModule": {
                            "IPDSharing": "No"
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000020370",
                                        "ConditionMeshTerm": "Osteoarthritis, Knee"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000010003",
                                        "ConditionAncestorTerm": "Osteoarthritis"
                                    },
                                    {
                                        "ConditionAncestorId": "D000001168",
                                        "ConditionAncestorTerm": "Arthritis"
                                    },
                                    {
                                        "ConditionAncestorId": "D000007592",
                                        "ConditionAncestorTerm": "Joint Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009140",
                                        "ConditionAncestorTerm": "Musculoskeletal Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000012216",
                                        "ConditionAncestorTerm": "Rheumatic Diseases"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M12078",
                                        "ConditionBrowseLeafName": "Osteoarthritis",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M21321",
                                        "ConditionBrowseLeafName": "Osteoarthritis, Knee",
                                        "ConditionBrowseLeafAsFound": "Osteoarthritis, Knee",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M3628",
                                        "ConditionBrowseLeafName": "Arthritis",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M9773",
                                        "ConditionBrowseLeafName": "Joint Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M11249",
                                        "ConditionBrowseLeafName": "Musculoskeletal Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M14197",
                                        "ConditionBrowseLeafName": "Rheumatic Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M5475",
                                        "ConditionBrowseLeafName": "Collagen Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC05",
                                        "ConditionBrowseBranchName": "Musculoskeletal Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC17",
                                        "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionMeshList": {
                                "InterventionMesh": [
                                    {
                                        "InterventionMeshId": "D000014221",
                                        "InterventionMeshTerm": "Triamcinolone"
                                    },
                                    {
                                        "InterventionMeshId": "D000014222",
                                        "InterventionMeshTerm": "Triamcinolone Acetonide"
                                    },
                                    {
                                        "InterventionMeshId": "C000005900",
                                        "InterventionMeshTerm": "Triamcinolone hexacetonide"
                                    },
                                    {
                                        "InterventionMeshId": "C000030262",
                                        "InterventionMeshTerm": "Triamcinolone diacetate"
                                    }
                                ]
                            },
                            "InterventionAncestorList": {
                                "InterventionAncestor": [
                                    {
                                        "InterventionAncestorId": "D000000893",
                                        "InterventionAncestorTerm": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000005938",
                                        "InterventionAncestorTerm": "Glucocorticoids"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006728",
                                        "InterventionAncestorTerm": "Hormones"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006730",
                                        "InterventionAncestorTerm": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045505",
                                        "InterventionAncestorTerm": "Physiological Effects of Drugs"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007166",
                                        "InterventionAncestorTerm": "Immunosuppressive Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007155",
                                        "InterventionAncestorTerm": "Immunologic Factors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000004791",
                                        "InterventionAncestorTerm": "Enzyme Inhibitors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045504",
                                        "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                                    }
                                ]
                            },
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafAsFound": "Deep",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M3369",
                                        "InterventionBrowseLeafName": "Anti-Inflammatory Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8199",
                                        "InterventionBrowseLeafName": "Glucocorticoids",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8941",
                                        "InterventionBrowseLeafName": "Hormones",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8940",
                                        "InterventionBrowseLeafName": "Hormone Antagonists",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9364",
                                        "InterventionBrowseLeafName": "Immunosuppressive Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9353",
                                        "InterventionBrowseLeafName": "Immunologic Factors",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 44,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT03290326",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "2017P000373"
                            },
                            "Organization": {
                                "OrgFullName": "Massachusetts General Hospital",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "tACS for Amyloid-β Reduction in Alzheimer's Disease",
                            "OfficialTitle": "Feasibility and Safety of a High-Frequency Transcranial Alternating Current Stimulation Intervention for Amyloid-β Reduction in Alzheimer's Disease"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "March 2022",
                            "OverallStatus": "Completed",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "November 27, 2017",
                                "StartDateType": "Actual"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "May 14, 2019",
                                "PrimaryCompletionDateType": "Actual"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "May 14, 2019",
                                "CompletionDateType": "Actual"
                            },
                            "StudyFirstSubmitDate": "September 15, 2017",
                            "StudyFirstSubmitQCDate": "September 19, 2017",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "September 21, 2017",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "ResultsFirstSubmitDate": "July 20, 2020",
                            "ResultsFirstSubmitQCDate": "March 1, 2022",
                            "ResultsFirstPostDateStruct": {
                                "ResultsFirstPostDate": "March 3, 2022",
                                "ResultsFirstPostDateType": "Actual"
                            },
                            "ResultsFirstPostedQCCommentsDateStruct": {
                                "ResultsFirstPostedQCCommentsDate": "August 10, 2020",
                                "ResultsFirstPostedQCCommentsDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "March 1, 2022",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "March 3, 2022",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Principal Investigator",
                                "ResponsiblePartyInvestigatorFullName": "Emiliano Santarnecchi",
                                "ResponsiblePartyInvestigatorTitle": "Associate Professor of Radiology",
                                "ResponsiblePartyInvestigatorAffiliation": "Massachusetts General Hospital"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Massachusetts General Hospital",
                                "LeadSponsorClass": "OTHER"
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "Yes",
                            "IsFDARegulatedDrug": "No",
                            "IsFDARegulatedDevice": "Yes",
                            "IsUnapprovedDevice": "Yes",
                            "IsUSExport": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "Alzheimer's Disease (AD) is characterized by amyloid-β (Aβ) plaque buildup and phosphorylated tau (p-tau) in the brain, as well as widespread neurodegeneration. The evidence suggests that both amyloid and tau play a critical role in AD and interventions that reliably and safely decrease the intracerebral burden of amyloid or tau could potentially be of marked clinical importance. Currently, therapeutic options are very limited and while there are pharmacologic interventions that transiently improve cognitive function, there are no treatments that alter disease progression. The current study seeks to use a novel therapeutic intervention that uses noninvasive brain stimulation to target amyloid in the brain. The investigators anticipate this will decrease the amyloid levels in the brain, as evidence by Positron Emission Tomography (PET) imaging.",
                            "DetailedDescription": "Alzheimer's Disease (AD) is characterized by amyloid-β (Aβ) plaque buildup and phosphorylated tau (p-tau) in the brain, as well as widespread neurodegeneration. There is no current treatments that alter disease progression.\n\nInvestigators will recruit 20 individuals with AD with evidence of amyloid placques in the brain through Positron Emission Tomography (PET) imaging. Investigators will use a novel approach, transcranial alternating current stimulation (tACS), to target the region of maximum amyloid burden in the brain. All participants will receive tACS. Each individual's participation in the study will consist of approximately 16 visits: 3 days for screening/baseline procedures as described below, 10 tACS study visits, and 3 days for follow-up assessments. Subjects will undergo baseline cognitive assessment, structural and functional MRI characterization, and resting-state EEG measurement. Additionally, patients will undergo a tACS-EEG recording session to assess brain plasticity levels and identify markers of response to stimulation. All subjects will then undergo 10 1-hour sessions of gamma-frequency (40 Hz) tACS, targeted to the region of maximal tracer uptake on the amyloid PET study. Subjects will take a standardized adverse effect questionnaire before and after each session and complete a short cognitive test after each session to demonstrate safety and tolerability. At the end of the 10 sessions, subjects will then repeat the baseline assessments, followed by repeat amyloid PET imaging to assess for changes in amyloid burden.\n\nInvestigators anticipate that targeting the region of amyloid burden in the brain with tACS will reduce the amyloid burden as evidence by the follow up PET imaging and show improvement on electrophysiological measures of brain function and on cognitive testing. If our prediction is correct, this will will provide a critical first step in the development of a novel intervention to prevent and treat AD."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Alzheimer Disease"
                                ]
                            },
                            "KeywordList": {
                                "Keyword": [
                                    "Alzheimer",
                                    "Memory Problems"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Not Applicable"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "N/A",
                                "DesignInterventionModel": "Single Group Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "None (Open Label)"
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "17",
                                "EnrollmentType": "Actual"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "tACS",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "Transcranial alternating current stimulation (tACS) tuned at the frequency of 40Hz (gamma frequency) will be applied for 1 hour in 10 sessions on consecutive weekdays. The tACS intervention (10 sessions) will be preceded and followed by amyloid PET imaging as well as a clinical/cognitive evaluation. The assessment of adverse effects will constitute a Primary outcome measure. Changes in amyloid load in the stimulated brain region will be evaluated and constitute a secondary outcome of the study. Clinically relevant changes in cognitive and clinical scores will be also evaluated as secondary outcomes. Stimulation will be also preceded and followed by electroencephalography (EEG) recording aimed at assessing changes in spectral power in the gamma band.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: Transcranial Alternating Current Stimulation (tACS)"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "Transcranial Alternating Current Stimulation (tACS)",
                                        "InterventionDescription": "tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "tACS"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Change in Amyloid Burden",
                                        "PrimaryOutcomeDescription": "Changes in the amyloid load observed via PET imaging will be evaluated by comparing PET data acquired before and after the 10 tACS sessions. The metric used is SUVR, a measure of the amount of proteins in the brain identified at the PET exam. We will calculate the difference between pre and post tACS SUVR (dSUVR) for the entire brain and report the average value (and standard deviation) for the entire group of patients. A negative value express a decrease in the amount of proteins in the brain post tACS intervention. It must be considered that dSUVR values refer to the entire brain, however patients were treated according to personalized tACS montages targeting patient-specific regions mostly affected by the pathology. This might have led to slightly different changes in SUVR in different part of the brain across participants. Also, as per standard procedures, results are presented at group level, i.e. without considering individual differences in longitudinal amyloid load changes.",
                                        "PrimaryOutcomeTimeFrame": "Up to six weeks"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "Change in EEG Gamma-band Spectral Power",
                                        "SecondaryOutcomeDescription": "EEG power spectral densities (PSD) before and after the tACS intervention were evaluated, specifically absolute and relative power density values (μV2/Hz) were calculated within the gamma band (35-45Hz). Changes in the spectral power are reported in term of percentage of changes in relative spectral power from Pre to Post tACS intervention.",
                                        "SecondaryOutcomeTimeFrame": "Up to six weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Change in Adas-Cog Score",
                                        "SecondaryOutcomeDescription": "Change in Adas-Cog score will be reported, to document a potential clinical benefit of tACS. The scale ranges from a total score of 0-70 with higher score indicating greater cognitive impairment.",
                                        "SecondaryOutcomeTimeFrame": "Up to six weeks"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nClinical Diagnosis of mild AD defined by: Clinical Dementia Rating (CDR) = 0.5-1, Mini Mental State Examination (MMSE) >/= 20, Demonstration or history of memory impairments\nAmyloid positive PET imaging\nAt least 45 years old\nOn a stable dose of medications for memory loss including cholinesterase inhibitors (e.g. donepezil, rivastigmine or memantine) as defined as 6 consecutive weeks of treatment at an unchanging dose\nIntelligence Quotient (IQ) > 85 as determined by the Wechsler Test of Adult Reading (WTAR) and no history of intellectual disability\n\nExclusion Criteria:\n\nCurrent history of poorly controlled migraines including chronic medication for migraine prevention\nCurrent or past history of any neurological disorder other than dementia, such as epilepsy, stroke, progressive neurologic disease (e.g. multiple sclerosis) or intracranial brain lesions; and history of previous neurosurgery or head trauma that resulted in residual neurologic impairment.\nPast or current history of major depression, bipolar disorder or psychotic disorders, or any other major psychiatric condition.\n\nContraindication for undergoing MRI or receiving Transcranial Magnetic Stimulation (TMS) or tACS,\n\n• History of fainting spells of unknown or undetermined etiology that might constitute seizures.\n\nHistory of seizures, diagnosis of epilepsy, history of abnormal (epileptiform) EEG or immediate (1st degree relative) family history of epilepsy; with the exception of a single seizure of benign etiology (e.g. febrile seizure) in the judgment of the investigator.\nChronic (particularly) uncontrolled medical conditions that may cause a medical emergency in case of a provoked seizure (cardiac malformation, cardiac dysrhythmia, asthma, etc.).\nMetal implants (excluding dental fillings) or devices such as pacemaker, medication pump, nerve stimulator, Transcutaneous Electrical Nerve Stimulator (TENS) unit, ventriculo-peritoneal shunt, cochlear implant, unless cleared by the study MD.\nSubstance abuse or dependence within the past six months.\nMedications will be reviewed by the responsible MD and a decision about inclusion will be made based on the following: The patient's past medical history, drug dose, history of recent medication changes or duration of treatment, and combination of Central Nervous System (CNS) active drugs.\nAll female participants that are pre-menopausal will be required to have a pregnancy test; any participant who is pregnant will not be enrolled in the study.\nBMI > 40 kg/m2. We will limit the BMI to <40 kg/m2 because of weight limits of the scanner bed and width limits of the MRI.\nSubjects who, in the investigator's opinion, might not be suitable for the study\nA hair style or head dress that prevents electrode contact with the scalp or would interfere with the stimulation (for example: thick braids, hair weave, afro, wig)",
                            "HealthyVolunteers": "No",
                            "Gender": "All",
                            "MinimumAge": "45 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Emiliano Santarnecchi",
                                        "OverallOfficialAffiliation": "Massachusetts General Hospital",
                                        "OverallOfficialRole": "Principal Investigator"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "Beth Israel Deaconess Medical Center",
                                        "LocationCity": "Boston",
                                        "LocationState": "Massachusetts",
                                        "LocationZip": "02215",
                                        "LocationCountry": "United States"
                                    }
                                ]
                            }
                        },
                        "ReferencesModule": {
                            "ReferenceList": {
                                "Reference": [
                                    {
                                        "ReferencePMID": "34930421",
                                        "ReferenceType": "derived",
                                        "ReferenceCitation": "Sprugnoli G, Munsch F, Cappon D, Paciorek R, Macone J, Connor A, El Fakhri G, Salvador R, Ruffini G, Donohoe K, Shafi MM, Press D, Alsop DC, Pascual Leone A, Santarnecchi E. Impact of multisession 40Hz tACS on hippocampal perfusion in patients with Alzheimer's disease. Alzheimers Res Ther. 2021 Dec 20;13(1):203. doi: 10.1186/s13195-021-00922-4."
                                    }
                                ]
                            }
                        }
                    },
                    "ResultsSection": {
                        "ParticipantFlowModule": {
                            "FlowPreAssignmentDetails": "During the screening and baseline procedures 7 participants screened out for the following reasons: 4 participants screened out on cognitive testing measures, being either too advanced or too mild, 2 participants did not meet 6 weeks stable medication inclusion criteria, and 1 participant screened out due to incidental findings on the baseline MRI",
                            "FlowRecruitmentDetails": "Of 17 enrolled participants, 10 met inclusion criteria and underwent transcranial alternating current stimulation (tACS)",
                            "FlowGroupList": {
                                "FlowGroup": [
                                    {
                                        "FlowGroupId": "FG000",
                                        "FlowGroupTitle": "tACS",
                                        "FlowGroupDescription": "Transcranial alternating current stimulation (tACS) tuned at the frequency of 40Hz (gamma frequency) was applied for 1 hour in 10 sessions on consecutive weekdays."
                                    }
                                ]
                            },
                            "FlowPeriodList": {
                                "FlowPeriod": [
                                    {
                                        "FlowPeriodTitle": "Overall Study",
                                        "FlowMilestoneList": {
                                            "FlowMilestone": [
                                                {
                                                    "FlowMilestoneType": "STARTED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "10"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowMilestoneType": "COMPLETED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "10"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowMilestoneType": "NOT COMPLETED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "0"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "BaselineCharacteristicsModule": {
                            "BaselineGroupList": {
                                "BaselineGroup": [
                                    {
                                        "BaselineGroupId": "BG000",
                                        "BaselineGroupTitle": "tACS",
                                        "BaselineGroupDescription": "Transcranial alternating current stimulation (tACS) tuned at the frequency of 40Hz (gamma frequency) was applied for 1 hour in 10 sessions on consecutive weekdays."
                                    }
                                ]
                            },
                            "BaselineDenomList": {
                                "BaselineDenom": [
                                    {
                                        "BaselineDenomUnits": "Participants",
                                        "BaselineDenomCountList": {
                                            "BaselineDenomCount": [
                                                {
                                                    "BaselineDenomCountGroupId": "BG000",
                                                    "BaselineDenomCountValue": "10"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "BaselineMeasureList": {
                                "BaselineMeasure": [
                                    {
                                        "BaselineMeasureTitle": "Age, Customized",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineClassTitle": "Age",
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineCategoryTitle": "55",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "1"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "57",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "1"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "63",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "1"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "75",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "1"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "76",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "2"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "78",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "2"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "79",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "1"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "83",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "1"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Sex: Female, Male",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineCategoryTitle": "Female",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "4"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Male",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "6"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Race (NIH/OMB)",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineCategoryTitle": "American Indian or Alaska Native",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Asian",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Native Hawaiian or Other Pacific Islander",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Black or African American",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "White",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "10"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "More than one race",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Unknown or Not Reported",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Region of Enrollment",
                                        "BaselineMeasureParamType": "Number",
                                        "BaselineMeasureUnitOfMeasure": "participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineClassTitle": "United States",
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "10"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomeMeasuresModule": {
                            "OutcomeMeasureList": {
                                "OutcomeMeasure": [
                                    {
                                        "OutcomeMeasureType": "Primary",
                                        "OutcomeMeasureTitle": "Change in Amyloid Burden",
                                        "OutcomeMeasureDescription": "Changes in the amyloid load observed via PET imaging will be evaluated by comparing PET data acquired before and after the 10 tACS sessions. The metric used is SUVR, a measure of the amount of proteins in the brain identified at the PET exam. We will calculate the difference between pre and post tACS SUVR (dSUVR) for the entire brain and report the average value (and standard deviation) for the entire group of patients. A negative value express a decrease in the amount of proteins in the brain post tACS intervention. It must be considered that dSUVR values refer to the entire brain, however patients were treated according to personalized tACS montages targeting patient-specific regions mostly affected by the pathology. This might have led to slightly different changes in SUVR in different part of the brain across participants. Also, as per standard procedures, results are presented at group level, i.e. without considering individual differences in longitudinal amyloid load changes.",
                                        "OutcomeMeasurePopulationDescription": "Mild to Moderate Alzheimer's Disease patients",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Mean",
                                        "OutcomeMeasureDispersionType": "Standard Deviation",
                                        "OutcomeMeasureUnitOfMeasure": "dSUVR",
                                        "OutcomeMeasureTimeFrame": "Up to six weeks",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "tACS",
                                                    "OutcomeGroupDescription": "Transcranial alternating current stimulation (tACS) tuned at the frequency of 40Hz (gamma frequency) will be applied for 1 hour in 10 sessions on consecutive weekdays. The tACS intervention (10 sessions) will be preceded and followed by amyloid PET imaging as well as a clinical/cognitive evaluation. The assessment of adverse effects will constitute a Primary outcome measure. Changes in amyloid load in the stimulated brain region will be evaluated and constitute a secondary outcome of the study. Clinically relevant changes in cognitive and clinical scores will be also evaluated as secondary outcomes. Stimulation will be also preceded and followed by electroencephalography (EEG) recording aimed at assessing changes in spectral power in the gamma band.\n\ntACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "10"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "-1.55",
                                                                            "OutcomeMeasurementSpread": "0.9"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Secondary",
                                        "OutcomeMeasureTitle": "Change in EEG Gamma-band Spectral Power",
                                        "OutcomeMeasureDescription": "EEG power spectral densities (PSD) before and after the tACS intervention were evaluated, specifically absolute and relative power density values (μV2/Hz) were calculated within the gamma band (35-45Hz). Changes in the spectral power are reported in term of percentage of changes in relative spectral power from Pre to Post tACS intervention.",
                                        "OutcomeMeasurePopulationDescription": "The assessment of the effect of 40 Hz tACS on EEG gamma-band spectral power.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Mean",
                                        "OutcomeMeasureDispersionType": "Standard Deviation",
                                        "OutcomeMeasureUnitOfMeasure": "% difference in spectral power (μV2/Hz)",
                                        "OutcomeMeasureTimeFrame": "Up to six weeks",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "tACS 40Hz",
                                                    "OutcomeGroupDescription": "Transcranial alternating current stimulation (tACS) tuned at the frequency of 40Hz (gamma frequency) will be applied for 1 hour in 10 sessions on consecutive weekdays. The tACS intervention (10 sessions) will be preceded and followed by amyloid, microglia and tau PET imaging as well as a clinical/cognitive evaluation. The assessment of the effect of stimulation on microglia activation, amyloid deposition and tau deposition will constitute a primary outcome measure. Assessment of adverse effects will be also evaluated as a secondary outcome. The effect of brain stimulation on brain connectivity will be assessed by EEG and cognitive function.\n\nTranscranial Alternating Current Stimulation (tACS): tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "10"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "23.5",
                                                                            "OutcomeMeasurementSpread": "13.4"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeAnalysisList": {
                                            "OutcomeAnalysis": [
                                                {
                                                    "OutcomeAnalysisGroupIdList": {
                                                        "OutcomeAnalysisGroupId": [
                                                            "OG000"
                                                        ]
                                                    },
                                                    "OutcomeAnalysisGroupDescription": "One-way ANOVA was conducted to compare the effect of 40Hz tACS on EEG gamma-band spectral power. Power changes were expressed as percentage relative power variations, accordingly with the event-related synchronization/desynchronization (ERS/ERD) index.",
                                                    "OutcomeAnalysisNonInferiorityType": "Other",
                                                    "OutcomeAnalysisPValue": "< 0.01",
                                                    "OutcomeAnalysisStatisticalMethod": "ANOVA"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OutcomeMeasureType": "Secondary",
                                        "OutcomeMeasureTitle": "Change in Adas-Cog Score",
                                        "OutcomeMeasureDescription": "Change in Adas-Cog score will be reported, to document a potential clinical benefit of tACS. The scale ranges from a total score of 0-70 with higher score indicating greater cognitive impairment.",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Mean",
                                        "OutcomeMeasureDispersionType": "Standard Deviation",
                                        "OutcomeMeasureUnitOfMeasure": "Scores on a scale",
                                        "OutcomeMeasureTimeFrame": "Up to six weeks",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "tACS",
                                                    "OutcomeGroupDescription": "Transcranial alternating current stimulation (tACS) tuned at the frequency of 40Hz (gamma frequency) will be applied for 1 hour in 10 sessions on consecutive weekdays."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "10"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "-0.97",
                                                                            "OutcomeMeasurementSpread": "3.88"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "AdverseEventsModule": {
                            "EventsFrequencyThreshold": "0",
                            "EventsTimeFrame": "5 months",
                            "EventGroupList": {
                                "EventGroup": [
                                    {
                                        "EventGroupId": "EG000",
                                        "EventGroupTitle": "tACS",
                                        "EventGroupDescription": "Transcranial alternating current stimulation (tACS) tuned at the frequency of 40Hz (gamma frequency) will be applied for 1 hour in 10 sessions on consecutive weekdays.",
                                        "EventGroupDeathsNumAffected": "0",
                                        "EventGroupDeathsNumAtRisk": "10",
                                        "EventGroupSeriousNumAffected": "0",
                                        "EventGroupSeriousNumAtRisk": "10",
                                        "EventGroupOtherNumAffected": "8",
                                        "EventGroupOtherNumAtRisk": "10"
                                    }
                                ]
                            },
                            "OtherEventList": {
                                "OtherEvent": [
                                    {
                                        "OtherEventTerm": "Headache",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "10"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Scalp Pain",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "10"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Neck Pain",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventNotes": "related to TMS positioning",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "10"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Skin Irritation",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumAffected": "5",
                                                    "OtherEventStatsNumAtRisk": "10"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Sensations under electrodes",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventNotes": "tingling, burning, itching",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumAffected": "8",
                                                    "OtherEventStatsNumAtRisk": "10"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Visual Changes",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventNotes": "flashing lights in peripheral vision",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumAffected": "6",
                                                    "OtherEventStatsNumAtRisk": "10"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Nervousness",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventNotes": "related to cognitive testing",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumAffected": "3",
                                                    "OtherEventStatsNumAtRisk": "10"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Difficulty concentrating",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "10"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Hand tingling",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "10"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Eye pain",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventAssessmentType": "Systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "10"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "MoreInfoModule": {
                            "CertainAgreement": {
                                "AgreementPISponsorEmployee": "Yes"
                            },
                            "PointOfContact": {
                                "PointOfContactTitle": "Principal Investigator - Emiliano Santarnecchi",
                                "PointOfContactOrganization": "BIDMC",
                                "PointOfContactEMail": "esantarn@bidmc.harvard.edu",
                                "PointOfContactPhone": "617-667-0326"
                            }
                        }
                    },
                    "DocumentSection": {
                        "LargeDocumentModule": {
                            "LargeDocList": {
                                "LargeDoc": [
                                    {
                                        "LargeDocTypeAbbrev": "Prot_SAP",
                                        "LargeDocHasProtocol": "Yes",
                                        "LargeDocHasSAP": "Yes",
                                        "LargeDocHasICF": "No",
                                        "LargeDocLabel": "Study Protocol and Statistical Analysis Plan",
                                        "LargeDocDate": "May 15, 2018",
                                        "LargeDocUploadDate": "05/05/2020 16:58",
                                        "LargeDocFilename": "Prot_SAP_000.pdf"
                                    }
                                ]
                            }
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022",
                            "SubmissionTracking": {}
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000000544",
                                        "ConditionMeshTerm": "Alzheimer Disease"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000003704",
                                        "ConditionAncestorTerm": "Dementia"
                                    },
                                    {
                                        "ConditionAncestorId": "D000001927",
                                        "ConditionAncestorTerm": "Brain Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000002493",
                                        "ConditionAncestorTerm": "Central Nervous System Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009422",
                                        "ConditionAncestorTerm": "Nervous System Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000024801",
                                        "ConditionAncestorTerm": "Tauopathies"
                                    },
                                    {
                                        "ConditionAncestorId": "D000019636",
                                        "ConditionAncestorTerm": "Neurodegenerative Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000019965",
                                        "ConditionAncestorTerm": "Neurocognitive Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000001523",
                                        "ConditionAncestorTerm": "Mental Disorders"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M3037",
                                        "ConditionBrowseLeafName": "Alzheimer Disease",
                                        "ConditionBrowseLeafAsFound": "Alzheimer's Disease",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M3173",
                                        "ConditionBrowseLeafName": "Amyloidosis",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M6056",
                                        "ConditionBrowseLeafName": "Dementia",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M4356",
                                        "ConditionBrowseLeafName": "Brain Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M4894",
                                        "ConditionBrowseLeafName": "Central Nervous System Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M22155",
                                        "ConditionBrowseLeafName": "Tauopathies",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M20711",
                                        "ConditionBrowseLeafName": "Neurodegenerative Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M20989",
                                        "ConditionBrowseLeafName": "Neurocognitive Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M3967",
                                        "ConditionBrowseLeafName": "Mental Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M13625",
                                        "ConditionBrowseLeafName": "Psychotic Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "T2192",
                                        "ConditionBrowseLeafName": "Familial Alzheimer Disease",
                                        "ConditionBrowseLeafAsFound": "Alzheimer's Disease",
                                        "ConditionBrowseLeafRelevance": "high"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC10",
                                        "ConditionBrowseBranchName": "Nervous System Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BXM",
                                        "ConditionBrowseBranchName": "Behaviors and Mental Disorders"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC18",
                                        "ConditionBrowseBranchName": "Nutritional and Metabolic Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "Rare",
                                        "ConditionBrowseBranchName": "Rare Diseases"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 45,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT04658836",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "TACCSF"
                            },
                            "Organization": {
                                "OrgFullName": "Medical University of Vienna",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Triamcinolone Levels in Cochlear Perilymph, Lateral Canal and CSF",
                            "OfficialTitle": "Triamcinolone Acetonide Levels in Cochlear Perilymph, Lateral Canal and CSF in Patients With Vestibular Schwannomas"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "December 2020",
                            "OverallStatus": "Recruiting",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "February 1, 2020",
                                "StartDateType": "Actual"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "December 31, 2022",
                                "PrimaryCompletionDateType": "Anticipated"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "March 31, 2023",
                                "CompletionDateType": "Anticipated"
                            },
                            "StudyFirstSubmitDate": "June 23, 2020",
                            "StudyFirstSubmitQCDate": "December 7, 2020",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "December 9, 2020",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "December 7, 2020",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "December 9, 2020",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Principal Investigator",
                                "ResponsiblePartyInvestigatorFullName": "Christoph Arnoldner",
                                "ResponsiblePartyInvestigatorTitle": "Principal Investigator",
                                "ResponsiblePartyInvestigatorAffiliation": "Medical University of Vienna"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Medical University of Vienna",
                                "LeadSponsorClass": "OTHER"
                            }
                        },
                        "OversightModule": {
                            "IsFDARegulatedDrug": "No",
                            "IsFDARegulatedDevice": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "Patients undergoing surgery of a vestibular schwannoma will be included in the study. Patients will receive triamcinolone acetonide 24h before surgery. During translabyrinthine surgery cochlear perilymph, perilymph from the semicircular canal and cerebrospinal fluid will be taken and analyzed for triamcinolone content. In patients undergoing middle fossa or retrosigmoid resection only cerebrospinal fluid will be taken and analyzed for triamcinolone acetonide level.",
                            "DetailedDescription": "Patients between 18 and 90 years undergoing surgery of a vestibular schwannoma will be included in the study. Patients will be offered an application of triamcinolone acetonide intratympanically on the day before surgery.\n\nDuring surgery samples will be taken to define how much triamcinolone acetonide enters into the perilymphatic fluid, the perilymph of the semicircular canals and CSF.\n\nPatients undergoing translabyrinthine surgery will undergoing labyrinthectomy during which samples of the semicircular canal can be taken. During translabyrinthine surgery nerve monitoring will be carried out using an intracochlear electrode. Before inserting the electrode perilymph of the cochlea can be taken. Immediately after opening the dura cerebrospinal fluid will be taken. Patients undergoing middle fossa or retrosigmoid resection of the vestibular schwannoma will not undergo sampling of the perilymph. In these patients cerebrospinal fluid will be taken to determine triamcinolone acetonide levels."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Vestibular Schwannoma"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Phase 1"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "N/A",
                                "DesignInterventionModel": "Single Group Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "None (Open Label)"
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "60",
                                "EnrollmentType": "Anticipated"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "Triamcinolone application",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "Patients will recieve intratympanic triamcinolone acetonide 24h before vestibular schwannoma surgery",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: Triamcinolone Acetonide 40mg/mL"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "Triamcinolone Acetonide 40mg/mL",
                                        "InterventionDescription": "Intratympanic application of triamcinolone acetonide",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Triamcinolone application"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Triamcinolone acetonide level",
                                        "PrimaryOutcomeDescription": "Drug level",
                                        "PrimaryOutcomeTimeFrame": "one day"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nPatients between 18 and 90 years undergoing a surgery of the cerebellopontine angle due to vestibular schwannoma and who are willing to participate in the study\n\nExclusion Criteria:\n\nPatients younger than 18 years Patients who receive cortison regularly or receive cortison i.v. or p.o. preoperatively Patients with contraindications against the administration of VolonâA",
                            "HealthyVolunteers": "No",
                            "Gender": "All",
                            "MinimumAge": "18 Years",
                            "MaximumAge": "90 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "CentralContactList": {
                                "CentralContact": [
                                    {
                                        "CentralContactName": "Valerie Dahm, MD",
                                        "CentralContactRole": "Contact",
                                        "CentralContactPhone": "+43/1/40400/33300",
                                        "CentralContactEMail": "valerie.dahm@meduniwien.ac.at"
                                    }
                                ]
                            },
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Christoph Arnoldner",
                                        "OverallOfficialAffiliation": "Medical University of Vienna, Otorhinolaryngology, Head and Neck Surgery",
                                        "OverallOfficialRole": "Principal Investigator"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "Medical University of Vienna (AKH)",
                                        "LocationStatus": "Recruiting",
                                        "LocationCity": "Vienna",
                                        "LocationZip": "1090",
                                        "LocationCountry": "Austria",
                                        "LocationContactList": {
                                            "LocationContact": [
                                                {
                                                    "LocationContactName": "Valerie Dahm, MD",
                                                    "LocationContactRole": "Contact",
                                                    "LocationContactPhone": "0043/1/40400",
                                                    "LocationContactPhoneExt": "33300",
                                                    "LocationContactEMail": "valerie.dahm@meduniwien.ac.at"
                                                },
                                                {
                                                    "LocationContactName": "Christoph Arnoldner, Prof.",
                                                    "LocationContactRole": "Principal Investigator"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "IPDSharingStatementModule": {
                            "IPDSharing": "No"
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000009442",
                                        "ConditionMeshTerm": "Neurilemmoma"
                                    },
                                    {
                                        "ConditionMeshId": "D000009464",
                                        "ConditionMeshTerm": "Neuroma, Acoustic"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000018358",
                                        "ConditionAncestorTerm": "Neuroendocrine Tumors"
                                    },
                                    {
                                        "ConditionAncestorId": "D000017599",
                                        "ConditionAncestorTerm": "Neuroectodermal Tumors"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009373",
                                        "ConditionAncestorTerm": "Neoplasms, Germ Cell and Embryonal"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009370",
                                        "ConditionAncestorTerm": "Neoplasms by Histologic Type"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009369",
                                        "ConditionAncestorTerm": "Neoplasms"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009463",
                                        "ConditionAncestorTerm": "Neuroma"
                                    },
                                    {
                                        "ConditionAncestorId": "D000018317",
                                        "ConditionAncestorTerm": "Nerve Sheath Neoplasms"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009380",
                                        "ConditionAncestorTerm": "Neoplasms, Nerve Tissue"
                                    },
                                    {
                                        "ConditionAncestorId": "D000003390",
                                        "ConditionAncestorTerm": "Cranial Nerve Neoplasms"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009423",
                                        "ConditionAncestorTerm": "Nervous System Neoplasms"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009371",
                                        "ConditionAncestorTerm": "Neoplasms by Site"
                                    },
                                    {
                                        "ConditionAncestorId": "D000010524",
                                        "ConditionAncestorTerm": "Peripheral Nervous System Neoplasms"
                                    },
                                    {
                                        "ConditionAncestorId": "D000000160",
                                        "ConditionAncestorTerm": "Vestibulocochlear Nerve Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000012181",
                                        "ConditionAncestorTerm": "Retrocochlear Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000004427",
                                        "ConditionAncestorTerm": "Ear Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000010038",
                                        "ConditionAncestorTerm": "Otorhinolaryngologic Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000010039",
                                        "ConditionAncestorTerm": "Otorhinolaryngologic Neoplasms"
                                    },
                                    {
                                        "ConditionAncestorId": "D000003389",
                                        "ConditionAncestorTerm": "Cranial Nerve Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009422",
                                        "ConditionAncestorTerm": "Nervous System Diseases"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M11538",
                                        "ConditionBrowseLeafName": "Neurilemmoma",
                                        "ConditionBrowseLeafAsFound": "Schwannoma",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M11559",
                                        "ConditionBrowseLeafName": "Neuroma, Acoustic",
                                        "ConditionBrowseLeafAsFound": "Vestibular Schwannoma",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M11558",
                                        "ConditionBrowseLeafName": "Neuroma",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M19648",
                                        "ConditionBrowseLeafName": "Neuroendocrine Tumors",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M18997",
                                        "ConditionBrowseLeafName": "Neuroectodermal Tumors",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M19540",
                                        "ConditionBrowseLeafName": "Neuroectodermal Tumors, Primitive",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M11470",
                                        "ConditionBrowseLeafName": "Neoplasms, Germ Cell and Embryonal",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M11467",
                                        "ConditionBrowseLeafName": "Neoplasms by Histologic Type",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M19614",
                                        "ConditionBrowseLeafName": "Nerve Sheath Neoplasms",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M11477",
                                        "ConditionBrowseLeafName": "Neoplasms, Nerve Tissue",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M11519",
                                        "ConditionBrowseLeafName": "Nervous System Neoplasms",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M12585",
                                        "ConditionBrowseLeafName": "Peripheral Nervous System Neoplasms",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M2671",
                                        "ConditionBrowseLeafName": "Vestibulocochlear Nerve Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M14168",
                                        "ConditionBrowseLeafName": "Retrocochlear Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M6753",
                                        "ConditionBrowseLeafName": "Ear Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M12113",
                                        "ConditionBrowseLeafName": "Otorhinolaryngologic Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M12114",
                                        "ConditionBrowseLeafName": "Otorhinolaryngologic Neoplasms",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M5757",
                                        "ConditionBrowseLeafName": "Cranial Nerve Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "T5139",
                                        "ConditionBrowseLeafName": "Schwannoma",
                                        "ConditionBrowseLeafAsFound": "Schwannoma",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "T107",
                                        "ConditionBrowseLeafName": "Acoustic Neuroma",
                                        "ConditionBrowseLeafAsFound": "Vestibular Schwannoma",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "T4091",
                                        "ConditionBrowseLeafName": "Neuroendocrine Tumor",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "T4092",
                                        "ConditionBrowseLeafName": "Neuroepithelioma",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC04",
                                        "ConditionBrowseBranchName": "Neoplasms"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC09",
                                        "ConditionBrowseBranchName": "Ear, Nose, and Throat Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC10",
                                        "ConditionBrowseBranchName": "Nervous System Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "Rare",
                                        "ConditionBrowseBranchName": "Rare Diseases"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionMeshList": {
                                "InterventionMesh": [
                                    {
                                        "InterventionMeshId": "D000014221",
                                        "InterventionMeshTerm": "Triamcinolone"
                                    },
                                    {
                                        "InterventionMeshId": "D000014222",
                                        "InterventionMeshTerm": "Triamcinolone Acetonide"
                                    },
                                    {
                                        "InterventionMeshId": "C000005900",
                                        "InterventionMeshTerm": "Triamcinolone hexacetonide"
                                    },
                                    {
                                        "InterventionMeshId": "C000030262",
                                        "InterventionMeshTerm": "Triamcinolone diacetate"
                                    }
                                ]
                            },
                            "InterventionAncestorList": {
                                "InterventionAncestor": [
                                    {
                                        "InterventionAncestorId": "D000000893",
                                        "InterventionAncestorTerm": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000005938",
                                        "InterventionAncestorTerm": "Glucocorticoids"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006728",
                                        "InterventionAncestorTerm": "Hormones"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006730",
                                        "InterventionAncestorTerm": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045505",
                                        "InterventionAncestorTerm": "Physiological Effects of Drugs"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007166",
                                        "InterventionAncestorTerm": "Immunosuppressive Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007155",
                                        "InterventionAncestorTerm": "Immunologic Factors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000004791",
                                        "InterventionAncestorTerm": "Enzyme Inhibitors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045504",
                                        "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                                    }
                                ]
                            },
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafAsFound": "Deep",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafAsFound": "Embryo",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M3369",
                                        "InterventionBrowseLeafName": "Anti-Inflammatory Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8199",
                                        "InterventionBrowseLeafName": "Glucocorticoids",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8941",
                                        "InterventionBrowseLeafName": "Hormones",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8940",
                                        "InterventionBrowseLeafName": "Hormone Antagonists",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9364",
                                        "InterventionBrowseLeafName": "Immunosuppressive Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9353",
                                        "InterventionBrowseLeafName": "Immunologic Factors",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 46,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT04783350",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "Pro00044646"
                            },
                            "Organization": {
                                "OrgFullName": "Hebrew SeniorLife",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Home-based Brain Stimulation for Memory",
                            "OfficialTitle": "Home-based Transcranial Alternating Current Stimulation (tACS) for Older Adults at Risk of Memory Decline",
                            "Acronym": "MemStim-home"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "March 2021",
                            "OverallStatus": "Recruiting",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "July 6, 2020",
                                "StartDateType": "Actual"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "December 6, 2022",
                                "PrimaryCompletionDateType": "Anticipated"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "December 6, 2022",
                                "CompletionDateType": "Anticipated"
                            },
                            "StudyFirstSubmitDate": "February 26, 2021",
                            "StudyFirstSubmitQCDate": "March 3, 2021",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "March 5, 2021",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "March 3, 2021",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "March 5, 2021",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Principal Investigator",
                                "ResponsiblePartyInvestigatorFullName": "Alvaro Pascual-Leone",
                                "ResponsiblePartyInvestigatorTitle": "Senior Scientist",
                                "ResponsiblePartyInvestigatorAffiliation": "Hebrew SeniorLife"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Hebrew SeniorLife",
                                "LeadSponsorClass": "OTHER"
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "No",
                            "IsFDARegulatedDrug": "No",
                            "IsFDARegulatedDevice": "Yes"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "The proposed project aims to systematically examine the feasibility of remote, caregiver-led tACS for older adults who are vulnerable to memory decline.",
                            "DetailedDescription": "This is a feasibility study, which will include older adult participants (Ps) with memory deficits together with willing and able administrators (As) to administer tACS to the participants. This study will include 20 older Ps and 20 As to assess the feasibility of deploying home-based tACS in larger clinical trials, and to prepare for the development and implementation of such trials. The proposed project will systematically examine the feasibility of remote, caregiver-led tACS for older adults who are vulnerable to memory decline. This study will provide data to support the safety and effectiveness of home-based tACS in this population and will lead to future research to increase access of tACS as a part of memory decline prevention and treatment for older adults who have more difficulty reaching a clinic for treatment due to disability or who live more remotely."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Alzheimer Disease",
                                    "Memory Loss"
                                ]
                            },
                            "KeywordList": {
                                "Keyword": [
                                    "alzheimer disease",
                                    "memory and cognition",
                                    "autobiographical memory",
                                    "transcranial alternating current stimulation (tACS)",
                                    "guided high-density electroencephalography (hdEEG)"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Not Applicable"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "N/A",
                                "DesignInterventionModel": "Single Group Assignment",
                                "DesignPrimaryPurpose": "Basic Science",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "None (Open Label)"
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "20",
                                "EnrollmentType": "Anticipated"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "Transcranial alternating current stimulation (tACS)",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "Participants (Ps) will undergo 20min of daily home-based tACS intervention at 40Hz over the left angular gyrus for 4 weeks by trained administrators (As) (phase 1). In case of cognitive and mental improvement participants will undergo further 10 weeks of 20 minutes session of tACS daily (phase 2). Additionally, those P/A pairs who completed the 14 weeks of home-based tACS intervention and express an interest in an open label extension may be enrolled in further 34 weeks of 20 minutes tACS sessions.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: Transcranial alternating current stimulation (tACS)"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "Transcranial alternating current stimulation (tACS)",
                                        "InterventionDescription": "tACS will be administered to the left angular gyrus at gamma frequency to improve cognitive functioning (MoCA score) and resting-state EEG signatures.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Transcranial alternating current stimulation (tACS)"
                                            ]
                                        },
                                        "InterventionOtherNameList": {
                                            "InterventionOtherName": [
                                                "non-invasive brain stimulation"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Clinical Evaluation and Cognitive Assessment",
                                        "PrimaryOutcomeDescription": "a trained clinician will administer the Montreal Cognitive Assessment (MOCA) to characterize cognitive status and the level of dementia",
                                        "PrimaryOutcomeTimeFrame": "48 weeks"
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "Electroencephalography (EEG) measures",
                                        "PrimaryOutcomeDescription": "High-density EEG (257 channels) will be recorded before and after the tACS intervention and changes in spatiotemporal dynamics in different frequency bands (theta, alpha, beta, gamma) will be assessed",
                                        "PrimaryOutcomeTimeFrame": "48 weeks"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nParticipants (Ps)\n\nwilling and capable to give informed consent for the participation in the study after it has been thoroughly explained\nable and willing to comply with all study requirements\nan informed consent form was signed\nable to read, write, and communicate in English\nable to identify an eligible administrator to participate with them in the study\n\nAdministrators (As)\n\nat least 21 years of age\nable to read, write, and communicate in English\nself-reported computer proficiency and willingness to learn how to use tACS as defined by \"yes\" answers to the questions \"Do you feel comfortable using a computer?\" and \"Are you willing to be the primary caregiver for a participant and learn how to administer tACS?\"\nstated availability during weekdays throughout the study period to administer tACS to the Ps\n\nExclusion Criteria:\n\nParticipants (Ps)\n\nmajor psychiatric co-morbidity including major depressive disorder, schizophrenia or psychosis\nblindness or other disabilities that prevent task performance\ncontraindications to tACS, as recorded on a standardized screening questionnaire, which include a reported seizure within the past two years, use of neuroactive drugs, self-reported presence of specific implanted medical devices (e.g., deep brain stimulator, medication infusion pump, cochlear implant, pacemaker, etc.)\nthe presence of any active dermatological condition, such as eczema, on the scalp a score of 18 or less on the Montreal Cognitive Assessment (MoCA) during the in-person screen\nan inability to understand study procedures following review of the Informed Consent form\nUnderstanding will be assessed by asking the participant to answer the following three questions: 1) What is the purpose of this study? 2) What are the risks of study involvement? 3) If you decide to participate, are you allowed to withdraw from the study at any time? Answers will be recorded by study personnel on the \"Assessment of Protocol Understanding\" form (see attached). Insufficient understanding will be defined by one or more incorrect answers, as determined at the discretion of the investigator\n\nAdministrators (As)\n\nmild cognitive impairment defined by a MoCA score ≤26 during the in-person screen\ninsufficient understanding of study procedures following review of the Informed Consent form\nUnderstanding will be assessed by asking the participant to answer the following three questions: 1) What is the purpose of this study? 2) What are the risks of study involvement? 3) If you decide to participate, are you allowed to withdraw from the study at any time? Answers will be recorded by study personnel on the \"Assessment of Protocol Understanding\" form (see attached). Insufficient understanding will be defined by one or more incorrect answers, as determined at the discretion of the investigator.\npoor eyesight, severe arthritis in the hands, pain, deformity or other condition that interferes with successful administration of tACS",
                            "HealthyVolunteers": "Accepts Healthy Volunteers",
                            "Gender": "All",
                            "MinimumAge": "55 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "CentralContactList": {
                                "CentralContact": [
                                    {
                                        "CentralContactName": "Alvaro Pascual-Leone, Dr.",
                                        "CentralContactRole": "Contact",
                                        "CentralContactPhone": "617-971-5372",
                                        "CentralContactEMail": "apleone@hsl.harvard.edu"
                                    },
                                    {
                                        "CentralContactName": "Lucie Bréchet, Dr.",
                                        "CentralContactRole": "Contact",
                                        "CentralContactPhone": "617-971-15349",
                                        "CentralContactEMail": "luciebrechet@hsl.harvard.edu"
                                    }
                                ]
                            },
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Alvaro Pascual-Leone, Dr.",
                                        "OverallOfficialAffiliation": "Hinda and Arthur Marcus Institute for Aging Research",
                                        "OverallOfficialRole": "Principal Investigator"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "Hinda and Arthur Marcus Institute for Aging Research",
                                        "LocationStatus": "Recruiting",
                                        "LocationCity": "Boston",
                                        "LocationState": "Massachusetts",
                                        "LocationZip": "02131",
                                        "LocationCountry": "United States",
                                        "LocationContactList": {
                                            "LocationContact": [
                                                {
                                                    "LocationContactName": "Alvaro Pascual-Leone, Dr.",
                                                    "LocationContactRole": "Contact",
                                                    "LocationContactPhone": "617-971-5372",
                                                    "LocationContactEMail": "apleone@hsl.harvard.edu"
                                                },
                                                {
                                                    "LocationContactName": "Lucie Bréchet, Dr.",
                                                    "LocationContactRole": "Contact",
                                                    "LocationContactPhone": "617-971-15349",
                                                    "LocationContactEMail": "luciebrechet@hsl.harvard.edu"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "ReferencesModule": {
                            "ReferenceList": {
                                "Reference": [
                                    {
                                        "ReferencePMID": "32240665",
                                        "ReferenceType": "background",
                                        "ReferenceCitation": "Strüber D, Herrmann CS. Modulation of gamma oscillations as a possible therapeutic tool for neuropsychiatric diseases: A review and perspective. Int J Psychophysiol. 2020 Jun;152:15-25. doi: 10.1016/j.ijpsycho.2020.03.003. Epub 2020 Mar 30. Review."
                                    },
                                    {
                                        "ReferencePMID": "28709880",
                                        "ReferenceType": "result",
                                        "ReferenceCitation": "Antal A, Alekseichuk I, Bikson M, Brockmöller J, Brunoni AR, Chen R, Cohen LG, Dowthwaite G, Ellrich J, Flöel A, Fregni F, George MS, Hamilton R, Haueisen J, Herrmann CS, Hummel FC, Lefaucheur JP, Liebetanz D, Loo CK, McCaig CD, Miniussi C, Miranda PC, Moliadze V, Nitsche MA, Nowak R, Padberg F, Pascual-Leone A, Poppendieck W, Priori A, Rossi S, Rossini PM, Rothwell J, Rueger MA, Ruffini G, Schellhorn K, Siebner HR, Ugawa Y, Wexler A, Ziemann U, Hallett M, Paulus W. Low intensity transcranial electric stimulation: Safety, ethical, legal regulatory and application guidelines. Clin Neurophysiol. 2017 Sep;128(9):1774-1809. doi: 10.1016/j.clinph.2017.06.001. Epub 2017 Jun 19. Review."
                                    },
                                    {
                                        "ReferencePMID": "31739167",
                                        "ReferenceType": "result",
                                        "ReferenceCitation": "Babiloni C, Blinowska K, Bonanni L, Cichocki A, De Haan W, Del Percio C, Dubois B, Escudero J, Fernández A, Frisoni G, Guntekin B, Hajos M, Hampel H, Ifeachor E, Kilborn K, Kumar S, Johnsen K, Johannsson M, Jeong J, LeBeau F, Lizio R, Lopes da Silva F, Maestú F, McGeown WJ, McKeith I, Moretti DV, Nobili F, Olichney J, Onofrj M, Palop JJ, Rowan M, Stocchi F, Struzik ZM, Tanila H, Teipel S, Taylor JP, Weiergräber M, Yener G, Young-Pearse T, Drinkenburg WH, Randall F. What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons. Neurobiol Aging. 2020 Jan;85:58-73. doi: 10.1016/j.neurobiolaging.2019.09.008. Epub 2019 Sep 19. Review."
                                    },
                                    {
                                        "ReferencePMID": "30720478",
                                        "ReferenceType": "result",
                                        "ReferenceCitation": "Buss SS, Fried PJ, Pascual-Leone A. Therapeutic noninvasive brain stimulation in Alzheimer's disease and related dementias. Curr Opin Neurol. 2019 Apr;32(2):292-304. doi: 10.1097/WCO.0000000000000669. Review."
                                    },
                                    {
                                        "ReferencePMID": "24345389",
                                        "ReferenceType": "result",
                                        "ReferenceCitation": "Ruffini G, Fox MD, Ripolles O, Miranda PC, Pascual-Leone A. Optimization of multifocal transcranial current stimulation for weighted cortical pattern targeting from realistic modeling of electric fields. Neuroimage. 2014 Apr 1;89:216-25. doi: 10.1016/j.neuroimage.2013.12.002. Epub 2013 Dec 15."
                                    },
                                    {
                                        "ReferencePMID": "30902640",
                                        "ReferenceType": "result",
                                        "ReferenceCitation": "Bréchet L, Brunet D, Birot G, Gruetter R, Michel CM, Jorge J. Capturing the spatiotemporal dynamics of self-generated, task-initiated thoughts with EEG and fMRI. Neuroimage. 2019 Jul 1;194:82-92. doi: 10.1016/j.neuroimage.2019.03.029. Epub 2019 Mar 19."
                                    }
                                ]
                            }
                        },
                        "IPDSharingStatementModule": {
                            "IPDSharing": "No"
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000000544",
                                        "ConditionMeshTerm": "Alzheimer Disease"
                                    },
                                    {
                                        "ConditionMeshId": "D000008569",
                                        "ConditionMeshTerm": "Memory Disorders"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000003704",
                                        "ConditionAncestorTerm": "Dementia"
                                    },
                                    {
                                        "ConditionAncestorId": "D000001927",
                                        "ConditionAncestorTerm": "Brain Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000002493",
                                        "ConditionAncestorTerm": "Central Nervous System Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009422",
                                        "ConditionAncestorTerm": "Nervous System Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000024801",
                                        "ConditionAncestorTerm": "Tauopathies"
                                    },
                                    {
                                        "ConditionAncestorId": "D000019636",
                                        "ConditionAncestorTerm": "Neurodegenerative Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000019965",
                                        "ConditionAncestorTerm": "Neurocognitive Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000001523",
                                        "ConditionAncestorTerm": "Mental Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000019954",
                                        "ConditionAncestorTerm": "Neurobehavioral Manifestations"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009461",
                                        "ConditionAncestorTerm": "Neurologic Manifestations"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M3037",
                                        "ConditionBrowseLeafName": "Alzheimer Disease",
                                        "ConditionBrowseLeafAsFound": "Alzheimer's Disease",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M3137",
                                        "ConditionBrowseLeafName": "Amnesia",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M10704",
                                        "ConditionBrowseLeafName": "Memory Disorders",
                                        "ConditionBrowseLeafAsFound": "Memory Loss",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M6056",
                                        "ConditionBrowseLeafName": "Dementia",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M4356",
                                        "ConditionBrowseLeafName": "Brain Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M4894",
                                        "ConditionBrowseLeafName": "Central Nervous System Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M22155",
                                        "ConditionBrowseLeafName": "Tauopathies",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M20711",
                                        "ConditionBrowseLeafName": "Neurodegenerative Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M20989",
                                        "ConditionBrowseLeafName": "Neurocognitive Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M3967",
                                        "ConditionBrowseLeafName": "Mental Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M13625",
                                        "ConditionBrowseLeafName": "Psychotic Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M20979",
                                        "ConditionBrowseLeafName": "Neurobehavioral Manifestations",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M11556",
                                        "ConditionBrowseLeafName": "Neurologic Manifestations",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "T2192",
                                        "ConditionBrowseLeafName": "Familial Alzheimer Disease",
                                        "ConditionBrowseLeafAsFound": "Alzheimer's Disease",
                                        "ConditionBrowseLeafRelevance": "high"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC10",
                                        "ConditionBrowseBranchName": "Nervous System Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BXM",
                                        "ConditionBrowseBranchName": "Behaviors and Mental Disorders"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC23",
                                        "ConditionBrowseBranchName": "Symptoms and General Pathology"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "Rare",
                                        "ConditionBrowseBranchName": "Rare Diseases"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 47,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT00484679",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "0609M91989"
                            },
                            "Organization": {
                                "OrgFullName": "University of Minnesota",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata",
                            "OfficialTitle": "Adrenal Function and Use of Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10) in Patients With Alopecia Areata"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "April 2017",
                            "OverallStatus": "Completed",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "May 2007"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "June 2009",
                                "PrimaryCompletionDateType": "Actual"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "March 2011",
                                "CompletionDateType": "Actual"
                            },
                            "StudyFirstSubmitDate": "June 8, 2007",
                            "StudyFirstSubmitQCDate": "June 8, 2007",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "June 11, 2007",
                                "StudyFirstPostDateType": "Estimate"
                            },
                            "ResultsFirstSubmitDate": "February 27, 2013",
                            "ResultsFirstSubmitQCDate": "May 20, 2014",
                            "ResultsFirstPostDateStruct": {
                                "ResultsFirstPostDate": "June 20, 2014",
                                "ResultsFirstPostDateType": "Estimate"
                            },
                            "LastUpdateSubmitDate": "May 30, 2018",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "June 29, 2018",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Sponsor"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "University of Minnesota",
                                "LeadSponsorClass": "OTHER"
                            },
                            "CollaboratorList": {
                                "Collaborator": [
                                    {
                                        "CollaboratorName": "National Alopecia Areata Foundation",
                                        "CollaboratorClass": "OTHER"
                                    }
                                ]
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "The purpose of the study is to see whether treating alopecia areata with injections of the corticosteroid, Triamcinolone acetonide 10mg/cc (Kenalog-10), has an impact on the adrenal glands.",
                            "DetailedDescription": "To determine the effects of intralesional Triamcinolone Acetonide 10mg/cc (Kenalog 10) use for the treatment of alopecia areata on adrenal function.\nTo evaluate the efficacy of intralesional corticosteroids (Kenalog-10)on hair regrowth in moderate to severe alopecia areata.\n\n18 subjects with moderate to severe alopecia areata were enrolled and 15 subjects completed all study visits.\n\nSubjects underwent intralesional triamcinolone acetonide (10mg/cc) (Kenalog-10) injections every 6 weeks for a period of 6 months in the General Clinical Research Center (GCRC). This period was followed by a 6 week, injection-free, safety follow-up visit. Adrenal function was assessed by utilization of the Low Dose Adrenocorticotropic Hormone Stimulation Test (ACTH) which measures adrenal gland production of cortisol after exogenously administered ACTH. Serum blood draws of 3 mL were done at baseline and 6-week intervals at the start of each scheduled appointment for intralesional treatment at approximately 0800 hours. Two blood draws were taken at time 0 and again 30 minutes after a 1 mcg bolus dose of synthetic ACTH (Cortrosyn).\n\nPatients underwent their scheduled course of intralesional corticosteroid (Kenalog-10) injections and other study data was collected, such as SALT scores and physician assessments of AA, during the time between blood draws."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Alopecia Areata"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Phase 2"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "N/A",
                                "DesignInterventionModel": "Single Group Assignment",
                                "DesignPrimaryPurpose": "Screening",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "None (Open Label)"
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "18",
                                "EnrollmentType": "Actual"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "1",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "Patients receiving Triamcinolone Acetonide 10 ml (Kenalog-10) intralesional injections.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: Triamcinolone Acetonide 10 mg/mL (Kenalog-10)"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "Triamcinolone Acetonide 10 mg/mL (Kenalog-10)",
                                        "InterventionDescription": "Triamcinolone Acetonide 10 mg/ml (Kenalog-10) intralesional injection",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "1"
                                            ]
                                        },
                                        "InterventionOtherNameList": {
                                            "InterventionOtherName": [
                                                "Kenalog 10"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Mean Change in Cortisol Levels From Baseline to Week 24",
                                        "PrimaryOutcomeDescription": "Mean change in cortisol levels from baseline to week 24 after four triamcinolone acetonide 10 ml injections 6 weeks apart.",
                                        "PrimaryOutcomeTimeFrame": "baseline, week 24"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nSubject has clinical diagnosis of alopecia areata.\n\nWritten informed consent and HIPAA authorization have been obtained.\n\nFemale subjects of childbearing potential have a negative pregnancy test and agree to use an acceptable method of birth control to prevent pregnancy.\nIn the opinion of the investigator, subject is a candidate for intralesional therapy for alopecia areata.\nSubject agrees to comply with protocol requirements and attend all required study visits and is considered to be a good study subject.\nSubject meets concomitant medication washout requirements.\nSubject is >/= 18 years of age.\n\nExclusion Criteria:\n\nSubject has alopecia universalis.\nSubject has known adrenocortical insufficiency or Cushing's Syndrome.\nSubject is pregnant or lactating.\nSubject has current controlled or uncontrolled bacterial, viral, fungal, atypical, or opportunistic infections.\nSubject possesses hypersensitivity to cortrosyn or Triamcinolone Acetonide (Kenalog-10) or any component of their formulation.\nSubject is currently or has undergone therapy for malignancy within the past five years.\nSubject has history of substance abuse within the past five years.\nSubject has used oral corticosteroids within the past 12 months.\nSubject has concurrent use of phenytion rifampin, phenobarbital, mitotane, or other formulations of corticosteroid medications.\nSubject has any medical condition that, in the judgement of the investigator, would jeopardize the subject's safety following exposure to the administered medications.",
                            "HealthyVolunteers": "Accepts Healthy Volunteers",
                            "Gender": "All",
                            "MinimumAge": "18 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Maria K Hordinsky, MD",
                                        "OverallOfficialAffiliation": "University of Minnesota",
                                        "OverallOfficialRole": "Study Director"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "University of Minnesota",
                                        "LocationCity": "Minneapolis",
                                        "LocationState": "Minnesota",
                                        "LocationZip": "55455",
                                        "LocationCountry": "United States"
                                    }
                                ]
                            }
                        }
                    },
                    "ResultsSection": {
                        "ParticipantFlowModule": {
                            "FlowGroupList": {
                                "FlowGroup": [
                                    {
                                        "FlowGroupId": "FG000",
                                        "FlowGroupTitle": "(Kenalog-10) Intralesional Injections for Alopecia Areata",
                                        "FlowGroupDescription": "Patients received Triamcinolone Acetonide 10 ml (Kenalog-10) intralesional injections every 6 weeks for 6 months. Disease extent and efficacy was assessed along with safety studies involving regularly scheduled ACTH stimulation tests."
                                    }
                                ]
                            },
                            "FlowPeriodList": {
                                "FlowPeriod": [
                                    {
                                        "FlowPeriodTitle": "Overall Study",
                                        "FlowMilestoneList": {
                                            "FlowMilestone": [
                                                {
                                                    "FlowMilestoneType": "STARTED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "18"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowMilestoneType": "COMPLETED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "15"
                                                            }
                                                        ]
                                                    }
                                                },
                                                {
                                                    "FlowMilestoneType": "NOT COMPLETED",
                                                    "FlowAchievementList": {
                                                        "FlowAchievement": [
                                                            {
                                                                "FlowAchievementGroupId": "FG000",
                                                                "FlowAchievementNumSubjects": "3"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "FlowDropWithdrawList": {
                                            "FlowDropWithdraw": [
                                                {
                                                    "FlowDropWithdrawType": "Withdrawal by Subject",
                                                    "FlowReasonList": {
                                                        "FlowReason": [
                                                            {
                                                                "FlowReasonGroupId": "FG000",
                                                                "FlowReasonNumSubjects": "3"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "BaselineCharacteristicsModule": {
                            "BaselinePopulationDescription": "15 completed the study and were used for analysis.",
                            "BaselineGroupList": {
                                "BaselineGroup": [
                                    {
                                        "BaselineGroupId": "BG000",
                                        "BaselineGroupTitle": "(Kenalog-10) Intralesional Injections for Alopecia Areata",
                                        "BaselineGroupDescription": "Patients received Triamcinolone Acetonide 10 ml (Kenalog-10) intralesional injections every 6 weeks for 6 months. Disease extent and efficacy was assessed along with safety studies involving regularly scheduled ACTH stimulation tests."
                                    }
                                ]
                            },
                            "BaselineDenomList": {
                                "BaselineDenom": [
                                    {
                                        "BaselineDenomUnits": "Participants",
                                        "BaselineDenomCountList": {
                                            "BaselineDenomCount": [
                                                {
                                                    "BaselineDenomCountGroupId": "BG000",
                                                    "BaselineDenomCountValue": "15"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            },
                            "BaselineMeasureList": {
                                "BaselineMeasure": [
                                    {
                                        "BaselineMeasureTitle": "Age, Categorical",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineCategoryTitle": "<=18 years",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "0"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Between 18 and 65 years",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "14"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": ">=65 years",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "1"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Age, Continuous",
                                        "BaselineMeasureParamType": "Mean",
                                        "BaselineMeasureDispersionType": "Standard Deviation",
                                        "BaselineMeasureUnitOfMeasure": "years",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "46.6",
                                                                            "BaselineMeasurementSpread": "14.53"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Sex: Female, Male",
                                        "BaselineMeasureParamType": "Count of Participants",
                                        "BaselineMeasureUnitOfMeasure": "Participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineCategoryTitle": "Female",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "10"
                                                                        }
                                                                    ]
                                                                }
                                                            },
                                                            {
                                                                "BaselineCategoryTitle": "Male",
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "5"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "BaselineMeasureTitle": "Region of Enrollment",
                                        "BaselineMeasureParamType": "Number",
                                        "BaselineMeasureUnitOfMeasure": "participants",
                                        "BaselineClassList": {
                                            "BaselineClass": [
                                                {
                                                    "BaselineClassTitle": "United States",
                                                    "BaselineCategoryList": {
                                                        "BaselineCategory": [
                                                            {
                                                                "BaselineMeasurementList": {
                                                                    "BaselineMeasurement": [
                                                                        {
                                                                            "BaselineMeasurementGroupId": "BG000",
                                                                            "BaselineMeasurementValue": "15"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomeMeasuresModule": {
                            "OutcomeMeasureList": {
                                "OutcomeMeasure": [
                                    {
                                        "OutcomeMeasureType": "Primary",
                                        "OutcomeMeasureTitle": "Mean Change in Cortisol Levels From Baseline to Week 24",
                                        "OutcomeMeasureDescription": "Mean change in cortisol levels from baseline to week 24 after four triamcinolone acetonide 10 ml injections 6 weeks apart.",
                                        "OutcomeMeasurePopulationDescription": "Participants who completed all treatment and follow-up visits",
                                        "OutcomeMeasureReportingStatus": "Posted",
                                        "OutcomeMeasureParamType": "Mean",
                                        "OutcomeMeasureDispersionType": "Standard Deviation",
                                        "OutcomeMeasureUnitOfMeasure": "mg/dL",
                                        "OutcomeMeasureTimeFrame": "baseline, week 24",
                                        "OutcomeGroupList": {
                                            "OutcomeGroup": [
                                                {
                                                    "OutcomeGroupId": "OG000",
                                                    "OutcomeGroupTitle": "(Kenalog-10) Intralesional Injections for Alopecia Areata",
                                                    "OutcomeGroupDescription": "Patients received Triamcinolone Acetonide 10 ml (Kenalog-10) intralesional injections every 6 weeks for 6 months. Disease extent and efficacy was assessed along with safety studies involving regularly scheduled ACTH stimulation tests."
                                                }
                                            ]
                                        },
                                        "OutcomeDenomList": {
                                            "OutcomeDenom": [
                                                {
                                                    "OutcomeDenomUnits": "Participants",
                                                    "OutcomeDenomCountList": {
                                                        "OutcomeDenomCount": [
                                                            {
                                                                "OutcomeDenomCountGroupId": "OG000",
                                                                "OutcomeDenomCountValue": "15"
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        },
                                        "OutcomeClassList": {
                                            "OutcomeClass": [
                                                {
                                                    "OutcomeCategoryList": {
                                                        "OutcomeCategory": [
                                                            {
                                                                "OutcomeMeasurementList": {
                                                                    "OutcomeMeasurement": [
                                                                        {
                                                                            "OutcomeMeasurementGroupId": "OG000",
                                                                            "OutcomeMeasurementValue": "0.187",
                                                                            "OutcomeMeasurementSpread": "6.019"
                                                                        }
                                                                    ]
                                                                }
                                                            }
                                                        ]
                                                    }
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "AdverseEventsModule": {
                            "EventsFrequencyThreshold": "5",
                            "EventGroupList": {
                                "EventGroup": [
                                    {
                                        "EventGroupId": "EG000",
                                        "EventGroupTitle": "(Kenalog-10) Intralesional Injections for Alopecia Areata",
                                        "EventGroupDescription": "Patients received Triamcinolone Acetonide 10 ml (Kenalog-10) intralesional injections every 6 weeks for 6 months. Disease extent and efficacy was assessed along with safety studies involving regularly scheduled ACTH stimulation tests.",
                                        "EventGroupSeriousNumAffected": "0",
                                        "EventGroupSeriousNumAtRisk": "18",
                                        "EventGroupOtherNumAffected": "17",
                                        "EventGroupOtherNumAtRisk": "18"
                                    }
                                ]
                            },
                            "OtherEventList": {
                                "OtherEvent": [
                                    {
                                        "OtherEventTerm": "acne",
                                        "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                                        "OtherEventAssessmentType": "Non-systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "18"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "anemia",
                                        "OtherEventOrganSystem": "Blood and lymphatic system disorders",
                                        "OtherEventAssessmentType": "Non-systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "18"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "atrophy of scalp",
                                        "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                                        "OtherEventAssessmentType": "Non-systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "18"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "benign keratosis",
                                        "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                                        "OtherEventAssessmentType": "Non-systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "18"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Broken left elbow",
                                        "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                                        "OtherEventAssessmentType": "Non-systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "18"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Diarrhea",
                                        "OtherEventOrganSystem": "Gastrointestinal disorders",
                                        "OtherEventAssessmentType": "Non-systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "18"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "erythema of ear canal",
                                        "OtherEventOrganSystem": "Ear and labyrinth disorders",
                                        "OtherEventAssessmentType": "Non-systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "18"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "excoriations",
                                        "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                                        "OtherEventAssessmentType": "Non-systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "18"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "facial flushing",
                                        "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                                        "OtherEventAssessmentType": "Non-systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "18"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "feelings of sadness",
                                        "OtherEventOrganSystem": "Psychiatric disorders",
                                        "OtherEventAssessmentType": "Non-systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "18"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "influenza",
                                        "OtherEventOrganSystem": "Infections and infestations",
                                        "OtherEventAssessmentType": "Non-systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "18"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "folliculitis",
                                        "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                                        "OtherEventAssessmentType": "Non-systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "18"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Headaches",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventAssessmentType": "Non-systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "6",
                                                    "OtherEventStatsNumAffected": "4",
                                                    "OtherEventStatsNumAtRisk": "18"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "increased number of telantascias along frontal hair line",
                                        "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                                        "OtherEventAssessmentType": "Non-systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "18"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Increase scalp hair loss",
                                        "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                                        "OtherEventAssessmentType": "Non-systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "18"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Irregular periods",
                                        "OtherEventOrganSystem": "Reproductive system and breast disorders",
                                        "OtherEventAssessmentType": "Non-systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "18"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "conjunctivitis",
                                        "OtherEventOrganSystem": "Eye disorders",
                                        "OtherEventAssessmentType": "Non-systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "18"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "throat erythema",
                                        "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                                        "OtherEventAssessmentType": "Non-systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "18"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "nasal septal fracture",
                                        "OtherEventOrganSystem": "Musculoskeletal and connective tissue disorders",
                                        "OtherEventAssessmentType": "Non-systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "18"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "intermittant nose bleeds",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventAssessmentType": "Non-systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "18"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "pinguecula",
                                        "OtherEventOrganSystem": "Eye disorders",
                                        "OtherEventAssessmentType": "Non-systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "18"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Pneumonia",
                                        "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                                        "OtherEventAssessmentType": "Non-systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "18"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Restless leg syndrome",
                                        "OtherEventOrganSystem": "Nervous system disorders",
                                        "OtherEventAssessmentType": "Non-systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "18"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "scale in ear canal",
                                        "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                                        "OtherEventAssessmentType": "Non-systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "18"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "tonsilar gland enlargement",
                                        "OtherEventOrganSystem": "General disorders",
                                        "OtherEventAssessmentType": "Non-systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "18"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "Upper respiratory infection",
                                        "OtherEventOrganSystem": "Respiratory, thoracic and mediastinal disorders",
                                        "OtherEventAssessmentType": "Non-systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "3",
                                                    "OtherEventStatsNumAffected": "3",
                                                    "OtherEventStatsNumAtRisk": "18"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "vaginal bleeding",
                                        "OtherEventOrganSystem": "Reproductive system and breast disorders",
                                        "OtherEventAssessmentType": "Non-systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "2",
                                                    "OtherEventStatsNumAffected": "2",
                                                    "OtherEventStatsNumAtRisk": "18"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "vaginal yeast infection",
                                        "OtherEventOrganSystem": "Infections and infestations",
                                        "OtherEventAssessmentType": "Non-systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "18"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "worsening ear dermatitis",
                                        "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                                        "OtherEventAssessmentType": "Non-systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "18"
                                                }
                                            ]
                                        }
                                    },
                                    {
                                        "OtherEventTerm": "xerotic skin",
                                        "OtherEventOrganSystem": "Skin and subcutaneous tissue disorders",
                                        "OtherEventAssessmentType": "Non-systematic Assessment",
                                        "OtherEventStatsList": {
                                            "OtherEventStats": [
                                                {
                                                    "OtherEventStatsGroupId": "EG000",
                                                    "OtherEventStatsNumEvents": "1",
                                                    "OtherEventStatsNumAffected": "1",
                                                    "OtherEventStatsNumAtRisk": "18"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "MoreInfoModule": {
                            "CertainAgreement": {
                                "AgreementPISponsorEmployee": "Yes",
                                "AgreementRestrictiveAgreement": "No"
                            },
                            "PointOfContact": {
                                "PointOfContactTitle": "Maria Hordinsky, MD",
                                "PointOfContactOrganization": "University of Minnesota",
                                "PointOfContactEMail": "hordi001@umn.edu",
                                "PointOfContactPhone": "612-624-5721"
                            }
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000000505",
                                        "ConditionMeshTerm": "Alopecia"
                                    },
                                    {
                                        "ConditionMeshId": "D000000506",
                                        "ConditionMeshTerm": "Alopecia Areata"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000007039",
                                        "ConditionAncestorTerm": "Hypotrichosis"
                                    },
                                    {
                                        "ConditionAncestorId": "D000006201",
                                        "ConditionAncestorTerm": "Hair Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000012871",
                                        "ConditionAncestorTerm": "Skin Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000020763",
                                        "ConditionAncestorTerm": "Pathological Conditions, Anatomical"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M2998",
                                        "ConditionBrowseLeafName": "Alopecia",
                                        "ConditionBrowseLeafAsFound": "Alopecia",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M2999",
                                        "ConditionBrowseLeafName": "Alopecia Areata",
                                        "ConditionBrowseLeafAsFound": "Alopecia Areata",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M9241",
                                        "ConditionBrowseLeafName": "Hypotrichosis",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M8445",
                                        "ConditionBrowseLeafName": "Hair Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M14826",
                                        "ConditionBrowseLeafName": "Skin Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M21672",
                                        "ConditionBrowseLeafName": "Pathological Conditions, Anatomical",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC17",
                                        "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC23",
                                        "ConditionBrowseBranchName": "Symptoms and General Pathology"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionMeshList": {
                                "InterventionMesh": [
                                    {
                                        "InterventionMeshId": "D000014221",
                                        "InterventionMeshTerm": "Triamcinolone"
                                    },
                                    {
                                        "InterventionMeshId": "D000014222",
                                        "InterventionMeshTerm": "Triamcinolone Acetonide"
                                    },
                                    {
                                        "InterventionMeshId": "C000005900",
                                        "InterventionMeshTerm": "Triamcinolone hexacetonide"
                                    },
                                    {
                                        "InterventionMeshId": "C000030262",
                                        "InterventionMeshTerm": "Triamcinolone diacetate"
                                    }
                                ]
                            },
                            "InterventionAncestorList": {
                                "InterventionAncestor": [
                                    {
                                        "InterventionAncestorId": "D000000893",
                                        "InterventionAncestorTerm": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000005938",
                                        "InterventionAncestorTerm": "Glucocorticoids"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006728",
                                        "InterventionAncestorTerm": "Hormones"
                                    },
                                    {
                                        "InterventionAncestorId": "D000006730",
                                        "InterventionAncestorTerm": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045505",
                                        "InterventionAncestorTerm": "Physiological Effects of Drugs"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007166",
                                        "InterventionAncestorTerm": "Immunosuppressive Agents"
                                    },
                                    {
                                        "InterventionAncestorId": "D000007155",
                                        "InterventionAncestorTerm": "Immunologic Factors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000004791",
                                        "InterventionAncestorTerm": "Enzyme Inhibitors"
                                    },
                                    {
                                        "InterventionAncestorId": "D000045504",
                                        "InterventionAncestorTerm": "Molecular Mechanisms of Pharmacological Action"
                                    }
                                ]
                            },
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M7144",
                                        "InterventionBrowseLeafName": "Epinephrine",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafAsFound": "Cross-sectional Survey",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafAsFound": "Laryngoscope",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafAsFound": "Cross-sectional Survey",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafAsFound": "Cross-sectional Survey",
                                        "InterventionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M29524",
                                        "InterventionBrowseLeafName": "Racepinephrine",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M211051",
                                        "InterventionBrowseLeafName": "Epinephryl borate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M3369",
                                        "InterventionBrowseLeafName": "Anti-Inflammatory Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8199",
                                        "InterventionBrowseLeafName": "Glucocorticoids",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8941",
                                        "InterventionBrowseLeafName": "Hormones",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M8940",
                                        "InterventionBrowseLeafName": "Hormone Antagonists",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9364",
                                        "InterventionBrowseLeafName": "Immunosuppressive Agents",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M9353",
                                        "InterventionBrowseLeafName": "Immunologic Factors",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "VaCoAg",
                                        "InterventionBrowseBranchName": "Vasoconstrictor Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "Resp",
                                        "InterventionBrowseBranchName": "Respiratory System Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 48,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT03175029",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "10054040"
                            },
                            "Organization": {
                                "OrgFullName": "Taiho Pharmaceutical Co., Ltd.",
                                "OrgClass": "INDUSTRY"
                            },
                            "BriefTitle": "Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder.",
                            "OfficialTitle": "Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder."
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "August 2020",
                            "OverallStatus": "Completed",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "August 1, 2017",
                                "StartDateType": "Actual"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "November 1, 2019",
                                "PrimaryCompletionDateType": "Actual"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "March 27, 2020",
                                "CompletionDateType": "Actual"
                            },
                            "StudyFirstSubmitDate": "May 25, 2017",
                            "StudyFirstSubmitQCDate": "May 31, 2017",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "June 5, 2017",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "August 26, 2020",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "August 27, 2020",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Sponsor"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Taiho Pharmaceutical Co., Ltd.",
                                "LeadSponsorClass": "INDUSTRY"
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "No",
                            "IsFDARegulatedDrug": "No",
                            "IsFDARegulatedDevice": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "The purpose of this study is to evaluate the efficacy and safety of TAC-302 in detrusor underactivity patients with overactive bladder.",
                            "DetailedDescription": "The main purpose of this study is to assess the efficacy of TAC-302 for 12 weeks in detrusor underactivity patients with overactive bladder by measuring the following parameters of pressure-flow study.\n\nMale; bladder contractility index (BCI)\nFemale; projected isovolumetric pressure (PIP) 1"
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Detrusor Underactivity",
                                    "Overactive Bladder"
                                ]
                            },
                            "KeywordList": {
                                "Keyword": [
                                    "Lower Urinary Tract Symptoms"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Phase 2"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "Randomized",
                                "DesignInterventionModel": "Parallel Assignment",
                                "DesignPrimaryPurpose": "Treatment",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "Quadruple",
                                    "DesignWhoMaskedList": {
                                        "DesignWhoMasked": [
                                            "Participant",
                                            "Care Provider",
                                            "Investigator",
                                            "Outcomes Assessor"
                                        ]
                                    }
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "76",
                                "EnrollmentType": "Actual"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "TAC-302",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: TAC-302"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "Placebo",
                                        "ArmGroupType": "Placebo Comparator",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: Placebo"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "TAC-302",
                                        "InterventionDescription": "TAC-302 200 mg administered orally twice per day after meals, for 12 weeks.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "TAC-302"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "Placebo",
                                        "InterventionDescription": "Placebo administered orally twice per day after meals, for 12 weeks.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "Placebo"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "Male; bladder contractility index (BCI)",
                                        "PrimaryOutcomeDescription": "Pressure-flow study parameters of the detrusor pressure at maximum flow rate (PdetQmax) and the maximum flow rate (Qmax) will be combined to report BCI.\n\nBCI=PdetQmax + 5Qmax The detrusor pressure at maximum flow rate (PdetQmax) in centimeters water, the maximum flow rate (Qmax) in milliliters per second.",
                                        "PrimaryOutcomeTimeFrame": "12 weeks"
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "Female; projected isovolumetric pressure (PIP) 1",
                                        "PrimaryOutcomeDescription": "Pressure-flow study parameters of the detrusor pressure at maximum flow rate (PdetQmax) and the maximum flow rate (Qmax) will be combined to report PIP1.\n\nPIP1=PdetQmax + Qmax The detrusor pressure at maximum flow rate (PdetQmax) in centimeters water, the maximum flow rate (Qmax) in milliliters per second.",
                                        "PrimaryOutcomeTimeFrame": "12 weeks"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "Bladder capacity of first desire to void",
                                        "SecondaryOutcomeDescription": "The urodynamic parameter of pressure-flow study during filling phase Bladder capacity of first desire to void in milliliters",
                                        "SecondaryOutcomeTimeFrame": "Baseline, 12 weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Bladder compliance",
                                        "SecondaryOutcomeDescription": "The urodynamic parameter of pressure-flow study during filling phase Bladder compliance in milliliters per centimeters water",
                                        "SecondaryOutcomeTimeFrame": "Baseline, 12 weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Appearance of bladder involuntary contraction",
                                        "SecondaryOutcomeDescription": "The urodynamic parameter of pressure-flow study during filling phase",
                                        "SecondaryOutcomeTimeFrame": "Baseline, 12 weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Qmax",
                                        "SecondaryOutcomeDescription": "The urodynamic parameter of pressure-flow study during voiding phase Qmax in milliliters per second",
                                        "SecondaryOutcomeTimeFrame": "Baseline, 12 weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "PdetQmax",
                                        "SecondaryOutcomeDescription": "The urodynamic parameter of pressure-flow study during voiding phase PdetQmax in centimeters water",
                                        "SecondaryOutcomeTimeFrame": "Baseline, 12 weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Bladder contraction duration",
                                        "SecondaryOutcomeDescription": "The urodynamic parameter of pressure-flow study during voiding phase Bladder contraction duration in seconds",
                                        "SecondaryOutcomeTimeFrame": "Baseline, 12 weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Maximum free flow rate (free Qmax)",
                                        "SecondaryOutcomeDescription": "The urodynamic parameter of free uroflowmetry Free Qmax in milliliters per second",
                                        "SecondaryOutcomeTimeFrame": "Baseline, 4 weeks, 8 weeks, 12 weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Voided volume",
                                        "SecondaryOutcomeDescription": "The urodynamic parameter of free uroflowmetry Voided volume in milliliters",
                                        "SecondaryOutcomeTimeFrame": "Baseline, 4 weeks, 8 weeks, 12 weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Voiding time",
                                        "SecondaryOutcomeDescription": "The urodynamic parameter of free uroflowmetry Voiding time in seconds",
                                        "SecondaryOutcomeTimeFrame": "Baseline, 4 weeks, 8 weeks, 12 weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Post Void Residual",
                                        "SecondaryOutcomeDescription": "Determining the volume of post void residual by ultrasonography Post Void Residual in milliliters",
                                        "SecondaryOutcomeTimeFrame": "Baseline, 4 weeks, 8 weeks, 12 weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Bladder Voiding Efficiency (BVE)",
                                        "SecondaryOutcomeDescription": "Voided volume and Post Void Residual will be combined to report BVE BVE(%)=[Voided volume/(Voided volume+ Post Void Residual)]×100",
                                        "SecondaryOutcomeTimeFrame": "Baseline, 4 weeks, 8 weeks, 12 weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The changes in the international prostate symptom score (IPSS)",
                                        "SecondaryOutcomeTimeFrame": "Baseline, 4 weeks, 8 weeks, 12 weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The changes in the overactive bladder symptom score (OABSS)",
                                        "SecondaryOutcomeTimeFrame": "Baseline, 4 weeks, 8 weeks, 12 weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The changes in the king's health questionnaire (KHQ)",
                                        "SecondaryOutcomeTimeFrame": "Baseline, 12 weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "The changes in mean urinary frequency per day, mean frequency of urgency and urge urinary incontinence episodes per day",
                                        "SecondaryOutcomeDescription": "The bladder diary data",
                                        "SecondaryOutcomeTimeFrame": "Baseline, 4 weeks, 8 weeks, 12 weeks"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "Safety assessed by incidence rate and severity of adverse events",
                                        "SecondaryOutcomeTimeFrame": "Up to 13 Weeks"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Key Inclusion Criteria:\n\nTo have Lower Urinary Tract Symptoms for at least 12 weeks prior to study entry\nTo have at least 1 urinary urgency episodes per day, and diurnal urinary frequency of 8 or more per day.\nTo meet the detrusor underactivity criteria by urodynamic study\n\nKey Exclusion Criteria:\n\nNeurogenic bladder by the central nervous system diseases.\nStageIII or more cystocele of pelvic organ prolapse quantification system (women)\nProstate volume ≥30mL (Men)\nAny symptoms of Urinary tract infection (UTI)",
                            "HealthyVolunteers": "No",
                            "Gender": "All",
                            "MinimumAge": "20 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Taiho Pharmaceutical Co., Ltd",
                                        "OverallOfficialAffiliation": "Taiho Pharmaceutical Co., Ltd.",
                                        "OverallOfficialRole": "Study Director"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "Taiho Pharmaceutical Co., Ltd selected site",
                                        "LocationCity": "Kumamoto",
                                        "LocationCountry": "Japan"
                                    }
                                ]
                            }
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000018476",
                                        "ConditionMeshTerm": "Hypokinesia"
                                    },
                                    {
                                        "ConditionMeshId": "D000053201",
                                        "ConditionMeshTerm": "Urinary Bladder, Overactive"
                                    },
                                    {
                                        "ConditionMeshId": "D000077295",
                                        "ConditionMeshTerm": "Urinary Bladder, Underactive"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000001745",
                                        "ConditionAncestorTerm": "Urinary Bladder Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000014570",
                                        "ConditionAncestorTerm": "Urologic Diseases"
                                    },
                                    {
                                        "ConditionAncestorId": "D000059411",
                                        "ConditionAncestorTerm": "Lower Urinary Tract Symptoms"
                                    },
                                    {
                                        "ConditionAncestorId": "D000020924",
                                        "ConditionAncestorTerm": "Urological Manifestations"
                                    },
                                    {
                                        "ConditionAncestorId": "D000020820",
                                        "ConditionAncestorTerm": "Dyskinesias"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009461",
                                        "ConditionAncestorTerm": "Neurologic Manifestations"
                                    },
                                    {
                                        "ConditionAncestorId": "D000009422",
                                        "ConditionAncestorTerm": "Nervous System Diseases"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M26320",
                                        "ConditionBrowseLeafName": "Urinary Bladder, Overactive",
                                        "ConditionBrowseLeafAsFound": "Overactive Bladder",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M28617",
                                        "ConditionBrowseLeafName": "Lower Urinary Tract Symptoms",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M19735",
                                        "ConditionBrowseLeafName": "Hypokinesia",
                                        "ConditionBrowseLeafAsFound": "Underactivity",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M1748",
                                        "ConditionBrowseLeafName": "Urinary Bladder, Underactive",
                                        "ConditionBrowseLeafAsFound": "Detrusor Underactivity",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M4178",
                                        "ConditionBrowseLeafName": "Urinary Bladder Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M16471",
                                        "ConditionBrowseLeafName": "Urologic Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M21812",
                                        "ConditionBrowseLeafName": "Urological Manifestations",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M21727",
                                        "ConditionBrowseLeafName": "Dyskinesias",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M11556",
                                        "ConditionBrowseLeafName": "Neurologic Manifestations",
                                        "ConditionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BXS",
                                        "ConditionBrowseBranchName": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC23",
                                        "ConditionBrowseBranchName": "Symptoms and General Pathology"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC10",
                                        "ConditionBrowseBranchName": "Nervous System Diseases"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 49,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT04036630",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "PP00P1_163726"
                            },
                            "Organization": {
                                "OrgFullName": "University of Zurich",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Enhancing Speech Intelligibility Using Transcranial Alternating Current Stimulation (tACS)",
                            "OfficialTitle": "Enhancing Speech Intelligibility Using Transcranial Alternating Current Stimulation (tACS)",
                            "Acronym": "StimSpeechCom"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "April 2021",
                            "OverallStatus": "Recruiting",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "December 1, 2020",
                                "StartDateType": "Actual"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "October 1, 2022",
                                "PrimaryCompletionDateType": "Anticipated"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "October 1, 2022",
                                "CompletionDateType": "Anticipated"
                            },
                            "StudyFirstSubmitDate": "July 15, 2019",
                            "StudyFirstSubmitQCDate": "July 24, 2019",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "July 30, 2019",
                                "StudyFirstPostDateType": "Actual"
                            },
                            "LastUpdateSubmitDate": "April 27, 2021",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "April 29, 2021",
                                "LastUpdatePostDateType": "Actual"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Sponsor"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "University of Zurich",
                                "LeadSponsorClass": "OTHER"
                            },
                            "CollaboratorList": {
                                "Collaborator": [
                                    {
                                        "CollaboratorName": "University Hospital Inselspital, Berne",
                                        "CollaboratorClass": "OTHER"
                                    }
                                ]
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "Yes",
                            "IsFDARegulatedDrug": "No",
                            "IsFDARegulatedDevice": "No"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "This study contributes to fundamental research investigating the role of the articulatory-motor integration and cerebro-acoustic coherence in speech comprehension. In a series of experiments non-invasive brain stimulation (NIBS) techniques including transcranial electric stimulation with alternating current waveforms (tACS) and transcranial magnetic stimulation (TMS) will be applied to the left ventral motor cortex (vMC) to test the contribution of this area to speech comprehension under challenging listening situations. As long as the exclusion criteria for TMS and tACS are strictly considered, only very minimal risks and no long-term effects are expected.\n\nThere are no known risks associated with NIBS and pregnancy; however, since risks cannot be completely excluded, pregnant women will be excluded from participation. If a female participant is uncertain whether she is pregnant, she will be provided with a pregnancy test at no cost.",
                            "DetailedDescription": "Background and Rationale In Europe, 71 million people - 16% of the population - suffer from hearing difficulties. One of the major consequences of hearing impairment is reduced speech-comprehension ability, especially in acoustically challenging conditions such as in reverberant or noisy environments.\n\nThe proposed project is intended to develop our understanding of the mechanisms that can be exploited to support speech comprehension under challenging listening conditions, and how they can be enhanced in hearing-impaired and older listeners.\n\nTo this end, the compensatory neural mechanisms of articulatory-motor integration will be tested by applying transcranial alternating current stimulation (tACS) over the vMC.\n\nObjective(s) The overall objective of the study is to shed light on the compensatory mechanisms supporting speech comprehension under perceptually-challenging conditions.\n\nExperiment 1 to 3 The primary objective is to test the utility of auditory-motor integration for degraded speech (DS) comprehension.\n\nOne secondary objective is to assess the interaction between degradation level of DS and tACS-induced improvement of performance. Another secondary objective is to explore potential differences of tACS-induced improvements in younger and older hearing-impaired listeners.\n\nExperiment 4 The primary objective is to test the utility of cerebro-acoustic coherence for SIN comprehension. The secondary objective of Experiment 4 is to test whether cerebro-acoustic coherence reflects syllable-level processing.\n\nStatistical Considerations:\n\nFor all experiments, mixed effect repeated measures ANOVAs will be conducted. Paired t-tests corrected for multiple comparisons will be applied for posthoc comparisons.\n\nNumber of Participants with Rationale\n\nPower analyses were conducted separately for every experiment assuming an intermediate effect size. The result of the power analysis suggests the minimal total sample size for Experiments 1 to be 30, for Experiments 2+3 to be 50, and 60 for experiment 4.\n\nExperiment 1 The result of the power analysis suggests a minimal total sample size of 30 younger participants.\n\nExperiment 2-3 The result of the power analysis suggests a minimal total sample size 50, including 25 younger and 25 older participants; Experiment 4 The result of the power analysis suggests a minimal total sample size of 60, including 30 younger and 30 older participants in the experiment.\n\nHandling of Missing Data and Dropouts Drop-outs as well as participants who have to be excluded due to sub-normal hearing thresholds as determined by pretest screening will be replaced by newly recruited participants. In case of missing data, the analyses are made with the data available. Data of drop-out will be analysed and anonymized upon termination of data analysis.\n\nStudy Intervention\n\nThe main study intervention is tACS stimulation. Two stimulation protocols will be used.\n\nStimulation Protocol 1 (SP1) used in Experiments 1-3 involves continuous high-frequency (2 kHz) stimulation. In experiment 1, SP1 will be applied online (during aMEP recording). In experiments 2-3, SP1 will be applied offline (before the start of the task) during 20 minutes.\n\nStimulation Protocol 2 (SP2) used in Experiment 4, involves online (during task execution) low-frequency speech-envelope (env) tACS stimulation (1-8Hz).\n\nIn all experiments, the stimulation intensity will be 2 mA (peak-to-peak value, corresponding to a sine wave of ±1 mA amplitude).\n\nStimulation will be delivered through conductive rubber electrodes placed over the ventral motor cortex (vMC). The electrodes will be placed according to the 10-20 International EEG System to identify the target location.\n\nIn addition, TMS stimulation will be applied in experiment 1 to measure articulatory motor-evoked potentials (aMEPs).\n\nStimulation intensity will be 120% of the individual motor threshold of the participants [3].\n\nMonophasic single pulse TMS will be applied over the lip motor cortex in the vMC to induce aMEPs.\n\nStudy Procedures\n\nPre-screening\n\nassessment of the inclusion/exclusion criteria\ncollection of demographic information\n\nScreening of audition and speech perception\n\nScreening of the hearing threshold\nSpeech reception threshold\nText reception threshold\n\nSubjective intelligibility level Prior to the experimental session of every experiment, the subjective intelligibility level will be assessed, in order to estimate the degradation levels that yield recognition performance of 75% (easy), 50% (medium) and 25% (difficult). Degradation will take the form of noise vocoding, which allows parametric manipulation of speech intelligibility. This is a manipulation that reduces the spectral content of speech, without affecting its temporal content. The outcome resembles a hoarse robotic whisper.\n\nExperiment 1:\n\nEach participant undergoes two tACS sessions: an experimental session with online tACS at 2kHz, and a control session, in which sham stimulation is delivered, each lasting 20 minutes (session order is counterbalanced). During the experiment, TMS-induced aMEPs will be recorded from the participants' lip muscles.\n\nExperiment 2:\n\nEach participant undergoes two tACS sessions: an experimental session in which 2kHz tACS is delivered and a control session in which sham stimulation is delivered, each lasting 10 minutes (session order is counterbalanced). In the 20-minute period following each tACS session, participants will hear speech stimuli degraded at various levels of intelligibility. They will be asked to transcribe the words they hear (using a computer keyboard) as quickly as possible, and with a maximum of 10s per item. They will be presented with 30 words at each of low, medium and high levels of degradation as well as 30 clear stimuli, in a random order.\n\nExperiment 3:\n\nParticipants' baseline noise-vocoded speech comprehension (for a description of the procedure see section 3.2) will be assessed using the same testing procedure as in Experiment 1. In an experimental group, tACS with the same settings as described above (SP1) will be used to induce increased articulatory-motor excitability; in a control group, sham tACS will be delivered. In the following 20-minute period, participants will receive training on noise-vocoded speech. Training will consist of 250 words presented in pairs, first a clear instance of a word, then its degraded counterpart, 200ms after the offset of the clear word. Word pairs will be presented with a jittered inter-trial interval (ITI) of 1500±500ms. It has been shown that this type of presentation can be highly effective for rapidly improving noise-vocoded word comprehension: with the presentation of 120 items (taking around 10 minutes to present) participants' accuracy in word identification improved from approximately 20% to over 30% [4]. Noise-vocoded word comprehension will be assessed again after training.\n\nExperiment 4:\n\nParticipants undergo two tACS sessions, in which they will be tested in DS comprehension whilst they receive either env-tACS or time-reversed env-tACS trials, interleaved by sham stimulation trials. As in Experiment 1, participants will be presented with 30 stimuli degraded to each of three different extents, and 30 clear stimuli and will be asked to transcribe the words they hear within 10 seconds.\n\nFurther Aspects Overall Ethical Considerations The study has the potential to carry both a scientific value, associated with improving the understanding of the compensatory mechanisms supporting degraded speech comprehension, and a social value, as its results might inform the development of new intervention strategies for overcoming hearing impairment or inform the amelioration of existing ones. The results of the study are generalizable to many (if not most of all) situations of listening under perceptually-challenging conditions, such as hearing impairment. Given that the greatest societal burdens of hearing impairment are associated with normal age-related hearing decline (i.e., presbycusis), we aim at extending the generalizability of the results to the third age by including, a sample of participants from an elderly population.\n\nGood Clinical Practice (GCP) Statement This study will be conducted in compliance with the protocol, the current version of the Declaration of Helsinki, the International Conference on Harmonization-GCP, the Swiss Human Research Act as well as other locally relevant legal and regulatory requirements\n\nRisk-Benefit Assessment There are no risks associated with the study interventions themselves, as long as exclusion criteria are respected, with the exception of rare mild and transient effects of tACS stimulation. Neither are risks of unauthorised data access through third parties or unwanted identification of participants expected.\n\nThe studies neither expects immediate benefits to the participant. However, participants (and anyone else) may benefit from the potentially strong scientific and social values of the study resulting from a better understanding of the (compensatory) neural mechanisms involved in challenging speech perception and medical devices (e.g., hearing aids) that may follow.\n\nQuality Control and Data Protections Quality Measures In order to assure a good data quality, all the project members are trained on all the important study-related aspects. Personnel will be provided with theoretical and practical knowledge about the specific non-invasive electric brain stimulation device as well as experimental protocol used in the particular experiment in which he/she is involved, through careful consideration of the experimental protocol and performance of practice sessions. In order to ensure that the data are not lost or damaged, they will be stored dually. The investigator will perform regular data quality checks.\n\nFor quality assurance the sponsor, the Ethics Committee or an independent trial monitor may visit the research sites. Direct access to the source data and all study related files is granted on such occasions. All involved parties keep the participant data strictly confidential.\n\nData Recording and Source Data\n\nAn electronic case report form (e-CRF) will be held for:\n\nparticipants who were included* and successfully concluded the study\nparticipants who were included* in the study but had to be excluded due to sub-normal hearing as determined by pre-screening (participants are aware of this possibility, as it will be stated both in the participant information sheet and informed consent) *inclusion is determined by signing the consent form. It is the responsibility of the investigator to assure that all data in the course of the study will be entered completely and correctly in the respective database. Essential documents must be retained for at least 10 years after the regular end or a premature termination of the respective study (Art. 25 der KlinV). e-CRFs will not identify participants by their name or birth date, but will provide appropriate dummy-coded identification IDs. e-CRFs will be stored into a password-protected Excel sheet and will only be accessible to authorised personnel who require the data to fulfil their duties within the scope of the study. The principal investigator will control the correct data entry in the database.\n\nSource documents in this study are demographic data, informed consent forms, randomization numbers, (S)AEs, and results of relevant examinations. Data recorded in the e-CRFs are the anonymized participant ID, age, date of participation, inclusion and exclusion criteria, hearing thresholds, assigned conditions and subjective treatment evaluation.\n\nConfidentiality and Coding Trial and participant data will be handled with uttermost discretion and will only be accessible to authorised personnel who require the data to fulfil their duties within the scope of the study. On the CRFs and other study specific documents, participants are only identified by a unique participant number, stored in the participant identification list.\n\nIn order to protect it from unauthorised or accidental disclosure, alteration, deletion, copying and theft, but at the same time to ensure traceability (audit trail; ClinO, Art. 18), the investigator will store the participant identification list in two formats. An electronic version will be stored on a secure network folder of the responsible research centre (the University of Zurich (UZH) or Inselspital Bern) accessible only by the investigators. In addition, a paper version will be locked in the Psychologisches Institut building of the UZH and accessible only to the investigator.\n\nRetention and Destruction of Study Data All study data are archived for 10 years after study termination or premature termination of the study. All the study data (including digital copies of physical documents) will be stored in two archives, in order to guarantee availability of a backup copy in case files in one of the archives become corrupted, incorrectly modified or lost. Thus, data will be stored on a secure network folder of the UZH accessible only by the project members and only within the University of Zurich network as well as on a folder of a mass storage hard disk drive (HDD) protected by password. If a UZH central backup storage unit will become available prior to termination of the study, data from the hard disk drive will be moved there. The paper data (i.e., informed consent and questionnaires) will be locked in the UZH building.\n\nMonitoring and Registration Due to the low risks associated with this study, an internal study monitoring will be applied: the principal investigator will check the protocol, data, and informed consents obtained by the project members regularly for accuracy and will ensure that no data is missing and data storage in compliance with the protocol. The source data/documents will be accessible to monitors and questions will be answered during monitoring.\n\nThe study will be also registered in a national language (German) in the Swiss National Clinical Trial Portal (SNCTP) via BASEC.\n\nFunding/Publication/Declaration of Interest The study is fully funded by the Swiss National Science Foundation (SNSF). After statistical analyses of each experiment, the project manager will make the unpublished not peer-reviewed pre-prints accessible through an open-access portal (e.g., BioRχive®) and will make every endeavour to publish the data in a scientific, peer-reviewed journal. Only non-clinical data will be made available in anonymized form. Trial results will be communicated to participants if they indicate that they wish to be informed of the study results.\n\nAll the project members declare no conflict of interest."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Electric Stimulation Therapy",
                                    "Transcranial Magnetic Stimulation"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Not Applicable"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "Randomized",
                                "DesignInterventionModel": "Crossover Assignment",
                                "DesignInterventionModelDescription": "The current study includes 4 different experiments (i.e., arms) including different experimental designs. See separate design description for each arm of the study",
                                "DesignPrimaryPurpose": "Basic Science",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "Single",
                                    "DesignMaskingDescription": "single-blind",
                                    "DesignWhoMaskedList": {
                                        "DesignWhoMasked": [
                                            "Participant"
                                        ]
                                    }
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "190",
                                "EnrollmentType": "Anticipated"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "2kHz tACS (Experiment 1)",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: Transcranial alternating current stimulation (tACS)",
                                                "Device: Transcranial magnetic stimulation (TMS) induced motor-evoked potentials (MEPs)"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "sham tACS (Experiment 1)",
                                        "ArmGroupType": "Sham Comparator",
                                        "ArmGroupDescription": "The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: Transcranial alternating current stimulation (tACS)",
                                                "Device: Transcranial magnetic stimulation (TMS) induced motor-evoked potentials (MEPs)"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "2kHz tACS (Experiment 2)",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: Transcranial alternating current stimulation (tACS)"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "sham tACS (Experiment 2)",
                                        "ArmGroupType": "Sham Comparator",
                                        "ArmGroupDescription": "The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: Transcranial alternating current stimulation (tACS)"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "2kHz tACS (Experiment 3)",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: Transcranial alternating current stimulation (tACS)"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "sham tACS (Experiment 3)",
                                        "ArmGroupType": "Sham Comparator",
                                        "ArmGroupDescription": "The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: Transcranial alternating current stimulation (tACS)"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "env tACS (Experiment 4)",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: Transcranial alternating current stimulation (tACS)"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "time-reversed env-tACS (Experiment 4)",
                                        "ArmGroupType": "Active Comparator",
                                        "ArmGroupDescription": "The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: Transcranial alternating current stimulation (tACS)"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "sham tACS (Experiment 4)",
                                        "ArmGroupType": "Sham Comparator",
                                        "ArmGroupDescription": "The subjects in this arm will undertake 20min tACS stimulation applied over the left ventral motor cortex.",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Device: Transcranial alternating current stimulation (tACS)"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "Transcranial alternating current stimulation (tACS)",
                                        "InterventionDescription": "The main study intervention is tACS stimulation. TACS is a non-invasive brain stimulation (NIBS) techniques that belong to the class of low current transcranial electric stimulation. In contrast to the better known transcranial direct current stimulation (tDCS), the tACS current is not constant, but alternates with a certain frequency.\n\nThe aim of the tACS stimulation is to enhance degraded speech comprehension in healthy individuals.\n\nTACS stimulation will be applied over the left ventral motor cortex, with a current intensity of 2mA (peak-to-peak)\n\nThe arm will be compared to the tACS sham stimulation condition.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "2kHz tACS (Experiment 1)",
                                                "2kHz tACS (Experiment 2)",
                                                "2kHz tACS (Experiment 3)",
                                                "env tACS (Experiment 4)",
                                                "sham tACS (Experiment 1)",
                                                "sham tACS (Experiment 2)",
                                                "sham tACS (Experiment 3)",
                                                "sham tACS (Experiment 4)",
                                                "time-reversed env-tACS (Experiment 4)"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Device",
                                        "InterventionName": "Transcranial magnetic stimulation (TMS) induced motor-evoked potentials (MEPs)",
                                        "InterventionDescription": "TMS is a technique where a transient magnetic field (or \"pulse\") is used to cause an electric current to flow in a targeted brain area via electromagnetic induction. The pulse causes the rapid and above-threshold depolarisation of cell membranes affected by the current. Therefore, TMS induces a current that elicits action potentials in neurons.\n\nMEPs are electrical potentials recorded from a target muscle after TMS stimulation. In experiment 1, so-called articulatory MEPs will be recorded from participants' lip muscle (orbicularis oris). Articulatory MEPs will be recorded by placing two recording electrodes on the right part of orbicularis oris and a reference electrode on the right temple.",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "2kHz tACS (Experiment 1)",
                                                "sham tACS (Experiment 1)"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "articulatory motor-evoked potential (aMEP) amplitude (Experiment 1) - time point 1",
                                        "PrimaryOutcomeDescription": "The comparison of articulatory motor-evoked potential (aMEP) amplitude after tACS and sham stimulation",
                                        "PrimaryOutcomeTimeFrame": "online (during tACS intervention)"
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "articulatory motor-evoked potential (aMEP) amplitude (Experiment 1) - time point 2",
                                        "PrimaryOutcomeDescription": "The comparison of articulatory motor-evoked potential (aMEP) amplitude after tACS and sham stimulation",
                                        "PrimaryOutcomeTimeFrame": "5min after tACS"
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "articulatory motor-evoked potential (aMEP) amplitude (Experiment 1) - time point 3",
                                        "PrimaryOutcomeDescription": "The comparison of articulatory motor-evoked potential (aMEP) amplitude after tACS and sham stimulation",
                                        "PrimaryOutcomeTimeFrame": "55min after (tACS)"
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "degraded speech comprehension (Experiment 2)",
                                        "PrimaryOutcomeDescription": "Subjects will listen and transcribe noise-vocoded sentence according to their subjective intelligibility levels (75% (easy), 50% (medium) and 25% (difficult)) assessed prior to the expermental manipulation\n\nComparison of degraded speech comprehension following tACS over the left ventral motor cortex (vMC) with performance following sham stimulation over the same region.",
                                        "PrimaryOutcomeTimeFrame": "right after tACS or sham stimulation (cross-over design)"
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "degraded speech comprehension (Experiment 3)",
                                        "PrimaryOutcomeDescription": "Subjects will listen and transcribe noise-vocoded sentence according to their subjective intelligibility levels (75% (easy), 50% (medium) and 25% (difficult)) assessed prior to the expermental manipulation\n\nComparison of degraded speech comprehension following tACS over the left ventral motor cortex (vMC) with performance following sham stimulation over the same region.",
                                        "PrimaryOutcomeTimeFrame": "20min after tACS or sham stimulation (between-group design), following a training of degraded speech comprehension"
                                    },
                                    {
                                        "PrimaryOutcomeMeasure": "degraded speech comprehension (Experiment 4)",
                                        "PrimaryOutcomeDescription": "Subjects will listen and transcribe noise-vocoded sentence according to their subjective intelligibility levels (75% (easy), 50% (medium) and 25% (difficult)) assessed prior to the expermental manipulation\n\nThe comparison of degraded speech comprehension between concomitant low-frequency (theta-band) speech envelope-shaped tACS (env-tACS), reversed env-tACS, and sham stimulation over left ventral motor cortex",
                                        "PrimaryOutcomeTimeFrame": "during env-tACS or sham stimulation (online)"
                                    }
                                ]
                            },
                            "SecondaryOutcomeList": {
                                "SecondaryOutcome": [
                                    {
                                        "SecondaryOutcomeMeasure": "syllable discrimination ability (Experiment 1) - time point 1",
                                        "SecondaryOutcomeDescription": "Subjects will be presented with two different eight-step syllable continua (da-ba or da-ga). Discrimination ability will be assessed by fitting logistic curves to obtain the slopes and positions of phonetic category boundaries before and after tACS stimulation. The slope index will be taken as an estimate for the steepness of the fitted curve. The steepness of the curve reflects the syllable discrimination ability of the participants. Participants with steeper logic are better in discriminating the two syllables of the continuum\n\nThe comparison of syllable discrimination ability following tACS stimulation and sham stimulation",
                                        "SecondaryOutcomeTimeFrame": "before tACS or sham stimulation (cross-over design)"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "syllable discrimination ability (Experiment 1) - time point 2",
                                        "SecondaryOutcomeDescription": "Subjects will be presented with two different eight-step syllable continua (da-ba or da-ga). Discrimination ability will be assessed by fitting logistic curves to obtain the slopes and positions of phonetic category boundaries before and after tACS stimulation. The slope index will be taken as an estimate for the steepness of the fitted curve. The steepness of the curve reflects the syllable discrimination ability of the participants. Participants with steeper logic are better in discriminating the two syllables of the continuum\n\nThe comparison of syllable discrimination ability following tACS stimulation and sham stimulation",
                                        "SecondaryOutcomeTimeFrame": "5min after tACS or sham stimulation (cross-over design)"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "speech degradation level (Experiment 2)",
                                        "SecondaryOutcomeDescription": "Subjects will listen and transcribe noise-vocoded sentence according to their subjective intelligibility levels (75% (easy), 50% (medium) and 25% (difficult)) assessed prior to the expermental manipulation\n\nWe will compare the impact of tACS stimulation (relative to sham) across different speech degradation levels.",
                                        "SecondaryOutcomeTimeFrame": "right after tACS or sham stimulation (cross-over design)"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "age group dependent tACS modulation (Experiment 2)",
                                        "SecondaryOutcomeDescription": "Subjects will listen and transcribe noise-vocoded sentence according to their subjective intelligibility levels (75% (easy), 50% (medium) and 25% (difficult)) assessed prior to the expermental manipulation\n\nWe will compare the impact of tACS stimulation (relative to sham) across different age groups, i.e., comparison of degraded speech comprehension between younger and older participants.",
                                        "SecondaryOutcomeTimeFrame": "right after tACS or sham stimulation (cross-over design)"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "speech degradation level (Experiment 3)",
                                        "SecondaryOutcomeDescription": "Subjects will listen and transcribe noise-vocoded sentence according to their subjective intelligibility levels (75% (easy), 50% (medium) and 25% (difficult)) assessed prior to the expermental manipulation\n\nWe will compare the impact of tACS stimulation (relative to sham) across different speech degradation levels.",
                                        "SecondaryOutcomeTimeFrame": "20min after tACS or sham stimulation, following a training of degraded speech comprehension"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "age group dependent tACS modulation (Experiment 3)",
                                        "SecondaryOutcomeDescription": "Subjects will listen and transcribe noise-vocoded sentence according to their subjective intelligibility levels (75% (easy), 50% (medium) and 25% (difficult)) assessed prior to the expermental manipulation\n\nWe will compare the impact of tACS stimulation (relative to sham) across different age groups, i.e., comparison of degraded speech comprehension between younger and older participants.",
                                        "SecondaryOutcomeTimeFrame": "20min after tACS or sham stimulation (between-group design), following a training of degraded speech comprehension"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "word length (Experiment 4)",
                                        "SecondaryOutcomeDescription": "comparison of the effects of tACS-induced modulation of speech-brain entrainment on the comprehension of monosyllabic vs. polysyllabic items.",
                                        "SecondaryOutcomeTimeFrame": "during env-tACS or sham stimulation (online)"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "tACS-auditory stimulus timing (Experiment 4)",
                                        "SecondaryOutcomeDescription": "We will compared degraded speech comprehension across different tACS-auditory stimulus onset lags.",
                                        "SecondaryOutcomeTimeFrame": "during env-tACS"
                                    },
                                    {
                                        "SecondaryOutcomeMeasure": "age group dependent tACS modulation (Experiment 4)",
                                        "SecondaryOutcomeDescription": "Subjects will listen and transcribe noise-vocoded sentence according to their subjective intelligibility levels (75% (easy), 50% (medium) and 25% (difficult)) assessed prior to the expermental manipulation\n\nWe will compare the impact of tACS stimulation (relative to sham) across different age groups, i.e., comparison of degraded speech comprehension between younger and older participants.",
                                        "SecondaryOutcomeTimeFrame": "during env-tACS, reversed env-tACS or sham stimulation (online)"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nWritten informed consent by the participant\nAge: 18-35 / 65+\nNormal (or corrected to normal) vision\nGerman as a first language\nRight-handed\n\nExclusion Criteria:\n\nhearing loss\nRaised bi- or multilingual\nWomen who are currently pregnant or breastfeeding\nKnown or suspected drug or alcohol abuse\nHistory of brain injury or any neurological disorder (y/n)\nFor example, stroke, traumatic brain injury, brain surgery, epilepsy etc.\nDyslexia\nHistory of psychiatric disorder\nRecent drug consumption\nMedication with cognitive side effects (e.g. psychoactive medications or sleeping pills)\nMetallic implants in the head region (excluding fixed braces and tooth fillings)\nAny implanted medical device (e.g. cardiac pacemakers)\nprevious enrolment in one of the experiments comprising the main investigational plan",
                            "HealthyVolunteers": "Accepts Healthy Volunteers",
                            "Gender": "All",
                            "MinimumAge": "18 Years",
                            "MaximumAge": "80 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "CentralContactList": {
                                "CentralContact": [
                                    {
                                        "CentralContactName": "Basil C Preisig, Dr.",
                                        "CentralContactRole": "Contact",
                                        "CentralContactPhone": "+41 44 635 72 34",
                                        "CentralContactEMail": "basil.preisig@psychologie.uzh.ch"
                                    }
                                ]
                            },
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Alexis Hervais-Adelman, Prof. Dr.",
                                        "OverallOfficialAffiliation": "University of Zurich, Institute for Psychology",
                                        "OverallOfficialRole": "Principal Investigator"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "Department of Psychology, University of Zurich",
                                        "LocationStatus": "Recruiting",
                                        "LocationCity": "Zürich",
                                        "LocationZip": "8050",
                                        "LocationCountry": "Switzerland",
                                        "LocationContactList": {
                                            "LocationContact": [
                                                {
                                                    "LocationContactName": "Basil C Preisig, Ph.D.",
                                                    "LocationContactRole": "Contact"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "IPDSharingStatementModule": {
                            "IPDSharing": "Yes",
                            "IPDSharingDescription": "We intend to share the raw data of the included participants and the analysis code",
                            "IPDSharingInfoTypeList": {
                                "IPDSharingInfoType": [
                                    "Analytic Code"
                                ]
                            },
                            "IPDSharingTimeFrame": "after the project is completed",
                            "IPDSharingAccessCriteria": "upon personal request"
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "InterventionBrowseModule": {
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            },
            {
                "Rank": 50,
                "Study": {
                    "ProtocolSection": {
                        "IdentificationModule": {
                            "NCTId": "NCT01571518",
                            "OrgStudyIdInfo": {
                                "OrgStudyId": "2011-91"
                            },
                            "Organization": {
                                "OrgFullName": "Sunchonhang University",
                                "OrgClass": "OTHER"
                            },
                            "BriefTitle": "Prevention of Neutropenia After Using G-CSF With TAC Chemotherapy",
                            "OfficialTitle": "Optimal Timing and Duration of Daily G-CSF With Adjuvant TAC Chemotherapy in Node-positive Breast Cancer;Multicenter, Randomized, Open Label, Clinically IV Phase"
                        },
                        "StatusModule": {
                            "StatusVerifiedDate": "April 2012",
                            "OverallStatus": "Unknown status",
                            "LastKnownStatus": "Not yet recruiting",
                            "ExpandedAccessInfo": {
                                "HasExpandedAccess": "No"
                            },
                            "StartDateStruct": {
                                "StartDate": "April 2012"
                            },
                            "PrimaryCompletionDateStruct": {
                                "PrimaryCompletionDate": "October 2013",
                                "PrimaryCompletionDateType": "Anticipated"
                            },
                            "CompletionDateStruct": {
                                "CompletionDate": "October 2013",
                                "CompletionDateType": "Anticipated"
                            },
                            "StudyFirstSubmitDate": "March 29, 2012",
                            "StudyFirstSubmitQCDate": "April 3, 2012",
                            "StudyFirstPostDateStruct": {
                                "StudyFirstPostDate": "April 5, 2012",
                                "StudyFirstPostDateType": "Estimate"
                            },
                            "LastUpdateSubmitDate": "April 3, 2012",
                            "LastUpdatePostDateStruct": {
                                "LastUpdatePostDate": "April 5, 2012",
                                "LastUpdatePostDateType": "Estimate"
                            }
                        },
                        "SponsorCollaboratorsModule": {
                            "ResponsibleParty": {
                                "ResponsiblePartyType": "Sponsor-Investigator",
                                "ResponsiblePartyInvestigatorFullName": "Hyuk moon Kim",
                                "ResponsiblePartyInvestigatorTitle": "Assistant professor",
                                "ResponsiblePartyInvestigatorAffiliation": "Sunchonhang University"
                            },
                            "LeadSponsor": {
                                "LeadSponsorName": "Hyuk moon Kim",
                                "LeadSponsorClass": "OTHER"
                            },
                            "CollaboratorList": {
                                "Collaborator": [
                                    {
                                        "CollaboratorName": "Dong-A Pharmaceutical Co., Ltd.",
                                        "CollaboratorClass": "INDUSTRY"
                                    }
                                ]
                            }
                        },
                        "OversightModule": {
                            "OversightHasDMC": "Yes"
                        },
                        "DescriptionModule": {
                            "BriefSummary": "After resection of lymph node positive breast cancer, the injection duration and timing of Granulocyte-colony stimulating factor (G-CSF) could affect the neutropenia with TAC (Taxotere, Adriamycin, cyclophosphamide) chemotherapy.",
                            "DetailedDescription": "The duration and the injection timing of G-CSF are effective in the prevention of neutropenia, incidence of infection and non hematologic toxicity. With the TAC chemotherapy after resection of breast cancer, the G-CSF early injection versus late injection could change the frequency of neutropenia."
                        },
                        "ConditionsModule": {
                            "ConditionList": {
                                "Condition": [
                                    "Neutropenia"
                                ]
                            },
                            "KeywordList": {
                                "Keyword": [
                                    "G-CSF",
                                    "neutropenia",
                                    "TAC"
                                ]
                            }
                        },
                        "DesignModule": {
                            "StudyType": "Interventional",
                            "PhaseList": {
                                "Phase": [
                                    "Phase 4"
                                ]
                            },
                            "DesignInfo": {
                                "DesignAllocation": "Randomized",
                                "DesignInterventionModel": "Parallel Assignment",
                                "DesignPrimaryPurpose": "Prevention",
                                "DesignMaskingInfo": {
                                    "DesignMasking": "None (Open Label)"
                                }
                            },
                            "EnrollmentInfo": {
                                "EnrollmentCount": "60",
                                "EnrollmentType": "Anticipated"
                            }
                        },
                        "ArmsInterventionsModule": {
                            "ArmGroupList": {
                                "ArmGroup": [
                                    {
                                        "ArmGroupLabel": "early injection",
                                        "ArmGroupType": "Experimental",
                                        "ArmGroupDescription": "injection of G-CSF (leukostim)5㎍/kg from day 2 of TAC chemotherapy",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: late leukostim"
                                            ]
                                        }
                                    },
                                    {
                                        "ArmGroupLabel": "late injection",
                                        "ArmGroupType": "Sham Comparator",
                                        "ArmGroupDescription": "injection of G-CSF (leukostim)5㎍/kg from day 5 of TAC chemotherapy",
                                        "ArmGroupInterventionList": {
                                            "ArmGroupInterventionName": [
                                                "Drug: early leukostim"
                                            ]
                                        }
                                    }
                                ]
                            },
                            "InterventionList": {
                                "Intervention": [
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "late leukostim",
                                        "InterventionDescription": "injection of G-CSF (leukostim)5㎍/kg from day 5 of TAC chemotherapy",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "early injection"
                                            ]
                                        },
                                        "InterventionOtherNameList": {
                                            "InterventionOtherName": [
                                                "5leuko"
                                            ]
                                        }
                                    },
                                    {
                                        "InterventionType": "Drug",
                                        "InterventionName": "early leukostim",
                                        "InterventionDescription": "injection of G-CSF (leukostim)5㎍/kg from day 2 of TAC chemotherapy",
                                        "InterventionArmGroupLabelList": {
                                            "InterventionArmGroupLabel": [
                                                "late injection"
                                            ]
                                        },
                                        "InterventionOtherNameList": {
                                            "InterventionOtherName": [
                                                "2leuko"
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "OutcomesModule": {
                            "PrimaryOutcomeList": {
                                "PrimaryOutcome": [
                                    {
                                        "PrimaryOutcomeMeasure": "frequency of neutropenia",
                                        "PrimaryOutcomeDescription": "during the 1 cycle (21days) of ajuvant chemotherapy with TAC, record the frequency of neutropenia aftr using G-CSF (Leucostim)",
                                        "PrimaryOutcomeTimeFrame": "Change from Baseline in neutrophil count at 21days"
                                    }
                                ]
                            }
                        },
                        "EligibilityModule": {
                            "EligibilityCriteria": "Inclusion Criteria:\n\nprimary invasive breast carcinoma with lymph node positive with curative surgery with TAC chemotherapy\n\nExclusion Criteria:\n\npregnancy,\ncardiovascualr disease,\nabnormal renal function,\nhematologic disorder",
                            "HealthyVolunteers": "No",
                            "Gender": "Female",
                            "MinimumAge": "20 Years",
                            "MaximumAge": "70 Years",
                            "StdAgeList": {
                                "StdAge": [
                                    "Adult",
                                    "Older Adult"
                                ]
                            }
                        },
                        "ContactsLocationsModule": {
                            "CentralContactList": {
                                "CentralContact": [
                                    {
                                        "CentralContactName": "Chul Wan Lim, M.D., Ph.D",
                                        "CentralContactRole": "Contact",
                                        "CentralContactPhone": "82-32-621-5114",
                                        "CentralContactEMail": "cylim@soonchunhyang.com"
                                    }
                                ]
                            },
                            "OverallOfficialList": {
                                "OverallOfficial": [
                                    {
                                        "OverallOfficialName": "Chul Wan Lim, MD,PhD",
                                        "OverallOfficialAffiliation": "Soonchunhyang U Puchun Hospital",
                                        "OverallOfficialRole": "Study Chair"
                                    }
                                ]
                            },
                            "LocationList": {
                                "Location": [
                                    {
                                        "LocationFacility": "Soonchunhyang university Puchun Hospital",
                                        "LocationCity": "Puchun",
                                        "LocationCountry": "Korea, Republic of",
                                        "LocationContactList": {
                                            "LocationContact": [
                                                {
                                                    "LocationContactName": "Hyuk moon Kim, MD",
                                                    "LocationContactRole": "Contact",
                                                    "LocationContactPhone": "82-32-621-5114",
                                                    "LocationContactEMail": "hmkim@soonchunhyang.com"
                                                },
                                                {
                                                    "LocationContactName": "ChulWan Lim, MD.PhD",
                                                    "LocationContactRole": "Principal Investigator"
                                                }
                                            ]
                                        }
                                    }
                                ]
                            }
                        },
                        "ReferencesModule": {
                            "ReferenceList": {
                                "Reference": [
                                    {
                                        "ReferencePMID": "20232087",
                                        "ReferenceType": "result",
                                        "ReferenceCitation": "Chan A, Fu WH, Shih V, Coyuco JC, Tan SH, Ng R. Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy. Support Care Cancer. 2011 Apr;19(4):497-504. doi: 10.1007/s00520-010-0843-8. Epub 2010 Mar 17."
                                    }
                                ]
                            }
                        }
                    },
                    "DerivedSection": {
                        "MiscInfoModule": {
                            "VersionHolder": "April 29, 2022"
                        },
                        "ConditionBrowseModule": {
                            "ConditionMeshList": {
                                "ConditionMesh": [
                                    {
                                        "ConditionMeshId": "D000009503",
                                        "ConditionMeshTerm": "Neutropenia"
                                    }
                                ]
                            },
                            "ConditionAncestorList": {
                                "ConditionAncestor": [
                                    {
                                        "ConditionAncestorId": "D000000380",
                                        "ConditionAncestorTerm": "Agranulocytosis"
                                    },
                                    {
                                        "ConditionAncestorId": "D000007970",
                                        "ConditionAncestorTerm": "Leukopenia"
                                    },
                                    {
                                        "ConditionAncestorId": "D000007960",
                                        "ConditionAncestorTerm": "Leukocyte Disorders"
                                    },
                                    {
                                        "ConditionAncestorId": "D000006402",
                                        "ConditionAncestorTerm": "Hematologic Diseases"
                                    }
                                ]
                            },
                            "ConditionBrowseLeafList": {
                                "ConditionBrowseLeaf": [
                                    {
                                        "ConditionBrowseLeafId": "M4372",
                                        "ConditionBrowseLeafName": "Breast Neoplasms",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M11595",
                                        "ConditionBrowseLeafName": "Neutropenia",
                                        "ConditionBrowseLeafAsFound": "Neutropenia",
                                        "ConditionBrowseLeafRelevance": "high"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M2882",
                                        "ConditionBrowseLeafName": "Agranulocytosis",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M10125",
                                        "ConditionBrowseLeafName": "Leukopenia",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M10115",
                                        "ConditionBrowseLeafName": "Leukocyte Disorders",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "M8642",
                                        "ConditionBrowseLeafName": "Hematologic Diseases",
                                        "ConditionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "ConditionBrowseLeafId": "T2606",
                                        "ConditionBrowseLeafName": "Granulocytopenia",
                                        "ConditionBrowseLeafAsFound": "Neutropenia",
                                        "ConditionBrowseLeafRelevance": "high"
                                    }
                                ]
                            },
                            "ConditionBrowseBranchList": {
                                "ConditionBrowseBranch": [
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC04",
                                        "ConditionBrowseBranchName": "Neoplasms"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC17",
                                        "ConditionBrowseBranchName": "Skin and Connective Tissue Diseases"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "All",
                                        "ConditionBrowseBranchName": "All Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "BC15",
                                        "ConditionBrowseBranchName": "Blood and Lymph Conditions"
                                    },
                                    {
                                        "ConditionBrowseBranchAbbrev": "Rare",
                                        "ConditionBrowseBranchName": "Rare Diseases"
                                    }
                                ]
                            }
                        },
                        "InterventionBrowseModule": {
                            "InterventionBrowseLeafList": {
                                "InterventionBrowseLeaf": [
                                    {
                                        "InterventionBrowseLeafId": "M16126",
                                        "InterventionBrowseLeafName": "Triamcinolone",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M16127",
                                        "InterventionBrowseLeafName": "Triamcinolone Acetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M237968",
                                        "InterventionBrowseLeafName": "Triamcinolone hexacetonide",
                                        "InterventionBrowseLeafRelevance": "low"
                                    },
                                    {
                                        "InterventionBrowseLeafId": "M209570",
                                        "InterventionBrowseLeafName": "Triamcinolone diacetate",
                                        "InterventionBrowseLeafRelevance": "low"
                                    }
                                ]
                            },
                            "InterventionBrowseBranchList": {
                                "InterventionBrowseBranch": [
                                    {
                                        "InterventionBrowseBranchAbbrev": "Infl",
                                        "InterventionBrowseBranchName": "Anti-Inflammatory Agents"
                                    },
                                    {
                                        "InterventionBrowseBranchAbbrev": "All",
                                        "InterventionBrowseBranchName": "All Drugs and Chemicals"
                                    }
                                ]
                            }
                        }
                    }
                }
            }
        ]
    }
}